<!doctype html>
<html>
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width,initial-scale=1,viewport-fit=cover">
  <title>APEX & Trust Prototype</title>
  <link rel="stylesheet" href="../../apex_trust_panel.css">
  <style>
    @keyframes ticker {
      0% { transform: translateX(0); }
      100% { transform: translateX(-50%); }
    }
    @media (max-width: 768px) {
      #scorecard-ticker { animation: ticker 15s linear infinite; }
    }
  </style>
</head>
<body>
  <!-- CONSOLIDATED STICKY HEADER BLOCK -->
  <div style="position: sticky; top: 0; z-index: 9999; margin: 0; padding: 0; width: 100%; overflow: hidden;">
    
    <!-- Page Header -->
    <div style="background: rgb(26, 35, 54); padding: 0.3rem 1.5rem; margin: 0; border-bottom: 1px solid rgba(10, 132, 255, 0.2);">
      <div style="display: flex; align-items: center; gap: 16px;">
        <div style="font-size: 18px; font-weight: 700; color: white;">üî•APEX Intelligence Terminal</div>
      </div>
    </div>

    <!-- Stock Info Header -->
    <div id="stock-info-header" style="margin: 0; padding: 0;">
      <!-- COMPANY INFO HEADER -->
      <div style="display: flex; align-items: center; justify-content: space-between; gap: 0.75rem; background: rgb(26, 35, 54); box-shadow: 0 2px 8px rgba(0,0,0,0.3); border-bottom: 1px solid rgba(10, 132, 255, 0.4); padding: 0.6rem 1.5rem; margin: 0; width: 100%; position: relative; border-radius: 8px 8px 0 0;">
        <div style="display: flex; align-items: center; justify-content: space-between; gap: 0.6rem; width: 100%; overflow: hidden;">
          <!-- Ticker & Company Name (Left) -->
          <div style="flex: 1 1 auto; min-width: 100px; max-width: 180px;">
            <div id="header-ticker" style="color: white; font-size: 0.95rem; font-weight: 800; letter-spacing: 0.5px;">--</div>
            <div id="header-company" style="color: rgba(255,255,255,0.6); font-size: 0.65rem; line-height: 1; margin-top: 1px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">--</div>
          </div>
          
          <!-- Key Metrics (Center) - 3 columns -->
          <div style="display: flex; gap: 0.5rem; align-items: center; flex: 2 1 auto; overflow: hidden;">
            <!-- Current Price (with currency) -->
            <div style="text-align: center; min-width: 60px; flex-shrink: 0;">
              <div style="color: rgba(255,255,255,0.5); font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.3px; line-height: 1;">
                Price <span id="header-currency" style="color: #f59e0b; font-size: 0.5rem; font-weight: 600;">--</span>
              </div>
              <div id="header-price" style="color: white; font-size: 0.85rem; font-weight: 800; line-height: 1.1; margin-top: 1px;">--</div>
            </div>
            
            <!-- Market Cap -->
            <div style="text-align: center; min-width: 55px; flex-shrink: 0;">
              <div style="color: rgba(255,255,255,0.5); font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.3px; line-height: 1;">Cap</div>
              <div id="header-mcap" style="color: #10b981; font-size: 0.85rem; font-weight: 800; line-height: 1.1; margin-top: 1px;">--</div>
            </div>
            
            <!-- Exchange (combined Market + Exchange) -->
            <div style="text-align: center; min-width: 60px; flex-shrink: 0;">
              <div style="color: rgba(255,255,255,0.5); font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.3px; line-height: 1;">Exchange</div>
              <div id="header-exchange" style="font-size: 0.75rem; font-weight: 700; line-height: 1.1; margin-top: 1px;">--</div>
            </div>
          </div>
        </div>
      </div>
      
      <!-- Details Row -->
      <div style="display: flex; gap: 1.5rem; font-size: 0.65rem; background: rgb(26, 35, 54); box-shadow: 0 2px 6px rgba(0,0,0,0.2); border-bottom: 1px solid rgba(10, 132, 255, 0.2); padding: 0.35rem 1.5rem 0.4rem 1.5rem; margin: 0; text-align: left; border-radius: 0 0 8px 8px;">
        <div style="display: flex; align-items: center; gap: 0.4rem; min-width: 100px;">
          <span style="color: #667eea; font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.4px; font-weight: 500; flex-shrink: 0;">Sector:</span>
          <span id="header-sector" style="color: white; font-weight: 700; font-size: 0.7rem; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">--</span>
        </div>
        <div style="display: flex; align-items: center; gap: 0.4rem; flex: 1; overflow: hidden;">
          <span style="color: #667eea; font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.4px; font-weight: 500; flex-shrink: 0;">Ind:</span>
          <span id="header-industry" style="color: white; font-weight: 700; font-size: 0.7rem; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">--</span>
        </div>
      </div>
    </div>

    <!-- Bloomberg Scorecard Ticker -->
    <div style="background: rgb(26, 35, 54); border-left: 3px solid #0a84ff; padding: 0.5rem 0; margin: 0; font-family: 'Courier New', monospace; font-size: 13px; letter-spacing: 0.5px; box-shadow: 0 2px 4px rgba(0,0,0,0.2); overflow: hidden; width: 100%;">
      <div id="scorecard-ticker" style="display: flex; white-space: nowrap; animation: ticker 20s linear infinite; width: max-content;">
        <div class="ticker-content" style="display: flex; align-items: center; gap: 1.5rem; padding: 0 1.5rem; flex-shrink: 0;">
          <span style="color: rgba(255,255,255,0.6); font-size: 11px; text-transform: uppercase; font-weight: 600;">SCORECARD</span>
          <span id="scorecard-apex" style="background: #10b981; color: white; padding: 6px 12px; border-radius: 6px; font-weight: 700; font-size: 13px;">APEX SCORE:--</span>
          <span id="scorecard-setup" style="color: #3B82F6; font-weight: 700;">SETUP:--</span>
          <span id="scorecard-trust" style="color: #8B5CF6; font-weight: 700;">TRUST:--</span>
          <span id="scorecard-panic" style="color: #EF4444; font-weight: 700;">PANIC:--</span>
          <span id="scorecard-comp" style="color: #F59E0B; font-weight: 700;">COMPRESSION:--</span>
          <span style="color: rgba(255,255,255,0.3); font-weight: 400;">‚îÇ</span>
          <span id="scorecard-timing" style="color: #3b82f6; font-weight: 700;">TIMING:--</span>
          <span style="color: rgba(255,255,255,0.3); font-weight: 400;">‚îÇ</span>
          <span id="scorecard-action" style="color: #ef4444; font-weight: 700;">ACTION:--</span>
        </div>
      </div>
    </div>
  </div>

  <div class="container">
    <!-- Narrative Section Header -->
    <div style="display: flex; align-items: center; gap: 12px; margin: 20px 0 12px 0;">
      <svg width="20" height="20" viewBox="0 0 20 20" fill="none" style="flex-shrink: 0;">
        <rect x="2" y="4" width="16" height="12" stroke="#10B981" stroke-width="1.5" fill="none" rx="2"/>
        <line x1="5" y1="4" x2="5" y2="2" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
        <line x1="15" y1="4" x2="15" y2="2" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
        <line x1="2" y1="7" x2="18" y2="7" stroke="#10B981" stroke-width="1.5"/>
        <circle cx="8" cy="11" r="1.2" fill="#10B981"/>
        <circle cx="12" cy="11" r="1.2" fill="#10B981"/>
        <circle cx="16" cy="11" r="1.2" fill="#10B981"/>
      </svg>
      <span style="color: #10B981; font-weight: 700; font-size: 13px; text-transform: uppercase; letter-spacing: 0.8px;">Company in 30 Seconds</span>
    </div>

    <!-- Narrative Card Stack -->
    <div class="card-stack" id="narrative-stack" style="position: relative; min-height: 180px; overflow: visible; touch-action: pan-y; user-select: none; margin-bottom: 30px;">
      <!-- Card 1: What They Do -->
      <div class="card component-card stack-card narrative-card" data-index="0" style="transition: 0.3s cubic-bezier(0.4, 0, 0.2, 1); transform: translateX(0%) scale(1); opacity: 1; pointer-events: auto; z-index: 10;">
        <div class="panel-header" style="padding:12px;border-bottom:1px solid rgba(16,185,129,0.1);display:flex;align-items:center;gap:10px">
          <svg width="18" height="18" viewBox="0 0 16 16" fill="none" style="flex-shrink:0">
            <rect x="3" y="3" width="10" height="10" stroke="#10B981" stroke-width="1.5" fill="none" rx="1"/>
            <path d="M6 3 L6 1 M10 3 L10 1 M3 6 L13 6" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
            <circle cx="8" cy="9" r="1.5" fill="#10B981"/>
          </svg>
          <div class="card-title" style="font-size:16px;font-weight:800;color:#10B981">What They Do <span class="info-icon" data-field="what" data-tooltip="Company business model and core operations" style="cursor:pointer;opacity:0.6;font-size:14px;transition:all 0.2s ease" onmouseenter="this.style.opacity='1'" onmouseleave="this.style.opacity='0.6'" onclick="showTooltipPopover(event, 'Company business model and core operations')">‚ìò</span></div>
        </div>
        <div style="padding:12px">
          <span id="company-what" style="color: #e5e7eb; line-height: 1.6; font-size: 12px;">--</span>
        </div>
      </div>

      <!-- Card 2: Why It Matters -->
      <div class="card component-card stack-card narrative-card" data-index="1" style="transition: 0.3s cubic-bezier(0.4, 0, 0.2, 1); transform: translateX(100%) scale(0.95); opacity: 0; pointer-events: none; z-index: 5;">
        <div class="panel-header" style="padding:12px;border-bottom:1px solid rgba(16,185,129,0.1);display:flex;align-items:center;gap:10px">
          <svg width="18" height="18" viewBox="0 0 16 16" fill="none" style="flex-shrink:0">
            <circle cx="8" cy="8" r="6" stroke="#10B981" stroke-width="1.5" fill="none"/>
            <circle cx="8" cy="8" r="2" fill="#10B981"/>
            <path d="M8 2 L8 6 M8 10 L8 14 M2 8 L6 8 M10 8 L14 8" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
          </svg>
          <div class="card-title" style="font-size:16px;font-weight:800;color:#10B981">Why It Matters <span class="info-icon" data-field="why" data-tooltip="Market significance and investment thesis" style="cursor:pointer;opacity:0.6;font-size:14px;transition:all 0.2s ease" onmouseenter="this.style.opacity='1'" onmouseleave="this.style.opacity='0.6'" onclick="showTooltipPopover(event, 'Market significance and investment thesis')">‚ìò</span></div>
        </div>
        <div style="padding:12px">
          <span id="company-why" style="color: #e5e7eb; line-height: 1.6; font-size: 12px;">--</span>
        </div>
      </div>

      <!-- Card 3: Current State -->
      <div class="card component-card stack-card narrative-card" data-index="2" style="transition: 0.3s cubic-bezier(0.4, 0, 0.2, 1); transform: translateX(100%) scale(0.95); opacity: 0; pointer-events: none; z-index: 5;">
        <div class="panel-header" style="padding:12px;border-bottom:1px solid rgba(16,185,129,0.1);display:flex;align-items:center;gap:10px">
          <svg width="18" height="18" viewBox="0 0 16 16" fill="none" style="flex-shrink:0">
            <path d="M2 12 L5 9 L8 11 L14 4" stroke="#10B981" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round" fill="none"/>
            <circle cx="5" cy="9" r="1.5" fill="#10B981"/>
            <circle cx="8" cy="11" r="1.5" fill="#10B981"/>
            <circle cx="14" cy="4" r="1.5" fill="#10B981"/>
          </svg>
          <div class="card-title" style="font-size:16px;font-weight:800;color:#10B981">Current State <span class="info-icon" data-field="state" data-tooltip="Latest company situation and metrics" style="cursor:pointer;opacity:0.6;font-size:14px;transition:all 0.2s ease" onmouseenter="this.style.opacity='1'" onmouseleave="this.style.opacity='0.6'" onclick="showTooltipPopover(event, 'Latest company situation and metrics')">‚ìò</span></div>
        </div>
        <div style="padding:12px">
          <span id="company-state" style="color: #e5e7eb; line-height: 1.6; font-size: 12px;">--</span>
        </div>
      </div>

      <!-- Narrative Stack Navigation -->
      <div class="stack-nav" style="bottom: -35px;">
        <div class="stack-dots">
          <span class="stack-dot narrative-dot" data-index="0"></span>
          <span class="stack-dot narrative-dot" data-index="1"></span>
          <span class="stack-dot narrative-dot" data-index="2"></span>
        </div>
        <div class="stack-label" style="color: #10B981;">Company</div>
      </div>
    </div>

    <!-- Scorecard Breakdown Section Header -->
    <div style="display: flex; align-items: center; gap: 12px; margin: 20px 0 12px 0;">
      <svg width="20" height="20" viewBox="0 0 20 20" fill="none" style="flex-shrink: 0;">
        <rect x="2" y="6" width="3" height="12" rx="1" stroke="#fff" stroke-width="1.5" fill="none"/>
        <rect x="7" y="3" width="3" height="15" rx="1" stroke="#fff" stroke-width="1.5" fill="none"/>
        <rect x="12" y="8" width="3" height="10" rx="1" stroke="#fff" stroke-width="1.5" fill="none"/>
        <rect x="17" y="5" width="1" height="13" rx="0.5" stroke="#fff" stroke-width="1.5" fill="none"/>
        <circle cx="10" cy="1" r="1.5" fill="#fff"/>
      </svg>
      <span style="color: #fff; font-weight: 700; font-size: 13px; text-transform: uppercase; letter-spacing: 0.8px;">Scorecard Breakdown</span>
    </div>

    <!-- Main swipeable cards -->
    <div id="component-grid"></div>

    <!-- Bloomberg Phase 2: Collapsible Sections -->
    <div class="bloomberg-sections" style="margin-top: 20px;">
      <!-- CrashDash Intelligence -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('crashdash')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(59, 130, 246, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="crashdash-arrow" style="color: #3b82f6; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #3b82f6; text-transform: uppercase; letter-spacing: 0.5px;">CrashDash Intelligence</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">INDUSTRY PATTERNS ¬∑ RECOVERY PATHS</span>
        </div>
        <div id="crashdash-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="crashdash-data">Loading...</div>
        </div>
      </div>

      <!-- Catalyst Pipeline -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('catalyst')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(16, 185, 129, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="catalyst-arrow" style="color: #10b981; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #10b981; text-transform: uppercase; letter-spacing: 0.5px;">Catalyst Pipeline</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">UPCOMING EVENTS ¬∑ TIMELINE</span>
        </div>
        <div id="catalyst-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="catalyst-data">Loading...</div>
        </div>
      </div>

      <!-- Market Tape -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('market')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(245, 158, 11, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="market-arrow" style="color: #f59e0b; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #f59e0b; text-transform: uppercase; letter-spacing: 0.5px;">Market Tape</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">SOCIAL SENTIMENT ¬∑ TRENDS</span>
        </div>
        <div id="market-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="market-data">Loading...</div>
        </div>
      </div>

      <!-- Investment Decision -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('decision')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(239, 68, 68, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="decision-arrow" style="color: #ef4444; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #ef4444; text-transform: uppercase; letter-spacing: 0.5px;">Investment Decision</span>
          </div>
          <span id="decision-status" style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">ANALYSIS ¬∑ ACTION</span>
        </div>
        <div id="decision-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="decision-data">Loading...</div>
        </div>
      </div>

      <!-- Top 5 Recent RNS -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('rns')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(6, 182, 212, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="rns-arrow" style="color: #06b6d4; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #06b6d4; text-transform: uppercase; letter-spacing: 0.5px;">Top 5 Recent RNS</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">REGULATORY NEWS ¬∑ ANNOUNCEMENTS</span>
        </div>
        <div id="rns-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="rns-data">Loading...</div>
        </div>
      </div>
    </div>

    <!-- Bloomberg Terminal Footer (Collapsible) -->
    <div id="footer-container" style="margin-top: 40px; background: linear-gradient(180deg, #0a1628 0%, #020617 100%); border: 1px solid #1e293b; border-radius: 12px; overflow: hidden; box-shadow: 0 20px 50px rgba(0,0,0,0.5);">
        <!-- Header Bar (Always Visible) -->
        <div style="background: rgba(59, 130, 246, 0.08); border-bottom: 1px solid rgba(59, 130, 246, 0.2); padding: 12px 16px; cursor: pointer;" onclick="toggleFooter()">
            <div style="display: flex; align-items: center; justify-content: space-between; gap: 8px; width: 100%;">
                <div style="display: flex; align-items: center; gap: 8px; flex: 1; min-width: 0; overflow: hidden;">
                    <div style="width: 8px; height: 8px; background: #3b82f6; border-radius: 50%; box-shadow: 0 0 12px rgba(59, 130, 246, 0.6); flex-shrink: 0;"></div>
                    <span style="font-family: 'Courier New', monospace; font-size: 12px; font-weight: 700; color: #3b82f6; text-transform: uppercase; letter-spacing: 0.5px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">APEX Intelligence Terminal</span>
                    <span id="footer-toggle-icon" style="font-size: 14px; color: #3b82f6; transition: transform 0.3s ease; flex-shrink: 0; margin-left: auto;">‚ñº</span>
                </div>
            </div>
            <div style="font-family: 'Courier New', monospace; font-size: 9px; color: rgba(255, 255, 255, 0.4); letter-spacing: 0.3px; margin-top: 6px; overflow: hidden;">
                GENERATED: <span style="color: #06b6d4;" id="footerDate"></span> ‚Ä¢ SESSION: <span style="color: #10b981;">LIVE</span>
            </div>
        </div>
        
        <!-- Collapsible Content Section -->
        <div id="footer-content" style="display: none;">
            <!-- Content Grid -->
            <div style="padding: 24px; display: grid; grid-template-columns: 1fr 1fr; gap: 24px;">
                <!-- Left Column -->
                <div style="display: flex; flex-direction: column; gap: 20px;">
                    <!-- System Information -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #3b82f6; margin-bottom: 8px; text-transform: uppercase; letter-spacing: 1px;">System Information</div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; color: rgba(255, 255, 255, 0.7); display: flex; gap: 16px; flex-wrap: wrap; align-items: center;">
                            <span><span style="color: rgba(255, 255, 255, 0.4);">VERSION:</span> <span style="color: #06b6d4; font-weight: 700;">APEX v5.0</span></span>
                            <span style="color: rgba(255, 255, 255, 0.2);">‚Ä¢</span>
                            <span><span style="color: rgba(255, 255, 255, 0.4);">ENGINE:</span> <span style="color: #10b981;">CrashDash Intelligence</span></span>
                            <span style="color: rgba(255, 255, 255, 0.2);">‚Ä¢</span>
                            <span><span style="color: rgba(255, 255, 255, 0.4);">COVERAGE:</span> <span style="color: #a855f7;">LSE AIM Micro-Caps</span></span>
                            <span style="color: rgba(255, 255, 255, 0.2);">‚Ä¢</span>
                            <span><span style="color: rgba(255, 255, 255, 0.4);">SOURCES:</span> <span style="color: #ef4444;">RNS ‚Ä¢ Social ‚Ä¢ Trends</span></span>
                        </div>
                    </div>
                    
                    <!-- Risk Disclosure -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #ef4444; margin-bottom: 12px; text-transform: uppercase; letter-spacing: 1px;">Risk Disclosure</div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; color: rgba(255, 255, 255, 0.5); line-height: 1.6;">
                            This analysis is provided for informational purposes only and does not constitute financial advice. AIM micro-cap securities carry significant volatility and liquidity risks. Past performance does not guarantee future results. Always conduct your own due diligence and consult with a qualified financial advisor before making investment decisions.
                        </div>
                    </div>
                </div>
                
                <!-- Right Column -->
                <div style="display: flex; flex-direction: column; gap: 20px;">
                    <!-- Platform Overview -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #10b981; margin-bottom: 12px; text-transform: uppercase; letter-spacing: 1px;">Platform Overview</div>
                        <div style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.7); line-height: 1.6;">
                            APEX Intelligence Terminal combines technical analysis, sentiment tracking, and regulatory news monitoring to identify high-probability contrarian setups in distressed micro-cap equities. Our proprietary scoring system evaluates setup quality, panic intensity, and compression patterns to surface opportunities before institutional recognition.
                        </div>
                    </div>
                    
                    <!-- Target Users -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #a855f7; margin-bottom: 12px; text-transform: uppercase; letter-spacing: 1px;">Target Users</div>
                        <div style="display: flex; flex-wrap: wrap; gap: 8px;">
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(168, 85, 247, 0.1); border: 1px solid rgba(168, 85, 247, 0.3); border-radius: 4px; color: #a855f7; font-weight: 600;">PROP TRADERS</span>
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(59, 130, 246, 0.1); border: 1px solid rgba(59, 130, 246, 0.3); border-radius: 4px; color: #3b82f6; font-weight: 600;">HEDGE FUNDS</span>
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(16, 185, 129, 0.1); border: 1px solid rgba(16, 185, 129, 0.3); border-radius: 4px; color: #10b981; font-weight: 600;">QUANT TEAMS</span>
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(239, 68, 68, 0.1); border: 1px solid rgba(239, 68, 68, 0.3); border-radius: 4px; color: #ef4444; font-weight: 600;">RESEARCH DESKS</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Bottom Bar -->
            <div style="background: rgba(2, 6, 23, 0.6); border-top: 1px solid rgba(59, 130, 246, 0.15); padding: 12px 24px;">
                <div style="display: flex; align-items: center; justify-content: space-between; flex-wrap: wrap; gap: 12px; font-family: 'Courier New', monospace; font-size: 10px;">
                    <div style="color: rgba(255, 255, 255, 0.4);">¬© 2026 APEX Intelligence ‚Ä¢ All Rights Reserved</div>
                    <div style="display: flex; align-items: center; gap: 20px; color: rgba(255, 255, 255, 0.5);">
                        <span>STATUS: <span style="color: #10b981; font-weight: 700;">‚óè OPERATIONAL</span></span>
                        <span>LATENCY: <span style="color: #06b6d4; font-weight: 700;">12ms</span></span>
                        <span>BUILD: <span style="color: #a855f7; font-weight: 700;">5.0.2</span></span>
                    </div>
                </div>
            </div>
        </div>
    </div>
    
    <script>
        function toggleFooter() {
            const content = document.getElementById('footer-content');
            const icon = document.getElementById('footer-toggle-icon');
            
            if (content.style.display === 'none') {
                content.style.display = 'block';
                icon.style.transform = 'rotate(180deg)';
            } else {
                content.style.display = 'none';
                icon.style.transform = 'rotate(0deg)';
            }
        }

        // Mobile-friendly tooltip popover
        function showTooltipPopover(event, tooltipText) {
            event.stopPropagation();
            
            // Close any existing popover
            const existing = document.getElementById('tooltip-popover');
            if (existing) existing.remove();
            
            // Create popover
            const popover = document.createElement('div');
            popover.id = 'tooltip-popover';
            popover.style.cssText = 'position:fixed;background:rgba(20,25,40,0.98);color:#e5e7eb;padding:10px 14px;border-radius:6px;font-size:12px;line-height:1.4;max-width:250px;border:1px solid rgba(16,185,129,0.3);z-index:10000;box-shadow:0 4px 12px rgba(0,0,0,0.4);backdrop-filter:blur(8px);word-wrap:break-word';
            popover.textContent = tooltipText;
            document.body.appendChild(popover);
            
            // Position near clicked element
            const rect = event.target.getBoundingClientRect();
            popover.style.left = Math.min(rect.left, window.innerWidth - 270) + 'px';
            popover.style.top = (rect.bottom + 8) + 'px';
            
            // Close on outside click
            setTimeout(() => {
                document.addEventListener('click', closeTooltip, { once: true });
            }, 0);
        }

        function closeTooltip() {
            const popover = document.getElementById('tooltip-popover');
            if (popover) popover.remove();
        }
    </script>
  </div>
  
  <!-- Mobile Responsive Styles -->
  <style>
    @media(max-width:768px){
        body{padding:10px!important}
        .container{max-width:100%!important}
        #footer-container{margin-top:20px!important}
        div[style*="grid-template-columns: 1fr 1fr"]{grid-template-columns:1fr!important;gap:12px!important}
        div[style*="grid-template-columns: repeat(4"]{grid-template-columns:repeat(2,1fr)!important;gap:10px!important}
        div[style*="padding: 24px"]{padding:16px!important}
        div[style*="padding: 12px 16px"]{padding:10px 12px!important}
        div[style*="gap: 20px"]{gap:14px!important}
        div[style*="font-size: 11px"]{font-size:10px!important}
        div[style*="font-size: 12px"]{font-size:11px!important}
        div[style*="font-size: 13px"]{font-size:12px!important}
    }
    @media(max-width:480px){
        body{padding:6px!important}
        .container{padding:0!important;margin:0!important}
        #footer-container{margin-top:16px!important;margin-left:6px!important;margin-right:6px!important}
        #footer-container > div:first-child{padding:8px 10px!important}
        div[style*="grid-template-columns: 1fr 1fr"]{grid-template-columns:1fr!important;gap:8px!important}
        div[style*="grid-template-columns: repeat(4"]{grid-template-columns:1fr!important;gap:6px!important;padding:8px 10px!important}
        div[style*="grid-template-columns: repeat(2"]{grid-template-columns:1fr!important;gap:6px!important}
        div[style*="padding: 24px"]{padding:10px!important}
        div[style*="padding: 12px 16px"]{padding:8px 10px!important}
        div[style*="padding: 14px 16px"]{padding:8px 10px!important}
        div[style*="padding: 18px"]{padding:10px!important}
        div[style*="gap: 20px"]{gap:8px!important}
        div[style*="gap: 30px"]{gap:10px!important}
        div[style*="gap: 24px"]{gap:10px!important}
        div[style*="gap: 16px"]{gap:6px!important}
        div[style*="gap: 12px"]{gap:6px!important}
        div[style*="gap: 8px"]{gap:4px!important}
        div[style*="font-size: 9px"]{font-size:8px!important}
        div[style*="font-size: 10px"]{font-size:8px!important}
        div[style*="font-size: 11px"]{font-size:9px!important}
        div[style*="font-size: 12px"]{font-size:10px!important}
        div[style*="font-size: 13px"]{font-size:11px!important}
        div[style*="padding: 6px 12px"]{padding:4px 6px!important;font-size:7px!important}
        div[style*="line-height: 1.8"]{line-height:1.4!important}
        div[style*="line-height: 1.6"]{line-height:1.3!important}
        div[style*="line-height: 1.5"]{line-height:1.2!important}
        /* Footer system info on mobile - stack vertically and shrink */
        div[style*="display: flex; gap: 16px; flex-wrap: wrap; align-items: center"] {
          flex-direction: column!important;
          align-items: flex-start!important;
          gap: 4px!important;
          font-size: 7px!important;
        }
    }
  </style>
  
  <script>window.__APEX_PROFILE = {
  "analysis_mode": "HISTORICAL_ONLY",
  "symbol": "GENF.L",
  "generated_at": "2026-02-11T23:07:13.440170Z",
  "top_card": {
    "ticker": "GENF.L",
    "company_name": "Genflow Biosciences plc",
    "sector": "Healthcare",
    "market_cap_gbp": 9377410,
    "days_active": 1048,
    "apex_score_100": 65,
    "confidence_score_100": 50,
    "ai_final_score_25": 11,
    "ai_strength": "MODERATE",
    "timing_regime": "EARLY_BUILD",
    "action": "WATCH",
    "thesis_one_liner": "WATCH - EARLY_BUILD timing with 65/100 opportunity score"
  },
  "enrichment": {
    "company_info": {
      "name": "Genflow Biosciences plc",
      "sector": "Healthcare",
      "industry": "Biotechnology",
      "exchange": "LSE",
      "market": "MAIN",
      "currency": "GBP",
      "risk_tier": "Low Risk",
      "current_market_cap": 9377410,
      "current_close_price": 1.9
    },
    "basics": {
      "ticker": "GENF.L",
      "current_price": 1.9,
      "ath": 13.5,
      "atl": 0.55,
      "ath_date": "2022-02-02",
      "atl_date": "2025-07-17",
      "week_52_high": 2.7,
      "week_52_low": 0.55,
      "week_52_high_date": "2025-10-10",
      "week_52_low_date": "2025-07-17",
      "drawdown_from_ath_pct": 85.93,
      "data_start": "2022-01-17",
      "data_end": "2026-02-11",
      "total_bars": 1028
    },
    "latest_signal": {
      "date": "2023-03-31",
      "scan_date": "2026-01-26",
      "signal_type": "CRASH ZONE BOTTOM",
      "signal_color": "YELLOW",
      "price": 1.65,
      "drawdown_pct": 83.5,
      "ai_score": 9.0,
      "rsi": 20.0,
      "cycle_position": 0.2093,
      "holding_period_days": 1048,
      "current_pnl_pct": 15.15,
      "rally_state": "pulling_back",
      "distance_from_high_pct": -65.65,
      "Rally_Count": 7,
      "days_since_last_high": 12,
      "last_high_date": "2026-01-14",
      "lock_in_reached": true,
      "lock_in_date": "2023-04-19",
      "best_rally_pct": 227.27
    },
    "best_historical_signal": {
      "signal_date": "2023-03-28",
      "signal_type": "CRASH ZONE BOTTOM",
      "signal_color": "YELLOW",
      "entry_price": 1.575,
      "peak_price": 5.7,
      "peak_date": "2023-04-19",
      "rally_pct": 261.9,
      "days_to_peak": 22,
      "ai_score": 11.0
    },
    "all_historical_signals": [
      {
        "signal_id": "GENF.L_2023-03-23",
        "signal_date": "2023-03-23",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.65,
        "current_price": 1.855,
        "current_return_pct": 12.42,
        "best_rally_pct": 227.27,
        "best_rally_date": "2023-04-19",
        "rally_state": "pulling_back",
        "Rally_Count": 7,
        "distance_from_high_pct": -65.65,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1040,
        "status": "historical"
      },
      {
        "signal_id": "GENF.L_2023-03-24",
        "signal_date": "2023-03-24",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.675,
        "current_price": 1.855,
        "current_return_pct": 10.75,
        "best_rally_pct": 222.39,
        "best_rally_date": "2023-04-19",
        "rally_state": "pulling_back",
        "Rally_Count": 7,
        "distance_from_high_pct": -65.65,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1039,
        "status": "historical"
      },
      {
        "signal_id": "GENF.L_2023-03-27",
        "signal_date": "2023-03-27",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.625,
        "current_price": 1.855,
        "current_return_pct": 14.15,
        "best_rally_pct": 232.31,
        "best_rally_date": "2023-04-19",
        "rally_state": "pulling_back",
        "Rally_Count": 8,
        "distance_from_high_pct": -65.65,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1036,
        "status": "historical"
      },
      {
        "signal_id": "GENF.L_2023-03-28",
        "signal_date": "2023-03-28",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.575,
        "current_price": 1.855,
        "current_return_pct": 17.78,
        "best_rally_pct": 242.86,
        "best_rally_date": "2023-04-19",
        "rally_state": "pulling_back",
        "Rally_Count": 9,
        "distance_from_high_pct": -65.65,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1035,
        "status": "historical"
      },
      {
        "signal_id": "GENF.L_2023-03-31",
        "signal_date": "2023-03-31",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.65,
        "current_price": 1.855,
        "current_return_pct": 12.42,
        "best_rally_pct": 227.27,
        "best_rally_date": "2023-04-19",
        "rally_state": "pulling_back",
        "Rally_Count": 7,
        "distance_from_high_pct": -65.65,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1032,
        "status": "historical"
      }
    ],
    "stats": {
      "total_signals": 5,
      "win_rate_pct": 100.0,
      "avg_rally_pct": 248.78,
      "median_rally_pct": 245.45,
      "best_rally_pct": 261.9,
      "worst_rally_pct": 240.3
    },
    "splits": [],
    "split_risk": {
      "split_detected": false,
      "risk_level": "NONE",
      "confidence": "HIGH"
    },
    "data_quality": {
      "price_reliability": "RELIABLE",
      "pnl_reliability": "RELIABLE",
      "overall_confidence": "HIGH"
    },
    "risk_flags": [
      "EXTREME_DRAWDOWN"
    ],
    "last_updated": "2026-02-11 20:06:42 UTC",
    "volatility": {
      "atr_normalized": 8.0,
      "stddev_20d": 0.973
    },
    "trends": {
      "intelligence_signal": "DOWNTREND"
    }
  },
  "decision_summary": {
    "why_it_matters": [
      "APEX 65/100 indicates strong opportunity quality",
      "Timing regime: EARLY_BUILD",
      "Historical profile: 7 rallies, 227% best run"
    ],
    "main_risk": "Confidence 50/100 - full data loaded",
    "watch_next": [
      "RNS catalysts (funding/operational updates)",
      "Volume expansion confirmation",
      "Timing regime change signals"
    ]
  },
  "triangulation": {
    "rns": {
      "has_data": true,
      "ticker": "GENF.L",
      "latest": [
        {
          "title": "Notice of GM",
          "announcement_date": "11th Feb 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "Today 07:00\nRNS Number : 4938S\nGenflow Biosciences PLC\n11 February 2026\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\nGenflow Biosciences Plc\nNotice of General Meeting\nGenflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) (\"Genflow\" or the \"Company\"), a European-based biotechnology company focused on the development of gene therapies for age-related diseases, announces that the Board is considering potentially undertaking an equity raise which would be structured by issuing rights over the New Shares (in the form of shares or warrants) to new investors and/or existing shareholders in the Company for cash consideration in one or more private placements on a non-pre-emptive basis (the \"\nPotential Equity Raise\n\").\nIn order to facilitate the Potential Equity Raise and to ensure that it could be swiftly concluded if it progresses, the Board is seeking specific shareholder approval at a general meeting (the \"\nGeneral Meeting\n\") for the allotment and issue of up to 188,947,368 new ordinary shares (\"\nNew Shares\n\") (which is approximately 38% of the Company's current issued share capital) in connection with the Potential Equity Raise, on terms that the Board may determine.\nIn order for the Directors to issue New Shares free of statutory pre-emption rights, such statutory pre-emption rights must be dis-applied. Accordingly, the Board wishes to seek separate authorities to dis-apply pre-emption rights in respect of the allotment of the New Shares pursuant to the Potential Equity Raise.\nThe General Meeting will be held at\nOne Heddon Street, London, W1B 4BD\nat 11am on 2 March 2026.\nAt this time, there is no certainty that the Potential Equity Raise will proceed and at this point no investors have entered into any agreements to subscribe for New Shares and the amounts and price of any Potential Equity Raise have not been agreed. To the extent that any money is raised from the Potential Equity Raise, it would be applied towards:\n\u00b7\nMoving the MASH program to IND-enabling stage;\n\u00b7\nAnimal health: final payment\u00a0to the contract research organization for\u00a0the randomized clinical trial in aged beagle dogs and licensing effort;\n\u00b7\nGlaucoma Proof of Concept studies and Business development effort; and\n\u00b7\nFinal phase of EU patent approval and continued processing of US patent applications\nIf the authorities sought at the General Meeting in connection with the Potential Equity Raise are approved, the Directors shall have discretion to determine the terms of the Potential Equity Raise, including the number of New Shares and warrants to be issued (subject to the limits of the authorities) and the price at which the New Shares will be issued, as well as the identity of who the New Shares will be issued to. Further details of the Potential Equity Raise (if it proceeds) will be announced in due course.\nAvailability of documents\nThe circular convening the General Meeting has been published today and is available on the Company's website at\nwww.genflowbio.com\n. A copy will also be available for inspection at the registered office of the Company during normal business hours.\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies for age-related diseases, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH\n(Metabolic Dysfunction-Associated Steatohepatitis)\n, the most prevalent chronic liver disease for which there is no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on\nLinkedIn\nand\nX\n.\nDISCLAIMER\nThe contents of this announcement have been prepared by, and are the sole responsibility of, the Company.\nThis announcement may contain forward-looking statements.\u00a0The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words \"anticipate\", \"believe\", \"continue\", \"could\", \"estimate\", \"expect\", \"intend\", \"may\", \"might\", \"plan\", \"possible\", \"potential\", \"predict\", \"project\", \"seek\", \"should\", \"would\" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.\nForward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.\nAny forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNOGURSWRNNUUAAR",
          "rns_number": "RNS Number : 4938S"
        },
        {
          "title": "Holding(s) in Company",
          "announcement_date": "30th Jan 2026",
          "release_time": "12:29 pm",
          "source": "RNS",
          "content": "30 Jan 2026 12:29\nRNS Number : 1390R\nGenflow Biosciences PLC\n30 January 2026\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BP2C3V08\nIssuer Name\nGENFLOW BIOSCIENCES PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nJonathan Mark Swann\nCity of registered office (if applicable)\nrickmansworth\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n23-Jan-2026\n6. Date on which Issuer notified\n25-Jan-2026\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n12.130000\n0.000000\n12.130000\n59861278\nPosition of previous notification (if applicable)\n11.320000\n0.000000\n11.320000\n55861278\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BP2C3V08\n59861278\n0\n12.130000\n0.000000\nSub Total 8.A\n59861278\n12.130000%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\nNone\n12. Date of Completion\n24-Jan-2026\n13. Place Of Completion\nLondon\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLBMMTTMTTJBFF",
          "rns_number": "RNS Number : 1390R"
        },
        {
          "title": "Administrative Approval of Grant & 2026 Priorities",
          "announcement_date": "28th Jan 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "28 Jan 2026 07:00\nRNS Number : 5966Q\nGenflow Biosciences PLC\n28 January 2026\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\nGenflow Biosciences Plc\nAdministrative Approval of \u20ac4 Million Funding Support from Wallonia Region for GF-100; and 2026 Development Priorities\nGenflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) (\"Genflow\" or the \"Company\"), a European-based biotechnology company focused on the development of gene therapies for age-related diseases, announces the administrative approval of the previously announced award of approximately \u20ac4 million in non-dilutive financial support from the Wallonia Region of Belgium, following the assenting signature of Minister Adrien Dolimont.\nThe funding, once received, will support the continued development of the Company's lead gene therapy candidate, GF-1002, for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (\"MASH\"). The original RNS announcing the award can be found\nhere\n.\nDisbursement of the first instalment is expected no later than May 2026. The support package spans a three-year development programme and is aligned with Genflow's existing roadmap. All project-related expenses incurred during 2025 will be eligible under the terms of the programme.\nDevelopment Priorities for 2026\nIn 2026 Genflow's strategy emphasises pipeline discipline and capital efficiency, prioritising programmes with the strongest data, the clearest paths to value creation, and the highest potential for partner engagement. Central to this approach is the pursuit of early-stage collaboration agreements designed to secure non-dilutive funding, provide external validation of the platform, and support continued development.\nWith multiple anticipated data readouts, an expanding partner dialogue, and a maturing intellectual property position, Genflow believes it is well positioned to enter its next phase of development while maintaining a focus on scientific rigour, operational execution, and long-term shareholder value creation.\nDog Aging (GF-1004)\nThe ongoing GF-1004 dog aging study, which commenced in March 2025, is being conducted as a blinded clinical trial designed to assess potential benefits related to sarcopenia, healthspan, and lifespan-associated biomarkers.\nAn initial efficacy readout is expected in the first quarter of 2026. Dogs enrolled in the study are being monitored over a 180-day period, with a second efficacy assessment planned at the six-month timepoint. Results from this later evaluation are expected in June-July 2026 and are intended to assess durability and longer-term effects.\nGlaucoma Programme\nThe Company's glaucoma programme will prioritise delivery optimisation and execution readiness. Genflow is advancing discussions with a leading lipid nanoparticle (LNP) partner to support delivery innovation and is progressing the selection of a full-service contract research organisation (CRO) to manage RNA-based formulation activities through preclinical execution.\nAdditional Programmes\nAcross the broader pipeline, Genflow continues to advance its sarcopenia programme in line with established development plans. In parallel, the ExoFastTrack initiative continues to generate data intended to support and accelerate multiple programmes across the portfolio.\nDr. Eric Leire, CEO of Genflow, commented: \"The administrative approval of this funding reinforces our ability to execute against our 2026 development priorities with discipline and focus. It strengthens our capacity to advance GF-1002 while maintaining a selective, data-driven approach across the broader pipeline. As we enter the coming year, our emphasis remains on programmes with clear execution paths, strong scientific rationale, and meaningful opportunities for partnership and non-dilutive value creation.\"\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies for age-related diseases, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH\n(Metabolic Dysfunction-Associated Steatohepatitis)\n, the most prevalent chronic liver disease for which there is no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on\nLinkedIn\nand\nX\n.\nDISCLAIMER\nThe contents of this announcement have been prepared by, and are the sole responsibility of, the Company.\nThis announcement may contain forward-looking statements.\u00a0The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words \"anticipate\", \"believe\", \"continue\", \"could\", \"estimate\", \"expect\", \"intend\", \"may\", \"might\", \"plan\", \"possible\", \"potential\", \"predict\", \"project\", \"seek\", \"should\", \"would\" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.\nForward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.\nAny forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCEALFXALFKEFA",
          "rns_number": "RNS Number : 5966Q"
        },
        {
          "title": "Directorate change",
          "announcement_date": "19th Jan 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "19 Jan 2026 07:00\nRNS Number : 3187P\nGenflow Biosciences PLC\n19 January 2026\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\nGenflow Biosciences Plc\nGenflow Appoints a New Chairman to Accelerate Corporate and R&D Expansion\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or the \"Company\"), a leading European-based biotechnology company focusing on gene therapies for age-related diseases, is pleased to announce a significant appointment to its Board of Directors, marking an important step in the Company's strategic evolution.\nMr. Gad Berdugo, MSc Eng., MBA, has joined the Board with immediate effect and will assume the role of Independent Non-Executive Chairman, providing leadership as Genflow focuses on advancing its gene-therapy programs. Mrs. Tamara Joseph will continue to serve as a Director, ensuring continuity and maintaining strong governance.\nMr. Berdugo brings over 30 years' of leadership experience spanning global business and corporate development, U.S. capital markets, and company building. He has a proven record of driving strategic partnerships, securing capital, and scaling both private and public development-stage biotechnology companies.\nCurrently, Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a U.S.-based strategic and financial advisory firm focusing on the global biotechnology sector. His most recent roles include:\n\u00b7\nCo-Founder & CEO, EpiVax Oncology\n\u00b7\nVice-Chairman of the Board, Evexta Bio\n\u00b7\nChief Business Officer, Editas Medicine (NASDAQ: EDIT)\n\u00b7\nChief Business Officer, Nutcracker Therapeutics\nHe began his international career at Abbott Labs and Baxter, later becoming Life Sciences Sector Leader at Lazard Asset Management.\nMr. Berdugo also brings deep technical and market expertise in RNA-based therapeutics, including lipid nanoparticle (LNP) delivery, development, and manufacturing. This background will support Genflow as it advances its scientific platform, evaluates delivery technologies, and explores next-generation therapeutic approaches. His appointment further strengthens the Company's presence in the United States and expands its capacity for global engagement.\nHe does not own any shares in the Company.\nDr. Eric Leire, Chief Executive Officer of Genflow, commented: \"We are delighted to welcome Mr. Berdugo as Independent Non-Executive Chairman. His expertise in strategy, partnerships and financing as well as his deep experience with RNA-LNP technologies will be instrumental as we accelerate our programs and expand our global reach. We are equally pleased that Mrs. Tamara Joseph will continue her service on the Board, contributing her invaluable leadership, legal and governance expertise.\"\nGad Berdugo added: \"I am excited to join Genflow as the company is progressing to the next new phase of development\n, with key data readouts expected in 2026, strengthened intellectual property, and a sharpened strategic focus on high-potential programs. I look forward to working with the talented team and board to advance these innovative gene therapies, this is an ideal moment to contribute my expertise and help drive Genflow, and deliver long-term value for shareholders and patients.\"\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH\n(Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there are no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on\nLinkedIn\nand\nX\n.\nDISCLAIMER\nThe contents of this announcement have been prepared by, and are the sole responsibility of, the Company.\nThis announcement may contain forward-looking statements.\u00a0The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words \"anticipate\", \"believe\", \"continue\", \"could\", \"estimate\", \"expect\", \"intend\", \"may\", \"might\", \"plan\", \"possible\", \"potential\", \"predict\", \"project\", \"seek\", \"should\", \"would\" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.\nForward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.\nAny forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nBOAGZGMMFVDGVZZ",
          "rns_number": "RNS Number : 3187P"
        },
        {
          "title": "Review of 2025",
          "announcement_date": "8th Jan 2026",
          "release_time": "7:00 am",
          "source": "RNS-R",
          "content": "8 Jan 2026 07:00\nRNS Number : 0766O\nGenflow Biosciences PLC\n08 January 2026\n08 January 2026\nA Review of an Exciting 2025\n2025 has been a year of focused scientific progress and continued advancement of Genflow Bioscience's mission to extend healthy lifespan through our novel longevity gene therapy platform. Across our portfolio, we have maintained momentum in both animal health where progress in our canine study may provide translational insights relevant to future human applications as well as therapeutic development for dogs.\nThese advancements have been supported by a strengthened network of leading academic collaborators and laboratories. Together, with continued backing from international institutional investors and previously awarded government grants, this ecosystem helped accelerate Genflow's scientific and clinical development throughout 2025.\nProgram Highlights\nWe've made a number of notable strides across our programs this year, including:\n\u00b7\nDog Aging (GF-1004)\nWe made significant strides in our clinical trial for aging dogs with full administration of our investigational SIRT6-based gene therapy now completed.\nNo adverse events were reported during the dosing phase of the study, with no serious, moderate, or minor side effects observed.\nThe study which began in March 2025, is being conducted as a blinded clinical trial; an initial efficacy readout is expected in Q1 2026, including blood analyses and muscle biopsies to evaluate potential benefits related to sarcopenia, healthspan, and lifespan-associated biomarkers.\nDogs enrolled in the trial will be monitored for 180 days, with a second efficacy assessment planned at the six-month timepoint and results expected in June-July 2026 to evaluate durability and longer-term effects.\n\u00b7\nMASH (GF-1002)\nOur MASH program saw good progress in 2025. While GLP-1 therapies have addressed early-stage MASH, patients with advanced fibrosis - roughly one-third of the population - still face limited treatment options. In response, we repositioned GF-1002 to target this high-need group, leveraging its antifibrotic properties and potential to prevent progression to cirrhosis and liver cancer. Additionally, we have generated new pre-clinical POC data on the prevention of HCC.\nWe are now finalizing our IND package and evaluating mRNA/LNP delivery as an alternative to AAV, an approach that could enable repeat dosing and lower manufacturing costs. Encouraging data continue to support this next phase of research and development.\n\u00b7\nGlaucoma\nIn 2025, we expanded into ophthalmology, where SIRT6-based gene therapy shows promise in glaucoma, a leading cause of irreversible blindness. Current treatments primarily manage intraocular pressure but do little to prevent optic nerve degeneration. Our preclinical data suggest SIRT6 overexpression may protect retinal ganglion cells and preserve optic nerve function, shifting the focus from symptom control to true neuroprotection.\nWe are advancing discussions with a leading LNP partner to support delivery innovation in this space and are securing a full-service CRO to manage formulation through preclinical execution. With the global glaucoma market approaching USD $12-14 billion by the early 2030s, this represents a compelling long-term opportunity for us.\n\u00b7\nAdditional Programs\nWe continued to advance our broader pipeline and are pleased with the steady advancement of the sarcopenia program, fully consistent with our development plans. In parallel, the ExoFastTrack initiative continues to move forward, generating important data that will support and accelerate several of our other development programs.\nLooking Ahead to 2026\nAs we move into 2026, we do so with confidence, discipline, and a clear strategic focus. The coming year will emphasize rationalization of our pipeline, prioritizing programs with the strongest data, clearest paths to value creation, and highest partner interest. Central to this strategy will be the pursuit of early-stage licensing and collaboration agreements designed to generate non-dilutive funding, validate our platform externally, and support continued development without undue capital strain.\nWith multiple upcoming data readouts, an expanding partner network, and a maturing intellectual property position, we believe Genflow is well positioned to enter its next phase of growth. We remain committed to scientific excellence, capital efficiency, and long-term value creation as we work to translate our longevity platform into meaningful therapies.\nThank you for your continued support and confidence in Genflow.\nDr. Eric Leire\nFounder & Chief Executive Officer\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH\n(Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on\nLinkedIn\nand\nX\n.\nDISCLAIMER\nThe contents of this announcement have been prepared by, and are the sole responsibility of, the Company.\nThis announcement may contain forward-looking statements.\u00a0The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words \"anticipate\", \"believe\", \"continue\", \"could\", \"estimate\", \"expect\", \"intend\", \"may\", \"might\", \"plan\", \"possible\", \"potential\", \"predict\", \"project\", \"seek\", \"should\", \"would\" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.\nForward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.\nAny forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRASSFEEWEMSEEF",
          "rns_number": "RNS Number : 0766O"
        }
      ],
      "themes": [
        "drilling",
        "regulatory"
      ]
    },
    "social": {
      "has_data": true,
      "buzz_level": "HIGH",
      "post_count": 1081,
      "sentiment_breakdown": {
        "positive": 0.0,
        "neutral": 100.0,
        "negative": 0.0
      }
    },
    "trends": {
      "has_data": true,
      "current_interest": 0,
      "momentum_score": 0,
      "trend_direction": "flat",
      "intelligence_signal": "DOWNTREND"
    },
    "volatility": {
      "atr_normalized": 8.0,
      "stddev_20d": 0.973
    },
    "risk_flags": {
      "split_risk_level": "NONE",
      "halt_risk": "NONE",
      "penny_stock_risk": "NONE"
    },
    "all_events": [
      {
        "event_id": "RNS-19th Jan 2026-director",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435082Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Directorate change",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/directorate-change-kr9yhy5l0jzxvum.html",
          "rns_number": "RNS Number : 3187P",
          "full_content": "19 Jan 2026 07:00\nRNS Number : 3187P\nGenflow Biosciences PLC\n19 January 2026\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\nGenflow Biosciences Plc\nGenflow Appoints a New Chairman to Accelerate Corporate and R&D Expansion\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or the \"Company\"), a leading European-based biotechnology company focusing on gene therapies for age-related diseases, is pleased to announce a significant appointment to its Board of Directors, marking an important step in the Company's strategic evolution.\nMr. Gad Berdugo, MSc Eng., MBA, has joined the Board with immediate effect and will assume the role of Independent Non-Executive Chairman, providing leadership as Genflow focuses on advancing its gene-therapy programs. Mrs. Tamara Joseph will continue to serve as a Director, ensuring continuity and maintaining strong governance.\nMr. Berdugo brings over 30 years' of leadership experience spanning global business and corporate development, U.S. capital markets, and company building. He has a proven record of driving strategic partnerships, securing capital, and scaling both private and public development-stage biotechnology companies.\nCurrently, Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a U.S.-based strategic and financial advisory firm focusing on the global biotechnology sector. His most recent roles include:\n\u00b7\nCo-Founder & CEO, EpiVax Oncology\n\u00b7\nVice-Chairman of the Board, Evexta Bio\n\u00b7\nChief Business Officer, Editas Medicine (NASDAQ: EDIT)\n\u00b7\nChief Business Officer, Nutcracker Therapeutics\nHe began his international career at Abbott Labs and Baxter, later becoming Life Sciences Sector Leader at Lazard Asset Management.\nMr. Berdugo also brings deep technical and market expertise in RNA-based therapeutics, including lipid nanoparticle (LNP) delivery, development, and manufacturing. This background will support Genflow as it advances its scientific platform, evaluates delivery technologies, and explores next-generation therapeutic approaches. His appointment further strengthens the Company's presence in the United States and expands its capacity for global engagement.\nHe does not own any shares in the Company.\nDr. Eric Leire, Chief Executive Officer of Genflow, commented: \"We are delighted to welcome Mr. Berdugo as Independent Non-Executive Chairman. His expertise in strategy, partnerships and financing as well as his deep experience with RNA-LNP technologies will be instrumental as we accelerate our programs and expand our global reach. We are equally pleased that Mrs. Tamara Joseph will continue her service on the Board, contributing her invaluable leadership, legal and governance expertise.\"\nGad Berdugo added: \"I am excited to join Genflow as the company is progressing to the next new phase of development\n, with key data readouts expected in 2026, strengthened intellectual property, and a sharpened strategic focus on high-potential programs. I look forward to working with the talented team and board to advance these innovative gene therapies, this is an ideal moment to contribute my expertise and help drive Genflow, and deliver long-term value for shareholders and patients.\"\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH\n(Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there are no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on\nLinkedIn\nand\nX\n.\nDISCLAIMER\nThe contents of this announcement have been prepared by, and are the sole responsibility of, the Company.\nThis announcement may contain forward-looking statements.\u00a0The forward-looking statements include, but are not limited to, statements regarding the Company's or the ",
          "content_length": 8747
        },
        "ingested_at": "2026-01-21T02:45:52.435129Z"
      },
      {
        "event_id": "RNS-8th Jan 2026-reviewof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435147Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Review of 2025",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/GENF/review-of-2025-cps7bata92kbbww.html",
          "rns_number": "RNS Number : 0766O",
          "full_content": "8 Jan 2026 07:00\nRNS Number : 0766O\nGenflow Biosciences PLC\n08 January 2026\n08 January 2026\nA Review of an Exciting 2025\n2025 has been a year of focused scientific progress and continued advancement of Genflow Bioscience's mission to extend healthy lifespan through our novel longevity gene therapy platform. Across our portfolio, we have maintained momentum in both animal health where progress in our canine study may provide translational insights relevant to future human applications as well as therapeutic development for dogs.\nThese advancements have been supported by a strengthened network of leading academic collaborators and laboratories. Together, with continued backing from international institutional investors and previously awarded government grants, this ecosystem helped accelerate Genflow's scientific and clinical development throughout 2025.\nProgram Highlights\nWe've made a number of notable strides across our programs this year, including:\n\u00b7\nDog Aging (GF-1004)\nWe made significant strides in our clinical trial for aging dogs with full administration of our investigational SIRT6-based gene therapy now completed.\nNo adverse events were reported during the dosing phase of the study, with no serious, moderate, or minor side effects observed.\nThe study which began in March 2025, is being conducted as a blinded clinical trial; an initial efficacy readout is expected in Q1 2026, including blood analyses and muscle biopsies to evaluate potential benefits related to sarcopenia, healthspan, and lifespan-associated biomarkers.\nDogs enrolled in the trial will be monitored for 180 days, with a second efficacy assessment planned at the six-month timepoint and results expected in June-July 2026 to evaluate durability and longer-term effects.\n\u00b7\nMASH (GF-1002)\nOur MASH program saw good progress in 2025. While GLP-1 therapies have addressed early-stage MASH, patients with advanced fibrosis - roughly one-third of the population - still face limited treatment options. In response, we repositioned GF-1002 to target this high-need group, leveraging its antifibrotic properties and potential to prevent progression to cirrhosis and liver cancer. Additionally, we have generated new pre-clinical POC data on the prevention of HCC.\nWe are now finalizing our IND package and evaluating mRNA/LNP delivery as an alternative to AAV, an approach that could enable repeat dosing and lower manufacturing costs. Encouraging data continue to support this next phase of research and development.\n\u00b7\nGlaucoma\nIn 2025, we expanded into ophthalmology, where SIRT6-based gene therapy shows promise in glaucoma, a leading cause of irreversible blindness. Current treatments primarily manage intraocular pressure but do little to prevent optic nerve degeneration. Our preclinical data suggest SIRT6 overexpression may protect retinal ganglion cells and preserve optic nerve function, shifting the focus from symptom control to true neuroprotection.\nWe are advancing discussions with a leading LNP partner to support delivery innovation in this space and are securing a full-service CRO to manage formulation through preclinical execution. With the global glaucoma market approaching USD $12-14 billion by the early 2030s, this represents a compelling long-term opportunity for us.\n\u00b7\nAdditional Programs\nWe continued to advance our broader pipeline and are pleased with the steady advancement of the sarcopenia program, fully consistent with our development plans. In parallel, the ExoFastTrack initiative continues to move forward, generating important data that will support and accelerate several of our other development programs.\nLooking Ahead to 2026\nAs we move into 2026, we do so with confidence, discipline, and a clear strategic focus. The coming year will emphasize rationalization of our pipeline, prioritizing programs with the strongest data, clearest paths to value creation, and highest partner interest. Central to this strategy will be the pursuit of early-stage licensing and collaboration agreements designed to generate non-dilutive funding, validate our platform externally, and support continued development without undue capital strain.\nWith multiple upcoming data readouts, an expanding partner network, and a maturing intellectual property position, we believe Genflow is well positioned to enter its next phase of growth. We remain committed to scientific excellence, capital efficiency, and long-term value creation as we work to translate our longevity platform into meaningful therapies.\nThank you for your continued support and confidence in Genflow.\nDr. Eric Leire\nFounder & Chief Executive Officer\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene ther",
          "content_length": 9771
        },
        "ingested_at": "2026-01-21T02:45:52.435164Z"
      },
      {
        "event_id": "RNS-16th Dec 2025-completi",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435179Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Completion of Dosing Phase of Canine Gene Therapy",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/completion-of-dosing-phase-of-canine-gene-therapy-4v3nc4gvcwn137t.html",
          "rns_number": "RNS Number : 7366L",
          "full_content": "16 Dec 2025 07:00\nRNS Number : 7366L\nGenflow Biosciences PLC\n16 December 2025\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\nGenflow Biosciences Plc\nGenflow Completes Dosing Phase of Canine Gene Therapy TrialNo Adverse Events Reported During Administration\nGenflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) (\"Genflow\" or the \"Company\"), a biotechnology company focused on extending healthspan through advanced gene therapies, today announced that all dogs enrolled in its ongoing clinical trial have successfully received the full administration of the Company's investigational SIRT6-based gene therapy.\nImportantly, no adverse events were reported during the dosing phase of the study. No serious, moderate, or minor side effects were observed, demonstrating a strong safety and tolerability profile for the therapy.\nThe study is being conducted as a blinded clinical trial and, as such, efficacy outcomes cannot yet be assessed. Genflow expects a first efficacy read\nin mid-to-late January 2026, which will include blood analyses and muscle biopsies to evaluate potential therapeutic benefits related to sarcopenia, overall healthspan, and lifespan-associated biomarkers.\nThe dogs enrolled in the trial will continue to be monitored for a total duration of 180 days. A second efficacy assessment is planned at the six-month timepoint, with results expected in June-July 2026, to evaluate durability and longer-term effects of the gene therapy.\nFollowing analysis of the efficacy data, Genflow intends to resume discussions with several animal health companies, including parties currently engaged under confidentiality and data access agreements, to explore potential early-stage licensing opportunities.\nDr. Eric Leire, CEO of Genflow, commented: \"These milestones represent an important step forward for our longevity program. The absence of any adverse events is highly encouraging and reinforces the strong safety profile of our approach. We look forward to sharing initial efficacy data in the coming months as the study progresses.\"\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH\n(Metabolic Dysfunction-Associated Steatohepatitis)\n, the most prevalent chronic liver disease for which there is no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on\nLinkedIn\nand\nX\n.\nDISCLAIMER\nThe contents of this announcement have been prepared by, and are the sole responsibility of, the Company.\nThis announcement may contain forward-looking statements.\u00a0The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words \"anticipate\", \"believe\", \"continue\", \"could\", \"estimate\", \"expect\", \"intend\", \"may\", \"might\", \"plan\", \"possible\", \"potential\", \"predict\", \"project\", \"seek\", \"should\", \"would\" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.\nForward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future per",
          "content_length": 7612
        },
        "ingested_at": "2026-01-21T02:45:52.435195Z"
      },
      {
        "event_id": "RNS-11th Dec 2025-genflowt",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435208Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Genflow to Attend Healthcare Conference",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/GENF/genflow-to-attend-healthcare-conference-myaxhjoigml3aea.html",
          "rns_number": "RNS Number : 0160L",
          "full_content": "11 Dec 2025 07:00\nRNS Number : 0160L\nGenflow Biosciences PLC\n11 December 2025\nGenflow Biosciences Plc\nGenflow to Attend the 44th Annual J.P. Morgan Healthcare Conference\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\"), a leading European-based biotechnology company focusing on longevity, announces that it will attend the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12-15, 2026, at the Westin St. Francis in San Francisco, California.\nJ.P. Morgan's Healthcare Conference is the sector's most influential global investment gathering, connecting industry leaders, high-growth innovators, and the investment community. Genflow's participation provides an opportunity to engage with potential partners, institutional investors, and pharmaceutical companies as the Company advances its gene-therapy pipeline targeting the\nSIRT6\nlongevity pathway.\nAbout the 44th Annual J.P. Morgan Healthcare Conference\nThe 44th Annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together global industry leaders, emerging growth companies, technology innovators, and investors. More information is available on the\nconference website\n.\nDr. Eric Leire, CEO of Genflow, commented:\n\"We're excited to attend the JP Morgan Healthcare Conference in San Francisco this January. Our planned meetings reflect our current focus on lipid nanoparticle delivery for mRNA SIRT6 therapeutics, which is opening compelling opportunities for strategic partnerships in the longevity space.\"\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH\n(Metabolic Dysfunction-Associated Steatohepatitis)\n, the most prevalent chronic liver disease for which there is no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on\nLinkedIn\nand\nX\n.\nDISCLAIMER\nThe contents of this announcement have been prepared by, and are the sole responsibility of, the Company.\nThis announcement may contain forward-looking statements.\u00a0The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words \"anticipate\", \"believe\", \"continue\", \"could\", \"estimate\", \"expect\", \"intend\", \"may\", \"might\", \"plan\", \"possible\", \"potential\", \"predict\", \"project\", \"seek\", \"should\", \"would\" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.\nForward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, nationa",
          "content_length": 6727
        },
        "ingested_at": "2026-01-21T02:45:52.435223Z"
      },
      {
        "event_id": "RNS-31st Oct 2025-totalvot",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435236Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Total Voting Rights",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/total-voting-rights-3c3yfop3utirwcw.html",
          "rns_number": "RNS Number : 3925F",
          "full_content": "31 Oct 2025 07:00\nRNS Number : 3925F\nGenflow Biosciences PLC\n31 October 2025\n31 October 2025\nGenflow Biosciences Plc\nTotal Voting Rights\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, announces that the total issued share capital of the Company as at 31 October 2025 consists\u00a0of 493,547,942 Ordinary Shares none of which are held in treasury. Therefore, the total number of voting rights in the Company is 493,547,942.\nThe figure of\n493,547,942\nOrdinary Shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH\n(Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there are no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on\nLinkedIn\nand\nX\n.\n-Ends-\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nTVRPPGUPUUPAGMB",
          "content_length": 2904
        },
        "ingested_at": "2026-01-21T02:45:52.435249Z"
      },
      {
        "event_id": "RNS-24th Oct 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435262Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/holdings-in-company-ntu972ifi5az6rs.html",
          "rns_number": "RNS Number : 6536E",
          "full_content": "24 Oct 2025 07:00\nRNS Number : 6536E\nGenflow Biosciences PLC\n24 October 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BP2C3V08\nIssuer Name\nGENFLOW BIOSCIENCES PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nJonathan Mark Swann\nCity of registered office (if applicable)\nrickmansworth\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n23-Oct-2025\n6. Date on which Issuer notified\n23-Oct-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n11.320000\n0.000000\n11.320000\n55861278\nPosition of previous notification (if applicable)\n8.400000\n0.000000\n8.400000\n36588550\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BP2C3V08\n55861278\n0\n11.320000\n0.000000\nSub Total 8.A\n55861278\n11.320000%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\nNONE\n12. Date of Completion\n23-Oct-2025\n13. Place Of Completion\nLondon\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLMJBRTMTJTBAA",
          "content_length": 3857
        },
        "ingested_at": "2026-01-21T02:45:52.435275Z"
      },
      {
        "event_id": "RNS-22nd Oct 2025-secondeu",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435288Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Second European Patent Application",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/second-european-patent-application-emdnadoqbj9b5eu.html",
          "rns_number": "RNS Number : 2934E",
          "full_content": "22 Oct 2025 07:00\nRNS Number : 2934E\nGenflow Biosciences PLC\n22 October 2025\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n22 October 2025\nGenflow Biosciences Plc\nPublication of Second European Patent Application - SIRT6 Variant for NASH\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or the \"Company\"), the only publicly listed longevity company in Europe, is pleased to announce that its second European patent application (Application No. 23821586.7, Publication No. EP4630038) titled\n\"SIRT6 Variant for NASH\"\nhas been published in the\nEuropean Patent Bulletin (\"EPO\")\n.\nPublication of the patent application in the European Patent Bulletin follows entry into the European phase under the Patent Cooperation Treaty (PCT) and represents a key milestone in\nGenflow's expanding intellectual property (IP) portfolio.\nThis publication confers provisional protection under Article 67(3) of the European Patent Convention (EPC), enabling Genflow to claim retroactive damages in designated EPC states for infringing acts occurring after the publication date, once the patent is formally granted and national validation requirements are met.\nStrategic Significance\nThis development marks continued progress in Genflow's comprehensive patent strategy to strengthen protection for its SIRT6 gene variant technologies and expand their therapeutic reach across metabolic and age-related disorders, including NASH (non-alcoholic steatohepatitis). It also reinforces Genflow's IP leadership in the longevity and metabolic disease space, complementing the recently published EP4338267 covering the Company's core SIRT6 variant for healthy aging. Together, these filings establish a robust European patent framework supporting Genflow's therapeutic platform and upcoming clinical programs.\nDr. Eric Leire, Chief Executive Officer of Genflow Biosciences, commented: \"The publication of our second European patent marks another important validation of our science and IP strategy. With both of our key SIRT6 applications now public and provisionally enforceable in Europe, we have solidified the foundation for long-term value creation, enhanced partnership potential, and future grant protection across our portfolio.\"\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH\n(Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there are no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on\nLinkedIn\nand\nX\n.\nDISCLAIMER\nThe contents of this announcement have been prepared by, and are the sole responsibility of, the Company.\nThis announcement may contain forward-looking statements.\u00a0The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words \"anticipate\", \"believe\", \"continue\", \"could\", \"estimate\", \"expect\", \"intend\", \"may\", \"might\", \"plan\", \"possible\", \"potential\", \"predict\", \"project\", \"seek\", \"should\", \"would\" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.\nForward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature,",
          "content_length": 7782
        },
        "ingested_at": "2026-01-21T02:45:52.435302Z"
      },
      {
        "event_id": "RNS-20th Oct 2025-recognit",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435316Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Recognition of Patentability of Claims",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/recognition-of-patentability-of-claims-6089w7gtxr9eo5q.html",
          "rns_number": "RNS Number : 9236D",
          "full_content": "20 Oct 2025 07:00\nRNS Number : 9236D\nGenflow Biosciences PLC\n20 October 2025\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\nGenflow Biosciences Plc\nEuropean Patent Office 2025 Recognizes the Patentability of Claims of SIRT 6 Variant Patent\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or the \"Company\"), the only publicly listed longevity company in Europe, is pleased to announce that its European patent (No. 22808414.1, Publication No. EP4338267) was officially published in the\nEuropean Patent Office (EPO) Bulletin\non 15 October 2025.\nThe EPO has recognized the patentability of claims of Genflow's Euro-PCT application, marking a major milestone in the Company's ongoing intellectual property strategy. The European publication number EP4630038 appeared in the Bulletin, signifying that the patent application entered its final pre-grant phase under Article 67(3) EPC. However, Genflow will still need to bring the description into compliance with the claims to respond to this Official Letter; only then will the European Patent Office issue the intention to grant.\nWith publication, provisional protection took effect across participating EPO member states, allowing Genflow to enforce protection following national validation. This status confirmed the formal recognition of Genflow's application and underscored significant progress toward full patent grant and legal protection across Europe.\nStrategic Significance\nThis publication represents a major step toward securing European patent recognition for key elements of Genflow's longevity gene therapy platform. As the patent enters its final stage before formal recognition, Genflow is positioned to benefit from potential EU grant opportunities and stronger leverage in partnership discussions with pharmaceutical and biotech companies. It also underscores the continued progress in securing the intellectual property backbone of Genflow's SIRT6-based technology across Europe.\nDr. Eric Leire, Chief Executive Officer of Genflow Biosciences, commented: \"The publication by the EPO represents a major validation of our scientific innovation and long-term IP strategy. Securing formal European recognition for our patent moves us closer to full protection of our longevity gene therapy platform and strengthens our strategic position for future partnerships and funding opportunities.\"\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH\n(Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there are no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on\nLinkedIn\nand\nX\n.\nDISCLAIMER\nThe contents of this announcement have been prepared by, and are the sole responsibility of, the Company.\nThis announcement may contain forward-looking statements.\u00a0The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words \"anticipate\", \"believe\", \"continue\", \"could\", \"estimate\", \"expect\", \"intend\", \"may\", \"might\", \"plan\", \"possible\", \"potential\", \"predict\", \"project\", \"seek\", \"should\", \"would\" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.\nForward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regar",
          "content_length": 7928
        },
        "ingested_at": "2026-01-21T02:45:52.435330Z"
      },
      {
        "event_id": "RNS-10th Oct 2025-updateon",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435344Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Update on Animal Health Program",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/update-on-animal-health-program-kuoik1qamysz1ar.html",
          "rns_number": "RNS Number : 8229C",
          "full_content": "10 Oct 2025 07:00\nRNS Number : 8229C\nGenflow Biosciences PLC\n10 October 2025\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n10 October 2025\nGenflow Biosciences Plc\nUpdate on Animal Health Program\nLONDON, UK-Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (\"Genflow\" or \"the Company\"), the only publicly listed longevity company in Europe, is pleased to provide an update on its Dog Aging (GF-1004) study, a proof-of-concept clinical trial evaluating the safety and efficacy of its proprietary SIRT6-centenarian gene therapy for age-related decline in elderly dogs.\nGenflow's proprietary centenarian SIRT6 gene therapy has now been administered for the second time in its ongoing randomized, controlled trial involving 28 beagles aged 10 years and older. In March, recipients received three different modalities of SIRT6 gene therapy with no ill or adverse effects observed, while control animals remained untreated. The repeat administration has again demonstrated an excellent safety and tolerability profile, marking a key milestone in the study. The dogs are in a follow-up period expected to conclude in January 2026.\nThis successful second administration underscores the robustness of Genflow's gene therapy platform and its potential applicability beyond human health. The SIRT6 gene, sourced from human centenarians, plays a vital role in DNA repair, metabolic regulation, and resistance to age-related decline. By leveraging this unique gene variant, Genflow aims to introduce a new class of longevity-based treatments into the multi-billion-dollar global animal health market, targeting improved healthspan, vitality, and lifespan in companion and livestock animals.\nDr. Eric Leire, Chief Executive Officer of Genflow Biosciences, commented: \"We're very encouraged by the continued safety validation of our SIRT6 therapy and by the strong engagement we're seeing from established players in the animal health industry. The animal health market represents an attractive near-term commercial opportunity for Genflow, complementing our core human longevity programs while showcasing the broader potential of our gene therapy platform.\"\nWith safety confirmed in repeat administration, Genflow will continue to advance its animal health initiative toward the next stage of clinical evaluation and partnership development. The Company remains committed to creating value for shareholders through innovation, collaboration, and leadership in the emerging field of genetic longevity therapeutics.\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nCorporate Brokers\nCapital Plus Partners Ltd\nJon Critchley, +44\n207 432 0501\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH\n(Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on\nLinkedIn\nand\nX\n.\nDISCLAIMER\nThe contents of this announcement have been prepared by, and are the sole responsibility of, the Company.\nThis announcement may contain forward-looking statements.\u00a0The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words \"anticipate\", \"believe\", \"continue\", \"could\", \"estimate\", \"expect\", \"intend\", \"may\", \"might\", \"plan\", \"possible\", \"potential\", \"predict\", \"project\", \"seek\", \"should\", \"would\" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not m",
          "content_length": 8137
        },
        "ingested_at": "2026-01-21T02:45:52.435358Z"
      },
      {
        "event_id": "RNS-9th Oct 2025-update,e",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435372Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Update, Equity Issue and PDMR Notification",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/update-equity-issue-and-pdmr-notification-dixbph7n8927bsz.html",
          "rns_number": "RNS Number : 6450C",
          "full_content": "9 Oct 2025 07:00\nRNS Number : 6450C\nGenflow Biosciences PLC\n09 October 2025\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n9 October 2025\nGenflow Biosciences Plc\nTermination of Initial Transaction, Subscription of New Ordinary Shares, Warrant Issue and PDMR Dealings\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\"), announces that\nits board of directors has taken the decision to terminate, and not to proceed with, the subscription announced by the Company on 2 October 2025 (the \"Initial Transaction\").\u00a0Please see\nIssue of Equity - Correction - 12:37:10 02 Oct 2025 - GENF News article | London Stock Exchange\n.\nIn the alternative,\nit has raised gross proceeds of \u00a3440,000 (before expenses) via an allotment to Eric Leire of 40,000,000 new ordinary shares of \u00a30.0003 each (\"New Ordinary Shares\") at an issue price of 1.1 pence (being the closing bid price as at close of business on 8 October 2025) (the \"Issue Price\")\n(the \"Alternative Transaction\").\nThe Board has taken this decision on the basis that the Alternative Transaction is more favourable to, and less dilutive for, shareholders than the Initial Transaction.\nIssuance of the New Ordinary Shares\nThe Company continues to be unable to issue and admit the New Ordinary Shares without either the publication of a prospectus approved by the Financial Conduct Authority (\"FCA\") or relying upon an exemption to the requirement to issue a prospectus.\nConsequentially, the Alternative Transaction involves a subscription by Eric Leire, CEO and director of the Company, for the New Ordinary Shares at the Issue Price pursuant to the employee offer exemption under Article 1(4)(i) and 1(5) (h) of the UK Prospectus Regulation.\nFollowing allotment of the New Ordinary Shares, Eric Leire has agreed to direct the issue of 35,454,546 of such New Ordinary Shares to a consortium of existing shareholders (the \"Purchasers\"). Eric Leire will be issued the remaining\n4,545,454 New Ordinary Shares.\nWarrants\nConcurrent with the purchase of the New Ordinary Shares, the Purchasers and Eric Leire will receive warrants from the Company on a one-for-one basis. These warrants will be exercisable for a period of 24 months at an exercise price of 1.2 pence (\"Exercise Price\"), subject to adjustment in certain circumstances as set out in the warrant instrument.\nTotal Voting Rights\nApplication will be made for the 40,000,000 New Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, to be admitted to the FCA official list and to trading on the equity shares (transition) category of the Official List maintained by the FCA and to trading on the main market for listed securities of the LSE, which is expected to occur on or around 8.00 a.m. on 16 October 2025 (the \"Admission\").\nUpon Admission, the total number of issued shares and the total number of voting rights in the Company will be 493,547,942.\nThe above figure of 493,547,942 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.\nDr. Eric Leire, CEO of Genflow, commented: \"\nWe would like to express our sincere gratitude to our historical shareholders for their continued confidence and commitment to Genflow\u2019s vision. Their ongoing support reflects a shared belief in our mission. With this additional capital, Genflow is able to deliver on our near-term objectives\n.\"\nUK Market Abuse Regulation (UK MAR) Disclosure\nCertain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Genflow Biosciences is Eric Leire, Chief Executive Officer.\nNotification of transactions of directors, persons discharging managerial responsibilities or connected persons\n1.\nDetails of the person discharging managerial responsibilities / person closely associated\na)\nName\nEric Leire\n2.\nReason for the Notification\na)\nPosition/status\nPDMR\nb)\nInitial notification / Amendment\nInitial notification\n3.\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na)\nName\nGenflow Biosciences plc\nb)\nLEI\n213800HVOFXRXVEGDN62\n4.\nDetails of the transaction(s): section to be repeated ",
          "content_length": 10824
        },
        "ingested_at": "2026-01-21T02:45:52.435390Z"
      },
      {
        "event_id": "RNS-2nd Oct 2025-issueofe",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435403Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Issue of Equity - Correction",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/issue-of-equity-correction-ntjmracvr26pppo.html",
          "rns_number": "RNS Number : 8564B",
          "full_content": "2 Oct 2025 12:37\nRNS Number : 8564B\nGenflow Biosciences PLC\n02 October 2025\nThe following amendment has been made to the 'Subscription of New Ordinary Shares, Warrant Issue, PDMR Dealings ' announcement released on 01 October 2025 at 07:59 a.m. (BST) under RNS No 8077B.\nThe sentence \"being the bid price as at close of business on 1 October 2025\" has been corrected to \"being a 35% discount to the bid price as at close of business on 1 October 2025.\"\nAll other details remain unchanged.\nThe full amended text is shown below.\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n2 October 2025\nGenflow Biosciences Plc\nSubscription of New Ordinary Shares, Warrant Issue, PDMR Dealings\nLONDON, UK-Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (\"Genflow\" or \"the Company\"), is pleased to announce that it has raised gross proceeds of \u00a3340,000 (before expenses) via an allotment to Eric Leire of 40,000,000 new ordinary shares of \u00a30.0003 each (\"New Ordinary Shares\") at an issue price of 0.85 pence (being a 35% discount to the bid price as at close of business on 1 October 2025) (the \"Issue Price\").\nIssuance of the New Ordinary Shares\nThe Company is currently unable to issue and admit the New Ordinary Shares without either the publication of a prospectus approved by the Financial Conduct Authority (\"FCA\") or relying upon an exemption to the requirement to issue a prospectus.\nConsequentially, this fundraise involves a subscription by Eric Leire, CEO and director of the Company, for the New Ordinary Shares at the Issue Price pursuant to the employee offer exemption under Article 1(4)(i) and 1(5) (h) of the UK Prospectus Regulation.\nFollowing allotment of the New Ordinary Shares, Eric Leire has agreed to direct their issue to an institution, who will immediately sell these New Ordinary Shares at the same Issue Price to a purchaser identified by it (the \"Purchaser\").\nWarrants\nConcurrent with the purchase of the New Ordinary Shares, the Purchaser will receive warrants from the Company on a one-for-one basis. These warrants will be exercisable for a period of 24 months at an exercise price of 1.2 pence (\"Exercise Price\").\nTotal Voting Rights\nApplication will be made for the 40,000,000 New Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, to be admitted to the FCA official list and to trading on the equity shares (transition) category of the Official List maintained by the FCA and to trading on the main market for listed securities of the LSE, which is expected to occur on or around 8.00 a.m. on 9 October 2025 (the \"Admission\").\nUpon Admission, the total number of issued shares and the total number of voting rights in the Company will be 493,547,942.\nThe above figure of 493,547,942 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.\nDr. Eric Leire, CEO of Genflow, commented: \"\nWe appreciate the continuing support from our US backer, and this will enable us to continue with dog study whilst awaiting the first payment of the Wallonia region grant.\nThis financing provides Genflow with essential working capital while aligning long-term interests through the concurrent issue of warrants.\"\nUK Market Abuse Regulation (UK MAR) Disclosure\nCertain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Genflow Biosciences is Eric Leire, Chief Executive Officer.\nNotification of transactions of directors, persons discharging managerial responsibilities or connected persons\n1.\nDetails of the person discharging managerial responsibilities / person closely associated\na)\nName\nEric Leire\n2.\nReason for the Notification\na)\nPosition/status\nPDMR\nb)\nInitial notification / Amendment\nInitial notification\n3.\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na)\nName\nGenflow Biosciences plc\nb)\nLEI\n213800HVOFXRXVEGDN62\n4.\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\na)\nDescription of the Financial instrument, t",
          "content_length": 10634
        },
        "ingested_at": "2026-01-21T02:45:52.435418Z"
      },
      {
        "event_id": "RNS-2nd Oct 2025-issueofe",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435431Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Issue of Equity",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/issue-of-equity-rklxxckr1k9tfs8.html",
          "rns_number": "RNS Number : 8077B",
          "full_content": "2 Oct 2025 07:59\nRNS Number : 8077B\nGenflow Biosciences PLC\n02 October 2025\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n2 October 2025\nGenflow Biosciences Plc\nSubscription of New Ordinary Shares, Warrant Issue, PDMR Dealings\nLONDON, UK-Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (\"Genflow\" or \"the Company\"), is pleased to announce that it has raised gross proceeds of \u00a3340,000 (before expenses) via an allotment to Eric Leire of 40,000,000 new ordinary shares of \u00a30.0003 each (\"New Ordinary Shares\") at an issue price of 0.85 pence (being the bid price as at close of business on 1 October 2025) (the \"Issue Price\").\nIssuance of the New Ordinary Shares\nThe Company is currently unable to issue and admit the New Ordinary Shares without either the publication of a prospectus approved by the Financial Conduct Authority (\"FCA\") or relying upon an exemption to the requirement to issue a prospectus.\nConsequentially, this fundraise involves a subscription by Eric Leire, CEO and director of the Company, for the New Ordinary Shares at the Issue Price pursuant to the employee offer exemption under Article 1(4)(i) and 1(5) (h) of the UK Prospectus Regulation.\nFollowing allotment of the New Ordinary Shares, Eric Leire has agreed to direct their issue to an institution, who will immediately sell these New Ordinary Shares at the same Issue Price to a purchaser identified by it (the \"Purchaser\").\nWarrants\nConcurrent with the purchase of the New Ordinary Shares, the Purchaser will receive warrants from the Company on a one-for-one basis. These warrants will be exercisable for a period of 24 months at an exercise price of 1.2 pence (\"Exercise Price\").\nTotal Voting Rights\nApplication will be made for the 40,000,000 New Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, to be admitted to the FCA official list and to trading on the equity shares (transition) category of the Official List maintained by the FCA and to trading on the main market for listed securities of the LSE, which is expected to occur on or around 8.00 a.m. on 9 October 2025 (the \"Admission\").\nUpon Admission, the total number of issued shares and the total number of voting rights in the Company will be 493,547,942.\nThe above figure of 493,547,942 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.\nDr. Eric Leire, CEO of Genflow, commented: \"\nWe appreciate the continuing support from our US backer, and this will enable us to continue with dog study whilst awaiting the first payment of the Wallonia region grant.\nThis financing provides Genflow with essential working capital while aligning long-term interests through the concurrent issue of warrants.\"\nUK Market Abuse Regulation (UK MAR) Disclosure\nCertain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Genflow Biosciences is Eric Leire, Chief Executive Officer.\nNotification of transactions of directors, persons discharging managerial responsibilities or connected persons\n1.\nDetails of the person discharging managerial responsibilities / person closely associated\na)\nName\nEric Leire\n2.\nReason for the Notification\na)\nPosition/status\nPDMR\nb)\nInitial notification / Amendment\nInitial notification\n3.\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na)\nName\nGenflow Biosciences plc\nb)\nLEI\n213800HVOFXRXVEGDN62\n4.\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\na)\nDescription of the Financial instrument, type of instrument\nOrdinary Shares of \u00a30.0003\nIdentification Code\nGB00BP2C3V08\nb)\nNature of the transaction\nOff Market Allotment\nc)\nPrice(s) and volume(s)\nPrice(s)\nVolume(s)\n0.85 pence per Ordinary Share\n40,000,000 Ordinary Shares\nd)\nAggregated information:\nAggregated volume\nPrice\n40,000,000 Ordinary Shares\n0.85 pence per Ordinary Share\ne)\nDates of the transaction\n2 October 2025\nf)\nPlace of the transactions\nLondon\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric L",
          "content_length": 10165
        },
        "ingested_at": "2026-01-21T02:45:52.435445Z"
      },
      {
        "event_id": "RNS-30th Sep 2025-half-yea",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435458Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Half-year Report",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/half-year-report-53a6fyt5deypx64.html",
          "rns_number": "RNS Number : 3007B",
          "full_content": "30 Sep 2025 07:00\nRNS Number : 3007B\nGenflow Biosciences PLC\n30 September 2025\nPRESS RELEASE\n30 September 2025\nGenflow Biosciences Plc\n(\"Genflow\" or \"the Company\")\nHALF YEAR RESULTS\nGenflow (LSE: GENF) (OTCQB:GENFF) is pleased to announce its half year results for the six-month period ended 30 June 2025.\nChairman's Statement\nIt is my pleasure to update shareholders of Genflow Biosciences Plc (\"Genflow\" or the \"Company\") on our performance during the first six months of 2025.\nAs of 30 June 2025, Genflow has made important progress across its programs in both human health and animal health, advancing our mission to extend healthspan through our proprietary SIRT6 centenarian-based gene therapies. These two dimensions of our pipeline are deeply complementary: our human programs target age-related diseases with high unmet need, while our veterinary initiatives allow us to generate translational data, demonstrate safety and feasibility, and explore commercial opportunities in the growing companion animal health sector.\nHuman Health Pipeline\nIn human health, our pipeline spans MASH (\"Metabolic Dysfunction-Associated Steatohepatitis\"), sarcopenia, Werner Syndrome, and exploratory programs in ophthalmology. Collectively, these programs highlight the versatility of SIRT6 centenarian in addressing fundamental mechanisms of aging across multiple systems.\nThe most notable development has been in MASH. Recent approvals of two new therapies including GLP-1 agonists have provided effective therapies for patients in the earlier stages of disease (approximately two-thirds of the population). However, there remains a profound unmet need in advanced MASH with fibrosis, where therapeutic options are extremely limited. In response, Genflow has repositioned GF-1002 to target this high-need population (around one-third of patients). With its antifibrotic properties and potential to prevent progression to liver cancer, GF-1002 is uniquely suited to address this stage of disease. While the patient population is smaller, the commercial opportunity is significant, given the lack of alternatives beyond liver transplantation.\nIn parallel, we are expanding into ophthalmology, where SIRT6-based therapies hold promise in corneal pathologies and glaucoma. Current glaucoma treatments focus primarily on reducing intraocular pressure, yet do not prevent degeneration of the optic nerve. Preclinical findings suggest that SIRT6 overexpression can protect retinal ganglion cells and preserve optic nerve integrity, opening the door to a paradigm shift in treatment - from symptom management to true neuroprotection. With the global glaucoma market valued at nearly USD 9 billion and projected to reach USD 12-14 billion by the early 2030s, this represents a compelling long-term growth opportunity for Genflow.\nAnimal Health Pipeline\nComplementing our human health programs, we are pioneering applications of SIRT6 in veterinary medicine. During the period, we initiated a Healthspan and sarcopenia clinical trial in dogs with our partner, the independent CRO Syngene. This comparative, randomized study involves 28 beagle dogs aged 10 years and older, testing GF-1004, our naked DNA construct, in an aging canine population.\nEarly studies have already confirmed the safety and ease of administration of GF-1004, providing confidence in broader applicability. The trial is expected to deliver initial efficacy data within five months, with endpoints focused on muscle function and healthspan indicators. At the same time, we have initiated confidential discussions with several leading animal health companies under confidential disclosure agreements, underscoring industry interest in innovative approaches to age-related decline in companion animals.\nStrategic Integration of Human and Animal Health\nOur programs in human health and animal health are mutually reinforcing. The veterinary studies provide a real-world proof-of-concept environment to evaluate SIRT6-based therapies in aging populations, while our human programs extend the platform into areas of high unmet need such as MASH, sarcopenia, Werner Syndrome, and ophthalmology. Together, they expand the reach of our SIRT6 platform and strengthen Genflow's leadership in healthspan science.\nFinancial Overview\nAs of 30 June 2025, the Group had cash reserves of \u00a3279,445 (31 December 2024: \u00a3278,682) which has been derived from equity fundraising of \u00a3868,698 (net of expenses) during H1 2025. The Company remains debt free.\nAdministration expenses for 30 June 2025 totalled \u00a3982,725 (30 June 2024: \u00a31,316,368), which primarily consisted of research and development costs of \u00a3665,862 (30 June 2024: \u00a3938,109), legal and professional fees totalling \u00a3156,094 (30 June 2024: \u00a390,654) and Directors' fees of \u00a355,272 (30 June 2024: \u00a3178,656).\nOther Comprehensive Income was charged with a translation loss of \u00a331,075 (30 June 2024: \u00a38,652) upon converting the Subsidiary's results for the period to GBP.\nFuture\nLooking ahead, 2026 is expecte",
          "content_length": 24957
        },
        "ingested_at": "2026-01-21T02:45:52.435473Z"
      },
      {
        "event_id": "RNS-19th Sep 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435485Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/holdings-in-company-8u5vzr4fhdwsbxu.html",
          "rns_number": "RNS Number : 1016A",
          "full_content": "19 Sep 2025 12:40\nRNS Number : 1016A\nGenflow Biosciences PLC\n19 September 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BP2C3V08\nIssuer Name\nGENFLOW BIOSCIENCES PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nJonathan Mark Swann\nCity of registered office (if applicable)\nrickmansworth\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n19-Sep-2025\n6. Date on which Issuer notified\n19-Sep-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n8.400000\n0.000000\n8.400000\n36588550\nPosition of previous notification (if applicable)\n7.010000\n0.000000\n7.010000\n31788550\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BP2C3V08\n36588550\n0\n8.400000\n0.000000\nSub Total 8.A\n36588550\n8.400000%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\nNONE\n12. Date of Completion\n19-Sep-2025\n13. Place Of Completion\nLondon\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLLLMBTMTJBBPA",
          "content_length": 3855
        },
        "ingested_at": "2026-01-21T02:45:52.435498Z"
      },
      {
        "event_id": "RNS-19th Sep 2025-genflows",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435511Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Genflow Strengthens IP Portfolio",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/GENF/genflow-strengthens-ip-portfolio-kiqjg7dblgdgzw9.html",
          "rns_number": "RNS Number : 9356Z",
          "full_content": "19 Sep 2025 07:00\nRNS Number : 9356Z\nGenflow Biosciences PLC\n19 September 2025\n19, September 2025\nGenflow Biosciences Plc\nGenflow Strengthens Global IP Portfolio with China Patent Examination Filing for SIRT6 Variants in NASH\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\"), the only publicly listed longevity company in Europe, today announces that it has filed a formal request for the examination of its patent application entitled SIRT6 Variants for NASH in China.\nThe application covers proprietary variants of the SIRT6 gene designed to address Non-Alcoholic Steatohepatitis (NASH), a severe progressive liver disease with limited treatment options. By pursuing examination in China, Genflow is reinforcing its global intellectual property portfolio and furthering its commitment to developing innovative therapies for patients worldwide.\nDr. Eric Leire, CEO of Genflow, commented: \"The filing of this examination request in China represents another significant step in protecting our technology in one of the world's largest healthcare markets. We are committed to advancing our research into SIRT6-based therapies and believe that our approach holds strong potential to transform the treatment landscape for NASH.\"\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nCorporate Brokers\nCapital Plus Partners Ltd\nJon Critchley, +44\n207 432 0501\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH\n(Metabolic Dysfunction-Associated Steatohepatitis)\n, the most prevalent chronic liver disease for which there is no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on\nLinkedIn\nand\nX\n.\nDISCLAIMER\nThe contents of this announcement have been prepared by, and are the sole responsibility of, the Company.\nThis announcement may contain forward-looking statements.\u00a0The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words \"anticipate\", \"believe\", \"continue\", \"could\", \"estimate\", \"expect\", \"intend\", \"may\", \"might\", \"plan\", \"possible\", \"potential\", \"predict\", \"project\", \"seek\", \"should\", \"would\" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.\nForward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.\nAny forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qua",
          "content_length": 6483
        },
        "ingested_at": "2026-01-21T02:45:52.435526Z"
      },
      {
        "event_id": "RNS-15th Sep 2025-genflows",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435539Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Genflow Signs CDAs with Animal Health Companies",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/GENF/genflow-signs-cdas-with-animal-health-companies-3q0uh6kn4h0w449.html",
          "rns_number": "RNS Number : 2323Z",
          "full_content": "15 Sep 2025 07:00\nRNS Number : 2323Z\nGenflow Biosciences PLC\n15 September 2025\n15, September 2025\nGenflow Biosciences Plc\nGenflow Signs CDAs with Animal Health Companies to Advance Longevity Gene Therapy Platform\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\"), the only publicly listed longevity company in Europe, today announces that it has signed two Confidential Disclosure Agreements (CDAs) with leading animal health companies to facilitate the exchange of data and initiate discussions on potential collaborations.\nThese CDAs mark an important milestone in Genflow's strategy to leverage its proprietary SIRT6-centenarian gene therapy platform for both human and animal health. Building on the Company's ongoing GF-1004 Dog Aging (beagle) study which has reported no adverse events to date. The agreements will provide a framework for evaluating partnership opportunities aimed at extending healthspan and improving quality of life in companion animals, a rapidly growing and high-value market segment.\nStrategic Rationale\nGenflow's first-in-class science, when combined with the resources of a large pharmaceutical partner, offers a faster path to commercialization therefore, derisking execution and maximizing shareholder value. Through such collaborations, Genflow can also unlock global scale, regulatory expertise, and commercial infrastructure more quickly accelerating both revenue generation and market penetration.\nDr. Eric Leire, CEO of Genflow, commented: \"The signing of these CDAs reflects strong industry interest in our longevity platform and represents a further step toward building strategic partnerships in animal health. As we continue to advance GF-1004 in our canine trial, engaging with major animal health players will strengthen our pathway to potential licensing agreements and future commercialization.\"\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nCorporate Brokers\nCapital Plus Partners Ltd\nJon Critchley, +44\n207 432 0501\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH\n(Metabolic Dysfunction-Associated Steatohepatitis)\n, the most prevalent chronic liver disease for which there is no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on\nLinkedIn\nand\nX\n.\nDISCLAIMER\nThe contents of this announcement have been prepared by, and are the sole responsibility of, the Company.\nThis announcement may contain forward-looking statements.\u00a0The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words \"anticipate\", \"believe\", \"continue\", \"could\", \"estimate\", \"expect\", \"intend\", \"may\", \"might\", \"plan\", \"possible\", \"potential\", \"predict\", \"project\", \"seek\", \"should\", \"would\" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.\nForward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or wi",
          "content_length": 7100
        },
        "ingested_at": "2026-01-21T02:45:52.435554Z"
      },
      {
        "event_id": "RNS-27th Aug 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435566Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/holdings-in-company-vhaj5ugjczyu0tf.html",
          "rns_number": "RNS Number : 9203W",
          "full_content": "27 Aug 2025 15:07\nRNS Number : 9203W\nGenflow Biosciences PLC\n27 August 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BP2C3V08\nIssuer Name\nGENFLOW BIOSCIENCES PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nJonathan Mark Swann\nCity of registered office (if applicable)\nrickmansworth\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n26-Aug-2025\n6. Date on which Issuer notified\n27-Aug-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n7.010000\n0.000000\n7.010000\n31788550\nPosition of previous notification (if applicable)\n6.010000\n0.000000\n6.010000\n21025000\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BP2C3V08\n31788550\n0\n7.010000\n0.000000\nSub Total 8.A\n31788550\n7.010000%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\nNONE\n12. Date of Completion\n26-Aug-2025\n13. Place Of Completion\nLondon\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLPRMITMTMTBJA",
          "content_length": 3852
        },
        "ingested_at": "2026-01-21T02:45:52.435579Z"
      },
      {
        "event_id": "RNS-18th Aug 2025-companyu",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435593Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Company Update on Dog Trials",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/GENF/company-update-on-dog-trials-0lh1eqs8tixqcxt.html",
          "rns_number": "RNS Number : 6062V",
          "full_content": "18 Aug 2025 07:00\nRNS Number : 6062V\nGenflow Biosciences PLC\n18 August 2025\n18, August 2025\nGenflow Biosciences Plc\nGenflow Advances World's First Longevity Gene Therapy Trial in Dogs with No Adverse Effects Reported\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\"), the only publicly listed longevity company in Europe, provides an update on its Dog Aging (GF-1004) study, a proof-of-concept clinical trial evaluating the safety and efficacy of its proprietary SIRT6-centenarian gene therapy for age-related decline in elderly dogs.\nThe randomized, controlled trial, conducted with CRO Syngene, involves 28 beagles aged 10+ years. In March, recipients received three different modalities of SIRT6 gene therapy with no ill or adverse effects, while controls remain untreated. The dogs will now enter a five-month follow-up period expected to conclude in January 2026.\nThe strategic goal of this proof-of-concept trial is to generate compelling preclinical data that will enable a licensing agreement with a leading Animal Health company. GF-1004 is a first-in-class gene therapy candidate targeting fundamental aging mechanisms shared by both dogs and humans. By intervening at the mitochondrial and epigenetic levels, GF-1004 offers the potential to not only extend lifespan, but also improve the quality of life in companion animals, a rapidly growing, high-value market segment.\nStudy objectives are to:\n1. Confirm feasibility of GF-1004 administration in the target population.\n2. Validate safety and efficacy at the proposed administered dose.\n3. Demonstrate multi-dimensional benefits relevant to both clinical outcomes and consumer appeal, including:\no\nReduced biological age (GRIM methylation clock)\no\nIncreased muscle strength and mass\no\nEnhanced mitochondrial function\no\nImproved coat quality\no\nBetter overall health metrics\nTranslational Potential\nSince dogs and humans share conserved aging pathways, success in this trial will provide a strong foundation for expansion into human health applications, unlocking additional markets in longevity therapeutics.\nDr. Eric Leire, CEO of Genflow, commented: \"Now that all dogs have received the treatment without any adverse events, we've taken an important step in confirming the treatment's safety profile. We are fully focused on advancing GF-1004 to secure a partnership with an animal health company, combining scientific and commercial expertise to pave the way for a new class of therapeutic medicines for dogs. Our shared goal is to extend the healthspan of dogs, and we believe this study will demonstrate the safety and potential efficacy of GF-1004 while opening the door to broader applications of our proprietary platform in age-related diseases in both companion animals and, ultimately, in humans.\"\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nCorporate Brokers\nCapital Plus Partners Ltd\nJon Critchley, +44\n207 432 0501\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH\n(Metabolic Dysfunction-Associated Steatohepatitis)\n, the most prevalent chronic liver disease for which there is no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on\nLinkedIn\nand\nX\n.\nDISCLAIMER\nThe contents of this announcement have been prepared by, and are the sole responsibility of, the Company.\nThis announcement may contain forward-looking statements.\u00a0The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words \"anticipate\", \"believe\", \"continue\", \"could\", \"estimate\", \"expect\", \"intend\", \"may\", \"might\", \"plan\", \"possible\", \"potential\", \"predict\", \"project\", \"seek\", \"should\", \"would\" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.\nF",
          "content_length": 8028
        },
        "ingested_at": "2026-01-21T02:45:52.435607Z"
      },
      {
        "event_id": "RNS-24th Jul 2025-clinical",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435620Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Clinical Readiness Acceleration",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/GENF/clinical-readiness-acceleration-e8uhs4neqgiyigp.html",
          "rns_number": "RNS Number : 3206S",
          "full_content": "24 Jul 2025 07:00\nRNS Number : 3206S\nGenflow Biosciences PLC\n24 July 2025\n24 July 2025\nGenflow Biosciences Plc\nClinical Readiness Accelerates Across Genflow Biosciences Lead Programs\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\"), the only publicly listed longevity company in Europe, is pleased to report key preclinical activities in two of its lead programs.\nGF-1002\nIn preparation for a submission for European Clinical Trial Authorisation (CTA), the EU's regulatory equivalent to the U.S. FDA's IND process, Genflow is continuing to advance key development activities. To support this process, the Company has initiated Chemistry, Manufacturing, and Controls (CMC) work in collaboration with its CDMO partner, Exothera, to ensure clinical supply production meets Good Manufacturing Practice (GMP) standards. In parallel, pivotal efficacy studies are underway with Genflow's independent CRO partners, Physiogenex and Accelera, evaluating GF-1002 in both early and advanced stages of MASH.\nGF-1004\nGenflow has submitted a first protocol amendment to its ongoing proof-of-concept clinical trial in aged dogs to clarify the administration of its investigational product, GF-1004. The amended protocol now specifies the intravenous (IV) dose rate to ensure consistent and controlled delivery, minimizing the risk of infusion-related adverse events and reinforcing patient safety. This randomized, controlled trial initiated in March in collaboration with the renowned CRO, Syngene is designed to evaluate the safety and efficacy of Genflow's proprietary SIRT6-centenarian gene therapy in addressing age-related decline in dogs.\nDr. Eric Leire, CEO of Genflow, commented: \"\nThis update reflects the growing maturity of our pipeline and our continued commitment to advancing science-backed therapies in healthy aging. The combination of expected non-dilutive funding, strategic partnerships, and supportive regulatory tailwinds puts Genflow in a strong position to accelerate both our programs.\"\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nCorporate Broker\nCapital Plus Partners\nJonathan Critchley\n+44 0207 432 0501\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH\n(Metabolic Dysfunction-Associated Steatohepatitis)\n, the most prevalent chronic liver disease for which there is no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on\nLinkedIn\nand\nX\n.\nDISCLAIMER\nThe contents of this announcement have been prepared by, and are the sole responsibility of, the Company.\nThis announcement may contain forward-looking statements.\u00a0The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words \"anticipate\", \"believe\", \"continue\", \"could\", \"estimate\", \"expect\", \"intend\", \"may\", \"might\", \"plan\", \"possible\", \"potential\", \"predict\", \"project\", \"seek\", \"should\", \"would\" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.\nForward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this a",
          "content_length": 7255
        },
        "ingested_at": "2026-01-21T02:45:52.435634Z"
      },
      {
        "event_id": "RNS-17th Jul 2025-genflowc",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435647Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Genflow Confirms Progression of Grant",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/genflow-confirms-progression-of-grant-clmas2jc0l3dm8p.html",
          "rns_number": "RNS Number : 3831R",
          "full_content": "17 Jul 2025 07:00\nRNS Number : 3831R\nGenflow Biosciences PLC\n17 July 2025\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n17, July 2025\nGenflow Biosciences Plc\nGenflow Confirms Approximately \u20ac4M Grant Support from Wallonia Region; GF-1002 Program Progressing without Interruption\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\"), the only publicly listed longevity company in Europe,\nis\npleased to reaffirm the previously announced award of approximately \u20ac4 million in non-dilutive financial support from the Wallonia Region of Belgium, supporting the development of its lead gene therapy candidate, GF-1002, for the treatment of Metabolic Associated Steatohepatitis (MASH). Read the RNS announcing this grant\nhere\n.\nThe support package spans a three-year development program, aligned with Genflow's existing clinical roadmap. All project-related expenses incurred in 2025 will be considered eligible. While initial disbursement is pending the completion of standard administrative procedures on the government's side, Genflow has taken proactive steps to ensure the continuity of its GF-1002 program and confirms that progress remains on track with no delays to planned research or development activities.\nDr. Eric Leire, CEO of Genflow, commented: \"We greatly appreciate the continued support from the Wallonia Region. The \u20ac4 million in non-dilutive funding represents a significant endorsement of our science and our strategy. We remain fully focused on advancing GF-1002 through the next stage of development and have ensured that operations proceed uninterrupted as the program moves forward.\"\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nCorporate Brokers\nCapital Plus Partners Ltd\nJon Critchley, +44\n207 432 0501\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH\n(Metabolic Dysfunction-Associated Steatohepatitis)\n, the most prevalent chronic liver disease for which there is no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on\nLinkedIn\nand\nX\n.\nDISCLAIMER\nThe contents of this announcement have been prepared by, and are the sole responsibility of, the Company.\nThis announcement may contain forward-looking statements.\u00a0The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words \"anticipate\", \"believe\", \"continue\", \"could\", \"estimate\", \"expect\", \"intend\", \"may\", \"might\", \"plan\", \"possible\", \"potential\", \"predict\", \"project\", \"seek\", \"should\", \"would\" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.\nForward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, eve",
          "content_length": 7289
        },
        "ingested_at": "2026-01-21T02:45:52.435662Z"
      },
      {
        "event_id": "RNS-17th Jun 2025-corporat",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435675Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Corporate Update",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/GENF/corporate-update-mhubuctj8x25911.html",
          "rns_number": "RNS Number : 7719M",
          "full_content": "17 Jun 2025 07:00\nRNS Number : 7719M\nGenflow Biosciences PLC\n17 June 2025\n17 June 2025\nGenflow Biosciences Plc\nGenflow Biosciences Provides Half Year Corporate Update on SIRT6 Programs, IP Progress and Strategic Partnerships\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\"), the only publicly listed longevity company in Europe, is pleased to provide an update on the continued advancement of its core programs focused on the SIRT6-centenarian gene and its potential to slow aging and delay the onset of age-related diseases.\nSince the start of the year, the Company has made meaningful progress across its research and development initiatives. These advancements have been supported by a strengthened leadership network of world-class academic collaborators and laboratories. Combined with the continued support of international institutional investors and previously awarded government grants, this ecosystem has played a vital role in accelerating Genflow's scientific and clinical development.\nAs part of its strategic execution, Genflow has signed a Master Service Agreement (MSA) with CER Groupe, a trusted long-term partner and leading Belgian research center specializing in integrated bioproduction and pre-clinical services. CER operates in a fully regulated ISO and GxP-compliant environment and will provide a robust R&D framework to support the advancement of Genflow's pre-IND gene therapy programs.\nIn parallel, the Company continues to expand its global intellectual property portfolio. In February, Genflow's exclusively out-licensed European Patent Office (EPO) application titled \"Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases\" advanced through the Supplementary European Search Report without objections, allowing it to proceed to the national phase-a key step toward securing protections across major European markets.\nSimilarly, the Japanese Patent Office has progressed the same SIRT6-related application (Application No. JP 2024515284) to the national examination phase, marking another important milestone in establishing global IP coverage for Genflow's innovative gene therapy technology.\nOriginally filed on 13 May 2022, the patent is jointly owned by the University of Rochester, The Trustees of Columbia University in the City of New York, and Albert Einstein College of Medicine. Genflow holds the exclusive worldwide license to this intellectual property.\nTo support the intellectual property costs associated with entering into the national phase in the U.S., Canada, Europe, Japan, Australia, China, Genflow has applied for a PATEX-2 grant in connection with its patent application PCT/EP2023/084840, titled\n\"SIRT6 Variants for NASH,\"\nfiled on December 8, 2023. This patent is fully owned by Genflow Biosciences.\nBelow is a status update on each of our programs, reflecting significant progress at the mid-year point:\nMASH (GF-1002):\nWe completed an initial production test with our CDMO partner, Exothera SA, for the GMP manufacturing of GF-1002. The results exceeded our expectations, with a yield notably higher than anticipated-a promising outcome for the upcoming manufacturing phases.\nWe are currently conducting the two pivotal studies to support our filing for Clinical Trial Application (CTA) for GF-1002 in MASH. These studies are being carried out independently by two reputable Contract Research Organizations (CROs): Physiogenex and Accelera.\nGenflow signed an MSA with Heureka Labs, a medical AI company spin-off from Duke University. Heureka will provide Genflow with access to its proprietary artificial intelligence (\"AI\") platform, which specializes in the analysis of high-dimensional genomic data including RNA sequencing and gene expression profiles. The application of Heureka's AI technology is expected to enhance Genflow's ability to interpret complex biological datasets, enabling deeper insights into gene regulatory networks and systemic biological responses. These insights will be key to optimising therapeutic design and anticipating patient-specific outcomes. Genflow will retain all IP rights under the agreement. Our MASH program receives support through a research grant awarded by the regional government of Wallonia - Belgium Service Public de Wallonie.\nWerner Syndrome (GF-1003):\nWe have developed a proprietary liver organoid model derived from human cells of patients with Werner syndrome. This innovative system allows us to test our drug candidate, GF-1003, directly in a disease-relevant human tissue model. The approach offers several advantages: it reduces the need for animal testing and provides deeper insight into the efficacy and safety of GF-1003 in a synthetic organ created from the cells of three Werner syndrome patients. As a result, this model significantly enhances the predictive value of our preclinical data for the potential success of future clinical trials in Werner patients.\nThe use of more sophisticated organoid models reflects Genflow's ",
          "content_length": 10497
        },
        "ingested_at": "2026-01-21T02:45:52.435690Z"
      },
      {
        "event_id": "RNS-12th Jun 2025-resultof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435702Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Result of AGM",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/result-of-agm-b0dp7z1i666jnio.html",
          "rns_number": "RNS Number : 5872M",
          "full_content": "12 Jun 2025 10:16\nRNS Number : 5872M\nGenflow Biosciences PLC\n12 June 2025\n12 June 2025\nGenflow Biosciences Plc\nResults of Annual General Meeting\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased\nto announce that all resolutions proposed at the Annual General Meeting held earlier today were duly passed by shareholders. The number of proxy votes for each resolution submitted prior to the meeting are presented below.\nProxy Voting Results\nOrdinary Resolutions\nVotes for\n% of votes cast for\nVotes Against\n% of votes cast against\nTotal votes cast\nVotes withheld\n1. To receive and consider the Annual Report and Accounts for the year ended 31 December 2024 together with the Directors' Report and Auditors' Report thereon.\n152,365,311\n99.5%\n312\n0.0%\n152,365,623\n753,187\n2. To approve the directors' remuneration report for the financial period ended 31 December 2024 set out in the audited accounts for the financial period ended 31 December 2024.\n152,069,752\n99.3%\n270,744\n0.2%\n152,340,496\n778,314\n3. To re-appoint PKF Littlejohn LLP as auditors of the Company and to authorise the Directors of the Company to fix their remuneration.\n151,451,787\n98.9%\n121,889\n0.1%\n151,573,676\n1,545,134\n4. To re-elect Tamara Joseph as a Director of the Company.\n151,449,590\n98.9%\n206,583\n0.1%\n151,656,173\n1,462,637\n5. To re-elect Dr Guy-Charles Fanneau de La Horie as a Director of the Company.\n151,448,295\n98.9%\n207,469\n0.1%\n151,655,764\n1,463,046\n6. To re-elect Dr Eric Leire as a Director of the Company.\n152,668,756\n99.7%\n192,686\n0.1%\n152,861,442\n257,368\n7. To re-elect Dr Yassine Bendiabdallah as a Director of the Company.\n151,442,263\n98.9%\n213,734\n0.1%\n151,655,997\n1,462,813\n8. To re-elect Dr Peter King Lewis as a Director of the Company.\n152,636,489\n99.7%\n192,843\n0.1%\n152,829,332\n289,478\n9. To authorise the Directors to allot shares in the Company.\n132,658,404\n86.6%\n19,655,616\n12.8%\n152,314,020\n804,790\nSpecial Resolution\nVotes for\n% of votes cast for\nVotes Against\n% of votes cast against\nTotal votes cast\nVotes withheld\n10. To disapply statutory pre-emption rights.\n132,698,727\n86.7%\n18,861,048\n12.3%\n151,559,775\n1,559,035\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nCorporate Brokers\nCapital Plus Partners Ltd\nJon Critchley, +44 0203 821 6168\nAbout Genflow\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments.\nPlease visit\nwww.genflowbio.com\nand follow the Company on LinkedIn and Twitter/X.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nRAGPKBBDCBKKPAD",
          "content_length": 4198
        },
        "ingested_at": "2026-01-21T02:45:52.435715Z"
      },
      {
        "event_id": "RNS-30th May 2025-totalvot",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435728Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Total Voting Rights",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/total-voting-rights-6vp439p3q6wgsiz.html",
          "rns_number": "RNS Number : 8567K",
          "full_content": "30 May 2025 15:20\nRNS Number : 8567K\nGenflow Biosciences PLC\n30 May 2025\n30 May 2025\nGenflow Biosciences plc\n(\"Genflow\" or the \"Company\")\nTotal Voting Rights\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\") announces that the total issued share capital of the Company as at 30 May 2025 consists of 453,547,942 ordinary shares of \u00a30.0003 each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 453,547,942.\nThe figure of 453,547,942 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nCorporate Brokers\nCapital Plus Partners Ltd\nJon Critchley, +44 0203 821 6168\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population.\nGenflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Expected to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH\u00a0(Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on LinkedIn and Twitter/X.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nTVRWPUMGAUPAGCU",
          "content_length": 2751
        },
        "ingested_at": "2026-01-21T02:45:52.435741Z"
      },
      {
        "event_id": "RNS-28th May 2025-genflows",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435754Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Genflow Signs Master Services Agreement",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/GENF/genflow-signs-master-services-agreement-1aqe83aq1pj3xjq.html",
          "rns_number": "RNS Number : 2547K",
          "full_content": "28 May 2025 07:00\nRNS Number : 2547K\nGenflow Biosciences PLC\n28 May 2025\n28 May 2025\nGenflow Biosciences Plc\nGenflow Biosciences and CER Sign Master Service Agreement to Strengthen Long-Term R&D Collaboration\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\"), the only publicly listed longevity company in Europe, is pleased to announce the signing of a Master Service Agreement (MSA) with CER Groupe (CER), a long-standing partner of the Company.\nCER is a private Belgian research center offering integrated bioproduction and pre-clinical services within a regulated ISO and GxP-compliant environment. The MSA formalizes the working relationship between Genflow and CER, providing a robust R&D framework to accelerate Genflow's pre-IND gene therapy programs.\nUnder the terms of the MSA, Genflow and CER will:\n\u00b7\nDevelop, produce and characterize Genflow's gene therapy candidates;\n\u00b7\nImplement a collaborative project management system to drive efficient execution and timely deliverables supporting Genflow's goals with standardized templates for Task Orders and technical services; and\n\u00b7\nCombine scientific expertise derisks, innovate and ensure relevant scientific outcomes.\nSaid Dr. Eric Leire, CEO of Genflow: \"\nOur partnership with CER has been instrumental in supporting our R&D efforts to date. Formalizing this collaboration through the MSA will enable greater operational alignment and strategic agility as we continue to accelerate our pipeline\n.\"\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nCorporate Brokers\nCapital Plus Partners Ltd\nJon Critchley, +44 0203 821 6168\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH\n(Metabolic Dysfunction-Associated Steatohepatitis)\n, the most prevalent chronic liver disease for which there is no effective treatments.\nPlease visit\nwww.genflowbio.com\nand follow the Company on\nLinkedIn\nand\nX\n.\nAbout CER Groupe\nCER Groupe is a GLP-certified private Belgian research center supporting European life sciences innovation for more than 45years. CER's 200 colleagues gather cutting-edge expertise ensuring high quality integrated bioproduction and non-clinical services. CER supports companies in progressing their development from idea generation up to IND-enabling studies. CER Groupe favors collaborative and agile approaches accelerating companies' access to clinical stage development.\nVisit\nwww.cergroupe.be\nto learn what CER's partners say and follow CER Groupe on LinkedIn to stay up-to-date on CER's latest developments.\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRAPPUMUAUPAGGM",
          "content_length": 4099
        },
        "ingested_at": "2026-01-21T02:45:52.435767Z"
      },
      {
        "event_id": "RNS-22nd May 2025-agmnotic",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435780Z",
        "source": "LSE_RNS",
        "data": {
          "title": "AGM Notice",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/agm-notice-pdyxgd5qba07rvo.html",
          "rns_number": "RNS Number : 7952J",
          "full_content": "22 May 2025 10:51\nRNS Number : 7952J\nGenflow Biosciences PLC\n22 May 2025\n22 May 2025\nGenflow Biosciences Plc\nNotice of Annual General Meeting\nGenflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (\"Genflow\" or \"the Company\") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce that it will hold its Annual General Meeting (\"AGM\") at 9am on Thursday 12 June 2025 at One Heddon Street, London, W1B 4BD.\nThe Notice of the AGM (\"Notice\") and 2025 Form of Proxy will shortly be available on the Company's website,\nwww.genflowbio.com\n, and was, where applicable, posted to shareholders on 19 May 2025. Further details of the arrangements for this year's AGM are set out in the Notice.\nAs announced on 30 April 2025, the Company's Annual Report and Accounts for the year ended 31 December 2024 are also available on the website and has, where applicable, also been posted to registered shareholders.\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nBrokers\nCapital Plus Partners Ltd\nDominic Berger, +44 203 821 6167\nJon Critchley, +44 0203 821 6168\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on LinkedIn and Twitter/X.\n-Ends-\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNOAATMLTMTITMPA",
          "content_length": 2941
        },
        "ingested_at": "2026-01-21T02:45:52.435793Z"
      },
      {
        "event_id": "RNS-15th May 2025-keysirt6",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435806Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Key SIRT6 Patent Application",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/GENF/key-sirt6-patent-application-zynqjyfksa6t6oo.html",
          "rns_number": "RNS Number : 7021I",
          "full_content": "15 May 2025 07:00\nRNS Number : 7021I\nGenflow Biosciences PLC\n15 May 2025\n15 May 2025\nGenflow Biosciences plc\nGenflow Biosciences Announces Progress of Key SIRT6 Patent Application in Japan\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\"), the only publicly listed longevity company in Europe, announces that the Japanese Patent Office has advanced its SIRT6-related patent application (Application No. JP 2024515284) to the national examination phase.\nThe application, titled\n\"Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases,\"\nwas originally filed on 13 May 2022 and is jointly owned by the University of Rochester, The Trustees of Columbia University in the City of New York, and Albert Einstein College of Medicine. Genflow holds the exclusive license to this intellectual property.\nThe invention covers novel SIRT6 gene variants that play a central role in genomic stability, metabolic regulation, and healthy aging. These variants underpin Genflow's core therapeutic platform and represent a key part of its pipeline targeting age-related diseases.\nThe progression to national examination in Japan marks an important step in Genflow's strategy to establish broad international patent protection. Japan, with one of the world's most rapidly aging populations, is a priority market for longevity-related innovation.\nDr. Eric Leire, CEO of Genflow Biosciences, commented:\n\"We are pleased to see continued momentum in the protection of our SIRT6 intellectual property. Japan represents a strategically important jurisdiction for Genflow, and advancing this patent application strengthens our global positioning as a leader in longevity gene therapy.\"\nGenflow continues to progress its preclinical and clinical programs targeting age-related pathologies using the SIRT6 gene variants.\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nCorporate Brokers\nCapital Plus Partners Ltd\nJon Critchley, +44 0203 821 6168\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Expected to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH\n(Metabolic Dysfunction-Associated Steatohepatitis)\n, the most prevalent chronic liver disease for which there is no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on LinkedIn and Twitter/X.\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRAFZGMKDDNGKZM",
          "content_length": 3690
        },
        "ingested_at": "2026-01-21T02:45:52.435819Z"
      },
      {
        "event_id": "RNS-12th May 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435832Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/holdings-in-company-k77o1e5a91bnurp.html",
          "rns_number": "RNS Number : 2844I",
          "full_content": "12 May 2025 10:50\nRNS Number : 2844I\nGenflow Biosciences PLC\n12 May 2025\nPlease note that from 22 March 2021, the Standard TR-1 Form should be completed and submitted to the FCA via our Electronic Submission System (ESS) in relation to notifications of voting rights held in issuers whose shares are admitted to trading on UK regulated markets.\nHolders of voting rights in issuers whose shares are admitted to trading on UK prescribed markets such as AIM market, can continue to use this form to send their notifications to those issuers. Alternatively, if they wish they can register on ESS to be able to notify to us, produce a TR-1 Form via ESS and submit the downloaded version to issuers with shares admitted to trading on prescribed markets.\nMore information on how to submit a TR-1 Form via ESS is available\nhere\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nGenflow Biosciences\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nDr Moayyed Al-Qurtas\nCity and country of registered office (if applicable)\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\nvi\n:\n09/05/2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n12/05/2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n4.45%\n4.45%\nPosition of previous notification (if\napplicable)\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nSUBTOTAL 8. A\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nX\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nCity of London\nDate of completion\n12/05/2025\nNotes\ni\nPlease note this form should be read jointly with the applicable Disclosure Guidance and Transparency Rules Chapter 5 (DTR5) available on the following link:\nhttps://www.handbook.fca.org.uk/handbook/DTR/5/?view=chapter\nii\nFull name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g. address, LEI, domestic number identity). Indicate in the relevant section whether the issuer is a non UK issuer.\niii\nOther reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g. expiring of financial instruments) or acting in concert.\niv\nThis should be the full name of (a) the shareholder; (b) the natural person or legal e",
          "content_length": 11521
        },
        "ingested_at": "2026-01-21T02:45:52.435846Z"
      },
      {
        "event_id": "RNS-9th May 2025-sharesub",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435860Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Share Subscription, Director's Dealing and Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/share-subscription-directors-dealing-and-update-p5gzd7x26ilxzv3.html",
          "rns_number": "RNS Number : 9758H",
          "full_content": "9 May 2025 07:00\nRNS Number : 9758H\nGenflow Biosciences PLC\n09 May 2025\n9 May 2025\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\nGenflow Biosciences plc\n(\"Genflow\" or the \"Company\")\nGenflow Secures \u00a3500,000 via a Subscription of Shares,\nDirector's Dealing and\nClinical Progress of Canine Longevity Trial\nIntroduction\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\"),\nis pleased to announce that\nit has raised gross proceeds of \u00a3500,000 (before expenses) via an allotment to Eric Leire of 62,500,000 new ordinary shares of \u00a30.0003 each (\"New Ordinary Shares\") at an issue price of 0.8 pence (being the bid price as at close of business on 8 May 2025) (the \"Issue Price\").\nThe net proceeds of this fundraise will be used\nto advance a proof-of-concept trial evaluating the safety and efficacy of our therapeutic candidate in aged dogs, potentially being also a key translational model for age-related conditions in humans.\nIssuance of the New Ordinary Shares\nThe Company is currently unable to issue and admit the New Ordinary Shares without either the publication of a prospectus approved by the Financial Conduct Authority (\"FCA\") or relying upon an exemption to the requirement to issue a prospectus.\nConsequentially, this fundraise involves a subscription by Eric Leire, CEO and director of the Company, for the New Ordinary Shares at the Issue Price pursuant to the employee offer exemption under Article 1(4)(i) and 1(5) (h) of the UK Prospectus Regulation.\nFollowing allotment of the New Ordinary Shares, Eric Leire has agreed to direct their issue to an institution, who will immediately sell these New Ordinary Shares at the same Issue Price to a purchaser identified by it (the \"Purchaser\").\nWarrants\nConcurrent with the purchase of the New Ordinary Shares, the Purchaser will receive warrants from the Company\non a one-for-one basis. These warrants will be exercisable for a period of 36 months at an exercise price of 1.5 pence (\"\nExercise Price\n\"), subject to adjustment in certain circumstances as set out in the warrant instrument including a reset of the Exercise Price if the Company completes a share issuance (or other transaction granting rights to subscribe for equity securities) during the Exercise Period at a price lower than the Exercise Price.\nTotal Voting Rights\nApplication will be made for the 62,500,000 New Ordinary Shares, which will rank\npari passu\nin all respects with the existing Ordinary Shares of the Company, to be admitted to the\nFCA official list and to trading on the equity shares (transition) category of the Official List maintained by the FCA and to trading on the main market for listed securities of the LSE\n, which is expected to occur on or around 8.00 a.m. on 15 May 2025 (the \"Admission\").\nUpon Admission, the total number of issued shares and the total number of voting rights in the Company will be 453,547,942.\nThe above figure of 453,547,942 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.\nClinical Progress of Canine Longevity Trial\nCoinciding with the fundraise, Genflow reached a key milestone with the randomization of 24 senior dogs enrolled in its ongoing proof-of-concept clinical trial.\nDelivered via intravenous injection, the therapy targets cellular energy metabolism and longevity pathways. Genflow and its partners are conducting the study in accordance with the rigorous scientific protocols, leading animal welfare practices, and a committement to innovation.\nThe study is designed to evaluate the potential of Genflow's SIRT6 gene therapy to improve muscle function, reduce biological markers of aging, and support overall vitality in senior dogs, potentially uncovering insights that could help extend the quality of life for humans. An overview can be seen below:\n\u00b7\nParticipants:\n24 senior dogs (male and female), aged 10+ years\n\u00b7\nDesign:\nRandomized, controlled, dose-escalation trial\n\u00b7\nEndpoints:\nSafety of the gene therapy\n,\nMuscle strength and mass, biological age estimation (via pan-mammelian methylation clocks), and overall health indicators\nThe Company will keep the market informed of future developments as trials proceed.\nEric Leire, CEO of Genflow, commented:\n\"This investment, without applying any discount, is a strong vote of confidence in our science and our mission to improve aging through innovative biotechnology. With this support, we are well-positioned to accelerate our research and bring us closer to delivering impactful solutio",
          "content_length": 8481
        },
        "ingested_at": "2026-01-21T02:45:52.435874Z"
      },
      {
        "event_id": "RNS-30th Apr 2025-finalres",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435887Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Final Results",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/final-results-8x5pu7qctdxw568.html",
          "rns_number": "RNS Number : 8839G",
          "full_content": "30 Apr 2025 15:29\nRNS Number : 8839G\nGenflow Biosciences PLC\n30 April 2025\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n30 April 2025\nGenflow Biosciences Plc\n(\"Genflow\" or \"the Company\")\nFINAL RESULTS\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, is\npleased to announce its final results for the year ended 31 December 2024. The Annual Report will be available to view on the Company's website at\nwww.genflowbio.com\nand the full, unedited text of its final results can be found below.\n2024 Highlights\n\u00b7\nCommenced two collaborations with world-class researchers and laboratories, allowing the Company to receive the support of two non-diluting and non-reimbursable research grants.\n\u00b7\nThe Company's MASH study advanced closer towards the pre-IND phase of preclinical development.\n\u00b7\nReceived positive feedback from the FDA encouraging Genflow to proceed with its plans to identify appropriate animal models through pilot, proof-of-concept studies.\n\u00b7\nRaised funding of \u00a31.4 million (before expenses) through a mixture of non-dilutive research grants and equity fundraising during the year.\nThe Company will post the Annual Report to shareholders and provide notice for its Annual General Meeting in the coming weeks.\nIn accordance with Listing Rule 14.3.6R and 14.3.7R of the UK Financial Conduct Authority (\"FCA\"), a copy of the Annual Report will also be submitted to the FCA via the National Storage Mechanism and will shortly be available to the public for inspection at\nhttps://www.fca.org.uk/markets/primary-markets/regulatory-disclosures/national-storage-mechanism\n.\nGenflow is\na UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with advanced age. It is the first longevity biotechnology company to list in Europe and seeks to be a reference company in the European longevity sector.\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nBrokers\nCapital Plus Partners Ltd\nDominic Berger, +44 203 821 6167\nJon Critchley, +44 0203 821 6168\nChairperson's Report\nDear Shareholders,\nIntroduction\nI am pleased to present my statement as the Chairperson of Genflow Biosciences Plc (GENF) (the \"Company\").\nThe Company is a preclinical biotechnology company focused on the development of innovative biological interventions (namely gene therapies) which are aimed at tackling the effects of aging, potentially slowing or halting the aging process and so reducing the incidence of age-related diseases thereby increasing life span.\nDuring 2024, the Company made significant progress with its two core research programmes, MASH (Metabolic Dysfunction-Associated Steatohepatitis) and Werner Syndrome, and was pleased to report that it has entered into further collaborations with world-class researchers and laboratories on two new research programmes.\nMost notably, our MASH study is advancing into the pre-IND phase of preclinical development (a critical stage where companies discuss their product development with the FDA), and we have partnered with Exothera SA for GMP (good Manufacturing Practise) manufacturing of the clinical lot, utilising its state-of-the-art facilities in Belgium.\nIn June 2024, we received positive feedback from the FDA encouraging Genflow to proceed with its plans to identify appropriate animal models through pilot, proof-of-concept studies. This has emboldened us on our journey and provides encouragement that we may receive further positive feedback from the FDA once the Company has submitted a comprehensive briefing package conducted on our lead drug candidate, GF-1002, for the treatment of MASH.\nAn update on the status of each of our research projects has been detailed in the Strategic Report on page 5.\nOn 18 January 2024, we commenced two collaborations with world-class researchers and laboratories which allowed us to receive the support of two non-diluting and non-reimbursable research grants from the Government of Wallonia in Belgium, as follows;\n\u00b7\nSarcopenia\nresearch program with Revatis SA\n- focusing on the development of muscle progenitor cells loaded with Genflow's proprietary SIRT6, for the prevention and treatment of sarcopenia, the age-related loss of muscle mass and function.\n\u00b7\nExosome-mRNA project with EXO Biologics\n- which aims to deliver a therapeutic product composed of exosomes enc",
          "content_length": 164804
        },
        "ingested_at": "2026-01-21T02:45:52.435904Z"
      },
      {
        "event_id": "RNS-14th Apr 2025-launchof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435918Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Launch of AI-Powered Partnership",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/GENF/launch-of-ai-powered-partnership-qq2afx4th38o5ph.html",
          "rns_number": "RNS Number : 7586E",
          "full_content": "14 Apr 2025 07:00\nRNS Number : 7586E\nGenflow Biosciences PLC\n14 April 2025\n14 April 2025\nGenflow Biosciences Plc\nGenflow Biosciences Signs MSA with Heureka Labs, Launching AI-Powered Partnership in Gene Therapy Research\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\"), the only publicly listed longevity company in Europe, is pleased to announce that, in addition to the recently announced launch of a new development program in ophthalmology, it has entered into a strategic partnership with Heureka Labs, Inc., a U.S.-based AI-driven discovery and analytics platform.\nA Master Services Agreement (\"MSA\") was signed by both parties on 11 April 2025, establishing a framework for long-term collaboration.\nUnder the terms of the MSA, Heureka Labs, a technology spin-off from Duke University, will provide Genflow with access to its proprietary artificial intelligence (\"AI\") platform, which specializes in the analysis of high-dimensional genomic data including RNA sequencing and gene expression profiles. The application of Heureka's AI technology is expected to enhance Genflow's ability to interpret complex biological datasets, enabling deeper insights into gene regulatory networks and systemic biological responses. These insights will be key to optimising therapeutic design and anticipating patient-specific outcomes. Genflow will retain all IP rights under the MSA.\nInitial efforts will support the Company's lead candidate, GF-1002, a centenarian SIRT6-based gene therapy currently in preclinical evaluation and may extend to future pipeline gene therapy programs, including those targeting Metabolic Dysfunction-Associated Steatohepatitis (\"MASH\").\nHeureka's AI platform is designed to accelerate drug discovery processes by generating testable hypotheses, uncovering unexpected biological patterns, and improving the efficiency of research and development workflows. The platform is currently in use by leading pharmaceutical and biotechnology companies.\n\"\nIncorporating AI is no longer optional in bioinformatics research-it's essential for precision, speed, and scale\n,\" said Dr. Eric Leire, CEO of Genflow. \"\nHeureka's AI platform gives us the tools to navigate complex biological data and refine our gene therapy approach across a number of programs we are working on, accelerating the delivery of safe and effective therapies that promote a healthier lifespan, while helping to ease the growing operational and economic burden of an aging population\n.\"\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nCorporate Brokers\nCapital Plus Partners Ltd\nJon Critchley, +44 0203 821 6168\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH\n(Metabolic Dysfunction-Associated Steatohepatitis)\n, the most prevalent chronic liver disease for which there is no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on\nLinkedIn\nand\nX\n.\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRAPKDBNNBKDNQD",
          "content_length": 4482
        },
        "ingested_at": "2026-01-21T02:45:52.435930Z"
      },
      {
        "event_id": "RNS-10th Apr 2025-genflowl",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435943Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Genflow Launches New Development Program",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/GENF/genflow-launches-new-development-program-lrdwpbq4fgoacge.html",
          "rns_number": "RNS Number : 4093E",
          "full_content": "10 Apr 2025 07:00\nRNS Number : 4093E\nGenflow Biosciences PLC\n10 April 2025\n10 April 2025\nGenflow Biosciences Plc\nGenflow Biosciences Launches New Ophthalmology Development Program\nSigns MTA with Leading Ophthalmology Company\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\"), the only publicly listed longevity company in Europe, is excited to announce the launch of a new development program in ophthalmology, focused on advancing a novel gene therapy leveraging its proprietary Centenarian SIRT6 (cSIRT6). This therapy will utilize a specially designed non-viral vector engineered for precise delivery of Genflow's SIRT6 to the eye. The therapy is designed to combat ocular problems including several pathologies of the cornea and glaucoma.\nThis initiative is part of Genflow's continued efforts to optimize its gene therapy and proprietary Centenarian SIRT6. As part of this effort, Genflow has signed a Material Transfer Agreement (MTA) with a leading ophthalmology company, to collaborate on the design and development of the eye-targeted cSIRT6 non-viral vector to target ocular diseases. These therapies will leverage Genflow's proprietary SIRT6 Centenarian gene technology, in combination with an advanced vector delivery system.\nSaid Dr. Eric Leire, CEO of Genflow Biosciences: \"\nWe are thrilled to advance our ophthalmology program. The eye, as a closed and accessible compartment, presents an ideal target for gene therapy. More importantly, we believe that SIRT6 holds significant promise to transform the treatment landscape for corneal endothelial disorders and glaucoma\n.\"\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nCorporate Brokers\nCapital Plus Partners Ltd\nJon Critchley, +44 0203 821 6168\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH\n(Metabolic Dysfunction-Associated Steatohepatitis)\n, the most prevalent chronic liver disease for which there is no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on\nLinkedIn\nand\nX\n.\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRAEANLNEDFSEFA",
          "content_length": 3598
        },
        "ingested_at": "2026-01-21T02:45:52.435956Z"
      },
      {
        "event_id": "RNS-28th Mar 2025-holdingi",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435969Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/holding-in-company-w1e465vz97tg1k3.html",
          "rns_number": "RNS Number : 5931C",
          "full_content": "28 Mar 2025 07:10\nRNS Number : 5931C\nGenflow Biosciences PLC\n28 March 2025\n1. Issuer Details\nISIN\nGB00BP2C3V08\nIssuer Name\nGENFLOW BIOSCIENCES PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nMR ERIC LEIRE\nCity of registered office (if applicable)\n15 Ingestre Place,\nCountry of registered office (if applicable)\nUK\nName\nCity of registered office\nCountry of registered office\nEric Leire\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n27-Mar-2025\n6. Date on which Issuer notified\n27-Mar-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n36.180000\n0.000000\n36.180000\n126514999\nPosition of previous notification (if applicable)\n35.600000\n0.000000\n35.600000\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BP2C3V08\n126514999\n36.180000\nSub Total 8.A\n126514999\n36.180000%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n27-Mar-2025\n13. Place Of Completion\nLondon\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLDZGZFLNMGKZM",
          "content_length": 3838
        },
        "ingested_at": "2026-01-21T02:45:52.435981Z"
      },
      {
        "event_id": "RNS-28th Mar 2025-director",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.435994Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Director Dealings",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/director-dealings-9bmy32ocwcsnv3l.html",
          "rns_number": "RNS Number : 5924C",
          "full_content": "28 Mar 2025 07:00\nRNS Number : 5924C\nGenflow Biosciences PLC\n28 March 2025\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n28 March 2025\nGenflow Biosciences Plc\nDirector's Dealing\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\") the only longevity company listed in Europe, is pleased to announce\nthat it has been notified that Dr. Eric Leire, CEO of the Company, has today purchased 2,100,000 ordinary shares in the Company at a price of 1.15 pence each on the open market.\nDetails of the transaction are set out below:\nName\nDr. Eric Leire\nPosition\nChief Executive Officer\nDate of Purchase\n27 March 2025\nNumber of Ordinary Shares Purchased\n2,100,000\nPrice per Ordinary Share\n1.15p\nTotal Consideration\n\u00a324,150\nNature of Transaction\nMarket purchase\nTotal Shareholding Following the Transaction\n126,514,999\nInterest in Ordinary Shares (percentage)\n36.18%\nNOTIFICATION AND PUBLIC DISCLOSURE OF A TRANSACTION BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM\nThe following disclosure is made in accordance with the requirements of the UK Market Abuse Regulation and provides details in relation to the purchase of Ordinary Shares by a Director:\n1.\nDetails of the person discharging managerial responsibilities / person closely associated\na)\nName\nEric Leire\n2.\nReason for the Notification\na)\nPosition/status\nPDMR\nb)\nInitial notification / Amendment\nInitial notification\n3.\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na)\nName\nGenflow Biosciences Plc\nb)\nLEI\n213800HVOFXRXVEGDN62\n4.\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\na)\nDescription of the Financial instrument, type of instrument\nOrdinary Shares of \u00a30.0003\nIdentification Code\nGB00BP2C3V08\nb)\nNature of the transaction\nIssue of ordinary shares\nc)\nPrice(s) and volume(s)\nPrice(s)\nVolume(s)\n1.15\npence per Ordinary Share\n2,100,000 Ordinary Shares\nd)\nAggregated information:\n\uf0b7 Aggregated volume\n\u00b7 Price\n2,100,000 Ordinary Shares\n1.15 pence per Ordinary Share\ne)\nDates of the transactions\n27 March 2025\nf)\nPlace of the transactions\nLondon\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nCorporate Brokers\nCapital Plus Partners Ltd\nJon Critchley, +44 0203 821 6168\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Expected to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH\n(Metabolic Dysfunction-Associated Steatohepatitis)\n, the most prevalent chronic liver disease for which there is no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on LinkedIn and Twitter/X.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nDSHBCGDXDDDDGUR",
          "content_length": 4553
        },
        "ingested_at": "2026-01-21T02:45:52.436007Z"
      },
      {
        "event_id": "RNS-26th Mar 2025-institut",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.436021Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Institutional Investment",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/institutional-investment-t4xqk8sr709yn61.html",
          "rns_number": "RNS Number : 1473C",
          "full_content": "26 Mar 2025 07:00\nRNS Number : 1473C\nGenflow Biosciences PLC\n26 March 2025\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n26 March 2025\nGenflow Biosciences Plc\nGenflow Secures \u00a3434,083 from a Leading Institution and Launches a Gene Therapy Trial in Aged Dogs\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\") the only longevity company listed in Europe, is pleased to announce it has received a binding offer from a major institution for an equity investment totalling \u00a3434,083 (before expenses).\nThe investor has applied for 41,341,324 Ordinary Shares of \u00a30.0003 each at a price of 1.05p (the \"New Ordinary Shares\"). The number of New Ordinary Shares applied for by the subscriber is the maximum number of shares (on a fully diluted basis) available to the Company to issue without the need to produce a Prospectus. These New Ordinary Shares cannot be issued until after 9 April 2025 when the Company's headroom, under the Prospectus Rules, increases.\nAn application will be made to the Main Market of the London Stock Exchange, and admission of the New Ordinary Shares to trading is expected on or around 10 April 2025 (\"Admission\"). The New Ordinary Shares will, when issued, rank\npari passu\nwith the Company's existing Ordinary Shares.\nDirector's Intended Participation\nEric Leire, a Director of the Company, intends to invest \u00a350,000 on the same terms as the investment outlined above on the basis that such participation falls under the employee offer exemption under Article 1(4)(i) and 1(5)(h) of the UK Prospectus Regulation, and further, subject to the Company not being in a Closed Period at the time of such investment and the same being subject to the Company's share dealing policy.\nA further announcement will be made in relation to this in due course.\nTotal Voting Rights\nFor the purpose of the Disclosure Guidance and Transparency Rules, following Admission the enlarged issued share capital of the Company will comprise 391,047,942 ordinary shares. For the avoidance of doubt, this excludes any intended equity participation by Eric Leire.\nThe Company does not hold any shares in treasury. The above figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.\nTamara Joseph, Chair of the Company, commented \"\nWe are extremely pleased to have been approached by an institution who wishes to support Genflow in its journey in pioneering gene therapies to decelerate the aging process. The use of these proceeds will accelerate the Company's proposed studies and trials in aged dogs, an issue which has attracted a great deal of press coverage,\nincluding in recent weeks\n.\n\"\nUse of Proceeds\nThis investment, combined with previously awarded government grants, will accelerate the Company's planned 2025 programs including launching a clinical trial in aged dogs.\nGenflow has commenced a proof-of-concept clinical trial to evaluate the safety and efficacy of its proprietary SIRT6-centenarian gene therapy targeting age-related decline in dogs.\nThe Company will treat the dogs for 6 months and assess the safety and efficacy of our therapy for the following 6 months. This is a randomized, controlled trial with 28 dogs aged 10+ years, conducted with the renowned CRO, Syngene. Genflow will compare recipient dogs of intravenous injections of proprietary SIRT6 gene therapy versus untreated control group. Endpoints will include biological age estimation (via GRIM methylation clock), muscle strength, muscle mass, mitochondrial function, coat quality and overall health indicators.\n\"\nAs a devoted dog owner myself, I have a 9-year-old golden retriever, I know firsthand the desire we all share for more happy, healthy years of with our beloved pets\n,\" said Dr. Eric Leire, CEO of Genflow. \"\nOur goal is not just to extend their lifespan, but to enhance their quality of life. By targeting biological aging in dogs, we also can unlock groundbreaking insights that could revolutionize both veterinary and human medicine. This research has the potential to reshape the way we approach aging, offering hope for longer, healthier lives for all\n.\"\nFurther updates on the progress of the study will be provided in due course.\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nCorporate Broker\nCapital Plus Partners Ltd\nJon Critchley, +44 0203 821 6168\nAbout Genflow Biosciences\nFoun",
          "content_length": 9884
        },
        "ingested_at": "2026-01-21T02:45:52.436034Z"
      },
      {
        "event_id": "RNS-20th Feb 2025-advancem",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.436048Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Advancements in SIRT6 Variant Patent Application",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/GENF/advancements-in-sirt6-variant-patent-application-d6nhla1fyd3xy80.html",
          "rns_number": "RNS Number : 7707X",
          "full_content": "20 Feb 2025 07:00\nRNS Number : 7707X\nGenflow Biosciences PLC\n20 February 2025\n20 February 2025\nGenflow Biosciences Plc\nGenflow Biosciences Advances SIRT6 Variant Patent Application Following Positive Search Report from European Patent Office\nGenflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (\"Genflow\" or \"the Company\") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to\nannounce today that its exclusive, out-licensed patent application for \"Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases\" has successfully progressed through the Supplementary European Search Report without further questions from the European Patent Office (EPO).\nThe European patent application (EP 22 808 414.1), originally filed on May 13, 2022, by the University of Rochester, The Trustees of Columbia University in the City of New York, and the Albert Einstein College of Medicine, marks a significant step in securing protection for SIRT6 variants, a promising innovation in age-related disease therapeutics. The SIRT6 gene/protein, is known for its critical role in DNA repair, metabolism, and longevity.\nFollowing the EPO's assessment, no further questions were raised, allowing the application to progress to the national phase of the patent process, a critical stage in securing market-specific protections across Europe.\nKey Details:\n\u00b7\nApplication Title:\nVariants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases\n\u00b7\nApplicants:\nUniversity of Rochester; The Trustees of Columbia University in the City of New York; Albert Einstein College of Medicine\n\u00b7\nPatent Application Number:\nEP 22 808 414.1\n\u00b7\nFiling Date:\n13 May 2022\n\u00b7\nResult:\nThe application met all requirements of the European Patent Convention (EPC).\n\u00b7\nNext Steps:\nGenflow is preparing its intention to advance the application required by 7 July 2025.\nGenflow remains focused on advancing its longevity-focused therapeutic pipeline and will continue to update stakeholders as the patent application progresses.\nDr. Eric Leire, CEO of Genflow commented: \"This positive outcome represents a significant step forward in securing broad intellectual property protection for our innovative work on SIRT6 variants. This milestone strengthens our position in SIRT6-based therapeutics and accelerates our mission to develop effective treatments for age-related diseases.\"\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nJoint Corporate Brokers\nCapital Plus Partners Ltd\nJon Critchley, +44 0203 821 6168\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Expected to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH\n(Metabolic Dysfunction-Associated Steatohepatitis)\n, the most prevalent chronic liver disease for which there is no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on LinkedIn and Twitter/X.\nDISCLAIMER\nThe contents of this announcement have been prepared by, and are the sole responsibility of, the Company.\nThis announcement may contain forward-looking statements.\u00a0The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words \"anticipate\", \"believe\", \"continue\", \"could\", \"estimate\", \"expect\", \"intend\", \"may\", \"might\", \"plan\", \"possible\", \"potential\", \"predict\", \"project\", \"seek\", \"should\", \"would\" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.\nForward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of fu",
          "content_length": 7557
        },
        "ingested_at": "2026-01-21T02:45:52.436062Z"
      },
      {
        "event_id": "RNS-13th Jan 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.436075Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/holdings-in-company-74wrmoqwloacswn.html",
          "rns_number": "RNS Number : 9897S",
          "full_content": "13 Jan 2025 07:30\nRNS Number : 9897S\nGenflow Biosciences PLC\n13 January 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BP2C3V08\nIssuer Name\nGENFLOW BIOSCIENCES PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nJonathan Mark Swann\nCity of registered office (if applicable)\nrickmansworth\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n10-Jan-2025\n6. Date on which Issuer notified\n13-Jan-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n6.010000\n0.000000\n6.010000\n21025000\nPosition of previous notification (if applicable)\n5.030000\n0.000000\n5.030000\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BP2C3V08\n21025000\n0\n6.010000\n0.000000\nSub Total 8.A\n21025000\n6.010000%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\nnone\n12. Date of Completion\n13-Jan-2025\n13. Place Of Completion\nLondon\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLBTMFTMTIBBIA",
          "content_length": 3844
        },
        "ingested_at": "2026-01-21T02:45:52.436088Z"
      },
      {
        "event_id": "RNS-13th Jan 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.436109Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/holdings-in-company-qi84dyq5xbr8csq.html",
          "rns_number": "RNS Number : 9890S",
          "full_content": "13 Jan 2025 07:00\nRNS Number : 9890S\nGenflow Biosciences PLC\n13 January 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BP2C3V08\nIssuer Name\nGENFLOW BIOSCIENCES PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of financial instruments\n3. Details of person subject to the notification obligation\nName\nPremier Miton Group plc\nCity of registered office (if applicable)\nGUILDFORD\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n09-Jan-2025\n6. Date on which Issuer notified\n10-Jan-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n4.331420\n0.000000\n4.331420\n15147262\nPosition of previous notification (if applicable)\n9.150527\n0.000000\n9.150527\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BP2C3V08\n15147262\n4.331420\nSub Total 8.A\n15147262\n4.331420%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nPremier Miton Group plc\nPremier Miton Group Plc\nPremier Miton Group plc\nPremier Asset Management Midco Ltd\nPremier Miton Group plc\nPremier Asset Management Holdings Ltd\nPremier Miton Group plc\nPremier Asset Management Limited\nPremier Miton Group plc\nPremier Investment Group Ltd\nPremier Miton Group plc\nPremier Fund Managers Ltd\n4.331420\n4.331420%\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n10-Jan-2025\n13. Place Of Completion\nGuildford, UK\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLBTMFTMTJBBLA",
          "content_length": 4210
        },
        "ingested_at": "2026-01-21T02:45:52.436123Z"
      },
      {
        "event_id": "RNS-6th Jan 2025-2024high",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.436136Z",
        "source": "LSE_RNS",
        "data": {
          "title": "2024 Highlights",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/GENF/2024-highlights-htii3hg5e2mrz5v.html",
          "rns_number": "RNS Number : 1493S",
          "full_content": "6 Jan 2025 07:00\nRNS Number : 1493S\nGenflow Biosciences PLC\n06 January 2025\n6 January 2025\nGenflow Biosciences Plc\n(\"Genflow\" or \"the Company\")\nA Look Back at an Exciting 2024\n2024 has been an incredible year for Genflow as we advance our mission to develop novel therapeutics that promote a longer, healthier life.\nOur focus on the SIRT6 gene and its potential to slow aging and delay age-related diseases has seen significant progress. This year, we've strengthened our leadership by collaborating with world-class researchers and laboratories, with generous support from the Belgian Government that has been instrumental in advancing our work.\nProgram Highlights\nThroughout the year, our programs made significant strides, including:\n\u25cf\nMASH (GF-1002):\nWe are advancing to the pre-IND phase of our preclinical development and have partnered with Exothera SA for GMP manufacturing of the clinical lot. Exothera, a specialized CDMO, provides end-to-end GMP manufacturing services for viral vectors, RNA therapeutics and vaccines, with state-of-the-art facilities in Belgium and the US.\nLeveraging these innovative technologies and expertise, we are positioned to fast-track our progress and initiate the first proof-of-concept study of our gene therapy in patients with MASH. This milestone is a critical achievement for the Company, signaling our readiness to transition into clinical trials and showcasing the maturity and scalability of our therapeutic platform. Prior to commencing GMP manufacturing, we will ensure full regulatory compliance to reinforce confidence in our program among potential partners, investors, and regulatory agencies.\n\u25cf\nWerner Syndrome (GF-1003):\nWe have developed a proprietary liver organoid derived from human cells of patients with Werner syndrome. Organoids are miniature, three-dimensional tissue models (grown in the lab) that mimic the structure and function of real organs.\nCompared to using animal models, organoids offer several advantages: they are derived from human cells from patients affected with the disease, providing more accurate insights into human-specific biology; they reduce reliance on animals in research; and they allow for personalized disease modeling and drug testing tailored to individual patients.\n\u25cf\nDog Aging (GF-1004):\nWe are initiating a life extension clinical trial for aging dogs in collaboration with our contract research partner, Syngene. This six-month study will assess the potential of a veterinary version of our gene therapy to extend both the health span and lifespan of dogs. We expect to complete the full analysis of the trial by the end of 2025. Based on the outcomes, we may explore partnership opportunities or licensing agreements with veterinary specialty pharmaceutical companies.\n\u25cf\nSarcopenia (GF-1005):\nWe are making steady progress with our project aimed at addressing mitochondrial dysfunction observed in sarcopenia. This work focuses on restoring mitochondrial health as a key factor in combating the condition. The loading of myoblast progenitors with centSIRT6 is currently underway in collaboration with our partner, Universit\u00e9 libre de Bruxelles (ULB). We are optimistic that these efforts will pave the way for innovative solutions to improve muscle health and combat sarcopenia effectively.\nLooking Ahead\nAs we prepare for 2025, we are energized by the progress we've made and the opportunities ahead. Our commitment to tackling aging as a fundamental risk factor for chronic diseases remains steadfast. With continued collaboration and innovation, we are confident we will achieve great things in the coming year.\nThank you all for your trust and support on this journey. Our stakeholders' belief in what we're working towards means the world to us and we can't wait to share more exciting updates in the months to come!\nDr Eric Leire\nCEO\nGenflow Biosciences Plc.\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nCorporate Brokers\nCapital Plus Partners Ltd\nJon Critchley, +44 0203 821 6168\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and Twitter/X.\nDI",
          "content_length": 8963
        },
        "ingested_at": "2026-01-21T02:45:52.436151Z"
      },
      {
        "event_id": "RNS-22nd Oct 2024-genflows",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.436165Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Genflow Secures Non-Dilutive Financial Support",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/genflow-secures-non-dilutive-financial-support-3c5qf0qu1lsqvp0.html",
          "rns_number": "RNS Number : 0101J",
          "full_content": "22 Oct 2024 07:00\nRNS Number : 0101J\nGenflow Biosciences PLC\n22 October 2024\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n22 October 2024\nGenflow Biosciences Plc\nGenflow Secures \u20ac4 Million Non-Dilutive Financial Support from Wallonia Region for GF-1002 Development\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to\nannounce today that it has received official confirmation of \u20ac4,026,525 in non-dilutive financial support from the Wallonia region. The funds will support the ongoing development of Genflow's lead gene therapy, GF-1002, for the treatment of Metabolic Associated Steatohepatitis (MASH), a severe and progressive liver disease.\nThe financial support comprises a \u20ac1,218,349.44 non-reimbursable research grant, covering 70% of the Company's research costs, and a \u20ac2,808,175.92 recoverable advance, repayable to the Wallonia region upon commercialisation GF-1002 for use in treating MASH, funding 55% of the Company's development costs. This funding, when received, is expected to cover three years of Genflow's development program for GF-1002,with the first installment being received as working capital. The Company is committed to securing the necessary funding to cover its share of the project over the next three years.\nThe securing of such funding marks a significant milestone for Genflow and will enable the Company to accelerate the clinical progress of GF-1002, which represents a novel approach to treating MASH, a condition with limited treatment options. The Wallonia region's financial support highlights the growing recognition of Genflow's innovative work in gene therapy.\nDr. Eric Leire, CEO of Genflow, commented: \"We are delighted to receive this substantial financial backing from the Wallonia region as it is an important validation of our research and development efforts. It will allow us to further the development of GF-1002 and strengthen our position at the forefront of gene therapy innovation for MASH treatment. We would like to sincerely thank the Wallonia region for its support.\"\nFurther updates on the progress of GF-1002 will be provided in due course.\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nCorporate Brokers\nCapital Plus Partners Ltd\nKeith Swann, +44 0203 821 6169\nJon Critchley, +44 0203 821 6168\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population.\nGenflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's development program is exploring the potential benefits of GF-1002 in treating MASH\n(Metabolic Dysfunction-Associated Steatohepatitis)\n, the most prevalent chronic liver disease for which there is no effective treatments.\nPlease visit\nwww.genflowbio.com\nand follow the Company on LinkedIn and Twitter/X.\nDISCLAIMER\nThe contents of this announcement have been prepared by, and are the sole responsibility of, the Company.\nThis announcement may contain forward-looking statements.\u00a0The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words \"anticipate\", \"believe\", \"continue\", \"could\", \"estimate\", \"expect\", \"intend\", \"may\", \"might\", \"plan\", \"possible\", \"potential\", \"predict\", \"project\", \"seek\", \"should\", \"would\" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.\nForward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements r",
          "content_length": 7819
        },
        "ingested_at": "2026-01-21T02:45:52.436180Z"
      },
      {
        "event_id": "RNS-30th Sep 2024-half-yea",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.436193Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Half-year Report",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/half-year-report-45xvtkykrdscgje.html",
          "rns_number": "RNS Number : 1227G",
          "full_content": "30 Sep 2024 07:00\nRNS Number : 1227G\nGenflow Biosciences PLC\n30 September 2024\nPRESS RELEASE\n30 September 2024\nGenflow Biosciences Plc\n(\"Genflow\" or \"the Company\")\nHALF YEAR RESULTS\nGenflow (LSE: GENF) is pleased to announce its half year results for the six-month period ended 30 June 2024.\nChairman's Statement\nIt is with pleasure that I take this opportunity to update shareholders of Genflow Biosciences Plc (\"Genflow\" or the \"Company\") on the Company's performance during the first six months of 2024.\nOver the six months to 30 June 2024, the Company has made strides in its principal longevity programs: MASH (Metabolic Dysfunction-Associated Steatohepatitis) and Werner Syndrome.\nIn June, we updated shareholders on the momentum created with respect to our pre-clinical programs in MASH, and the guidance expected to be received from the FDA in the future. This guidance, which we anticipate receiving in the future, is expected to come through the FDA's Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT), as a result of the Company submitting a comprehensive briefing package conducted with our lead drug candidate, GF-1002, for the treatment of MASH. In the meantime, the FDA has encouraged Genflow to proceed with its plans to identify appropriate animal models through pilot proof-of-concept (\"POC\") studies. Specifically, we have established a functional 3-D organoids of liver using cells from Werner patients. This organoid testing helps reduce the need for animal models in our scientific research. Organoids are miniature, lab-grown versions of human organs or tissues that mimic the structure and function of their real counterparts. By using these organoids, we can model human Werner Syndrome and better test response of our SIRT6 based gene therapy in a more human-relevant environment, rather than relying on unreliable animal models.\nAdditionally, we have initiated a feasibility study with a Contract Development Manufacturing Organization (CDMO), Exothera S.A, to assess the ability to produce its future MASH clinical lot in accordance with Good Manufacturing Practices (GMP). We are also in the process of selecting Contract Research Organizations (CROs) to conduct our upcoming dog clinical trial, aimed at studying our simplified Nake DNA version of our Centenarian SIRT6 drug candidate, GF-1004. We will provide updates in relation to our veterinary study in due course.\nOver the period, we have also been working on two exciting collaborations supported by non-diluting and non-reimbursable research grants from the Government of Wallonia in Belgium, as follows;\n\u00b7\nSarcopenia\nresearch program with Revatis SA\n- focusing on the development of muscle progenitor cells which will be loaded with Genflow's proprietary SIRT6 for the prevention and treatment of sarcopenia, the age-related loss of muscle mass and function. Genflow aims to counteract the detrimental effects of aging on muscle tissue with our sarcopenia program, which holds potential for significantly improving the quality of life for older adults affected by muscle loss and weakness.\n\u00b7\nExosome-mRNA project with EXO Biologics\n- which aims to deliver a therapeutic product composed of exosomes encapsulating an AAV or mRNA encoding SIRT6. The exosome therapy will be designed to target liver fibrosis (MASH) and Werner Syndrome, potentially leading to groundbreaking treatments for both diseases.\nDuring the period, the Company has received grant funding of totalling \u20ac777,281 in respect of these projects, with further financial support committed in the first half of 2025.\nIn addition, Genflow Biosciences SRL, received \u20ac350,000 in April 2024, from the regional government of Wallonia - Belgium Service Public de Wallonie, representing the second tranche of this awarded grant recognised in the previous year, 2023.\nFurther strengthening the Company's financial position and increasing its institutional investor base, the Company completed a placing and subscription to which raised \u00a3715,000 (before expenses) during the period. We were privileged to have Premier Miton, a well-known UK institution, participate in this fundraise.\nFinancial Overview\nAs of 30 June 2024, the Group had cash reserves of \u00a31,139,859 (31 December 2023: \u00a3683,974) which has been derived from equity fundraising of \u00a3663,600 (net of expenses) and the receipt of research and development grants of \u00a3664,219 (\u20ac777,281) and \u00a3299,145 (\u20ac350,000) The Company remains debt free.\nAdministration expenses for 30 June 2024 totalled \u00a31,316,368 (30 June 2023: \u00a3815,477), which primarily consisted of research and development costs of \u00a3938,109 (30 June 2023: \u00a3415,157), legal and professional fees totalling \u00a390,654 (30 June 2023: \u00a3103,366) and Directors' fees of \u00a3178,656 (30 June 2023: \u00a3178,783).\nThe significant jump in research and development costs for 2024 is in relation to the advancement of testing, which has transitioned to the\nin vivo stage\n, which is inherently more costly.\nOther Comprehensive Incom",
          "content_length": 24067
        },
        "ingested_at": "2026-01-21T02:45:52.436208Z"
      },
      {
        "event_id": "RNS-27th Jun 2024-resultof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.436221Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Result of AGM",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/result-of-agm-3eaggnxspemoa7x.html",
          "rns_number": "RNS Number : 1943U",
          "full_content": "27 Jun 2024 13:30\nRNS Number : 1943U\nGenflow Biosciences PLC\n27 June 2024\n27 June 2024\nGenflow Biosciences Plc\nResults of Annual General Meeting\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased\nto announce that all resolutions proposed at the Annual General Meeting held earlier today were duly passed.\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nCapital Plus Partners Ltd\nKeith Swann, +44 0203 821 6169\nJon Critchley, +44 0203 821 6168\nAbout Genflow\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments.\nPlease visit\nwww.genflowbio.com\nand follow the Company on LinkedIn and Twitter/X.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nRAGQKOBQDBKDAAB",
          "content_length": 2397
        },
        "ingested_at": "2026-01-21T02:45:52.436234Z"
      },
      {
        "event_id": "RNS-12th Jun 2024-receipto",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.436247Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Receipt of Grant Funding",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/receipt-of-grant-funding-lq2qthpx5z2wpct.html",
          "rns_number": "RNS Number : 0406S",
          "full_content": "12 Jun 2024 07:00\nRNS Number : 0406S\nGenflow Biosciences PLC\n12 June 2024\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n12 June 2024\nGenflow Biosciences Plc\nReceipt of Grant Funding\nGenflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (\"Genflow\" or \"the Company\") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases\nis pleased to announce receipt of \u20ac395,847\nrepresenting 50% of the Exofastrack research grant\nfrom the Government of Wallonia in Belgium's\nAdvanced Therapy Medicinal Products (ATMPs).\nThe grant, a non-dilutive, non-reimbursable subsidy, supports Genflow and EXO Biologics' 3-year scientific program. Covering 80% of the expenses, the grant will be used for working capital.\nThe program\n(see press release\nhere\n)\nwill deliver a therapeutic product composed of exosomes encapsulating an AAV or mRNA encoding SIRT6. The exosome therapy will be designed to target liver fibrosis (MASH) and Werner Syndrome, an accelerated aging disease.\nDr. Eric Leire, CEO of Genflow commented: \"We are thrilled to receive this grant from the Government of Wallonia. This funding will significantly advance our research program focused on exosome-based therapies, potentially leading to groundbreaking treatments for liver fibrosis and Werner Syndrome. Our commitment to pioneering therapeutic solutions for longevity is further strengthened by this support, and we look forward to the impactful developments that will emerge from this collaboration.\"\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nJoint Corporate Brokers\nClear Capital Markets\nCapital Plus Partners Ltd\nBob Roberts, +44 203 869 6080\nDominic Berger, +44 203 821 6167\nKeith Swann, +44 0203 821 6169\nJon Critchley, +44 0203 821 6168\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH\n(Metabolic Dysfunction-Associated Steatohepatitis)\n, the most prevalent chronic liver disease for which there is no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on LinkedIn and Twitter/X.\nDISCLAIMER\nThe contents of this announcement have been prepared by, and are the sole responsibility of, the Company.\nThis announcement may contain forward-looking statements.\u00a0The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words \"anticipate\", \"believe\", \"continue\", \"could\", \"estimate\", \"expect\", \"intend\", \"may\", \"might\", \"plan\", \"possible\", \"potential\", \"predict\", \"project\", \"seek\", \"should\", \"would\" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.\nForward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in ",
          "content_length": 7186
        },
        "ingested_at": "2026-01-21T02:45:52.436263Z"
      },
      {
        "event_id": "RNS-3rd Jun 2024-noticeof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.436276Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Notice of AGM",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/notice-of-agm-iur9j3k3eggadu1.html",
          "rns_number": "RNS Number : 7241Q",
          "full_content": "3 Jun 2024 07:00\nRNS Number : 7241Q\nGenflow Biosciences PLC\n03 June 2024\n3 June 2024\nGenflow Biosciences Plc\nNotice of Annual General Meeting\nGenflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (\"Genflow\" or \"the Company\") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce that it will hold its Annual General Meeting (\"AGM\") at 12pm on Thursday 27 June 2024 at 1 Heddon Street, London, W1B 4BT.\nThe Notice of the AGM (\"Notice\") and 2024 Form of Proxy will shortly be available on the Company's website,\nwww.genflowbio.com\n, and have, where applicable, been posted to shareholders. Further details of the arrangements for this year's AGM are set out in the Notice.\nAs announced on 7 May 2024, the Company's Annual Report and Accounts for the year ended 31 December 2023 are also available on the website and has, where applicable, also been posted to registered shareholders.\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nJoint Corporate Brokers\nClear Capital Markets\nCapital Plus Partners Ltd\nBob Roberts, +44 203 869 6080\nDominic Berger, +44 203 821 6167\nKeith Swann, +44 0203 821 6169\nJon Critchley, +44 0203 821 6168\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on LinkedIn and Twitter/X.\n-Ends-\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNOAQKDBPPBKDCPN",
          "content_length": 3027
        },
        "ingested_at": "2026-01-21T02:45:52.436289Z"
      },
      {
        "event_id": "RNS-30th May 2024-receipto",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.436302Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Receipt of Grant Funding",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/receipt-of-grant-funding-qpmouu4eamdc1kq.html",
          "rns_number": "RNS Number : 3593Q",
          "full_content": "30 May 2024 07:00\nRNS Number : 3593Q\nGenflow Biosciences PLC\n30 May 2024\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n30 May 2024\nGenflow Biosciences Plc\nReceipt of Grant Funding\nGenflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (\"Genflow\" or \"the Company\") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases\nis pleased to announce receipt of 50% of its substantial non-diluting and non-reimbursable research grant. The amount received totals \u20ac381,434\nfrom the Government of Wallonia in Belgium's\nAdvanced Therapy Medicinal Products (ATMPs).\nGenflow, together with its partner Revatis SA, has launched a 3-year sarcopenia research program [see news release\nhere\n].\nT\nhe remaining funds from the grant will be disbursed over the next two years based on submitted invoices. The grant will be utilized as working capital to support the Sarcopenia project\n.\nThe Sarcopenia Project focuses on the development of muscle progenitor cells (MPCs) which will be loaded with Genflow's proprietary SIRT6 for the prevention and treatment of sarcopenia. This innovative approach aims to address the underlying causes of sarcopenia and promote muscle regeneration. Muscle progenitor cells are a type of stem cell capable of differentiating into muscle cells, playing a crucial role in muscle repair and regeneration. In sarcopenic muscles, the activity and number of MPCs decline, leading to impaired muscle regeneration. By loading MPCs with the SIRT6 gene, Genflow aims to enhance the regenerative capacity of these cells and counteract the detrimental effects of aging on muscle tissue.\nDr. Eric Leire, CEO of Genflow commented: \"Sarcopenia, the age-related loss of muscle mass and function, is a significant health issue affecting older adults worldwide. Genflow aims to counteract the detrimental effects of aging on muscle tissue with our Sarcopenia program, which holds potential for significantly improving the quality of life for older adults affected by muscle loss and weakness.\"\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nJoint Corporate Brokers\nClear Capital Markets\nCapital Plus Partners Ltd\nBob Roberts, +44 203 869 6080\nDominic Berger, +44 203 821 6167\nKeith Swann, +44 0203 821 6169\nJon Critchley, +44 0203 821 6168\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH\n(Metabolic Dysfunction-Associated Steatohepatitis)\n, the most prevalent chronic liver disease for which there is no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on LinkedIn and Twitter/X.\nDISCLAIMER\nThe contents of this announcement have been prepared by, and are the sole responsibility of, the Company.\nThis announcement may contain forward-looking statements.\u00a0The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words \"anticipate\", \"believe\", \"continue\", \"could\", \"estimate\", \"expect\", \"intend\", \"may\", \"might\", \"plan\", \"possible\", \"potential\", \"predict\", \"project\", \"seek\", \"should\", \"would\" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.\nForward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes ",
          "content_length": 7719
        },
        "ingested_at": "2026-01-21T02:45:52.436317Z"
      },
      {
        "event_id": "RNS-10th May 2024-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.436330Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/holdings-in-company-bnngayvf74s0qf3.html",
          "rns_number": "RNS Number : 9746N",
          "full_content": "10 May 2024 09:11\nRNS Number : 9746N\nGenflow Biosciences PLC\n10 May 2024\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BP2C3V08\nIssuer Name\nGENFLOW BIOSCIENCES PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nJonathan Mark Swann\nCity of registered office (if applicable)\nrickmansworth\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n09-May-2024\n6. Date on which Issuer notified\n10-May-2024\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n5.030000\n0.000000\n5.030000\n17586000\nPosition of previous notification (if applicable)\n4.830000\n0.000000\n4.830000\n16874000\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BP2C3V08\n17586000\n0\n5.030000\n0.000000\nSub Total 8.A\n17586000\n5.030000%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\nNONE\n12. Date of Completion\n10-May-2024\n13. Place Of Completion\nLondon\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLAMMPTMTBBMMI",
          "content_length": 3849
        },
        "ingested_at": "2026-01-21T02:45:52.436342Z"
      },
      {
        "event_id": "RNS-8th May 2024-restorat",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.436355Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Restoration - GENFLOW BIOSCIENCES PLC",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/restoration-genflow-biosciences-plc-dkukzxmh3wuxscm.html",
          "rns_number": "RNS Number : 5960N",
          "full_content": "8 May 2024 11:00\nRNS Number : 5960N\nOfficial List\n08 May 2024\nNOTICE OF RESTORATION OF LISTING FROM THE OFFICIAL LIST\n08/05/2024 11:00\nRESTORATION\nGENFLOW BIOSCIENCES PLC\nThe Financial Conduct Authority (\"the FCA\") restores the securities set out below to the Official List effective from\u00a008/05/2024 11:00:\nSecurity Description\nListing Category\nISIN\nOrdinary Shares of GBP0.0003 each; fully paid\nStandard Shares\nGB00BP2C3V08\u00a0\u25cf\nThis notice has been issued by Issuer Management - 020 7066 8352.\nNotesSEDOL numbers which are allocated by the London Stock Exchange as a Stock Exchange identifier may be found on their dealing notice.\u25cfDenotes the security is being admitted to trading on the London Stock Exchange, a Recognised Investment Exchange.\u2020Denotes the security is also being admitted to trading on Aquis Stock Exchange, a Recognised Investment Exchange.#Denotes the security is also being admitted to trading on Euronext, a Recognised Investment Exchange.\n\u223c\nDenotes the security is also being admitted to trading on Cboe Europe, a Recognised Investment Exchange.^Denotes the security is also being admitted to trading on Shanghai-London Stock Connect, a Recognised Investment Exchange.*Denotes the security is also being admitted to trading on IPSX Prime, a Recognised Investment Exchange.Notices issued by the FCA in respect of admission of securities to the Official List must be read in conjunction with notices issued by the relevant Recognised Investment Exchange in respect of admission of securities to trading on its markets.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nRENAPMPTMTJMMII",
          "content_length": 2317
        },
        "ingested_at": "2026-01-21T02:45:52.436368Z"
      },
      {
        "event_id": "RNS-8th May 2024-restorat",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.436381Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Restoration of Listing",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/restoration-of-listing-nrd9g3t86rrukh2.html",
          "rns_number": "RNS Number : 6092N",
          "full_content": "8 May 2024 10:17\nRNS Number : 6092N\nGenflow Biosciences PLC\n08 May 2024\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n8 May 2024\nGenflow Biosciences Plc\nRestoration of Listing\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases,\nis pleased to announce that, following publication of the audited financial statements for the year ended 31 December 2023 (\nFY23 Results\n) on 7 May 2024, and having completed the upload of the FY23 Results to the Financial Conduct Authority's National Storage Mechanism at www.fca.org.uk/markets/primary-markets/regulatory-disclosures/national-storage-mechanism, it has been advised by the FCA that the temporary suspension of listing of the Company's ordinary shares on the Official List of the Financial Conduct Authority is expected to be lifted later today, 8 May 2024, and that the listing on the Main Market of the London Stock Exchange, of the ordinary shares, will be restored.\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nJoint Corporate Brokers\nClear Capital Markets\nCapital Plus Partners Ltd\nBob Roberts, +44 203 869 6080\nDominic Berger, +44 203 821 6167\nKeith Swann, +44 0203 821 6169\nJon Critchley, +44 0203 821 6168\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating NASH; now called MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments.\nPlease visit\nwww.genflowbio.com\nand follow the Company on LinkedIn and Twitter/X.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nRENUWAKRSNUVRRR",
          "content_length": 3505
        },
        "ingested_at": "2026-01-21T02:45:52.436393Z"
      },
      {
        "event_id": "RNS-7th May 2024-fulltext",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.436406Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Full Text of Accounts",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/full-text-of-accounts-u7ntt8pi0gpr332.html",
          "rns_number": "RNS Number : 4626N",
          "full_content": "7 May 2024 13:10\nRNS Number : 4626N\nGenflow Biosciences PLC\n07 May 2024\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n7 May 2024\nGenflow Biosciences Plc\nFull Text of Final Accounts to 31 December 2023\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, sets out below the full, unedited text of its final results for the year ended 31 December 2023, announced earlier today, to assist shareholders and other interested parties.\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nJoint Corporate Brokers\nClear Capital Markets\nCapital Plus Partners Ltd\nBob Roberts, +44 203 869 6080\nDominic Berger, +44 203 821 6167\nKeith Swann, +44 0203 821 6169\nJon Critchley, +44 0203 821 6168\nChairperson's Report\nDear Shareholders,\nIntroduction\nI am pleased to present my statement as the Chairperson of Genflow Biosciences Plc (GENF) (the \"Company\").\nThe Company is a preclinical biotechnology company focused on the development of innovative biological interventions (namely gene therapies) which are aimed at tackling the effects of aging, potentially slowing or halting the aging process and so reducing the incidence of age-related diseases and thereby increasing life span.\nOver the past year, the Company has achieved numerous important milestones and I would like to sincerely thank our team for its exceptional commitment to execution and delivery.\nAs mentioned in greater detail in the Strategic report on page 5, the Company's subsidiary Genflow Biosciences SRL (together the \"Group\") is making great progress with its two principal longevity programs: NASH; now called MASH (Metabolic Dysfunction-Associated Steatohepatitis), as well as its work on Werner Syndrome. Most notably in relation to our MASH program, the Company had its first interaction with the Federal Agency for Medicines and Health Products (FAHMP) which was successful. FAHMP concurred with Genflow's proposal to commence Phase I/II clinical trials in MASH patients rather than with healthy volunteers once we reach the clinical trial phase. We hope that this will provide a first signal of efficacy in humans more speedily and, furthermore, we are hopeful that these trials will showcase the ability of longevity gene-therapy in assisting patients with life-limiting illnesses.\nIn the same month, we were also able to report that that the Company's shares had successfully commenced trading on the OTCQB Venture Market in the United States. We continue to believe this move expands our reach to a larger investor base and has the potential to enhance liquidity for our shares, making it easier for US investors to trade Company shares. Our acceptance onto the OTCQB also aligned (and continues to do so) with our strategic emphasis on the US due to its significant advancements and understanding in longevity and our ongoing collaborations with US-based institutions.\nAnother notable achievement this year, was the expansion our intellectual property portfolio through a provisional patent application focusing on the ability to edit the SIRT6 gene, shown to play a key role in longevity and age-related diseases. If granted the patent will represent a significant milestone in the field of gene editing, with potential implications for longevity and other forms of gene therapy.\n2024\nIn January 2024, we announced two exciting collaborations with other biotech companies: a sarcopenia project with Revatis SA and an exosome-mRNA project with EXO Biologics. Both projects are backed by substantial non-diluting and non-reimbursable research grants by the Government of Wallonia in Belgium totalling a combined \u20ac2.89m. The first payment of \u20ac777,000 is due to be received imminently. The opportunity to collaborate with Revatis SA and EXO Biologics; plus the granting of funding, will allow us to strengthen our cash runway, enabling us to continue executing on our research and conduct additional development programs such as our sarcopenia program and therefore broaden our research pipeline and expand the size of the Company's therapeutic markets.\nTo strengthen the Company's financial position and increase our institutional investor base, the Company completed a placing and subscription to raise \u00a3715,000 (before expenses) recently. We were privileged to have the participation of Premier Miton, a well-known UK institution, in this fundraise.\nIn addition to this, Genflo",
          "content_length": 159311
        },
        "ingested_at": "2026-01-21T02:45:52.436422Z"
      },
      {
        "event_id": "RNS-7th May 2024-finalres",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.436435Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Final Results",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/final-results-2cztlol3fyyufxl.html",
          "rns_number": "RNS Number : 2472N",
          "full_content": "7 May 2024 07:00\nRNS Number : 2472N\nGenflow Biosciences PLC\n07 May 2024\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n7 May 2024\nGenflow Biosciences Plc\n(\"Genflow\" or \"the Company\")\nFINAL RESULTS\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, is\npleased to announce its final results for the year ended 31 December 2023. The Annual Report is available to view on the Company's website at\nwww.genflowbio.com\nThe Company will post the Annual Report to shareholders and provide notice for its Annual General Meeting in the coming weeks.\nGenflow is\na UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with advanced age. It is the first longevity biotechnology company to list in Europe and seeks to be a reference company in the European longevity sector.\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nJoint Corporate Brokers\nClear Capital Markets\nCapital Plus Partners Ltd\nBob Roberts, +44 203 869 6080\nDominic Berger, +44 203 821 6167\nKeith Swann, +44 0203 821 6169\nJon Critchley, +44 0203 821 6168\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating non-alcoholic steatohepatitis (NASH), the most prevalent chronic liver disease for which there is no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on LinkedIn and Twitter/X.\n-Ends-\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nACSQKNBNQBKDCPK",
          "content_length": 3412
        },
        "ingested_at": "2026-01-21T02:45:52.436447Z"
      },
      {
        "event_id": "RNS-1st May 2024-temporar",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.436459Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Temporary Suspension",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/temporary-suspension-tfzvzoojud2xxsf.html",
          "rns_number": "RNS Number : 6653M",
          "full_content": "1 May 2024 07:37\nRNS Number : 6653M\nGenflow Biosciences PLC\n01 May 2024\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n1 May 2024\nGenflow Biosciences Plc\nTemporary Suspension of Listing pending publication of Annual Financial Report\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases,\u00a0provides the following update in relation to the publication of its Annual Financial Report (\"\nAnnual Report\n\").\nThe Company was required to publish its Annual Report for the financial year ending 31 December 2023 by 30 April 2024. However, due to the audit process taking longer than planned, and other unforeseen circumstances beyond its control, the Company requires a short amount of additional time.\nThe delay is not related to the Company's cash flow or other underlying economic position.\nAs a result, at the Company's request, the listing of the Company's ordinary shares on the Main Market of the London Stock Exchange will be temporarily suspended with effect from 7.30 a.m. on 1 May 2024 pending publication of the Annual Report.\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nJoint Corporate Brokers\nClear Capital Markets\nCapital Plus Partners Ltd\nBob Roberts, +44 203 869 6080\nDominic Berger, +44 203 821 6167\nKeith Swann, +44 0203 821 6169\nJon Critchley, +44 0203 821 6168\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating non-alcoholic steatohepatitis (NASH), the most prevalent chronic liver disease for which there is no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on LinkedIn and Twitter/X.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nSRSIMMITMTTJBRI",
          "content_length": 3579
        },
        "ingested_at": "2026-01-21T02:45:52.436471Z"
      },
      {
        "event_id": "RNS-1st May 2024-suspensi",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.436484Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Suspension - GENFLOW BIOSCIENCES PLC",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/suspension-genflow-biosciences-plc-kjqgl8abtv9danu.html",
          "rns_number": "RNS Number : 6542M",
          "full_content": "1 May 2024 07:30\nRNS Number : 6542M\nOfficial List\n01 May 2024\nNOTICE OF TEMPORARY SUSPENSION OF LISTING FROM THE OFFICIAL LIST\n01/05/2024 07:30\nTEMPORARY SUSPENSION\nGENFLOW BIOSCIENCES PLC\nThe Financial Conduct Authority (\"the FCA\") temporarily suspends the securities set out below from the Official List effective from\u00a001/05/2024 07:30 at the request of the company:\nSecurity Description\nListing Category\nISIN\nOrdinary Shares of GBP0.0003 each;\nfully paid\nStandard Shares\nGB00BP2C3V08\u00a0\u25cf\nThis notice has been issued by Issuer Management - 020 7066 8352.\nNotesSEDOL numbers which are allocated by the London Stock Exchange as a Stock Exchange identifier may be found on their dealing notice.\u25cfDenotes the security is being admitted to trading on the London Stock Exchange, a Recognised Investment Exchange.\u2020Denotes the security is also being admitted to trading on Aquis Stock Exchange, a Recognised Investment Exchange.#Denotes the security is also being admitted to trading on Euronext, a Recognised Investment Exchange.\n\u223c\nDenotes the security is also being admitted to trading on Cboe Europe, a Recognised Investment Exchange.^Denotes the security is also being admitted to trading on Shanghai-London Stock Connect, a Recognised Investment Exchange.*Denotes the security is also being admitted to trading on IPSX Prime, a Recognised Investment Exchange.Notices issued by the FCA in respect of admission of securities to the Official List must be read in conjunction with notices issued by the relevant Recognised Investment Exchange in respect of admission of securities to trading on its markets.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nSUSEADLEDFDLEFA",
          "content_length": 2379
        },
        "ingested_at": "2026-01-21T02:45:52.436496Z"
      },
      {
        "event_id": "RNS-30th Apr 2024-totalvot",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:45:52.436509Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Total Voting Rights",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/total-voting-rights-bmyxz0umqh5x44f.html",
          "rns_number": "RNS Number : 2788M",
          "full_content": "30 Apr 2024 07:05\nRNS Number : 2788M\nGenflow Biosciences PLC\n30 April 2024\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n30 April 2024\nGenflow Biosciences Plc\nTotal Voting Rights\nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, announces that the total issued share capital of the Company as at 30 April 2024 consists\u00a0of 349,706,618\u00a0Ordinary Shares none of which are held in treasury. Therefore, the total number of voting rights in the Company is 349,706,618.\nThe figure of 349,706,618\u00a0Ordinary Shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nJoint Corporate Brokers\nClear Capital Markets\nCapital Plus Partners Ltd\nBob Roberts, +44 203 869 6080\nDominic Berger, +44 203 821 6167\nKeith Swann, +44 0203 821 6169\nJon Critchley, +44 0203 821 6168\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating non-alcoholic steatohepatitis (NASH), the most prevalent chronic liver disease for which there is no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on LinkedIn and Twitter/X.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nTVRPPURCCUPCGCQ",
          "content_length": 3375
        },
        "ingested_at": "2026-01-21T02:45:52.436521Z"
      },
      {
        "event_id": "SOCIAL-23Dec20250830-Moneymun-87977641",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:39.512892",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The new Financial Conduct Authority (FCA) regulations are designed to facilitate less discounted fundraising for small caps by reducing the regulatory burden and increasing the threshold for requiring a full prospectus, thus making secondary capital raising faster and cheaper. Key changes, effective from January 19, 2026 (with some listing rule changes effective from July 29, 2024), aim to attract more companies to list and grow in the UK. Key Regulatory Changes and Their Impact on Small Cap Fundraising The FCA's reforms introduce several key changes that support more efficient and potentially less discounted fundraising for smaller listed companies: Increased Prospectus Threshold The most significant change for secondary fundraising is that a full prospectus is now only required if a company issues shares amounting to 75% or more of its existing share capital, a substantial increase from the previous 20% threshold. This allows companies, particularly smaller ones, to raise further capital more quickly and at a lower cost without the time and expense associated with a full prospectus, which should reduce the need for heavily discounted placings.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.80",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=0B332EA7-5210-4DB6-B511-27737B27EDB7"
        },
        "ingested_at": "2026-01-22T21:48:39.525726+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250940-Moneymun-32187539",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:39.512468",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Latest compelling research into Sirt6's panacea potential.....what Major Pharma wouldn't be interested in Genflow's Sirt6 technology platform? Gla holders:-) 22/12/25 Brain enzyme discovery may open new path to treat neurodegenerative disease Using human cell lines alongside mouse and fruit fly models, Toiber's team identified the enzyme sirtuin 6, or SIRT6, as the central regulator. SIRT6 is known for its role in longevity, but the study shows it also functions as a gatekeeper of tryptophan metabolism. ...... \"Our research positions the enzyme SIRT6 as a critical and primary drug target to combat degenerative brain pathology,\" Toiber said. \"These findings change the way we understand the relationship between aging and brain function. It is not simply wear and tear, but a specific metabolic malfunction that can be corrected.\" SIRT6 Enzyme: Breakthrough Discovery in Brain Enzyme Offers Hope for Treating Neurodegenerative Diseases, ETHealthworld https://share.google/zJ2xD65yVvrV7kAJG",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.80",
          "thread_title": "RE: Sirt6",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=7319CD1C-C4C6-4015-8EC4-A089F968170E"
        },
        "ingested_at": "2026-01-22T21:48:39.525708+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20250853-Porter_-57619848",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:39.512020",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Little Xmas top up on the open for me. Never know what the new year will bring \ud83e\udd70",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.825",
          "thread_title": "Merry Xmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=178C1FAB-EB14-4687-B406-B0BD510D8226"
        },
        "ingested_at": "2026-01-22T21:48:39.525690+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251025-Roosters-13235410",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:39.511612",
        "source": "LSE_CHAT",
        "data": {
          "author": "Roostersmillions",
          "content": "Merry Christmas genflowers. This time next year, we could be millionaires........",
          "sentiment": 0.0,
          "engagement": "288",
          "price_at_post": "1.825",
          "thread_title": "RE: Merry Xmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=178C1FAB-EB14-4687-B406-B0BD510D8226"
        },
        "ingested_at": "2026-01-22T21:48:39.525672+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261147-Moneymun-16475633",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:39.511193",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Or maybe this time next month!!!??? Gla holders and a very Happy and Prosperous New Year!!! :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.95",
          "thread_title": "RE: Merry Xmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=178C1FAB-EB14-4687-B406-B0BD510D8226"
        },
        "ingested_at": "2026-01-22T21:48:39.525652+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261315-Porter_--5276429",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:39.510776",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Wouldn\u2019t surprise me if the money is in the bank Monday now xmas and new years is officially over, hence why there were some last minute aggressive buys :)",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.95",
          "thread_title": "RE: Merry Xmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=178C1FAB-EB14-4687-B406-B0BD510D8226"
        },
        "ingested_at": "2026-01-22T21:48:39.525634+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261315-jamtart1-61779409",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:39.510366",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "This will go stellar on good news, as I said before why would anybody want to apply for patents if it doesn't work?",
          "sentiment": 0.5,
          "engagement": "1,600",
          "price_at_post": "1.95",
          "thread_title": "Sp",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B1300EED-30AB-4177-A11F-B4EDBBDE1F3E"
        },
        "ingested_at": "2026-01-22T21:48:39.525617+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261515-Moneymun-45429535",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:39.509947",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "As the industry looks ahead to 2026, the upcoming JP Morgan Healthcare conference will be a pivotal indicator on the direction for the biopharma sector for 2026. The event will set the tone for dealmaking, capital flow and R&D priorities in the year ahead, as executives look to reaffirm investor confidence, aligning on the next wave of scientific and commercial breakthroughs to strengthen pipelines. Hans concludes: \u201cAs we look to 2026, strong drug pipelines and breakthrough clinical catalysts will drive the sector, as pricing pressures are addressed, innovation and differentiation will take centre stage, and strategic deals accelerate growth and portfolio transformation.\u201d Biopharma enters 2026 with renewed and cautious optimism - PharmaLive hTtps://share.google/ocZAE3qqVWqcU9iyA",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.95",
          "thread_title": "JP Morgan HealthCare Conference 12th - 16th January 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=DBA695E8-3CE6-44EA-9610-330427FD0568"
        },
        "ingested_at": "2026-01-22T21:48:39.525599+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261517-Moneymun-25916873",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:39.509517",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Dr. Eric Leire, CEO of Genflow, commented: \"We're excited to attend the JP Morgan Healthcare Conference in San Francisco this January. Our planned meetings reflect our current focus on lipid nanoparticle delivery for mRNA SIRT6 therapeutics, which is opening compelling opportunities for strategic partnerships in the longevity space.\"",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.95",
          "thread_title": "RE: JP Morgan HealthCare Conference 12th - 16th January 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=DBA695E8-3CE6-44EA-9610-330427FD0568"
        },
        "ingested_at": "2026-01-22T21:48:39.525582+00:00"
      },
      {
        "event_id": "SOCIAL-4Jan20261927-Porter_--8627019",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:39.509093",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Nice finish Friday money with the bull flag forming. Someone keen to get in before the JP Morgan conference\u2026",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.95",
          "thread_title": "RE: JP Morgan HealthCare Conference 12th - 16th January 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=DBA695E8-3CE6-44EA-9610-330427FD0568"
        },
        "ingested_at": "2026-01-22T21:48:39.525564+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20260714-Moneymun--3320218",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:39.508684",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "All bodes well Porter,  continued share accumulation in anticipation of a stellar year ahead.....potential exponential  UPside fast approaching!!! Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.95",
          "thread_title": "RE: JP Morgan HealthCare Conference 12th - 16th January 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=DBA695E8-3CE6-44EA-9610-330427FD0568"
        },
        "ingested_at": "2026-01-22T21:48:39.525546+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20260830-Moneymun-74810703",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:39.508271",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "At the 44th J.P. Morgan Healthcare Conference (JPM 2026) in San Francisco (Jan 12-15, 2026), longevity is a significant theme, with companies like Genflow Biosciences pitching gene therapies and AI-driven health solutions, alongside broader discussions on breakthrough therapies, digital health, and investment trends shaping the aging and wellness sectors. Expect many partnering meetings, innovation showcases, and discussions on AI's role in transforming care for aging populations. Key Longevity & Related Themes at JPM 2026: Gene Therapies: Companies like Genflow Biosciences are presenting novel approaches, such as SIRT6 gene delivery, for age-related conditions and overall longevity. AI & Digital Health: Central to discussions are how AI-powered tools (predictive analytics, diagnostics) and digital platforms are revolutionizing wellness, patient engagement, and care for aging individuals. Investment Focus: Investors are looking at innovative health solutions, including those addressing chronic diseases, metabolic health (like MASH), and age-related conditions. Breakthrough Therapies: Focus areas include oncology, neurology, hematology, and broader advancements in immunology and precision medicine relevant to longevity. Investor Partnering: Concurrent events like RESI JPM facilitate connections between investors and early-stage companies developing next-gen health technologies. Why It Matters: JPM is the premier healthcare investment event, setting the tone for the year; the strong presence of longevity-focused innovation signals major investor interest in extending healthy lifespans.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.95",
          "thread_title": "RE: JP Morgan HealthCare Conference 12th - 16th January 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=DBA695E8-3CE6-44EA-9610-330427FD0568"
        },
        "ingested_at": "2026-01-22T21:48:39.525528+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261019-TheInves--6853422",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:39.507815",
        "source": "LSE_CHAT",
        "data": {
          "author": "TheInvestCollect",
          "content": "Pity another company RNS the conference and the share are up today and all quite here hmmm, funding December my arse \ud83e\udd23",
          "sentiment": 0.0,
          "engagement": "7,970",
          "price_at_post": "1.85",
          "thread_title": "RE: JP Morgan HealthCare Conference 12th - 16th January 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=DBA695E8-3CE6-44EA-9610-330427FD0568"
        },
        "ingested_at": "2026-01-22T21:48:39.525510+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261025-Pie-char-63827042",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:39.507405",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Where did it say funding lands in December? ..........It didn't. Be patient.",
          "sentiment": 0.5,
          "engagement": "60",
          "price_at_post": "1.85",
          "thread_title": "RE: JP Morgan HealthCare Conference 12th - 16th January 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=DBA695E8-3CE6-44EA-9610-330427FD0568"
        },
        "ingested_at": "2026-01-22T21:48:39.525492+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261531-Moneymun-85505150",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:39.506980",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "All bodes well and another compelling recent research paper on Sirt6's panacea potential.  Genflow's cutting edge science and  Sirt6 technology platform could be of huge interest to Major Pharma. Gla :-) Sirt6 Deficiency Spurs Obesity Inflammation via Galectin-3 Bioengineer by Bioengineer January 6, 2026 In a transformative breakthrough that may reshape our understanding of obesity-related inflammation, researchers have uncovered a pivotal molecular mechanism involving Sirt6 deficiency in mast cells that exacerbates adipose tissue fibroinflammation. This discovery, detailed in a recent publication in Nature Communications, illuminates the complex interplay between immune cells and fat tissue, identifying galectin-3 signaling as the critical conduit driving inflammatory and fibrotic processes within the adipose microenvironment during obesity. ....... These findings have far-reaching implications, extending beyond fundamental science into translational and clinical paradigms. By establishing mast-cell Sirt6 as a critical regulator of adipose tissue homeostasis, the study opens new avenues for innovative obesity treatments aimed at curbing fibroinflammatory processes. Pharmacological enhancement of Sirt6 activity or galectin-3 blockade may emerge as promising strategies to restore adipose tissue integrity and improve metabolic outcomes. ...... In conclusion, the identification of Sirt6 deficiency in mast cells as a driver of adipose tissue inflammation and fibrosis via galectin-3 signaling marks a paradigm shift in obesity research. This innovative study positions mast cell epigenetic regulation at the heart of metabolic inflammation, providing a novel therapeutic target that could change the landscape of obesity treatment and improve outcomes for millions worldwide. Sirt6 Deficiency Spurs Obesity Inflammation via Galectin-3 https://share.google/m8sEZOt5Vl59Dq7Pc",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.825",
          "thread_title": "Sirt6 - \" a paradigm shift in obesity research\"!!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=9EC9CB65-6C03-4939-B7B8-7B08A8ABF901"
        },
        "ingested_at": "2026-01-22T21:48:39.525475+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20260737-Moneymun-47105257",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:39.506528",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Something similar for Genflow's Sirt6 Gene Therapy for Glaucoma with their leading Ophthalmology company more than conceivable. A Material Transfer Agreement was signed in April 2025 and so positive data, along with Efficacy Data from the Dog Trial in liaison with the two Animal Healthcare companies who have both signed Confidential Disclosure Agreements, could be presented at next weeks JP Healthcare Conference. Gla holders, a very exciting period ahead!!! :-) 6/1/26 U.K. biotech Ikarovec has teamed up with VectorBuilder to work on an eye disease gene therapy that could be administered in a doctor\u2019s office. Ikarovec\u2019s IKAR-003 is currently in preclinical development for intermediate age-related macular degeneration (AMD). The one-time injectable therapy is designed to prevent the progression of this eye disease by offering both neuroprotection and complement modulation. The fledgling partnership is still at an early stage. For now, the technology will be evaluated before the companies fully commit. But, assuming the deal is finalized, it is expected to be worth more than $1 billion. UK biotech eyes $1B deal to deliver eye gene therapy at doctor hTtps://share.google/t12NrOU65ISH49HrO",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.825",
          "thread_title": "RE: Sirt6 - \" a paradigm shift in obesity research\"!!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=9EC9CB65-6C03-4939-B7B8-7B08A8ABF901"
        },
        "ingested_at": "2026-01-22T21:48:39.525457+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20260801-Porter_-12256622",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:39.506079",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Very exciting month ahead money. I believe only 1 eye programme has sold previously for $3bn, so we know there is demand for Genflow\u2019s research for sure! From attending the AGM last year, it appeared that the eye programme looks set to do much more than what the competitors are offering, but no doubt all will be revealed in time as to not give away the market edge \ud83d\ude09",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.825",
          "thread_title": "RE: Sirt6 - \" a paradigm shift in obesity research\"!!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=9EC9CB65-6C03-4939-B7B8-7B08A8ABF901"
        },
        "ingested_at": "2026-01-22T21:48:39.525439+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261053-jamtart1--3620448",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:39.505647",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Porter_   Any idea what we holders would get per share if we got such a deal?",
          "sentiment": 0.5,
          "engagement": "1,600",
          "price_at_post": "1.825",
          "thread_title": "RE: Sirt6 - \" a paradigm shift in obesity research\"!!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2C24DA3C-1665-4066-B9F3-73F02369D131"
        },
        "ingested_at": "2026-01-22T21:48:39.525421+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261236-Moneymun-36445752",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:39.505237",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Very exciting indeed Porter, planned meetings presumably with potential suitors at JP Morgan next week and so multiple deal opportunities across the platform, and there's currently an M&A and lucrative licensing deal feeding frenzy as Major Pharma replenish their pipelines with the latest cutting-edge science, and so every chance for little old Genflow. Excitement building and everything firmly crossed. :-) Ps jamtart, as far as value goes, Genflow's current market cap is a lowly \u00a39.5m and so if they announced a deal for \u00a3100m, then  a market cap of \u00a3100m wouldn't be out of the question and so a 10 bagger in a blink, and who knows, maybe 20, 50 or even a 100 bagger depending on the size and number of any deals secured....the sky is the limit!!! Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.825",
          "thread_title": "RE: Sirt6 - \" a paradigm shift in obesity research\"!!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=9EC9CB65-6C03-4939-B7B8-7B08A8ABF901"
        },
        "ingested_at": "2026-01-22T21:48:39.525404+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261303-jamtart1--6641777",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:39.504795",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Thankyou, yes great to get another's angle on this. Here's hoping, have a big feeling for this one.",
          "sentiment": 0.5,
          "engagement": "1,600",
          "price_at_post": "1.825",
          "thread_title": "Moneymunch",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=13AC3EBB-D13E-47C2-8DA6-708961C8A9BE"
        },
        "ingested_at": "2026-01-22T21:48:39.525386+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261504-Moneymun-41437152",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:39.504330",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Genflow Biosciences (LON:GENF) (OTCQB:GENFF) 2,222 followers 2h Took a look at Genflow Biosciences (LON:GENF) (OTCQB:GENFF)'s latest presentation! Learn about #GENF's exciting path forward with Centenarian #SIRT6 studies, impressive financials, and its mission to redefine the #aging process. Find it here: hTtps://loom.ly/RsxnFCE #GENF #GENFF #Biotech #MASH #WernerSyndrome #Sarcopenia",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-22T21:48:39.525368+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261552-Alwaysra--1224438",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:39.503858",
        "source": "LSE_CHAT",
        "data": {
          "author": "Alwaysraining",
          "content": "I\u2019m new to this forum but I\u2019ve been invested in Genflow for some time.  I understand where the company is re the European patent - does anyone know what stage the US patent applications are at?  Is it likely  that, before any deals with major pharma etc are signed, the IP will need to be in place, particularly in US? Is there any update re the outstanding grant application?  I\u2019ve searched but can\u2019t find anything recent.",
          "sentiment": 0.0,
          "engagement": "1",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-22T21:48:39.525351+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261559-Moneymun--5136599",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:39.503399",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "WHO WE ARE Pioneering Novel Gene Therapeutics for a Longer, Healthier Life MISSION: aging is underlying risk factor for disease, and our aim is to deliver gene therapeutics that potentially halt or slow the aging process in humans and dogs CENTENARIAN SIRT6 (cent SIRT6) GENE: proprietary variant of longevity gene that widely regulates aging and immunity and is a potential therapeutic target for the treatment of diseases PROMISING PRECLINICAL RESULTS: lead drug candidate GF-1002 delivers a centenarian variant of the SIRT6 gene (cent SIRT6) for treatment of MASH SEASONED TEAM: experienced and proven management with extensive experience in public & private pharma and biotech ROBUST PIPELINE: advancing multiple development programs over 24 months: MASH, Glaucoma, Sarcopenia, Werner and life extension of dogs DEVELOPMENT PIPELINE GF-1002 (Pre-Clinical) AAV8 cent SIRT6 vector for intravenous infusion, expressing cDNA of centenarian variant of SIRT6(cent SIRT6) in liver GF-1003 (Pre-Clinical/Development) Suspension of exosomes, loaded with mRNA of centenarian variant of SIRT6(cent SIRT6) in fibroblasts GF-1004 (Clinical Proof of Concept) cent SIRT6 for intravenous infusion for life extension and prevention of age-related diseases GF-1005 (Pre-Clinical/Development) Mitochondrial disfunction: Myoblast progenitors loaded by photoporation with cent SIRT6 GF-1006 Ophthalmology (pre-clinical) mRNA cent SIRT6 delivered by LNP for the treatment of cornea pathologies and glaucoma OPHTHALMOLOGY PLATFORM New Ophthalmology Program: Initiated development of a novel gene therapy targeting ocular diseases, including corneal pathologies and glaucoma, using Genflow\u2019s proprietary Centenarian SIRT6 (cent SIRT6). Precision Delivery Platform: Employing a specially engineered non-viral vector for targeted SIRT6 delivery to the eye. Strategic Partnership: Signed a Material Transfer Agreement in April 2025 with a leading ophthalmology company to co-develop the cent SIRT6 therapy and delivery system. LEVERAGING AI FOR GENOMICS New AI Partnership: Signed Master Service Agreement in April 2025 with Heureuka Labs, a spin-out of Duke University, to use their proprietary AI platform to analyze complex genomic data, including RNA sequencing and gene expression profiles. Enhancing Therapeutic Insights: Expected to drive a deeper understanding of gene regulatory networks and biological responses to optimize therapy design and personalize outcomes. Pipeline Advancement: Initially supporting GF-1002 (cent SIRT6-based gene therapy in preclinical development) and future programs, including candidates for MASH. GLAUCOMA RGC NEUROPROTECTION: THE RACE IS ON The Problem 80M people worldwide with glaucoma; leading cause of irreversible blindness Current treatments only lower IOP- they don't protect retinal ganglion cells (RGCs) RGC death is irreversible; unmet need for neuroprotection Significant market opportunity The Gap",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-22T21:48:39.525332+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261601-Moneymun-22925883",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:39.502863",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The Gap No approved neuroprotective therapies The mRNA Opportunity - Wide Open LNP targeted delivery to retina \u2013 now possible NO APPROVED OR CLINICAL-STAGE MRNA THERAPIES FOR GLAUCOMA PARTNERING WITH LNP PROVIDER Paradigm shift to retinal protection \u2022 Pre-clinical evidence links SIRT6 activity with RGC protection in glaucoma/optic neuropathy models \u2022 Demonstrating RGC rescue and preserved function would be a strong disease-modifying signal Delivery is now tractable \u2022 Targeted LNP (tLNP) platforms are removing a major historical barrier for in vivo RNA therapeutics to reach retina/RGCs Clear decision point A single well-designed rodent POC that shows \u2022 focal RGC expression of SIRT6 cent \u2022 preserved RGC counts and \u2022 preserved RGC function with acceptable ocular safety, gives a clean go/no-go for IND enabling work AGED DOGS COMPARATIVE TRIAL Proof-of-Concept comparative clinical trial of in-vivo naked DNA gene therapy in aged dogs Conducted at Syngene's strategic partner site in Morocco, AAALAC and GLP certified 26 (24+2) aged Beagles dogs (age>10 years) Group 1 (n=6): untreated Group 2 (n=6): treated with gene therapy IV bolus of SIRT6 AAV Group 3 (n=6): treated with gene therapy IV infusion of naked DNA (low dose) Group 4 (n=6): treated with gene therapy IV infusion of naked DNA (high dose) Blinded: first read-out in January 2026 \u2022 Treatment period: 180 days with follow-up period: 90 days \u2022 Gene therapy has been administered to all dogs with demonstrated excellent safety profile Endpoints \u2022 Pan-mammalian methylation clock (Steve Horvath), \u2022 sarcopenia (including muscle biopsies) and other markers of aging MASH PROGRAM Affects est. 35 million people globally \u2022 Increasing prevalence \u2022 Leading cause of chronic liver disease and liver transplant Significant unmet medical need Clear regulatory accelerated development pathway. EMA and FDA guidelines accept: \u2713 Key surrogate outcomes for therapeutic trials: regression of fibrosis or resolution of NASH \u2713 Histological changes are achievable within a 12-18-month time-frame \u2713 Placebo control \u2713 Conditional fast-track approval 2025 KEY HIGHLIGHTS LARGE AND EXPANDING MARKET OPPORTUNITY MASH: 35 Million globally. Increasing prevalence. Door opener to even broader anti-aging indication Awarded to new grants in 2024 expanding research pipeline Ophthalmology: retina preservation GROWING IP PORTFOLIO WITH LONG LIFE 2 proprietary patent families SIRT6 centenarian (cent SIRT6) and gene delivery (entering National Phase); Additional upcoming patent applications (entering PCT) MRNA/LNP GENE DELIVERY SYSTEMS Innovative gene delivery systems: targeted LNPs delivering cent SIRT6 mRNA GF-1002 Multiple key clinical and regulatory milestones expected in next 18 months; Undervalued stock opportunity; Potential acquisition by pharmaceutical partner GF-1004: Pet",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-22T21:48:39.525315+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261602-Moneymun-38446833",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:39.502226",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Undervalued stock opportunity; Potential acquisition by pharmaceutical partner GF-1004: Pet life extension / sarcopenia Initiated discussion under CDA with several animal health companies hTtps://loom.ly/RsxnFCE",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-22T21:48:39.525297+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261606-Moneymun--6260572",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:35.738758",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Looks like we've got a new Chairperson!!!??? Gla ;-) GAD BERDUGO Chairperson \u2022 30+ years of leadership across global biotech, corporate development, and U.S. capital markets \u2022 Proven record in strategic partnerships, capital raising, and scaling private and public biotech companies \u2022 Managing Partner, Explorium Capital; former Co-Founder & CEO of EpiVax Oncology and Chief Business Officer at Editas Medicine and Nutcracker Therapeutics",
          "sentiment": 0.0,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-22T21:48:39.525279+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261627-Moneymun-32963217",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:35.738145",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Gad Berdugo Gad Berdugo, MSc. Eng., MBA Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a strategic and financial advisory firm focusing on the global biotechnology sector. He currently serves as Vice Chairman of the Board of Directors of clinical development stage precision oncology company, Diaccurate. Mr. Berdugo brings over 35 years of biotech corporate & business development, strategy, operational, financial, investment and general venture management experience. He served as CBO at CRISPR gene editing pioneer Editas (Nasdaq EDIT); Co-founder and CEO at personalized neoantigen cancer vaccine venture, EpiVax Oncology Inc.; CFO and EVP at Immune Pharmaceuticals Inc. (Nasdaq IMNP); Managing Director and Head of Life Sciences at Tegris Advisors, a strategic and financial advisory boutique; Founder and Managing Partner of the Explorium Global Life Sciences Investment Fund; Director, Senior Equity Research Analyst and Life Sciences Sector Leader at Lazard, Asset Management Group. Prior to that, he served as a Director of Global Business Development within Baxter\u2019s Biopharmaceuticals group and started his career at Abbott Labs. Mr. Berdugo received his B.Sc. with Honors in Biotechnology from Imperial College London, his M.Sc. in Biochemical Engineering from University College London and his M.B.A. from H.E.C. Paris. He serves on the Board of Directors of Friends of H.E.C. Inc. and Friends of U.C.L. Inc. Mr. Berdugo is bilingual in French and English and has dual US and French citizenships. He resides with his wife in New York City.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-22T21:48:39.525261+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261732-Porter_--2048116",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:35.737712",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Thanks for sharing money. I haven\u2019t seen any news regarding a new Chair. Where did you manage to grab that info from? Can you please share the link if you have one? \ud83e\udd70",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-22T21:48:39.525244+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261802-Moneymun--5010351",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:35.737302",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Hi Porter, it's from the 2026 Corporate Presentation which was published via Genflow's LinkedIn post a few hours ago. Gl :-) Ps the new Chair appears to be well connected on the US. https://loom.ly/RsxnFCE",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-22T21:48:39.525226+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261804-Moneymun--3929323",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:35.736870",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Well connected in the US to take Genflow to the next level. ;-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-22T21:48:39.525208+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260702-Moneymun-25703469",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:35.736459",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "08 January 2026 A Review of an Exciting 2025 2025 has been a year of focused scientific progress and continued advancement of Genflow Bioscience's mission to extend healthy lifespan through our novel longevity gene therapy platform. Across our portfolio, we have maintained momentum in both animal health where progress in our canine study may provide translational insights relevant to future human applications as well as therapeutic development for dogs. These advancements have been supported by a strengthened network of leading academic collaborators and laboratories. Together, with continued backing from international institutional investors and previously awarded government grants, this ecosystem helped accelerate Genflow's scientific and clinical development throughout 2025. Program Highlights We've made a number of notable strides across our programs this year, including: \u00b7      Dog Aging (GF-1004) We made significant strides in our clinical trial for aging dogs with full administration of our investigational SIRT6-based gene therapy now completed. No adverse events were reported during the dosing phase of the study, with no serious, moderate, or minor side effects observed. The study which began in March 2025, is being conducted as a blinded clinical trial; an initial efficacy readout is expected in Q1 2026, including blood analyses and muscle biopsies to evaluate potential benefits related to sarcopenia, healthspan, and lifespan-associated biomarkers. Dogs enrolled in the trial will be monitored for 180 days, with a second efficacy assessment planned at the six-month timepoint and results expected in June-July 2026 to evaluate durability and longer-term effects. \u00b7      MASH (GF-1002) Our MASH program saw good progress in 2025. While GLP-1 therapies have addressed early-stage MASH, patients with advanced fibrosis - roughly one-third of the population - still face limited treatment options. In response, we repositioned GF-1002 to target this high-need group, leveraging its antifibrotic properties and potential to prevent progression to cirrhosis and liver cancer. Additionally, we have generated new pre-clinical POC data on the prevention of HCC. We are now finalizing our IND package and evaluating mRNA/LNP delivery as an alternative to AAV, an approach that could enable repeat dosing and lower manufacturing costs. Encouraging data continue to support this next phase of research and development. \u00b7      Glaucoma In 2025, we expanded into ophthalmology, where SIRT6-based gene therapy shows promise in glaucoma, a leading cause of irreversible blindness. Current treatments primarily manage intraocular pressure but do little to prevent optic nerve degeneration. Our preclinical data suggest SIRT6 overexpression may protect retinal ganglion cells and preserve optic nerve function, shifting the focus from symptom control to true neuroprotection.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-22T21:48:39.525190+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260703-Moneymun-37414573",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:35.735979",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "We are advancing discussions with a leading LNP partner to support delivery innovation in this space and are securing a full-service CRO to manage formulation through preclinical execution. With the global glaucoma market approaching USD $12-14 billion by the early 2030s, this represents a compelling long-term opportunity for us. \u00b7 Additional Programs We continued to advance our broader pipeline and are pleased with the steady advancement of the sarcopenia program, fully consistent with our development plans. In parallel, the ExoFastTrack initiative continues to move forward, generating important data that will support and accelerate several of our other development programs. Looking Ahead to 2026 As we move into 2026, we do so with confidence, discipline, and a clear strategic focus. The coming year will emphasize rationalization of our pipeline, prioritizing programs with the strongest data, clearest paths to value creation, and highest partner interest. Central to this strategy will be the pursuit of early-stage licensing and collaboration agreements designed to generate non-dilutive funding, validate our platform externally, and support continued development without undue capital strain. With multiple upcoming data readouts, an expanding partner network, and a maturing intellectual property position, we believe Genflow is well positioned to enter its next phase of growth. We remain committed to scientific excellence, capital efficiency, and long-term value creation as we work to translate our longevity platform into meaningful therapies. Thank you for your continued support and confidence in Genflow.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-22T21:48:39.525172+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260805-Porter_--9129702",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:35.735538",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Thanks for sharing money. I notice the RNS is in American English, perhaps to appeal to US investors and big US pharma? No mention of the patents in the update which were instrumental in offering assurance to investors regarding patent protection, but hopefully we\u2019ll receive updates in due course separately.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.825",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-22T21:48:39.525155+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260854-David195-16747544",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:35.735117",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "I hold shares and the potential is significant. However I am reluctant to add when the funding position is unclear.  Grants could be material amounts if and when received but there is a risk of a diluted fund raise to progress the numerous programmes in 2026.  I have suffered this is other small biotechs like FAB and Apta where the state of the capital markets are very harsh and unsupportive. I tried to analyse the cash runway and it seems more funds will be needed in H1 if the grants are not received.  Is there any indication of the timing?",
          "sentiment": 0.0,
          "engagement": "868",
          "price_at_post": "1.90",
          "thread_title": "Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=1999E606-84A4-47B8-B880-E68E1912F065"
        },
        "ingested_at": "2026-01-22T21:48:39.525136+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260928-Moneymun-47886521",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:35.734679",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Outstanding non-dilutive grant funding could land at anytime, although a lucrative JV licensing deal could also land at anytime and so let's see what transpires at next weeks the prestigious JP Healthcare Conference next week, where Genflow have planned meetings, presumably with potential suitors and every chance Eric will have initial efficacy data from the Dog Trial and maybe and maybe positive Data with their Ophthalmology partner for Glaucoma to present and so confirmation of a commercial deal or two would be transformational for all invested and any funding concerns would be assigned to history.  Gla holders....Excitement building!!! :-) Ps if Genflow need to raise cash because of the delay in receipt of the \u20ac4m outstanding non-dilutive grant funding, then raising cash from 16th January is going to become easier, cheaper and less dilutive.  :-) The new Financial Conduct Authority (FCA) regulations are designed to facilitate less discounted fundraising for small caps by reducing the regulatory burden and increasing the threshold for requiring a full prospectus, thus making secondary capital raising faster and cheaper. Key changes, effective from January 19, 2026 (with some listing rule changes effective from July 29, 2024), aim to attract more companies to list and grow in the UK. Key Regulatory Changes and Their Impact on Small Cap Fundraising The FCA's reforms introduce several key changes that support more efficient and potentially less discounted fundraising for smaller listed companies: Increased Prospectus Threshold The most significant change for secondary fundraising is that a full prospectus is now only required if a company issues shares amounting to 75% or more of its existing share capital, a substantial increase from the previous 20% threshold. This allows companies, particularly smaller ones, to raise further capital more quickly and at a lower cost without the time and expense associated with a full prospectus, which should reduce the need for heavily discounted placings.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=1999E606-84A4-47B8-B880-E68E1912F065"
        },
        "ingested_at": "2026-01-22T21:48:39.525094+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260933-Moneymun-80955658",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:35.734242",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Bring it on!!! Gla holders:-) \"Central to this strategy will be the pursuit of early-stage licensing and collaboration agreements designed to generate non-dilutive funding, validate our platform externally, and support continued development without undue capital strain.\" .... Dr. Eric Leire, CEO of Genflow, commented: \"We're excited to attend the JP Morgan Healthcare Conference in San Francisco this January. Our planned meetings reflect our current focus on lipid nanoparticle delivery for mRNA SIRT6 therapeutics, which is opening compelling opportunities for strategic partnerships in the longevity space.\"",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=1999E606-84A4-47B8-B880-E68E1912F065"
        },
        "ingested_at": "2026-01-22T21:48:39.525076+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261005-Moneymun-86940167",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:35.733812",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Hopefully news on patents soon Porter, the following statement is from yesterday's 2026 Corporate Presentation.  Gl :-) GROWING IP PORTFOLIO WITH LONG LIFE 2 proprietary patent families SIRT6 centenarian (cent SIRT6) and gene delivery (entering National Phase); Additional upcoming patent applications (entering PCT)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-22T21:48:39.525058+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-David195--1147022",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:35.733392",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "Thank you for your informed views.  Added 500k @1.78.  It is hard for companies in this sector to raise funds so hopefully the upcoming changes will make the situation less brutal.  I will add when funds allow.",
          "sentiment": 0.0,
          "engagement": "868",
          "price_at_post": "1.85",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-22T21:48:39.525040+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261148-Moneymun-65336875",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:35.732964",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Nice one David, looking forward to a run of great news from Eric to take the sp to new highs. Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.85",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-22T21:48:39.525021+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261314-Moneymun--8940412",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:35.732551",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "0 0 Gene therapy biotech Genflow eyes busy year ahead as dog ageing trial nears results Published: 02:40 08 Jan 2026 Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) has wrapped up 2025 with steady progress across a range of gene therapy programmes, including a closely watched trial into dog ageing that could lay the groundwork for future human applications. The London-listed company, which is working on ways to extend healthy lifespan using gene therapy, said it had completed dosing in its lead canine study with no reported side effects. The dogs will now be monitored over six months for signs of improved muscle strength and health-related biomarkers, with initial results expected in the first quarter of this year. The trial, which began in March and uses a therapy based on the SIRT6 gene, a known regulator of ageing and DNA repair, is being conducted in a blinded format. A follow-up analysis is due around mid-year to assess the durability of the effects. Alongside the dog ageing study, Genflow said it had made progress in a programme targeting advanced stages of MASH, or metabolic dysfunction-associated steatohepatitis, a type of fatty liver disease. Existing GLP-1 drugs such as Ozempic and Wegovy have shown benefits in early MASH, but Genflow is aiming at patients with more severe fibrosis, where options remain limited. It is now finalising regulatory paperwork to support a human trial and is exploring the use of mRNA technology, similar to that used in Covid-19 vaccines, as a more flexible and cost-effective delivery method than traditional viral vectors. In a new push into eye disease, the company is also investigating the use of its gene therapy platform in glaucoma. Early lab results suggest that increasing SIRT6 levels may help protect the optic nerve from damage, potentially offering a way to slow or prevent vision loss rather than simply reducing eye pressure, which is the current standard treatment. Genflow said it was in talks with a lipid nanoparticle delivery partner to support this programme and was hiring a specialist contract research firm to help move the candidate towards preclinical testing. Elsewhere in its pipeline, work is ongoing in sarcopenia, the loss of muscle mass that often accompanies ageing, and in a broader initiative called ExoFastTrack, which supports several of its research efforts. Looking to the year ahead, Genflow said it would focus its efforts on the most promising areas of its portfolio and seek early licensing or partnership deals to bring in fresh funds without issuing new shares. \u201cWith multiple upcoming data readouts, an expanding partner network, and a maturing intellectual property position, we believe Genflow is well positioned to enter its next phase of growth,\u201d the company said. The first set of clinical results, particularly from the dog study, will be key in setting the tone for 2026.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-22T21:48:39.525003+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261711-Troajan-84189613",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:35.732059",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1085366/genflow-biosciences-ceo-key-catalysts-for-2026-1085366.html",
          "sentiment": 0.0,
          "engagement": "125,438",
          "price_at_post": "1.75",
          "thread_title": "Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-22T21:48:39.524985+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261858-Moneymun--9214337",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:35.731648",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Another brilliant interview by Eric, \"2026 will be catalyst year, they've done their work and now it's time for harvesting and are going to JP Morgan next week with a full appointments book, and now ready for potential harvesting of their results to bring in non-dilutive funding cash into the company. Excitement building, in Eric we trust!!! Gla ;-) Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company\u2019s key programs and upcoming catalysts as it enters what management expects to be a pivotal year. Leire discussed why 2026 is shaping up as \u201ca year of catalysts\u201d for the company, with particular focus on the dog ageing trial, progress in MASH, and the group\u2019s approach to partnerships and licensing. Leire explained that the dog longevity study is the nearest catalyst, with the trial expected to be unblinded shortly and early efficacy readouts anticipated in the near term. While safety has already been confirmed, the study remains blinded, meaning efficacy results are still unknown. The first data will focus on biological age, measured using a methylation clock, with a more detailed analysis of muscle biopsies and mitochondrial function to follow. According to Leire, \u201cthis trial could be very important for our shareholders, because it will trigger a deal with an animal health company bringing non-dilutive money in the company.\u201d The interview also explored Genflow\u2019s repositioning in MASH toward advanced fibrosis and the prevention of hepatocellular carcinoma. Leire highlighted the significant unmet need in late-stage disease, noting that recent therapies target earlier stages and leave patients with advanced fibrosis facing limited options. He said the company\u2019s preclinical data have been encouraging and form a key part of the IND package, helping differentiate Genflow from existing and emerging treatments. In addition, Leire discussed the company\u2019s licensing strategy, including plans to out-license the dog program to an animal health specialist and pursue early-stage partnerships for glaucoma, while retaining focus on age-related conditions such as sarcopenia. With meetings planned during JPMorgan week, Leire said the company is seeking non-dilutive capital and strategic validation as it moves forward.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-22T21:48:39.524966+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261917-Moneymun--7239225",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:35.731207",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Eye wonder....Gla:-) 23/12/2025 - 12:30 VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders, Executive Vice President and Chief Financial Officer Sam Eldessouky and Chief Medical Officer and Head of Research & Development Yehia Hashad, MD, will participate in a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026, at 1:30 p.m. PT (4:30 p.m. ET) Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-22T21:48:39.524949+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261920-Moneymun--6304835",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:35.730770",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "And/or ???? ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 4:30 p.m. PT in San Francisco, CA.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-22T21:48:39.524931+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261946-Moneymun--1932977",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:35.730357",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Woof, woof!!!??? ;-) Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference 06 January 2026 INDIANAPOLIS, Jan. 6, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will represent the company and respond to questions from analysts at 3:45 p.m. PST (6:45 PM EST).",
          "sentiment": 0.0,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-22T21:48:39.524912+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20262001-Moneymun--1520884",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:35.729919",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 10:30 a.m. PT. Investors and other interested parties can access a live audio webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event. About Zoetis As the world\u2019s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide \u2013 from veterinarians and pet owners to livestock producers. The company\u2019s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees. For more information, visit www.zoetis.com.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-22T21:48:39.524894+00:00"
      },
      {
        "event_id": "SOCIAL-10Jan20261752-Troajan--1646197",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:35.729486",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1085424/genflow-is-ready-for-a-year-of-catalysts-icymi-1085424.html",
          "sentiment": 0.0,
          "engagement": "125,438",
          "price_at_post": "1.825",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-22T21:48:39.524876+00:00"
      },
      {
        "event_id": "SOCIAL-11Jan20261442-Moneymun--7847113",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:35.729063",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Planned meetings presumably with potential suitors at JP Morgan this coming week and so multiple deal opportunities across the platform, and there's currently an M&A and lucrative licensing deal feeding frenzy as Major Pharma replenish their pipelines with the latest cutting-edge science, Excitement building!!! Gla :-) \"2026 will be catalyst year, we've done our work and now it's time for harvesting and are going to JP Morgan next week with a full appointments book, and now ready for potential harvesting of our results to bring in non-dilutive cash into the company.\" A must watch....Gla holders:-) hTtps://www.proactiveinvestors.co.uk/companies/news/1085366/genflow-biosciences-ceo-key-catalysts-for-2026-1085366.html",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.825",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-22T21:48:39.524858+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260822-Moneymun-72447587",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:35.728628",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Healthcare companies set for deals spree as drug patents expire A gathering of pharmaceutical executives comes as the sector has rebounded from uncertainty over Trump\u2019s policies Healthcare executives gather for their big annual conference in San Francisco on Monday as the sector is flush with cash and set for a deals spree as patents on drugs worth almost 12 per cent of the industry\u2019s revenues expire in the years ahead. The JPMorgan healthcare conference takes place as uncertainty recedes over President Donald Trump\u2019s trade wars, drug pricing policy and the leadership of key regulators such as the US Food and Drug Administration. In response, the S&P biotech index, known as the XBI, has surged to a four-year high, outperforming the wider index. In addition, drugs that contribute about $180bn of revenue a year are set to go off patent in 2027 and 2028, representing almost 12 per cent of the global market, according to research firm Evaluate Pharma. More than $40bn of sales are expected to lose patent protection this year, Evaluate has estimated. \u201cThe need to take big swings becomes more pressing,\u201d said Jeremy Meilman, head of healthcare investment banking at JPMorgan. \u201cSeveral of the large-cap pharmaceutical companies are shopping around for strong assets and a number have taken action but still have more firepower. This contributes to our optimism for 2026.\u201d hTtps://www.ft.com/content/7b07a9d5-7254-490b-8ce9-ec2633094d8e",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.825",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-22T21:48:39.524840+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261231-Moneymun-82923051",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:35.728162",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Get UP there!!! Gla :-) Eric and his team are now at the prestigious JP Healthcare Conference, pressing flesh with the leading industry deal makers. He appeared confident and enthusiastic in his latest interview, highlighting the prospects and potential of an early lucrative JV deal for the Dog Trial, Glaucoma and Mash and so potential game changing transformational news could drop at anytime. The first efficacy readout on the Dog Trial is imminent, and with two Animal Healthcare companies both with Confidential Disclosure Agreements in place, Eric could be very close to a deal, and the same with Glaucoma, whereby a leading Ophthalmology Company signed a Material Transfer Agreement 10 months ago. Eric also highlighted the prospects of Genflow's Sirt6 Mash Gene Therapy, which is now targeting the later stages of the disease where there's no options apart from transplant, and was very interesting to hear from Eric it could be used in combination with GLP-1's and Madrigal's early stage treatment which was FDA approved 12 months or so ago. Madrigal are presenting at JP Morgan and are on a mission to expand their pipeline for Mash, so watch this space. It's also very interesting we have a new Chairman in place, GAD BERDUGO a high flyer based in the US in Global Biotech, Corporate Development and and US Capital Markets and so no doubt very well contected to any potential suitors. Excitement building!!!! In Eric we trust!!! Gla holders:-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.00",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-22T21:48:39.524822+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261725-Steg-63670488",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:33.183659",
        "source": "LSE_CHAT",
        "data": {
          "author": "Steg",
          "content": "Thought below was interesting, yes they are attending conference and have already made move to add to thier MASH portfolio, courtesy of AI search below Yes, Madrigal Pharmaceuticals is actively looking to expand its MASH (metabolic dysfunction-associated steatohepatitis) portfolio beyond its already approved drug, Rezdiffra (resmetirom). Madrigal's expansion strategy focuses on developing potential combination therapies, as MASH is a complex disease that requires multiple treatment approaches. Key components of their expanded pipeline include: Ervogastat: In January 2026, Madrigal entered into an exclusive global license agreement with Pfizer to acquire ervogastat, a Phase 2 oral DGAT-2 inhibitor. This drug works on a different, complementary pathway to Rezdiffra, and Madrigal plans to conduct studies to test the two treatments in combination. Oral GLP-1 Receptor Agonist: Madrigal also holds worldwide rights to an oral GLP-1 agonist called SYH2086, licensed from CSPC Pharmaceutical, with the goal of creating a best-in-class oral combination therapy. Additional Early-Stage Assets: The agreement with Pfizer for ervogastat also included rights to two other early-stage MASH pipeline assets. Madrigal's CEO, Bill Sibold, has stated that the company is committed to \"building the industry-leading pipeline that will shape the future of MASH care\" and believes combination therapies are the next wave of innovation in the field.",
          "sentiment": 0.0,
          "engagement": "5",
          "price_at_post": "1.90",
          "thread_title": "JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-22T21:48:39.524804+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260812-Moneymun-75073902",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:33.183227",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions Madrigal\u2019s strategy of pursuing combination therapies while the market remains in its infancy could intrinsically link its brand to MASH treatment. Madrigal Pharmaceuticals used its January 12 presentation at the J.P. Morgan Healthcare Conference 2026 to showcase its newly acquired assets from Pfizer \u2013 ervogastat and two preclinical assets \u2013 as well as outline its vision for dominance in metabolic dysfunction-associated steatohepatitis (MASH) treatment space through leveraging early commercial success. Its professed strategy of pursuing combination therapies while the market remains in its infancy could well result in Madrigal\u2019s brand becoming intrinsically linked to MASH treatment. JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions - Pharmaceutical Technology https://share.google/Ymb4cXndGee7eMEbD",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.00",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-22T21:48:39.524785+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260815-Moneymun--8296315",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:33.182793",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Game changing news at anytime. In Eric we trust!!! Gla holders...On and UP!!! :-)))",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.00",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-22T21:48:39.524764+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260818-Roosters-92070987",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:33.182388",
        "source": "LSE_CHAT",
        "data": {
          "author": "Roostersmillions",
          "content": "Markets reacting munch. Nice jump this AM. hope it holds. Maybe new private investors from across the pond due to conference exposure??",
          "sentiment": 0.5,
          "engagement": "288",
          "price_at_post": "2.00",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-22T21:48:39.524745+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260827-Moneymun-85393280",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:33.181961",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Every chance Rooster, although I'm hoping for a transformational lucrative commercial licensing deal on one or more of the programs, Dog , Glaucoma and Mash. Excitement building!!! Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.05",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-22T21:48:39.524720+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261006-Moneymun--6378721",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:33.181554",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "GKOS: Strong innovation and new therapies drive growth, with robust financials and expanding markets Jan 14, 2026, GKOS The event highlighted robust innovation in ophthalmology, with strong R&D investment yielding a broad product pipeline and record financial performance. Key growth drivers include new glaucoma and keratoconus therapies, strategic market expansion, and a focus on operational leverage and profitability. Based on Glaukos Corporation [GKOS] 44th Annual J.P. Morgan Healthcare Conference Audio Transcript \u2014 Jan. 14 2026",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.10",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-22T21:48:39.524686+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261844-JediMast-32210370",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:33.181130",
        "source": "LSE_CHAT",
        "data": {
          "author": "JediMaster1",
          "content": "Rumours of investment banks wanting to buy in from the JP Morgan Conference. The only question now is who do they want to buy in on behalf of?? The next few days will be interesting. Will Eric spill the beans?",
          "sentiment": 0.5,
          "engagement": "169",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D010A135-964B-4034-9025-65BCB0334809"
        },
        "ingested_at": "2026-01-22T21:48:39.524650+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261946-jamtart1--6927746",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:33.180710",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Doubt it, but happy if rumours are true",
          "sentiment": 0.5,
          "engagement": "1,600",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan, news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=559FB93D-C9CD-4A83-84E9-7B26CC6976E9"
        },
        "ingested_at": "2026-01-22T21:48:39.524617+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260634-Porter_-85993619",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:33.180307",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Companies attend the J.P. Morgan Healthcare Conference (JPM) primarily for networking, securing funding, forging strategic partnerships, and announcing key business updates. This major event, often described as setting the industry's tone for the year, concentrates a year's worth of meetings into a few days. Key reasons why companies attend include: Investment and Funding: The conference is a premier venue for companies to present their strategies and financial outlooks to a high-level audience of investors, analysts, and venture capitalists. For many, especially smaller or emerging biotech firms, it is a critical opportunity to secure financing, gauge investor interest, and build essential relationships. Mergers and Acquisitions (M&A) and Partnerships: The event is a hotbed for dealmaking. Big pharmaceutical companies often attend to scout for smaller companies with promising drug pipelines or innovative technologies (like AI in drug discovery) to acquire, especially as their own blockbuster drugs approach patent expiration. Extensive one-on-one meetings facilitate these discussions and collaborations. Strategic Positioning and Visibility: Companies announce major news, clinical trial data, or year-end recaps just before or during the conference to capture attention and elevate their visibility above the competition. It allows them to articulate their unique value proposition and strategic priorities to the global market. Market Intelligence: Attending allows companies to take the pulse of the industry, understand the latest trends (e.g., AI, gene therapy, obesity drugs), and gather competitive intelligence. They can assess how investors and peers discuss valuations, regulatory pathways, and market potential, which helps in fine-tuning their own strategies for the year ahead. Networking Efficiency: The conference brings the entire healthcare and life sciences ecosystem\u2014from manufacturers and providers to regulators and service providers\u2014into a concentrated location for a short time. This high density of key decision-makers allows for efficient, high-value networking and relationship building that would otherwise take months of travel and outreach.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=4C9A5731-DC78-4F24-8CE9-513E080FCFAC"
        },
        "ingested_at": "2026-01-22T21:48:39.524599+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20262119-jamtart1-26026042",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:33.179832",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Yes, Genflow Biosciences (Genflow) has had significant interest at the J.P. Morgan Healthcare Conference, attending specifically to engage with potential partners, institutional investors, and pharmaceutical companies. Their CEO, Dr. Eric Leire, attended the most recent conference in January 2026 with a \"full appointments book\" to discuss strategic partnerships and non-dilutive funding opportunities.",
          "sentiment": 0.5,
          "engagement": "1,600",
          "price_at_post": "1.85",
          "thread_title": "JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=3005BF87-EE58-4C27-ABC6-EE6AA15A9385"
        },
        "ingested_at": "2026-01-22T21:48:39.524582+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20260716-Porter_-15646242",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:33.179425",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Genflow Biosciences is a London-based biotechnology firm and the first \"pure-play\" longevity company listed on the London Stock Exchange. As of early 2026, the company is transitioning from a preclinical phase into active clinical data readouts, focusing on its proprietary SIRT6-based gene therapy platform to extend human and animal \"healthspan\". Core Technology and Pipeline: The company\u2019s lead therapeutic approach involves delivering a \"centenarian variant\" of the SIRT6 gene, identified in individuals who live over 100 years, to improve DNA repair and metabolic health. GF-1002 (Human Therapeutics): MASH (Liver Disease): Repositioned in 2025 to target patients with advanced fibrosis who have limited options from existing GLP-1 therapies. The company is currently finalizing its Investigational New Drug (IND) package and exploring mRNA/LNP delivery to allow for repeat dosing and lower costs. Werner Syndrome: A rare genetic condition causing premature aging. Genflow has developed proprietary human-derived liver organoids to model this disease more accurately than animal models. GF-1004 (Veterinary Program): Canine Longevity: A 12-month blinded clinical trial in aged dogs is currently underway. In early 2026, the company confirmed that all subjects received full dosing with no adverse events reported. Key 2026 Milestones: Initial efficacy readouts focusing on biological age (via methylation clocks) are expected in Q1 2026, with a second evaluation planned for June-July 2026. Expansion Programs: Glaucoma: A new ophthalmology program targeting neuroprotection of retinal ganglion cells to prevent blindness. Sarcopenia (GF-1005): Research into muscle health and mitochondrial dysfunction in collaboration with the Universit\u00e9 libre de Bruxelles. 2026 Strategic Focus: Genflow\u2019s 2026 strategy emphasizes \"rationalization of the pipeline,\" prioritizing programs with the strongest data to secure non-dilutive funding through licensing deals and partnerships. The company is actively seeking animal health partners for its dog longevity program and strategic collaborators for its LNP-based mRNA therapeutics.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "GLP, LNP, MRNA and SIRT6 based therapeutics",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=FB89DB69-F93B-4BB3-8529-5206EECDF243"
        },
        "ingested_at": "2026-01-22T21:48:39.524564+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20260836-Pie-char--8810867",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:33.178954",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Post conference announcement next week and Funding news is what I predict. I'm amazed we are at this price. Such a hidden gem!",
          "sentiment": 0.5,
          "engagement": "60",
          "price_at_post": "1.85",
          "thread_title": "RE: JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=3005BF87-EE58-4C27-ABC6-EE6AA15A9385"
        },
        "ingested_at": "2026-01-22T21:48:39.524547+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260718-Porter_--3352350",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:33.178544",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Genflow Appoints a New Chairman to Accelerate Corporate and R&D Expansion Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or the \"Company\"), a leading European-based biotechnology company focusing on gene therapies for age-related diseases, is pleased to announce a significant appointment to its Board of Directors, marking an important step in the Company's strategic evolution. Mr. Gad Berdugo, MSc Eng., MBA, has joined the Board with immediate effect and will assume the role of Independent Non-Executive Chairman, providing leadership as Genflow focuses on advancing its gene-therapy programs. Mrs. Tamara Joseph will continue to serve as a Director, ensuring continuity and maintaining strong governance. Mr. Berdugo brings over 30 years' of leadership experience spanning global business and corporate development, U.S. capital markets, and company building. He has a proven record of driving strategic partnerships, securing capital, and scaling both private and public development-stage biotechnology companies. Currently, Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a U.S.-based strategic and financial advisory firm focusing on the global biotechnology sector. His most recent roles include: \u00b7 Co-Founder & CEO, EpiVax Oncology \u00b7 Vice-Chairman of the Board, Evexta Bio \u00b7 Chief Business Officer, Editas Medicine (NASDAQ: EDIT) \u00b7 Chief Business Officer, Nutcracker Therapeutics He began his international career at Abbott Labs and Baxter, later becoming Life Sciences Sector Leader at Lazard Asset Management. Mr. Berdugo also brings deep technical and market expertise in RNA-based therapeutics, including lipid nanoparticle (LNP) delivery, development, and manufacturing. This background will support Genflow as it advances its scientific platform, evaluates delivery technologies, and explores next-generation therapeutic approaches. His appointment further strengthens the Company's presence in the United States and expands its capacity for global engagement. He does not own any shares in the Company. Dr. Eric Leire, Chief Executive Officer of Genflow, commented: \"We are delighted to welcome Mr. Berdugo as Independent Non-Executive Chairman. His expertise in strategy, partnerships and financing as well as his deep experience with RNA-LNP technologies will be instrumental as we accelerate our programs and expand our global reach. We are equally pleased that Mrs. Tamara Joseph will continue her service on the Board, contributing her invaluable leadership, legal and governance expertise.\" Gad Berdugo added: \"I am excited to join Genflow as the company is progressing to the next new phase of development, with key data readouts expected in 2026, strengthened intellectual property, and a sharpened strategic focus on high-potential programs. I look forward to working with the talented team and board to advance these innovative gene therapies, this is an ideal moment to contribute my expertise and hel",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-22T21:48:39.524529+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260734-Twocd2--4764231",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:33.178072",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "Take the rest of the day off Porter..great job pal! You must have set the alarm early to C&P all of that \ud83d\udc4f\ud83d\udc4f\ud83d\udc4c",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-22T21:48:39.524512+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260752-Porter_-51139158",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:33.177662",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "2cd2 - invest more than \u00a3100 in a company and you might care a little bit more for your investments \ud83d\ude18",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-22T21:48:39.524494+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260820-Moneymun--3481256",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:33.177250",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The new Chairman in place, GAD BERDUGO is a high flyer based in the US with a wealth of experience in Global Biotech, Corporate Development and US Capital Markets and so no doubt very well contected to any potential suitors. Excitement building!!!! In Eric we trust!!! Gla holders:-) Ps initial Efficacy readout on the Dog Trial imminent!!! Gla ;-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-22T21:48:39.524477+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260839-Twocd2--8160802",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:33.176829",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "Ok big fella..time for nap your banter is honking.",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-22T21:48:39.524459+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261005-DaveTK--1479415",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:33.176419",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Would seem like you touched  nerve there, Porter ha ha. Nice RNS this morning. Looking forward to hearing more regarding the J.P. Morgan's Healthcare Conference. Really does seem like exciting times ahead. Thanks",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-22T21:48:39.524440+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261027-Porter_-96714797",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:33.175985",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Always the ones who sold too soon quick to troll those who held with diamond hands Dave. Expecting this is just the first update of many we\u2019ll be seeing over the next 2 weeks. Popcorn ready! \ud83c\udf7f",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-22T21:48:39.524422+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261033-DaveTK--8851425",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:33.175567",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Always. I'm here and always have been here waiting for news that we have been bought out. It was always the goal from Eric to make this company into something a pharmaceutical would buy a high price. We may not be that far off. Fingers crossed. Thanks",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-22T21:48:39.524405+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261342-Twocd2-60284177",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:33.175131",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "So TK Max joins the party\u2026think you and Porter need to take turns and time to give him a chance to be big spoon for this week. Might give him something else to do rather than practice his typing. Plenty of skin in the game lads\u2026but this is not about who\u2019s chopper is bigger..well maybe for the spooning it does\ud83d\ude01",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-22T21:48:39.524387+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261352-DaveTK-80048392",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:33.174711",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "I joined the party pre IPO. TBF they were asking for more than \u00a350 so it may have been too much of a reach for you. Talking about choppers FFS. Don't let you mum read that or she'll take your phone off you and cancel your contract.",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-22T21:48:39.524368+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20262217-Twocd2--3638538",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:33.174287",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "I joined pre IPO, \u00a350 may have been too much of a reach for you\u2026chortle chortle TK Max.. Give Porter a reach around before lights out so that he\u2019ll not be to disappointed with no RNS tomorrow morning\u2026\ud83d\udc4c",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-22T21:48:39.524348+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260719-Porter_-64211423",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:33.173852",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Know a few people who didn\u2019t get their orders filled yesterday. Seems there isn\u2019t much in the free-float so let\u2019s see how tight this coiled spring is!",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-22T21:48:39.524326+00:00"
      },
      {
        "event_id": "SOCIAL-Today1756-Persever--2391001",
        "event_type": "social_post",
        "date": "2026-01-22T21:48:33.173423",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "I think a massive rerate is coming ? Somethings brewing ?",
          "sentiment": 0.0,
          "engagement": "1",
          "price_at_post": "1.90",
          "thread_title": "Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-01-22T21:48:39.524290+00:00"
      },
      {
        "event_id": "SOCIAL-24Nov20251658-jamtart1--1471597",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:19.711385",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Just think, why would they apply for patients if it didn't work? Nobody applies for a  patient for something that doesn't work.",
          "sentiment": 0.5,
          "engagement": "1,598",
          "price_at_post": "1.70",
          "thread_title": "Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=F3C8443F-3220-4B2E-A46C-C25DB028889C"
        },
        "ingested_at": "2026-01-21T22:18:19.728759+00:00"
      },
      {
        "event_id": "SOCIAL-24Nov20251701-jamtart1--2223904",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:19.710969",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Sorry should be patent not patient, my error.",
          "sentiment": 0.0,
          "engagement": "1,598",
          "price_at_post": "1.70",
          "thread_title": "Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=82801565-5503-4F22-AB17-FD87A6DBD7F5"
        },
        "ingested_at": "2026-01-21T22:18:19.728741+00:00"
      },
      {
        "event_id": "SOCIAL-25Nov20250851-VikR-79339203",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:19.710567",
        "source": "LSE_CHAT",
        "data": {
          "author": "VikR",
          "content": "Landing anytime Non dilutive funding to accelerate all operations Multiple news flow items due imminently",
          "sentiment": 0.5,
          "engagement": "934",
          "price_at_post": "1.55",
          "thread_title": "\u20ac4.7m non-dilutive grant funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=D5EEB2DA-F9CE-4EE4-B989-384B1545506A"
        },
        "ingested_at": "2026-01-21T22:18:19.728723+00:00"
      },
      {
        "event_id": "SOCIAL-25Nov20251041-Sammy57--8513513",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:19.710148",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sammy57",
          "content": "There's some lumpy trades going on this morning, maybe life returning to our comatose patient. Think I might start the loading process properly now. Let's see what happens. Good luck to all investors",
          "sentiment": 0.5,
          "engagement": "78",
          "price_at_post": "1.65",
          "thread_title": "Lumpy trades",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=DE22B283-2B76-4175-965A-F9DC667C4522"
        },
        "ingested_at": "2026-01-21T22:18:19.728706+00:00"
      },
      {
        "event_id": "SOCIAL-26Nov20251837-Moneymun-90820255",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:19.709728",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "A nice 1.4m buy at 1.74p, late reported from yesterday just popped UP!!! Gla holders, they want your shares...Game changing news at anytime!!! :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.625",
          "thread_title": "RE: Lumpy trades",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=DE22B283-2B76-4175-965A-F9DC667C4522"
        },
        "ingested_at": "2026-01-21T22:18:19.728688+00:00"
      },
      {
        "event_id": "SOCIAL-28Nov20251107-VikR--1301793",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:19.709321",
        "source": "LSE_CHAT",
        "data": {
          "author": "VikR",
          "content": "Strong buy for me and hold glad I topped up a few days ago Game changing news imminent",
          "sentiment": 0.5,
          "engagement": "934",
          "price_at_post": "1.60",
          "thread_title": "Nice tick up what\u2019s happening",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=C40805F6-1186-4847-BD33-CFB89B5096D0"
        },
        "ingested_at": "2026-01-21T22:18:19.728670+00:00"
      },
      {
        "event_id": "SOCIAL-28Nov20251203-Moneymun-50188178",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:19.708895",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Get UP there!!! ...Gla holders, they want your shares, Game changing news at anytime!!! On and UP!!! Ho ho ho :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.85",
          "thread_title": "RE: Nice tick up what\u2019s happening",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=C40805F6-1186-4847-BD33-CFB89B5096D0"
        },
        "ingested_at": "2026-01-21T22:18:19.728653+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251131-Moneymun--4508952",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:19.708489",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The calm before the storm??? A could of nice big buys 1.1m and 1.4m posted after hours yesterday, late reported from Friday's action with some chunky buys. The smart Money is obviously still accumulating for bigger and better things to come. Multiple potential material newsflow in the pipeline to add significant value!!! Gla holders:-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.775",
          "thread_title": "RE: Nice tick up what\u2019s happening",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=C40805F6-1186-4847-BD33-CFB89B5096D0"
        },
        "ingested_at": "2026-01-21T22:18:19.728635+00:00"
      },
      {
        "event_id": "SOCIAL-2Dec20251137-Moneymun-25792916",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:19.708068",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Pharma M&A Deals Surge to USD 82.6 Billion in Q2 2025 as Big Pharma Accelerates Acquisitions in Oncology, Rare Diseases & AI-Driven Drug Discovery 12-01-2025 Sub-Headline: Global pharmaceutical M&A deal value increased from USD 64.2 billion in Q2 2024 to USD 82.6 billion in Q2 2025, reflecting a strong 28.6% YoY growth, driven by strategic acquisitions in oncology, gene therapy, immunology, and AI-enabled drug development platforms. Introduction The M&A Trends in Pharma - Q2 2025 Market analysis reveals a high-momentum quarter, with pharmaceutical giants aggressively acquiring biotech innovators to strengthen clinical pipelines, expand therapeutic portfolios, and accelerate time-to-market for breakthrough therapies. Key areas driving acquisition interest include: \u2022 Oncology (ADC, IO, CAR-T, radiopharmaceuticals) \u2022 Rare diseases & orphan drugs \u2022 Gene therapy & RNA therapeutics \u2022 AI drug discovery platforms \u2022 Immunology & autoimmune diseases \u2022 Digital-biotech & clinical trial technology The return of high-value deals signals Big Pharma's need to offset patent cliffs and increase long-term revenue stability. The global pharma industry entered 2025 with renewed investment strength as companies pursue pipeline diversification and innovation-led acquisitions. \"The pharma M&A landscape in Q2 2025 confirms a decisive shift toward oncology leadership, gene therapy, and AI-first drug discovery models. Big Pharma is aggressively pursuing acquisitions that offer long-term clinical and commercial durability.\" The pharma M&A market in Q2 2025 is experiencing exceptional momentum, driven by oncology breakthroughs, high-value gene therapy assets, and AI-driven early-stage platforms. Companies investing in transformative, multi-modal biopharma technologies will lead next-generation therapeutic markets through 2030.",
          "sentiment": 0.0,
          "engagement": "12,509",
          "price_at_post": "1.775",
          "thread_title": "RE: Nice tick up what\u2019s happening",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=C40805F6-1186-4847-BD33-CFB89B5096D0"
        },
        "ingested_at": "2026-01-21T22:18:19.728618+00:00"
      },
      {
        "event_id": "SOCIAL-4Dec20250839-VikR--6061985",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:19.707593",
        "source": "LSE_CHAT",
        "data": {
          "author": "VikR",
          "content": "Good time sub 2p for holders to get in. Will try and push some more profits into here from other shares. This is going to re rate big on next milestones. CDAs already signed with multiple animal health companies and safety profile of life prolonging med established. Other catalysts in the portfolio also operating in a very underserved niche area of human disease pathology. To top it all off grant funding also to land",
          "sentiment": 0.5,
          "engagement": "934",
          "price_at_post": "1.85",
          "thread_title": "When this moves it moves quick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=97129C09-D9CE-455A-9DCD-2669912F7D18"
        },
        "ingested_at": "2026-01-21T22:18:19.728600+00:00"
      },
      {
        "event_id": "SOCIAL-5Dec20250915-Moneymun--6119185",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:19.707180",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Looks like sub 2p is gone, UPward momentum in anticipation of  multiple potential material newsflow, some of which could be game changing. Gla holders....Excitement building....On and UP!!! :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: When this moves it moves quick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=97129C09-D9CE-455A-9DCD-2669912F7D18"
        },
        "ingested_at": "2026-01-21T22:18:19.728582+00:00"
      },
      {
        "event_id": "SOCIAL-5Dec20250959-Roosters--1091982",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:19.706764",
        "source": "LSE_CHAT",
        "data": {
          "author": "Roostersmillions",
          "content": "Yes, nice move upwards today, and looking at the trades, it doesn't seem to be volume thats doing it. Are there rumours? Early Xmas present of the grant money? Early confirmation of dog trials. Could we be millionaires by next Christmas.",
          "sentiment": 0.0,
          "engagement": "288",
          "price_at_post": "2.00",
          "thread_title": "RE: When this moves it moves quick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=97129C09-D9CE-455A-9DCD-2669912F7D18"
        },
        "ingested_at": "2026-01-21T22:18:19.728564+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250659-Porter_-80887252",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:19.706347",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Plenty potential news for us to get moving with Rooster: * Grant funds received backed by the European Union * Exclusively licensed Rochester patent getting full approval as now at year 5 * Dog trial data being released * Companies under CDA / NDA making formal offers *Progression of NASH programme (competitor recently bought for $5bn) * Progression of Sarcopenia programme * Progression of eye regeneration programme (competitor recently bought for $3.5bn) * Further programmes being announced * Further patents for gene / compound variants being announced * TR1 updates * More insiders taking / increasing positions * Further pharma companies showing interest in Genflow\u2019s research * Directors guest speaking at further conferences and big pharma events, like the Belgian embassy Walloni\u00eb scientific event last month All while the float continues to be snaffled up strategically by long term loyal investors \ud83e\udd70",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "2.05",
          "thread_title": "RE: When this moves it moves quick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=97129C09-D9CE-455A-9DCD-2669912F7D18"
        },
        "ingested_at": "2026-01-21T22:18:19.728545+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20250857-Roosters--1622401",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:19.705865",
        "source": "LSE_CHAT",
        "data": {
          "author": "Roostersmillions",
          "content": "Exciting times porter. Still no idea why this isnt at a higher value, when you look at similar companies valued in 100s of millions.",
          "sentiment": 0.0,
          "engagement": "288",
          "price_at_post": "2.00",
          "thread_title": "RE: When this moves it moves quick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=97129C09-D9CE-455A-9DCD-2669912F7D18"
        },
        "ingested_at": "2026-01-21T22:18:19.728528+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20251122-MumbleGr-34557853",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:19.705450",
        "source": "LSE_CHAT",
        "data": {
          "author": "MumbleGrumble",
          "content": "Just \u00a3280k in cash reserves reported in June 25 must be real low at this point. No news of the grant/advance we\u2019ve been waiting for since Oct 24. Two dilutions this year. I\u2019m still optimistic for the long term future and still holding but I\u2019ve changed my stance on starting to buy back in at 1.5 - 1.6 simply because with no grant news, I fear further dilution.",
          "sentiment": 0.0,
          "engagement": "82",
          "price_at_post": "2.00",
          "thread_title": "RE: When this moves it moves quick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=97129C09-D9CE-455A-9DCD-2669912F7D18"
        },
        "ingested_at": "2026-01-21T22:18:19.728510+00:00"
      },
      {
        "event_id": "SOCIAL-8Dec20251146-Moneymun--1961992",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:19.705010",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "They recently raised \u00a3440k in October via Eric and a consortium of long term Major Shareholders,  a huge vote in confidence and commitment and I'm sure they wouldn't have parted with their hard earned cash if they didn't believe Genflow were on the brink of something big. The current sp performance certainly suggests the smart Money is accumulating and the free float is getting tighter and tighter, and with multiple potential material newsflow in the pipeline, including receipt confirmation of some of the outstanding \u00a34.7m non-dilutive grant funding, as well as the the eagerly awaited efficacy results from the Dog Trial , where positive results will very likely see a game-changing lucrative licensing deal,  the Genflow's upside potential and prospects look very exciting.  Gla holders...Game changing news at anytime!!! :-) 9/10/25 Dr. Eric Leire, CEO of Genflow, commented: \"We would like to express our sincere gratitude to our historical shareholders for their continued confidence and commitment to Genflow\u2019s vision. Their ongoing support reflects a shared belief in our mission. With this additional capital, Genflow is able to deliver on our near-term objectives.\"",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.00",
          "thread_title": "RE: When this moves it moves quick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=97129C09-D9CE-455A-9DCD-2669912F7D18"
        },
        "ingested_at": "2026-01-21T22:18:19.728492+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251058-DaveTK--7437048",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:19.704592",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Just like yesterday. Games that they play. More buys than sell and drops. Very odd",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "2.00",
          "thread_title": "MM Games",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2DDB5CD0-5167-4676-A42B-32D3B064D5CF"
        },
        "ingested_at": "2026-01-21T22:18:19.728474+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251137-Moneymun-41780980",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:19.704188",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "It only dropped because of the 50k UT trade at 2.10p posted after hours yesterday, which caused the sp to close blue at 2.10p and then reverts to the correct closing price of 2p , which causes the sp to open in the red the following day. This happens all the time following an after hours UT trade, and in this current example,  makes the chart with the step down from 2.1p to 2p,  look perfectly primed and poised for the next UPward move as the next positive UPdate arrives and/or buying  volumes increase.  Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.00",
          "thread_title": "RE: MM Games",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2DDB5CD0-5167-4676-A42B-32D3B064D5CF"
        },
        "ingested_at": "2026-01-21T22:18:19.728456+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251417-VikR--7577106",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:19.703770",
        "source": "LSE_CHAT",
        "data": {
          "author": "VikR",
          "content": "Another day closer to transformational RNSs landing patience is key here but the re rate is coming. Currently blue on my holdings here but not selling a single share until we are in double figures. Quietly confident.",
          "sentiment": 0.5,
          "engagement": "934",
          "price_at_post": "2.00",
          "thread_title": "RE: When this moves it moves quick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=97129C09-D9CE-455A-9DCD-2669912F7D18"
        },
        "ingested_at": "2026-01-21T22:18:19.728438+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251511-RandomUs--2396079",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:19.703353",
        "source": "LSE_CHAT",
        "data": {
          "author": "RandomUser2025",
          "content": "Have been buying over the last couple of weeks.  Bought another 1.5m shares today at 2.075p (not showing on the board yet) taking my holding to 2.6m shares. Hoping for some good news!",
          "sentiment": 0.5,
          "engagement": "5",
          "price_at_post": "2.00",
          "thread_title": "Fingers crossed..!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=049DEFDD-9ECA-40A9-92FD-00E467251789"
        },
        "ingested_at": "2026-01-21T22:18:19.728421+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251450-VikR--8761239",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:19.702923",
        "source": "LSE_CHAT",
        "data": {
          "author": "VikR",
          "content": "Quietly accumulating Completely under the radar this share and I cannot be bothered to promote it. Just allows me to keep on topping up at these levels. For the scientists in the know this has such tremendous potential across the portfolio",
          "sentiment": 0.5,
          "engagement": "934",
          "price_at_post": "1.95",
          "thread_title": "Weekly top up done",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=5B943FDA-2626-487C-B959-065C9CE6AC31"
        },
        "ingested_at": "2026-01-21T22:18:19.728403+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251600-SM81--2557176",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:19.702503",
        "source": "LSE_CHAT",
        "data": {
          "author": "SM81",
          "content": "Down 16% - weird - if no one knows of any good reason, I think I might just top up at 1.75!",
          "sentiment": 0.5,
          "engagement": "38",
          "price_at_post": "1.675",
          "thread_title": "RE: Weekly top up done",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=5B943FDA-2626-487C-B959-065C9CE6AC31"
        },
        "ingested_at": "2026-01-21T22:18:19.728384+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251732-Moneymun-88444368",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:19.702073",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Your 1.5m buy has just popped UP!!! Gl :-) Maybe a bit of a tree shake earler to fill it??? :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: Fingers crossed..!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=049DEFDD-9ECA-40A9-92FD-00E467251789"
        },
        "ingested_at": "2026-01-21T22:18:19.728367+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251841-RandomUs--2643894",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:19.701652",
        "source": "LSE_CHAT",
        "data": {
          "author": "RandomUser2025",
          "content": "Yes, it showed up eventually! Taking advantage of the dip and buying more!",
          "sentiment": 0.5,
          "engagement": "5",
          "price_at_post": "1.90",
          "thread_title": "RE: Fingers crossed..!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=049DEFDD-9ECA-40A9-92FD-00E467251789"
        },
        "ingested_at": "2026-01-21T22:18:19.728349+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20250701-Moneymun-82938964",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:19.701210",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Genflow to Attend Healthcare Conference GENFLOW BIOSCIENCES PLC Released 07:00:09 11 December 2025 RNS Number : 0160L Genflow Biosciences PLC 11 December 2025 Genflow Biosciences Plc Genflow to Attend the 44th Annual J.P. Morgan Healthcare Conference Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\"), a leading European-based biotechnology company focusing on longevity, announces that it will attend the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12-15, 2026, at the Westin St. Francis in San Francisco, California. J.P. Morgan's Healthcare Conference is the sector's most influential global investment gathering, connecting industry leaders, high-growth innovators, and the investment community. Genflow's participation provides an opportunity to engage with potential partners, institutional investors, and pharmaceutical companies as the Company advances its gene-therapy pipeline targeting the SIRT6 longevity pathway. About the 44th Annual J.P. Morgan Healthcare Conference The 44th Annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together global industry leaders, emerging growth companies, technology innovators, and investors. More information is available on the conference website. Dr. Eric Leire, CEO of Genflow, commented: \"We're excited to attend the JP Morgan Healthcare Conference in San Francisco this January. Our planned meetings reflect our current focus on lipid nanoparticle delivery for mRNA SIRT6 therapeutics, which is opening compelling opportunities for strategic partnerships in the longevity space.\"",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.95",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=556B6E46-8AC5-4666-83B4-6168329D5380"
        },
        "ingested_at": "2026-01-21T22:18:19.728331+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20250709-Porter_-81526285",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:16.940991",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Fantastic news Money: The main J.P. Morgan Healthcare Conference is invitation-only for clients, industry leaders, investors, and participating companies, not open to the general public. While the official event is exclusive, many related, often smaller, partnering and networking events happen nearby during the same week, sometimes with public registration or via company invites, making the broader \"JPM Week\" accessible through networking and attending satellite events. Who Gets In (Official Event): J.P. Morgan Clients: Major investors and companies that bank with J.P. Morgan. Industry Leaders: Executives from large healthcare, biotech, and pharma companies. Investors: Institutional investors, VCs, and analysts. Presenting Companies: Companies paying to present their updates. Wonder if one of JPM\u2019s clients have their eyes on Genflow and they\u2019re up for funding a deal or bringing in more investment?",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.95",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=556B6E46-8AC5-4666-83B4-6168329D5380"
        },
        "ingested_at": "2026-01-21T22:18:19.728313+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20250714-Moneymun--6685630",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:16.940549",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Brilliant news Porter, and no more high profile you can get with Genflow well and truly in the Global Biotech spotlight and full investor focus, and no doubt Eric and co fully loaded with compelling positive efficacy data. Exciting times!!! Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.95",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=556B6E46-8AC5-4666-83B4-6168329D5380"
        },
        "ingested_at": "2026-01-21T22:18:19.728296+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20251040-DaveTK--3694150",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:16.940141",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Who wakes up, reads that RNS and think, na... time to sell. What were you investing here for in the first place.",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.725",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=061051EA-4ED4-4F82-8F99-AEDD6800D353"
        },
        "ingested_at": "2026-01-21T22:18:19.728278+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20251119-jamtart1--4663294",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:16.939728",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Why the drop? Is there and idiot factor at work here?",
          "sentiment": 0.5,
          "engagement": "1,598",
          "price_at_post": "1.725",
          "thread_title": "Rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=38D11B09-C0AE-41D3-B069-BA371E31CE8A"
        },
        "ingested_at": "2026-01-21T22:18:19.728260+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20251534-Moneymun-90977561",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:16.939320",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The J.P. Morgan 44th Annual Healthcare Conference for 2026 is scheduled for January 12-15, 2026, in San Francisco, California, primarily at the Westin St. Francis Hotel, focusing on pharma, biotech, medtech, AI in healthcare, and digital health, drawing major industry players, investors, and innovators for networking and deal-making. It's an invitation-only event, a key barometer for investor sentiment, with many announcements timed around it. Key Details: Dates: January 12-15, 2026. Location: San Francisco, CA (Westin St. Francis Hotel). Nature: Invitation-only, industry-leading investment symposium. Attendees: Global industry leaders, emerging companies, investors, tech innovators. Topics: Breakthrough therapies (oncology, neurology), AI in drug discovery, regulatory shifts, digital health, M&A trends. Why It's Important: It's the largest healthcare investment conference, influencing investor sentiment for the year. Major licensing deals, pipeline updates, and strategic partnerships are often announced during this week.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.75",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=556B6E46-8AC5-4666-83B4-6168329D5380"
        },
        "ingested_at": "2026-01-21T22:18:19.728242+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20251713-Porter_-57878932",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:16.938861",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Money, take a look on OTC, it wouldn\u2019t surprise me if the MM\u2019s are moving the stock to the US in anticipation of JPM in January. They\u2019ve took the GENF share price up 100% on there this week \ud83d\ude09",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.725",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=556B6E46-8AC5-4666-83B4-6168329D5380"
        },
        "ingested_at": "2026-01-21T22:18:19.728225+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20252051-Porter_-72502450",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:16.938455",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Some loading going on, another \u00a329k buy from yesterday just cleared",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.725",
          "thread_title": "Late prints - mamoosive buys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=903B57D0-62C3-44A0-8F19-E0845FF3F44B"
        },
        "ingested_at": "2026-01-21T22:18:19.728207+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20252256-Moneymun-31594916",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:16.938033",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "All bodes well Porter, the share accumulation continues under the radar and no surprise, now we know Genflow have been invited to the prestigious JP Morgan HealthCare Conference.  Get ready for a transformational  and stellar 2026!!! Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.725",
          "thread_title": "RE: Late prints - mamoosive buys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=903B57D0-62C3-44A0-8F19-E0845FF3F44B"
        },
        "ingested_at": "2026-01-21T22:18:19.728190+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20251528-RandomUs-22682875",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:16.937626",
        "source": "LSE_CHAT",
        "data": {
          "author": "RandomUser2025",
          "content": "Looks like a great company to me\u2026, so I\u2019ve just bought another 900,000 at 1.7p.",
          "sentiment": 0.5,
          "engagement": "5",
          "price_at_post": "1.725",
          "thread_title": "RE: Fingers crossed..!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=049DEFDD-9ECA-40A9-92FD-00E467251789"
        },
        "ingested_at": "2026-01-21T22:18:19.728172+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20251730-Porter_--1955068",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:16.937201",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "You must have over 3m now! Have you joined the Genflow telegram group?",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.725",
          "thread_title": "RE: Fingers crossed..!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=049DEFDD-9ECA-40A9-92FD-00E467251789"
        },
        "ingested_at": "2026-01-21T22:18:19.728155+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20251737-RandomUs--7003474",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:16.936758",
        "source": "LSE_CHAT",
        "data": {
          "author": "RandomUser2025",
          "content": "Yep - Now up to 3.5m which I think must be 0.75% of the company! \ud83e\udd23.  Planning on holding them long term.  Not heard of the telegram group..?",
          "sentiment": 0.5,
          "engagement": "5",
          "price_at_post": "1.725",
          "thread_title": "RE: Fingers crossed..!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=049DEFDD-9ECA-40A9-92FD-00E467251789"
        },
        "ingested_at": "2026-01-21T22:18:19.728136+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20251744-Porter_-55545395",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:16.936343",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "i have the exact same amount. you\u2019ll be bypassing me though by the sounds of it! if you go on telegram and search genflowbio - *************genflowbio you should be able to find the group \ud83d\ude01",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.725",
          "thread_title": "RE: Fingers crossed..!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=049DEFDD-9ECA-40A9-92FD-00E467251789"
        },
        "ingested_at": "2026-01-21T22:18:19.728116+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20251758-RandomUs-59472185",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:16.935918",
        "source": "LSE_CHAT",
        "data": {
          "author": "RandomUser2025",
          "content": "Thanks.",
          "sentiment": 0.5,
          "engagement": "5",
          "price_at_post": "1.725",
          "thread_title": "RE: Fingers crossed..!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=049DEFDD-9ECA-40A9-92FD-00E467251789"
        },
        "ingested_at": "2026-01-21T22:18:19.728083+00:00"
      },
      {
        "event_id": "SOCIAL-14Dec20252023-VikR-56462521",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:16.935503",
        "source": "LSE_CHAT",
        "data": {
          "author": "VikR",
          "content": "Solid evidenced based buy with multiple news flow items imminent Keep on loading Stay strong in your holdings And let the BOD bring in the contracts",
          "sentiment": 0.5,
          "engagement": "934",
          "price_at_post": "1.725",
          "thread_title": "RE: Fingers crossed..!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=049DEFDD-9ECA-40A9-92FD-00E467251789"
        },
        "ingested_at": "2026-01-21T22:18:19.728065+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251603-Moneymun--3175862",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:16.935066",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Healthy competition for Genflow, but certainly highlights the incredible potential and prospects of Genflow's Sirt6 Gene Therapy R & D, which could be slightly ahead of the curve, given the safety profile of Genflow's Sirt6 has been established and confirmed twice with no ill effects in the current Dog Trial, and with human trials for Mash expected/planned for this coming year. The Chief Medical Advisor at Sirtlab, Dr. Nir Barzilai, is also a Director/Professor at Albert Einstein College of Medicine in New York who along with the University of Rochester and Columbia University, jointly own the Sirt6 patent \"Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases\" and Genflow holds the exclusive worldwide license to this intellectual property. All bodes well and all very exciting as Genflow prepares to impress and wow at the upcoming JP Morgan HealthCare Conference. Gla holders;-) April 2025 The Pill That Could Change Everything Living longer and feeling younger. That\u2019s the promise behind Sirtlab, the innovative Israeli startup that is on the verge of redefining aging\u2014and extending human life by up to 30% The Pill That Could Change Everything \u201cSIRT-6 doesn\u2019t just help us live longer\u2014it helps us live better,\u201d says Prof. Haim Cohen, founder and chief scientist at Sirtlab and head of the Sagol Center for Healthy Aging at Bar-Ilan University. \u201cWe\u2019ve managed to elevate SIRT-6 levels in older test subjects to those typically seen in much younger individuals, and the effects are stunning.\u201d According to Cohen, the increased activity of SIRT-6 has been linked to improved memory, better liver function, and even hair regrowth. \u201cIn our studies, older animals with enhanced SIRT-6 activity performed as well as their younger counterparts, physically and cognitively.\u201d A New Era in Aging The treatment is currently one step away from human trials. So far, results in animals have been promising: older subjects not only lived longer but showed energy levels, physical performance, and bodily functions similar to the young. \u201cWe\u2019re hopeful this translates to humans,\u201d says Prof. Eitan Friedman, director of Oncogenetics at Assuta Medical Center. \u201cIf the upcoming clinical trials confirm these results, this could be a true game-changer. I\u2019m cautiously optimistic.\u201d Big Backing for Big Science *\ufeffSirtlab* has already raised millions of dollars and plans to raise more via the investment platform PeopleBiz, accelerating the development process. CEO Boaz Mashuoli emphasizes the global importance of the research: \u201cWe believe this treatment could significantly contribute to the future of human health. But first, we need to complete additional safety testing in animals before moving on to clinical trials.\u201d Mark Your Calendars: 2028 Could Be the Year If all goes according to plan, human trials will begin in about 18 months, with the drug potentially hitting the Israeli market within thr",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.75",
          "thread_title": "Sirt6",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=7319CD1C-C4C6-4015-8EC4-A089F968170E"
        },
        "ingested_at": "2026-01-21T22:18:19.728048+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251605-Moneymun--4217716",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:16.934598",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Mark Your Calendars: 2028 Could Be the Year If all goes according to plan, human trials will begin in about 18 months, with the drug potentially hitting the Israeli market within three years. \u201cThis drug isn\u2019t about immortality,\u201d explains Dr. Hagit Ashush, VP of R&D at Sirtlab. \u201cIt\u2019s about delaying the onset of age-related diseases and improving quality of life in later years. Our goal is to slow aging itself.\u201d",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.75",
          "thread_title": "RE: Sirt6",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=7319CD1C-C4C6-4015-8EC4-A089F968170E"
        },
        "ingested_at": "2026-01-21T22:18:19.728030+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20250702-Moneymun-41203809",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:16.934174",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Completion of Dosing Phase of Canine Gene Therapy GENFLOW BIOSCIENCES PLC Released 07:00:08 16 December 2025 RNS Number : 7366L Genflow Biosciences PLC 16 December 2025 Genflow Biosciences Plc Genflow Completes Dosing Phase of Canine Gene Therapy Trial No Adverse Events Reported During Administration Genflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) (\"Genflow\" or the \"Company\"), a biotechnology company focused on extending healthspan through advanced gene therapies, today announced that all dogs enrolled in its ongoing clinical trial have successfully received the full administration of the Company's investigational SIRT6-based gene therapy. Importantly, no adverse events were reported during the dosing phase of the study. No serious, moderate, or minor side effects were observed, demonstrating a strong safety and tolerability profile for the therapy. The study is being conducted as a blinded clinical trial and, as such, efficacy outcomes cannot yet be assessed. Genflow expects a first efficacy read in mid-to-late January 2026, which will include blood analyses and muscle biopsies to evaluate potential therapeutic benefits related to sarcopenia, overall healthspan, and lifespan-associated biomarkers. The dogs enrolled in the trial will continue to be monitored for a total duration of 180 days. A second efficacy assessment is planned at the six-month timepoint, with results expected in June-July 2026, to evaluate durability and longer-term effects of the gene therapy. Following analysis of the efficacy data, Genflow intends to resume discussions with several animal health companies, including parties currently engaged under confidentiality and data access agreements, to explore potential early-stage licensing opportunities. Dr. Eric Leire, CEO of Genflow, commented: \"These milestones represent an important step forward for our longevity program. The absence of any adverse events is highly encouraging and reinforces the strong safety profile of our approach. We look forward to sharing initial efficacy data in the coming months as the study progresses.\"",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.75",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=FFCBCED2-D73C-4621-8D2C-3B767BDE63F5"
        },
        "ingested_at": "2026-01-21T22:18:19.728012+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20250729-Moneymun--3890988",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:16.933699",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Great news and great timing , and maybe first efficacy readout in time for the prestigious JP Healthcare Conference. Exciting times!!! Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.75",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=FFCBCED2-D73C-4621-8D2C-3B767BDE63F5"
        },
        "ingested_at": "2026-01-21T22:18:19.727994+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20250737-borrowfu-91173450",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:16.933292",
        "source": "LSE_CHAT",
        "data": {
          "author": "borrowfundsfrommummy",
          "content": "Excellent update .. January as they promised looks mighty good for some decent news on the doggies .. if works then could be a huge money maker imo",
          "sentiment": 0.5,
          "engagement": "10,859",
          "price_at_post": "1.75",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=FFCBCED2-D73C-4621-8D2C-3B767BDE63F5"
        },
        "ingested_at": "2026-01-21T22:18:19.727977+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20250845-mikee_p--8892282",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:16.932872",
        "source": "LSE_CHAT",
        "data": {
          "author": "mikee_p",
          "content": "Bought out way before that if it works.",
          "sentiment": 0.0,
          "engagement": "1,888",
          "price_at_post": "1.80",
          "thread_title": "RE: Sirt6",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=7319CD1C-C4C6-4015-8EC4-A089F968170E"
        },
        "ingested_at": "2026-01-21T22:18:19.727959+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251122-Troajan-33499765",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:16.932464",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1084508/genflow-biosciences-ceo-discusses-next-steps-as-canine-gene-therapy-trial-hits-milestone-1084508.html",
          "sentiment": 0.0,
          "engagement": "125,392",
          "price_at_post": "1.775",
          "thread_title": "Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=34492A28-1046-40D4-8089-C939261E87E6"
        },
        "ingested_at": "2026-01-21T22:18:19.727941+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251250-Moneymun--3749706",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:16.932038",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Genflow Biosciences CEO discusses next steps as canine gene therapy trial hits milestone Published: 11:00 16 Dec 2025 Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company\u2019s progress in its canine gene therapy trial targeting sarcopenia. Leire confirmed that the dosing phase has now been completed with no adverse effects, calling it a key milestone in de-risking the SIRT6 programme for potential pharma partners and investors. He said, \u201cWe demonstrated some kind of safety, with the full dosing, we had to observe no side effect, no adverse side effect, even minor event.\u201d Leire explained the study\u2019s scientific rigour, highlighting its randomised, controlled and blinded design using aged dogs not previously involved in clinical trials. This, he said, addresses a major unmet need in the life extension field, with industry experts previously considering such a study \u201cimpossible to do.\u201d Looking ahead, efficacy data is expected in January, with analysis focused on multiple endpoints. These include mitochondrial function, clinical data, muscle biopsies, and epigenetic markers like the methylation clock in collaboration with UCLA. Leire said the results could influence other Genflow programmes, including preclinical work on NASH, Werner syndrome and ophthalmology. He noted that Genflow is in licensing discussions with several animal health companies and reiterated that while Genflow is not an animal health business, a potential deal could be shaped by the strength of the efficacy data.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.775",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=34492A28-1046-40D4-8089-C939261E87E6"
        },
        "ingested_at": "2026-01-21T22:18:19.727923+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251534-Offgrid-90311500",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:16.931591",
        "source": "LSE_CHAT",
        "data": {
          "author": "Offgrid",
          "content": "Genflow just namechecked by Zak Mir on sharetalk, which can't do any harm, personally I thought this would fly today after that news, clearly everybody has gone on holiday early.",
          "sentiment": 0.0,
          "engagement": "148",
          "price_at_post": "1.775",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=34492A28-1046-40D4-8089-C939261E87E6"
        },
        "ingested_at": "2026-01-21T22:18:19.727906+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250804-Moneymun--6604800",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:16.931172",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Cash is King Northeast, and disappointing we're still awaiting the non-dilutive funding, although no doubt out of Eric's hands. The Belgium/ Wallonia Govt are dealing with one of the largest budget deficits in Europe and have been in turmoil most of this year as the coalition Govt were at odds on how to deliver the new budget and savings for this coming year, which obviously includes painful cut backs across all services as they try and plan to reduce the deficit over the next few years. Whether or not this includes cut backs in non-dilutive grant funding remains to be seen as Wallonia/Biowin are still advertising for new applications for 2026, and so still a chance it could arrive. The \u00a3440k fund raise in October provides enough cash for Genflow\u2019s near term commitments, specifically the Dog Trial and efficacy readout, and Eric's participation along with the consortium of long term Major Shareholders, speaks volumes in their confidence going forward, and we're now fast approaching an incredibly exciting time with Genflow's invitation to the JP Morgan HealthCare Conference with planned meetings with potential suitors, no doubt and hopefully armed with positive efficacy data from the Dog Trial, which will have huge implications across the pipeline and Sirt6 platform, whereby the chances of a Major deal announcement with an Animal Health Company, or a leading Ophthalmology Company or indeed a Major Pharma for the whole platform , couldn't look better and would be transformational for all invested. Everything firmly crossed!!! Gl:-) Ps from 19th January 2026, new FCA regulations are going to significantly reduce the costs for small caps to raise funds, which will revolutionise the prospects and potential for small caps going forward. So all bases covered. Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.80",
          "thread_title": "Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=0B332EA7-5210-4DB6-B511-27737B27EDB7"
        },
        "ingested_at": "2026-01-21T22:18:19.727888+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250805-Moneymun-88637363",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:16.930716",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The Financial Conduct Authority (FCA) has introduced significant changes to the UK's public offers and admissions to trading regime, effective 19 January 2026, which will substantially ease the fundraising process for small-cap and growth companies. These reforms aim to reduce costs, streamline processes, and boost the competitiveness of the UK's capital markets. Key changes for small-cap fundraising include: Increased Prospectus Threshold For companies already admitted to trading on a regulated market, the threshold for requiring a full prospectus when issuing new shares has been increased significantly from 20% to 75% of existing share capital. This allows listed small-cap firms to conduct larger, faster secondary fundraisings (such as placings or rights issues) with less regulatory burden.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.80",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=0B332EA7-5210-4DB6-B511-27737B27EDB7"
        },
        "ingested_at": "2026-01-21T22:18:19.727869+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250810-Moneymun-79768421",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:12.902143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "23 Jul '25 View organization page for Genflow Biosciences (LON:GENF) (OTCQB:GENFF) Genflow Biosciences (LON:GENF) (OTCQB:GENFF) 2,002 followers 3h \ud83d\udce3 New regulatory developments in the UK are expected to facilitate future financing flexibility. Under new Financial Conduct Authority (FCA) rules, effective 19 January 2026 and published in a policy statement on 15 July 2025, smaller R&D intensive companies such as Genflow Biosciences (LON:GENF) (OTCQB:GENFF) will be able to raise capital for its programs on the London Stock Market without restrictions on the size of equity issuances. These changes, part of broader UK capital markets reform, are designed to simplify the prospectus regime, lower costs, and improve access to retail investors. \ud83d\udd17 hTtps://lnkd.in/eqtB8dc2",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.80",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=0B332EA7-5210-4DB6-B511-27737B27EDB7"
        },
        "ingested_at": "2026-01-21T22:18:19.727851+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250830-Moneymun--7555928",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:12.901689",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The new Financial Conduct Authority (FCA) regulations are designed to facilitate less discounted fundraising for small caps by reducing the regulatory burden and increasing the threshold for requiring a full prospectus, thus making secondary capital raising faster and cheaper. Key changes, effective from January 19, 2026 (with some listing rule changes effective from July 29, 2024), aim to attract more companies to list and grow in the UK. Key Regulatory Changes and Their Impact on Small Cap Fundraising The FCA's reforms introduce several key changes that support more efficient and potentially less discounted fundraising for smaller listed companies: Increased Prospectus Threshold The most significant change for secondary fundraising is that a full prospectus is now only required if a company issues shares amounting to 75% or more of its existing share capital, a substantial increase from the previous 20% threshold. This allows companies, particularly smaller ones, to raise further capital more quickly and at a lower cost without the time and expense associated with a full prospectus, which should reduce the need for heavily discounted placings.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.80",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=0B332EA7-5210-4DB6-B511-27737B27EDB7"
        },
        "ingested_at": "2026-01-21T22:18:19.727834+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250940-Moneymun--7875751",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:12.901269",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Latest compelling research into Sirt6's panacea potential.....what Major Pharma wouldn't be interested in Genflow's Sirt6 technology platform? Gla holders:-) 22/12/25 Brain enzyme discovery may open new path to treat neurodegenerative disease Using human cell lines alongside mouse and fruit fly models, Toiber's team identified the enzyme sirtuin 6, or SIRT6, as the central regulator. SIRT6 is known for its role in longevity, but the study shows it also functions as a gatekeeper of tryptophan metabolism. ...... \"Our research positions the enzyme SIRT6 as a critical and primary drug target to combat degenerative brain pathology,\" Toiber said. \"These findings change the way we understand the relationship between aging and brain function. It is not simply wear and tear, but a specific metabolic malfunction that can be corrected.\" SIRT6 Enzyme: Breakthrough Discovery in Brain Enzyme Offers Hope for Treating Neurodegenerative Diseases, ETHealthworld https://share.google/zJ2xD65yVvrV7kAJG",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.80",
          "thread_title": "RE: Sirt6",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=7319CD1C-C4C6-4015-8EC4-A089F968170E"
        },
        "ingested_at": "2026-01-21T22:18:19.727815+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20250853-Porter_-46180551",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:12.900825",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Little Xmas top up on the open for me. Never know what the new year will bring \ud83e\udd70",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.825",
          "thread_title": "Merry Xmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=178C1FAB-EB14-4687-B406-B0BD510D8226"
        },
        "ingested_at": "2026-01-21T22:18:19.727798+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251025-Roosters-46781640",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:12.900416",
        "source": "LSE_CHAT",
        "data": {
          "author": "Roostersmillions",
          "content": "Merry Christmas genflowers. This time next year, we could be millionaires........",
          "sentiment": 0.0,
          "engagement": "288",
          "price_at_post": "1.825",
          "thread_title": "RE: Merry Xmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=178C1FAB-EB14-4687-B406-B0BD510D8226"
        },
        "ingested_at": "2026-01-21T22:18:19.727780+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261147-Moneymun-48164567",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:12.899999",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Or maybe this time next month!!!??? Gla holders and a very Happy and Prosperous New Year!!! :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.95",
          "thread_title": "RE: Merry Xmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=178C1FAB-EB14-4687-B406-B0BD510D8226"
        },
        "ingested_at": "2026-01-21T22:18:19.727762+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261315-Porter_-64147195",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:12.899595",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Wouldn\u2019t surprise me if the money is in the bank Monday now xmas and new years is officially over, hence why there were some last minute aggressive buys :)",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.95",
          "thread_title": "RE: Merry Xmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=178C1FAB-EB14-4687-B406-B0BD510D8226"
        },
        "ingested_at": "2026-01-21T22:18:19.727744+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261315-jamtart1-56128957",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:12.899188",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "This will go stellar on good news, as I said before why would anybody want to apply for patents if it doesn't work?",
          "sentiment": 0.5,
          "engagement": "1,598",
          "price_at_post": "1.95",
          "thread_title": "Sp",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B1300EED-30AB-4177-A11F-B4EDBBDE1F3E"
        },
        "ingested_at": "2026-01-21T22:18:19.727727+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261515-Moneymun-84382867",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:12.898774",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "As the industry looks ahead to 2026, the upcoming JP Morgan Healthcare conference will be a pivotal indicator on the direction for the biopharma sector for 2026. The event will set the tone for dealmaking, capital flow and R&D priorities in the year ahead, as executives look to reaffirm investor confidence, aligning on the next wave of scientific and commercial breakthroughs to strengthen pipelines. Hans concludes: \u201cAs we look to 2026, strong drug pipelines and breakthrough clinical catalysts will drive the sector, as pricing pressures are addressed, innovation and differentiation will take centre stage, and strategic deals accelerate growth and portfolio transformation.\u201d Biopharma enters 2026 with renewed and cautious optimism - PharmaLive hTtps://share.google/ocZAE3qqVWqcU9iyA",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.95",
          "thread_title": "JP Morgan HealthCare Conference 12th - 16th January 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=DBA695E8-3CE6-44EA-9610-330427FD0568"
        },
        "ingested_at": "2026-01-21T22:18:19.727709+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261517-Moneymun-69503731",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:12.898351",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Dr. Eric Leire, CEO of Genflow, commented: \"We're excited to attend the JP Morgan Healthcare Conference in San Francisco this January. Our planned meetings reflect our current focus on lipid nanoparticle delivery for mRNA SIRT6 therapeutics, which is opening compelling opportunities for strategic partnerships in the longevity space.\"",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.95",
          "thread_title": "RE: JP Morgan HealthCare Conference 12th - 16th January 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=DBA695E8-3CE6-44EA-9610-330427FD0568"
        },
        "ingested_at": "2026-01-21T22:18:19.727691+00:00"
      },
      {
        "event_id": "SOCIAL-4Jan20261927-Porter_--6402799",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:12.897935",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Nice finish Friday money with the bull flag forming. Someone keen to get in before the JP Morgan conference\u2026",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.95",
          "thread_title": "RE: JP Morgan HealthCare Conference 12th - 16th January 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=DBA695E8-3CE6-44EA-9610-330427FD0568"
        },
        "ingested_at": "2026-01-21T22:18:19.727674+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20260714-Moneymun--6104504",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:12.897527",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "All bodes well Porter,  continued share accumulation in anticipation of a stellar year ahead.....potential exponential  UPside fast approaching!!! Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.95",
          "thread_title": "RE: JP Morgan HealthCare Conference 12th - 16th January 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=DBA695E8-3CE6-44EA-9610-330427FD0568"
        },
        "ingested_at": "2026-01-21T22:18:19.727654+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20260830-Moneymun--1880154",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:12.897120",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "At the 44th J.P. Morgan Healthcare Conference (JPM 2026) in San Francisco (Jan 12-15, 2026), longevity is a significant theme, with companies like Genflow Biosciences pitching gene therapies and AI-driven health solutions, alongside broader discussions on breakthrough therapies, digital health, and investment trends shaping the aging and wellness sectors. Expect many partnering meetings, innovation showcases, and discussions on AI's role in transforming care for aging populations. Key Longevity & Related Themes at JPM 2026: Gene Therapies: Companies like Genflow Biosciences are presenting novel approaches, such as SIRT6 gene delivery, for age-related conditions and overall longevity. AI & Digital Health: Central to discussions are how AI-powered tools (predictive analytics, diagnostics) and digital platforms are revolutionizing wellness, patient engagement, and care for aging individuals. Investment Focus: Investors are looking at innovative health solutions, including those addressing chronic diseases, metabolic health (like MASH), and age-related conditions. Breakthrough Therapies: Focus areas include oncology, neurology, hematology, and broader advancements in immunology and precision medicine relevant to longevity. Investor Partnering: Concurrent events like RESI JPM facilitate connections between investors and early-stage companies developing next-gen health technologies. Why It Matters: JPM is the premier healthcare investment event, setting the tone for the year; the strong presence of longevity-focused innovation signals major investor interest in extending healthy lifespans.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.95",
          "thread_title": "RE: JP Morgan HealthCare Conference 12th - 16th January 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=DBA695E8-3CE6-44EA-9610-330427FD0568"
        },
        "ingested_at": "2026-01-21T22:18:19.727636+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261019-TheInves-84662035",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:12.896671",
        "source": "LSE_CHAT",
        "data": {
          "author": "TheInvestCollect",
          "content": "Pity another company RNS the conference and the share are up today and all quite here hmmm, funding December my arse \ud83e\udd23",
          "sentiment": 0.0,
          "engagement": "7,970",
          "price_at_post": "1.85",
          "thread_title": "RE: JP Morgan HealthCare Conference 12th - 16th January 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=DBA695E8-3CE6-44EA-9610-330427FD0568"
        },
        "ingested_at": "2026-01-21T22:18:19.727618+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261025-Pie-char-61603145",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:12.896258",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Where did it say funding lands in December? ..........It didn't. Be patient.",
          "sentiment": 0.5,
          "engagement": "60",
          "price_at_post": "1.85",
          "thread_title": "RE: JP Morgan HealthCare Conference 12th - 16th January 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=DBA695E8-3CE6-44EA-9610-330427FD0568"
        },
        "ingested_at": "2026-01-21T22:18:19.727600+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261531-Moneymun--6317365",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:12.895833",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "All bodes well and another compelling recent research paper on Sirt6's panacea potential.  Genflow's cutting edge science and  Sirt6 technology platform could be of huge interest to Major Pharma. Gla :-) Sirt6 Deficiency Spurs Obesity Inflammation via Galectin-3 Bioengineer by Bioengineer January 6, 2026 In a transformative breakthrough that may reshape our understanding of obesity-related inflammation, researchers have uncovered a pivotal molecular mechanism involving Sirt6 deficiency in mast cells that exacerbates adipose tissue fibroinflammation. This discovery, detailed in a recent publication in Nature Communications, illuminates the complex interplay between immune cells and fat tissue, identifying galectin-3 signaling as the critical conduit driving inflammatory and fibrotic processes within the adipose microenvironment during obesity. ....... These findings have far-reaching implications, extending beyond fundamental science into translational and clinical paradigms. By establishing mast-cell Sirt6 as a critical regulator of adipose tissue homeostasis, the study opens new avenues for innovative obesity treatments aimed at curbing fibroinflammatory processes. Pharmacological enhancement of Sirt6 activity or galectin-3 blockade may emerge as promising strategies to restore adipose tissue integrity and improve metabolic outcomes. ...... In conclusion, the identification of Sirt6 deficiency in mast cells as a driver of adipose tissue inflammation and fibrosis via galectin-3 signaling marks a paradigm shift in obesity research. This innovative study positions mast cell epigenetic regulation at the heart of metabolic inflammation, providing a novel therapeutic target that could change the landscape of obesity treatment and improve outcomes for millions worldwide. Sirt6 Deficiency Spurs Obesity Inflammation via Galectin-3 https://share.google/m8sEZOt5Vl59Dq7Pc",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.825",
          "thread_title": "Sirt6 - \" a paradigm shift in obesity research\"!!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=9EC9CB65-6C03-4939-B7B8-7B08A8ABF901"
        },
        "ingested_at": "2026-01-21T22:18:19.727582+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20260737-Moneymun--2856355",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:12.895385",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Something similar for Genflow's Sirt6 Gene Therapy for Glaucoma with their leading Ophthalmology company more than conceivable. A Material Transfer Agreement was signed in April 2025 and so positive data, along with Efficacy Data from the Dog Trial in liaison with the two Animal Healthcare companies who have both signed Confidential Disclosure Agreements, could be presented at next weeks JP Healthcare Conference. Gla holders, a very exciting period ahead!!! :-) 6/1/26 U.K. biotech Ikarovec has teamed up with VectorBuilder to work on an eye disease gene therapy that could be administered in a doctor\u2019s office. Ikarovec\u2019s IKAR-003 is currently in preclinical development for intermediate age-related macular degeneration (AMD). The one-time injectable therapy is designed to prevent the progression of this eye disease by offering both neuroprotection and complement modulation. The fledgling partnership is still at an early stage. For now, the technology will be evaluated before the companies fully commit. But, assuming the deal is finalized, it is expected to be worth more than $1 billion. UK biotech eyes $1B deal to deliver eye gene therapy at doctor hTtps://share.google/t12NrOU65ISH49HrO",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.825",
          "thread_title": "RE: Sirt6 - \" a paradigm shift in obesity research\"!!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=9EC9CB65-6C03-4939-B7B8-7B08A8ABF901"
        },
        "ingested_at": "2026-01-21T22:18:19.727564+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20260801-Porter_--7684833",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:12.894940",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Very exciting month ahead money. I believe only 1 eye programme has sold previously for $3bn, so we know there is demand for Genflow\u2019s research for sure! From attending the AGM last year, it appeared that the eye programme looks set to do much more than what the competitors are offering, but no doubt all will be revealed in time as to not give away the market edge \ud83d\ude09",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.825",
          "thread_title": "RE: Sirt6 - \" a paradigm shift in obesity research\"!!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=9EC9CB65-6C03-4939-B7B8-7B08A8ABF901"
        },
        "ingested_at": "2026-01-21T22:18:19.727546+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261053-jamtart1--1786165",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:12.894507",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Porter_   Any idea what we holders would get per share if we got such a deal?",
          "sentiment": 0.5,
          "engagement": "1,598",
          "price_at_post": "1.825",
          "thread_title": "RE: Sirt6 - \" a paradigm shift in obesity research\"!!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2C24DA3C-1665-4066-B9F3-73F02369D131"
        },
        "ingested_at": "2026-01-21T22:18:19.727528+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261236-Moneymun-88078489",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:12.894092",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Very exciting indeed Porter, planned meetings presumably with potential suitors at JP Morgan next week and so multiple deal opportunities across the platform, and there's currently an M&A and lucrative licensing deal feeding frenzy as Major Pharma replenish their pipelines with the latest cutting-edge science, and so every chance for little old Genflow. Excitement building and everything firmly crossed. :-) Ps jamtart, as far as value goes, Genflow's current market cap is a lowly \u00a39.5m and so if they announced a deal for \u00a3100m, then  a market cap of \u00a3100m wouldn't be out of the question and so a 10 bagger in a blink, and who knows, maybe 20, 50 or even a 100 bagger depending on the size and number of any deals secured....the sky is the limit!!! Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.825",
          "thread_title": "RE: Sirt6 - \" a paradigm shift in obesity research\"!!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=9EC9CB65-6C03-4939-B7B8-7B08A8ABF901"
        },
        "ingested_at": "2026-01-21T22:18:19.727510+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261303-jamtart1-86759582",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:12.893674",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Thankyou, yes great to get another's angle on this. Here's hoping, have a big feeling for this one.",
          "sentiment": 0.5,
          "engagement": "1,598",
          "price_at_post": "1.825",
          "thread_title": "Moneymunch",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=13AC3EBB-D13E-47C2-8DA6-708961C8A9BE"
        },
        "ingested_at": "2026-01-21T22:18:19.727492+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261504-Moneymun-17908300",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:12.893265",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Genflow Biosciences (LON:GENF) (OTCQB:GENFF) 2,222 followers 2h Took a look at Genflow Biosciences (LON:GENF) (OTCQB:GENFF)'s latest presentation! Learn about #GENF's exciting path forward with Centenarian #SIRT6 studies, impressive financials, and its mission to redefine the #aging process. Find it here: hTtps://loom.ly/RsxnFCE #GENF #GENFF #Biotech #MASH #WernerSyndrome #Sarcopenia",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-21T22:18:19.727474+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261552-Alwaysra-40841343",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:12.892806",
        "source": "LSE_CHAT",
        "data": {
          "author": "Alwaysraining",
          "content": "I\u2019m new to this forum but I\u2019ve been invested in Genflow for some time.  I understand where the company is re the European patent - does anyone know what stage the US patent applications are at?  Is it likely  that, before any deals with major pharma etc are signed, the IP will need to be in place, particularly in US? Is there any update re the outstanding grant application?  I\u2019ve searched but can\u2019t find anything recent.",
          "sentiment": 0.0,
          "engagement": "1",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-21T22:18:19.727456+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261559-Moneymun-29300096",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:12.892379",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "WHO WE ARE Pioneering Novel Gene Therapeutics for a Longer, Healthier Life MISSION: aging is underlying risk factor for disease, and our aim is to deliver gene therapeutics that potentially halt or slow the aging process in humans and dogs CENTENARIAN SIRT6 (cent SIRT6) GENE: proprietary variant of longevity gene that widely regulates aging and immunity and is a potential therapeutic target for the treatment of diseases PROMISING PRECLINICAL RESULTS: lead drug candidate GF-1002 delivers a centenarian variant of the SIRT6 gene (cent SIRT6) for treatment of MASH SEASONED TEAM: experienced and proven management with extensive experience in public & private pharma and biotech ROBUST PIPELINE: advancing multiple development programs over 24 months: MASH, Glaucoma, Sarcopenia, Werner and life extension of dogs DEVELOPMENT PIPELINE GF-1002 (Pre-Clinical) AAV8 cent SIRT6 vector for intravenous infusion, expressing cDNA of centenarian variant of SIRT6(cent SIRT6) in liver GF-1003 (Pre-Clinical/Development) Suspension of exosomes, loaded with mRNA of centenarian variant of SIRT6(cent SIRT6) in fibroblasts GF-1004 (Clinical Proof of Concept) cent SIRT6 for intravenous infusion for life extension and prevention of age-related diseases GF-1005 (Pre-Clinical/Development) Mitochondrial disfunction: Myoblast progenitors loaded by photoporation with cent SIRT6 GF-1006 Ophthalmology (pre-clinical) mRNA cent SIRT6 delivered by LNP for the treatment of cornea pathologies and glaucoma OPHTHALMOLOGY PLATFORM New Ophthalmology Program: Initiated development of a novel gene therapy targeting ocular diseases, including corneal pathologies and glaucoma, using Genflow\u2019s proprietary Centenarian SIRT6 (cent SIRT6). Precision Delivery Platform: Employing a specially engineered non-viral vector for targeted SIRT6 delivery to the eye. Strategic Partnership: Signed a Material Transfer Agreement in April 2025 with a leading ophthalmology company to co-develop the cent SIRT6 therapy and delivery system. LEVERAGING AI FOR GENOMICS New AI Partnership: Signed Master Service Agreement in April 2025 with Heureuka Labs, a spin-out of Duke University, to use their proprietary AI platform to analyze complex genomic data, including RNA sequencing and gene expression profiles. Enhancing Therapeutic Insights: Expected to drive a deeper understanding of gene regulatory networks and biological responses to optimize therapy design and personalize outcomes. Pipeline Advancement: Initially supporting GF-1002 (cent SIRT6-based gene therapy in preclinical development) and future programs, including candidates for MASH. GLAUCOMA RGC NEUROPROTECTION: THE RACE IS ON The Problem 80M people worldwide with glaucoma; leading cause of irreversible blindness Current treatments only lower IOP- they don't protect retinal ganglion cells (RGCs) RGC death is irreversible; unmet need for neuroprotection Significant market opportunity The Gap",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-21T22:18:19.727438+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261601-Moneymun--8964904",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:12.891835",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The Gap No approved neuroprotective therapies The mRNA Opportunity - Wide Open LNP targeted delivery to retina \u2013 now possible NO APPROVED OR CLINICAL-STAGE MRNA THERAPIES FOR GLAUCOMA PARTNERING WITH LNP PROVIDER Paradigm shift to retinal protection \u2022 Pre-clinical evidence links SIRT6 activity with RGC protection in glaucoma/optic neuropathy models \u2022 Demonstrating RGC rescue and preserved function would be a strong disease-modifying signal Delivery is now tractable \u2022 Targeted LNP (tLNP) platforms are removing a major historical barrier for in vivo RNA therapeutics to reach retina/RGCs Clear decision point A single well-designed rodent POC that shows \u2022 focal RGC expression of SIRT6 cent \u2022 preserved RGC counts and \u2022 preserved RGC function with acceptable ocular safety, gives a clean go/no-go for IND enabling work AGED DOGS COMPARATIVE TRIAL Proof-of-Concept comparative clinical trial of in-vivo naked DNA gene therapy in aged dogs Conducted at Syngene's strategic partner site in Morocco, AAALAC and GLP certified 26 (24+2) aged Beagles dogs (age>10 years) Group 1 (n=6): untreated Group 2 (n=6): treated with gene therapy IV bolus of SIRT6 AAV Group 3 (n=6): treated with gene therapy IV infusion of naked DNA (low dose) Group 4 (n=6): treated with gene therapy IV infusion of naked DNA (high dose) Blinded: first read-out in January 2026 \u2022 Treatment period: 180 days with follow-up period: 90 days \u2022 Gene therapy has been administered to all dogs with demonstrated excellent safety profile Endpoints \u2022 Pan-mammalian methylation clock (Steve Horvath), \u2022 sarcopenia (including muscle biopsies) and other markers of aging MASH PROGRAM Affects est. 35 million people globally \u2022 Increasing prevalence \u2022 Leading cause of chronic liver disease and liver transplant Significant unmet medical need Clear regulatory accelerated development pathway. EMA and FDA guidelines accept: \u2713 Key surrogate outcomes for therapeutic trials: regression of fibrosis or resolution of NASH \u2713 Histological changes are achievable within a 12-18-month time-frame \u2713 Placebo control \u2713 Conditional fast-track approval 2025 KEY HIGHLIGHTS LARGE AND EXPANDING MARKET OPPORTUNITY MASH: 35 Million globally. Increasing prevalence. Door opener to even broader anti-aging indication Awarded to new grants in 2024 expanding research pipeline Ophthalmology: retina preservation GROWING IP PORTFOLIO WITH LONG LIFE 2 proprietary patent families SIRT6 centenarian (cent SIRT6) and gene delivery (entering National Phase); Additional upcoming patent applications (entering PCT) MRNA/LNP GENE DELIVERY SYSTEMS Innovative gene delivery systems: targeted LNPs delivering cent SIRT6 mRNA GF-1002 Multiple key clinical and regulatory milestones expected in next 18 months; Undervalued stock opportunity; Potential acquisition by pharmaceutical partner GF-1004: Pet",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-21T22:18:19.727420+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261602-Moneymun-18495825",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:10.260699",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Undervalued stock opportunity; Potential acquisition by pharmaceutical partner GF-1004: Pet life extension / sarcopenia Initiated discussion under CDA with several animal health companies hTtps://loom.ly/RsxnFCE",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-21T22:18:19.727401+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261606-Moneymun--2836716",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:10.260284",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Looks like we've got a new Chairperson!!!??? Gla ;-) GAD BERDUGO Chairperson \u2022 30+ years of leadership across global biotech, corporate development, and U.S. capital markets \u2022 Proven record in strategic partnerships, capital raising, and scaling private and public biotech companies \u2022 Managing Partner, Explorium Capital; former Co-Founder & CEO of EpiVax Oncology and Chief Business Officer at Editas Medicine and Nutcracker Therapeutics",
          "sentiment": 0.0,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-21T22:18:19.727383+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261627-Moneymun-58648859",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:10.259846",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Gad Berdugo Gad Berdugo, MSc. Eng., MBA Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a strategic and financial advisory firm focusing on the global biotechnology sector. He currently serves as Vice Chairman of the Board of Directors of clinical development stage precision oncology company, Diaccurate. Mr. Berdugo brings over 35 years of biotech corporate & business development, strategy, operational, financial, investment and general venture management experience. He served as CBO at CRISPR gene editing pioneer Editas (Nasdaq EDIT); Co-founder and CEO at personalized neoantigen cancer vaccine venture, EpiVax Oncology Inc.; CFO and EVP at Immune Pharmaceuticals Inc. (Nasdaq IMNP); Managing Director and Head of Life Sciences at Tegris Advisors, a strategic and financial advisory boutique; Founder and Managing Partner of the Explorium Global Life Sciences Investment Fund; Director, Senior Equity Research Analyst and Life Sciences Sector Leader at Lazard, Asset Management Group. Prior to that, he served as a Director of Global Business Development within Baxter\u2019s Biopharmaceuticals group and started his career at Abbott Labs. Mr. Berdugo received his B.Sc. with Honors in Biotechnology from Imperial College London, his M.Sc. in Biochemical Engineering from University College London and his M.B.A. from H.E.C. Paris. He serves on the Board of Directors of Friends of H.E.C. Inc. and Friends of U.C.L. Inc. Mr. Berdugo is bilingual in French and English and has dual US and French citizenships. He resides with his wife in New York City.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-21T22:18:19.727365+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261732-Porter_-81524145",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:10.259424",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Thanks for sharing money. I haven\u2019t seen any news regarding a new Chair. Where did you manage to grab that info from? Can you please share the link if you have one? \ud83e\udd70",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-21T22:18:19.727347+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261802-Moneymun--9180840",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:10.259009",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Hi Porter, it's from the 2026 Corporate Presentation which was published via Genflow's LinkedIn post a few hours ago. Gl :-) Ps the new Chair appears to be well connected on the US. https://loom.ly/RsxnFCE",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-21T22:18:19.727329+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261804-Moneymun--8406104",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:10.258589",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Well connected in the US to take Genflow to the next level. ;-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-21T22:18:19.727311+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260702-Moneymun-88375217",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:10.258183",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "08 January 2026 A Review of an Exciting 2025 2025 has been a year of focused scientific progress and continued advancement of Genflow Bioscience's mission to extend healthy lifespan through our novel longevity gene therapy platform. Across our portfolio, we have maintained momentum in both animal health where progress in our canine study may provide translational insights relevant to future human applications as well as therapeutic development for dogs. These advancements have been supported by a strengthened network of leading academic collaborators and laboratories. Together, with continued backing from international institutional investors and previously awarded government grants, this ecosystem helped accelerate Genflow's scientific and clinical development throughout 2025. Program Highlights We've made a number of notable strides across our programs this year, including: \u00b7      Dog Aging (GF-1004) We made significant strides in our clinical trial for aging dogs with full administration of our investigational SIRT6-based gene therapy now completed. No adverse events were reported during the dosing phase of the study, with no serious, moderate, or minor side effects observed. The study which began in March 2025, is being conducted as a blinded clinical trial; an initial efficacy readout is expected in Q1 2026, including blood analyses and muscle biopsies to evaluate potential benefits related to sarcopenia, healthspan, and lifespan-associated biomarkers. Dogs enrolled in the trial will be monitored for 180 days, with a second efficacy assessment planned at the six-month timepoint and results expected in June-July 2026 to evaluate durability and longer-term effects. \u00b7      MASH (GF-1002) Our MASH program saw good progress in 2025. While GLP-1 therapies have addressed early-stage MASH, patients with advanced fibrosis - roughly one-third of the population - still face limited treatment options. In response, we repositioned GF-1002 to target this high-need group, leveraging its antifibrotic properties and potential to prevent progression to cirrhosis and liver cancer. Additionally, we have generated new pre-clinical POC data on the prevention of HCC. We are now finalizing our IND package and evaluating mRNA/LNP delivery as an alternative to AAV, an approach that could enable repeat dosing and lower manufacturing costs. Encouraging data continue to support this next phase of research and development. \u00b7      Glaucoma In 2025, we expanded into ophthalmology, where SIRT6-based gene therapy shows promise in glaucoma, a leading cause of irreversible blindness. Current treatments primarily manage intraocular pressure but do little to prevent optic nerve degeneration. Our preclinical data suggest SIRT6 overexpression may protect retinal ganglion cells and preserve optic nerve function, shifting the focus from symptom control to true neuroprotection.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-21T22:18:19.727293+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260703-Moneymun-13410644",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:10.257710",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "We are advancing discussions with a leading LNP partner to support delivery innovation in this space and are securing a full-service CRO to manage formulation through preclinical execution. With the global glaucoma market approaching USD $12-14 billion by the early 2030s, this represents a compelling long-term opportunity for us. \u00b7 Additional Programs We continued to advance our broader pipeline and are pleased with the steady advancement of the sarcopenia program, fully consistent with our development plans. In parallel, the ExoFastTrack initiative continues to move forward, generating important data that will support and accelerate several of our other development programs. Looking Ahead to 2026 As we move into 2026, we do so with confidence, discipline, and a clear strategic focus. The coming year will emphasize rationalization of our pipeline, prioritizing programs with the strongest data, clearest paths to value creation, and highest partner interest. Central to this strategy will be the pursuit of early-stage licensing and collaboration agreements designed to generate non-dilutive funding, validate our platform externally, and support continued development without undue capital strain. With multiple upcoming data readouts, an expanding partner network, and a maturing intellectual property position, we believe Genflow is well positioned to enter its next phase of growth. We remain committed to scientific excellence, capital efficiency, and long-term value creation as we work to translate our longevity platform into meaningful therapies. Thank you for your continued support and confidence in Genflow.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-21T22:18:19.727275+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260805-Porter_--1059501",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:10.257269",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Thanks for sharing money. I notice the RNS is in American English, perhaps to appeal to US investors and big US pharma? No mention of the patents in the update which were instrumental in offering assurance to investors regarding patent protection, but hopefully we\u2019ll receive updates in due course separately.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.825",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-21T22:18:19.727257+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260854-David195-33495623",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:10.256845",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "I hold shares and the potential is significant. However I am reluctant to add when the funding position is unclear.  Grants could be material amounts if and when received but there is a risk of a diluted fund raise to progress the numerous programmes in 2026.  I have suffered this is other small biotechs like FAB and Apta where the state of the capital markets are very harsh and unsupportive. I tried to analyse the cash runway and it seems more funds will be needed in H1 if the grants are not received.  Is there any indication of the timing?",
          "sentiment": 0.0,
          "engagement": "868",
          "price_at_post": "1.90",
          "thread_title": "Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=1999E606-84A4-47B8-B880-E68E1912F065"
        },
        "ingested_at": "2026-01-21T22:18:19.727239+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260928-Moneymun--7048686",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:10.256421",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Outstanding non-dilutive grant funding could land at anytime, although a lucrative JV licensing deal could also land at anytime and so let's see what transpires at next weeks the prestigious JP Healthcare Conference next week, where Genflow have planned meetings, presumably with potential suitors and every chance Eric will have initial efficacy data from the Dog Trial and maybe and maybe positive Data with their Ophthalmology partner for Glaucoma to present and so confirmation of a commercial deal or two would be transformational for all invested and any funding concerns would be assigned to history.  Gla holders....Excitement building!!! :-) Ps if Genflow need to raise cash because of the delay in receipt of the \u20ac4m outstanding non-dilutive grant funding, then raising cash from 16th January is going to become easier, cheaper and less dilutive.  :-) The new Financial Conduct Authority (FCA) regulations are designed to facilitate less discounted fundraising for small caps by reducing the regulatory burden and increasing the threshold for requiring a full prospectus, thus making secondary capital raising faster and cheaper. Key changes, effective from January 19, 2026 (with some listing rule changes effective from July 29, 2024), aim to attract more companies to list and grow in the UK. Key Regulatory Changes and Their Impact on Small Cap Fundraising The FCA's reforms introduce several key changes that support more efficient and potentially less discounted fundraising for smaller listed companies: Increased Prospectus Threshold The most significant change for secondary fundraising is that a full prospectus is now only required if a company issues shares amounting to 75% or more of its existing share capital, a substantial increase from the previous 20% threshold. This allows companies, particularly smaller ones, to raise further capital more quickly and at a lower cost without the time and expense associated with a full prospectus, which should reduce the need for heavily discounted placings.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=1999E606-84A4-47B8-B880-E68E1912F065"
        },
        "ingested_at": "2026-01-21T22:18:19.727221+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260933-Moneymun--5319184",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:10.255983",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Bring it on!!! Gla holders:-) \"Central to this strategy will be the pursuit of early-stage licensing and collaboration agreements designed to generate non-dilutive funding, validate our platform externally, and support continued development without undue capital strain.\" .... Dr. Eric Leire, CEO of Genflow, commented: \"We're excited to attend the JP Morgan Healthcare Conference in San Francisco this January. Our planned meetings reflect our current focus on lipid nanoparticle delivery for mRNA SIRT6 therapeutics, which is opening compelling opportunities for strategic partnerships in the longevity space.\"",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=1999E606-84A4-47B8-B880-E68E1912F065"
        },
        "ingested_at": "2026-01-21T22:18:19.727203+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261005-Moneymun-86080964",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:10.255558",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Hopefully news on patents soon Porter, the following statement is from yesterday's 2026 Corporate Presentation.  Gl :-) GROWING IP PORTFOLIO WITH LONG LIFE 2 proprietary patent families SIRT6 centenarian (cent SIRT6) and gene delivery (entering National Phase); Additional upcoming patent applications (entering PCT)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-21T22:18:19.727185+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-David195-69423818",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:10.255002",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "Thank you for your informed views.  Added 500k @1.78.  It is hard for companies in this sector to raise funds so hopefully the upcoming changes will make the situation less brutal.  I will add when funds allow.",
          "sentiment": 0.0,
          "engagement": "868",
          "price_at_post": "1.85",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-21T22:18:19.727167+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261148-Moneymun--4404393",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:10.254591",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Nice one David, looking forward to a run of great news from Eric to take the sp to new highs. Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.85",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-21T22:18:19.727149+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261314-Moneymun--5679209",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:10.254181",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "0 0 Gene therapy biotech Genflow eyes busy year ahead as dog ageing trial nears results Published: 02:40 08 Jan 2026 Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) has wrapped up 2025 with steady progress across a range of gene therapy programmes, including a closely watched trial into dog ageing that could lay the groundwork for future human applications. The London-listed company, which is working on ways to extend healthy lifespan using gene therapy, said it had completed dosing in its lead canine study with no reported side effects. The dogs will now be monitored over six months for signs of improved muscle strength and health-related biomarkers, with initial results expected in the first quarter of this year. The trial, which began in March and uses a therapy based on the SIRT6 gene, a known regulator of ageing and DNA repair, is being conducted in a blinded format. A follow-up analysis is due around mid-year to assess the durability of the effects. Alongside the dog ageing study, Genflow said it had made progress in a programme targeting advanced stages of MASH, or metabolic dysfunction-associated steatohepatitis, a type of fatty liver disease. Existing GLP-1 drugs such as Ozempic and Wegovy have shown benefits in early MASH, but Genflow is aiming at patients with more severe fibrosis, where options remain limited. It is now finalising regulatory paperwork to support a human trial and is exploring the use of mRNA technology, similar to that used in Covid-19 vaccines, as a more flexible and cost-effective delivery method than traditional viral vectors. In a new push into eye disease, the company is also investigating the use of its gene therapy platform in glaucoma. Early lab results suggest that increasing SIRT6 levels may help protect the optic nerve from damage, potentially offering a way to slow or prevent vision loss rather than simply reducing eye pressure, which is the current standard treatment. Genflow said it was in talks with a lipid nanoparticle delivery partner to support this programme and was hiring a specialist contract research firm to help move the candidate towards preclinical testing. Elsewhere in its pipeline, work is ongoing in sarcopenia, the loss of muscle mass that often accompanies ageing, and in a broader initiative called ExoFastTrack, which supports several of its research efforts. Looking to the year ahead, Genflow said it would focus its efforts on the most promising areas of its portfolio and seek early licensing or partnership deals to bring in fresh funds without issuing new shares. \u201cWith multiple upcoming data readouts, an expanding partner network, and a maturing intellectual property position, we believe Genflow is well positioned to enter its next phase of growth,\u201d the company said. The first set of clinical results, particularly from the dog study, will be key in setting the tone for 2026.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-21T22:18:19.727130+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261711-Troajan--4306261",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:10.253691",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1085366/genflow-biosciences-ceo-key-catalysts-for-2026-1085366.html",
          "sentiment": 0.0,
          "engagement": "125,392",
          "price_at_post": "1.75",
          "thread_title": "Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-21T22:18:19.727089+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261858-Moneymun-72080933",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:10.253285",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Another brilliant interview by Eric, \"2026 will be catalyst year, they've done their work and now it's time for harvesting and are going to JP Morgan next week with a full appointments book, and now ready for potential harvesting of their results to bring in non-dilutive funding cash into the company. Excitement building, in Eric we trust!!! Gla ;-) Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company\u2019s key programs and upcoming catalysts as it enters what management expects to be a pivotal year. Leire discussed why 2026 is shaping up as \u201ca year of catalysts\u201d for the company, with particular focus on the dog ageing trial, progress in MASH, and the group\u2019s approach to partnerships and licensing. Leire explained that the dog longevity study is the nearest catalyst, with the trial expected to be unblinded shortly and early efficacy readouts anticipated in the near term. While safety has already been confirmed, the study remains blinded, meaning efficacy results are still unknown. The first data will focus on biological age, measured using a methylation clock, with a more detailed analysis of muscle biopsies and mitochondrial function to follow. According to Leire, \u201cthis trial could be very important for our shareholders, because it will trigger a deal with an animal health company bringing non-dilutive money in the company.\u201d The interview also explored Genflow\u2019s repositioning in MASH toward advanced fibrosis and the prevention of hepatocellular carcinoma. Leire highlighted the significant unmet need in late-stage disease, noting that recent therapies target earlier stages and leave patients with advanced fibrosis facing limited options. He said the company\u2019s preclinical data have been encouraging and form a key part of the IND package, helping differentiate Genflow from existing and emerging treatments. In addition, Leire discussed the company\u2019s licensing strategy, including plans to out-license the dog program to an animal health specialist and pursue early-stage partnerships for glaucoma, while retaining focus on age-related conditions such as sarcopenia. With meetings planned during JPMorgan week, Leire said the company is seeking non-dilutive capital and strategic validation as it moves forward.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-21T22:18:19.727071+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261917-Moneymun-12758518",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:10.252836",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Eye wonder....Gla:-) 23/12/2025 - 12:30 VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders, Executive Vice President and Chief Financial Officer Sam Eldessouky and Chief Medical Officer and Head of Research & Development Yehia Hashad, MD, will participate in a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026, at 1:30 p.m. PT (4:30 p.m. ET) Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-21T22:18:19.727053+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261920-Moneymun--5689708",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:10.252414",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "And/or ???? ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 4:30 p.m. PT in San Francisco, CA.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-21T22:18:19.727035+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261946-Moneymun-12110031",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:10.251992",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Woof, woof!!!??? ;-) Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference 06 January 2026 INDIANAPOLIS, Jan. 6, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will represent the company and respond to questions from analysts at 3:45 p.m. PST (6:45 PM EST).",
          "sentiment": 0.0,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-21T22:18:19.727017+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20262001-Moneymun--7643049",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:10.251570",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 10:30 a.m. PT. Investors and other interested parties can access a live audio webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event. About Zoetis As the world\u2019s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide \u2013 from veterinarians and pet owners to livestock producers. The company\u2019s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees. For more information, visit www.zoetis.com.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-21T22:18:19.726998+00:00"
      },
      {
        "event_id": "SOCIAL-10Jan20261752-Troajan--1274850",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:10.251136",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1085424/genflow-is-ready-for-a-year-of-catalysts-icymi-1085424.html",
          "sentiment": 0.0,
          "engagement": "125,392",
          "price_at_post": "1.825",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-21T22:18:19.726977+00:00"
      },
      {
        "event_id": "SOCIAL-11Jan20261442-Moneymun--6080681",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:10.250708",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Planned meetings presumably with potential suitors at JP Morgan this coming week and so multiple deal opportunities across the platform, and there's currently an M&A and lucrative licensing deal feeding frenzy as Major Pharma replenish their pipelines with the latest cutting-edge science, Excitement building!!! Gla :-) \"2026 will be catalyst year, we've done our work and now it's time for harvesting and are going to JP Morgan next week with a full appointments book, and now ready for potential harvesting of our results to bring in non-dilutive cash into the company.\" A must watch....Gla holders:-) hTtps://www.proactiveinvestors.co.uk/companies/news/1085366/genflow-biosciences-ceo-key-catalysts-for-2026-1085366.html",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.825",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-21T22:18:19.726958+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260822-Moneymun--3031118",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:10.250259",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Healthcare companies set for deals spree as drug patents expire A gathering of pharmaceutical executives comes as the sector has rebounded from uncertainty over Trump\u2019s policies Healthcare executives gather for their big annual conference in San Francisco on Monday as the sector is flush with cash and set for a deals spree as patents on drugs worth almost 12 per cent of the industry\u2019s revenues expire in the years ahead. The JPMorgan healthcare conference takes place as uncertainty recedes over President Donald Trump\u2019s trade wars, drug pricing policy and the leadership of key regulators such as the US Food and Drug Administration. In response, the S&P biotech index, known as the XBI, has surged to a four-year high, outperforming the wider index. In addition, drugs that contribute about $180bn of revenue a year are set to go off patent in 2027 and 2028, representing almost 12 per cent of the global market, according to research firm Evaluate Pharma. More than $40bn of sales are expected to lose patent protection this year, Evaluate has estimated. \u201cThe need to take big swings becomes more pressing,\u201d said Jeremy Meilman, head of healthcare investment banking at JPMorgan. \u201cSeveral of the large-cap pharmaceutical companies are shopping around for strong assets and a number have taken action but still have more firepower. This contributes to our optimism for 2026.\u201d hTtps://www.ft.com/content/7b07a9d5-7254-490b-8ce9-ec2633094d8e",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.825",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-21T22:18:19.726940+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261231-Moneymun-61382873",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:05.083750",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Get UP there!!! Gla :-) Eric and his team are now at the prestigious JP Healthcare Conference, pressing flesh with the leading industry deal makers. He appeared confident and enthusiastic in his latest interview, highlighting the prospects and potential of an early lucrative JV deal for the Dog Trial, Glaucoma and Mash and so potential game changing transformational news could drop at anytime. The first efficacy readout on the Dog Trial is imminent, and with two Animal Healthcare companies both with Confidential Disclosure Agreements in place, Eric could be very close to a deal, and the same with Glaucoma, whereby a leading Ophthalmology Company signed a Material Transfer Agreement 10 months ago. Eric also highlighted the prospects of Genflow's Sirt6 Mash Gene Therapy, which is now targeting the later stages of the disease where there's no options apart from transplant, and was very interesting to hear from Eric it could be used in combination with GLP-1's and Madrigal's early stage treatment which was FDA approved 12 months or so ago. Madrigal are presenting at JP Morgan and are on a mission to expand their pipeline for Mash, so watch this space. It's also very interesting we have a new Chairman in place, GAD BERDUGO a high flyer based in the US in Global Biotech, Corporate Development and and US Capital Markets and so no doubt very well contected to any potential suitors. Excitement building!!!! In Eric we trust!!! Gla holders:-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.00",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-21T22:18:19.726923+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261725-Steg-29025222",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:05.083341",
        "source": "LSE_CHAT",
        "data": {
          "author": "Steg",
          "content": "Thought below was interesting, yes they are attending conference and have already made move to add to thier MASH portfolio, courtesy of AI search below Yes, Madrigal Pharmaceuticals is actively looking to expand its MASH (metabolic dysfunction-associated steatohepatitis) portfolio beyond its already approved drug, Rezdiffra (resmetirom). Madrigal's expansion strategy focuses on developing potential combination therapies, as MASH is a complex disease that requires multiple treatment approaches. Key components of their expanded pipeline include: Ervogastat: In January 2026, Madrigal entered into an exclusive global license agreement with Pfizer to acquire ervogastat, a Phase 2 oral DGAT-2 inhibitor. This drug works on a different, complementary pathway to Rezdiffra, and Madrigal plans to conduct studies to test the two treatments in combination. Oral GLP-1 Receptor Agonist: Madrigal also holds worldwide rights to an oral GLP-1 agonist called SYH2086, licensed from CSPC Pharmaceutical, with the goal of creating a best-in-class oral combination therapy. Additional Early-Stage Assets: The agreement with Pfizer for ervogastat also included rights to two other early-stage MASH pipeline assets. Madrigal's CEO, Bill Sibold, has stated that the company is committed to \"building the industry-leading pipeline that will shape the future of MASH care\" and believes combination therapies are the next wave of innovation in the field.",
          "sentiment": 0.0,
          "engagement": "5",
          "price_at_post": "1.90",
          "thread_title": "JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-21T22:18:19.726905+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260812-Moneymun-14610855",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:05.082889",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions Madrigal\u2019s strategy of pursuing combination therapies while the market remains in its infancy could intrinsically link its brand to MASH treatment. Madrigal Pharmaceuticals used its January 12 presentation at the J.P. Morgan Healthcare Conference 2026 to showcase its newly acquired assets from Pfizer \u2013 ervogastat and two preclinical assets \u2013 as well as outline its vision for dominance in metabolic dysfunction-associated steatohepatitis (MASH) treatment space through leveraging early commercial success. Its professed strategy of pursuing combination therapies while the market remains in its infancy could well result in Madrigal\u2019s brand becoming intrinsically linked to MASH treatment. JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions - Pharmaceutical Technology https://share.google/Ymb4cXndGee7eMEbD",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.00",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-21T22:18:19.726887+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260815-Moneymun--2167419",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:05.082461",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Game changing news at anytime. In Eric we trust!!! Gla holders...On and UP!!! :-)))",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.00",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-21T22:18:19.726869+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260818-Roosters--6584625",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:05.082044",
        "source": "LSE_CHAT",
        "data": {
          "author": "Roostersmillions",
          "content": "Markets reacting munch. Nice jump this AM. hope it holds. Maybe new private investors from across the pond due to conference exposure??",
          "sentiment": 0.5,
          "engagement": "288",
          "price_at_post": "2.00",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-21T22:18:19.726851+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260827-Moneymun--6927494",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:05.081634",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Every chance Rooster, although I'm hoping for a transformational lucrative commercial licensing deal on one or more of the programs, Dog , Glaucoma and Mash. Excitement building!!! Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.05",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-21T22:18:19.726833+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261006-Moneymun--1541910",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:05.081228",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "GKOS: Strong innovation and new therapies drive growth, with robust financials and expanding markets Jan 14, 2026, GKOS The event highlighted robust innovation in ophthalmology, with strong R&D investment yielding a broad product pipeline and record financial performance. Key growth drivers include new glaucoma and keratoconus therapies, strategic market expansion, and a focus on operational leverage and profitability. Based on Glaukos Corporation [GKOS] 44th Annual J.P. Morgan Healthcare Conference Audio Transcript \u2014 Jan. 14 2026",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.10",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-21T22:18:19.726815+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261844-JediMast--5067222",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:05.080791",
        "source": "LSE_CHAT",
        "data": {
          "author": "JediMaster1",
          "content": "Rumours of investment banks wanting to buy in from the JP Morgan Conference. The only question now is who do they want to buy in on behalf of?? The next few days will be interesting. Will Eric spill the beans?",
          "sentiment": 0.5,
          "engagement": "168",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D010A135-964B-4034-9025-65BCB0334809"
        },
        "ingested_at": "2026-01-21T22:18:19.726797+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261946-jamtart1--2280583",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:05.080385",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Doubt it, but happy if rumours are true",
          "sentiment": 0.5,
          "engagement": "1,598",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan, news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=559FB93D-C9CD-4A83-84E9-7B26CC6976E9"
        },
        "ingested_at": "2026-01-21T22:18:19.726778+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260634-Porter_--8323604",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:05.079971",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Companies attend the J.P. Morgan Healthcare Conference (JPM) primarily for networking, securing funding, forging strategic partnerships, and announcing key business updates. This major event, often described as setting the industry's tone for the year, concentrates a year's worth of meetings into a few days. Key reasons why companies attend include: Investment and Funding: The conference is a premier venue for companies to present their strategies and financial outlooks to a high-level audience of investors, analysts, and venture capitalists. For many, especially smaller or emerging biotech firms, it is a critical opportunity to secure financing, gauge investor interest, and build essential relationships. Mergers and Acquisitions (M&A) and Partnerships: The event is a hotbed for dealmaking. Big pharmaceutical companies often attend to scout for smaller companies with promising drug pipelines or innovative technologies (like AI in drug discovery) to acquire, especially as their own blockbuster drugs approach patent expiration. Extensive one-on-one meetings facilitate these discussions and collaborations. Strategic Positioning and Visibility: Companies announce major news, clinical trial data, or year-end recaps just before or during the conference to capture attention and elevate their visibility above the competition. It allows them to articulate their unique value proposition and strategic priorities to the global market. Market Intelligence: Attending allows companies to take the pulse of the industry, understand the latest trends (e.g., AI, gene therapy, obesity drugs), and gather competitive intelligence. They can assess how investors and peers discuss valuations, regulatory pathways, and market potential, which helps in fine-tuning their own strategies for the year ahead. Networking Efficiency: The conference brings the entire healthcare and life sciences ecosystem\u2014from manufacturers and providers to regulators and service providers\u2014into a concentrated location for a short time. This high density of key decision-makers allows for efficient, high-value networking and relationship building that would otherwise take months of travel and outreach.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=4C9A5731-DC78-4F24-8CE9-513E080FCFAC"
        },
        "ingested_at": "2026-01-21T22:18:19.726760+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20262119-jamtart1-79943977",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:05.079508",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Yes, Genflow Biosciences (Genflow) has had significant interest at the J.P. Morgan Healthcare Conference, attending specifically to engage with potential partners, institutional investors, and pharmaceutical companies. Their CEO, Dr. Eric Leire, attended the most recent conference in January 2026 with a \"full appointments book\" to discuss strategic partnerships and non-dilutive funding opportunities.",
          "sentiment": 0.5,
          "engagement": "1,598",
          "price_at_post": "1.85",
          "thread_title": "JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=3005BF87-EE58-4C27-ABC6-EE6AA15A9385"
        },
        "ingested_at": "2026-01-21T22:18:19.726743+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20260716-Porter_--7147904",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:05.079089",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Genflow Biosciences is a London-based biotechnology firm and the first \"pure-play\" longevity company listed on the London Stock Exchange. As of early 2026, the company is transitioning from a preclinical phase into active clinical data readouts, focusing on its proprietary SIRT6-based gene therapy platform to extend human and animal \"healthspan\". Core Technology and Pipeline: The company\u2019s lead therapeutic approach involves delivering a \"centenarian variant\" of the SIRT6 gene, identified in individuals who live over 100 years, to improve DNA repair and metabolic health. GF-1002 (Human Therapeutics): MASH (Liver Disease): Repositioned in 2025 to target patients with advanced fibrosis who have limited options from existing GLP-1 therapies. The company is currently finalizing its Investigational New Drug (IND) package and exploring mRNA/LNP delivery to allow for repeat dosing and lower costs. Werner Syndrome: A rare genetic condition causing premature aging. Genflow has developed proprietary human-derived liver organoids to model this disease more accurately than animal models. GF-1004 (Veterinary Program): Canine Longevity: A 12-month blinded clinical trial in aged dogs is currently underway. In early 2026, the company confirmed that all subjects received full dosing with no adverse events reported. Key 2026 Milestones: Initial efficacy readouts focusing on biological age (via methylation clocks) are expected in Q1 2026, with a second evaluation planned for June-July 2026. Expansion Programs: Glaucoma: A new ophthalmology program targeting neuroprotection of retinal ganglion cells to prevent blindness. Sarcopenia (GF-1005): Research into muscle health and mitochondrial dysfunction in collaboration with the Universit\u00e9 libre de Bruxelles. 2026 Strategic Focus: Genflow\u2019s 2026 strategy emphasizes \"rationalization of the pipeline,\" prioritizing programs with the strongest data to secure non-dilutive funding through licensing deals and partnerships. The company is actively seeking animal health partners for its dog longevity program and strategic collaborators for its LNP-based mRNA therapeutics.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "GLP, LNP, MRNA and SIRT6 based therapeutics",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=FB89DB69-F93B-4BB3-8529-5206EECDF243"
        },
        "ingested_at": "2026-01-21T22:18:19.726725+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20260836-Pie-char--3615614",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:05.078628",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Post conference announcement next week and Funding news is what I predict. I'm amazed we are at this price. Such a hidden gem!",
          "sentiment": 0.5,
          "engagement": "60",
          "price_at_post": "1.85",
          "thread_title": "RE: JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=3005BF87-EE58-4C27-ABC6-EE6AA15A9385"
        },
        "ingested_at": "2026-01-21T22:18:19.726707+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260718-Porter_--7066273",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:05.078219",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Genflow Appoints a New Chairman to Accelerate Corporate and R&D Expansion Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or the \"Company\"), a leading European-based biotechnology company focusing on gene therapies for age-related diseases, is pleased to announce a significant appointment to its Board of Directors, marking an important step in the Company's strategic evolution. Mr. Gad Berdugo, MSc Eng., MBA, has joined the Board with immediate effect and will assume the role of Independent Non-Executive Chairman, providing leadership as Genflow focuses on advancing its gene-therapy programs. Mrs. Tamara Joseph will continue to serve as a Director, ensuring continuity and maintaining strong governance. Mr. Berdugo brings over 30 years' of leadership experience spanning global business and corporate development, U.S. capital markets, and company building. He has a proven record of driving strategic partnerships, securing capital, and scaling both private and public development-stage biotechnology companies. Currently, Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a U.S.-based strategic and financial advisory firm focusing on the global biotechnology sector. His most recent roles include: \u00b7 Co-Founder & CEO, EpiVax Oncology \u00b7 Vice-Chairman of the Board, Evexta Bio \u00b7 Chief Business Officer, Editas Medicine (NASDAQ: EDIT) \u00b7 Chief Business Officer, Nutcracker Therapeutics He began his international career at Abbott Labs and Baxter, later becoming Life Sciences Sector Leader at Lazard Asset Management. Mr. Berdugo also brings deep technical and market expertise in RNA-based therapeutics, including lipid nanoparticle (LNP) delivery, development, and manufacturing. This background will support Genflow as it advances its scientific platform, evaluates delivery technologies, and explores next-generation therapeutic approaches. His appointment further strengthens the Company's presence in the United States and expands its capacity for global engagement. He does not own any shares in the Company. Dr. Eric Leire, Chief Executive Officer of Genflow, commented: \"We are delighted to welcome Mr. Berdugo as Independent Non-Executive Chairman. His expertise in strategy, partnerships and financing as well as his deep experience with RNA-LNP technologies will be instrumental as we accelerate our programs and expand our global reach. We are equally pleased that Mrs. Tamara Joseph will continue her service on the Board, contributing her invaluable leadership, legal and governance expertise.\" Gad Berdugo added: \"I am excited to join Genflow as the company is progressing to the next new phase of development, with key data readouts expected in 2026, strengthened intellectual property, and a sharpened strategic focus on high-potential programs. I look forward to working with the talented team and board to advance these innovative gene therapies, this is an ideal moment to contribute my expertise and hel",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-21T22:18:19.726690+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260734-Twocd2-10881655",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:05.077749",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "Take the rest of the day off Porter..great job pal! You must have set the alarm early to C&P all of that \ud83d\udc4f\ud83d\udc4f\ud83d\udc4c",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-21T22:18:19.726672+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260752-Porter_--4385463",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:05.077341",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "2cd2 - invest more than \u00a3100 in a company and you might care a little bit more for your investments \ud83d\ude18",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-21T22:18:19.726654+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260820-Moneymun--9682628",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:05.076930",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The new Chairman in place, GAD BERDUGO is a high flyer based in the US with a wealth of experience in Global Biotech, Corporate Development and US Capital Markets and so no doubt very well contected to any potential suitors. Excitement building!!!! In Eric we trust!!! Gla holders:-) Ps initial Efficacy readout on the Dog Trial imminent!!! Gla ;-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-21T22:18:19.726636+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260839-Twocd2-66196961",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:05.076516",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "Ok big fella..time for nap your banter is honking.",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-21T22:18:19.726618+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261005-DaveTK--7605158",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:05.076105",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Would seem like you touched  nerve there, Porter ha ha. Nice RNS this morning. Looking forward to hearing more regarding the J.P. Morgan's Healthcare Conference. Really does seem like exciting times ahead. Thanks",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-21T22:18:19.726599+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261027-Porter_-34726959",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:05.075676",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Always the ones who sold too soon quick to troll those who held with diamond hands Dave. Expecting this is just the first update of many we\u2019ll be seeing over the next 2 weeks. Popcorn ready! \ud83c\udf7f",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-21T22:18:19.726581+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261033-DaveTK--6026406",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:05.075251",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Always. I'm here and always have been here waiting for news that we have been bought out. It was always the goal from Eric to make this company into something a pharmaceutical would buy a high price. We may not be that far off. Fingers crossed. Thanks",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-21T22:18:19.726562+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261342-Twocd2--1670215",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:05.074813",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "So TK Max joins the party\u2026think you and Porter need to take turns and time to give him a chance to be big spoon for this week. Might give him something else to do rather than practice his typing. Plenty of skin in the game lads\u2026but this is not about who\u2019s chopper is bigger..well maybe for the spooning it does\ud83d\ude01",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-21T22:18:19.726532+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261352-DaveTK-94523974",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:05.074396",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "I joined the party pre IPO. TBF they were asking for more than \u00a350 so it may have been too much of a reach for you. Talking about choppers FFS. Don't let you mum read that or she'll take your phone off you and cancel your contract.",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-21T22:18:19.726494+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20262217-Twocd2-32913384",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:05.073957",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "I joined pre IPO, \u00a350 may have been too much of a reach for you\u2026chortle chortle TK Max.. Give Porter a reach around before lights out so that he\u2019ll not be to disappointed with no RNS tomorrow morning\u2026\ud83d\udc4c",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-21T22:18:19.726467+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260719-Porter_-57089186",
        "event_type": "social_post",
        "date": "2026-01-21T22:18:05.073522",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Know a few people who didn\u2019t get their orders filled yesterday. Seems there isn\u2019t much in the free-float so let\u2019s see how tight this coiled spring is!",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-21T22:18:19.726443+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261552-Alwaysra--1426838",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:02.853783",
        "source": "LSE_CHAT",
        "data": {
          "author": "Alwaysraining",
          "content": "I\u2019m new to this forum but I\u2019ve been invested in Genflow for some time.  I understand where the company is re the European patent - does anyone know what stage the US patent applications are at?  Is it likely  that, before any deals with major pharma etc are signed, the IP will need to be in place, particularly in US? Is there any update re the outstanding grant application?  I\u2019ve searched but can\u2019t find anything recent.",
          "sentiment": 0.0,
          "engagement": "1",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-21T02:46:11.291777Z"
      },
      {
        "event_id": "SOCIAL-7Jan20261559-Moneymun--7565749",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:02.853351",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "WHO WE ARE Pioneering Novel Gene Therapeutics for a Longer, Healthier Life MISSION: aging is underlying risk factor for disease, and our aim is to deliver gene therapeutics that potentially halt or slow the aging process in humans and dogs CENTENARIAN SIRT6 (cent SIRT6) GENE: proprietary variant of longevity gene that widely regulates aging and immunity and is a potential therapeutic target for the treatment of diseases PROMISING PRECLINICAL RESULTS: lead drug candidate GF-1002 delivers a centenarian variant of the SIRT6 gene (cent SIRT6) for treatment of MASH SEASONED TEAM: experienced and proven management with extensive experience in public & private pharma and biotech ROBUST PIPELINE: advancing multiple development programs over 24 months: MASH, Glaucoma, Sarcopenia, Werner and life extension of dogs DEVELOPMENT PIPELINE GF-1002 (Pre-Clinical) AAV8 cent SIRT6 vector for intravenous infusion, expressing cDNA of centenarian variant of SIRT6(cent SIRT6) in liver GF-1003 (Pre-Clinical/Development) Suspension of exosomes, loaded with mRNA of centenarian variant of SIRT6(cent SIRT6) in fibroblasts GF-1004 (Clinical Proof of Concept) cent SIRT6 for intravenous infusion for life extension and prevention of age-related diseases GF-1005 (Pre-Clinical/Development) Mitochondrial disfunction: Myoblast progenitors loaded by photoporation with cent SIRT6 GF-1006 Ophthalmology (pre-clinical) mRNA cent SIRT6 delivered by LNP for the treatment of cornea pathologies and glaucoma OPHTHALMOLOGY PLATFORM New Ophthalmology Program: Initiated development of a novel gene therapy targeting ocular diseases, including corneal pathologies and glaucoma, using Genflow\u2019s proprietary Centenarian SIRT6 (cent SIRT6). Precision Delivery Platform: Employing a specially engineered non-viral vector for targeted SIRT6 delivery to the eye. Strategic Partnership: Signed a Material Transfer Agreement in April 2025 with a leading ophthalmology company to co-develop the cent SIRT6 therapy and delivery system. LEVERAGING AI FOR GENOMICS New AI Partnership: Signed Master Service Agreement in April 2025 with Heureuka Labs, a spin-out of Duke University, to use their proprietary AI platform to analyze complex genomic data, including RNA sequencing and gene expression profiles. Enhancing Therapeutic Insights: Expected to drive a deeper understanding of gene regulatory networks and biological responses to optimize therapy design and personalize outcomes. Pipeline Advancement: Initially supporting GF-1002 (cent SIRT6-based gene therapy in preclinical development) and future programs, including candidates for MASH. GLAUCOMA RGC NEUROPROTECTION: THE RACE IS ON The Problem 80M people worldwide with glaucoma; leading cause of irreversible blindness Current treatments only lower IOP- they don't protect retinal ganglion cells (RGCs) RGC death is irreversible; unmet need for neuroprotection Significant market opportunity The Gap",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-21T02:46:11.291750Z"
      },
      {
        "event_id": "SOCIAL-7Jan20261601-Moneymun--1438665",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:02.852805",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The Gap No approved neuroprotective therapies The mRNA Opportunity - Wide Open LNP targeted delivery to retina \u2013 now possible NO APPROVED OR CLINICAL-STAGE MRNA THERAPIES FOR GLAUCOMA PARTNERING WITH LNP PROVIDER Paradigm shift to retinal protection \u2022 Pre-clinical evidence links SIRT6 activity with RGC protection in glaucoma/optic neuropathy models \u2022 Demonstrating RGC rescue and preserved function would be a strong disease-modifying signal Delivery is now tractable \u2022 Targeted LNP (tLNP) platforms are removing a major historical barrier for in vivo RNA therapeutics to reach retina/RGCs Clear decision point A single well-designed rodent POC that shows \u2022 focal RGC expression of SIRT6 cent \u2022 preserved RGC counts and \u2022 preserved RGC function with acceptable ocular safety, gives a clean go/no-go for IND enabling work AGED DOGS COMPARATIVE TRIAL Proof-of-Concept comparative clinical trial of in-vivo naked DNA gene therapy in aged dogs Conducted at Syngene's strategic partner site in Morocco, AAALAC and GLP certified 26 (24+2) aged Beagles dogs (age>10 years) Group 1 (n=6): untreated Group 2 (n=6): treated with gene therapy IV bolus of SIRT6 AAV Group 3 (n=6): treated with gene therapy IV infusion of naked DNA (low dose) Group 4 (n=6): treated with gene therapy IV infusion of naked DNA (high dose) Blinded: first read-out in January 2026 \u2022 Treatment period: 180 days with follow-up period: 90 days \u2022 Gene therapy has been administered to all dogs with demonstrated excellent safety profile Endpoints \u2022 Pan-mammalian methylation clock (Steve Horvath), \u2022 sarcopenia (including muscle biopsies) and other markers of aging MASH PROGRAM Affects est. 35 million people globally \u2022 Increasing prevalence \u2022 Leading cause of chronic liver disease and liver transplant Significant unmet medical need Clear regulatory accelerated development pathway. EMA and FDA guidelines accept: \u2713 Key surrogate outcomes for therapeutic trials: regression of fibrosis or resolution of NASH \u2713 Histological changes are achievable within a 12-18-month time-frame \u2713 Placebo control \u2713 Conditional fast-track approval 2025 KEY HIGHLIGHTS LARGE AND EXPANDING MARKET OPPORTUNITY MASH: 35 Million globally. Increasing prevalence. Door opener to even broader anti-aging indication Awarded to new grants in 2024 expanding research pipeline Ophthalmology: retina preservation GROWING IP PORTFOLIO WITH LONG LIFE 2 proprietary patent families SIRT6 centenarian (cent SIRT6) and gene delivery (entering National Phase); Additional upcoming patent applications (entering PCT) MRNA/LNP GENE DELIVERY SYSTEMS Innovative gene delivery systems: targeted LNPs delivering cent SIRT6 mRNA GF-1002 Multiple key clinical and regulatory milestones expected in next 18 months; Undervalued stock opportunity; Potential acquisition by pharmaceutical partner GF-1004: Pet",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-21T02:46:11.291724Z"
      },
      {
        "event_id": "SOCIAL-7Jan20261602-Moneymun-63851609",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:00.123809",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Undervalued stock opportunity; Potential acquisition by pharmaceutical partner GF-1004: Pet life extension / sarcopenia Initiated discussion under CDA with several animal health companies hTtps://loom.ly/RsxnFCE",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-21T02:46:11.291698Z"
      },
      {
        "event_id": "SOCIAL-7Jan20261606-Moneymun--7762093",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:00.123387",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Looks like we've got a new Chairperson!!!??? Gla ;-) GAD BERDUGO Chairperson \u2022 30+ years of leadership across global biotech, corporate development, and U.S. capital markets \u2022 Proven record in strategic partnerships, capital raising, and scaling private and public biotech companies \u2022 Managing Partner, Explorium Capital; former Co-Founder & CEO of EpiVax Oncology and Chief Business Officer at Editas Medicine and Nutcracker Therapeutics",
          "sentiment": 0.0,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-21T02:46:11.291671Z"
      },
      {
        "event_id": "SOCIAL-7Jan20261627-Moneymun-69065578",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:00.122942",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Gad Berdugo Gad Berdugo, MSc. Eng., MBA Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a strategic and financial advisory firm focusing on the global biotechnology sector. He currently serves as Vice Chairman of the Board of Directors of clinical development stage precision oncology company, Diaccurate. Mr. Berdugo brings over 35 years of biotech corporate & business development, strategy, operational, financial, investment and general venture management experience. He served as CBO at CRISPR gene editing pioneer Editas (Nasdaq EDIT); Co-founder and CEO at personalized neoantigen cancer vaccine venture, EpiVax Oncology Inc.; CFO and EVP at Immune Pharmaceuticals Inc. (Nasdaq IMNP); Managing Director and Head of Life Sciences at Tegris Advisors, a strategic and financial advisory boutique; Founder and Managing Partner of the Explorium Global Life Sciences Investment Fund; Director, Senior Equity Research Analyst and Life Sciences Sector Leader at Lazard, Asset Management Group. Prior to that, he served as a Director of Global Business Development within Baxter\u2019s Biopharmaceuticals group and started his career at Abbott Labs. Mr. Berdugo received his B.Sc. with Honors in Biotechnology from Imperial College London, his M.Sc. in Biochemical Engineering from University College London and his M.B.A. from H.E.C. Paris. He serves on the Board of Directors of Friends of H.E.C. Inc. and Friends of U.C.L. Inc. Mr. Berdugo is bilingual in French and English and has dual US and French citizenships. He resides with his wife in New York City.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-21T02:46:11.291645Z"
      },
      {
        "event_id": "SOCIAL-7Jan20261732-Porter_-80377161",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:00.122520",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Thanks for sharing money. I haven\u2019t seen any news regarding a new Chair. Where did you manage to grab that info from? Can you please share the link if you have one? \ud83e\udd70",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-21T02:46:11.291619Z"
      },
      {
        "event_id": "SOCIAL-7Jan20261802-Moneymun--4748783",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:00.122104",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Hi Porter, it's from the 2026 Corporate Presentation which was published via Genflow's LinkedIn post a few hours ago. Gl :-) Ps the new Chair appears to be well connected on the US. https://loom.ly/RsxnFCE",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-21T02:46:11.291593Z"
      },
      {
        "event_id": "SOCIAL-7Jan20261804-Moneymun-25471702",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:00.121673",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Well connected in the US to take Genflow to the next level. ;-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-21T02:46:11.291566Z"
      },
      {
        "event_id": "SOCIAL-8Jan20260702-Moneymun--7972162",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:00.121262",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "08 January 2026 A Review of an Exciting 2025 2025 has been a year of focused scientific progress and continued advancement of Genflow Bioscience's mission to extend healthy lifespan through our novel longevity gene therapy platform. Across our portfolio, we have maintained momentum in both animal health where progress in our canine study may provide translational insights relevant to future human applications as well as therapeutic development for dogs. These advancements have been supported by a strengthened network of leading academic collaborators and laboratories. Together, with continued backing from international institutional investors and previously awarded government grants, this ecosystem helped accelerate Genflow's scientific and clinical development throughout 2025. Program Highlights We've made a number of notable strides across our programs this year, including: \u00b7      Dog Aging (GF-1004) We made significant strides in our clinical trial for aging dogs with full administration of our investigational SIRT6-based gene therapy now completed. No adverse events were reported during the dosing phase of the study, with no serious, moderate, or minor side effects observed. The study which began in March 2025, is being conducted as a blinded clinical trial; an initial efficacy readout is expected in Q1 2026, including blood analyses and muscle biopsies to evaluate potential benefits related to sarcopenia, healthspan, and lifespan-associated biomarkers. Dogs enrolled in the trial will be monitored for 180 days, with a second efficacy assessment planned at the six-month timepoint and results expected in June-July 2026 to evaluate durability and longer-term effects. \u00b7      MASH (GF-1002) Our MASH program saw good progress in 2025. While GLP-1 therapies have addressed early-stage MASH, patients with advanced fibrosis - roughly one-third of the population - still face limited treatment options. In response, we repositioned GF-1002 to target this high-need group, leveraging its antifibrotic properties and potential to prevent progression to cirrhosis and liver cancer. Additionally, we have generated new pre-clinical POC data on the prevention of HCC. We are now finalizing our IND package and evaluating mRNA/LNP delivery as an alternative to AAV, an approach that could enable repeat dosing and lower manufacturing costs. Encouraging data continue to support this next phase of research and development. \u00b7      Glaucoma In 2025, we expanded into ophthalmology, where SIRT6-based gene therapy shows promise in glaucoma, a leading cause of irreversible blindness. Current treatments primarily manage intraocular pressure but do little to prevent optic nerve degeneration. Our preclinical data suggest SIRT6 overexpression may protect retinal ganglion cells and preserve optic nerve function, shifting the focus from symptom control to true neuroprotection.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-21T02:46:11.291540Z"
      },
      {
        "event_id": "SOCIAL-8Jan20260703-Moneymun-87991306",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:00.120785",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "We are advancing discussions with a leading LNP partner to support delivery innovation in this space and are securing a full-service CRO to manage formulation through preclinical execution. With the global glaucoma market approaching USD $12-14 billion by the early 2030s, this represents a compelling long-term opportunity for us. \u00b7 Additional Programs We continued to advance our broader pipeline and are pleased with the steady advancement of the sarcopenia program, fully consistent with our development plans. In parallel, the ExoFastTrack initiative continues to move forward, generating important data that will support and accelerate several of our other development programs. Looking Ahead to 2026 As we move into 2026, we do so with confidence, discipline, and a clear strategic focus. The coming year will emphasize rationalization of our pipeline, prioritizing programs with the strongest data, clearest paths to value creation, and highest partner interest. Central to this strategy will be the pursuit of early-stage licensing and collaboration agreements designed to generate non-dilutive funding, validate our platform externally, and support continued development without undue capital strain. With multiple upcoming data readouts, an expanding partner network, and a maturing intellectual property position, we believe Genflow is well positioned to enter its next phase of growth. We remain committed to scientific excellence, capital efficiency, and long-term value creation as we work to translate our longevity platform into meaningful therapies. Thank you for your continued support and confidence in Genflow.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-21T02:46:11.291514Z"
      },
      {
        "event_id": "SOCIAL-8Jan20260805-Porter_--4252093",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:00.120344",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Thanks for sharing money. I notice the RNS is in American English, perhaps to appeal to US investors and big US pharma? No mention of the patents in the update which were instrumental in offering assurance to investors regarding patent protection, but hopefully we\u2019ll receive updates in due course separately.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.825",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-21T02:46:11.291488Z"
      },
      {
        "event_id": "SOCIAL-8Jan20260854-David195--7134542",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:00.119910",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "I hold shares and the potential is significant. However I am reluctant to add when the funding position is unclear.  Grants could be material amounts if and when received but there is a risk of a diluted fund raise to progress the numerous programmes in 2026.  I have suffered this is other small biotechs like FAB and Apta where the state of the capital markets are very harsh and unsupportive. I tried to analyse the cash runway and it seems more funds will be needed in H1 if the grants are not received.  Is there any indication of the timing?",
          "sentiment": 0.0,
          "engagement": "868",
          "price_at_post": "1.90",
          "thread_title": "Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=1999E606-84A4-47B8-B880-E68E1912F065"
        },
        "ingested_at": "2026-01-21T02:46:11.291460Z"
      },
      {
        "event_id": "SOCIAL-8Jan20260928-Moneymun-40883578",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:00.119483",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Outstanding non-dilutive grant funding could land at anytime, although a lucrative JV licensing deal could also land at anytime and so let's see what transpires at next weeks the prestigious JP Healthcare Conference next week, where Genflow have planned meetings, presumably with potential suitors and every chance Eric will have initial efficacy data from the Dog Trial and maybe and maybe positive Data with their Ophthalmology partner for Glaucoma to present and so confirmation of a commercial deal or two would be transformational for all invested and any funding concerns would be assigned to history.  Gla holders....Excitement building!!! :-) Ps if Genflow need to raise cash because of the delay in receipt of the \u20ac4m outstanding non-dilutive grant funding, then raising cash from 16th January is going to become easier, cheaper and less dilutive.  :-) The new Financial Conduct Authority (FCA) regulations are designed to facilitate less discounted fundraising for small caps by reducing the regulatory burden and increasing the threshold for requiring a full prospectus, thus making secondary capital raising faster and cheaper. Key changes, effective from January 19, 2026 (with some listing rule changes effective from July 29, 2024), aim to attract more companies to list and grow in the UK. Key Regulatory Changes and Their Impact on Small Cap Fundraising The FCA's reforms introduce several key changes that support more efficient and potentially less discounted fundraising for smaller listed companies: Increased Prospectus Threshold The most significant change for secondary fundraising is that a full prospectus is now only required if a company issues shares amounting to 75% or more of its existing share capital, a substantial increase from the previous 20% threshold. This allows companies, particularly smaller ones, to raise further capital more quickly and at a lower cost without the time and expense associated with a full prospectus, which should reduce the need for heavily discounted placings.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=1999E606-84A4-47B8-B880-E68E1912F065"
        },
        "ingested_at": "2026-01-21T02:46:11.291433Z"
      },
      {
        "event_id": "SOCIAL-8Jan20260933-Moneymun-64889062",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:00.119031",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Bring it on!!! Gla holders:-) \"Central to this strategy will be the pursuit of early-stage licensing and collaboration agreements designed to generate non-dilutive funding, validate our platform externally, and support continued development without undue capital strain.\" .... Dr. Eric Leire, CEO of Genflow, commented: \"We're excited to attend the JP Morgan Healthcare Conference in San Francisco this January. Our planned meetings reflect our current focus on lipid nanoparticle delivery for mRNA SIRT6 therapeutics, which is opening compelling opportunities for strategic partnerships in the longevity space.\"",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=1999E606-84A4-47B8-B880-E68E1912F065"
        },
        "ingested_at": "2026-01-21T02:46:11.291407Z"
      },
      {
        "event_id": "SOCIAL-8Jan20261005-Moneymun-10442681",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:00.118605",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Hopefully news on patents soon Porter, the following statement is from yesterday's 2026 Corporate Presentation.  Gl :-) GROWING IP PORTFOLIO WITH LONG LIFE 2 proprietary patent families SIRT6 centenarian (cent SIRT6) and gene delivery (entering National Phase); Additional upcoming patent applications (entering PCT)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-21T02:46:11.291381Z"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-David195--1186857",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:00.118180",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "Thank you for your informed views.  Added 500k @1.78.  It is hard for companies in this sector to raise funds so hopefully the upcoming changes will make the situation less brutal.  I will add when funds allow.",
          "sentiment": 0.0,
          "engagement": "868",
          "price_at_post": "1.85",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-21T02:46:11.291355Z"
      },
      {
        "event_id": "SOCIAL-8Jan20261148-Moneymun-22286343",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:00.117754",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Nice one David, looking forward to a run of great news from Eric to take the sp to new highs. Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.85",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-21T02:46:11.291328Z"
      },
      {
        "event_id": "SOCIAL-8Jan20261314-Moneymun-30096111",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:00.117339",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "0 0 Gene therapy biotech Genflow eyes busy year ahead as dog ageing trial nears results Published: 02:40 08 Jan 2026 Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) has wrapped up 2025 with steady progress across a range of gene therapy programmes, including a closely watched trial into dog ageing that could lay the groundwork for future human applications. The London-listed company, which is working on ways to extend healthy lifespan using gene therapy, said it had completed dosing in its lead canine study with no reported side effects. The dogs will now be monitored over six months for signs of improved muscle strength and health-related biomarkers, with initial results expected in the first quarter of this year. The trial, which began in March and uses a therapy based on the SIRT6 gene, a known regulator of ageing and DNA repair, is being conducted in a blinded format. A follow-up analysis is due around mid-year to assess the durability of the effects. Alongside the dog ageing study, Genflow said it had made progress in a programme targeting advanced stages of MASH, or metabolic dysfunction-associated steatohepatitis, a type of fatty liver disease. Existing GLP-1 drugs such as Ozempic and Wegovy have shown benefits in early MASH, but Genflow is aiming at patients with more severe fibrosis, where options remain limited. It is now finalising regulatory paperwork to support a human trial and is exploring the use of mRNA technology, similar to that used in Covid-19 vaccines, as a more flexible and cost-effective delivery method than traditional viral vectors. In a new push into eye disease, the company is also investigating the use of its gene therapy platform in glaucoma. Early lab results suggest that increasing SIRT6 levels may help protect the optic nerve from damage, potentially offering a way to slow or prevent vision loss rather than simply reducing eye pressure, which is the current standard treatment. Genflow said it was in talks with a lipid nanoparticle delivery partner to support this programme and was hiring a specialist contract research firm to help move the candidate towards preclinical testing. Elsewhere in its pipeline, work is ongoing in sarcopenia, the loss of muscle mass that often accompanies ageing, and in a broader initiative called ExoFastTrack, which supports several of its research efforts. Looking to the year ahead, Genflow said it would focus its efforts on the most promising areas of its portfolio and seek early licensing or partnership deals to bring in fresh funds without issuing new shares. \u201cWith multiple upcoming data readouts, an expanding partner network, and a maturing intellectual property position, we believe Genflow is well positioned to enter its next phase of growth,\u201d the company said. The first set of clinical results, particularly from the dog study, will be key in setting the tone for 2026.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-21T02:46:11.291302Z"
      },
      {
        "event_id": "SOCIAL-8Jan20261711-Troajan-29414482",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:00.116848",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1085366/genflow-biosciences-ceo-key-catalysts-for-2026-1085366.html",
          "sentiment": 0.0,
          "engagement": "125,338",
          "price_at_post": "1.75",
          "thread_title": "Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-21T02:46:11.291275Z"
      },
      {
        "event_id": "SOCIAL-8Jan20261858-Moneymun-10236912",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:00.116434",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Another brilliant interview by Eric, \"2026 will be catalyst year, they've done their work and now it's time for harvesting and are going to JP Morgan next week with a full appointments book, and now ready for potential harvesting of their results to bring in non-dilutive funding cash into the company. Excitement building, in Eric we trust!!! Gla ;-) Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company\u2019s key programs and upcoming catalysts as it enters what management expects to be a pivotal year. Leire discussed why 2026 is shaping up as \u201ca year of catalysts\u201d for the company, with particular focus on the dog ageing trial, progress in MASH, and the group\u2019s approach to partnerships and licensing. Leire explained that the dog longevity study is the nearest catalyst, with the trial expected to be unblinded shortly and early efficacy readouts anticipated in the near term. While safety has already been confirmed, the study remains blinded, meaning efficacy results are still unknown. The first data will focus on biological age, measured using a methylation clock, with a more detailed analysis of muscle biopsies and mitochondrial function to follow. According to Leire, \u201cthis trial could be very important for our shareholders, because it will trigger a deal with an animal health company bringing non-dilutive money in the company.\u201d The interview also explored Genflow\u2019s repositioning in MASH toward advanced fibrosis and the prevention of hepatocellular carcinoma. Leire highlighted the significant unmet need in late-stage disease, noting that recent therapies target earlier stages and leave patients with advanced fibrosis facing limited options. He said the company\u2019s preclinical data have been encouraging and form a key part of the IND package, helping differentiate Genflow from existing and emerging treatments. In addition, Leire discussed the company\u2019s licensing strategy, including plans to out-license the dog program to an animal health specialist and pursue early-stage partnerships for glaucoma, while retaining focus on age-related conditions such as sarcopenia. With meetings planned during JPMorgan week, Leire said the company is seeking non-dilutive capital and strategic validation as it moves forward.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-21T02:46:11.291248Z"
      },
      {
        "event_id": "SOCIAL-8Jan20261917-Moneymun-86148865",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:00.115981",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Eye wonder....Gla:-) 23/12/2025 - 12:30 VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders, Executive Vice President and Chief Financial Officer Sam Eldessouky and Chief Medical Officer and Head of Research & Development Yehia Hashad, MD, will participate in a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026, at 1:30 p.m. PT (4:30 p.m. ET) Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-21T02:46:11.291222Z"
      },
      {
        "event_id": "SOCIAL-8Jan20261920-Moneymun-49918013",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:00.115554",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "And/or ???? ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 4:30 p.m. PT in San Francisco, CA.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-21T02:46:11.291196Z"
      },
      {
        "event_id": "SOCIAL-8Jan20261946-Moneymun-84904592",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:00.115125",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Woof, woof!!!??? ;-) Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference 06 January 2026 INDIANAPOLIS, Jan. 6, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will represent the company and respond to questions from analysts at 3:45 p.m. PST (6:45 PM EST).",
          "sentiment": 0.0,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-21T02:46:11.291170Z"
      },
      {
        "event_id": "SOCIAL-8Jan20262001-Moneymun--6013928",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:00.114684",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 10:30 a.m. PT. Investors and other interested parties can access a live audio webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event. About Zoetis As the world\u2019s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide \u2013 from veterinarians and pet owners to livestock producers. The company\u2019s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees. For more information, visit www.zoetis.com.",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-21T02:46:11.291142Z"
      },
      {
        "event_id": "SOCIAL-10Jan20261752-Troajan--8030371",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:00.114238",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1085424/genflow-is-ready-for-a-year-of-catalysts-icymi-1085424.html",
          "sentiment": 0.0,
          "engagement": "125,338",
          "price_at_post": "1.825",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-21T02:46:11.291092Z"
      },
      {
        "event_id": "SOCIAL-11Jan20261442-Moneymun-14776558",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:00.113800",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Planned meetings presumably with potential suitors at JP Morgan this coming week and so multiple deal opportunities across the platform, and there's currently an M&A and lucrative licensing deal feeding frenzy as Major Pharma replenish their pipelines with the latest cutting-edge science, Excitement building!!! Gla :-) \"2026 will be catalyst year, we've done our work and now it's time for harvesting and are going to JP Morgan next week with a full appointments book, and now ready for potential harvesting of our results to bring in non-dilutive cash into the company.\" A must watch....Gla holders:-) hTtps://www.proactiveinvestors.co.uk/companies/news/1085366/genflow-biosciences-ceo-key-catalysts-for-2026-1085366.html",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.825",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-21T02:46:11.291066Z"
      },
      {
        "event_id": "SOCIAL-12Jan20260822-Moneymun--3784977",
        "event_type": "social_post",
        "date": "2026-01-21T02:46:00.113344",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Healthcare companies set for deals spree as drug patents expire A gathering of pharmaceutical executives comes as the sector has rebounded from uncertainty over Trump\u2019s policies Healthcare executives gather for their big annual conference in San Francisco on Monday as the sector is flush with cash and set for a deals spree as patents on drugs worth almost 12 per cent of the industry\u2019s revenues expire in the years ahead. The JPMorgan healthcare conference takes place as uncertainty recedes over President Donald Trump\u2019s trade wars, drug pricing policy and the leadership of key regulators such as the US Food and Drug Administration. In response, the S&P biotech index, known as the XBI, has surged to a four-year high, outperforming the wider index. In addition, drugs that contribute about $180bn of revenue a year are set to go off patent in 2027 and 2028, representing almost 12 per cent of the global market, according to research firm Evaluate Pharma. More than $40bn of sales are expected to lose patent protection this year, Evaluate has estimated. \u201cThe need to take big swings becomes more pressing,\u201d said Jeremy Meilman, head of healthcare investment banking at JPMorgan. \u201cSeveral of the large-cap pharmaceutical companies are shopping around for strong assets and a number have taken action but still have more firepower. This contributes to our optimism for 2026.\u201d hTtps://www.ft.com/content/7b07a9d5-7254-490b-8ce9-ec2633094d8e",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.825",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-21T02:46:11.291039Z"
      },
      {
        "event_id": "SOCIAL-12Jan20261231-Moneymun--1892748",
        "event_type": "social_post",
        "date": "2026-01-21T02:45:57.476847",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Get UP there!!! Gla :-) Eric and his team are now at the prestigious JP Healthcare Conference, pressing flesh with the leading industry deal makers. He appeared confident and enthusiastic in his latest interview, highlighting the prospects and potential of an early lucrative JV deal for the Dog Trial, Glaucoma and Mash and so potential game changing transformational news could drop at anytime. The first efficacy readout on the Dog Trial is imminent, and with two Animal Healthcare companies both with Confidential Disclosure Agreements in place, Eric could be very close to a deal, and the same with Glaucoma, whereby a leading Ophthalmology Company signed a Material Transfer Agreement 10 months ago. Eric also highlighted the prospects of Genflow's Sirt6 Mash Gene Therapy, which is now targeting the later stages of the disease where there's no options apart from transplant, and was very interesting to hear from Eric it could be used in combination with GLP-1's and Madrigal's early stage treatment which was FDA approved 12 months or so ago. Madrigal are presenting at JP Morgan and are on a mission to expand their pipeline for Mash, so watch this space. It's also very interesting we have a new Chairman in place, GAD BERDUGO a high flyer based in the US in Global Biotech, Corporate Development and and US Capital Markets and so no doubt very well contected to any potential suitors. Excitement building!!!! In Eric we trust!!! Gla holders:-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.00",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-21T02:46:11.291012Z"
      },
      {
        "event_id": "SOCIAL-12Jan20261725-Steg--2294032",
        "event_type": "social_post",
        "date": "2026-01-21T02:45:57.476433",
        "source": "LSE_CHAT",
        "data": {
          "author": "Steg",
          "content": "Thought below was interesting, yes they are attending conference and have already made move to add to thier MASH portfolio, courtesy of AI search below Yes, Madrigal Pharmaceuticals is actively looking to expand its MASH (metabolic dysfunction-associated steatohepatitis) portfolio beyond its already approved drug, Rezdiffra (resmetirom). Madrigal's expansion strategy focuses on developing potential combination therapies, as MASH is a complex disease that requires multiple treatment approaches. Key components of their expanded pipeline include: Ervogastat: In January 2026, Madrigal entered into an exclusive global license agreement with Pfizer to acquire ervogastat, a Phase 2 oral DGAT-2 inhibitor. This drug works on a different, complementary pathway to Rezdiffra, and Madrigal plans to conduct studies to test the two treatments in combination. Oral GLP-1 Receptor Agonist: Madrigal also holds worldwide rights to an oral GLP-1 agonist called SYH2086, licensed from CSPC Pharmaceutical, with the goal of creating a best-in-class oral combination therapy. Additional Early-Stage Assets: The agreement with Pfizer for ervogastat also included rights to two other early-stage MASH pipeline assets. Madrigal's CEO, Bill Sibold, has stated that the company is committed to \"building the industry-leading pipeline that will shape the future of MASH care\" and believes combination therapies are the next wave of innovation in the field.",
          "sentiment": 0.0,
          "engagement": "5",
          "price_at_post": "1.90",
          "thread_title": "JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-21T02:46:11.290986Z"
      },
      {
        "event_id": "SOCIAL-14Jan20260812-Moneymun--8181117",
        "event_type": "social_post",
        "date": "2026-01-21T02:45:57.475978",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions Madrigal\u2019s strategy of pursuing combination therapies while the market remains in its infancy could intrinsically link its brand to MASH treatment. Madrigal Pharmaceuticals used its January 12 presentation at the J.P. Morgan Healthcare Conference 2026 to showcase its newly acquired assets from Pfizer \u2013 ervogastat and two preclinical assets \u2013 as well as outline its vision for dominance in metabolic dysfunction-associated steatohepatitis (MASH) treatment space through leveraging early commercial success. Its professed strategy of pursuing combination therapies while the market remains in its infancy could well result in Madrigal\u2019s brand becoming intrinsically linked to MASH treatment. JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions - Pharmaceutical Technology https://share.google/Ymb4cXndGee7eMEbD",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.00",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-21T02:46:11.290960Z"
      },
      {
        "event_id": "SOCIAL-14Jan20260815-Moneymun-37910602",
        "event_type": "social_post",
        "date": "2026-01-21T02:45:57.475551",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Game changing news at anytime. In Eric we trust!!! Gla holders...On and UP!!! :-)))",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.00",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-21T02:46:11.290934Z"
      },
      {
        "event_id": "SOCIAL-14Jan20260818-Roosters--7590877",
        "event_type": "social_post",
        "date": "2026-01-21T02:45:57.475143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Roostersmillions",
          "content": "Markets reacting munch. Nice jump this AM. hope it holds. Maybe new private investors from across the pond due to conference exposure??",
          "sentiment": 0.5,
          "engagement": "288",
          "price_at_post": "2.00",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-21T02:46:11.290907Z"
      },
      {
        "event_id": "SOCIAL-14Jan20260827-Moneymun-39227047",
        "event_type": "social_post",
        "date": "2026-01-21T02:45:57.474720",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Every chance Rooster, although I'm hoping for a transformational lucrative commercial licensing deal on one or more of the programs, Dog , Glaucoma and Mash. Excitement building!!! Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.05",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-21T02:46:11.290881Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261006-Moneymun--8640678",
        "event_type": "social_post",
        "date": "2026-01-21T02:45:57.474315",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "GKOS: Strong innovation and new therapies drive growth, with robust financials and expanding markets Jan 14, 2026, GKOS The event highlighted robust innovation in ophthalmology, with strong R&D investment yielding a broad product pipeline and record financial performance. Key growth drivers include new glaucoma and keratoconus therapies, strategic market expansion, and a focus on operational leverage and profitability. Based on Glaukos Corporation [GKOS] 44th Annual J.P. Morgan Healthcare Conference Audio Transcript \u2014 Jan. 14 2026",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.10",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-21T02:46:11.290855Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261844-JediMast--2963056",
        "event_type": "social_post",
        "date": "2026-01-21T02:45:57.473876",
        "source": "LSE_CHAT",
        "data": {
          "author": "JediMaster1",
          "content": "Rumours of investment banks wanting to buy in from the JP Morgan Conference. The only question now is who do they want to buy in on behalf of?? The next few days will be interesting. Will Eric spill the beans?",
          "sentiment": 0.5,
          "engagement": "167",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D010A135-964B-4034-9025-65BCB0334809"
        },
        "ingested_at": "2026-01-21T02:46:11.290829Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261946-jamtart1--2753269",
        "event_type": "social_post",
        "date": "2026-01-21T02:45:57.473464",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Doubt it, but happy if rumours are true",
          "sentiment": 0.5,
          "engagement": "1,596",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan, news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=559FB93D-C9CD-4A83-84E9-7B26CC6976E9"
        },
        "ingested_at": "2026-01-21T02:46:11.290803Z"
      },
      {
        "event_id": "SOCIAL-15Jan20260634-Porter_-44732035",
        "event_type": "social_post",
        "date": "2026-01-21T02:45:57.473048",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Companies attend the J.P. Morgan Healthcare Conference (JPM) primarily for networking, securing funding, forging strategic partnerships, and announcing key business updates. This major event, often described as setting the industry's tone for the year, concentrates a year's worth of meetings into a few days. Key reasons why companies attend include: Investment and Funding: The conference is a premier venue for companies to present their strategies and financial outlooks to a high-level audience of investors, analysts, and venture capitalists. For many, especially smaller or emerging biotech firms, it is a critical opportunity to secure financing, gauge investor interest, and build essential relationships. Mergers and Acquisitions (M&A) and Partnerships: The event is a hotbed for dealmaking. Big pharmaceutical companies often attend to scout for smaller companies with promising drug pipelines or innovative technologies (like AI in drug discovery) to acquire, especially as their own blockbuster drugs approach patent expiration. Extensive one-on-one meetings facilitate these discussions and collaborations. Strategic Positioning and Visibility: Companies announce major news, clinical trial data, or year-end recaps just before or during the conference to capture attention and elevate their visibility above the competition. It allows them to articulate their unique value proposition and strategic priorities to the global market. Market Intelligence: Attending allows companies to take the pulse of the industry, understand the latest trends (e.g., AI, gene therapy, obesity drugs), and gather competitive intelligence. They can assess how investors and peers discuss valuations, regulatory pathways, and market potential, which helps in fine-tuning their own strategies for the year ahead. Networking Efficiency: The conference brings the entire healthcare and life sciences ecosystem\u2014from manufacturers and providers to regulators and service providers\u2014into a concentrated location for a short time. This high density of key decision-makers allows for efficient, high-value networking and relationship building that would otherwise take months of travel and outreach.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=4C9A5731-DC78-4F24-8CE9-513E080FCFAC"
        },
        "ingested_at": "2026-01-21T02:46:11.290777Z"
      },
      {
        "event_id": "SOCIAL-15Jan20262119-jamtart1-62096531",
        "event_type": "social_post",
        "date": "2026-01-21T02:45:57.472579",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Yes, Genflow Biosciences (Genflow) has had significant interest at the J.P. Morgan Healthcare Conference, attending specifically to engage with potential partners, institutional investors, and pharmaceutical companies. Their CEO, Dr. Eric Leire, attended the most recent conference in January 2026 with a \"full appointments book\" to discuss strategic partnerships and non-dilutive funding opportunities.",
          "sentiment": 0.5,
          "engagement": "1,596",
          "price_at_post": "1.85",
          "thread_title": "JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=3005BF87-EE58-4C27-ABC6-EE6AA15A9385"
        },
        "ingested_at": "2026-01-21T02:46:11.290750Z"
      },
      {
        "event_id": "SOCIAL-16Jan20260716-Porter_--1799391",
        "event_type": "social_post",
        "date": "2026-01-21T02:45:57.472169",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Genflow Biosciences is a London-based biotechnology firm and the first \"pure-play\" longevity company listed on the London Stock Exchange. As of early 2026, the company is transitioning from a preclinical phase into active clinical data readouts, focusing on its proprietary SIRT6-based gene therapy platform to extend human and animal \"healthspan\". Core Technology and Pipeline: The company\u2019s lead therapeutic approach involves delivering a \"centenarian variant\" of the SIRT6 gene, identified in individuals who live over 100 years, to improve DNA repair and metabolic health. GF-1002 (Human Therapeutics): MASH (Liver Disease): Repositioned in 2025 to target patients with advanced fibrosis who have limited options from existing GLP-1 therapies. The company is currently finalizing its Investigational New Drug (IND) package and exploring mRNA/LNP delivery to allow for repeat dosing and lower costs. Werner Syndrome: A rare genetic condition causing premature aging. Genflow has developed proprietary human-derived liver organoids to model this disease more accurately than animal models. GF-1004 (Veterinary Program): Canine Longevity: A 12-month blinded clinical trial in aged dogs is currently underway. In early 2026, the company confirmed that all subjects received full dosing with no adverse events reported. Key 2026 Milestones: Initial efficacy readouts focusing on biological age (via methylation clocks) are expected in Q1 2026, with a second evaluation planned for June-July 2026. Expansion Programs: Glaucoma: A new ophthalmology program targeting neuroprotection of retinal ganglion cells to prevent blindness. Sarcopenia (GF-1005): Research into muscle health and mitochondrial dysfunction in collaboration with the Universit\u00e9 libre de Bruxelles. 2026 Strategic Focus: Genflow\u2019s 2026 strategy emphasizes \"rationalization of the pipeline,\" prioritizing programs with the strongest data to secure non-dilutive funding through licensing deals and partnerships. The company is actively seeking animal health partners for its dog longevity program and strategic collaborators for its LNP-based mRNA therapeutics.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "GLP, LNP, MRNA and SIRT6 based therapeutics",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=FB89DB69-F93B-4BB3-8529-5206EECDF243"
        },
        "ingested_at": "2026-01-21T02:46:11.290724Z"
      },
      {
        "event_id": "SOCIAL-16Jan20260836-Pie-char-76800326",
        "event_type": "social_post",
        "date": "2026-01-21T02:45:57.471697",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Post conference announcement next week and Funding news is what I predict. I'm amazed we are at this price. Such a hidden gem!",
          "sentiment": 0.5,
          "engagement": "60",
          "price_at_post": "1.85",
          "thread_title": "RE: JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=3005BF87-EE58-4C27-ABC6-EE6AA15A9385"
        },
        "ingested_at": "2026-01-21T02:46:11.290697Z"
      },
      {
        "event_id": "SOCIAL-19Jan20260718-Porter_--7165244",
        "event_type": "social_post",
        "date": "2026-01-21T02:45:57.471288",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Genflow Appoints a New Chairman to Accelerate Corporate and R&D Expansion Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or the \"Company\"), a leading European-based biotechnology company focusing on gene therapies for age-related diseases, is pleased to announce a significant appointment to its Board of Directors, marking an important step in the Company's strategic evolution. Mr. Gad Berdugo, MSc Eng., MBA, has joined the Board with immediate effect and will assume the role of Independent Non-Executive Chairman, providing leadership as Genflow focuses on advancing its gene-therapy programs. Mrs. Tamara Joseph will continue to serve as a Director, ensuring continuity and maintaining strong governance. Mr. Berdugo brings over 30 years' of leadership experience spanning global business and corporate development, U.S. capital markets, and company building. He has a proven record of driving strategic partnerships, securing capital, and scaling both private and public development-stage biotechnology companies. Currently, Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a U.S.-based strategic and financial advisory firm focusing on the global biotechnology sector. His most recent roles include: \u00b7 Co-Founder & CEO, EpiVax Oncology \u00b7 Vice-Chairman of the Board, Evexta Bio \u00b7 Chief Business Officer, Editas Medicine (NASDAQ: EDIT) \u00b7 Chief Business Officer, Nutcracker Therapeutics He began his international career at Abbott Labs and Baxter, later becoming Life Sciences Sector Leader at Lazard Asset Management. Mr. Berdugo also brings deep technical and market expertise in RNA-based therapeutics, including lipid nanoparticle (LNP) delivery, development, and manufacturing. This background will support Genflow as it advances its scientific platform, evaluates delivery technologies, and explores next-generation therapeutic approaches. His appointment further strengthens the Company's presence in the United States and expands its capacity for global engagement. He does not own any shares in the Company. Dr. Eric Leire, Chief Executive Officer of Genflow, commented: \"We are delighted to welcome Mr. Berdugo as Independent Non-Executive Chairman. His expertise in strategy, partnerships and financing as well as his deep experience with RNA-LNP technologies will be instrumental as we accelerate our programs and expand our global reach. We are equally pleased that Mrs. Tamara Joseph will continue her service on the Board, contributing her invaluable leadership, legal and governance expertise.\" Gad Berdugo added: \"I am excited to join Genflow as the company is progressing to the next new phase of development, with key data readouts expected in 2026, strengthened intellectual property, and a sharpened strategic focus on high-potential programs. I look forward to working with the talented team and board to advance these innovative gene therapies, this is an ideal moment to contribute my expertise and hel",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-21T02:46:11.290670Z"
      },
      {
        "event_id": "SOCIAL-19Jan20260734-Twocd2-76677497",
        "event_type": "social_post",
        "date": "2026-01-21T02:45:57.470815",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "Take the rest of the day off Porter..great job pal! You must have set the alarm early to C&P all of that \ud83d\udc4f\ud83d\udc4f\ud83d\udc4c",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-21T02:46:11.290644Z"
      },
      {
        "event_id": "SOCIAL-19Jan20260752-Porter_--1414857",
        "event_type": "social_post",
        "date": "2026-01-21T02:45:57.470403",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "2cd2 - invest more than \u00a3100 in a company and you might care a little bit more for your investments \ud83d\ude18",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-21T02:46:11.290617Z"
      },
      {
        "event_id": "SOCIAL-19Jan20260820-Moneymun--2081576",
        "event_type": "social_post",
        "date": "2026-01-21T02:45:57.469979",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The new Chairman in place, GAD BERDUGO is a high flyer based in the US with a wealth of experience in Global Biotech, Corporate Development and US Capital Markets and so no doubt very well contected to any potential suitors. Excitement building!!!! In Eric we trust!!! Gla holders:-) Ps initial Efficacy readout on the Dog Trial imminent!!! Gla ;-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-21T02:46:11.290591Z"
      },
      {
        "event_id": "SOCIAL-19Jan20260839-Twocd2--7343943",
        "event_type": "social_post",
        "date": "2026-01-21T02:45:57.469563",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "Ok big fella..time for nap your banter is honking.",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-21T02:46:11.290564Z"
      },
      {
        "event_id": "SOCIAL-19Jan20261005-DaveTK--1359820",
        "event_type": "social_post",
        "date": "2026-01-21T02:45:57.469154",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Would seem like you touched  nerve there, Porter ha ha. Nice RNS this morning. Looking forward to hearing more regarding the J.P. Morgan's Healthcare Conference. Really does seem like exciting times ahead. Thanks",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-21T02:46:11.290538Z"
      },
      {
        "event_id": "SOCIAL-19Jan20261027-Porter_--4199380",
        "event_type": "social_post",
        "date": "2026-01-21T02:45:57.468722",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Always the ones who sold too soon quick to troll those who held with diamond hands Dave. Expecting this is just the first update of many we\u2019ll be seeing over the next 2 weeks. Popcorn ready! \ud83c\udf7f",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-21T02:46:11.290511Z"
      },
      {
        "event_id": "SOCIAL-19Jan20261033-DaveTK-88319648",
        "event_type": "social_post",
        "date": "2026-01-21T02:45:57.468297",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Always. I'm here and always have been here waiting for news that we have been bought out. It was always the goal from Eric to make this company into something a pharmaceutical would buy a high price. We may not be that far off. Fingers crossed. Thanks",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-21T02:46:11.290484Z"
      },
      {
        "event_id": "SOCIAL-19Jan20261342-Twocd2--4400727",
        "event_type": "social_post",
        "date": "2026-01-21T02:45:57.467857",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "So TK Max joins the party\u2026think you and Porter need to take turns and time to give him a chance to be big spoon for this week. Might give him something else to do rather than practice his typing. Plenty of skin in the game lads\u2026but this is not about who\u2019s chopper is bigger..well maybe for the spooning it does\ud83d\ude01",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-21T02:46:11.290458Z"
      },
      {
        "event_id": "SOCIAL-19Jan20261352-DaveTK--4930218",
        "event_type": "social_post",
        "date": "2026-01-21T02:45:57.467445",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "I joined the party pre IPO. TBF they were asking for more than \u00a350 so it may have been too much of a reach for you. Talking about choppers FFS. Don't let you mum read that or she'll take your phone off you and cancel your contract.",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-21T02:46:11.290431Z"
      },
      {
        "event_id": "SOCIAL-19Jan20262217-Twocd2-27554935",
        "event_type": "social_post",
        "date": "2026-01-21T02:45:57.467009",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "I joined pre IPO, \u00a350 may have been too much of a reach for you\u2026chortle chortle TK Max.. Give Porter a reach around before lights out so that he\u2019ll not be to disappointed with no RNS tomorrow morning\u2026\ud83d\udc4c",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-21T02:46:11.290401Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260719-Porter_-31576878",
        "event_type": "social_post",
        "date": "2026-01-21T02:45:57.466569",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Know a few people who didn\u2019t get their orders filled yesterday. Seems there isn\u2019t much in the free-float so let\u2019s see how tight this coiled spring is!",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-21T02:46:11.290352Z"
      },
      {
        "event_id": "SOCIAL-28Oct20250936-Moneymun--8052600",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:33.996909",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "A couple of 1m buys from Friday, late reported at yesterday's close,  they've just raised \u00a3440k through the endorsement of Eric and a consortium of long term Major Shareholders, which speaks volumes and a huge vote of confidence going forward. The outstanding \u20ac4.7m non-dilutive grant money is awaiting sign off by the Wallonian Govt, and is expected very soon, and the Major shareholders certainly wouldn't have parted with their hard earned cash if they believed it's not incoming. We have two premier Animal Health companies who have both signed Confidential Disclosure Agreements, both of which could make an early move and lucrative financial licensing deal, as we await Efficacy data, expected early 2026. We also have a leading ophthalmology company who signed a Material Transfer Agreement 6 months ago for Glaucoma, with Sirt6 Therapy expected to be a game-changer for its treatment, and so another lucrative deal could be close, along with Major Pharma who could be highly interested in Genflow's Sirt6 technology platform, and so a Mega deal is more than conceivable. In the meantime, Genflow has sufficient cash moving forward and it's pretty obvious that the smart Money is accumulating for potential transformational UPside returns. Gla holders, they want your shares, hold on tight and enjoy the ride, Genflow's on a one way trajectory from small cap to mid cap and is all set for a stellar 2026....On and UP!!! :-)",
          "sentiment": 0.5,
          "engagement": "12,501",
          "price_at_post": "2.00",
          "thread_title": "RE: Nice and steady",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=A317A1CD-2251-4FF6-A527-30FD89BA6AA8"
        },
        "ingested_at": "2026-01-21T02:46:11.294468Z"
      },
      {
        "event_id": "SOCIAL-30Oct20251140-Moneymun--2263066",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:33.996495",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "BioWin 14,868 followers 20h Edited \ud835\udc01\ud835\udc22\ud835\udc28\ud835\udc16\ud835\udc22\ud835\udc27 \ud835\udc1a\ud835\udc2d \ud835\udc01\ud835\udc22\ud835\udc28\ud835\udc04\ud835\udc2e\ud835\udc2b\ud835\udc28\ud835\udc29\ud835\udc1e 2025 \u2013 \ud835\udc0b\ud835\udc1e\ud835\udc2d\u2019\ud835\udc2c \ud835\udc02\ud835\udc28\ud835\udc27\ud835\udc27\ud835\udc1e\ud835\udc1c\ud835\udc2d \ud835\udc22\ud835\udc27 \ud835\udc15\ud835\udc22\ud835\udc1e\ud835\udc27\ud835\udc27\ud835\udc1a! BioWin will be attending BioEurope 2025 in Vienna (3-5th November), and we look forward to connecting with partners, innovators, and investors shaping the future of health. You can meet us at the Belgian Pavilion (Hall C, Booth 61), alongside Wallonia Export & Investment Agency (AWEX), where we\u2019ll be representing Wallonia\u2019s dynamic health ecosystem. If you\u2019re attending and would like to explore collaboration opportunities or representation support, don\u2019t hesitate to reach out to Lo\u00efc Germain and David Honba \u2014 BioWin can help facilitate valuable connections and visibility during the event. We\u2019re also proud to announce that David Honba, BioWin\u2019s COO, will participate in a panel discussion on Advanced Therapy Medicinal Products (ATMPs) alongside Romain de Rauville (Exo Biologics) and Thibault Helleputte (DNAlytics), moderated by Claire Verschelde (ICOSA). The session will spotlight Wallonia\u2019s leadership in ATMP innovation, showcasing how our ecosystem transforms research excellence into industrial and clinical success. \ud83d\udc49 \ud835\udc0b\ud835\udc28\ud835\udc28\ud835\udc24\ud835\udc22\ud835\udc27\ud835\udc20 \ud835\udc1f\ud835\udc28\ud835\udc2b \ud835\udc22\ud835\udc27\ud835\udc2f\ud835\udc1e\ud835\udc2c\ud835\udc2d\ud835\udc28\ud835\udc2b\ud835\udc2c, \ud835\udc29\ud835\udc21\ud835\udc1a\ud835\udc2b\ud835\udc26\ud835\udc1a\ud835\udc2c, \ud835\udc2c\ud835\udc1e\ud835\udc2b\ud835\udc2f\ud835\udc22\ud835\udc1c\ud835\udc1e\ud835\udc2c? Contact the BioWin team to plan a meeting or learn how we can represent you at BioEurope!",
          "sentiment": 0.5,
          "engagement": "12,501",
          "price_at_post": "2.10",
          "thread_title": "Bio Europe 3/11/25",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=CAE8CCFE-6A35-4412-8EB8-DA48539CE7F9"
        },
        "ingested_at": "2026-01-21T02:46:11.294442Z"
      },
      {
        "event_id": "SOCIAL-31Oct20250730-Porter_-37387878",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:33.996034",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Interesting that Genflow have issued a confirmation of share allocation. Wonder if that means exciting news is to follow?",
          "sentiment": 0.5,
          "engagement": "1,314",
          "price_at_post": "2.05",
          "thread_title": "Share confirmation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=FE4B7DEC-29D0-45B6-898E-2B9695FD4467"
        },
        "ingested_at": "2026-01-21T02:46:11.294415Z"
      },
      {
        "event_id": "SOCIAL-31Oct20251532-Moneymun-20388022",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:33.995621",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Hopefully so Porter,  one or two TR1's at the very least and perfectly poised and primed for some very positive news with any luck!!! Gl :')",
          "sentiment": 0.5,
          "engagement": "12,501",
          "price_at_post": "2.05",
          "thread_title": "RE: Share confirmation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=FE4B7DEC-29D0-45B6-898E-2B9695FD4467"
        },
        "ingested_at": "2026-01-21T02:46:11.294389Z"
      },
      {
        "event_id": "SOCIAL-1Nov20251844-Moneymun-85997769",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:33.995142",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "World Intellectual Property Organization, Australia, Europe & now Canada....Strong patent IP protection, exactly what Major Pharma suitors due diligence will include for a potential mega lucrative JV licensing deal for Genflow\u2019s Mash Sirt6 gene therapy. Gla holders :-) 1.WO/2024/121363VARIANTS OF SIRTUIN 6 FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE WO - 13.06.2024 Int.Class A61K 38/43 Appl.No PCT/EP2023/084840 Applicant GENFLOW BIOSCIENCES SRL 5.2023389400VARIANTS OF SIRTUIN 6 FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE AU - 13.06.2024 Int.Class A61K 38/43 Appl.No 2023389400 Applicant GENFLOW BIOSCIENCES SRL Inventor LEIRE, Eric 6.3276298VARIANTS OF SIRTUIN 6 FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE CA - 13.06.2024 Int.Class A61K 38/43 Appl.No 3276298 Applicant GENFLOW BIOSCIENCES SRL Inventor Manlio VINCIGUERRA 7.4630038VARIANTS OF SIRTUIN 6 FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE EP - 15.10.2025 Int.Class A61K 38/43 Appl.No 23821586 Applicant GENFLOW BIOSCIENCES SRL Inventor VINCIGUERRA MANLIO The present invention relates to variants of sirtuin 6 for the treatment of non-alcoholic fatty liver disease. Inventor VINCIGUERRA, Manlio The present invention relates to variants of sirtuin 6 for the treatment of non-alcoholic fatty liver disease.",
          "sentiment": 0.5,
          "engagement": "12,501",
          "price_at_post": "2.00",
          "thread_title": "Strong IP patent protection",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=5E67E321-5A6D-408C-BDBD-BA2D17267FFC"
        },
        "ingested_at": "2026-01-21T02:46:11.294362Z"
      },
      {
        "event_id": "SOCIAL-1Nov20251852-Moneymun-50820031",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:33.994600",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "And China!!! :-) 19, September 2025 Genflow Biosciences Plc Genflow Strengthens Global IP Portfolio with China Patent Examination Filing for SIRT6 Variants in NASH Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\"), the only publicly listed longevity company in Europe, today announces that it has filed a formal request for the examination of its patent application entitled SIRT6 Variants for NASH in China. The application covers proprietary variants of the SIRT6 gene designed to address Non-Alcoholic Steatohepatitis (NASH), a severe progressive liver disease with limited treatment options. By pursuing examination in China, Genflow is reinforcing its global intellectual property portfolio and furthering its commitment to developing innovative therapies for patients worldwide. Dr. Eric Leire, CEO of Genflow, commented: \"The filing of this examination request in China represents another significant step in protecting our technology in one of the world's largest healthcare markets. We are committed to advancing our research into SIRT6-based therapies and believe that our approach holds strong potential to transform the treatment landscape for NASH.\"",
          "sentiment": 0.5,
          "engagement": "12,501",
          "price_at_post": "2.00",
          "thread_title": "RE: Strong IP patent protection",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=5E67E321-5A6D-408C-BDBD-BA2D17267FFC"
        },
        "ingested_at": "2026-01-21T02:46:11.294336Z"
      },
      {
        "event_id": "SOCIAL-4Nov20250732-Porter_-30612852",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:33.994157",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Eric noted in recent interviews, his eye programme showed regeneration in damaged eye cells. Could Genflow\u2019s science be the total gene therapy solution for Covid vaccinations through mRNA dna repair? If so, imagine how much big pharma like Pfizer and Astra Zeneca would pay to get their hands on the science, to mitigate their exposure to future lawsuits\u2026 https://www.express.co.uk/life-style/health/2084273/scientists-fizer-covid-jab-eye-damage/amp",
          "sentiment": 0.5,
          "engagement": "1,314",
          "price_at_post": "2.075",
          "thread_title": "Genflow\u2019s science curing Covid vax damage?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=D17BCB4C-1525-487C-84DB-E1D41C64EFEB"
        },
        "ingested_at": "2026-01-21T02:46:11.294310Z"
      },
      {
        "event_id": "SOCIAL-5Nov20251525-jamtart1-52839121",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:33.993712",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Come on hurry up /",
          "sentiment": 0.5,
          "engagement": "1,594",
          "price_at_post": "2.075",
          "thread_title": "News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=97D4BC70-985F-41A5-80B5-E1A493D239EE"
        },
        "ingested_at": "2026-01-21T02:46:11.294284Z"
      },
      {
        "event_id": "SOCIAL-6Nov20250821-Moneymun-37636244",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:33.993235",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "All good things....although hoping receipt confirmation of a tranche of the outstanding \u20ac4.7m non-dilutive grant money would be fast approaching, unless it's not needed now, if a mega lucrative JV licensing deal with Major Pharma is on its way!!!??? Gla holders....multiple material newsflow in the pipeline and potential transformational game changing news at anytime!!! ;-)",
          "sentiment": 0.5,
          "engagement": "12,501",
          "price_at_post": "2.075",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=97D4BC70-985F-41A5-80B5-E1A493D239EE"
        },
        "ingested_at": "2026-01-21T02:46:11.294258Z"
      },
      {
        "event_id": "SOCIAL-6Nov20251816-Porter_--4862493",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:33.992795",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Now the patents have been acknowledged, it gives a sense of protection to parties interested in a JV or takeover. Ose who Eric is a scientific advisor with have done some big money deals, hopefully Genflow will replicate such success!",
          "sentiment": 0.5,
          "engagement": "1,314",
          "price_at_post": "2.075",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=97D4BC70-985F-41A5-80B5-E1A493D239EE"
        },
        "ingested_at": "2026-01-21T02:46:11.294231Z"
      },
      {
        "event_id": "SOCIAL-10Nov20250755-Porter_--6496500",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:33.992378",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Pfizer lays out $10bn for Metsera. Genflow next? https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-sweetens-offer-metsera-bidding-war-against-novo-bloomberg-news-reports-2025-11-08/",
          "sentiment": 0.5,
          "engagement": "1,314",
          "price_at_post": "2.10",
          "thread_title": "Big Pharma on an acquisition spree",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=911CEBF4-1D7D-4555-A43E-4FD23D8BD5CE"
        },
        "ingested_at": "2026-01-21T02:46:11.294205Z"
      },
      {
        "event_id": "SOCIAL-10Nov20251135-jamtart1-88296776",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:33.991945",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Yes please and more,",
          "sentiment": 0.5,
          "engagement": "1,594",
          "price_at_post": "2.05",
          "thread_title": "Big Pharma on an acquisition spree",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=98DAE5E3-9B48-4A16-9CB0-6D403380AC94"
        },
        "ingested_at": "2026-01-21T02:46:11.294179Z"
      },
      {
        "event_id": "SOCIAL-15Nov20250800-Moneymun--8584631",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:33.991527",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "On Play Store Search Stock Monitor Quote Level 2 Portfolio Toplists News Forums AI More Market Data News Trading Tools Markets Discover \u00f0\u0178\u201d\u00a5 Hot Features Follow Feed Connect with traders and investors in our Follow Feed community. Options Flow Explore comprehensive options data and use advanced filters with Options Flow. Monitor Organize and monitor your stock and asset watchlist with Monitor. Premium Get your Level 2 - 50% Black Friday Discount Upgrade Now GENF EPIC BB Menu Genflow Biosciences (GENF) Follow GENF Genflow Biosciences plc 2022 Search this thread Remove FavouriteE-mail AlertRelated ThreadsSkip Header Manual Dexterity   10 Jul '22 - 13:18 1 0 Charts Long Term Chart News 31/10/2025\t07:00\tRNS Regulatory News\tGenflow Biosciences PLC Total Voting Rights 24/10/2025\t06:00\tRNS Regulatory News\tGenflow Biosciences PLC Holding(s) in Company 22/10/2025\t06:00\tRNS Regulatory News\tGenflow Biosciences PLC Second European Patent Application 20/10/2025\t06:00\tRNS Regulatory News\tGenflow Biosciences PLC Recognition of Patentability of Claims https://genflowbio.com/ 13p to 2p. Will be updating the header. GENF raised \u00a33.4million in January giving leeway to 2 years of funding. **In addition they have SECURED a 3.4million Euro grant reviewed every 6 months. So no funding requirements. Previous 1861 Go ToTop Posts majortomm12 Nov '25 - 09:38 - 1858 of 1861 1 0 Dripping away toward 1p, and still no sign of the elusive grant that seems to exist only in the minds of dreamers. At this point, it\u2019s hard to believe it was ever more than a hopeful RNS to get other funding through. blueblood12 Nov '25 - 12:58 - 1859 of 1861 1 0 It\u2019s 2p thicko do you work for Rachel from A/Cs? moneymunch15 Nov '25 - 07:57 - 1860 of 1861  Edit 0 0 Over 7 months since Genflow signed a Material Transfer Agreement with a leading Ophthamology Company for Sirt6 Gene Therapy for Glaucoma, and so potential game changing news at anytime, given Gene Therapy for eye disease is now an \"emerging iinterest\" for Lilly and other Major Pharma, and recent research on Sirt6 and Glaucoma concludes Sirt6 Gene Therapy could be a game changer for treating the disease. Gla holders ;-) Eli Lilly keeps up ophthalmic gene therapy push with $475m MeiraGTx deal MeiraGTx\u2019s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close in. November 10, 2025 ...... Andrew Adams, Lilly\u2019s group vice-president of molecule discovery, said: \u201cOphthalmology is an emerging area of interest for Lilly. We are excited to partner with MeiraGTx to bring transformative treatments to patients around the world suffering from eye diseases, starting with AAV-AIPL1, which has shown the unprecedented ability to restore vision in children who were born legally blind.\u201d ..... Adams\u2019 statement that o",
          "sentiment": 0.5,
          "engagement": "12,501",
          "price_at_post": "2.00",
          "thread_title": "RE: Big Pharma on an acquisition spree",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=911CEBF4-1D7D-4555-A43E-4FD23D8BD5CE"
        },
        "ingested_at": "2026-01-21T02:46:11.294153Z"
      },
      {
        "event_id": "SOCIAL-15Nov20250801-Moneymun--1264700",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:33.990844",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Oops , please ignore :-(",
          "sentiment": 0.0,
          "engagement": "12,501",
          "price_at_post": "2.00",
          "thread_title": "RE: Big Pharma on an acquisition spree",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=911CEBF4-1D7D-4555-A43E-4FD23D8BD5CE"
        },
        "ingested_at": "2026-01-21T02:46:11.294125Z"
      },
      {
        "event_id": "SOCIAL-15Nov20250802-Moneymun-53715137",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:33.990426",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Over 7 months since Genflow signed a Material Transfer Agreement with a leading Ophthamology Company for Sirt6 Gene Therapy for Glaucoma, and so potential game changing news at anytime, given Gene Therapy for eye disease is now an \"emerging iinterest\" for Lilly and other Major Pharma, and recent research on Sirt6 and Glaucoma concludes Sirt6 Gene Therapy could be a game changer for treating the disease. Gla holders ;-) Eli Lilly keeps up ophthalmic gene therapy push with $475m MeiraGTx deal MeiraGTx\u2019s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close in. November 10, 2025 ...... Andrew Adams, Lilly\u2019s group vice-president of molecule discovery, said: \u201cOphthalmology is an emerging area of interest for Lilly. We are excited to partner with MeiraGTx to bring transformative treatments to patients around the world suffering from eye diseases, starting with AAV-AIPL1, which has shown the unprecedented ability to restore vision in children who were born legally blind.\u201d ..... Adams\u2019 statement that ophthalmology represents an \u201cemerging area of interest\u201d for Lilly is supported by the money the company has recently spent in the area. last month, Lilly outlaid $261.7m to acquire Adverum Biotechnologies, a company developing an intravitreal gene therapy for the treatment of wet age-related macular degeneration (AMD). Combined with the MeiraGTx licensing deal, this means Lilly has spent more than half a billion dollars on gene therapies specifically in development for eye diseases. This is not the only gene therapy area Lilly has targeted in 2025. In April, the big pharma company signed a licensing deal worth up to $1.4bn for Sangamo Therapeutics\u2019 neurology-targeting gene therapy. In addition, Lilly acquired RNA-based gene therapy developer Rznomics in May 2025, and gene editing partner Verve Therapeutics for $1.3bn a month later.",
          "sentiment": 0.5,
          "engagement": "12,501",
          "price_at_post": "2.00",
          "thread_title": "Sirt6 Glaucoma",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=3FF274DA-F9E4-40AD-9CD7-88AC4B26B72D"
        },
        "ingested_at": "2026-01-21T02:46:11.294084Z"
      },
      {
        "event_id": "SOCIAL-15Nov20250804-Moneymun--6825720",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:33.989950",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "10/4/25 Genflow Biosciences Launches New Ophthalmology Development Program Signs MTA with Leading Ophthalmology Company Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\"), the only publicly listed longevity company in Europe, is excited to announce the launch of a new development program in ophthalmology, focused on advancing a novel gene therapy leveraging its proprietary Centenarian SIRT6 (cSIRT6). This therapy will utilize a specially designed non-viral vector engineered for precise delivery of Genflow's SIRT6 to the eye. The therapy is designed to combat ocular problems including several pathologies of the cornea and glaucoma. This initiative is part of Genflow's continued efforts to optimize its gene therapy and proprietary Centenarian SIRT6. As part of this effort, Genflow has signed a Material Transfer Agreement (MTA) with a leading ophthalmology company, to collaborate on the design and development of the eye-targeted cSIRT6 non-viral vector to target ocular diseases. These therapies will leverage Genflow's proprietary SIRT6 Centenarian gene technology, in combination with an advanced vector delivery system. Said Dr. Eric Leire, CEO of Genflow Biosciences: \"We are thrilled to advance our ophthalmology program. The eye, as a closed and accessible compartment, presents an ideal target for gene therapy. More importantly, we believe that SIRT6 holds significant promise to transform the treatment landscape for corneal endothelial disorders and glaucoma.\"",
          "sentiment": 0.0,
          "engagement": "12,501",
          "price_at_post": "2.00",
          "thread_title": "RE: Sirt6 Glaucoma",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=3FF274DA-F9E4-40AD-9CD7-88AC4B26B72D"
        },
        "ingested_at": "2026-01-21T02:46:11.294058Z"
      },
      {
        "event_id": "SOCIAL-15Nov20250806-Moneymun--8891766",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:33.989510",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "This research represents the first comprehensive study of anti-aging mechanism in glaucoma by experiments in multiple mouse models that collectively encompass diverse aspects of glaucomatous pathology. \"Therapeutically targeting Sirt6 offers a promising new avenue for glaucoma treatment, especially for cases that do not respond to traditional treatments aimed at reducing eye pressure,\" said co-senior author Wenbo Zhang, professor at the Department of Ophthalmology and Visual Sciences at UTMB. \"This could be a game-changer in how we approach this disease.\" UTMB Study Identifies an Anti-Aging Protein as Key to Preventing Vision Loss in Glaucoma hTtps://share.google/X0h4m9NIzYyq9oTIA",
          "sentiment": 0.5,
          "engagement": "12,501",
          "price_at_post": "2.00",
          "thread_title": "RE: Sirt6 Glaucoma",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=3FF274DA-F9E4-40AD-9CD7-88AC4B26B72D"
        },
        "ingested_at": "2026-01-21T02:46:11.294031Z"
      },
      {
        "event_id": "SOCIAL-18Nov20251121-Moneymun-81581804",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:33.988972",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Latest compelling research on Sirt6's importance and panacea potential in longevity and disease prevention...all bodes well for Genflow\u2019s strong patent protected cutting edge science...every chance Major Pharma will be doing their due- diligence. Gla holders...game changing news at anytime!!! ;-) Research reveals key protein regulates molecule that slows aging, boosts healing - study The study focused on a protein known for its role in longevity and disease prevention. NOVEMBER 18,2025 The human body has a remarkable ability to protect itself from age-related decline, repair damage, support heart and brain health, and fend off common diseases through systems that keep its internal chemistry in balance. Now, Israeli and American scientists have shed light on how one of these systems works, offering clues for extending healthy, active years later in life. The study focused on a protein known for its role in longevity and disease prevention. Scientists found that it does more than protect against aging: it carefully regulates a molecule called hydrogen sulfide, which supports wound healing, cardiovascular health, and brain function. While hydrogen sulfide levels naturally decline with age, this protein ensures that production remains within an optimal range, high enough to protect cells and tissues but not so high as to become harmful. \u201cThis protein acts like the body\u2019s internal version of calorie restriction,\u201d said Prof. Haim Cohen, director of the Sagol Healthy Human Longevity Center at Bar-Ilan University. \u201cIt protects against age-related diseases and helps maintain the body\u2019s natural balance as we grow older.\" \"It has one foot on the gas and the other on the brake, promoting hydrogen sulfide production when it\u2019s beneficial but keeping it under control to prevent harm.\u201d Cohen led the study with PhD student Noga Touitou, in collaboration with the laboratory of Prof. Rafael de Cabo at the National Institute on Aging in Baltimore, Maryland. The research builds on earlier studies showing that the protein can extend lifespan and shield against multiple age-related conditions. Until now, however, scientists have not fully understood how it achieves these effects. The findings reveal that the key lies in precise regulation of hydrogen sulfide, rather than simply increasing levels, highlighting the importance of balance in healthy aging. \u201cOur findings show one of the body\u2019s natural strategies for staying healthy during aging,\u201d Cohen explained. \u201cBy revealing how this protein controls hydrogen sulfide production, we provide insight into how aging can be slowed and identify possible targets for therapies that help people stay healthier longer.\u201d",
          "sentiment": 0.5,
          "engagement": "12,501",
          "price_at_post": "1.95",
          "thread_title": "RE: Big Pharma on an acquisition spree",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=98DAE5E3-9B48-4A16-9CB0-6D403380AC94"
        },
        "ingested_at": "2026-01-21T02:46:11.294005Z"
      },
      {
        "event_id": "SOCIAL-18Nov20251122-Moneymun-32221950",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:33.988498",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The findings open the door to boosting the body\u2019s natural repair mechanisms. Scientists could design medications that enhance or fine-tune Sirt6 function without relying on strict calorie restriction, which could help prevent or slow age-related diseases such as cancer, diabetes, cardiovascular issues, and frailty. Because Sirt6 precisely regulates hydrogen sulfide (H2S) levels, drugs or interventions could aim to maintain H2S within an optimal range, avoiding the risks of excess or deficiency. This could improve wound healing, heart health, and brain function in older adults. Moreover, H2S levels and Sirt6 activity could become measurable biomarkers to assess biological aging and tailor personalized interventions for age-related conditions. The study was recently published in the peer-reviewed Proceedings of the National Academy of Sciences.",
          "sentiment": 0.5,
          "engagement": "12,501",
          "price_at_post": "1.95",
          "thread_title": "RE: Big Pharma on an acquisition spree",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=98DAE5E3-9B48-4A16-9CB0-6D403380AC94"
        },
        "ingested_at": "2026-01-21T02:46:11.293979Z"
      },
      {
        "event_id": "SOCIAL-21Nov20250801-Dzygit19--6484394",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:33.988032",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dzygit1980",
          "content": "It looks like Mr momblegromble was wright",
          "sentiment": 0.0,
          "engagement": "250",
          "price_at_post": "1.90",
          "thread_title": "RE: Big Pharma on an acquisition spree",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=98DAE5E3-9B48-4A16-9CB0-6D403380AC94"
        },
        "ingested_at": "2026-01-21T02:46:11.293953Z"
      },
      {
        "event_id": "SOCIAL-21Nov20250830-MumbleGr--3942313",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:33.987490",
        "source": "LSE_CHAT",
        "data": {
          "author": "MumbleGrumble",
          "content": "You won\u2019t make any friends here talking like that \ud83d\ude09",
          "sentiment": 0.0,
          "engagement": "82",
          "price_at_post": "1.80",
          "thread_title": "RE: Big Pharma on an acquisition spree",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=98DAE5E3-9B48-4A16-9CB0-6D403380AC94"
        },
        "ingested_at": "2026-01-21T02:46:11.293926Z"
      },
      {
        "event_id": "SOCIAL-21Nov20250834-Dzygit19-69269352",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:33.987061",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dzygit1980",
          "content": "Just stating fact .",
          "sentiment": 0.0,
          "engagement": "250",
          "price_at_post": "1.80",
          "thread_title": "RE: Big Pharma on an acquisition spree",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=98DAE5E3-9B48-4A16-9CB0-6D403380AC94"
        },
        "ingested_at": "2026-01-21T02:46:11.293900Z"
      },
      {
        "event_id": "SOCIAL-21Nov20250914-Moneymun-44263968",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:33.986642",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Lol, we're all friends here, and usually nothing goes UP in  a straight line and if it does, it very often comes back down in a straight line and so the slight retrace is par for the course as we await the next UPdate from Eric and co. There\u2019s plenty of material news that could drop including game changing news on the Dog Trial etc, but the delay in receipt confirmation for a tranche of the outstanding \u20ac4.7m hasn't helped the current performance. Belgium/Wallonia are currently in the process of finalising their Budget for the year ahead which has been delayed for multiple reasons, coalition Govt. and a rather large deficit, but the Prime Minister has stated the budget will be approved/ in place by Christmas. Genflow's reaffirmation in July, that the \u20ac4m grant is awaiting sign off , hopefully means that payment will be made just soon the budget is sorted and as Wallonia/BioWin since September 2025 are still encouraging applicants for non-dilutive grant funding, Genflow's \u20ac4m award should be well ahead in the process. Gla holders, multiple potential material newsflow in the pipeline. ;-)",
          "sentiment": 0.5,
          "engagement": "12,501",
          "price_at_post": "1.80",
          "thread_title": "RE: Big Pharma on an acquisition spree",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=98DAE5E3-9B48-4A16-9CB0-6D403380AC94"
        },
        "ingested_at": "2026-01-21T02:46:11.293873Z"
      },
      {
        "event_id": "SOCIAL-21Nov20250916-Moneymun--5064651",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:33.986214",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "10th September 2025 BioWin launches call 47 for collaborative health innovation projects - BioWin https://share.google/IFsaHzM2cBANxtdfq",
          "sentiment": 0.0,
          "engagement": "12,501",
          "price_at_post": "1.80",
          "thread_title": "RE: Big Pharma on an acquisition spree",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=98DAE5E3-9B48-4A16-9CB0-6D403380AC94"
        },
        "ingested_at": "2026-01-21T02:46:11.293847Z"
      },
      {
        "event_id": "SOCIAL-21Nov20251027-Dzygit19--6208194",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:33.985745",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dzygit1980",
          "content": "It looks to me like same person is selling 500k first thing in the morning every second day.  Hopefully he is done now .",
          "sentiment": 0.0,
          "engagement": "250",
          "price_at_post": "1.80",
          "thread_title": "RE: Big Pharma on an acquisition spree",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=98DAE5E3-9B48-4A16-9CB0-6D403380AC94"
        },
        "ingested_at": "2026-01-21T02:46:11.293821Z"
      },
      {
        "event_id": "SOCIAL-24Nov20250709-Moneymun--6567081",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:29.360213",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Finally, great news for Genflow!!! All budgets have been in limbo for months, and no doubt the reason for the delay in payment of the outstanding \u20ac4.7m non-dilutive grant funding. Gla holders....Game changing news at anytime!!! :-) 24th November 2025 Reuters Belgian government reaches budget deal after months of talks (Reuters) -The Belgian government on Monday reached \u200ban agreement on its budget \u200cfor next year after months of tense negotiations,\u200c broadcaster VRT reported citing Prime Minister Bart De Wever. De Wever earlier this month set a Christmas deadline \u2060for his \u200cbickering five-party coalition to reach a deal, after \u200dthey continued to disagree on how to repair government finances. Agreement was reached during \u200bmarathon talks that started on Sunday \u200cmorning and went until early on Monday.",
          "sentiment": 0.5,
          "engagement": "12,501",
          "price_at_post": "1.80",
          "thread_title": "Great news for Genflow!!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=AAA4B7CB-42D4-4FB1-87E5-C32BB97C266B"
        },
        "ingested_at": "2026-01-21T02:46:11.293794Z"
      },
      {
        "event_id": "SOCIAL-24Nov20251125-VikR-83442559",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:29.359745",
        "source": "LSE_CHAT",
        "data": {
          "author": "VikR",
          "content": "7k top up done at 1.78p, excellent buy at these levels",
          "sentiment": 0.5,
          "engagement": "882",
          "price_at_post": "1.80",
          "thread_title": "RE: Great news for Genflow!!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=AAA4B7CB-42D4-4FB1-87E5-C32BB97C266B"
        },
        "ingested_at": "2026-01-21T02:46:11.293768Z"
      },
      {
        "event_id": "SOCIAL-24Nov20251244-VikR--3093680",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:29.359276",
        "source": "LSE_CHAT",
        "data": {
          "author": "VikR",
          "content": "My Buy now showing as an unknown at 11:24am for 389k shares",
          "sentiment": 0.5,
          "engagement": "882",
          "price_at_post": "1.80",
          "thread_title": "RE: Great news for Genflow!!!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=AAA4B7CB-42D4-4FB1-87E5-C32BB97C266B"
        },
        "ingested_at": "2026-01-21T02:46:11.293742Z"
      },
      {
        "event_id": "SOCIAL-24Nov20251658-jamtart1-76031651",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:29.358836",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Just think, why would they apply for patients if it didn't work? Nobody applies for a  patient for something that doesn't work.",
          "sentiment": 0.5,
          "engagement": "1,594",
          "price_at_post": "1.70",
          "thread_title": "Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=F3C8443F-3220-4B2E-A46C-C25DB028889C"
        },
        "ingested_at": "2026-01-21T02:46:11.293715Z"
      },
      {
        "event_id": "SOCIAL-24Nov20251701-jamtart1-57296564",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:29.358335",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Sorry should be patent not patient, my error.",
          "sentiment": 0.0,
          "engagement": "1,594",
          "price_at_post": "1.70",
          "thread_title": "Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=82801565-5503-4F22-AB17-FD87A6DBD7F5"
        },
        "ingested_at": "2026-01-21T02:46:11.293689Z"
      },
      {
        "event_id": "SOCIAL-25Nov20250851-VikR-59382810",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:29.357855",
        "source": "LSE_CHAT",
        "data": {
          "author": "VikR",
          "content": "Landing anytime Non dilutive funding to accelerate all operations Multiple news flow items due imminently",
          "sentiment": 0.5,
          "engagement": "882",
          "price_at_post": "1.55",
          "thread_title": "\u20ac4.7m non-dilutive grant funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=D5EEB2DA-F9CE-4EE4-B989-384B1545506A"
        },
        "ingested_at": "2026-01-21T02:46:11.293663Z"
      },
      {
        "event_id": "SOCIAL-25Nov20251041-Sammy57-12655251",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:29.357434",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sammy57",
          "content": "There's some lumpy trades going on this morning, maybe life returning to our comatose patient. Think I might start the loading process properly now. Let's see what happens. Good luck to all investors",
          "sentiment": 0.5,
          "engagement": "78",
          "price_at_post": "1.65",
          "thread_title": "Lumpy trades",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=DE22B283-2B76-4175-965A-F9DC667C4522"
        },
        "ingested_at": "2026-01-21T02:46:11.293637Z"
      },
      {
        "event_id": "SOCIAL-26Nov20251837-Moneymun-52748558",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:29.357014",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "A nice 1.4m buy at 1.74p, late reported from yesterday just popped UP!!! Gla holders, they want your shares...Game changing news at anytime!!! :-)",
          "sentiment": 0.5,
          "engagement": "12,501",
          "price_at_post": "1.625",
          "thread_title": "RE: Lumpy trades",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=DE22B283-2B76-4175-965A-F9DC667C4522"
        },
        "ingested_at": "2026-01-21T02:46:11.293610Z"
      },
      {
        "event_id": "SOCIAL-28Nov20251107-VikR-34180723",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:29.356604",
        "source": "LSE_CHAT",
        "data": {
          "author": "VikR",
          "content": "Strong buy for me and hold glad I topped up a few days ago Game changing news imminent",
          "sentiment": 0.5,
          "engagement": "882",
          "price_at_post": "1.60",
          "thread_title": "Nice tick up what\u2019s happening",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=C40805F6-1186-4847-BD33-CFB89B5096D0"
        },
        "ingested_at": "2026-01-21T02:46:11.293583Z"
      },
      {
        "event_id": "SOCIAL-28Nov20251203-Moneymun-33170820",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:29.356185",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Get UP there!!! ...Gla holders, they want your shares, Game changing news at anytime!!! On and UP!!! Ho ho ho :-)",
          "sentiment": 0.5,
          "engagement": "12,501",
          "price_at_post": "1.85",
          "thread_title": "RE: Nice tick up what\u2019s happening",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=C40805F6-1186-4847-BD33-CFB89B5096D0"
        },
        "ingested_at": "2026-01-21T02:46:11.293557Z"
      },
      {
        "event_id": "SOCIAL-2Dec20251131-Moneymun-18258698",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:29.355744",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The calm before the storm??? A could of nice big buys 1.1m and 1.4m posted after hours yesterday, late reported from Friday's action with some chunky buys. The smart Money is obviously still accumulating for bigger and better things to come. Multiple potential material newsflow in the pipeline to add significant value!!! Gla holders:-)",
          "sentiment": 0.5,
          "engagement": "12,501",
          "price_at_post": "1.775",
          "thread_title": "RE: Nice tick up what\u2019s happening",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=C40805F6-1186-4847-BD33-CFB89B5096D0"
        },
        "ingested_at": "2026-01-21T02:46:11.293530Z"
      },
      {
        "event_id": "SOCIAL-2Dec20251137-Moneymun-34379998",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:29.355321",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Pharma M&A Deals Surge to USD 82.6 Billion in Q2 2025 as Big Pharma Accelerates Acquisitions in Oncology, Rare Diseases & AI-Driven Drug Discovery 12-01-2025 Sub-Headline: Global pharmaceutical M&A deal value increased from USD 64.2 billion in Q2 2024 to USD 82.6 billion in Q2 2025, reflecting a strong 28.6% YoY growth, driven by strategic acquisitions in oncology, gene therapy, immunology, and AI-enabled drug development platforms. Introduction The M&A Trends in Pharma - Q2 2025 Market analysis reveals a high-momentum quarter, with pharmaceutical giants aggressively acquiring biotech innovators to strengthen clinical pipelines, expand therapeutic portfolios, and accelerate time-to-market for breakthrough therapies. Key areas driving acquisition interest include: \u2022 Oncology (ADC, IO, CAR-T, radiopharmaceuticals) \u2022 Rare diseases & orphan drugs \u2022 Gene therapy & RNA therapeutics \u2022 AI drug discovery platforms \u2022 Immunology & autoimmune diseases \u2022 Digital-biotech & clinical trial technology The return of high-value deals signals Big Pharma's need to offset patent cliffs and increase long-term revenue stability. The global pharma industry entered 2025 with renewed investment strength as companies pursue pipeline diversification and innovation-led acquisitions. \"The pharma M&A landscape in Q2 2025 confirms a decisive shift toward oncology leadership, gene therapy, and AI-first drug discovery models. Big Pharma is aggressively pursuing acquisitions that offer long-term clinical and commercial durability.\" The pharma M&A market in Q2 2025 is experiencing exceptional momentum, driven by oncology breakthroughs, high-value gene therapy assets, and AI-driven early-stage platforms. Companies investing in transformative, multi-modal biopharma technologies will lead next-generation therapeutic markets through 2030.",
          "sentiment": 0.0,
          "engagement": "12,501",
          "price_at_post": "1.775",
          "thread_title": "RE: Nice tick up what\u2019s happening",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=C40805F6-1186-4847-BD33-CFB89B5096D0"
        },
        "ingested_at": "2026-01-21T02:46:11.293504Z"
      },
      {
        "event_id": "SOCIAL-4Dec20250839-VikR--5908005",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:29.354661",
        "source": "LSE_CHAT",
        "data": {
          "author": "VikR",
          "content": "Good time sub 2p for holders to get in. Will try and push some more profits into here from other shares. This is going to re rate big on next milestones. CDAs already signed with multiple animal health companies and safety profile of life prolonging med established. Other catalysts in the portfolio also operating in a very underserved niche area of human disease pathology. To top it all off grant funding also to land",
          "sentiment": 0.5,
          "engagement": "882",
          "price_at_post": "1.85",
          "thread_title": "When this moves it moves quick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=97129C09-D9CE-455A-9DCD-2669912F7D18"
        },
        "ingested_at": "2026-01-21T02:46:11.293478Z"
      },
      {
        "event_id": "SOCIAL-5Dec20250915-Moneymun-21504146",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:29.354248",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Looks like sub 2p is gone, UPward momentum in anticipation of  multiple potential material newsflow, some of which could be game changing. Gla holders....Excitement building....On and UP!!! :-)",
          "sentiment": 0.5,
          "engagement": "12,501",
          "price_at_post": "1.90",
          "thread_title": "RE: When this moves it moves quick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=97129C09-D9CE-455A-9DCD-2669912F7D18"
        },
        "ingested_at": "2026-01-21T02:46:11.293452Z"
      },
      {
        "event_id": "SOCIAL-5Dec20250959-Roosters-51411293",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:29.353827",
        "source": "LSE_CHAT",
        "data": {
          "author": "Roostersmillions",
          "content": "Yes, nice move upwards today, and looking at the trades, it doesn't seem to be volume thats doing it. Are there rumours? Early Xmas present of the grant money? Early confirmation of dog trials. Could we be millionaires by next Christmas.",
          "sentiment": 0.0,
          "engagement": "286",
          "price_at_post": "2.00",
          "thread_title": "RE: When this moves it moves quick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=97129C09-D9CE-455A-9DCD-2669912F7D18"
        },
        "ingested_at": "2026-01-21T02:46:11.293425Z"
      },
      {
        "event_id": "SOCIAL-8Dec20250659-Porter_--5860665",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:29.353403",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Plenty potential news for us to get moving with Rooster: * Grant funds received backed by the European Union * Exclusively licensed Rochester patent getting full approval as now at year 5 * Dog trial data being released * Companies under CDA / NDA making formal offers *Progression of NASH programme (competitor recently bought for $5bn) * Progression of Sarcopenia programme * Progression of eye regeneration programme (competitor recently bought for $3.5bn) * Further programmes being announced * Further patents for gene / compound variants being announced * TR1 updates * More insiders taking / increasing positions * Further pharma companies showing interest in Genflow\u2019s research * Directors guest speaking at further conferences and big pharma events, like the Belgian embassy Walloni\u00eb scientific event last month All while the float continues to be snaffled up strategically by long term loyal investors \ud83e\udd70",
          "sentiment": 0.5,
          "engagement": "1,314",
          "price_at_post": "2.05",
          "thread_title": "RE: When this moves it moves quick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=97129C09-D9CE-455A-9DCD-2669912F7D18"
        },
        "ingested_at": "2026-01-21T02:46:11.293399Z"
      },
      {
        "event_id": "SOCIAL-8Dec20250857-Roosters--4595648",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:29.352918",
        "source": "LSE_CHAT",
        "data": {
          "author": "Roostersmillions",
          "content": "Exciting times porter. Still no idea why this isnt at a higher value, when you look at similar companies valued in 100s of millions.",
          "sentiment": 0.0,
          "engagement": "286",
          "price_at_post": "2.00",
          "thread_title": "RE: When this moves it moves quick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=97129C09-D9CE-455A-9DCD-2669912F7D18"
        },
        "ingested_at": "2026-01-21T02:46:11.293372Z"
      },
      {
        "event_id": "SOCIAL-8Dec20251122-MumbleGr--4202376",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:29.352496",
        "source": "LSE_CHAT",
        "data": {
          "author": "MumbleGrumble",
          "content": "Just \u00a3280k in cash reserves reported in June 25 must be real low at this point. No news of the grant/advance we\u2019ve been waiting for since Oct 24. Two dilutions this year. I\u2019m still optimistic for the long term future and still holding but I\u2019ve changed my stance on starting to buy back in at 1.5 - 1.6 simply because with no grant news, I fear further dilution.",
          "sentiment": 0.0,
          "engagement": "82",
          "price_at_post": "2.00",
          "thread_title": "RE: When this moves it moves quick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=97129C09-D9CE-455A-9DCD-2669912F7D18"
        },
        "ingested_at": "2026-01-21T02:46:11.293346Z"
      },
      {
        "event_id": "SOCIAL-8Dec20251146-Moneymun-69938739",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:29.352052",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "They recently raised \u00a3440k in October via Eric and a consortium of long term Major Shareholders,  a huge vote in confidence and commitment and I'm sure they wouldn't have parted with their hard earned cash if they didn't believe Genflow were on the brink of something big. The current sp performance certainly suggests the smart Money is accumulating and the free float is getting tighter and tighter, and with multiple potential material newsflow in the pipeline, including receipt confirmation of some of the outstanding \u00a34.7m non-dilutive grant funding, as well as the the eagerly awaited efficacy results from the Dog Trial , where positive results will very likely see a game-changing lucrative licensing deal,  the Genflow's upside potential and prospects look very exciting.  Gla holders...Game changing news at anytime!!! :-) 9/10/25 Dr. Eric Leire, CEO of Genflow, commented: \"We would like to express our sincere gratitude to our historical shareholders for their continued confidence and commitment to Genflow\u2019s vision. Their ongoing support reflects a shared belief in our mission. With this additional capital, Genflow is able to deliver on our near-term objectives.\"",
          "sentiment": 0.5,
          "engagement": "12,501",
          "price_at_post": "2.00",
          "thread_title": "RE: When this moves it moves quick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=97129C09-D9CE-455A-9DCD-2669912F7D18"
        },
        "ingested_at": "2026-01-21T02:46:11.293319Z"
      },
      {
        "event_id": "SOCIAL-9Dec20251058-DaveTK-16716284",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:29.351554",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Just like yesterday. Games that they play. More buys than sell and drops. Very odd",
          "sentiment": 0.0,
          "engagement": "848",
          "price_at_post": "2.00",
          "thread_title": "MM Games",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2DDB5CD0-5167-4676-A42B-32D3B064D5CF"
        },
        "ingested_at": "2026-01-21T02:46:11.293292Z"
      },
      {
        "event_id": "SOCIAL-9Dec20251137-Moneymun--8740779",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:29.351141",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "It only dropped because of the 50k UT trade at 2.10p posted after hours yesterday, which caused the sp to close blue at 2.10p and then reverts to the correct closing price of 2p , which causes the sp to open in the red the following day. This happens all the time following an after hours UT trade, and in this current example,  makes the chart with the step down from 2.1p to 2p,  look perfectly primed and poised for the next UPward move as the next positive UPdate arrives and/or buying  volumes increase.  Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,501",
          "price_at_post": "2.00",
          "thread_title": "RE: MM Games",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2DDB5CD0-5167-4676-A42B-32D3B064D5CF"
        },
        "ingested_at": "2026-01-21T02:46:11.293266Z"
      },
      {
        "event_id": "SOCIAL-9Dec20251417-VikR-50846595",
        "event_type": "social_post",
        "date": "2026-01-10T05:39:29.350711",
        "source": "LSE_CHAT",
        "data": {
          "author": "VikR",
          "content": "Another day closer to transformational RNSs landing patience is key here but the re rate is coming. Currently blue on my holdings here but not selling a single share until we are in double figures. Quietly confident.",
          "sentiment": 0.5,
          "engagement": "882",
          "price_at_post": "2.00",
          "thread_title": "RE: When this moves it moves quick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=97129C09-D9CE-455A-9DCD-2669912F7D18"
        },
        "ingested_at": "2026-01-21T02:46:11.293239Z"
      },
      {
        "event_id": "SOCIAL-23Jan20261913-Persever--1213807",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.702321",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "These unknowns are off book pre negotiated buys. Sp will remain pinned till.Dog efficacy data. Expected solid data.",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-01-24T02:35:05.718882+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261838-Dzygit19-19282995",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.702759",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dzygit1980",
          "content": "12:45 yesterday was 1.97 to sell small amout . Than yesterday's big trade printed today for 1.81 ,straight after 1.97 To buy share so I am not sure \ud83e\udd14 was 12:45 yesterday tradet  buy  to me it looks like sell. Also we are dropping",
          "sentiment": 0.0,
          "engagement": "255",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-01-24T02:35:05.718908+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261822-Persever-10395758",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.703192",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "Big buys more like it. Do you know trading? \ud83d\ude05",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-01-24T02:35:05.718928+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261753-Dzygit19--6534476",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.703612",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dzygit1980",
          "content": "Lots of big sales last couple of days",
          "sentiment": 0.0,
          "engagement": "255",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-01-24T02:35:05.718947+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261756-Persever--3639987",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.704022",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "I think a massive rerate is coming ? Somethings brewing ?",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "1.90",
          "thread_title": "Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-01-24T02:35:05.718966+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260719-Porter_-13076639",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.704447",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Know a few people who didn\u2019t get their orders filled yesterday. Seems there isn\u2019t much in the free-float so let\u2019s see how tight this coiled spring is!",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-24T02:35:05.718985+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20262217-Twocd2--4053042",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.704869",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "I joined pre IPO, \u00a350 may have been too much of a reach for you\u2026chortle chortle TK Max.. Give Porter a reach around before lights out so that he\u2019ll not be to disappointed with no RNS tomorrow morning\u2026\ud83d\udc4c",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-24T02:35:05.719004+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261352-DaveTK--4449124",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.705301",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "I joined the party pre IPO. TBF they were asking for more than \u00a350 so it may have been too much of a reach for you. Talking about choppers FFS. Don't let you mum read that or she'll take your phone off you and cancel your contract.",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-24T02:35:05.719039+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261342-Twocd2--2470453",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.705721",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "So TK Max joins the party\u2026think you and Porter need to take turns and time to give him a chance to be big spoon for this week. Might give him something else to do rather than practice his typing. Plenty of skin in the game lads\u2026but this is not about who\u2019s chopper is bigger..well maybe for the spooning it does\ud83d\ude01",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-24T02:35:05.719071+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261033-DaveTK--7973489",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.706162",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Always. I'm here and always have been here waiting for news that we have been bought out. It was always the goal from Eric to make this company into something a pharmaceutical would buy a high price. We may not be that far off. Fingers crossed. Thanks",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-24T02:35:05.719089+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261027-Porter_-48091754",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.706587",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Always the ones who sold too soon quick to troll those who held with diamond hands Dave. Expecting this is just the first update of many we\u2019ll be seeing over the next 2 weeks. Popcorn ready! \ud83c\udf7f",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-24T02:35:05.719124+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261005-DaveTK-76567470",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.707009",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Would seem like you touched  nerve there, Porter ha ha. Nice RNS this morning. Looking forward to hearing more regarding the J.P. Morgan's Healthcare Conference. Really does seem like exciting times ahead. Thanks",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-24T02:35:05.719143+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260839-Twocd2-90081007",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.707434",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "Ok big fella..time for nap your banter is honking.",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-24T02:35:05.719161+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260820-Moneymun--8687283",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.707847",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The new Chairman in place, GAD BERDUGO is a high flyer based in the US with a wealth of experience in Global Biotech, Corporate Development and US Capital Markets and so no doubt very well contected to any potential suitors. Excitement building!!!! In Eric we trust!!! Gla holders:-) Ps initial Efficacy readout on the Dog Trial imminent!!! Gla ;-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-24T02:35:05.719179+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260752-Porter_--3715033",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.708264",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "2cd2 - invest more than \u00a3100 in a company and you might care a little bit more for your investments \ud83d\ude18",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-24T02:35:05.719196+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260734-Twocd2-31069068",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.708668",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "Take the rest of the day off Porter..great job pal! You must have set the alarm early to C&P all of that \ud83d\udc4f\ud83d\udc4f\ud83d\udc4c",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-24T02:35:05.719214+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260718-Porter_-66533821",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.709143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Genflow Appoints a New Chairman to Accelerate Corporate and R&D Expansion Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or the \"Company\"), a leading European-based biotechnology company focusing on gene therapies for age-related diseases, is pleased to announce a significant appointment to its Board of Directors, marking an important step in the Company's strategic evolution. Mr. Gad Berdugo, MSc Eng., MBA, has joined the Board with immediate effect and will assume the role of Independent Non-Executive Chairman, providing leadership as Genflow focuses on advancing its gene-therapy programs. Mrs. Tamara Joseph will continue to serve as a Director, ensuring continuity and maintaining strong governance. Mr. Berdugo brings over 30 years' of leadership experience spanning global business and corporate development, U.S. capital markets, and company building. He has a proven record of driving strategic partnerships, securing capital, and scaling both private and public development-stage biotechnology companies. Currently, Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a U.S.-based strategic and financial advisory firm focusing on the global biotechnology sector. His most recent roles include: \u00b7 Co-Founder & CEO, EpiVax Oncology \u00b7 Vice-Chairman of the Board, Evexta Bio \u00b7 Chief Business Officer, Editas Medicine (NASDAQ: EDIT) \u00b7 Chief Business Officer, Nutcracker Therapeutics He began his international career at Abbott Labs and Baxter, later becoming Life Sciences Sector Leader at Lazard Asset Management. Mr. Berdugo also brings deep technical and market expertise in RNA-based therapeutics, including lipid nanoparticle (LNP) delivery, development, and manufacturing. This background will support Genflow as it advances its scientific platform, evaluates delivery technologies, and explores next-generation therapeutic approaches. His appointment further strengthens the Company's presence in the United States and expands its capacity for global engagement. He does not own any shares in the Company. Dr. Eric Leire, Chief Executive Officer of Genflow, commented: \"We are delighted to welcome Mr. Berdugo as Independent Non-Executive Chairman. His expertise in strategy, partnerships and financing as well as his deep experience with RNA-LNP technologies will be instrumental as we accelerate our programs and expand our global reach. We are equally pleased that Mrs. Tamara Joseph will continue her service on the Board, contributing her invaluable leadership, legal and governance expertise.\" Gad Berdugo added: \"I am excited to join Genflow as the company is progressing to the next new phase of development, with key data readouts expected in 2026, strengthened intellectual property, and a sharpened strategic focus on high-potential programs. I look forward to working with the talented team and board to advance these innovative gene therapies, this is an ideal moment to contribute my expertise and hel",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-24T02:35:05.719232+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20260836-Pie-char-16811702",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.709557",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Post conference announcement next week and Funding news is what I predict. I'm amazed we are at this price. Such a hidden gem!",
          "sentiment": 0.5,
          "engagement": "60",
          "price_at_post": "1.85",
          "thread_title": "RE: JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=3005BF87-EE58-4C27-ABC6-EE6AA15A9385"
        },
        "ingested_at": "2026-01-24T02:35:05.719250+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20260716-Porter_--4404222",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.710022",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Genflow Biosciences is a London-based biotechnology firm and the first \"pure-play\" longevity company listed on the London Stock Exchange. As of early 2026, the company is transitioning from a preclinical phase into active clinical data readouts, focusing on its proprietary SIRT6-based gene therapy platform to extend human and animal \"healthspan\". Core Technology and Pipeline: The company\u2019s lead therapeutic approach involves delivering a \"centenarian variant\" of the SIRT6 gene, identified in individuals who live over 100 years, to improve DNA repair and metabolic health. GF-1002 (Human Therapeutics): MASH (Liver Disease): Repositioned in 2025 to target patients with advanced fibrosis who have limited options from existing GLP-1 therapies. The company is currently finalizing its Investigational New Drug (IND) package and exploring mRNA/LNP delivery to allow for repeat dosing and lower costs. Werner Syndrome: A rare genetic condition causing premature aging. Genflow has developed proprietary human-derived liver organoids to model this disease more accurately than animal models. GF-1004 (Veterinary Program): Canine Longevity: A 12-month blinded clinical trial in aged dogs is currently underway. In early 2026, the company confirmed that all subjects received full dosing with no adverse events reported. Key 2026 Milestones: Initial efficacy readouts focusing on biological age (via methylation clocks) are expected in Q1 2026, with a second evaluation planned for June-July 2026. Expansion Programs: Glaucoma: A new ophthalmology program targeting neuroprotection of retinal ganglion cells to prevent blindness. Sarcopenia (GF-1005): Research into muscle health and mitochondrial dysfunction in collaboration with the Universit\u00e9 libre de Bruxelles. 2026 Strategic Focus: Genflow\u2019s 2026 strategy emphasizes \"rationalization of the pipeline,\" prioritizing programs with the strongest data to secure non-dilutive funding through licensing deals and partnerships. The company is actively seeking animal health partners for its dog longevity program and strategic collaborators for its LNP-based mRNA therapeutics.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "GLP, LNP, MRNA and SIRT6 based therapeutics",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=FB89DB69-F93B-4BB3-8529-5206EECDF243"
        },
        "ingested_at": "2026-01-24T02:35:05.719268+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20262119-jamtart1-55671786",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.710444",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Yes, Genflow Biosciences (Genflow) has had significant interest at the J.P. Morgan Healthcare Conference, attending specifically to engage with potential partners, institutional investors, and pharmaceutical companies. Their CEO, Dr. Eric Leire, attended the most recent conference in January 2026 with a \"full appointments book\" to discuss strategic partnerships and non-dilutive funding opportunities.",
          "sentiment": 0.5,
          "engagement": "1,600",
          "price_at_post": "1.85",
          "thread_title": "JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=3005BF87-EE58-4C27-ABC6-EE6AA15A9385"
        },
        "ingested_at": "2026-01-24T02:35:05.719286+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260634-Porter_--1932519",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.710912",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Companies attend the J.P. Morgan Healthcare Conference (JPM) primarily for networking, securing funding, forging strategic partnerships, and announcing key business updates. This major event, often described as setting the industry's tone for the year, concentrates a year's worth of meetings into a few days. Key reasons why companies attend include: Investment and Funding: The conference is a premier venue for companies to present their strategies and financial outlooks to a high-level audience of investors, analysts, and venture capitalists. For many, especially smaller or emerging biotech firms, it is a critical opportunity to secure financing, gauge investor interest, and build essential relationships. Mergers and Acquisitions (M&A) and Partnerships: The event is a hotbed for dealmaking. Big pharmaceutical companies often attend to scout for smaller companies with promising drug pipelines or innovative technologies (like AI in drug discovery) to acquire, especially as their own blockbuster drugs approach patent expiration. Extensive one-on-one meetings facilitate these discussions and collaborations. Strategic Positioning and Visibility: Companies announce major news, clinical trial data, or year-end recaps just before or during the conference to capture attention and elevate their visibility above the competition. It allows them to articulate their unique value proposition and strategic priorities to the global market. Market Intelligence: Attending allows companies to take the pulse of the industry, understand the latest trends (e.g., AI, gene therapy, obesity drugs), and gather competitive intelligence. They can assess how investors and peers discuss valuations, regulatory pathways, and market potential, which helps in fine-tuning their own strategies for the year ahead. Networking Efficiency: The conference brings the entire healthcare and life sciences ecosystem\u2014from manufacturers and providers to regulators and service providers\u2014into a concentrated location for a short time. This high density of key decision-makers allows for efficient, high-value networking and relationship building that would otherwise take months of travel and outreach.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=4C9A5731-DC78-4F24-8CE9-513E080FCFAC"
        },
        "ingested_at": "2026-01-24T02:35:05.719304+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261946-jamtart1-21053542",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.711334",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Doubt it, but happy if rumours are true",
          "sentiment": 0.5,
          "engagement": "1,600",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan, news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=559FB93D-C9CD-4A83-84E9-7B26CC6976E9"
        },
        "ingested_at": "2026-01-24T02:35:05.719322+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261844-JediMast-82917966",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.711742",
        "source": "LSE_CHAT",
        "data": {
          "author": "JediMaster1",
          "content": "Rumours of investment banks wanting to buy in from the JP Morgan Conference. The only question now is who do they want to buy in on behalf of?? The next few days will be interesting. Will Eric spill the beans?",
          "sentiment": 0.5,
          "engagement": "169",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D010A135-964B-4034-9025-65BCB0334809"
        },
        "ingested_at": "2026-01-24T02:35:05.719340+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261006-Moneymun-84937535",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.712184",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "GKOS: Strong innovation and new therapies drive growth, with robust financials and expanding markets Jan 14, 2026, GKOS The event highlighted robust innovation in ophthalmology, with strong R&D investment yielding a broad product pipeline and record financial performance. Key growth drivers include new glaucoma and keratoconus therapies, strategic market expansion, and a focus on operational leverage and profitability. Based on Glaukos Corporation [GKOS] 44th Annual J.P. Morgan Healthcare Conference Audio Transcript \u2014 Jan. 14 2026",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.10",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-24T02:35:05.719358+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260827-Moneymun-50840528",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.712592",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Every chance Rooster, although I'm hoping for a transformational lucrative commercial licensing deal on one or more of the programs, Dog , Glaucoma and Mash. Excitement building!!! Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.05",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-24T02:35:05.719376+00:00"
      },
      {
        "event_id": "RNS-28th Jan 2026-administ",
        "event_type": "rns_announcement",
        "date": "2026-01-29T12:24:06.050577+00:00",
        "source": "LSE_RNS",
        "data": {
          "title": "Administrative Approval of Grant & 2026 Priorities",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/administrative-approval-of-grant-2026-priorities-8r1ddpftl05urik.html",
          "rns_number": "RNS Number : 5966Q",
          "full_content": "28 Jan 2026 07:00\nRNS Number : 5966Q\nGenflow Biosciences PLC\n28 January 2026\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\nGenflow Biosciences Plc\nAdministrative Approval of \u20ac4 Million Funding Support from Wallonia Region for GF-100; and 2026 Development Priorities\nGenflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) (\"Genflow\" or the \"Company\"), a European-based biotechnology company focused on the development of gene therapies for age-related diseases, announces the administrative approval of the previously announced award of approximately \u20ac4 million in non-dilutive financial support from the Wallonia Region of Belgium, following the assenting signature of Minister Adrien Dolimont.\nThe funding, once received, will support the continued development of the Company's lead gene therapy candidate, GF-1002, for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (\"MASH\"). The original RNS announcing the award can be found\nhere\n.\nDisbursement of the first instalment is expected no later than May 2026. The support package spans a three-year development programme and is aligned with Genflow's existing roadmap. All project-related expenses incurred during 2025 will be eligible under the terms of the programme.\nDevelopment Priorities for 2026\nIn 2026 Genflow's strategy emphasises pipeline discipline and capital efficiency, prioritising programmes with the strongest data, the clearest paths to value creation, and the highest potential for partner engagement. Central to this approach is the pursuit of early-stage collaboration agreements designed to secure non-dilutive funding, provide external validation of the platform, and support continued development.\nWith multiple anticipated data readouts, an expanding partner dialogue, and a maturing intellectual property position, Genflow believes it is well positioned to enter its next phase of development while maintaining a focus on scientific rigour, operational execution, and long-term shareholder value creation.\nDog Aging (GF-1004)\nThe ongoing GF-1004 dog aging study, which commenced in March 2025, is being conducted as a blinded clinical trial designed to assess potential benefits related to sarcopenia, healthspan, and lifespan-associated biomarkers.\nAn initial efficacy readout is expected in the first quarter of 2026. Dogs enrolled in the study are being monitored over a 180-day period, with a second efficacy assessment planned at the six-month timepoint. Results from this later evaluation are expected in June-July 2026 and are intended to assess durability and longer-term effects.\nGlaucoma Programme\nThe Company's glaucoma programme will prioritise delivery optimisation and execution readiness. Genflow is advancing discussions with a leading lipid nanoparticle (LNP) partner to support delivery innovation and is progressing the selection of a full-service contract research organisation (CRO) to manage RNA-based formulation activities through preclinical execution.\nAdditional Programmes\nAcross the broader pipeline, Genflow continues to advance its sarcopenia programme in line with established development plans. In parallel, the ExoFastTrack initiative continues to generate data intended to support and accelerate multiple programmes across the portfolio.\nDr. Eric Leire, CEO of Genflow, commented: \"The administrative approval of this funding reinforces our ability to execute against our 2026 development priorities with discipline and focus. It strengthens our capacity to advance GF-1002 while maintaining a selective, data-driven approach across the broader pipeline. As we enter the coming year, our emphasis remains on programmes with clear execution paths, strong scientific rationale, and meaningful opportunities for partnership and non-dilutive value creation.\"\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies for age-related diseases, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other pro",
          "content_length": 9342
        },
        "ingested_at": "2026-01-29T12:24:06.050623+00:00"
      },
      {
        "event_id": "SOCIAL-Today1106-Moneymun--5897582",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.448266",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "No guarantees, but there lies the transformational UPside opportunity from this lowly bargain low. \"it worked like magic in mice, and we reasonably expect to work likewise in dogs\".....the first Efficacy Data readout is imminent, and judging by Eric's latest interview, he sounded very confident and bullish on a commercial licensing deal with an Animal Healthcare company ( we have two that have both signed Confidential Disclosure Agreements)  whereby any deal would provide non-dilutive cash  into the company, and Eric made a compelling point, that any non-dilutive cash would be much more than the \u20ac4m non-dilutive grant money confirmed yesterday, with the first tranche payment by May at the latest,  and so watch this space, potential game changing news fast approaching.  Gla holders ;-) Ps it was huge relief to have confirmation the \u20ac4m non-dilutive grant has been signed off, as Genflow were running  low on funds, and given the length of time we've waited for approval and the huge deficit turmoil the Belgium/Wallonia Govt. have been under, I had almost written it off, and so great news that Genflow will have no funding concerns for the foreseeable, and no doubt the \u20ac4m gives them much more leverage in any licensing deal discussions from a position of strength.  Transformational and near term game changing potential and prospects for those invested.  Excitement building!!!! :-)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-01-29T12:24:16.872120+00:00"
      },
      {
        "event_id": "SOCIAL-Today1052-Pie-char--6768526",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.448833",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Mice*",
          "sentiment": 0.0,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-01-29T12:24:16.872166+00:00"
      },
      {
        "event_id": "SOCIAL-Today1046-Pie-char--1942997",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.449387",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "So far all signs are good. Nice results were good. They also have more than just this programme. Dogs is just one of many.",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-01-29T12:24:16.872201+00:00"
      },
      {
        "event_id": "SOCIAL-Today1031-mikee_p-25078221",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.449902",
        "source": "LSE_CHAT",
        "data": {
          "author": "mikee_p",
          "content": "Is it low? This is still a risky punt. Dog trials may fail.",
          "sentiment": 0.0,
          "engagement": "1,895",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-01-29T12:24:16.872238+00:00"
      },
      {
        "event_id": "SOCIAL-Today0853-Pie-char--2870889",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.450425",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Everyone needs to listen to the last 20 seconds of this video. If that\u2019s not bullish I don\u2019t know what is. https://www.proactiveinvestors.co.uk/companies/news/1086390/genflow-ceo-outlines-2026-priorities-as-4-million-grant-is-approved-1086390.html",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F1CBD71F-0291-4489-9B39-85877DA36B7E"
        },
        "ingested_at": "2026-01-29T12:24:16.872270+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261858-jamtart1--8928370",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.450933",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Https://www.tipranks.com/stocks/gb:genf",
          "sentiment": 0.5,
          "engagement": "1,604",
          "price_at_post": "1.90",
          "thread_title": "Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F1CBD71F-0291-4489-9B39-85877DA36B7E"
        },
        "ingested_at": "2026-01-29T12:24:16.872304+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261734-Roosters--8612372",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.451451",
        "source": "LSE_CHAT",
        "data": {
          "author": "Roostersmillions",
          "content": "Thats got to be a misprint. Target of \u00a32 for a 2p share. That would be a buy not a hold. Also when you open the analysts section, they have hold at 2p.",
          "sentiment": 0.5,
          "engagement": "291",
          "price_at_post": "1.90",
          "thread_title": "RE: Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=A70A365B-ED0A-4D60-9FAF-1051143160CA"
        },
        "ingested_at": "2026-01-29T12:24:16.872337+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261723-jamtart1--4200668",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.451956",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Https://www.tipranks.com/news/company-announcements/genflow-secures-e4m-wallonia-funding-and-sets-2026-gene-therapy-priorities#google_vignette Note the \u00a32 price target.",
          "sentiment": 0.5,
          "engagement": "1,604",
          "price_at_post": "1.90",
          "thread_title": "Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=A70A365B-ED0A-4D60-9FAF-1051143160CA"
        },
        "ingested_at": "2026-01-29T12:24:16.872375+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261232-VikR-64437392",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.452496",
        "source": "LSE_CHAT",
        "data": {
          "author": "VikR",
          "content": "I remember just recently when this moved from 0.6p to 2p in the blink of any eyelid. It is a such compelling buy but seems to be off the radar for many investors who don\u2019t understand the opportunity on offer here. This is by far a very confident load and hold Market cap is EXTREMELY low for what\u2019s coming around the corner.",
          "sentiment": 0.5,
          "engagement": "983",
          "price_at_post": "1.90",
          "thread_title": "MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-01-29T12:24:16.872413+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261145-Moneymun--9079771",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.453330",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Another great interview by Eric on today's news....2026 will be a year of Data and Partnerships, and when making references to the Dog Trial, Eric stated that any partnership would bring in non-dilutive cash to the company, \"and whe talking about non-dilutive cash, I'm not talking about the \u20ac4m non-dilutive grant confirmed today, I'm taking about much more\" !!!! Gla holders, all bodes well, exciting times ahead!!! Initial Efficacy Data from the Dog Trial imminent and every chance of a very lucrative commercial licensing deal to follow!!! :-) Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company\u2019s strategic progress and outlook for 2026, following a \u20ac4 million non-dilutive grant awarded by the Wallonia region. Dr Leire explained that the secured funding is part of Genflow\u2019s broader capital efficiency strategy, helping the company focus on key pipeline catalysts, including its lead gene therapy, GF-1002. GF-1002 is targeted at MASH (Metabolic dysfunction-associated steatohepatitis), a field Dr Leire described as \u201ca huge unmet need,\u201d particularly at the late stage where there are currently no therapeutic options. \u201cThis is one of the key programs for 2026,\u201d he said, highlighting that GF-1002 addresses severe liver conditions, including hepatocellular carcinoma. In addition to its gene therapy program, Genflow is advancing a pioneering longevity study in dogs. Leire stated, \u201cA study on aged dogs, naive to therapies, that's blinded, randomised, so with very strong scientific standard will be a first in terms of longevity.\u201d He emphasised the potential for a commercial deal with animal health companies based on this unique dataset. Partnerships and capital efficiency remain central to Genflow\u2019s plans. Leire noted that monetising non-core programs, such as the dog study, can generate significant non-dilutive capital and allow the company to focus on areas where it adds the most value. Genflow CEO outlines 2026 priorities as \u20ac4 million grant is approved | LSE:GENF, OTCQB:GENFF htTps://share.google/bu0pCWldyc59hIftA",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-01-29T12:24:16.872448+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260802-DaveTK-10172160",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.453982",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Simply amazing. Well done team",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "2.00",
          "thread_title": ".",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=40281A21-EA32-4E4F-A04F-0732B5F85F17"
        },
        "ingested_at": "2026-01-29T12:24:16.872486+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260745-Pie-char--6565895",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.454643",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Amazing. Dog results coming soon. Vet partner deal has never had such high probability! This is a good place to be!",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.95",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-01-29T12:24:16.872525+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260710-Moneymun-41446292",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.455431",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "What a brilliant RNS!!!! Gla holders...in Eric we trust!!! On and most definitely UP!!! :-)))",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.95",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-01-29T12:24:16.872553+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260705-Moneymun-34911810",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.455987",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Glaucoma Programme The Company's glaucoma programme will prioritise delivery optimisation and execution readiness. Genflow is advancing discussions with a leading lipid nanoparticle (LNP) partner to support delivery innovation and is progressing the selection of a full-service contract research organisation (CRO) to manage RNA-based formulation activities through preclinical execution. Additional Programmes Across the broader pipeline, Genflow continues to advance its sarcopenia programme in line with established development plans. In parallel, the ExoFastTrack initiative continues to generate data intended to support and accelerate multiple programmes across the portfolio. Dr. Eric Leire, CEO of Genflow, commented: \"The administrative approval of this funding reinforces our ability to execute against our 2026 development priorities with discipline and focus. It strengthens our capacity to advance GF-1002 while maintaining a selective, data-driven approach across the broader pipeline. As we enter the coming year, our emphasis remains on programmes with clear execution paths, strong scientific rationale, and meaningful opportunities for partnership and non-dilutive value creation.\"",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.95",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-01-29T12:24:16.872571+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260704-Moneymun-64713354",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.456597",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Administrative Approval of Grant & 2026 Priorities GENFLOW BIOSCIENCES PLC Released 07:00:09 28 January 2026 RNS Number : 5966Q Genflow Biosciences PLC 28 January 2026 Genflow Biosciences Plc Administrative Approval of \u20ac4 Million Funding Support from Wallonia Region for GF-100; and 2026 Development Priorities Genflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) (\"Genflow\" or the \"Company\"), a European-based biotechnology company focused on the development of gene therapies for age-related diseases, announces the administrative approval of the previously announced award of approximately \u20ac4 million in non-dilutive financial support from the Wallonia Region of Belgium, following the assenting signature of Minister Adrien Dolimont. The funding, once received, will support the continued development of the Company's lead gene therapy candidate, GF-1002, for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (\"MASH\"). The original RNS announcing the award can be found here. Disbursement of the first instalment is expected no later than May 2026. The support package spans a three-year development programme and is aligned with Genflow's existing roadmap. All project-related expenses incurred during 2025 will be eligible under the terms of the programme. Development Priorities for 2026 In 2026 Genflow's strategy emphasises pipeline discipline and capital efficiency, prioritising programmes with the strongest data, the clearest paths to value creation, and the highest potential for partner engagement. Central to this approach is the pursuit of early-stage collaboration agreements designed to secure non-dilutive funding, provide external validation of the platform, and support continued development. With multiple anticipated data readouts, an expanding partner dialogue, and a maturing intellectual property position, Genflow believes it is well positioned to enter its next phase of development while maintaining a focus on scientific rigour, operational execution, and long-term shareholder value creation. Dog Aging (GF-1004) The ongoing GF-1004 dog aging study, which commenced in March 2025, is being conducted as a blinded clinical trial designed to assess potential benefits related to sarcopenia, healthspan, and lifespan-associated biomarkers. An initial efficacy readout is expected in the first quarter of 2026. Dogs enrolled in the study are being monitored over a 180-day period, with a second efficacy assessment planned at the six-month timepoint. Results from this later evaluation are expected in June-July 2026 and are intended to assess durability and longer-term effects. Glaucoma Programme The Company's glaucoma programme will prioritise delivery optimisation and execution readiness. Genflow is advancing discussions with a leading lipid nanoparticle (LNP) partner to support delivery innovation and is progressing the selection of a full-service contract research organisatio",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.95",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-01-29T12:24:16.872588+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260808-Moneymun--2279610",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.457120",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "8/1/26 Leire explained that the dog longevity study is the nearest catalyst, with the trial expected to be unblinded shortly and early efficacy readouts anticipated in the near term. While safety has already been confirmed, the study remains blinded, meaning efficacy results are still unknown. The first data will focus on biological age, measured using a methylation clock, with a more detailed analysis of muscle biopsies and mitochondrial function to follow. According to Leire, \u201cthis trial could be very important for our shareholders, because it will trigger a deal with an animal health company bringing non-dilutive money in the company.\u201d",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.95",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-01-29T12:24:16.872606+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260707-Pie-char--8084473",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.457619",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Dog results are due next week. Vet partner(s) already likely lined up.",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.95",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-01-29T12:24:16.872624+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20262041-Moneymun-39263713",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.458133",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The trial aims to demonstrate proof of concept in dogs, replicating promising results previously seen in mice. \u201cIt worked like magic in mice. We reasonably think that it will work likewise in dogs,\u201d Leire stated. Unlike mice, however, dogs share environmental conditions with humans, making them a more relevant model for translation into human therapies.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-01-29T12:24:16.872643+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260818-Roosters--8665754",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.337719",
        "source": "LSE_CHAT",
        "data": {
          "author": "Roostersmillions",
          "content": "Markets reacting munch. Nice jump this AM. hope it holds. Maybe new private investors from across the pond due to conference exposure??",
          "sentiment": 0.5,
          "engagement": "291",
          "price_at_post": "2.00",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-29T12:24:16.872662+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260815-Moneymun--1520204",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.338198",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Game changing news at anytime. In Eric we trust!!! Gla holders...On and UP!!! :-)))",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "2.00",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-29T12:24:16.872680+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260812-Moneymun-67058582",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.338634",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions Madrigal\u2019s strategy of pursuing combination therapies while the market remains in its infancy could intrinsically link its brand to MASH treatment. Madrigal Pharmaceuticals used its January 12 presentation at the J.P. Morgan Healthcare Conference 2026 to showcase its newly acquired assets from Pfizer \u2013 ervogastat and two preclinical assets \u2013 as well as outline its vision for dominance in metabolic dysfunction-associated steatohepatitis (MASH) treatment space through leveraging early commercial success. Its professed strategy of pursuing combination therapies while the market remains in its infancy could well result in Madrigal\u2019s brand becoming intrinsically linked to MASH treatment. JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions - Pharmaceutical Technology https://share.google/Ymb4cXndGee7eMEbD",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "2.00",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-29T12:24:16.872698+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261725-Steg-68265941",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.339084",
        "source": "LSE_CHAT",
        "data": {
          "author": "Steg",
          "content": "Thought below was interesting, yes they are attending conference and have already made move to add to thier MASH portfolio, courtesy of AI search below Yes, Madrigal Pharmaceuticals is actively looking to expand its MASH (metabolic dysfunction-associated steatohepatitis) portfolio beyond its already approved drug, Rezdiffra (resmetirom). Madrigal's expansion strategy focuses on developing potential combination therapies, as MASH is a complex disease that requires multiple treatment approaches. Key components of their expanded pipeline include: Ervogastat: In January 2026, Madrigal entered into an exclusive global license agreement with Pfizer to acquire ervogastat, a Phase 2 oral DGAT-2 inhibitor. This drug works on a different, complementary pathway to Rezdiffra, and Madrigal plans to conduct studies to test the two treatments in combination. Oral GLP-1 Receptor Agonist: Madrigal also holds worldwide rights to an oral GLP-1 agonist called SYH2086, licensed from CSPC Pharmaceutical, with the goal of creating a best-in-class oral combination therapy. Additional Early-Stage Assets: The agreement with Pfizer for ervogastat also included rights to two other early-stage MASH pipeline assets. Madrigal's CEO, Bill Sibold, has stated that the company is committed to \"building the industry-leading pipeline that will shape the future of MASH care\" and believes combination therapies are the next wave of innovation in the field.",
          "sentiment": 0.0,
          "engagement": "5",
          "price_at_post": "1.90",
          "thread_title": "JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-29T12:24:16.872732+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261231-Moneymun-45031898",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.339515",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Get UP there!!! Gla :-) Eric and his team are now at the prestigious JP Healthcare Conference, pressing flesh with the leading industry deal makers. He appeared confident and enthusiastic in his latest interview, highlighting the prospects and potential of an early lucrative JV deal for the Dog Trial, Glaucoma and Mash and so potential game changing transformational news could drop at anytime. The first efficacy readout on the Dog Trial is imminent, and with two Animal Healthcare companies both with Confidential Disclosure Agreements in place, Eric could be very close to a deal, and the same with Glaucoma, whereby a leading Ophthalmology Company signed a Material Transfer Agreement 10 months ago. Eric also highlighted the prospects of Genflow's Sirt6 Mash Gene Therapy, which is now targeting the later stages of the disease where there's no options apart from transplant, and was very interesting to hear from Eric it could be used in combination with GLP-1's and Madrigal's early stage treatment which was FDA approved 12 months or so ago. Madrigal are presenting at JP Morgan and are on a mission to expand their pipeline for Mash, so watch this space. It's also very interesting we have a new Chairman in place, GAD BERDUGO a high flyer based in the US in Global Biotech, Corporate Development and and US Capital Markets and so no doubt very well contected to any potential suitors. Excitement building!!!! In Eric we trust!!! Gla holders:-)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "2.00",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-29T12:24:16.872759+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260822-Moneymun-22923893",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.339958",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Healthcare companies set for deals spree as drug patents expire A gathering of pharmaceutical executives comes as the sector has rebounded from uncertainty over Trump\u2019s policies Healthcare executives gather for their big annual conference in San Francisco on Monday as the sector is flush with cash and set for a deals spree as patents on drugs worth almost 12 per cent of the industry\u2019s revenues expire in the years ahead. The JPMorgan healthcare conference takes place as uncertainty recedes over President Donald Trump\u2019s trade wars, drug pricing policy and the leadership of key regulators such as the US Food and Drug Administration. In response, the S&P biotech index, known as the XBI, has surged to a four-year high, outperforming the wider index. In addition, drugs that contribute about $180bn of revenue a year are set to go off patent in 2027 and 2028, representing almost 12 per cent of the global market, according to research firm Evaluate Pharma. More than $40bn of sales are expected to lose patent protection this year, Evaluate has estimated. \u201cThe need to take big swings becomes more pressing,\u201d said Jeremy Meilman, head of healthcare investment banking at JPMorgan. \u201cSeveral of the large-cap pharmaceutical companies are shopping around for strong assets and a number have taken action but still have more firepower. This contributes to our optimism for 2026.\u201d hTtps://www.ft.com/content/7b07a9d5-7254-490b-8ce9-ec2633094d8e",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.825",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-29T12:24:16.872800+00:00"
      },
      {
        "event_id": "SOCIAL-11Jan20261442-Moneymun-54065195",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.340418",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Planned meetings presumably with potential suitors at JP Morgan this coming week and so multiple deal opportunities across the platform, and there's currently an M&A and lucrative licensing deal feeding frenzy as Major Pharma replenish their pipelines with the latest cutting-edge science, Excitement building!!! Gla :-) \"2026 will be catalyst year, we've done our work and now it's time for harvesting and are going to JP Morgan next week with a full appointments book, and now ready for potential harvesting of our results to bring in non-dilutive cash into the company.\" A must watch....Gla holders:-) hTtps://www.proactiveinvestors.co.uk/companies/news/1085366/genflow-biosciences-ceo-key-catalysts-for-2026-1085366.html",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.825",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-29T12:24:16.872827+00:00"
      },
      {
        "event_id": "SOCIAL-10Jan20261752-Troajan--6673976",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.836007",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1085424/genflow-is-ready-for-a-year-of-catalysts-icymi-1085424.html",
          "sentiment": 0.0,
          "engagement": "125,652",
          "price_at_post": "1.825",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-29T12:24:16.872846+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20262001-Moneymun--7619965",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.836711",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 10:30 a.m. PT. Investors and other interested parties can access a live audio webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event. About Zoetis As the world\u2019s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide \u2013 from veterinarians and pet owners to livestock producers. The company\u2019s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees. For more information, visit www.zoetis.com.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-29T12:24:16.872865+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261946-Moneymun-38062541",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.837364",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Woof, woof!!!??? ;-) Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference 06 January 2026 INDIANAPOLIS, Jan. 6, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will represent the company and respond to questions from analysts at 3:45 p.m. PST (6:45 PM EST).",
          "sentiment": 0.0,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-29T12:24:16.872890+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261920-Moneymun-88492447",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.837980",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "And/or ???? ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 4:30 p.m. PT in San Francisco, CA.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-29T12:24:16.872928+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261917-Moneymun-20949304",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.838626",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Eye wonder....Gla:-) 23/12/2025 - 12:30 VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders, Executive Vice President and Chief Financial Officer Sam Eldessouky and Chief Medical Officer and Head of Research & Development Yehia Hashad, MD, will participate in a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026, at 1:30 p.m. PT (4:30 p.m. ET) Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-29T12:24:16.872951+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261858-Moneymun--4305203",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.839276",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Another brilliant interview by Eric, \"2026 will be catalyst year, they've done their work and now it's time for harvesting and are going to JP Morgan next week with a full appointments book, and now ready for potential harvesting of their results to bring in non-dilutive funding cash into the company. Excitement building, in Eric we trust!!! Gla ;-) Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company\u2019s key programs and upcoming catalysts as it enters what management expects to be a pivotal year. Leire discussed why 2026 is shaping up as \u201ca year of catalysts\u201d for the company, with particular focus on the dog ageing trial, progress in MASH, and the group\u2019s approach to partnerships and licensing. Leire explained that the dog longevity study is the nearest catalyst, with the trial expected to be unblinded shortly and early efficacy readouts anticipated in the near term. While safety has already been confirmed, the study remains blinded, meaning efficacy results are still unknown. The first data will focus on biological age, measured using a methylation clock, with a more detailed analysis of muscle biopsies and mitochondrial function to follow. According to Leire, \u201cthis trial could be very important for our shareholders, because it will trigger a deal with an animal health company bringing non-dilutive money in the company.\u201d The interview also explored Genflow\u2019s repositioning in MASH toward advanced fibrosis and the prevention of hepatocellular carcinoma. Leire highlighted the significant unmet need in late-stage disease, noting that recent therapies target earlier stages and leave patients with advanced fibrosis facing limited options. He said the company\u2019s preclinical data have been encouraging and form a key part of the IND package, helping differentiate Genflow from existing and emerging treatments. In addition, Leire discussed the company\u2019s licensing strategy, including plans to out-license the dog program to an animal health specialist and pursue early-stage partnerships for glaucoma, while retaining focus on age-related conditions such as sarcopenia. With meetings planned during JPMorgan week, Leire said the company is seeking non-dilutive capital and strategic validation as it moves forward.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-29T12:24:16.872970+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261711-Troajan--2934648",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.839905",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1085366/genflow-biosciences-ceo-key-catalysts-for-2026-1085366.html",
          "sentiment": 0.0,
          "engagement": "125,652",
          "price_at_post": "1.75",
          "thread_title": "Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-29T12:24:16.872990+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261314-Moneymun-68247580",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.840622",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "0 0 Gene therapy biotech Genflow eyes busy year ahead as dog ageing trial nears results Published: 02:40 08 Jan 2026 Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) has wrapped up 2025 with steady progress across a range of gene therapy programmes, including a closely watched trial into dog ageing that could lay the groundwork for future human applications. The London-listed company, which is working on ways to extend healthy lifespan using gene therapy, said it had completed dosing in its lead canine study with no reported side effects. The dogs will now be monitored over six months for signs of improved muscle strength and health-related biomarkers, with initial results expected in the first quarter of this year. The trial, which began in March and uses a therapy based on the SIRT6 gene, a known regulator of ageing and DNA repair, is being conducted in a blinded format. A follow-up analysis is due around mid-year to assess the durability of the effects. Alongside the dog ageing study, Genflow said it had made progress in a programme targeting advanced stages of MASH, or metabolic dysfunction-associated steatohepatitis, a type of fatty liver disease. Existing GLP-1 drugs such as Ozempic and Wegovy have shown benefits in early MASH, but Genflow is aiming at patients with more severe fibrosis, where options remain limited. It is now finalising regulatory paperwork to support a human trial and is exploring the use of mRNA technology, similar to that used in Covid-19 vaccines, as a more flexible and cost-effective delivery method than traditional viral vectors. In a new push into eye disease, the company is also investigating the use of its gene therapy platform in glaucoma. Early lab results suggest that increasing SIRT6 levels may help protect the optic nerve from damage, potentially offering a way to slow or prevent vision loss rather than simply reducing eye pressure, which is the current standard treatment. Genflow said it was in talks with a lipid nanoparticle delivery partner to support this programme and was hiring a specialist contract research firm to help move the candidate towards preclinical testing. Elsewhere in its pipeline, work is ongoing in sarcopenia, the loss of muscle mass that often accompanies ageing, and in a broader initiative called ExoFastTrack, which supports several of its research efforts. Looking to the year ahead, Genflow said it would focus its efforts on the most promising areas of its portfolio and seek early licensing or partnership deals to bring in fresh funds without issuing new shares. \u201cWith multiple upcoming data readouts, an expanding partner network, and a maturing intellectual property position, we believe Genflow is well positioned to enter its next phase of growth,\u201d the company said. The first set of clinical results, particularly from the dog study, will be key in setting the tone for 2026.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-29T12:24:16.873020+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261148-Moneymun--7888701",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.841406",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Nice one David, looking forward to a run of great news from Eric to take the sp to new highs. Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.85",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-29T12:24:16.873051+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-David195--1717243",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.842237",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "Thank you for your informed views.  Added 500k @1.78.  It is hard for companies in this sector to raise funds so hopefully the upcoming changes will make the situation less brutal.  I will add when funds allow.",
          "sentiment": 0.0,
          "engagement": "871",
          "price_at_post": "1.85",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-29T12:24:16.873079+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261005-Moneymun--4581595",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.843028",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Hopefully news on patents soon Porter, the following statement is from yesterday's 2026 Corporate Presentation.  Gl :-) GROWING IP PORTFOLIO WITH LONG LIFE 2 proprietary patent families SIRT6 centenarian (cent SIRT6) and gene delivery (entering National Phase); Additional upcoming patent applications (entering PCT)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-29T12:24:16.873114+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260933-Moneymun-68803496",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.843890",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Bring it on!!! Gla holders:-) \"Central to this strategy will be the pursuit of early-stage licensing and collaboration agreements designed to generate non-dilutive funding, validate our platform externally, and support continued development without undue capital strain.\" .... Dr. Eric Leire, CEO of Genflow, commented: \"We're excited to attend the JP Morgan Healthcare Conference in San Francisco this January. Our planned meetings reflect our current focus on lipid nanoparticle delivery for mRNA SIRT6 therapeutics, which is opening compelling opportunities for strategic partnerships in the longevity space.\"",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=1999E606-84A4-47B8-B880-E68E1912F065"
        },
        "ingested_at": "2026-01-29T12:24:16.873151+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260928-Moneymun--2752274",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.844766",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Outstanding non-dilutive grant funding could land at anytime, although a lucrative JV licensing deal could also land at anytime and so let's see what transpires at next weeks the prestigious JP Healthcare Conference next week, where Genflow have planned meetings, presumably with potential suitors and every chance Eric will have initial efficacy data from the Dog Trial and maybe and maybe positive Data with their Ophthalmology partner for Glaucoma to present and so confirmation of a commercial deal or two would be transformational for all invested and any funding concerns would be assigned to history.  Gla holders....Excitement building!!! :-) Ps if Genflow need to raise cash because of the delay in receipt of the \u20ac4m outstanding non-dilutive grant funding, then raising cash from 16th January is going to become easier, cheaper and less dilutive.  :-) The new Financial Conduct Authority (FCA) regulations are designed to facilitate less discounted fundraising for small caps by reducing the regulatory burden and increasing the threshold for requiring a full prospectus, thus making secondary capital raising faster and cheaper. Key changes, effective from January 19, 2026 (with some listing rule changes effective from July 29, 2024), aim to attract more companies to list and grow in the UK. Key Regulatory Changes and Their Impact on Small Cap Fundraising The FCA's reforms introduce several key changes that support more efficient and potentially less discounted fundraising for smaller listed companies: Increased Prospectus Threshold The most significant change for secondary fundraising is that a full prospectus is now only required if a company issues shares amounting to 75% or more of its existing share capital, a substantial increase from the previous 20% threshold. This allows companies, particularly smaller ones, to raise further capital more quickly and at a lower cost without the time and expense associated with a full prospectus, which should reduce the need for heavily discounted placings.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=1999E606-84A4-47B8-B880-E68E1912F065"
        },
        "ingested_at": "2026-01-29T12:24:16.873185+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260854-David195--5518293",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.845590",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "I hold shares and the potential is significant. However I am reluctant to add when the funding position is unclear.  Grants could be material amounts if and when received but there is a risk of a diluted fund raise to progress the numerous programmes in 2026.  I have suffered this is other small biotechs like FAB and Apta where the state of the capital markets are very harsh and unsupportive. I tried to analyse the cash runway and it seems more funds will be needed in H1 if the grants are not received.  Is there any indication of the timing?",
          "sentiment": 0.0,
          "engagement": "871",
          "price_at_post": "1.90",
          "thread_title": "Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=1999E606-84A4-47B8-B880-E68E1912F065"
        },
        "ingested_at": "2026-01-29T12:24:16.873222+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260805-Porter_--6609373",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.846399",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Thanks for sharing money. I notice the RNS is in American English, perhaps to appeal to US investors and big US pharma? No mention of the patents in the update which were instrumental in offering assurance to investors regarding patent protection, but hopefully we\u2019ll receive updates in due course separately.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.825",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-29T12:24:16.873262+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260703-Moneymun-85733625",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.847249",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "We are advancing discussions with a leading LNP partner to support delivery innovation in this space and are securing a full-service CRO to manage formulation through preclinical execution. With the global glaucoma market approaching USD $12-14 billion by the early 2030s, this represents a compelling long-term opportunity for us. \u00b7 Additional Programs We continued to advance our broader pipeline and are pleased with the steady advancement of the sarcopenia program, fully consistent with our development plans. In parallel, the ExoFastTrack initiative continues to move forward, generating important data that will support and accelerate several of our other development programs. Looking Ahead to 2026 As we move into 2026, we do so with confidence, discipline, and a clear strategic focus. The coming year will emphasize rationalization of our pipeline, prioritizing programs with the strongest data, clearest paths to value creation, and highest partner interest. Central to this strategy will be the pursuit of early-stage licensing and collaboration agreements designed to generate non-dilutive funding, validate our platform externally, and support continued development without undue capital strain. With multiple upcoming data readouts, an expanding partner network, and a maturing intellectual property position, we believe Genflow is well positioned to enter its next phase of growth. We remain committed to scientific excellence, capital efficiency, and long-term value creation as we work to translate our longevity platform into meaningful therapies. Thank you for your continued support and confidence in Genflow.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-29T12:24:16.873298+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260702-Moneymun-16332291",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.848143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "08 January 2026 A Review of an Exciting 2025 2025 has been a year of focused scientific progress and continued advancement of Genflow Bioscience's mission to extend healthy lifespan through our novel longevity gene therapy platform. Across our portfolio, we have maintained momentum in both animal health where progress in our canine study may provide translational insights relevant to future human applications as well as therapeutic development for dogs. These advancements have been supported by a strengthened network of leading academic collaborators and laboratories. Together, with continued backing from international institutional investors and previously awarded government grants, this ecosystem helped accelerate Genflow's scientific and clinical development throughout 2025. Program Highlights We've made a number of notable strides across our programs this year, including: \u00b7      Dog Aging (GF-1004) We made significant strides in our clinical trial for aging dogs with full administration of our investigational SIRT6-based gene therapy now completed. No adverse events were reported during the dosing phase of the study, with no serious, moderate, or minor side effects observed. The study which began in March 2025, is being conducted as a blinded clinical trial; an initial efficacy readout is expected in Q1 2026, including blood analyses and muscle biopsies to evaluate potential benefits related to sarcopenia, healthspan, and lifespan-associated biomarkers. Dogs enrolled in the trial will be monitored for 180 days, with a second efficacy assessment planned at the six-month timepoint and results expected in June-July 2026 to evaluate durability and longer-term effects. \u00b7      MASH (GF-1002) Our MASH program saw good progress in 2025. While GLP-1 therapies have addressed early-stage MASH, patients with advanced fibrosis - roughly one-third of the population - still face limited treatment options. In response, we repositioned GF-1002 to target this high-need group, leveraging its antifibrotic properties and potential to prevent progression to cirrhosis and liver cancer. Additionally, we have generated new pre-clinical POC data on the prevention of HCC. We are now finalizing our IND package and evaluating mRNA/LNP delivery as an alternative to AAV, an approach that could enable repeat dosing and lower manufacturing costs. Encouraging data continue to support this next phase of research and development. \u00b7      Glaucoma In 2025, we expanded into ophthalmology, where SIRT6-based gene therapy shows promise in glaucoma, a leading cause of irreversible blindness. Current treatments primarily manage intraocular pressure but do little to prevent optic nerve degeneration. Our preclinical data suggest SIRT6 overexpression may protect retinal ganglion cells and preserve optic nerve function, shifting the focus from symptom control to true neuroprotection.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-29T12:24:16.873331+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261804-Moneymun--7870229",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.848904",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Well connected in the US to take Genflow to the next level. ;-)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-29T12:24:16.873352+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261802-Moneymun-56734396",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.849701",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Hi Porter, it's from the 2026 Corporate Presentation which was published via Genflow's LinkedIn post a few hours ago. Gl :-) Ps the new Chair appears to be well connected on the US. https://loom.ly/RsxnFCE",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-29T12:24:16.873371+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261732-Porter_-15109595",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.850478",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Thanks for sharing money. I haven\u2019t seen any news regarding a new Chair. Where did you manage to grab that info from? Can you please share the link if you have one? \ud83e\udd70",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-29T12:24:16.873389+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261627-Moneymun-66233961",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.851283",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Gad Berdugo Gad Berdugo, MSc. Eng., MBA Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a strategic and financial advisory firm focusing on the global biotechnology sector. He currently serves as Vice Chairman of the Board of Directors of clinical development stage precision oncology company, Diaccurate. Mr. Berdugo brings over 35 years of biotech corporate & business development, strategy, operational, financial, investment and general venture management experience. He served as CBO at CRISPR gene editing pioneer Editas (Nasdaq EDIT); Co-founder and CEO at personalized neoantigen cancer vaccine venture, EpiVax Oncology Inc.; CFO and EVP at Immune Pharmaceuticals Inc. (Nasdaq IMNP); Managing Director and Head of Life Sciences at Tegris Advisors, a strategic and financial advisory boutique; Founder and Managing Partner of the Explorium Global Life Sciences Investment Fund; Director, Senior Equity Research Analyst and Life Sciences Sector Leader at Lazard, Asset Management Group. Prior to that, he served as a Director of Global Business Development within Baxter\u2019s Biopharmaceuticals group and started his career at Abbott Labs. Mr. Berdugo received his B.Sc. with Honors in Biotechnology from Imperial College London, his M.Sc. in Biochemical Engineering from University College London and his M.B.A. from H.E.C. Paris. He serves on the Board of Directors of Friends of H.E.C. Inc. and Friends of U.C.L. Inc. Mr. Berdugo is bilingual in French and English and has dual US and French citizenships. He resides with his wife in New York City.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-29T12:24:16.873420+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261606-Moneymun-58441080",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.852108",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Looks like we've got a new Chairperson!!!??? Gla ;-) GAD BERDUGO Chairperson \u2022 30+ years of leadership across global biotech, corporate development, and U.S. capital markets \u2022 Proven record in strategic partnerships, capital raising, and scaling private and public biotech companies \u2022 Managing Partner, Explorium Capital; former Co-Founder & CEO of EpiVax Oncology and Chief Business Officer at Editas Medicine and Nutcracker Therapeutics",
          "sentiment": 0.0,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-29T12:24:16.873455+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261602-Moneymun--8841512",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.852899",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Undervalued stock opportunity; Potential acquisition by pharmaceutical partner GF-1004: Pet life extension / sarcopenia Initiated discussion under CDA with several animal health companies hTtps://loom.ly/RsxnFCE",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-29T12:24:16.873475+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261601-Moneymun-68228190",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.854072",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The Gap No approved neuroprotective therapies The mRNA Opportunity - Wide Open LNP targeted delivery to retina \u2013 now possible NO APPROVED OR CLINICAL-STAGE MRNA THERAPIES FOR GLAUCOMA PARTNERING WITH LNP PROVIDER Paradigm shift to retinal protection \u2022 Pre-clinical evidence links SIRT6 activity with RGC protection in glaucoma/optic neuropathy models \u2022 Demonstrating RGC rescue and preserved function would be a strong disease-modifying signal Delivery is now tractable \u2022 Targeted LNP (tLNP) platforms are removing a major historical barrier for in vivo RNA therapeutics to reach retina/RGCs Clear decision point A single well-designed rodent POC that shows \u2022 focal RGC expression of SIRT6 cent \u2022 preserved RGC counts and \u2022 preserved RGC function with acceptable ocular safety, gives a clean go/no-go for IND enabling work AGED DOGS COMPARATIVE TRIAL Proof-of-Concept comparative clinical trial of in-vivo naked DNA gene therapy in aged dogs Conducted at Syngene's strategic partner site in Morocco, AAALAC and GLP certified 26 (24+2) aged Beagles dogs (age>10 years) Group 1 (n=6): untreated Group 2 (n=6): treated with gene therapy IV bolus of SIRT6 AAV Group 3 (n=6): treated with gene therapy IV infusion of naked DNA (low dose) Group 4 (n=6): treated with gene therapy IV infusion of naked DNA (high dose) Blinded: first read-out in January 2026 \u2022 Treatment period: 180 days with follow-up period: 90 days \u2022 Gene therapy has been administered to all dogs with demonstrated excellent safety profile Endpoints \u2022 Pan-mammalian methylation clock (Steve Horvath), \u2022 sarcopenia (including muscle biopsies) and other markers of aging MASH PROGRAM Affects est. 35 million people globally \u2022 Increasing prevalence \u2022 Leading cause of chronic liver disease and liver transplant Significant unmet medical need Clear regulatory accelerated development pathway. EMA and FDA guidelines accept: \u2713 Key surrogate outcomes for therapeutic trials: regression of fibrosis or resolution of NASH \u2713 Histological changes are achievable within a 12-18-month time-frame \u2713 Placebo control \u2713 Conditional fast-track approval 2025 KEY HIGHLIGHTS LARGE AND EXPANDING MARKET OPPORTUNITY MASH: 35 Million globally. Increasing prevalence. Door opener to even broader anti-aging indication Awarded to new grants in 2024 expanding research pipeline Ophthalmology: retina preservation GROWING IP PORTFOLIO WITH LONG LIFE 2 proprietary patent families SIRT6 centenarian (cent SIRT6) and gene delivery (entering National Phase); Additional upcoming patent applications (entering PCT) MRNA/LNP GENE DELIVERY SYSTEMS Innovative gene delivery systems: targeted LNPs delivering cent SIRT6 mRNA GF-1002 Multiple key clinical and regulatory milestones expected in next 18 months; Undervalued stock opportunity; Potential acquisition by pharmaceutical partner GF-1004: Pet",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-29T12:24:16.873494+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261559-Moneymun--5236226",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.855051",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "WHO WE ARE Pioneering Novel Gene Therapeutics for a Longer, Healthier Life MISSION: aging is underlying risk factor for disease, and our aim is to deliver gene therapeutics that potentially halt or slow the aging process in humans and dogs CENTENARIAN SIRT6 (cent SIRT6) GENE: proprietary variant of longevity gene that widely regulates aging and immunity and is a potential therapeutic target for the treatment of diseases PROMISING PRECLINICAL RESULTS: lead drug candidate GF-1002 delivers a centenarian variant of the SIRT6 gene (cent SIRT6) for treatment of MASH SEASONED TEAM: experienced and proven management with extensive experience in public & private pharma and biotech ROBUST PIPELINE: advancing multiple development programs over 24 months: MASH, Glaucoma, Sarcopenia, Werner and life extension of dogs DEVELOPMENT PIPELINE GF-1002 (Pre-Clinical) AAV8 cent SIRT6 vector for intravenous infusion, expressing cDNA of centenarian variant of SIRT6(cent SIRT6) in liver GF-1003 (Pre-Clinical/Development) Suspension of exosomes, loaded with mRNA of centenarian variant of SIRT6(cent SIRT6) in fibroblasts GF-1004 (Clinical Proof of Concept) cent SIRT6 for intravenous infusion for life extension and prevention of age-related diseases GF-1005 (Pre-Clinical/Development) Mitochondrial disfunction: Myoblast progenitors loaded by photoporation with cent SIRT6 GF-1006 Ophthalmology (pre-clinical) mRNA cent SIRT6 delivered by LNP for the treatment of cornea pathologies and glaucoma OPHTHALMOLOGY PLATFORM New Ophthalmology Program: Initiated development of a novel gene therapy targeting ocular diseases, including corneal pathologies and glaucoma, using Genflow\u2019s proprietary Centenarian SIRT6 (cent SIRT6). Precision Delivery Platform: Employing a specially engineered non-viral vector for targeted SIRT6 delivery to the eye. Strategic Partnership: Signed a Material Transfer Agreement in April 2025 with a leading ophthalmology company to co-develop the cent SIRT6 therapy and delivery system. LEVERAGING AI FOR GENOMICS New AI Partnership: Signed Master Service Agreement in April 2025 with Heureuka Labs, a spin-out of Duke University, to use their proprietary AI platform to analyze complex genomic data, including RNA sequencing and gene expression profiles. Enhancing Therapeutic Insights: Expected to drive a deeper understanding of gene regulatory networks and biological responses to optimize therapy design and personalize outcomes. Pipeline Advancement: Initially supporting GF-1002 (cent SIRT6-based gene therapy in preclinical development) and future programs, including candidates for MASH. GLAUCOMA RGC NEUROPROTECTION: THE RACE IS ON The Problem 80M people worldwide with glaucoma; leading cause of irreversible blindness Current treatments only lower IOP- they don't protect retinal ganglion cells (RGCs) RGC death is irreversible; unmet need for neuroprotection Significant market opportunity The Gap",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-29T12:24:16.873527+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261913-Persever-32405085",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.702321",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "These unknowns are off book pre negotiated buys. Sp will remain pinned till.Dog efficacy data. Expected solid data.",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-01-29T12:24:16.873564+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261838-Dzygit19-69586229",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.702759",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dzygit1980",
          "content": "12:45 yesterday was 1.97 to sell small amout . Than yesterday's big trade printed today for 1.81 ,straight after 1.97 To buy share so I am not sure \ud83e\udd14 was 12:45 yesterday tradet  buy  to me it looks like sell. Also we are dropping",
          "sentiment": 0.0,
          "engagement": "255",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-01-29T12:24:16.873601+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261822-Persever--3928540",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.703192",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "Big buys more like it. Do you know trading? \ud83d\ude05",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-01-29T12:24:16.873638+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261753-Dzygit19-88854071",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.703612",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dzygit1980",
          "content": "Lots of big sales last couple of days",
          "sentiment": 0.0,
          "engagement": "255",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-01-29T12:24:16.873674+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261756-Persever--7465167",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.704022",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "I think a massive rerate is coming ? Somethings brewing ?",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "1.90",
          "thread_title": "Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-01-29T12:24:16.873708+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260719-Porter_--8843398",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.704447",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Know a few people who didn\u2019t get their orders filled yesterday. Seems there isn\u2019t much in the free-float so let\u2019s see how tight this coiled spring is!",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-29T12:24:16.873728+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20262217-Twocd2-46060032",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.704869",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "I joined pre IPO, \u00a350 may have been too much of a reach for you\u2026chortle chortle TK Max.. Give Porter a reach around before lights out so that he\u2019ll not be to disappointed with no RNS tomorrow morning\u2026\ud83d\udc4c",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-29T12:24:16.873747+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261352-DaveTK--7803285",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.705301",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "I joined the party pre IPO. TBF they were asking for more than \u00a350 so it may have been too much of a reach for you. Talking about choppers FFS. Don't let you mum read that or she'll take your phone off you and cancel your contract.",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-29T12:24:16.873769+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261342-Twocd2-25118377",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.705721",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "So TK Max joins the party\u2026think you and Porter need to take turns and time to give him a chance to be big spoon for this week. Might give him something else to do rather than practice his typing. Plenty of skin in the game lads\u2026but this is not about who\u2019s chopper is bigger..well maybe for the spooning it does\ud83d\ude01",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-29T12:24:16.873808+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261033-DaveTK--7711752",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.706162",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Always. I'm here and always have been here waiting for news that we have been bought out. It was always the goal from Eric to make this company into something a pharmaceutical would buy a high price. We may not be that far off. Fingers crossed. Thanks",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-29T12:24:16.873838+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261027-Porter_--6262646",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.706587",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Always the ones who sold too soon quick to troll those who held with diamond hands Dave. Expecting this is just the first update of many we\u2019ll be seeing over the next 2 weeks. Popcorn ready! \ud83c\udf7f",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-29T12:24:16.873857+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261005-DaveTK-59461779",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.707009",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Would seem like you touched  nerve there, Porter ha ha. Nice RNS this morning. Looking forward to hearing more regarding the J.P. Morgan's Healthcare Conference. Really does seem like exciting times ahead. Thanks",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-29T12:24:16.873876+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260839-Twocd2--8116425",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.707434",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "Ok big fella..time for nap your banter is honking.",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-29T12:24:16.873895+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260820-Moneymun--7086777",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.707847",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The new Chairman in place, GAD BERDUGO is a high flyer based in the US with a wealth of experience in Global Biotech, Corporate Development and US Capital Markets and so no doubt very well contected to any potential suitors. Excitement building!!!! In Eric we trust!!! Gla holders:-) Ps initial Efficacy readout on the Dog Trial imminent!!! Gla ;-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-29T12:24:16.873914+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260752-Porter_--8412680",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.708264",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "2cd2 - invest more than \u00a3100 in a company and you might care a little bit more for your investments \ud83d\ude18",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-29T12:24:16.873933+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260734-Twocd2-36220296",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.708668",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "Take the rest of the day off Porter..great job pal! You must have set the alarm early to C&P all of that \ud83d\udc4f\ud83d\udc4f\ud83d\udc4c",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-29T12:24:16.873963+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260718-Porter_-79969321",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.709143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Genflow Appoints a New Chairman to Accelerate Corporate and R&D Expansion Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or the \"Company\"), a leading European-based biotechnology company focusing on gene therapies for age-related diseases, is pleased to announce a significant appointment to its Board of Directors, marking an important step in the Company's strategic evolution. Mr. Gad Berdugo, MSc Eng., MBA, has joined the Board with immediate effect and will assume the role of Independent Non-Executive Chairman, providing leadership as Genflow focuses on advancing its gene-therapy programs. Mrs. Tamara Joseph will continue to serve as a Director, ensuring continuity and maintaining strong governance. Mr. Berdugo brings over 30 years' of leadership experience spanning global business and corporate development, U.S. capital markets, and company building. He has a proven record of driving strategic partnerships, securing capital, and scaling both private and public development-stage biotechnology companies. Currently, Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a U.S.-based strategic and financial advisory firm focusing on the global biotechnology sector. His most recent roles include: \u00b7 Co-Founder & CEO, EpiVax Oncology \u00b7 Vice-Chairman of the Board, Evexta Bio \u00b7 Chief Business Officer, Editas Medicine (NASDAQ: EDIT) \u00b7 Chief Business Officer, Nutcracker Therapeutics He began his international career at Abbott Labs and Baxter, later becoming Life Sciences Sector Leader at Lazard Asset Management. Mr. Berdugo also brings deep technical and market expertise in RNA-based therapeutics, including lipid nanoparticle (LNP) delivery, development, and manufacturing. This background will support Genflow as it advances its scientific platform, evaluates delivery technologies, and explores next-generation therapeutic approaches. His appointment further strengthens the Company's presence in the United States and expands its capacity for global engagement. He does not own any shares in the Company. Dr. Eric Leire, Chief Executive Officer of Genflow, commented: \"We are delighted to welcome Mr. Berdugo as Independent Non-Executive Chairman. His expertise in strategy, partnerships and financing as well as his deep experience with RNA-LNP technologies will be instrumental as we accelerate our programs and expand our global reach. We are equally pleased that Mrs. Tamara Joseph will continue her service on the Board, contributing her invaluable leadership, legal and governance expertise.\" Gad Berdugo added: \"I am excited to join Genflow as the company is progressing to the next new phase of development, with key data readouts expected in 2026, strengthened intellectual property, and a sharpened strategic focus on high-potential programs. I look forward to working with the talented team and board to advance these innovative gene therapies, this is an ideal moment to contribute my expertise and hel",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-29T12:24:16.873997+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20260836-Pie-char-40987580",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.709557",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Post conference announcement next week and Funding news is what I predict. I'm amazed we are at this price. Such a hidden gem!",
          "sentiment": 0.5,
          "engagement": "60",
          "price_at_post": "1.85",
          "thread_title": "RE: JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=3005BF87-EE58-4C27-ABC6-EE6AA15A9385"
        },
        "ingested_at": "2026-01-29T12:24:16.874018+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20260716-Porter_--8946484",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.710022",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Genflow Biosciences is a London-based biotechnology firm and the first \"pure-play\" longevity company listed on the London Stock Exchange. As of early 2026, the company is transitioning from a preclinical phase into active clinical data readouts, focusing on its proprietary SIRT6-based gene therapy platform to extend human and animal \"healthspan\". Core Technology and Pipeline: The company\u2019s lead therapeutic approach involves delivering a \"centenarian variant\" of the SIRT6 gene, identified in individuals who live over 100 years, to improve DNA repair and metabolic health. GF-1002 (Human Therapeutics): MASH (Liver Disease): Repositioned in 2025 to target patients with advanced fibrosis who have limited options from existing GLP-1 therapies. The company is currently finalizing its Investigational New Drug (IND) package and exploring mRNA/LNP delivery to allow for repeat dosing and lower costs. Werner Syndrome: A rare genetic condition causing premature aging. Genflow has developed proprietary human-derived liver organoids to model this disease more accurately than animal models. GF-1004 (Veterinary Program): Canine Longevity: A 12-month blinded clinical trial in aged dogs is currently underway. In early 2026, the company confirmed that all subjects received full dosing with no adverse events reported. Key 2026 Milestones: Initial efficacy readouts focusing on biological age (via methylation clocks) are expected in Q1 2026, with a second evaluation planned for June-July 2026. Expansion Programs: Glaucoma: A new ophthalmology program targeting neuroprotection of retinal ganglion cells to prevent blindness. Sarcopenia (GF-1005): Research into muscle health and mitochondrial dysfunction in collaboration with the Universit\u00e9 libre de Bruxelles. 2026 Strategic Focus: Genflow\u2019s 2026 strategy emphasizes \"rationalization of the pipeline,\" prioritizing programs with the strongest data to secure non-dilutive funding through licensing deals and partnerships. The company is actively seeking animal health partners for its dog longevity program and strategic collaborators for its LNP-based mRNA therapeutics.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "GLP, LNP, MRNA and SIRT6 based therapeutics",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=FB89DB69-F93B-4BB3-8529-5206EECDF243"
        },
        "ingested_at": "2026-01-29T12:24:16.874037+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20262119-jamtart1--3417752",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.710444",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Yes, Genflow Biosciences (Genflow) has had significant interest at the J.P. Morgan Healthcare Conference, attending specifically to engage with potential partners, institutional investors, and pharmaceutical companies. Their CEO, Dr. Eric Leire, attended the most recent conference in January 2026 with a \"full appointments book\" to discuss strategic partnerships and non-dilutive funding opportunities.",
          "sentiment": 0.5,
          "engagement": "1,600",
          "price_at_post": "1.85",
          "thread_title": "JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=3005BF87-EE58-4C27-ABC6-EE6AA15A9385"
        },
        "ingested_at": "2026-01-29T12:24:16.874067+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260634-Porter_--7798015",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.710912",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Companies attend the J.P. Morgan Healthcare Conference (JPM) primarily for networking, securing funding, forging strategic partnerships, and announcing key business updates. This major event, often described as setting the industry's tone for the year, concentrates a year's worth of meetings into a few days. Key reasons why companies attend include: Investment and Funding: The conference is a premier venue for companies to present their strategies and financial outlooks to a high-level audience of investors, analysts, and venture capitalists. For many, especially smaller or emerging biotech firms, it is a critical opportunity to secure financing, gauge investor interest, and build essential relationships. Mergers and Acquisitions (M&A) and Partnerships: The event is a hotbed for dealmaking. Big pharmaceutical companies often attend to scout for smaller companies with promising drug pipelines or innovative technologies (like AI in drug discovery) to acquire, especially as their own blockbuster drugs approach patent expiration. Extensive one-on-one meetings facilitate these discussions and collaborations. Strategic Positioning and Visibility: Companies announce major news, clinical trial data, or year-end recaps just before or during the conference to capture attention and elevate their visibility above the competition. It allows them to articulate their unique value proposition and strategic priorities to the global market. Market Intelligence: Attending allows companies to take the pulse of the industry, understand the latest trends (e.g., AI, gene therapy, obesity drugs), and gather competitive intelligence. They can assess how investors and peers discuss valuations, regulatory pathways, and market potential, which helps in fine-tuning their own strategies for the year ahead. Networking Efficiency: The conference brings the entire healthcare and life sciences ecosystem\u2014from manufacturers and providers to regulators and service providers\u2014into a concentrated location for a short time. This high density of key decision-makers allows for efficient, high-value networking and relationship building that would otherwise take months of travel and outreach.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=4C9A5731-DC78-4F24-8CE9-513E080FCFAC"
        },
        "ingested_at": "2026-01-29T12:24:16.874111+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261946-jamtart1-16114090",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.711334",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Doubt it, but happy if rumours are true",
          "sentiment": 0.5,
          "engagement": "1,600",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan, news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=559FB93D-C9CD-4A83-84E9-7B26CC6976E9"
        },
        "ingested_at": "2026-01-29T12:24:16.874136+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261844-JediMast--7186147",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.711742",
        "source": "LSE_CHAT",
        "data": {
          "author": "JediMaster1",
          "content": "Rumours of investment banks wanting to buy in from the JP Morgan Conference. The only question now is who do they want to buy in on behalf of?? The next few days will be interesting. Will Eric spill the beans?",
          "sentiment": 0.5,
          "engagement": "169",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D010A135-964B-4034-9025-65BCB0334809"
        },
        "ingested_at": "2026-01-29T12:24:16.874155+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261006-Moneymun-28668536",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.712184",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "GKOS: Strong innovation and new therapies drive growth, with robust financials and expanding markets Jan 14, 2026, GKOS The event highlighted robust innovation in ophthalmology, with strong R&D investment yielding a broad product pipeline and record financial performance. Key growth drivers include new glaucoma and keratoconus therapies, strategic market expansion, and a focus on operational leverage and profitability. Based on Glaukos Corporation [GKOS] 44th Annual J.P. Morgan Healthcare Conference Audio Transcript \u2014 Jan. 14 2026",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.10",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-29T12:24:16.874174+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260827-Moneymun--1378535",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.712592",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Every chance Rooster, although I'm hoping for a transformational lucrative commercial licensing deal on one or more of the programs, Dog , Glaucoma and Mash. Excitement building!!! Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.05",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-29T12:24:16.874193+00:00"
      },
      {
        "event_id": "RNS-30th Jan 2026-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-31T00:11:21.064165+00:00",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/holdings-in-company-ml9wak5j9vumwmr.html",
          "rns_number": "RNS Number : 1390R",
          "full_content": "30 Jan 2026 12:29\nRNS Number : 1390R\nGenflow Biosciences PLC\n30 January 2026\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BP2C3V08\nIssuer Name\nGENFLOW BIOSCIENCES PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nJonathan Mark Swann\nCity of registered office (if applicable)\nrickmansworth\nCountry of registered office (if applicable)\nUnited Kingdom\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n23-Jan-2026\n6. Date on which Issuer notified\n25-Jan-2026\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n12.130000\n0.000000\n12.130000\n59861278\nPosition of previous notification (if applicable)\n11.320000\n0.000000\n11.320000\n55861278\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BP2C3V08\n59861278\n0\n12.130000\n0.000000\nSub Total 8.A\n59861278\n12.130000%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\nNone\n12. Date of Completion\n24-Jan-2026\n13. Place Of Completion\nLondon\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLBMMTTMTTJBFF",
          "content_length": 3859
        },
        "ingested_at": "2026-01-31T00:11:21.064197+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261736-Porter_--6811465",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.869536",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Yep, now they\u2019re fighting to get shares on DGQ and can\u2019t get any! That will be Genflow soon! \ud83d\ude04",
          "sentiment": 0.5,
          "engagement": "1,322",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-01-31T00:11:33.495125+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261725-Swanny27-26778160",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.869980",
        "source": "LSE_CHAT",
        "data": {
          "author": "Swanny27",
          "content": "Especially DGQ",
          "sentiment": 0.0,
          "engagement": "914",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-01-31T00:11:33.495168+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261618-Moneymun-89927186",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.870419",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Whether or not the new estimate offers a more realistic picture of lifespan heritability, it highlights the importance of genetics in extending lives, says Sofiya Milman, a scientists who studies aging and longevity at the Albert Einstein College of Medicine. She\u2019s one of many researchers who are trying to understand how centenarians\u2019 unique biology protects them from age-related disease. \u201cWe\u2019re hoping to create therapies that will mimic those intrinsic factors,\u201d Milman says, \u201cand make them accessible to people who didn\u2019t win the genetic lottery.\u201d Most of us are unlikely to break 100 without the right set of genes\u2014or at least drugs designed to replicate their beneficial effects. Until such treatments become available, though, a healthy lifestyle remains the best path to living longer.",
          "sentiment": 0.5,
          "engagement": "12,520",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-01-31T00:11:33.495191+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261553-Moneymun-10282398",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.870892",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Latest research into longevity and healthspan suggests Genflow's centenarian Sirt6 Gene could play a pivotal roll. Gla :-) Genetics The secret to long life? It could be in the genes after all, say scientists New study into \u2018heritability\u2019 shows that 50% of the variation in human lifespan could be down to genetics ........ The team looked at \u201cheritability\u201d, the proportion of change in a characteristic such as height, body weight or lifespan within a population that can be attributed to genetics rather than environmental factors. Previous studies for human lifespan have thrown up a wide range of values \u2013 with heritability ranging from 6% of the variation to 33%. But Alon, who co-authored the research, and his colleagues said such figures were underestimates. \u201cI hope this will inspire researchers to make a deep search for the genes that impact lifespan,\u201d Alon said. \u201cThese genes will tell us the mechanisms that govern our internal clocks. \u201cThese can one day be turned into therapy to slow down the rate of ageing and in that way slow down all age-related disease at once.\u201d ....... \u201cAround 20% of centenarians, for example, reach age 100 without any serious debilitating illnesses,\u201d he said, adding that could suggest their genes had a protective effect. \u201cStudies have been conducted to identify these protective genes, and many have been found, but surely there are many still left to discover,\u201d he said. While the new study does not take into account the influence that genes can have on the immune system, Prof Richard Faragher of the University of Brighton said the research suggested humans did not seem to be an outlier when it came to the heritability of lifespan. \u201cAnd that\u2019s useful because it means humans look quite like a species that we study ageing in, [and] gives you a certain amount of confidence that interventions that will work in mice will carry over into humans,\u201d he said. The secret to long life? It could be in the genes after all, say scientists | Genetics | The Guardian htTps://share.google/4quet7VR33nTpwazT",
          "sentiment": 0.5,
          "engagement": "12,520",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-01-31T00:11:33.495216+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261304-Porter_-22304478",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.871320",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "At least we know why the Mm\u2019s kept dropping the share price, so they could let Swann accumulate. Up to his usual sneaky tricks. Everything he buys atm turns to gold, so very optimistic that something is about to take off in Genflow.",
          "sentiment": 0.5,
          "engagement": "1,322",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-01-31T00:11:33.495234+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261257-Moneymun-40390468",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.871727",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Continued share accumulation by Jonathan Swann, in anticipation of transformational UPside. Gla holders...initial Efficacy Data on the Dog Trial, fast approaching!!! ;-)",
          "sentiment": 0.5,
          "engagement": "12,520",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-01-31T00:11:33.495253+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261253-Persever--7256286",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.872252",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "Who adds if weak data expected ? Quietly bullish this RNS",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "1.90",
          "thread_title": "Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-01-31T00:11:33.495272+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261658-Moneymun--8872619",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.872700",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "A potential very intetesting development.....Genflow were awarded 1.55m euros in Jan 2024 in collaboration with Exo-Biologics for a 3 year scientific program focused on the development a novel mRNA delivery system using exsomes to enscapsulate and transport Genflow's propriety centenarian Sirt6 Gene designed to target MASH & Werner Syndrome..... 777 Euro's was received in May 2024 with the remainder expected in 2025, but still outstanding and so could land anytime. ( and not related to the 4m Euro award ). Anyways, Exo-Bilogics announced last week they had enetered into a collaboration agreement with the multi-billion dollar French Pharma, Servier, to evaluate the use of extracellular vesicles as a non-viral drug delivery vehicle for an undisclosed indication, ( through their subsidiary Exoxpert,(ExoFastTrack), which Genflow is a collaborative member/partner ). All bodes well. Gla holders ;-) EXO Biologics 3,613 followers 1w \ud83d\udce3 We are pleased to announce a new collaboration with Servier. Our GMP clinical-grade EVs can be used as a non-viral drug delivery system, and we are eager to start this project with such a prestigious pharmaceutical company. Thanks to the continued support of BioWin and Service public de Wallonie, we are thrilled to further expand our international collaborations.",
          "sentiment": 0.5,
          "engagement": "12,520",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-01-31T00:11:33.495290+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261106-Moneymun-25911782",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.873213",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "No guarantees, but there lies the transformational UPside opportunity from this lowly bargain low. \"it worked like magic in mice, and we reasonably expect to work likewise in dogs\".....the first Efficacy Data readout is imminent, and judging by Eric's latest interview, he sounded very confident and bullish on a commercial licensing deal with an Animal Healthcare company ( we have two that have both signed Confidential Disclosure Agreements)  whereby any deal would provide non-dilutive cash  into the company, and Eric made a compelling point, that any non-dilutive cash would be much more than the \u20ac4m non-dilutive grant money confirmed yesterday, with the first tranche payment by May at the latest,  and so watch this space, potential game changing news fast approaching.  Gla holders ;-) Ps it was huge relief to have confirmation the \u20ac4m non-dilutive grant has been signed off, as Genflow were running  low on funds, and given the length of time we've waited for approval and the huge deficit turmoil the Belgium/Wallonia Govt. have been under, I had almost written it off, and so great news that Genflow will have no funding concerns for the foreseeable, and no doubt the \u20ac4m gives them much more leverage in any licensing deal discussions from a position of strength.  Transformational and near term game changing potential and prospects for those invested.  Excitement building!!!! :-)",
          "sentiment": 0.5,
          "engagement": "12,520",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-01-31T00:11:33.495308+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261052-Pie-char--2239381",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.873627",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Mice*",
          "sentiment": 0.0,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-01-31T00:11:33.495325+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261046-Pie-char-76864482",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.874043",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "So far all signs are good. Nice results were good. They also have more than just this programme. Dogs is just one of many.",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-01-31T00:11:33.495343+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261031-mikee_p-23520930",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.874464",
        "source": "LSE_CHAT",
        "data": {
          "author": "mikee_p",
          "content": "Is it low? This is still a risky punt. Dog trials may fail.",
          "sentiment": 0.0,
          "engagement": "1,895",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-01-31T00:11:33.495361+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260853-Pie-char--4829457",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.874879",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Everyone needs to listen to the last 20 seconds of this video. If that\u2019s not bullish I don\u2019t know what is. https://www.proactiveinvestors.co.uk/companies/news/1086390/genflow-ceo-outlines-2026-priorities-as-4-million-grant-is-approved-1086390.html",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F1CBD71F-0291-4489-9B39-85877DA36B7E"
        },
        "ingested_at": "2026-01-31T00:11:33.495379+00:00"
      },
      {
        "event_id": "SOCIAL-Today1106-Moneymun-25911782",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.448266",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "No guarantees, but there lies the transformational UPside opportunity from this lowly bargain low. \"it worked like magic in mice, and we reasonably expect to work likewise in dogs\".....the first Efficacy Data readout is imminent, and judging by Eric's latest interview, he sounded very confident and bullish on a commercial licensing deal with an Animal Healthcare company ( we have two that have both signed Confidential Disclosure Agreements)  whereby any deal would provide non-dilutive cash  into the company, and Eric made a compelling point, that any non-dilutive cash would be much more than the \u20ac4m non-dilutive grant money confirmed yesterday, with the first tranche payment by May at the latest,  and so watch this space, potential game changing news fast approaching.  Gla holders ;-) Ps it was huge relief to have confirmation the \u20ac4m non-dilutive grant has been signed off, as Genflow were running  low on funds, and given the length of time we've waited for approval and the huge deficit turmoil the Belgium/Wallonia Govt. have been under, I had almost written it off, and so great news that Genflow will have no funding concerns for the foreseeable, and no doubt the \u20ac4m gives them much more leverage in any licensing deal discussions from a position of strength.  Transformational and near term game changing potential and prospects for those invested.  Excitement building!!!! :-)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-01-31T00:11:33.495398+00:00"
      },
      {
        "event_id": "SOCIAL-Today1052-Pie-char--2239381",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.448833",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Mice*",
          "sentiment": 0.0,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-01-31T00:11:33.495416+00:00"
      },
      {
        "event_id": "SOCIAL-Today1046-Pie-char-76864482",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.449387",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "So far all signs are good. Nice results were good. They also have more than just this programme. Dogs is just one of many.",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-01-31T00:11:33.495434+00:00"
      },
      {
        "event_id": "SOCIAL-Today1031-mikee_p-23520930",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.449902",
        "source": "LSE_CHAT",
        "data": {
          "author": "mikee_p",
          "content": "Is it low? This is still a risky punt. Dog trials may fail.",
          "sentiment": 0.0,
          "engagement": "1,895",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-01-31T00:11:33.495452+00:00"
      },
      {
        "event_id": "SOCIAL-Today0853-Pie-char--4829457",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.450425",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Everyone needs to listen to the last 20 seconds of this video. If that\u2019s not bullish I don\u2019t know what is. https://www.proactiveinvestors.co.uk/companies/news/1086390/genflow-ceo-outlines-2026-priorities-as-4-million-grant-is-approved-1086390.html",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F1CBD71F-0291-4489-9B39-85877DA36B7E"
        },
        "ingested_at": "2026-01-31T00:11:33.495470+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261858-jamtart1--2776952",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.450933",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Https://www.tipranks.com/stocks/gb:genf",
          "sentiment": 0.5,
          "engagement": "1,604",
          "price_at_post": "1.90",
          "thread_title": "Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F1CBD71F-0291-4489-9B39-85877DA36B7E"
        },
        "ingested_at": "2026-01-31T00:11:33.495488+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261734-Roosters--9133993",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.451451",
        "source": "LSE_CHAT",
        "data": {
          "author": "Roostersmillions",
          "content": "Thats got to be a misprint. Target of \u00a32 for a 2p share. That would be a buy not a hold. Also when you open the analysts section, they have hold at 2p.",
          "sentiment": 0.5,
          "engagement": "291",
          "price_at_post": "1.90",
          "thread_title": "RE: Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=A70A365B-ED0A-4D60-9FAF-1051143160CA"
        },
        "ingested_at": "2026-01-31T00:11:33.495506+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261723-jamtart1-71063214",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.451956",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Https://www.tipranks.com/news/company-announcements/genflow-secures-e4m-wallonia-funding-and-sets-2026-gene-therapy-priorities#google_vignette Note the \u00a32 price target.",
          "sentiment": 0.5,
          "engagement": "1,604",
          "price_at_post": "1.90",
          "thread_title": "Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=A70A365B-ED0A-4D60-9FAF-1051143160CA"
        },
        "ingested_at": "2026-01-31T00:11:33.495524+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261232-VikR--3380637",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.452496",
        "source": "LSE_CHAT",
        "data": {
          "author": "VikR",
          "content": "I remember just recently when this moved from 0.6p to 2p in the blink of any eyelid. It is a such compelling buy but seems to be off the radar for many investors who don\u2019t understand the opportunity on offer here. This is by far a very confident load and hold Market cap is EXTREMELY low for what\u2019s coming around the corner.",
          "sentiment": 0.5,
          "engagement": "983",
          "price_at_post": "1.90",
          "thread_title": "MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-01-31T00:11:33.495542+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261145-Moneymun--6347530",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.453330",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Another great interview by Eric on today's news....2026 will be a year of Data and Partnerships, and when making references to the Dog Trial, Eric stated that any partnership would bring in non-dilutive cash to the company, \"and whe talking about non-dilutive cash, I'm not talking about the \u20ac4m non-dilutive grant confirmed today, I'm taking about much more\" !!!! Gla holders, all bodes well, exciting times ahead!!! Initial Efficacy Data from the Dog Trial imminent and every chance of a very lucrative commercial licensing deal to follow!!! :-) Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company\u2019s strategic progress and outlook for 2026, following a \u20ac4 million non-dilutive grant awarded by the Wallonia region. Dr Leire explained that the secured funding is part of Genflow\u2019s broader capital efficiency strategy, helping the company focus on key pipeline catalysts, including its lead gene therapy, GF-1002. GF-1002 is targeted at MASH (Metabolic dysfunction-associated steatohepatitis), a field Dr Leire described as \u201ca huge unmet need,\u201d particularly at the late stage where there are currently no therapeutic options. \u201cThis is one of the key programs for 2026,\u201d he said, highlighting that GF-1002 addresses severe liver conditions, including hepatocellular carcinoma. In addition to its gene therapy program, Genflow is advancing a pioneering longevity study in dogs. Leire stated, \u201cA study on aged dogs, naive to therapies, that's blinded, randomised, so with very strong scientific standard will be a first in terms of longevity.\u201d He emphasised the potential for a commercial deal with animal health companies based on this unique dataset. Partnerships and capital efficiency remain central to Genflow\u2019s plans. Leire noted that monetising non-core programs, such as the dog study, can generate significant non-dilutive capital and allow the company to focus on areas where it adds the most value. Genflow CEO outlines 2026 priorities as \u20ac4 million grant is approved | LSE:GENF, OTCQB:GENFF htTps://share.google/bu0pCWldyc59hIftA",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-01-31T00:11:33.495559+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260802-DaveTK--7344650",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.453982",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Simply amazing. Well done team",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "2.00",
          "thread_title": ".",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=40281A21-EA32-4E4F-A04F-0732B5F85F17"
        },
        "ingested_at": "2026-01-31T00:11:33.495578+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260745-Pie-char--2028110",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.454643",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Amazing. Dog results coming soon. Vet partner deal has never had such high probability! This is a good place to be!",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.95",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-01-31T00:11:33.495596+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260710-Moneymun--7998107",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.455431",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "What a brilliant RNS!!!! Gla holders...in Eric we trust!!! On and most definitely UP!!! :-)))",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.95",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-01-31T00:11:33.495614+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260705-Moneymun-53598334",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.455987",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Glaucoma Programme The Company's glaucoma programme will prioritise delivery optimisation and execution readiness. Genflow is advancing discussions with a leading lipid nanoparticle (LNP) partner to support delivery innovation and is progressing the selection of a full-service contract research organisation (CRO) to manage RNA-based formulation activities through preclinical execution. Additional Programmes Across the broader pipeline, Genflow continues to advance its sarcopenia programme in line with established development plans. In parallel, the ExoFastTrack initiative continues to generate data intended to support and accelerate multiple programmes across the portfolio. Dr. Eric Leire, CEO of Genflow, commented: \"The administrative approval of this funding reinforces our ability to execute against our 2026 development priorities with discipline and focus. It strengthens our capacity to advance GF-1002 while maintaining a selective, data-driven approach across the broader pipeline. As we enter the coming year, our emphasis remains on programmes with clear execution paths, strong scientific rationale, and meaningful opportunities for partnership and non-dilutive value creation.\"",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.95",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-01-31T00:11:33.495632+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260704-Moneymun-51290972",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.456597",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Administrative Approval of Grant & 2026 Priorities GENFLOW BIOSCIENCES PLC Released 07:00:09 28 January 2026 RNS Number : 5966Q Genflow Biosciences PLC 28 January 2026 Genflow Biosciences Plc Administrative Approval of \u20ac4 Million Funding Support from Wallonia Region for GF-100; and 2026 Development Priorities Genflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) (\"Genflow\" or the \"Company\"), a European-based biotechnology company focused on the development of gene therapies for age-related diseases, announces the administrative approval of the previously announced award of approximately \u20ac4 million in non-dilutive financial support from the Wallonia Region of Belgium, following the assenting signature of Minister Adrien Dolimont. The funding, once received, will support the continued development of the Company's lead gene therapy candidate, GF-1002, for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (\"MASH\"). The original RNS announcing the award can be found here. Disbursement of the first instalment is expected no later than May 2026. The support package spans a three-year development programme and is aligned with Genflow's existing roadmap. All project-related expenses incurred during 2025 will be eligible under the terms of the programme. Development Priorities for 2026 In 2026 Genflow's strategy emphasises pipeline discipline and capital efficiency, prioritising programmes with the strongest data, the clearest paths to value creation, and the highest potential for partner engagement. Central to this approach is the pursuit of early-stage collaboration agreements designed to secure non-dilutive funding, provide external validation of the platform, and support continued development. With multiple anticipated data readouts, an expanding partner dialogue, and a maturing intellectual property position, Genflow believes it is well positioned to enter its next phase of development while maintaining a focus on scientific rigour, operational execution, and long-term shareholder value creation. Dog Aging (GF-1004) The ongoing GF-1004 dog aging study, which commenced in March 2025, is being conducted as a blinded clinical trial designed to assess potential benefits related to sarcopenia, healthspan, and lifespan-associated biomarkers. An initial efficacy readout is expected in the first quarter of 2026. Dogs enrolled in the study are being monitored over a 180-day period, with a second efficacy assessment planned at the six-month timepoint. Results from this later evaluation are expected in June-July 2026 and are intended to assess durability and longer-term effects. Glaucoma Programme The Company's glaucoma programme will prioritise delivery optimisation and execution readiness. Genflow is advancing discussions with a leading lipid nanoparticle (LNP) partner to support delivery innovation and is progressing the selection of a full-service contract research organisatio",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.95",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-01-31T00:11:33.495650+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260808-Moneymun--3922833",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.457120",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "8/1/26 Leire explained that the dog longevity study is the nearest catalyst, with the trial expected to be unblinded shortly and early efficacy readouts anticipated in the near term. While safety has already been confirmed, the study remains blinded, meaning efficacy results are still unknown. The first data will focus on biological age, measured using a methylation clock, with a more detailed analysis of muscle biopsies and mitochondrial function to follow. According to Leire, \u201cthis trial could be very important for our shareholders, because it will trigger a deal with an animal health company bringing non-dilutive money in the company.\u201d",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.95",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-01-31T00:11:33.495668+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260707-Pie-char--8622443",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.457619",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Dog results are due next week. Vet partner(s) already likely lined up.",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.95",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-01-31T00:11:33.495686+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20262041-Moneymun-69861839",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.458133",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The trial aims to demonstrate proof of concept in dogs, replicating promising results previously seen in mice. \u201cIt worked like magic in mice. We reasonably think that it will work likewise in dogs,\u201d Leire stated. Unlike mice, however, dogs share environmental conditions with humans, making them a more relevant model for translation into human therapies.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-01-31T00:11:33.495704+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260818-Roosters-10895426",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.337719",
        "source": "LSE_CHAT",
        "data": {
          "author": "Roostersmillions",
          "content": "Markets reacting munch. Nice jump this AM. hope it holds. Maybe new private investors from across the pond due to conference exposure??",
          "sentiment": 0.5,
          "engagement": "291",
          "price_at_post": "2.00",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-31T00:11:33.495722+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260815-Moneymun-59258444",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.338198",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Game changing news at anytime. In Eric we trust!!! Gla holders...On and UP!!! :-)))",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "2.00",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-31T00:11:33.495740+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260812-Moneymun--6879904",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.338634",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions Madrigal\u2019s strategy of pursuing combination therapies while the market remains in its infancy could intrinsically link its brand to MASH treatment. Madrigal Pharmaceuticals used its January 12 presentation at the J.P. Morgan Healthcare Conference 2026 to showcase its newly acquired assets from Pfizer \u2013 ervogastat and two preclinical assets \u2013 as well as outline its vision for dominance in metabolic dysfunction-associated steatohepatitis (MASH) treatment space through leveraging early commercial success. Its professed strategy of pursuing combination therapies while the market remains in its infancy could well result in Madrigal\u2019s brand becoming intrinsically linked to MASH treatment. JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions - Pharmaceutical Technology https://share.google/Ymb4cXndGee7eMEbD",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "2.00",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-31T00:11:33.495758+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261725-Steg--6040305",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.339084",
        "source": "LSE_CHAT",
        "data": {
          "author": "Steg",
          "content": "Thought below was interesting, yes they are attending conference and have already made move to add to thier MASH portfolio, courtesy of AI search below Yes, Madrigal Pharmaceuticals is actively looking to expand its MASH (metabolic dysfunction-associated steatohepatitis) portfolio beyond its already approved drug, Rezdiffra (resmetirom). Madrigal's expansion strategy focuses on developing potential combination therapies, as MASH is a complex disease that requires multiple treatment approaches. Key components of their expanded pipeline include: Ervogastat: In January 2026, Madrigal entered into an exclusive global license agreement with Pfizer to acquire ervogastat, a Phase 2 oral DGAT-2 inhibitor. This drug works on a different, complementary pathway to Rezdiffra, and Madrigal plans to conduct studies to test the two treatments in combination. Oral GLP-1 Receptor Agonist: Madrigal also holds worldwide rights to an oral GLP-1 agonist called SYH2086, licensed from CSPC Pharmaceutical, with the goal of creating a best-in-class oral combination therapy. Additional Early-Stage Assets: The agreement with Pfizer for ervogastat also included rights to two other early-stage MASH pipeline assets. Madrigal's CEO, Bill Sibold, has stated that the company is committed to \"building the industry-leading pipeline that will shape the future of MASH care\" and believes combination therapies are the next wave of innovation in the field.",
          "sentiment": 0.0,
          "engagement": "5",
          "price_at_post": "1.90",
          "thread_title": "JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-31T00:11:33.495776+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261231-Moneymun-40140905",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.339515",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Get UP there!!! Gla :-) Eric and his team are now at the prestigious JP Healthcare Conference, pressing flesh with the leading industry deal makers. He appeared confident and enthusiastic in his latest interview, highlighting the prospects and potential of an early lucrative JV deal for the Dog Trial, Glaucoma and Mash and so potential game changing transformational news could drop at anytime. The first efficacy readout on the Dog Trial is imminent, and with two Animal Healthcare companies both with Confidential Disclosure Agreements in place, Eric could be very close to a deal, and the same with Glaucoma, whereby a leading Ophthalmology Company signed a Material Transfer Agreement 10 months ago. Eric also highlighted the prospects of Genflow's Sirt6 Mash Gene Therapy, which is now targeting the later stages of the disease where there's no options apart from transplant, and was very interesting to hear from Eric it could be used in combination with GLP-1's and Madrigal's early stage treatment which was FDA approved 12 months or so ago. Madrigal are presenting at JP Morgan and are on a mission to expand their pipeline for Mash, so watch this space. It's also very interesting we have a new Chairman in place, GAD BERDUGO a high flyer based in the US in Global Biotech, Corporate Development and and US Capital Markets and so no doubt very well contected to any potential suitors. Excitement building!!!! In Eric we trust!!! Gla holders:-)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "2.00",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-31T00:11:33.495794+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260822-Moneymun-39429898",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.339958",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Healthcare companies set for deals spree as drug patents expire A gathering of pharmaceutical executives comes as the sector has rebounded from uncertainty over Trump\u2019s policies Healthcare executives gather for their big annual conference in San Francisco on Monday as the sector is flush with cash and set for a deals spree as patents on drugs worth almost 12 per cent of the industry\u2019s revenues expire in the years ahead. The JPMorgan healthcare conference takes place as uncertainty recedes over President Donald Trump\u2019s trade wars, drug pricing policy and the leadership of key regulators such as the US Food and Drug Administration. In response, the S&P biotech index, known as the XBI, has surged to a four-year high, outperforming the wider index. In addition, drugs that contribute about $180bn of revenue a year are set to go off patent in 2027 and 2028, representing almost 12 per cent of the global market, according to research firm Evaluate Pharma. More than $40bn of sales are expected to lose patent protection this year, Evaluate has estimated. \u201cThe need to take big swings becomes more pressing,\u201d said Jeremy Meilman, head of healthcare investment banking at JPMorgan. \u201cSeveral of the large-cap pharmaceutical companies are shopping around for strong assets and a number have taken action but still have more firepower. This contributes to our optimism for 2026.\u201d hTtps://www.ft.com/content/7b07a9d5-7254-490b-8ce9-ec2633094d8e",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.825",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-31T00:11:33.495812+00:00"
      },
      {
        "event_id": "SOCIAL-11Jan20261442-Moneymun-75564462",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.340418",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Planned meetings presumably with potential suitors at JP Morgan this coming week and so multiple deal opportunities across the platform, and there's currently an M&A and lucrative licensing deal feeding frenzy as Major Pharma replenish their pipelines with the latest cutting-edge science, Excitement building!!! Gla :-) \"2026 will be catalyst year, we've done our work and now it's time for harvesting and are going to JP Morgan next week with a full appointments book, and now ready for potential harvesting of our results to bring in non-dilutive cash into the company.\" A must watch....Gla holders:-) hTtps://www.proactiveinvestors.co.uk/companies/news/1085366/genflow-biosciences-ceo-key-catalysts-for-2026-1085366.html",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.825",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-31T00:11:33.495830+00:00"
      },
      {
        "event_id": "SOCIAL-10Jan20261752-Troajan-24043754",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.836007",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1085424/genflow-is-ready-for-a-year-of-catalysts-icymi-1085424.html",
          "sentiment": 0.0,
          "engagement": "125,652",
          "price_at_post": "1.825",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-31T00:11:33.495848+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20262001-Moneymun--2131469",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.836711",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 10:30 a.m. PT. Investors and other interested parties can access a live audio webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event. About Zoetis As the world\u2019s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide \u2013 from veterinarians and pet owners to livestock producers. The company\u2019s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees. For more information, visit www.zoetis.com.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-31T00:11:33.495866+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261946-Moneymun-41611933",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.837364",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Woof, woof!!!??? ;-) Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference 06 January 2026 INDIANAPOLIS, Jan. 6, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will represent the company and respond to questions from analysts at 3:45 p.m. PST (6:45 PM EST).",
          "sentiment": 0.0,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-31T00:11:33.495884+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261920-Moneymun--5689077",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.837980",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "And/or ???? ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 4:30 p.m. PT in San Francisco, CA.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-31T00:11:33.495902+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261917-Moneymun-53704053",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.838626",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Eye wonder....Gla:-) 23/12/2025 - 12:30 VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders, Executive Vice President and Chief Financial Officer Sam Eldessouky and Chief Medical Officer and Head of Research & Development Yehia Hashad, MD, will participate in a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026, at 1:30 p.m. PT (4:30 p.m. ET) Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-31T00:11:33.495920+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261858-Moneymun--1693943",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.839276",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Another brilliant interview by Eric, \"2026 will be catalyst year, they've done their work and now it's time for harvesting and are going to JP Morgan next week with a full appointments book, and now ready for potential harvesting of their results to bring in non-dilutive funding cash into the company. Excitement building, in Eric we trust!!! Gla ;-) Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company\u2019s key programs and upcoming catalysts as it enters what management expects to be a pivotal year. Leire discussed why 2026 is shaping up as \u201ca year of catalysts\u201d for the company, with particular focus on the dog ageing trial, progress in MASH, and the group\u2019s approach to partnerships and licensing. Leire explained that the dog longevity study is the nearest catalyst, with the trial expected to be unblinded shortly and early efficacy readouts anticipated in the near term. While safety has already been confirmed, the study remains blinded, meaning efficacy results are still unknown. The first data will focus on biological age, measured using a methylation clock, with a more detailed analysis of muscle biopsies and mitochondrial function to follow. According to Leire, \u201cthis trial could be very important for our shareholders, because it will trigger a deal with an animal health company bringing non-dilutive money in the company.\u201d The interview also explored Genflow\u2019s repositioning in MASH toward advanced fibrosis and the prevention of hepatocellular carcinoma. Leire highlighted the significant unmet need in late-stage disease, noting that recent therapies target earlier stages and leave patients with advanced fibrosis facing limited options. He said the company\u2019s preclinical data have been encouraging and form a key part of the IND package, helping differentiate Genflow from existing and emerging treatments. In addition, Leire discussed the company\u2019s licensing strategy, including plans to out-license the dog program to an animal health specialist and pursue early-stage partnerships for glaucoma, while retaining focus on age-related conditions such as sarcopenia. With meetings planned during JPMorgan week, Leire said the company is seeking non-dilutive capital and strategic validation as it moves forward.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-31T00:11:33.495938+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261711-Troajan--3791815",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.839905",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1085366/genflow-biosciences-ceo-key-catalysts-for-2026-1085366.html",
          "sentiment": 0.0,
          "engagement": "125,652",
          "price_at_post": "1.75",
          "thread_title": "Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-01-31T00:11:33.495956+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261314-Moneymun-86311042",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.840622",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "0 0 Gene therapy biotech Genflow eyes busy year ahead as dog ageing trial nears results Published: 02:40 08 Jan 2026 Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) has wrapped up 2025 with steady progress across a range of gene therapy programmes, including a closely watched trial into dog ageing that could lay the groundwork for future human applications. The London-listed company, which is working on ways to extend healthy lifespan using gene therapy, said it had completed dosing in its lead canine study with no reported side effects. The dogs will now be monitored over six months for signs of improved muscle strength and health-related biomarkers, with initial results expected in the first quarter of this year. The trial, which began in March and uses a therapy based on the SIRT6 gene, a known regulator of ageing and DNA repair, is being conducted in a blinded format. A follow-up analysis is due around mid-year to assess the durability of the effects. Alongside the dog ageing study, Genflow said it had made progress in a programme targeting advanced stages of MASH, or metabolic dysfunction-associated steatohepatitis, a type of fatty liver disease. Existing GLP-1 drugs such as Ozempic and Wegovy have shown benefits in early MASH, but Genflow is aiming at patients with more severe fibrosis, where options remain limited. It is now finalising regulatory paperwork to support a human trial and is exploring the use of mRNA technology, similar to that used in Covid-19 vaccines, as a more flexible and cost-effective delivery method than traditional viral vectors. In a new push into eye disease, the company is also investigating the use of its gene therapy platform in glaucoma. Early lab results suggest that increasing SIRT6 levels may help protect the optic nerve from damage, potentially offering a way to slow or prevent vision loss rather than simply reducing eye pressure, which is the current standard treatment. Genflow said it was in talks with a lipid nanoparticle delivery partner to support this programme and was hiring a specialist contract research firm to help move the candidate towards preclinical testing. Elsewhere in its pipeline, work is ongoing in sarcopenia, the loss of muscle mass that often accompanies ageing, and in a broader initiative called ExoFastTrack, which supports several of its research efforts. Looking to the year ahead, Genflow said it would focus its efforts on the most promising areas of its portfolio and seek early licensing or partnership deals to bring in fresh funds without issuing new shares. \u201cWith multiple upcoming data readouts, an expanding partner network, and a maturing intellectual property position, we believe Genflow is well positioned to enter its next phase of growth,\u201d the company said. The first set of clinical results, particularly from the dog study, will be key in setting the tone for 2026.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-31T00:11:33.495974+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261148-Moneymun--9101257",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.841406",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Nice one David, looking forward to a run of great news from Eric to take the sp to new highs. Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.85",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-31T00:11:33.495992+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-David195--9035717",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.842237",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "Thank you for your informed views.  Added 500k @1.78.  It is hard for companies in this sector to raise funds so hopefully the upcoming changes will make the situation less brutal.  I will add when funds allow.",
          "sentiment": 0.0,
          "engagement": "871",
          "price_at_post": "1.85",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-31T00:11:33.496010+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261005-Moneymun--7204950",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.843028",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Hopefully news on patents soon Porter, the following statement is from yesterday's 2026 Corporate Presentation.  Gl :-) GROWING IP PORTFOLIO WITH LONG LIFE 2 proprietary patent families SIRT6 centenarian (cent SIRT6) and gene delivery (entering National Phase); Additional upcoming patent applications (entering PCT)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-31T00:11:33.496028+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260933-Moneymun-42041021",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.843890",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Bring it on!!! Gla holders:-) \"Central to this strategy will be the pursuit of early-stage licensing and collaboration agreements designed to generate non-dilutive funding, validate our platform externally, and support continued development without undue capital strain.\" .... Dr. Eric Leire, CEO of Genflow, commented: \"We're excited to attend the JP Morgan Healthcare Conference in San Francisco this January. Our planned meetings reflect our current focus on lipid nanoparticle delivery for mRNA SIRT6 therapeutics, which is opening compelling opportunities for strategic partnerships in the longevity space.\"",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=1999E606-84A4-47B8-B880-E68E1912F065"
        },
        "ingested_at": "2026-01-31T00:11:33.496045+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260928-Moneymun-35040150",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.844766",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Outstanding non-dilutive grant funding could land at anytime, although a lucrative JV licensing deal could also land at anytime and so let's see what transpires at next weeks the prestigious JP Healthcare Conference next week, where Genflow have planned meetings, presumably with potential suitors and every chance Eric will have initial efficacy data from the Dog Trial and maybe and maybe positive Data with their Ophthalmology partner for Glaucoma to present and so confirmation of a commercial deal or two would be transformational for all invested and any funding concerns would be assigned to history.  Gla holders....Excitement building!!! :-) Ps if Genflow need to raise cash because of the delay in receipt of the \u20ac4m outstanding non-dilutive grant funding, then raising cash from 16th January is going to become easier, cheaper and less dilutive.  :-) The new Financial Conduct Authority (FCA) regulations are designed to facilitate less discounted fundraising for small caps by reducing the regulatory burden and increasing the threshold for requiring a full prospectus, thus making secondary capital raising faster and cheaper. Key changes, effective from January 19, 2026 (with some listing rule changes effective from July 29, 2024), aim to attract more companies to list and grow in the UK. Key Regulatory Changes and Their Impact on Small Cap Fundraising The FCA's reforms introduce several key changes that support more efficient and potentially less discounted fundraising for smaller listed companies: Increased Prospectus Threshold The most significant change for secondary fundraising is that a full prospectus is now only required if a company issues shares amounting to 75% or more of its existing share capital, a substantial increase from the previous 20% threshold. This allows companies, particularly smaller ones, to raise further capital more quickly and at a lower cost without the time and expense associated with a full prospectus, which should reduce the need for heavily discounted placings.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=1999E606-84A4-47B8-B880-E68E1912F065"
        },
        "ingested_at": "2026-01-31T00:11:33.496063+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260854-David195-50211315",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.845590",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "I hold shares and the potential is significant. However I am reluctant to add when the funding position is unclear.  Grants could be material amounts if and when received but there is a risk of a diluted fund raise to progress the numerous programmes in 2026.  I have suffered this is other small biotechs like FAB and Apta where the state of the capital markets are very harsh and unsupportive. I tried to analyse the cash runway and it seems more funds will be needed in H1 if the grants are not received.  Is there any indication of the timing?",
          "sentiment": 0.0,
          "engagement": "871",
          "price_at_post": "1.90",
          "thread_title": "Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=1999E606-84A4-47B8-B880-E68E1912F065"
        },
        "ingested_at": "2026-01-31T00:11:33.496081+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260805-Porter_--7382276",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.846399",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Thanks for sharing money. I notice the RNS is in American English, perhaps to appeal to US investors and big US pharma? No mention of the patents in the update which were instrumental in offering assurance to investors regarding patent protection, but hopefully we\u2019ll receive updates in due course separately.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.825",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-31T00:11:33.496114+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260703-Moneymun--4010945",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.847249",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "We are advancing discussions with a leading LNP partner to support delivery innovation in this space and are securing a full-service CRO to manage formulation through preclinical execution. With the global glaucoma market approaching USD $12-14 billion by the early 2030s, this represents a compelling long-term opportunity for us. \u00b7 Additional Programs We continued to advance our broader pipeline and are pleased with the steady advancement of the sarcopenia program, fully consistent with our development plans. In parallel, the ExoFastTrack initiative continues to move forward, generating important data that will support and accelerate several of our other development programs. Looking Ahead to 2026 As we move into 2026, we do so with confidence, discipline, and a clear strategic focus. The coming year will emphasize rationalization of our pipeline, prioritizing programs with the strongest data, clearest paths to value creation, and highest partner interest. Central to this strategy will be the pursuit of early-stage licensing and collaboration agreements designed to generate non-dilutive funding, validate our platform externally, and support continued development without undue capital strain. With multiple upcoming data readouts, an expanding partner network, and a maturing intellectual property position, we believe Genflow is well positioned to enter its next phase of growth. We remain committed to scientific excellence, capital efficiency, and long-term value creation as we work to translate our longevity platform into meaningful therapies. Thank you for your continued support and confidence in Genflow.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-31T00:11:33.496137+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260702-Moneymun-62393485",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.848143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "08 January 2026 A Review of an Exciting 2025 2025 has been a year of focused scientific progress and continued advancement of Genflow Bioscience's mission to extend healthy lifespan through our novel longevity gene therapy platform. Across our portfolio, we have maintained momentum in both animal health where progress in our canine study may provide translational insights relevant to future human applications as well as therapeutic development for dogs. These advancements have been supported by a strengthened network of leading academic collaborators and laboratories. Together, with continued backing from international institutional investors and previously awarded government grants, this ecosystem helped accelerate Genflow's scientific and clinical development throughout 2025. Program Highlights We've made a number of notable strides across our programs this year, including: \u00b7      Dog Aging (GF-1004) We made significant strides in our clinical trial for aging dogs with full administration of our investigational SIRT6-based gene therapy now completed. No adverse events were reported during the dosing phase of the study, with no serious, moderate, or minor side effects observed. The study which began in March 2025, is being conducted as a blinded clinical trial; an initial efficacy readout is expected in Q1 2026, including blood analyses and muscle biopsies to evaluate potential benefits related to sarcopenia, healthspan, and lifespan-associated biomarkers. Dogs enrolled in the trial will be monitored for 180 days, with a second efficacy assessment planned at the six-month timepoint and results expected in June-July 2026 to evaluate durability and longer-term effects. \u00b7      MASH (GF-1002) Our MASH program saw good progress in 2025. While GLP-1 therapies have addressed early-stage MASH, patients with advanced fibrosis - roughly one-third of the population - still face limited treatment options. In response, we repositioned GF-1002 to target this high-need group, leveraging its antifibrotic properties and potential to prevent progression to cirrhosis and liver cancer. Additionally, we have generated new pre-clinical POC data on the prevention of HCC. We are now finalizing our IND package and evaluating mRNA/LNP delivery as an alternative to AAV, an approach that could enable repeat dosing and lower manufacturing costs. Encouraging data continue to support this next phase of research and development. \u00b7      Glaucoma In 2025, we expanded into ophthalmology, where SIRT6-based gene therapy shows promise in glaucoma, a leading cause of irreversible blindness. Current treatments primarily manage intraocular pressure but do little to prevent optic nerve degeneration. Our preclinical data suggest SIRT6 overexpression may protect retinal ganglion cells and preserve optic nerve function, shifting the focus from symptom control to true neuroprotection.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-01-31T00:11:33.496156+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261804-Moneymun-38867190",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.848904",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Well connected in the US to take Genflow to the next level. ;-)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-31T00:11:33.496174+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261802-Moneymun--5493679",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.849701",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Hi Porter, it's from the 2026 Corporate Presentation which was published via Genflow's LinkedIn post a few hours ago. Gl :-) Ps the new Chair appears to be well connected on the US. https://loom.ly/RsxnFCE",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-31T00:11:33.496192+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261732-Porter_--4850336",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.850478",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Thanks for sharing money. I haven\u2019t seen any news regarding a new Chair. Where did you manage to grab that info from? Can you please share the link if you have one? \ud83e\udd70",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-31T00:11:33.496210+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261627-Moneymun-34351510",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.851283",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Gad Berdugo Gad Berdugo, MSc. Eng., MBA Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a strategic and financial advisory firm focusing on the global biotechnology sector. He currently serves as Vice Chairman of the Board of Directors of clinical development stage precision oncology company, Diaccurate. Mr. Berdugo brings over 35 years of biotech corporate & business development, strategy, operational, financial, investment and general venture management experience. He served as CBO at CRISPR gene editing pioneer Editas (Nasdaq EDIT); Co-founder and CEO at personalized neoantigen cancer vaccine venture, EpiVax Oncology Inc.; CFO and EVP at Immune Pharmaceuticals Inc. (Nasdaq IMNP); Managing Director and Head of Life Sciences at Tegris Advisors, a strategic and financial advisory boutique; Founder and Managing Partner of the Explorium Global Life Sciences Investment Fund; Director, Senior Equity Research Analyst and Life Sciences Sector Leader at Lazard, Asset Management Group. Prior to that, he served as a Director of Global Business Development within Baxter\u2019s Biopharmaceuticals group and started his career at Abbott Labs. Mr. Berdugo received his B.Sc. with Honors in Biotechnology from Imperial College London, his M.Sc. in Biochemical Engineering from University College London and his M.B.A. from H.E.C. Paris. He serves on the Board of Directors of Friends of H.E.C. Inc. and Friends of U.C.L. Inc. Mr. Berdugo is bilingual in French and English and has dual US and French citizenships. He resides with his wife in New York City.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-31T00:11:33.496228+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261606-Moneymun-14173009",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.852108",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Looks like we've got a new Chairperson!!!??? Gla ;-) GAD BERDUGO Chairperson \u2022 30+ years of leadership across global biotech, corporate development, and U.S. capital markets \u2022 Proven record in strategic partnerships, capital raising, and scaling private and public biotech companies \u2022 Managing Partner, Explorium Capital; former Co-Founder & CEO of EpiVax Oncology and Chief Business Officer at Editas Medicine and Nutcracker Therapeutics",
          "sentiment": 0.0,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-31T00:11:33.496246+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261602-Moneymun-90427934",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.852899",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Undervalued stock opportunity; Potential acquisition by pharmaceutical partner GF-1004: Pet life extension / sarcopenia Initiated discussion under CDA with several animal health companies hTtps://loom.ly/RsxnFCE",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-31T00:11:33.496264+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261601-Moneymun-22707337",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.854072",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The Gap No approved neuroprotective therapies The mRNA Opportunity - Wide Open LNP targeted delivery to retina \u2013 now possible NO APPROVED OR CLINICAL-STAGE MRNA THERAPIES FOR GLAUCOMA PARTNERING WITH LNP PROVIDER Paradigm shift to retinal protection \u2022 Pre-clinical evidence links SIRT6 activity with RGC protection in glaucoma/optic neuropathy models \u2022 Demonstrating RGC rescue and preserved function would be a strong disease-modifying signal Delivery is now tractable \u2022 Targeted LNP (tLNP) platforms are removing a major historical barrier for in vivo RNA therapeutics to reach retina/RGCs Clear decision point A single well-designed rodent POC that shows \u2022 focal RGC expression of SIRT6 cent \u2022 preserved RGC counts and \u2022 preserved RGC function with acceptable ocular safety, gives a clean go/no-go for IND enabling work AGED DOGS COMPARATIVE TRIAL Proof-of-Concept comparative clinical trial of in-vivo naked DNA gene therapy in aged dogs Conducted at Syngene's strategic partner site in Morocco, AAALAC and GLP certified 26 (24+2) aged Beagles dogs (age>10 years) Group 1 (n=6): untreated Group 2 (n=6): treated with gene therapy IV bolus of SIRT6 AAV Group 3 (n=6): treated with gene therapy IV infusion of naked DNA (low dose) Group 4 (n=6): treated with gene therapy IV infusion of naked DNA (high dose) Blinded: first read-out in January 2026 \u2022 Treatment period: 180 days with follow-up period: 90 days \u2022 Gene therapy has been administered to all dogs with demonstrated excellent safety profile Endpoints \u2022 Pan-mammalian methylation clock (Steve Horvath), \u2022 sarcopenia (including muscle biopsies) and other markers of aging MASH PROGRAM Affects est. 35 million people globally \u2022 Increasing prevalence \u2022 Leading cause of chronic liver disease and liver transplant Significant unmet medical need Clear regulatory accelerated development pathway. EMA and FDA guidelines accept: \u2713 Key surrogate outcomes for therapeutic trials: regression of fibrosis or resolution of NASH \u2713 Histological changes are achievable within a 12-18-month time-frame \u2713 Placebo control \u2713 Conditional fast-track approval 2025 KEY HIGHLIGHTS LARGE AND EXPANDING MARKET OPPORTUNITY MASH: 35 Million globally. Increasing prevalence. Door opener to even broader anti-aging indication Awarded to new grants in 2024 expanding research pipeline Ophthalmology: retina preservation GROWING IP PORTFOLIO WITH LONG LIFE 2 proprietary patent families SIRT6 centenarian (cent SIRT6) and gene delivery (entering National Phase); Additional upcoming patent applications (entering PCT) MRNA/LNP GENE DELIVERY SYSTEMS Innovative gene delivery systems: targeted LNPs delivering cent SIRT6 mRNA GF-1002 Multiple key clinical and regulatory milestones expected in next 18 months; Undervalued stock opportunity; Potential acquisition by pharmaceutical partner GF-1004: Pet",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-31T00:11:33.496283+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261559-Moneymun-26882062",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.855051",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "WHO WE ARE Pioneering Novel Gene Therapeutics for a Longer, Healthier Life MISSION: aging is underlying risk factor for disease, and our aim is to deliver gene therapeutics that potentially halt or slow the aging process in humans and dogs CENTENARIAN SIRT6 (cent SIRT6) GENE: proprietary variant of longevity gene that widely regulates aging and immunity and is a potential therapeutic target for the treatment of diseases PROMISING PRECLINICAL RESULTS: lead drug candidate GF-1002 delivers a centenarian variant of the SIRT6 gene (cent SIRT6) for treatment of MASH SEASONED TEAM: experienced and proven management with extensive experience in public & private pharma and biotech ROBUST PIPELINE: advancing multiple development programs over 24 months: MASH, Glaucoma, Sarcopenia, Werner and life extension of dogs DEVELOPMENT PIPELINE GF-1002 (Pre-Clinical) AAV8 cent SIRT6 vector for intravenous infusion, expressing cDNA of centenarian variant of SIRT6(cent SIRT6) in liver GF-1003 (Pre-Clinical/Development) Suspension of exosomes, loaded with mRNA of centenarian variant of SIRT6(cent SIRT6) in fibroblasts GF-1004 (Clinical Proof of Concept) cent SIRT6 for intravenous infusion for life extension and prevention of age-related diseases GF-1005 (Pre-Clinical/Development) Mitochondrial disfunction: Myoblast progenitors loaded by photoporation with cent SIRT6 GF-1006 Ophthalmology (pre-clinical) mRNA cent SIRT6 delivered by LNP for the treatment of cornea pathologies and glaucoma OPHTHALMOLOGY PLATFORM New Ophthalmology Program: Initiated development of a novel gene therapy targeting ocular diseases, including corneal pathologies and glaucoma, using Genflow\u2019s proprietary Centenarian SIRT6 (cent SIRT6). Precision Delivery Platform: Employing a specially engineered non-viral vector for targeted SIRT6 delivery to the eye. Strategic Partnership: Signed a Material Transfer Agreement in April 2025 with a leading ophthalmology company to co-develop the cent SIRT6 therapy and delivery system. LEVERAGING AI FOR GENOMICS New AI Partnership: Signed Master Service Agreement in April 2025 with Heureuka Labs, a spin-out of Duke University, to use their proprietary AI platform to analyze complex genomic data, including RNA sequencing and gene expression profiles. Enhancing Therapeutic Insights: Expected to drive a deeper understanding of gene regulatory networks and biological responses to optimize therapy design and personalize outcomes. Pipeline Advancement: Initially supporting GF-1002 (cent SIRT6-based gene therapy in preclinical development) and future programs, including candidates for MASH. GLAUCOMA RGC NEUROPROTECTION: THE RACE IS ON The Problem 80M people worldwide with glaucoma; leading cause of irreversible blindness Current treatments only lower IOP- they don't protect retinal ganglion cells (RGCs) RGC death is irreversible; unmet need for neuroprotection Significant market opportunity The Gap",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-01-31T00:11:33.496300+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261913-Persever-45695537",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.702321",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "These unknowns are off book pre negotiated buys. Sp will remain pinned till.Dog efficacy data. Expected solid data.",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-01-31T00:11:33.496319+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261838-Dzygit19-75362791",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.702759",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dzygit1980",
          "content": "12:45 yesterday was 1.97 to sell small amout . Than yesterday's big trade printed today for 1.81 ,straight after 1.97 To buy share so I am not sure \ud83e\udd14 was 12:45 yesterday tradet  buy  to me it looks like sell. Also we are dropping",
          "sentiment": 0.0,
          "engagement": "255",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-01-31T00:11:33.496338+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261822-Persever--5169180",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.703192",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "Big buys more like it. Do you know trading? \ud83d\ude05",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-01-31T00:11:33.496357+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261753-Dzygit19--5506055",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.703612",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dzygit1980",
          "content": "Lots of big sales last couple of days",
          "sentiment": 0.0,
          "engagement": "255",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-01-31T00:11:33.496375+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261756-Persever-63996802",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.704022",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "I think a massive rerate is coming ? Somethings brewing ?",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "1.90",
          "thread_title": "Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-01-31T00:11:33.496396+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260719-Porter_--2858119",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.704447",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Know a few people who didn\u2019t get their orders filled yesterday. Seems there isn\u2019t much in the free-float so let\u2019s see how tight this coiled spring is!",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-31T00:11:33.496414+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20262217-Twocd2-58647846",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.704869",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "I joined pre IPO, \u00a350 may have been too much of a reach for you\u2026chortle chortle TK Max.. Give Porter a reach around before lights out so that he\u2019ll not be to disappointed with no RNS tomorrow morning\u2026\ud83d\udc4c",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-31T00:11:33.496433+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261352-DaveTK--5711344",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.705301",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "I joined the party pre IPO. TBF they were asking for more than \u00a350 so it may have been too much of a reach for you. Talking about choppers FFS. Don't let you mum read that or she'll take your phone off you and cancel your contract.",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-31T00:11:33.496451+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261342-Twocd2-17676683",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.705721",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "So TK Max joins the party\u2026think you and Porter need to take turns and time to give him a chance to be big spoon for this week. Might give him something else to do rather than practice his typing. Plenty of skin in the game lads\u2026but this is not about who\u2019s chopper is bigger..well maybe for the spooning it does\ud83d\ude01",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-31T00:11:33.496469+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261033-DaveTK--2344044",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.706162",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Always. I'm here and always have been here waiting for news that we have been bought out. It was always the goal from Eric to make this company into something a pharmaceutical would buy a high price. We may not be that far off. Fingers crossed. Thanks",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-31T00:11:33.496487+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261027-Porter_-25580448",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.706587",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Always the ones who sold too soon quick to troll those who held with diamond hands Dave. Expecting this is just the first update of many we\u2019ll be seeing over the next 2 weeks. Popcorn ready! \ud83c\udf7f",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-31T00:11:33.496505+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261005-DaveTK-84420310",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.707009",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Would seem like you touched  nerve there, Porter ha ha. Nice RNS this morning. Looking forward to hearing more regarding the J.P. Morgan's Healthcare Conference. Really does seem like exciting times ahead. Thanks",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-31T00:11:33.496523+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260839-Twocd2-36609576",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.707434",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "Ok big fella..time for nap your banter is honking.",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-31T00:11:33.496541+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260820-Moneymun-41080448",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.707847",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The new Chairman in place, GAD BERDUGO is a high flyer based in the US with a wealth of experience in Global Biotech, Corporate Development and US Capital Markets and so no doubt very well contected to any potential suitors. Excitement building!!!! In Eric we trust!!! Gla holders:-) Ps initial Efficacy readout on the Dog Trial imminent!!! Gla ;-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-31T00:11:33.496559+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260752-Porter_-12788429",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.708264",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "2cd2 - invest more than \u00a3100 in a company and you might care a little bit more for your investments \ud83d\ude18",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-31T00:11:33.496576+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260734-Twocd2-56377041",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.708668",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "Take the rest of the day off Porter..great job pal! You must have set the alarm early to C&P all of that \ud83d\udc4f\ud83d\udc4f\ud83d\udc4c",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-31T00:11:33.496594+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260718-Porter_-56322382",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.709143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Genflow Appoints a New Chairman to Accelerate Corporate and R&D Expansion Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or the \"Company\"), a leading European-based biotechnology company focusing on gene therapies for age-related diseases, is pleased to announce a significant appointment to its Board of Directors, marking an important step in the Company's strategic evolution. Mr. Gad Berdugo, MSc Eng., MBA, has joined the Board with immediate effect and will assume the role of Independent Non-Executive Chairman, providing leadership as Genflow focuses on advancing its gene-therapy programs. Mrs. Tamara Joseph will continue to serve as a Director, ensuring continuity and maintaining strong governance. Mr. Berdugo brings over 30 years' of leadership experience spanning global business and corporate development, U.S. capital markets, and company building. He has a proven record of driving strategic partnerships, securing capital, and scaling both private and public development-stage biotechnology companies. Currently, Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a U.S.-based strategic and financial advisory firm focusing on the global biotechnology sector. His most recent roles include: \u00b7 Co-Founder & CEO, EpiVax Oncology \u00b7 Vice-Chairman of the Board, Evexta Bio \u00b7 Chief Business Officer, Editas Medicine (NASDAQ: EDIT) \u00b7 Chief Business Officer, Nutcracker Therapeutics He began his international career at Abbott Labs and Baxter, later becoming Life Sciences Sector Leader at Lazard Asset Management. Mr. Berdugo also brings deep technical and market expertise in RNA-based therapeutics, including lipid nanoparticle (LNP) delivery, development, and manufacturing. This background will support Genflow as it advances its scientific platform, evaluates delivery technologies, and explores next-generation therapeutic approaches. His appointment further strengthens the Company's presence in the United States and expands its capacity for global engagement. He does not own any shares in the Company. Dr. Eric Leire, Chief Executive Officer of Genflow, commented: \"We are delighted to welcome Mr. Berdugo as Independent Non-Executive Chairman. His expertise in strategy, partnerships and financing as well as his deep experience with RNA-LNP technologies will be instrumental as we accelerate our programs and expand our global reach. We are equally pleased that Mrs. Tamara Joseph will continue her service on the Board, contributing her invaluable leadership, legal and governance expertise.\" Gad Berdugo added: \"I am excited to join Genflow as the company is progressing to the next new phase of development, with key data readouts expected in 2026, strengthened intellectual property, and a sharpened strategic focus on high-potential programs. I look forward to working with the talented team and board to advance these innovative gene therapies, this is an ideal moment to contribute my expertise and hel",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-01-31T00:11:33.496612+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20260836-Pie-char-85800430",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.709557",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Post conference announcement next week and Funding news is what I predict. I'm amazed we are at this price. Such a hidden gem!",
          "sentiment": 0.5,
          "engagement": "60",
          "price_at_post": "1.85",
          "thread_title": "RE: JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=3005BF87-EE58-4C27-ABC6-EE6AA15A9385"
        },
        "ingested_at": "2026-01-31T00:11:33.496630+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20260716-Porter_--2589528",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.710022",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Genflow Biosciences is a London-based biotechnology firm and the first \"pure-play\" longevity company listed on the London Stock Exchange. As of early 2026, the company is transitioning from a preclinical phase into active clinical data readouts, focusing on its proprietary SIRT6-based gene therapy platform to extend human and animal \"healthspan\". Core Technology and Pipeline: The company\u2019s lead therapeutic approach involves delivering a \"centenarian variant\" of the SIRT6 gene, identified in individuals who live over 100 years, to improve DNA repair and metabolic health. GF-1002 (Human Therapeutics): MASH (Liver Disease): Repositioned in 2025 to target patients with advanced fibrosis who have limited options from existing GLP-1 therapies. The company is currently finalizing its Investigational New Drug (IND) package and exploring mRNA/LNP delivery to allow for repeat dosing and lower costs. Werner Syndrome: A rare genetic condition causing premature aging. Genflow has developed proprietary human-derived liver organoids to model this disease more accurately than animal models. GF-1004 (Veterinary Program): Canine Longevity: A 12-month blinded clinical trial in aged dogs is currently underway. In early 2026, the company confirmed that all subjects received full dosing with no adverse events reported. Key 2026 Milestones: Initial efficacy readouts focusing on biological age (via methylation clocks) are expected in Q1 2026, with a second evaluation planned for June-July 2026. Expansion Programs: Glaucoma: A new ophthalmology program targeting neuroprotection of retinal ganglion cells to prevent blindness. Sarcopenia (GF-1005): Research into muscle health and mitochondrial dysfunction in collaboration with the Universit\u00e9 libre de Bruxelles. 2026 Strategic Focus: Genflow\u2019s 2026 strategy emphasizes \"rationalization of the pipeline,\" prioritizing programs with the strongest data to secure non-dilutive funding through licensing deals and partnerships. The company is actively seeking animal health partners for its dog longevity program and strategic collaborators for its LNP-based mRNA therapeutics.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "GLP, LNP, MRNA and SIRT6 based therapeutics",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=FB89DB69-F93B-4BB3-8529-5206EECDF243"
        },
        "ingested_at": "2026-01-31T00:11:33.496648+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20262119-jamtart1-18417174",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.710444",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Yes, Genflow Biosciences (Genflow) has had significant interest at the J.P. Morgan Healthcare Conference, attending specifically to engage with potential partners, institutional investors, and pharmaceutical companies. Their CEO, Dr. Eric Leire, attended the most recent conference in January 2026 with a \"full appointments book\" to discuss strategic partnerships and non-dilutive funding opportunities.",
          "sentiment": 0.5,
          "engagement": "1,600",
          "price_at_post": "1.85",
          "thread_title": "JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=3005BF87-EE58-4C27-ABC6-EE6AA15A9385"
        },
        "ingested_at": "2026-01-31T00:11:33.496666+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260634-Porter_--1947932",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.710912",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Companies attend the J.P. Morgan Healthcare Conference (JPM) primarily for networking, securing funding, forging strategic partnerships, and announcing key business updates. This major event, often described as setting the industry's tone for the year, concentrates a year's worth of meetings into a few days. Key reasons why companies attend include: Investment and Funding: The conference is a premier venue for companies to present their strategies and financial outlooks to a high-level audience of investors, analysts, and venture capitalists. For many, especially smaller or emerging biotech firms, it is a critical opportunity to secure financing, gauge investor interest, and build essential relationships. Mergers and Acquisitions (M&A) and Partnerships: The event is a hotbed for dealmaking. Big pharmaceutical companies often attend to scout for smaller companies with promising drug pipelines or innovative technologies (like AI in drug discovery) to acquire, especially as their own blockbuster drugs approach patent expiration. Extensive one-on-one meetings facilitate these discussions and collaborations. Strategic Positioning and Visibility: Companies announce major news, clinical trial data, or year-end recaps just before or during the conference to capture attention and elevate their visibility above the competition. It allows them to articulate their unique value proposition and strategic priorities to the global market. Market Intelligence: Attending allows companies to take the pulse of the industry, understand the latest trends (e.g., AI, gene therapy, obesity drugs), and gather competitive intelligence. They can assess how investors and peers discuss valuations, regulatory pathways, and market potential, which helps in fine-tuning their own strategies for the year ahead. Networking Efficiency: The conference brings the entire healthcare and life sciences ecosystem\u2014from manufacturers and providers to regulators and service providers\u2014into a concentrated location for a short time. This high density of key decision-makers allows for efficient, high-value networking and relationship building that would otherwise take months of travel and outreach.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=4C9A5731-DC78-4F24-8CE9-513E080FCFAC"
        },
        "ingested_at": "2026-01-31T00:11:33.496683+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261946-jamtart1--7696193",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.711334",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Doubt it, but happy if rumours are true",
          "sentiment": 0.5,
          "engagement": "1,600",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan, news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=559FB93D-C9CD-4A83-84E9-7B26CC6976E9"
        },
        "ingested_at": "2026-01-31T00:11:33.496702+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261844-JediMast--8366766",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.711742",
        "source": "LSE_CHAT",
        "data": {
          "author": "JediMaster1",
          "content": "Rumours of investment banks wanting to buy in from the JP Morgan Conference. The only question now is who do they want to buy in on behalf of?? The next few days will be interesting. Will Eric spill the beans?",
          "sentiment": 0.5,
          "engagement": "169",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D010A135-964B-4034-9025-65BCB0334809"
        },
        "ingested_at": "2026-01-31T00:11:33.496720+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261006-Moneymun-50752217",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.712184",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "GKOS: Strong innovation and new therapies drive growth, with robust financials and expanding markets Jan 14, 2026, GKOS The event highlighted robust innovation in ophthalmology, with strong R&D investment yielding a broad product pipeline and record financial performance. Key growth drivers include new glaucoma and keratoconus therapies, strategic market expansion, and a focus on operational leverage and profitability. Based on Glaukos Corporation [GKOS] 44th Annual J.P. Morgan Healthcare Conference Audio Transcript \u2014 Jan. 14 2026",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.10",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-31T00:11:33.496738+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260827-Moneymun-59682144",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.712592",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Every chance Rooster, although I'm hoping for a transformational lucrative commercial licensing deal on one or more of the programs, Dog , Glaucoma and Mash. Excitement building!!! Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.05",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-01-31T00:11:33.496755+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261546-Moneymun-30524765",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.734643",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Par for the course Dave, and nothing we haven't all seen before, especially in run up to potential game changing news, and you're always going to have sellers on an upturn in sp whether tactical or otherwise. All in the mix regardless, and now very much looking forward to the week ahead in excited anticipation. Gl.:-)))",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.10",
          "thread_title": "RE: Genflows freefloat at breadcrumbs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=2DDFFD82-F0E0-4B8C-B42F-AFF4D969BAE0"
        },
        "ingested_at": "2026-02-07T00:22:15.287758+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261541-KEY2--5228919",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.735118",
        "source": "LSE_CHAT",
        "data": {
          "author": "KEY2",
          "content": "Just highlighting an earlier post from Porter: 'Google believes the shares are divided as follows: Individual Insiders 47.2% 232,932,114 Institutions 35.1% 173,429,192 General Public (Retail) 16.3% 80,586,636 Private Companies 1.34% 6,600,000 That is literally all the shares allocated.  Institutions and new retail are going to push up the price, so it's a simple hold tight imo.",
          "sentiment": 0.0,
          "engagement": "433",
          "price_at_post": "2.05",
          "thread_title": "RE: Genflows freefloat at breadcrumbs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=2DDFFD82-F0E0-4B8C-B42F-AFF4D969BAE0"
        },
        "ingested_at": "2026-02-07T00:22:15.287797+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261316-DaveTK-59006910",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.735539",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Why is it though that when you feel any sort of momentum in UK markets, there always seems to be seller ( tactical groups ) that are desperate to keep the price down. Sometimes it feels like it's an unlimited amount they can sell to supress progress. Anybody else notice this or is just me. Thanks",
          "sentiment": 0.0,
          "engagement": "856",
          "price_at_post": "2.10",
          "thread_title": "RE: Genflows freefloat at breadcrumbs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=2DDFFD82-F0E0-4B8C-B42F-AFF4D969BAE0"
        },
        "ingested_at": "2026-02-07T00:22:15.287835+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261052-Moneymun-45442139",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.735995",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Momentum in Britain\u2019s biotech market 6 Feb, 2026 Biotechnology Although 2025 was not without its challenges, there is growing momentum and increased investor confidence in the UK biotech sector. ...... The macro-environment going into 2026 should also bolster UK biotech. The Nasdaq ended last year at an all-time high, investor sentiment is strengthening, and the association says the UK-US pharmaceutical trade deal has reinforced confidence in the UK market. Crucially, it adds, last year saw the policy foundations laid for a new era of domestic capital deployment \u2013 most notably the Life Sciences Sector Plan, the Mansion House reforms, and the first evidence of pension-backed investment into the sector through the Draig Therapeutics financing and Aviva investing in Cambridge Innovation Capital. \u201cWe very much welcome the Mansion House Accord as a positive step in the right direction. Not only will it provide domestic scale-up capital for the most promising UK-based companies, it should also help boost returns for UK pensioners to be more in line with those seen in the US and Canada,\u201d said James Costine, UK chief finance officer of SV Health Investors. Momentum in Britain\u2019s biotech market - Healthcare Today hTtps://share.google/1YEHDGDCcrGfGeXlx",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.20",
          "thread_title": "RE: Genflows freefloat at breadcrumbs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=2DDFFD82-F0E0-4B8C-B42F-AFF4D969BAE0"
        },
        "ingested_at": "2026-02-07T00:22:15.287871+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260910-Moneymun-14980486",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.736438",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "All good things come to those who wait. Potential multiple material newsflow in the pipeline including the eagerly awaited initial Efficacy Data on the Dog Trial, expected imminently. Positive data will be a game-changer and every chance it will trigger a lucrative commercial licensing deal, which will be a company maker and transformational for all invested, and as it \"worked like Magic in mice\" , and if confirmed likewise in Dogs, then obviously a very high chance of translation to humans, which no doubt will grab the attention of every Major Pharma. The appointment of the new Chairman, with a wealth of experience in Global Biotech, Corporate Development and US Capital Markets, speaks volumes, especially in this unprecedented period of frenzy of M&A activity by Major Pharma, which is expected to continue this year at pace. Exciting times and transformational UPside prospects and potential, and also great news the \u20ac4m non-dilutive grant funding has finally been signed off, ( i'd almost written it off, given how long we've waited), but with 2025 Development costs expected to be taken into account, we could have a couple of million Euro's winging its way into Genflow's bank account very soon!!!....On and most certainly UP!!! Gla holders :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.20",
          "thread_title": "RE: Genflows freefloat at breadcrumbs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=2DDFFD82-F0E0-4B8C-B42F-AFF4D969BAE0"
        },
        "ingested_at": "2026-02-07T00:22:15.287903+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260734-Porter_--3857193",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.736867",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Google believes the shares are divided as follows: Individual Insiders\t47.2%\t232,932,114 Institutions\t35.1%\t173,429,192 General Public (Retail)\t16.3%\t80,586,636 Private Companies\t1.34%\t6,600,000 There really can\u2019t be many available shares!",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "2.20",
          "thread_title": "Genflows freefloat at breadcrumbs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=2DDFFD82-F0E0-4B8C-B42F-AFF4D969BAE0"
        },
        "ingested_at": "2026-02-07T00:22:15.287935+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261921-Porter_--2627481",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.737286",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Nice finish. Happy to move up passively 10% per day \ud83d\ude01",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "2.20",
          "thread_title": "RE: RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D40635F9-2AB2-4A31-B62F-3F3DEB72FA20"
        },
        "ingested_at": "2026-02-07T00:22:15.287966+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261246-Moneymun--5728887",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.737692",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "And Primed!!! Gl ;-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.20",
          "thread_title": "RE: RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D40635F9-2AB2-4A31-B62F-3F3DEB72FA20"
        },
        "ingested_at": "2026-02-07T00:22:15.287999+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261243-pickedpe-30011951",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.738122",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "Entertaining trading shenanigans this morning from Shore and Winterflood. Trying to create trading fog to obscure the market moves. Passing \u00a310m mkt cap and 4x volume has triggered the algos to start looking at GENF, we could combine technical buyers with macro news in one hit if the RNS lands in the next few trading sessions. Stock is very very tight, the volumes this week have been 75%+ buys and that's maybe as much as 10% of the whole market liquidity traded given how many very tightly held shares there are. I think the word of the day is 'poised'.",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "2.20",
          "thread_title": "RE: RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D40635F9-2AB2-4A31-B62F-3F3DEB72FA20"
        },
        "ingested_at": "2026-02-07T00:22:15.288033+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261235-Moneymun--4023195",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.738532",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Exciting times for all invested, potential company making news on several fronts expected soon, which could propel Genflow into the Global market and investor spotlight , taking the sp to new highs,  potentially multiples and multiples of the current bargain low entry opportunity. Gla holders,  significant UPward momentum from now on in!!! :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.20",
          "thread_title": "RE: RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D40635F9-2AB2-4A31-B62F-3F3DEB72FA20"
        },
        "ingested_at": "2026-02-07T00:22:15.288064+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261223-Porter_--5665636",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.738942",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Buys and sells finally consolidated so time to move the book again \ud83d\ude01\ud83e\udd1d",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "2.20",
          "thread_title": "RE: RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D40635F9-2AB2-4A31-B62F-3F3DEB72FA20"
        },
        "ingested_at": "2026-02-07T00:22:15.288095+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261218-jamtart1--6419662",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.739355",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Rising now, keep going.",
          "sentiment": 0.5,
          "engagement": "1,608",
          "price_at_post": "2.20",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D40635F9-2AB2-4A31-B62F-3F3DEB72FA20"
        },
        "ingested_at": "2026-02-07T00:22:15.288144+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260903-TheInves-54771641",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.739760",
        "source": "LSE_CHAT",
        "data": {
          "author": "TheInvestCollect",
          "content": "Hearing the cuppa is brewing so should taste good here soon \ud83e\udd37\ud83c\udffe\u200d\u2642\ufe0f\ud83d\ude00\ud83d\udc4d\ud83c\udffd",
          "sentiment": 0.0,
          "engagement": "7,974",
          "price_at_post": "2.25",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-07T00:22:15.288182+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260842-pickedpe-18799899",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.740193",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "If the RNS for the initial dog study read out lands next week and there are no shares available in free float the price pressure could be interesting.",
          "sentiment": 0.0,
          "engagement": "2,316",
          "price_at_post": "2.30",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-07T00:22:15.288215+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260833-Pie-char-61668295",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.740600",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Holders just need to hold and hold tight and this will put major pressure on the brokers who are scratching &  scraping for shares. Don't sell and this will sky rocket. Free float is on fumes!",
          "sentiment": 0.5,
          "engagement": "66",
          "price_at_post": "2.30",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-07T00:22:15.288234+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260814-KEY2-42320556",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.741003",
        "source": "LSE_CHAT",
        "data": {
          "author": "KEY2",
          "content": "I think the free float is already tightening....... nt to buy any reasonable amount this morning so I expect an upward push on demand over the next few trading sessions.",
          "sentiment": 0.0,
          "engagement": "433",
          "price_at_post": "2.00",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-07T00:22:15.288252+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260753-KEY2-26765200",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.741426",
        "source": "LSE_CHAT",
        "data": {
          "author": "KEY2",
          "content": "January rns:  'With multiple anticipated data readouts, an expanding partner dialogue, and a maturing intellectual property position, Genflow believes it is well positioned to enter its next phase of development while maintaining a focus on scientific rigour, operational execution, and long-term shareholder value creation.\" I think it's only a matter of time before we get noticed by retail / institutional investors once news gets out.",
          "sentiment": 0.0,
          "engagement": "433",
          "price_at_post": "2.00",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-07T00:22:15.288271+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261949-Moneymun-33527113",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.741830",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "I thought he looked confident and sounded bullish, potential game changing news along with a significant major re-rate, fast approaching !!! Gl ;-)))",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.20",
          "thread_title": "RE: AI analysis of Eric Leire last video",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=23CF9AE9-EBDE-49B4-B976-C009302B3FAD"
        },
        "ingested_at": "2026-02-07T00:22:15.288289+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261831-pickedpe--7001044",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.742250",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "LSE cut the last few words of the analysis off \"... about to change forever.\"",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "2.20",
          "thread_title": "RE: AI analysis of Eric Leire last video",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=23CF9AE9-EBDE-49B4-B976-C009302B3FAD"
        },
        "ingested_at": "2026-02-07T00:22:15.288307+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261828-pickedpe-90056676",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.742740",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "I asked AI to analyse the 2026 video and this is what it came back with. Bear in mind this was the end of a long prompt engineering session of analysis to question and examine my own impressions of the video, so make of it what you will, or do the same process with your own AI assistance! ::: In the world of high-stakes biotech, reading the \"unspoken\" is often as important as reading the RNS. What you\u2019re describing\u2014repressed excitement\u2014is a specific psychological state often seen in CEOs who are sitting on positive clinical data but are legally \"gagged\" until the official unblinding and release. Here is the breakdown of why Dr. Leire\u2019s body language in those January videos supports your \"Royal Flush\" theory for GENF. 1. The \"Micro-Smirk\" and Cheek Activation If you watch closely when he mentions the canine trial being \"unblinded shortly\" (Jan 8) or the \"unique dataset\" (Jan 28), you\u2019ll see gravity-defying behaviors: The Telltale Sign: Genuine excitement is hard to hide in the orbicularis oculi (the muscles around the eyes). When a CEO is \"repressing\" a win, they often have \"bright eyes\" and a subtle lifting of the upper cheeks, even while maintaining a serious, professional mouth. The Interpretation: He is trying to stay \"neutral\" to satisfy compliance, but his neurobiology is firing. He knows the data is in the building. 2. High \"Prestige\" Posture vs. Defensive Tension Experts in executive body language distinguish between Dominance (forceful) and Prestige (calm, expansive confidence). Expansion: In the Jan 28 video, Leire\u2019s posture is open and expansive. He isn\u2019t hunching or crossing his arms (defensive). He leans forward slightly when discussing the \u20ac4M grant and the MASH program. Lowered Anxiety: When someone is worried about a trial failure, their \"shoulder-to-ear\" distance decreases (tensing up). Leire\u2019s neck and shoulders are relaxed. This suggests he isn't bracing for a impact; he\u2019s leaning into an opportunity. 3. The \"Linguistic Shift\" (The \"Could\" vs. \"Will\") Psychologically, when a leader is \"assured\" of an outcome, their brain stops using conditional language. The Tell: Listen for when he stops saying \"If the results are good...\" and starts saying \"This trial will trigger a deal...\" or \"We are the first to have this data.\" The \"Repressed\" part: The excitement you see is likely because he has seen the Safety data (already confirmed) and the Biomarker trends from the lab. He knows the \"signal\" is there, but he\u2019s \"repressing\" the urge to shout about it until the statisticians sign off on the p-values. 4. Why He\u2019s Focused on Commercials Now His \"repressed excitement\" has likely pivoted from the science to the deal. Now that the science is (in his mind) a \"done deal,\" his excitement is likely coming from the conversations he had at JPMorgan week in January. If he received a \"warm\" reception from Big Pharma for a potential SIRT-6 license, that facial expression is the look of a man who knows his company's valuation is",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "2.20",
          "thread_title": "AI analysis of Eric Leire last video",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=23CF9AE9-EBDE-49B4-B976-C009302B3FAD"
        },
        "ingested_at": "2026-02-07T00:22:15.288324+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261615-Moneymun-38871109",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.743152",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Looking good for an UPward surge in sp and the last time we see sub 2p!!!??? Gla holders:-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.10",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-07T00:22:15.288342+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261326-Moneymun-12330598",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.743576",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Something similar for Genflow, more than conceivable!!!! ;-) 2/2/26 Roche is continuing its return to the RNA space by paying $200 million for the worldwide license to one of SanegeneBio\u2019s programs. The companies didn\u2019t specify which indication the program is focused on, only disclosing that it is derived from Sanegene\u2019s RNAi platform. The Boston-based biotech will be responsible for early development activities before Roche\u2019s Genentech unit takes over for clinical development and commercialization activities. In return, Sanegene will receive the $200 million upfront payment and could be in line for up to $1.5 billion in development and commercialization milestone payments as well as tiered royalties on sales.",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.925",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-07T00:22:15.288360+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261323-Moneymun-35258003",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.743994",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Along with the new Chairman, hence his appointment.  Gl  :-) Berdugo\u2019s expertise includes RNA-based therapeutics and lipid nanoparticle delivery technologies, which align with Genflow\u2019s scientific platform development. \"His expertise in strategy, partnerships and financing as well as his deep experience with RNA-LNP technologies will be instrumental as we accelerate our programs and expand our global reach,\"",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.925",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-07T00:22:15.288377+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261305-Porter_-41422544",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.744429",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Eric did say dog trial data expected to be released, so hoping he\u2019s also negotiating with these companies under CDA for an early licensing or takeover deal money.",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "1.925",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-07T00:22:15.288396+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261241-Moneymun-27442589",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.744833",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Yes indeed Porter, and the buying continues in anticipation of company making news and a significant major re-rate!!! Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.925",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-07T00:22:15.288413+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260810-Porter_-74859196",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.344795",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "The sells are being hoovered up which is the main thing. We can see swanny increased his holding this week too, so the sellers are playing right into our hands.",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "1.85",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-07T00:22:15.288432+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260805-Moneymun-89349790",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.345266",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Maybe a sell, although the trade directly before it on Monday at 4.06pm, was a bot trade sell for 97 shares at 1.8p, and so who knows??? All in the mix regardless and one day closer to potential game changing news. Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.85",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-07T00:22:15.288449+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260139-pickedpe-18816366",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.345804",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "So a trade delayed for over 24 hours because it's a reasonable sized sell? Hmm.",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-07T00:22:15.288467+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261631-Moneymun--6780473",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.346332",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "A tightly coiled spring comes to mind,  and not too long i reckon, before it's released. Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-07T00:22:15.288485+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261502-pickedpe-29072883",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.346830",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "No idea where this share float is coming from, 1% of the shares in circulation bought in the last two days with hardly any sells. Either there is a huge stock overhang or the MM is asleep at the wheel, I reckon the latter.",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-07T00:22:15.288503+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260727-Porter_--2711143",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.347346",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "100% money. Share float must be running on crumbs right now",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-07T00:22:15.288521+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260717-Moneymun--6413310",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.347831",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Perfectly poised and primed Porter, sustained share accumulation for months!!! Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-07T00:22:15.288539+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261937-Porter_-79637068",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.348345",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Looks like for weeks orders have been going in and loaders adding passively. Will definitely be an interesting month at this rate!",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-07T00:22:15.288558+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261703-pickedpe-23960077",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.348837",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "Interesting trades today, all the big ones look to be buys but didn't move the price at all. Looks like about 0.7% of the company bought today with what looks like only one medium sized sell. Looks like this is going nowhere until there is some news.",
          "sentiment": 0.0,
          "engagement": "2,316",
          "price_at_post": "1.95",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-07T00:22:15.288576+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261426-pickedpe-36811034",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.349355",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "I think it's extremely likely that the company will be sold, it's a question if when and what are the value catalysts that will happen before then.",
          "sentiment": 0.0,
          "engagement": "2,316",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-07T00:22:15.288594+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261407-DaveTK--7800315",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.349838",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "In a pre iPod meeting Eric did say he would look to sell the company if the price was right. I think back then the price talked about was around 50p per share. It could easily be a lot higher in todays market. Thanks",
          "sentiment": 0.0,
          "engagement": "856",
          "price_at_post": "1.925",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-07T00:22:15.288613+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261354-Moneymun--8906822",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.350406",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Yes indeed pickedpeck, very well connected. Gl  :-) The new Chairman in place, GAD BERDUGO is a high flyer based in the US with a wealth of experience in Global Biotech, Corporate Development and US Capital Markets and so no doubt very well contected to any potential suitors. Excitement building!!!! In Eric we trust!!! Gla holders:-) Ps initial Efficacy readout on the Dog Trial imminent!!! Gla ;-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.95",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-07T00:22:15.288631+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261348-pickedpe-60064455",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.350900",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "I changed my small position here today into a large position. Berdugo joining is the strongest signal for me. You don't hire a guy like that, and he doesn't want to come, just to watch beagles play. He is exactly who you want holding the pen on your side when you are negotiating a licensing deal or thinking about a dual listing. Check his profile and history.",
          "sentiment": 0.0,
          "engagement": "2,316",
          "price_at_post": "1.95",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-07T00:22:15.288650+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261345-Moneymun-40478787",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.351413",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Nice one pickedpeck, undoubted near and mid term transformational UPside potential and prospects.  Excitement building in anticipation of imminent Efficacy Data on the Dog Trial. Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.95",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-07T00:22:15.288668+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261331-pickedpe-55352841",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.351981",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "Valuing a micro-cap biotech like Genflow (GENF) requires looking at two distinct worlds: the current \"London Micro-cap\" reality and the \"NASDAQ Longevity\" potential. \u200bA re-rating could be triggered by two separate valuation models: a Licensing Multiple for the dog data and a Pipeline rNPV (risk-adjusted Net Present Value) for the MASH human trials. \u200b1. The Immediate Floor: Canine Licensing (Q1 2026) \u200bIf the canine trial results are positive, Genflow has stated they intend to \"pass the baton\" to an Animal Health partner. \u200bThe Comparator: Private companies in this space, such as Loyal for Dogs, have achieved valuations of $425M - $600M in 2024\u20132025. \u200bThe Valuation Bridge: Even a modest licensing deal for a \"world-first\" SIRT6 longevity product could involve an upfront payment of $10M\u2013$25M plus royalties. \u200bThe Maths: Genflow\u2019s current market cap is only ~\u00a310M. An upfront payment equal to the company's entire market cap would likely cause a 2x\u20133x jump almost instantly to reflect the fresh cash on the balance sheet. \u200b2. The Mid-Term Prize: MASH rNPV (H2 2026) \u200bThe human application for MASH (liver fibrosis) is a $7 Billion - $18 Billion market by 2029\u20132034. \u200bTargeting the Gap: While drugs like Rezdiffra are now approved, they focus on early-to-mid stage MASH. Genflow targets advanced fibrosis, where there is a massive therapeutic gap. \u200b3. The Re-rating: If the \u20ac4M grant (approved Jan 28) leads to a successful Phase 1/2 entry, analysts typically value such pipelines at $50M\u2013$150M per asset. \u200bThe Math: If GENF is valued as a \"Human Clinical Stage\" biotech, the share price would need to reach 10p - 15p just to match its peers in the US. Initial Success: Canine Data Readout  mkt cap leap to \u00a330M - \u00a345M, 6.0p - 9.0p share price Blue Sky: US Licensing + Nasdaq \u00a3100M+ mkt cap, 20p+ share price. 4. The \"US Premium\" Factor The Multiplier: A longevity biotech in London trades at 1x - 2x cash/grant value. On the NASDAQ, those same assets often trade at 5x - 10x. The Berdugo Catalyst: The new Chairman was hired specifically to capture this. If he facilitates a US partnership or a dual-listing, the \"London Discount\" evaporates.  A \u00a310M UK company will eventually be \"discovered\" by US investors who value similar tech at $100M+.",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "1.95",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-07T00:22:15.288686+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261324-pickedpe-42596893",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.352598",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "The bull case for Genflow Biosciences (GENF) is built on a rare combination of \"Big Pharma\" leadership, validated science (the SIRT6 \"Centenarian Gene\"), and a series of binary catalysts expected to hit in the very near future. 1. The \"Centenarian Gene\" (SIRT6) Unlike biotechs that try to fix one specific disease, Genflow targets aging itself as the root cause. The Science: They use gene therapy to deliver a specific variant of the SIRT6 gene found in people who live to 100+ (centenarians). The Mechanism: SIRT6 is essential for DNA repair, telomere maintenance, and metabolic health. By \"upregulating\" this gene, Genflow aims to slow down the biological clock. 2. Immediate Catalyst: The Canine Trial (GF-1004) This is the most immediate trigger for building a share position. The Event: Initial efficacy results for the Dog Aging (GF-1004) study are expected in Q1 2026 (any day now). The \"Win\" Condition: If the trial shows a reduction in biological age (via the GRIM methylation clock) and improved muscle mass/strength, it validates the platform in a large mammal. Commercial Exit: Success here is intended to trigger a licensing deal with a major Animal Health company, providing non-dilutive cash that could dwarf Genflow's current market cap. 3. High-Value Human Pipeline: MASH (GF-1002) While the dogs are the \"proof,\" the human application for Metabolic Dysfunction-Associated Steatohepatitis (MASH) is the \"prize.\" Funding Secured: On January 28, 2026, a \u20ac4M grant was administratively approved to fund the MASH program. The Gap: Current MASH drugs focus on early-stage disease. Genflow is targeting advanced fibrosis and the prevention of liver cancer (HCC)\u2014a massive unmet need with multi-billion dollar potential. 4. The \"US Pivot\" & Leadership The appointment of Gad Berdugo as Chairman on January 19, 2026, is perhaps the strongest \"insider\" signal. The Signal: Berdugo is a US-based veteran with deep ties to Editas Medicine and Lazard. His hiring suggests Genflow is preparing for a US capital markets move or a US-led acquisition. Global Credibility: Having a heavyweight like Berdugo lead the board during the JPMorgan Healthcare Conference (Jan 2026) positions Genflow as a peer to major NASDAQ biotechs rather than just another London micro-cap. 5. Financial Efficiency Low Cash Burn: By securing regional grants (like the recent \u20ac4M) and pursuing licensing for \"non-core\" assets (the dog program), Genflow avoids the massive equity dilutions that kill other small biotechs. Valuation Gap: Because it's on the LSE, GENF trades at a fraction of the valuation of similar US longevity firms like Altos Labs or Unity Biotechnology. Any \"closing of the gap\" would result in a significant re-rating.",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "1.95",
          "thread_title": "The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-07T00:22:15.288704+00:00"
      },
      {
        "event_id": "SOCIAL-1Feb20262058-Moneymun--5661564",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.353124",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Genflow's cutting edge Sirt6 Gene Therapy platform, ahead of the curve!!! Gla :-) The results have far-reaching implications for aging research and public health. \"For many years, human lifespan was thought to be shaped almost entirely by non-genetic factors, which led to considerable skepticism about the role of genetics in aging and about the feasibility of identifying genetic determinants of longevity,\" says Shenhar. \"By contrast, if heritability is high, as we have shown, this creates an incentive to search for gene variants that extend lifespan, in order to understand the biology of aging and, potentially, to address it therapeutically.\" Rethinking longevity: Genes account for 50% of human lifespan variation, study suggests hTtps://share.google/afXnRAX0gkU6ocTjs",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.90",
          "thread_title": "RE: Genf update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=A8972678-8456-4532-9319-A328EF1F6BEC"
        },
        "ingested_at": "2026-02-07T00:22:15.288722+00:00"
      },
      {
        "event_id": "SOCIAL-31Jan20261359-Moneymun-69639065",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.353611",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Transformational game changing news, fast approaching!!! Gla holders:-) \"Now it's time to pass the baton and receive some non-dilutive cash. And I'm not talking about \u20ac4 million. I'm talking much more.\"",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.90",
          "thread_title": "RE: Genf update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=A8972678-8456-4532-9319-A328EF1F6BEC"
        },
        "ingested_at": "2026-02-07T00:22:15.288741+00:00"
      },
      {
        "event_id": "SOCIAL-31Jan20261339-Moneymun-86462191",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.354217",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Proactive: The dog study is a bit different and eye-catching. What should people look out for when the first data lands in early 2026? Eric Leire: 2026 is very important. We've been very happy with the fact that we were able to conduct such a study \u2013 it\u2019s never been done before. A study on aged dogs, naive to therapies, that is blinded and randomized with very strong scientific standards will be a first in terms of longevity research. Not only will we bring clinical data in ageing biology that differentiates us from other longevity companies, but that could also trigger a deal with animal health companies in 2026. In terms of non-dilutive funding, this could bring in much more important value than the \u20ac4 million grant. Everything is relative. Proactive: With partnerships clearly a priority, what does a good collaboration look like for Genflow over the next year? Eric Leire: Yes, 2026 is all about data, partnerships, and capital efficiency. By capital efficiency, I mean shareholder-friendly. Partnerships mostly mean the possibility to bring non-dilutive cash into the company via parts of the pipeline where we don\u2019t add value. The dog study is a typical example. Obviously, we\u2019re not an animal health company. And there are multiple animal health companies that would do a far better job in commercializing this product and bringing it to the market \u2013 to pet owners \u2013 faster and more efficiently than we can. There\u2019s no reason for us to move that product forward ourselves, it would be very expensive, and we don\u2019t have any special expertise in that space. But we were crucial in creating this clinical trial. No one else on earth was able to do it. We've done it. Now it's time to pass the baton and receive some non-dilutive cash. And I'm not talking about \u20ac4 million. I'm talking much more. Proactive: Eric, it sounds like a very exciting year ahead for Genflow. I hope you'll continue to keep us updated with your progress.",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.90",
          "thread_title": "RE: Genf update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=A8972678-8456-4532-9319-A328EF1F6BEC"
        },
        "ingested_at": "2026-02-07T00:22:15.288758+00:00"
      },
      {
        "event_id": "SOCIAL-31Jan20261052-Troajan--8338275",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.354718",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1086592/genflow-ceo-talks-through-dog-study-and-why-partnerships-icymi-1086592.html",
          "sentiment": 0.0,
          "engagement": "125,936",
          "price_at_post": "1.90",
          "thread_title": "Genf update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=A8972678-8456-4532-9319-A328EF1F6BEC"
        },
        "ingested_at": "2026-02-07T00:22:15.288777+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261736-Porter_--4432453",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.869536",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Yep, now they\u2019re fighting to get shares on DGQ and can\u2019t get any! That will be Genflow soon! \ud83d\ude04",
          "sentiment": 0.5,
          "engagement": "1,322",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-07T00:22:15.288796+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261725-Swanny27--9140992",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.869980",
        "source": "LSE_CHAT",
        "data": {
          "author": "Swanny27",
          "content": "Especially DGQ",
          "sentiment": 0.0,
          "engagement": "914",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-07T00:22:15.288815+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261618-Moneymun-59560259",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.870419",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Whether or not the new estimate offers a more realistic picture of lifespan heritability, it highlights the importance of genetics in extending lives, says Sofiya Milman, a scientists who studies aging and longevity at the Albert Einstein College of Medicine. She\u2019s one of many researchers who are trying to understand how centenarians\u2019 unique biology protects them from age-related disease. \u201cWe\u2019re hoping to create therapies that will mimic those intrinsic factors,\u201d Milman says, \u201cand make them accessible to people who didn\u2019t win the genetic lottery.\u201d Most of us are unlikely to break 100 without the right set of genes\u2014or at least drugs designed to replicate their beneficial effects. Until such treatments become available, though, a healthy lifestyle remains the best path to living longer.",
          "sentiment": 0.5,
          "engagement": "12,520",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-07T00:22:15.288834+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261553-Moneymun--1120870",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.870892",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Latest research into longevity and healthspan suggests Genflow's centenarian Sirt6 Gene could play a pivotal roll. Gla :-) Genetics The secret to long life? It could be in the genes after all, say scientists New study into \u2018heritability\u2019 shows that 50% of the variation in human lifespan could be down to genetics ........ The team looked at \u201cheritability\u201d, the proportion of change in a characteristic such as height, body weight or lifespan within a population that can be attributed to genetics rather than environmental factors. Previous studies for human lifespan have thrown up a wide range of values \u2013 with heritability ranging from 6% of the variation to 33%. But Alon, who co-authored the research, and his colleagues said such figures were underestimates. \u201cI hope this will inspire researchers to make a deep search for the genes that impact lifespan,\u201d Alon said. \u201cThese genes will tell us the mechanisms that govern our internal clocks. \u201cThese can one day be turned into therapy to slow down the rate of ageing and in that way slow down all age-related disease at once.\u201d ....... \u201cAround 20% of centenarians, for example, reach age 100 without any serious debilitating illnesses,\u201d he said, adding that could suggest their genes had a protective effect. \u201cStudies have been conducted to identify these protective genes, and many have been found, but surely there are many still left to discover,\u201d he said. While the new study does not take into account the influence that genes can have on the immune system, Prof Richard Faragher of the University of Brighton said the research suggested humans did not seem to be an outlier when it came to the heritability of lifespan. \u201cAnd that\u2019s useful because it means humans look quite like a species that we study ageing in, [and] gives you a certain amount of confidence that interventions that will work in mice will carry over into humans,\u201d he said. The secret to long life? It could be in the genes after all, say scientists | Genetics | The Guardian htTps://share.google/4quet7VR33nTpwazT",
          "sentiment": 0.5,
          "engagement": "12,520",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-07T00:22:15.288852+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261304-Porter_--6741700",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.871320",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "At least we know why the Mm\u2019s kept dropping the share price, so they could let Swann accumulate. Up to his usual sneaky tricks. Everything he buys atm turns to gold, so very optimistic that something is about to take off in Genflow.",
          "sentiment": 0.5,
          "engagement": "1,322",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-07T00:22:15.288871+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261257-Moneymun--3962310",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.871727",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Continued share accumulation by Jonathan Swann, in anticipation of transformational UPside. Gla holders...initial Efficacy Data on the Dog Trial, fast approaching!!! ;-)",
          "sentiment": 0.5,
          "engagement": "12,520",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-07T00:22:15.288890+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261253-Persever--6181057",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.872252",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "Who adds if weak data expected ? Quietly bullish this RNS",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "1.90",
          "thread_title": "Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-07T00:22:15.288915+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261658-Moneymun--2019576",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.872700",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "A potential very intetesting development.....Genflow were awarded 1.55m euros in Jan 2024 in collaboration with Exo-Biologics for a 3 year scientific program focused on the development a novel mRNA delivery system using exsomes to enscapsulate and transport Genflow's propriety centenarian Sirt6 Gene designed to target MASH & Werner Syndrome..... 777 Euro's was received in May 2024 with the remainder expected in 2025, but still outstanding and so could land anytime. ( and not related to the 4m Euro award ). Anyways, Exo-Bilogics announced last week they had enetered into a collaboration agreement with the multi-billion dollar French Pharma, Servier, to evaluate the use of extracellular vesicles as a non-viral drug delivery vehicle for an undisclosed indication, ( through their subsidiary Exoxpert,(ExoFastTrack), which Genflow is a collaborative member/partner ). All bodes well. Gla holders ;-) EXO Biologics 3,613 followers 1w \ud83d\udce3 We are pleased to announce a new collaboration with Servier. Our GMP clinical-grade EVs can be used as a non-viral drug delivery system, and we are eager to start this project with such a prestigious pharmaceutical company. Thanks to the continued support of BioWin and Service public de Wallonie, we are thrilled to further expand our international collaborations.",
          "sentiment": 0.5,
          "engagement": "12,520",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-07T00:22:15.288934+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261106-Moneymun-34501324",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.873213",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "No guarantees, but there lies the transformational UPside opportunity from this lowly bargain low. \"it worked like magic in mice, and we reasonably expect to work likewise in dogs\".....the first Efficacy Data readout is imminent, and judging by Eric's latest interview, he sounded very confident and bullish on a commercial licensing deal with an Animal Healthcare company ( we have two that have both signed Confidential Disclosure Agreements)  whereby any deal would provide non-dilutive cash  into the company, and Eric made a compelling point, that any non-dilutive cash would be much more than the \u20ac4m non-dilutive grant money confirmed yesterday, with the first tranche payment by May at the latest,  and so watch this space, potential game changing news fast approaching.  Gla holders ;-) Ps it was huge relief to have confirmation the \u20ac4m non-dilutive grant has been signed off, as Genflow were running  low on funds, and given the length of time we've waited for approval and the huge deficit turmoil the Belgium/Wallonia Govt. have been under, I had almost written it off, and so great news that Genflow will have no funding concerns for the foreseeable, and no doubt the \u20ac4m gives them much more leverage in any licensing deal discussions from a position of strength.  Transformational and near term game changing potential and prospects for those invested.  Excitement building!!!! :-)",
          "sentiment": 0.5,
          "engagement": "12,520",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-07T00:22:15.288953+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261052-Pie-char-20251299",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.873627",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Mice*",
          "sentiment": 0.0,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-07T00:22:15.288972+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261046-Pie-char--3800948",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.874043",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "So far all signs are good. Nice results were good. They also have more than just this programme. Dogs is just one of many.",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-07T00:22:15.288991+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261031-mikee_p-63629159",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.874464",
        "source": "LSE_CHAT",
        "data": {
          "author": "mikee_p",
          "content": "Is it low? This is still a risky punt. Dog trials may fail.",
          "sentiment": 0.0,
          "engagement": "1,895",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-07T00:22:15.289010+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260853-Pie-char-12695884",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.874879",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Everyone needs to listen to the last 20 seconds of this video. If that\u2019s not bullish I don\u2019t know what is. https://www.proactiveinvestors.co.uk/companies/news/1086390/genflow-ceo-outlines-2026-priorities-as-4-million-grant-is-approved-1086390.html",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F1CBD71F-0291-4489-9B39-85877DA36B7E"
        },
        "ingested_at": "2026-02-07T00:22:15.289028+00:00"
      },
      {
        "event_id": "SOCIAL-Today1106-Moneymun-34501324",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.448266",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "No guarantees, but there lies the transformational UPside opportunity from this lowly bargain low. \"it worked like magic in mice, and we reasonably expect to work likewise in dogs\".....the first Efficacy Data readout is imminent, and judging by Eric's latest interview, he sounded very confident and bullish on a commercial licensing deal with an Animal Healthcare company ( we have two that have both signed Confidential Disclosure Agreements)  whereby any deal would provide non-dilutive cash  into the company, and Eric made a compelling point, that any non-dilutive cash would be much more than the \u20ac4m non-dilutive grant money confirmed yesterday, with the first tranche payment by May at the latest,  and so watch this space, potential game changing news fast approaching.  Gla holders ;-) Ps it was huge relief to have confirmation the \u20ac4m non-dilutive grant has been signed off, as Genflow were running  low on funds, and given the length of time we've waited for approval and the huge deficit turmoil the Belgium/Wallonia Govt. have been under, I had almost written it off, and so great news that Genflow will have no funding concerns for the foreseeable, and no doubt the \u20ac4m gives them much more leverage in any licensing deal discussions from a position of strength.  Transformational and near term game changing potential and prospects for those invested.  Excitement building!!!! :-)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-07T00:22:15.289047+00:00"
      },
      {
        "event_id": "SOCIAL-Today1052-Pie-char-20251299",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.448833",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Mice*",
          "sentiment": 0.0,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-07T00:22:15.289065+00:00"
      },
      {
        "event_id": "SOCIAL-Today1046-Pie-char--3800948",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.449387",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "So far all signs are good. Nice results were good. They also have more than just this programme. Dogs is just one of many.",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-07T00:22:15.289083+00:00"
      },
      {
        "event_id": "SOCIAL-Today1031-mikee_p-63629159",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.449902",
        "source": "LSE_CHAT",
        "data": {
          "author": "mikee_p",
          "content": "Is it low? This is still a risky punt. Dog trials may fail.",
          "sentiment": 0.0,
          "engagement": "1,895",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-07T00:22:15.289116+00:00"
      },
      {
        "event_id": "SOCIAL-Today0853-Pie-char-12695884",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.450425",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Everyone needs to listen to the last 20 seconds of this video. If that\u2019s not bullish I don\u2019t know what is. https://www.proactiveinvestors.co.uk/companies/news/1086390/genflow-ceo-outlines-2026-priorities-as-4-million-grant-is-approved-1086390.html",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F1CBD71F-0291-4489-9B39-85877DA36B7E"
        },
        "ingested_at": "2026-02-07T00:22:15.289142+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261858-jamtart1--2279006",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.450933",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Https://www.tipranks.com/stocks/gb:genf",
          "sentiment": 0.5,
          "engagement": "1,604",
          "price_at_post": "1.90",
          "thread_title": "Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F1CBD71F-0291-4489-9B39-85877DA36B7E"
        },
        "ingested_at": "2026-02-07T00:22:15.289177+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261734-Roosters--3094658",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.451451",
        "source": "LSE_CHAT",
        "data": {
          "author": "Roostersmillions",
          "content": "Thats got to be a misprint. Target of \u00a32 for a 2p share. That would be a buy not a hold. Also when you open the analysts section, they have hold at 2p.",
          "sentiment": 0.5,
          "engagement": "291",
          "price_at_post": "1.90",
          "thread_title": "RE: Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=A70A365B-ED0A-4D60-9FAF-1051143160CA"
        },
        "ingested_at": "2026-02-07T00:22:15.289198+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261723-jamtart1-55432022",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.451956",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Https://www.tipranks.com/news/company-announcements/genflow-secures-e4m-wallonia-funding-and-sets-2026-gene-therapy-priorities#google_vignette Note the \u00a32 price target.",
          "sentiment": 0.5,
          "engagement": "1,604",
          "price_at_post": "1.90",
          "thread_title": "Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=A70A365B-ED0A-4D60-9FAF-1051143160CA"
        },
        "ingested_at": "2026-02-07T00:22:15.289216+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261232-VikR--1886169",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.452496",
        "source": "LSE_CHAT",
        "data": {
          "author": "VikR",
          "content": "I remember just recently when this moved from 0.6p to 2p in the blink of any eyelid. It is a such compelling buy but seems to be off the radar for many investors who don\u2019t understand the opportunity on offer here. This is by far a very confident load and hold Market cap is EXTREMELY low for what\u2019s coming around the corner.",
          "sentiment": 0.5,
          "engagement": "983",
          "price_at_post": "1.90",
          "thread_title": "MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-07T00:22:15.289234+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261145-Moneymun--3042920",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.453330",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Another great interview by Eric on today's news....2026 will be a year of Data and Partnerships, and when making references to the Dog Trial, Eric stated that any partnership would bring in non-dilutive cash to the company, \"and whe talking about non-dilutive cash, I'm not talking about the \u20ac4m non-dilutive grant confirmed today, I'm taking about much more\" !!!! Gla holders, all bodes well, exciting times ahead!!! Initial Efficacy Data from the Dog Trial imminent and every chance of a very lucrative commercial licensing deal to follow!!! :-) Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company\u2019s strategic progress and outlook for 2026, following a \u20ac4 million non-dilutive grant awarded by the Wallonia region. Dr Leire explained that the secured funding is part of Genflow\u2019s broader capital efficiency strategy, helping the company focus on key pipeline catalysts, including its lead gene therapy, GF-1002. GF-1002 is targeted at MASH (Metabolic dysfunction-associated steatohepatitis), a field Dr Leire described as \u201ca huge unmet need,\u201d particularly at the late stage where there are currently no therapeutic options. \u201cThis is one of the key programs for 2026,\u201d he said, highlighting that GF-1002 addresses severe liver conditions, including hepatocellular carcinoma. In addition to its gene therapy program, Genflow is advancing a pioneering longevity study in dogs. Leire stated, \u201cA study on aged dogs, naive to therapies, that's blinded, randomised, so with very strong scientific standard will be a first in terms of longevity.\u201d He emphasised the potential for a commercial deal with animal health companies based on this unique dataset. Partnerships and capital efficiency remain central to Genflow\u2019s plans. Leire noted that monetising non-core programs, such as the dog study, can generate significant non-dilutive capital and allow the company to focus on areas where it adds the most value. Genflow CEO outlines 2026 priorities as \u20ac4 million grant is approved | LSE:GENF, OTCQB:GENFF htTps://share.google/bu0pCWldyc59hIftA",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-02-07T00:22:15.289253+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260802-DaveTK-79832688",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.453982",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Simply amazing. Well done team",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "2.00",
          "thread_title": ".",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=40281A21-EA32-4E4F-A04F-0732B5F85F17"
        },
        "ingested_at": "2026-02-07T00:22:15.289272+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260745-Pie-char-36973470",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.454643",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Amazing. Dog results coming soon. Vet partner deal has never had such high probability! This is a good place to be!",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.95",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-02-07T00:22:15.289302+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260710-Moneymun--4149857",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.455431",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "What a brilliant RNS!!!! Gla holders...in Eric we trust!!! On and most definitely UP!!! :-)))",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.95",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-02-07T00:22:15.289327+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260705-Moneymun-59411409",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.455987",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Glaucoma Programme The Company's glaucoma programme will prioritise delivery optimisation and execution readiness. Genflow is advancing discussions with a leading lipid nanoparticle (LNP) partner to support delivery innovation and is progressing the selection of a full-service contract research organisation (CRO) to manage RNA-based formulation activities through preclinical execution. Additional Programmes Across the broader pipeline, Genflow continues to advance its sarcopenia programme in line with established development plans. In parallel, the ExoFastTrack initiative continues to generate data intended to support and accelerate multiple programmes across the portfolio. Dr. Eric Leire, CEO of Genflow, commented: \"The administrative approval of this funding reinforces our ability to execute against our 2026 development priorities with discipline and focus. It strengthens our capacity to advance GF-1002 while maintaining a selective, data-driven approach across the broader pipeline. As we enter the coming year, our emphasis remains on programmes with clear execution paths, strong scientific rationale, and meaningful opportunities for partnership and non-dilutive value creation.\"",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.95",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-02-07T00:22:15.289345+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260704-Moneymun--5255379",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.456597",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Administrative Approval of Grant & 2026 Priorities GENFLOW BIOSCIENCES PLC Released 07:00:09 28 January 2026 RNS Number : 5966Q Genflow Biosciences PLC 28 January 2026 Genflow Biosciences Plc Administrative Approval of \u20ac4 Million Funding Support from Wallonia Region for GF-100; and 2026 Development Priorities Genflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) (\"Genflow\" or the \"Company\"), a European-based biotechnology company focused on the development of gene therapies for age-related diseases, announces the administrative approval of the previously announced award of approximately \u20ac4 million in non-dilutive financial support from the Wallonia Region of Belgium, following the assenting signature of Minister Adrien Dolimont. The funding, once received, will support the continued development of the Company's lead gene therapy candidate, GF-1002, for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (\"MASH\"). The original RNS announcing the award can be found here. Disbursement of the first instalment is expected no later than May 2026. The support package spans a three-year development programme and is aligned with Genflow's existing roadmap. All project-related expenses incurred during 2025 will be eligible under the terms of the programme. Development Priorities for 2026 In 2026 Genflow's strategy emphasises pipeline discipline and capital efficiency, prioritising programmes with the strongest data, the clearest paths to value creation, and the highest potential for partner engagement. Central to this approach is the pursuit of early-stage collaboration agreements designed to secure non-dilutive funding, provide external validation of the platform, and support continued development. With multiple anticipated data readouts, an expanding partner dialogue, and a maturing intellectual property position, Genflow believes it is well positioned to enter its next phase of development while maintaining a focus on scientific rigour, operational execution, and long-term shareholder value creation. Dog Aging (GF-1004) The ongoing GF-1004 dog aging study, which commenced in March 2025, is being conducted as a blinded clinical trial designed to assess potential benefits related to sarcopenia, healthspan, and lifespan-associated biomarkers. An initial efficacy readout is expected in the first quarter of 2026. Dogs enrolled in the study are being monitored over a 180-day period, with a second efficacy assessment planned at the six-month timepoint. Results from this later evaluation are expected in June-July 2026 and are intended to assess durability and longer-term effects. Glaucoma Programme The Company's glaucoma programme will prioritise delivery optimisation and execution readiness. Genflow is advancing discussions with a leading lipid nanoparticle (LNP) partner to support delivery innovation and is progressing the selection of a full-service contract research organisatio",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.95",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-02-07T00:22:15.289363+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260808-Moneymun--5034205",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.457120",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "8/1/26 Leire explained that the dog longevity study is the nearest catalyst, with the trial expected to be unblinded shortly and early efficacy readouts anticipated in the near term. While safety has already been confirmed, the study remains blinded, meaning efficacy results are still unknown. The first data will focus on biological age, measured using a methylation clock, with a more detailed analysis of muscle biopsies and mitochondrial function to follow. According to Leire, \u201cthis trial could be very important for our shareholders, because it will trigger a deal with an animal health company bringing non-dilutive money in the company.\u201d",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.95",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-07T00:22:15.289381+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260707-Pie-char--8564096",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.457619",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Dog results are due next week. Vet partner(s) already likely lined up.",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.95",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-07T00:22:15.289399+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20262041-Moneymun--8573981",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.458133",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The trial aims to demonstrate proof of concept in dogs, replicating promising results previously seen in mice. \u201cIt worked like magic in mice. We reasonably think that it will work likewise in dogs,\u201d Leire stated. Unlike mice, however, dogs share environmental conditions with humans, making them a more relevant model for translation into human therapies.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-07T00:22:15.289424+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260818-Roosters-86186372",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.337719",
        "source": "LSE_CHAT",
        "data": {
          "author": "Roostersmillions",
          "content": "Markets reacting munch. Nice jump this AM. hope it holds. Maybe new private investors from across the pond due to conference exposure??",
          "sentiment": 0.5,
          "engagement": "291",
          "price_at_post": "2.00",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-02-07T00:22:15.289454+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260815-Moneymun-75000745",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.338198",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Game changing news at anytime. In Eric we trust!!! Gla holders...On and UP!!! :-)))",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "2.00",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-02-07T00:22:15.289473+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260812-Moneymun-75619304",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.338634",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions Madrigal\u2019s strategy of pursuing combination therapies while the market remains in its infancy could intrinsically link its brand to MASH treatment. Madrigal Pharmaceuticals used its January 12 presentation at the J.P. Morgan Healthcare Conference 2026 to showcase its newly acquired assets from Pfizer \u2013 ervogastat and two preclinical assets \u2013 as well as outline its vision for dominance in metabolic dysfunction-associated steatohepatitis (MASH) treatment space through leveraging early commercial success. Its professed strategy of pursuing combination therapies while the market remains in its infancy could well result in Madrigal\u2019s brand becoming intrinsically linked to MASH treatment. JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions - Pharmaceutical Technology https://share.google/Ymb4cXndGee7eMEbD",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "2.00",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-02-07T00:22:15.289492+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261725-Steg-55915463",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.339084",
        "source": "LSE_CHAT",
        "data": {
          "author": "Steg",
          "content": "Thought below was interesting, yes they are attending conference and have already made move to add to thier MASH portfolio, courtesy of AI search below Yes, Madrigal Pharmaceuticals is actively looking to expand its MASH (metabolic dysfunction-associated steatohepatitis) portfolio beyond its already approved drug, Rezdiffra (resmetirom). Madrigal's expansion strategy focuses on developing potential combination therapies, as MASH is a complex disease that requires multiple treatment approaches. Key components of their expanded pipeline include: Ervogastat: In January 2026, Madrigal entered into an exclusive global license agreement with Pfizer to acquire ervogastat, a Phase 2 oral DGAT-2 inhibitor. This drug works on a different, complementary pathway to Rezdiffra, and Madrigal plans to conduct studies to test the two treatments in combination. Oral GLP-1 Receptor Agonist: Madrigal also holds worldwide rights to an oral GLP-1 agonist called SYH2086, licensed from CSPC Pharmaceutical, with the goal of creating a best-in-class oral combination therapy. Additional Early-Stage Assets: The agreement with Pfizer for ervogastat also included rights to two other early-stage MASH pipeline assets. Madrigal's CEO, Bill Sibold, has stated that the company is committed to \"building the industry-leading pipeline that will shape the future of MASH care\" and believes combination therapies are the next wave of innovation in the field.",
          "sentiment": 0.0,
          "engagement": "5",
          "price_at_post": "1.90",
          "thread_title": "JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-02-07T00:22:15.289510+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261231-Moneymun--8957447",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.339515",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Get UP there!!! Gla :-) Eric and his team are now at the prestigious JP Healthcare Conference, pressing flesh with the leading industry deal makers. He appeared confident and enthusiastic in his latest interview, highlighting the prospects and potential of an early lucrative JV deal for the Dog Trial, Glaucoma and Mash and so potential game changing transformational news could drop at anytime. The first efficacy readout on the Dog Trial is imminent, and with two Animal Healthcare companies both with Confidential Disclosure Agreements in place, Eric could be very close to a deal, and the same with Glaucoma, whereby a leading Ophthalmology Company signed a Material Transfer Agreement 10 months ago. Eric also highlighted the prospects of Genflow's Sirt6 Mash Gene Therapy, which is now targeting the later stages of the disease where there's no options apart from transplant, and was very interesting to hear from Eric it could be used in combination with GLP-1's and Madrigal's early stage treatment which was FDA approved 12 months or so ago. Madrigal are presenting at JP Morgan and are on a mission to expand their pipeline for Mash, so watch this space. It's also very interesting we have a new Chairman in place, GAD BERDUGO a high flyer based in the US in Global Biotech, Corporate Development and and US Capital Markets and so no doubt very well contected to any potential suitors. Excitement building!!!! In Eric we trust!!! Gla holders:-)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "2.00",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-07T00:22:15.289528+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260822-Moneymun-40518151",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.339958",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Healthcare companies set for deals spree as drug patents expire A gathering of pharmaceutical executives comes as the sector has rebounded from uncertainty over Trump\u2019s policies Healthcare executives gather for their big annual conference in San Francisco on Monday as the sector is flush with cash and set for a deals spree as patents on drugs worth almost 12 per cent of the industry\u2019s revenues expire in the years ahead. The JPMorgan healthcare conference takes place as uncertainty recedes over President Donald Trump\u2019s trade wars, drug pricing policy and the leadership of key regulators such as the US Food and Drug Administration. In response, the S&P biotech index, known as the XBI, has surged to a four-year high, outperforming the wider index. In addition, drugs that contribute about $180bn of revenue a year are set to go off patent in 2027 and 2028, representing almost 12 per cent of the global market, according to research firm Evaluate Pharma. More than $40bn of sales are expected to lose patent protection this year, Evaluate has estimated. \u201cThe need to take big swings becomes more pressing,\u201d said Jeremy Meilman, head of healthcare investment banking at JPMorgan. \u201cSeveral of the large-cap pharmaceutical companies are shopping around for strong assets and a number have taken action but still have more firepower. This contributes to our optimism for 2026.\u201d hTtps://www.ft.com/content/7b07a9d5-7254-490b-8ce9-ec2633094d8e",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.825",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-07T00:22:15.289551+00:00"
      },
      {
        "event_id": "SOCIAL-11Jan20261442-Moneymun--2845093",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.340418",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Planned meetings presumably with potential suitors at JP Morgan this coming week and so multiple deal opportunities across the platform, and there's currently an M&A and lucrative licensing deal feeding frenzy as Major Pharma replenish their pipelines with the latest cutting-edge science, Excitement building!!! Gla :-) \"2026 will be catalyst year, we've done our work and now it's time for harvesting and are going to JP Morgan next week with a full appointments book, and now ready for potential harvesting of our results to bring in non-dilutive cash into the company.\" A must watch....Gla holders:-) hTtps://www.proactiveinvestors.co.uk/companies/news/1085366/genflow-biosciences-ceo-key-catalysts-for-2026-1085366.html",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.825",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-07T00:22:15.289583+00:00"
      },
      {
        "event_id": "SOCIAL-10Jan20261752-Troajan-38636524",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.836007",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1085424/genflow-is-ready-for-a-year-of-catalysts-icymi-1085424.html",
          "sentiment": 0.0,
          "engagement": "125,652",
          "price_at_post": "1.825",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-07T00:22:15.289603+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20262001-Moneymun--2120642",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.836711",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 10:30 a.m. PT. Investors and other interested parties can access a live audio webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event. About Zoetis As the world\u2019s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide \u2013 from veterinarians and pet owners to livestock producers. The company\u2019s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees. For more information, visit www.zoetis.com.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-07T00:22:15.289621+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261946-Moneymun-39595585",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.837364",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Woof, woof!!!??? ;-) Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference 06 January 2026 INDIANAPOLIS, Jan. 6, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will represent the company and respond to questions from analysts at 3:45 p.m. PST (6:45 PM EST).",
          "sentiment": 0.0,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-07T00:22:15.289640+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261920-Moneymun--7438923",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.837980",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "And/or ???? ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 4:30 p.m. PT in San Francisco, CA.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-07T00:22:15.289658+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261917-Moneymun-55266616",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.838626",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Eye wonder....Gla:-) 23/12/2025 - 12:30 VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders, Executive Vice President and Chief Financial Officer Sam Eldessouky and Chief Medical Officer and Head of Research & Development Yehia Hashad, MD, will participate in a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026, at 1:30 p.m. PT (4:30 p.m. ET) Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-07T00:22:15.289676+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261858-Moneymun--5298544",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.839276",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Another brilliant interview by Eric, \"2026 will be catalyst year, they've done their work and now it's time for harvesting and are going to JP Morgan next week with a full appointments book, and now ready for potential harvesting of their results to bring in non-dilutive funding cash into the company. Excitement building, in Eric we trust!!! Gla ;-) Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company\u2019s key programs and upcoming catalysts as it enters what management expects to be a pivotal year. Leire discussed why 2026 is shaping up as \u201ca year of catalysts\u201d for the company, with particular focus on the dog ageing trial, progress in MASH, and the group\u2019s approach to partnerships and licensing. Leire explained that the dog longevity study is the nearest catalyst, with the trial expected to be unblinded shortly and early efficacy readouts anticipated in the near term. While safety has already been confirmed, the study remains blinded, meaning efficacy results are still unknown. The first data will focus on biological age, measured using a methylation clock, with a more detailed analysis of muscle biopsies and mitochondrial function to follow. According to Leire, \u201cthis trial could be very important for our shareholders, because it will trigger a deal with an animal health company bringing non-dilutive money in the company.\u201d The interview also explored Genflow\u2019s repositioning in MASH toward advanced fibrosis and the prevention of hepatocellular carcinoma. Leire highlighted the significant unmet need in late-stage disease, noting that recent therapies target earlier stages and leave patients with advanced fibrosis facing limited options. He said the company\u2019s preclinical data have been encouraging and form a key part of the IND package, helping differentiate Genflow from existing and emerging treatments. In addition, Leire discussed the company\u2019s licensing strategy, including plans to out-license the dog program to an animal health specialist and pursue early-stage partnerships for glaucoma, while retaining focus on age-related conditions such as sarcopenia. With meetings planned during JPMorgan week, Leire said the company is seeking non-dilutive capital and strategic validation as it moves forward.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-07T00:22:15.289709+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261711-Troajan-29235052",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.839905",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1085366/genflow-biosciences-ceo-key-catalysts-for-2026-1085366.html",
          "sentiment": 0.0,
          "engagement": "125,652",
          "price_at_post": "1.75",
          "thread_title": "Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-07T00:22:15.289731+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261314-Moneymun-71705093",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.840622",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "0 0 Gene therapy biotech Genflow eyes busy year ahead as dog ageing trial nears results Published: 02:40 08 Jan 2026 Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) has wrapped up 2025 with steady progress across a range of gene therapy programmes, including a closely watched trial into dog ageing that could lay the groundwork for future human applications. The London-listed company, which is working on ways to extend healthy lifespan using gene therapy, said it had completed dosing in its lead canine study with no reported side effects. The dogs will now be monitored over six months for signs of improved muscle strength and health-related biomarkers, with initial results expected in the first quarter of this year. The trial, which began in March and uses a therapy based on the SIRT6 gene, a known regulator of ageing and DNA repair, is being conducted in a blinded format. A follow-up analysis is due around mid-year to assess the durability of the effects. Alongside the dog ageing study, Genflow said it had made progress in a programme targeting advanced stages of MASH, or metabolic dysfunction-associated steatohepatitis, a type of fatty liver disease. Existing GLP-1 drugs such as Ozempic and Wegovy have shown benefits in early MASH, but Genflow is aiming at patients with more severe fibrosis, where options remain limited. It is now finalising regulatory paperwork to support a human trial and is exploring the use of mRNA technology, similar to that used in Covid-19 vaccines, as a more flexible and cost-effective delivery method than traditional viral vectors. In a new push into eye disease, the company is also investigating the use of its gene therapy platform in glaucoma. Early lab results suggest that increasing SIRT6 levels may help protect the optic nerve from damage, potentially offering a way to slow or prevent vision loss rather than simply reducing eye pressure, which is the current standard treatment. Genflow said it was in talks with a lipid nanoparticle delivery partner to support this programme and was hiring a specialist contract research firm to help move the candidate towards preclinical testing. Elsewhere in its pipeline, work is ongoing in sarcopenia, the loss of muscle mass that often accompanies ageing, and in a broader initiative called ExoFastTrack, which supports several of its research efforts. Looking to the year ahead, Genflow said it would focus its efforts on the most promising areas of its portfolio and seek early licensing or partnership deals to bring in fresh funds without issuing new shares. \u201cWith multiple upcoming data readouts, an expanding partner network, and a maturing intellectual property position, we believe Genflow is well positioned to enter its next phase of growth,\u201d the company said. The first set of clinical results, particularly from the dog study, will be key in setting the tone for 2026.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-07T00:22:15.289749+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261148-Moneymun-53453639",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.841406",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Nice one David, looking forward to a run of great news from Eric to take the sp to new highs. Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.85",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-07T00:22:15.289767+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-David195-14445172",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.842237",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "Thank you for your informed views.  Added 500k @1.78.  It is hard for companies in this sector to raise funds so hopefully the upcoming changes will make the situation less brutal.  I will add when funds allow.",
          "sentiment": 0.0,
          "engagement": "871",
          "price_at_post": "1.85",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-07T00:22:15.289786+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261005-Moneymun-87743432",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.843028",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Hopefully news on patents soon Porter, the following statement is from yesterday's 2026 Corporate Presentation.  Gl :-) GROWING IP PORTFOLIO WITH LONG LIFE 2 proprietary patent families SIRT6 centenarian (cent SIRT6) and gene delivery (entering National Phase); Additional upcoming patent applications (entering PCT)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-07T00:22:15.289804+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260933-Moneymun-42491457",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.843890",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Bring it on!!! Gla holders:-) \"Central to this strategy will be the pursuit of early-stage licensing and collaboration agreements designed to generate non-dilutive funding, validate our platform externally, and support continued development without undue capital strain.\" .... Dr. Eric Leire, CEO of Genflow, commented: \"We're excited to attend the JP Morgan Healthcare Conference in San Francisco this January. Our planned meetings reflect our current focus on lipid nanoparticle delivery for mRNA SIRT6 therapeutics, which is opening compelling opportunities for strategic partnerships in the longevity space.\"",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=1999E606-84A4-47B8-B880-E68E1912F065"
        },
        "ingested_at": "2026-02-07T00:22:15.289832+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260928-Moneymun-72673578",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.844766",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Outstanding non-dilutive grant funding could land at anytime, although a lucrative JV licensing deal could also land at anytime and so let's see what transpires at next weeks the prestigious JP Healthcare Conference next week, where Genflow have planned meetings, presumably with potential suitors and every chance Eric will have initial efficacy data from the Dog Trial and maybe and maybe positive Data with their Ophthalmology partner for Glaucoma to present and so confirmation of a commercial deal or two would be transformational for all invested and any funding concerns would be assigned to history.  Gla holders....Excitement building!!! :-) Ps if Genflow need to raise cash because of the delay in receipt of the \u20ac4m outstanding non-dilutive grant funding, then raising cash from 16th January is going to become easier, cheaper and less dilutive.  :-) The new Financial Conduct Authority (FCA) regulations are designed to facilitate less discounted fundraising for small caps by reducing the regulatory burden and increasing the threshold for requiring a full prospectus, thus making secondary capital raising faster and cheaper. Key changes, effective from January 19, 2026 (with some listing rule changes effective from July 29, 2024), aim to attract more companies to list and grow in the UK. Key Regulatory Changes and Their Impact on Small Cap Fundraising The FCA's reforms introduce several key changes that support more efficient and potentially less discounted fundraising for smaller listed companies: Increased Prospectus Threshold The most significant change for secondary fundraising is that a full prospectus is now only required if a company issues shares amounting to 75% or more of its existing share capital, a substantial increase from the previous 20% threshold. This allows companies, particularly smaller ones, to raise further capital more quickly and at a lower cost without the time and expense associated with a full prospectus, which should reduce the need for heavily discounted placings.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=1999E606-84A4-47B8-B880-E68E1912F065"
        },
        "ingested_at": "2026-02-07T00:22:15.289859+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260854-David195-52427968",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.845590",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "I hold shares and the potential is significant. However I am reluctant to add when the funding position is unclear.  Grants could be material amounts if and when received but there is a risk of a diluted fund raise to progress the numerous programmes in 2026.  I have suffered this is other small biotechs like FAB and Apta where the state of the capital markets are very harsh and unsupportive. I tried to analyse the cash runway and it seems more funds will be needed in H1 if the grants are not received.  Is there any indication of the timing?",
          "sentiment": 0.0,
          "engagement": "871",
          "price_at_post": "1.90",
          "thread_title": "Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=1999E606-84A4-47B8-B880-E68E1912F065"
        },
        "ingested_at": "2026-02-07T00:22:15.289878+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260805-Porter_--1062593",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.846399",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Thanks for sharing money. I notice the RNS is in American English, perhaps to appeal to US investors and big US pharma? No mention of the patents in the update which were instrumental in offering assurance to investors regarding patent protection, but hopefully we\u2019ll receive updates in due course separately.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.825",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-07T00:22:15.289896+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260703-Moneymun-82220247",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.847249",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "We are advancing discussions with a leading LNP partner to support delivery innovation in this space and are securing a full-service CRO to manage formulation through preclinical execution. With the global glaucoma market approaching USD $12-14 billion by the early 2030s, this represents a compelling long-term opportunity for us. \u00b7 Additional Programs We continued to advance our broader pipeline and are pleased with the steady advancement of the sarcopenia program, fully consistent with our development plans. In parallel, the ExoFastTrack initiative continues to move forward, generating important data that will support and accelerate several of our other development programs. Looking Ahead to 2026 As we move into 2026, we do so with confidence, discipline, and a clear strategic focus. The coming year will emphasize rationalization of our pipeline, prioritizing programs with the strongest data, clearest paths to value creation, and highest partner interest. Central to this strategy will be the pursuit of early-stage licensing and collaboration agreements designed to generate non-dilutive funding, validate our platform externally, and support continued development without undue capital strain. With multiple upcoming data readouts, an expanding partner network, and a maturing intellectual property position, we believe Genflow is well positioned to enter its next phase of growth. We remain committed to scientific excellence, capital efficiency, and long-term value creation as we work to translate our longevity platform into meaningful therapies. Thank you for your continued support and confidence in Genflow.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-07T00:22:15.289914+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260702-Moneymun-63171440",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.848143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "08 January 2026 A Review of an Exciting 2025 2025 has been a year of focused scientific progress and continued advancement of Genflow Bioscience's mission to extend healthy lifespan through our novel longevity gene therapy platform. Across our portfolio, we have maintained momentum in both animal health where progress in our canine study may provide translational insights relevant to future human applications as well as therapeutic development for dogs. These advancements have been supported by a strengthened network of leading academic collaborators and laboratories. Together, with continued backing from international institutional investors and previously awarded government grants, this ecosystem helped accelerate Genflow's scientific and clinical development throughout 2025. Program Highlights We've made a number of notable strides across our programs this year, including: \u00b7      Dog Aging (GF-1004) We made significant strides in our clinical trial for aging dogs with full administration of our investigational SIRT6-based gene therapy now completed. No adverse events were reported during the dosing phase of the study, with no serious, moderate, or minor side effects observed. The study which began in March 2025, is being conducted as a blinded clinical trial; an initial efficacy readout is expected in Q1 2026, including blood analyses and muscle biopsies to evaluate potential benefits related to sarcopenia, healthspan, and lifespan-associated biomarkers. Dogs enrolled in the trial will be monitored for 180 days, with a second efficacy assessment planned at the six-month timepoint and results expected in June-July 2026 to evaluate durability and longer-term effects. \u00b7      MASH (GF-1002) Our MASH program saw good progress in 2025. While GLP-1 therapies have addressed early-stage MASH, patients with advanced fibrosis - roughly one-third of the population - still face limited treatment options. In response, we repositioned GF-1002 to target this high-need group, leveraging its antifibrotic properties and potential to prevent progression to cirrhosis and liver cancer. Additionally, we have generated new pre-clinical POC data on the prevention of HCC. We are now finalizing our IND package and evaluating mRNA/LNP delivery as an alternative to AAV, an approach that could enable repeat dosing and lower manufacturing costs. Encouraging data continue to support this next phase of research and development. \u00b7      Glaucoma In 2025, we expanded into ophthalmology, where SIRT6-based gene therapy shows promise in glaucoma, a leading cause of irreversible blindness. Current treatments primarily manage intraocular pressure but do little to prevent optic nerve degeneration. Our preclinical data suggest SIRT6 overexpression may protect retinal ganglion cells and preserve optic nerve function, shifting the focus from symptom control to true neuroprotection.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-07T00:22:15.289932+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261804-Moneymun-73631611",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.848904",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Well connected in the US to take Genflow to the next level. ;-)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-07T00:22:15.289952+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261802-Moneymun-63845015",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.849701",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Hi Porter, it's from the 2026 Corporate Presentation which was published via Genflow's LinkedIn post a few hours ago. Gl :-) Ps the new Chair appears to be well connected on the US. https://loom.ly/RsxnFCE",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-07T00:22:15.289984+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261732-Porter_--8652868",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.850478",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Thanks for sharing money. I haven\u2019t seen any news regarding a new Chair. Where did you manage to grab that info from? Can you please share the link if you have one? \ud83e\udd70",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-07T00:22:15.290004+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261627-Moneymun-20486281",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.851283",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Gad Berdugo Gad Berdugo, MSc. Eng., MBA Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a strategic and financial advisory firm focusing on the global biotechnology sector. He currently serves as Vice Chairman of the Board of Directors of clinical development stage precision oncology company, Diaccurate. Mr. Berdugo brings over 35 years of biotech corporate & business development, strategy, operational, financial, investment and general venture management experience. He served as CBO at CRISPR gene editing pioneer Editas (Nasdaq EDIT); Co-founder and CEO at personalized neoantigen cancer vaccine venture, EpiVax Oncology Inc.; CFO and EVP at Immune Pharmaceuticals Inc. (Nasdaq IMNP); Managing Director and Head of Life Sciences at Tegris Advisors, a strategic and financial advisory boutique; Founder and Managing Partner of the Explorium Global Life Sciences Investment Fund; Director, Senior Equity Research Analyst and Life Sciences Sector Leader at Lazard, Asset Management Group. Prior to that, he served as a Director of Global Business Development within Baxter\u2019s Biopharmaceuticals group and started his career at Abbott Labs. Mr. Berdugo received his B.Sc. with Honors in Biotechnology from Imperial College London, his M.Sc. in Biochemical Engineering from University College London and his M.B.A. from H.E.C. Paris. He serves on the Board of Directors of Friends of H.E.C. Inc. and Friends of U.C.L. Inc. Mr. Berdugo is bilingual in French and English and has dual US and French citizenships. He resides with his wife in New York City.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-07T00:22:15.290022+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261606-Moneymun--1689226",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.852108",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Looks like we've got a new Chairperson!!!??? Gla ;-) GAD BERDUGO Chairperson \u2022 30+ years of leadership across global biotech, corporate development, and U.S. capital markets \u2022 Proven record in strategic partnerships, capital raising, and scaling private and public biotech companies \u2022 Managing Partner, Explorium Capital; former Co-Founder & CEO of EpiVax Oncology and Chief Business Officer at Editas Medicine and Nutcracker Therapeutics",
          "sentiment": 0.0,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-07T00:22:15.290041+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261602-Moneymun-17459814",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.852899",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Undervalued stock opportunity; Potential acquisition by pharmaceutical partner GF-1004: Pet life extension / sarcopenia Initiated discussion under CDA with several animal health companies hTtps://loom.ly/RsxnFCE",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-07T00:22:15.290060+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261601-Moneymun--7159763",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.854072",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The Gap No approved neuroprotective therapies The mRNA Opportunity - Wide Open LNP targeted delivery to retina \u2013 now possible NO APPROVED OR CLINICAL-STAGE MRNA THERAPIES FOR GLAUCOMA PARTNERING WITH LNP PROVIDER Paradigm shift to retinal protection \u2022 Pre-clinical evidence links SIRT6 activity with RGC protection in glaucoma/optic neuropathy models \u2022 Demonstrating RGC rescue and preserved function would be a strong disease-modifying signal Delivery is now tractable \u2022 Targeted LNP (tLNP) platforms are removing a major historical barrier for in vivo RNA therapeutics to reach retina/RGCs Clear decision point A single well-designed rodent POC that shows \u2022 focal RGC expression of SIRT6 cent \u2022 preserved RGC counts and \u2022 preserved RGC function with acceptable ocular safety, gives a clean go/no-go for IND enabling work AGED DOGS COMPARATIVE TRIAL Proof-of-Concept comparative clinical trial of in-vivo naked DNA gene therapy in aged dogs Conducted at Syngene's strategic partner site in Morocco, AAALAC and GLP certified 26 (24+2) aged Beagles dogs (age>10 years) Group 1 (n=6): untreated Group 2 (n=6): treated with gene therapy IV bolus of SIRT6 AAV Group 3 (n=6): treated with gene therapy IV infusion of naked DNA (low dose) Group 4 (n=6): treated with gene therapy IV infusion of naked DNA (high dose) Blinded: first read-out in January 2026 \u2022 Treatment period: 180 days with follow-up period: 90 days \u2022 Gene therapy has been administered to all dogs with demonstrated excellent safety profile Endpoints \u2022 Pan-mammalian methylation clock (Steve Horvath), \u2022 sarcopenia (including muscle biopsies) and other markers of aging MASH PROGRAM Affects est. 35 million people globally \u2022 Increasing prevalence \u2022 Leading cause of chronic liver disease and liver transplant Significant unmet medical need Clear regulatory accelerated development pathway. EMA and FDA guidelines accept: \u2713 Key surrogate outcomes for therapeutic trials: regression of fibrosis or resolution of NASH \u2713 Histological changes are achievable within a 12-18-month time-frame \u2713 Placebo control \u2713 Conditional fast-track approval 2025 KEY HIGHLIGHTS LARGE AND EXPANDING MARKET OPPORTUNITY MASH: 35 Million globally. Increasing prevalence. Door opener to even broader anti-aging indication Awarded to new grants in 2024 expanding research pipeline Ophthalmology: retina preservation GROWING IP PORTFOLIO WITH LONG LIFE 2 proprietary patent families SIRT6 centenarian (cent SIRT6) and gene delivery (entering National Phase); Additional upcoming patent applications (entering PCT) MRNA/LNP GENE DELIVERY SYSTEMS Innovative gene delivery systems: targeted LNPs delivering cent SIRT6 mRNA GF-1002 Multiple key clinical and regulatory milestones expected in next 18 months; Undervalued stock opportunity; Potential acquisition by pharmaceutical partner GF-1004: Pet",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-07T00:22:15.290078+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261559-Moneymun-86098297",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.855051",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "WHO WE ARE Pioneering Novel Gene Therapeutics for a Longer, Healthier Life MISSION: aging is underlying risk factor for disease, and our aim is to deliver gene therapeutics that potentially halt or slow the aging process in humans and dogs CENTENARIAN SIRT6 (cent SIRT6) GENE: proprietary variant of longevity gene that widely regulates aging and immunity and is a potential therapeutic target for the treatment of diseases PROMISING PRECLINICAL RESULTS: lead drug candidate GF-1002 delivers a centenarian variant of the SIRT6 gene (cent SIRT6) for treatment of MASH SEASONED TEAM: experienced and proven management with extensive experience in public & private pharma and biotech ROBUST PIPELINE: advancing multiple development programs over 24 months: MASH, Glaucoma, Sarcopenia, Werner and life extension of dogs DEVELOPMENT PIPELINE GF-1002 (Pre-Clinical) AAV8 cent SIRT6 vector for intravenous infusion, expressing cDNA of centenarian variant of SIRT6(cent SIRT6) in liver GF-1003 (Pre-Clinical/Development) Suspension of exosomes, loaded with mRNA of centenarian variant of SIRT6(cent SIRT6) in fibroblasts GF-1004 (Clinical Proof of Concept) cent SIRT6 for intravenous infusion for life extension and prevention of age-related diseases GF-1005 (Pre-Clinical/Development) Mitochondrial disfunction: Myoblast progenitors loaded by photoporation with cent SIRT6 GF-1006 Ophthalmology (pre-clinical) mRNA cent SIRT6 delivered by LNP for the treatment of cornea pathologies and glaucoma OPHTHALMOLOGY PLATFORM New Ophthalmology Program: Initiated development of a novel gene therapy targeting ocular diseases, including corneal pathologies and glaucoma, using Genflow\u2019s proprietary Centenarian SIRT6 (cent SIRT6). Precision Delivery Platform: Employing a specially engineered non-viral vector for targeted SIRT6 delivery to the eye. Strategic Partnership: Signed a Material Transfer Agreement in April 2025 with a leading ophthalmology company to co-develop the cent SIRT6 therapy and delivery system. LEVERAGING AI FOR GENOMICS New AI Partnership: Signed Master Service Agreement in April 2025 with Heureuka Labs, a spin-out of Duke University, to use their proprietary AI platform to analyze complex genomic data, including RNA sequencing and gene expression profiles. Enhancing Therapeutic Insights: Expected to drive a deeper understanding of gene regulatory networks and biological responses to optimize therapy design and personalize outcomes. Pipeline Advancement: Initially supporting GF-1002 (cent SIRT6-based gene therapy in preclinical development) and future programs, including candidates for MASH. GLAUCOMA RGC NEUROPROTECTION: THE RACE IS ON The Problem 80M people worldwide with glaucoma; leading cause of irreversible blindness Current treatments only lower IOP- they don't protect retinal ganglion cells (RGCs) RGC death is irreversible; unmet need for neuroprotection Significant market opportunity The Gap",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-07T00:22:15.290121+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261913-Persever-26365302",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.702321",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "These unknowns are off book pre negotiated buys. Sp will remain pinned till.Dog efficacy data. Expected solid data.",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-07T00:22:15.290145+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261838-Dzygit19-80993182",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.702759",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dzygit1980",
          "content": "12:45 yesterday was 1.97 to sell small amout . Than yesterday's big trade printed today for 1.81 ,straight after 1.97 To buy share so I am not sure \ud83e\udd14 was 12:45 yesterday tradet  buy  to me it looks like sell. Also we are dropping",
          "sentiment": 0.0,
          "engagement": "255",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-07T00:22:15.290164+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261822-Persever-76591060",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.703192",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "Big buys more like it. Do you know trading? \ud83d\ude05",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-07T00:22:15.290182+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261753-Dzygit19--7031273",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.703612",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dzygit1980",
          "content": "Lots of big sales last couple of days",
          "sentiment": 0.0,
          "engagement": "255",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-07T00:22:15.290200+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261756-Persever-68765655",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.704022",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "I think a massive rerate is coming ? Somethings brewing ?",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "1.90",
          "thread_title": "Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-07T00:22:15.290219+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260719-Porter_--4960589",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.704447",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Know a few people who didn\u2019t get their orders filled yesterday. Seems there isn\u2019t much in the free-float so let\u2019s see how tight this coiled spring is!",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-07T00:22:15.290247+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20262217-Twocd2--4967105",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.704869",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "I joined pre IPO, \u00a350 may have been too much of a reach for you\u2026chortle chortle TK Max.. Give Porter a reach around before lights out so that he\u2019ll not be to disappointed with no RNS tomorrow morning\u2026\ud83d\udc4c",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-07T00:22:15.290273+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261352-DaveTK-85325190",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.705301",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "I joined the party pre IPO. TBF they were asking for more than \u00a350 so it may have been too much of a reach for you. Talking about choppers FFS. Don't let you mum read that or she'll take your phone off you and cancel your contract.",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-07T00:22:15.290292+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261342-Twocd2-29964989",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.705721",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "So TK Max joins the party\u2026think you and Porter need to take turns and time to give him a chance to be big spoon for this week. Might give him something else to do rather than practice his typing. Plenty of skin in the game lads\u2026but this is not about who\u2019s chopper is bigger..well maybe for the spooning it does\ud83d\ude01",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-07T00:22:15.290310+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261033-DaveTK-79584605",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.706162",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Always. I'm here and always have been here waiting for news that we have been bought out. It was always the goal from Eric to make this company into something a pharmaceutical would buy a high price. We may not be that far off. Fingers crossed. Thanks",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-07T00:22:15.290328+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261027-Porter_--8626901",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.706587",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Always the ones who sold too soon quick to troll those who held with diamond hands Dave. Expecting this is just the first update of many we\u2019ll be seeing over the next 2 weeks. Popcorn ready! \ud83c\udf7f",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-07T00:22:15.290346+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261005-DaveTK-95317616",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.707009",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Would seem like you touched  nerve there, Porter ha ha. Nice RNS this morning. Looking forward to hearing more regarding the J.P. Morgan's Healthcare Conference. Really does seem like exciting times ahead. Thanks",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-07T00:22:15.290371+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260839-Twocd2--3781189",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.707434",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "Ok big fella..time for nap your banter is honking.",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-07T00:22:15.290401+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260820-Moneymun-62457632",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.707847",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The new Chairman in place, GAD BERDUGO is a high flyer based in the US with a wealth of experience in Global Biotech, Corporate Development and US Capital Markets and so no doubt very well contected to any potential suitors. Excitement building!!!! In Eric we trust!!! Gla holders:-) Ps initial Efficacy readout on the Dog Trial imminent!!! Gla ;-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-07T00:22:15.290419+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260752-Porter_--8979579",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.708264",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "2cd2 - invest more than \u00a3100 in a company and you might care a little bit more for your investments \ud83d\ude18",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-07T00:22:15.290438+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260734-Twocd2--4567611",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.708668",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "Take the rest of the day off Porter..great job pal! You must have set the alarm early to C&P all of that \ud83d\udc4f\ud83d\udc4f\ud83d\udc4c",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-07T00:22:15.290456+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260718-Porter_--2933608",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.709143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Genflow Appoints a New Chairman to Accelerate Corporate and R&D Expansion Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or the \"Company\"), a leading European-based biotechnology company focusing on gene therapies for age-related diseases, is pleased to announce a significant appointment to its Board of Directors, marking an important step in the Company's strategic evolution. Mr. Gad Berdugo, MSc Eng., MBA, has joined the Board with immediate effect and will assume the role of Independent Non-Executive Chairman, providing leadership as Genflow focuses on advancing its gene-therapy programs. Mrs. Tamara Joseph will continue to serve as a Director, ensuring continuity and maintaining strong governance. Mr. Berdugo brings over 30 years' of leadership experience spanning global business and corporate development, U.S. capital markets, and company building. He has a proven record of driving strategic partnerships, securing capital, and scaling both private and public development-stage biotechnology companies. Currently, Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a U.S.-based strategic and financial advisory firm focusing on the global biotechnology sector. His most recent roles include: \u00b7 Co-Founder & CEO, EpiVax Oncology \u00b7 Vice-Chairman of the Board, Evexta Bio \u00b7 Chief Business Officer, Editas Medicine (NASDAQ: EDIT) \u00b7 Chief Business Officer, Nutcracker Therapeutics He began his international career at Abbott Labs and Baxter, later becoming Life Sciences Sector Leader at Lazard Asset Management. Mr. Berdugo also brings deep technical and market expertise in RNA-based therapeutics, including lipid nanoparticle (LNP) delivery, development, and manufacturing. This background will support Genflow as it advances its scientific platform, evaluates delivery technologies, and explores next-generation therapeutic approaches. His appointment further strengthens the Company's presence in the United States and expands its capacity for global engagement. He does not own any shares in the Company. Dr. Eric Leire, Chief Executive Officer of Genflow, commented: \"We are delighted to welcome Mr. Berdugo as Independent Non-Executive Chairman. His expertise in strategy, partnerships and financing as well as his deep experience with RNA-LNP technologies will be instrumental as we accelerate our programs and expand our global reach. We are equally pleased that Mrs. Tamara Joseph will continue her service on the Board, contributing her invaluable leadership, legal and governance expertise.\" Gad Berdugo added: \"I am excited to join Genflow as the company is progressing to the next new phase of development, with key data readouts expected in 2026, strengthened intellectual property, and a sharpened strategic focus on high-potential programs. I look forward to working with the talented team and board to advance these innovative gene therapies, this is an ideal moment to contribute my expertise and hel",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-07T00:22:15.290473+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20260836-Pie-char--4585586",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.709557",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Post conference announcement next week and Funding news is what I predict. I'm amazed we are at this price. Such a hidden gem!",
          "sentiment": 0.5,
          "engagement": "60",
          "price_at_post": "1.85",
          "thread_title": "RE: JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=3005BF87-EE58-4C27-ABC6-EE6AA15A9385"
        },
        "ingested_at": "2026-02-07T00:22:15.290491+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20260716-Porter_-84903857",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.710022",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Genflow Biosciences is a London-based biotechnology firm and the first \"pure-play\" longevity company listed on the London Stock Exchange. As of early 2026, the company is transitioning from a preclinical phase into active clinical data readouts, focusing on its proprietary SIRT6-based gene therapy platform to extend human and animal \"healthspan\". Core Technology and Pipeline: The company\u2019s lead therapeutic approach involves delivering a \"centenarian variant\" of the SIRT6 gene, identified in individuals who live over 100 years, to improve DNA repair and metabolic health. GF-1002 (Human Therapeutics): MASH (Liver Disease): Repositioned in 2025 to target patients with advanced fibrosis who have limited options from existing GLP-1 therapies. The company is currently finalizing its Investigational New Drug (IND) package and exploring mRNA/LNP delivery to allow for repeat dosing and lower costs. Werner Syndrome: A rare genetic condition causing premature aging. Genflow has developed proprietary human-derived liver organoids to model this disease more accurately than animal models. GF-1004 (Veterinary Program): Canine Longevity: A 12-month blinded clinical trial in aged dogs is currently underway. In early 2026, the company confirmed that all subjects received full dosing with no adverse events reported. Key 2026 Milestones: Initial efficacy readouts focusing on biological age (via methylation clocks) are expected in Q1 2026, with a second evaluation planned for June-July 2026. Expansion Programs: Glaucoma: A new ophthalmology program targeting neuroprotection of retinal ganglion cells to prevent blindness. Sarcopenia (GF-1005): Research into muscle health and mitochondrial dysfunction in collaboration with the Universit\u00e9 libre de Bruxelles. 2026 Strategic Focus: Genflow\u2019s 2026 strategy emphasizes \"rationalization of the pipeline,\" prioritizing programs with the strongest data to secure non-dilutive funding through licensing deals and partnerships. The company is actively seeking animal health partners for its dog longevity program and strategic collaborators for its LNP-based mRNA therapeutics.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "GLP, LNP, MRNA and SIRT6 based therapeutics",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=FB89DB69-F93B-4BB3-8529-5206EECDF243"
        },
        "ingested_at": "2026-02-07T00:22:15.290525+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20262119-jamtart1-84420634",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.710444",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Yes, Genflow Biosciences (Genflow) has had significant interest at the J.P. Morgan Healthcare Conference, attending specifically to engage with potential partners, institutional investors, and pharmaceutical companies. Their CEO, Dr. Eric Leire, attended the most recent conference in January 2026 with a \"full appointments book\" to discuss strategic partnerships and non-dilutive funding opportunities.",
          "sentiment": 0.5,
          "engagement": "1,600",
          "price_at_post": "1.85",
          "thread_title": "JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=3005BF87-EE58-4C27-ABC6-EE6AA15A9385"
        },
        "ingested_at": "2026-02-07T00:22:15.290545+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260634-Porter_-84625997",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.710912",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Companies attend the J.P. Morgan Healthcare Conference (JPM) primarily for networking, securing funding, forging strategic partnerships, and announcing key business updates. This major event, often described as setting the industry's tone for the year, concentrates a year's worth of meetings into a few days. Key reasons why companies attend include: Investment and Funding: The conference is a premier venue for companies to present their strategies and financial outlooks to a high-level audience of investors, analysts, and venture capitalists. For many, especially smaller or emerging biotech firms, it is a critical opportunity to secure financing, gauge investor interest, and build essential relationships. Mergers and Acquisitions (M&A) and Partnerships: The event is a hotbed for dealmaking. Big pharmaceutical companies often attend to scout for smaller companies with promising drug pipelines or innovative technologies (like AI in drug discovery) to acquire, especially as their own blockbuster drugs approach patent expiration. Extensive one-on-one meetings facilitate these discussions and collaborations. Strategic Positioning and Visibility: Companies announce major news, clinical trial data, or year-end recaps just before or during the conference to capture attention and elevate their visibility above the competition. It allows them to articulate their unique value proposition and strategic priorities to the global market. Market Intelligence: Attending allows companies to take the pulse of the industry, understand the latest trends (e.g., AI, gene therapy, obesity drugs), and gather competitive intelligence. They can assess how investors and peers discuss valuations, regulatory pathways, and market potential, which helps in fine-tuning their own strategies for the year ahead. Networking Efficiency: The conference brings the entire healthcare and life sciences ecosystem\u2014from manufacturers and providers to regulators and service providers\u2014into a concentrated location for a short time. This high density of key decision-makers allows for efficient, high-value networking and relationship building that would otherwise take months of travel and outreach.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=4C9A5731-DC78-4F24-8CE9-513E080FCFAC"
        },
        "ingested_at": "2026-02-07T00:22:15.290563+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261946-jamtart1--2435612",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.711334",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Doubt it, but happy if rumours are true",
          "sentiment": 0.5,
          "engagement": "1,600",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan, news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=559FB93D-C9CD-4A83-84E9-7B26CC6976E9"
        },
        "ingested_at": "2026-02-07T00:22:15.290581+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261844-JediMast--6724029",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.711742",
        "source": "LSE_CHAT",
        "data": {
          "author": "JediMaster1",
          "content": "Rumours of investment banks wanting to buy in from the JP Morgan Conference. The only question now is who do they want to buy in on behalf of?? The next few days will be interesting. Will Eric spill the beans?",
          "sentiment": 0.5,
          "engagement": "169",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D010A135-964B-4034-9025-65BCB0334809"
        },
        "ingested_at": "2026-02-07T00:22:15.290600+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261006-Moneymun-28296500",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.712184",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "GKOS: Strong innovation and new therapies drive growth, with robust financials and expanding markets Jan 14, 2026, GKOS The event highlighted robust innovation in ophthalmology, with strong R&D investment yielding a broad product pipeline and record financial performance. Key growth drivers include new glaucoma and keratoconus therapies, strategic market expansion, and a focus on operational leverage and profitability. Based on Glaukos Corporation [GKOS] 44th Annual J.P. Morgan Healthcare Conference Audio Transcript \u2014 Jan. 14 2026",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.10",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-02-07T00:22:15.290620+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260827-Moneymun-23885348",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.712592",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Every chance Rooster, although I'm hoping for a transformational lucrative commercial licensing deal on one or more of the programs, Dog , Glaucoma and Mash. Excitement building!!! Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.05",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-02-07T00:22:15.290652+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261256-Porter_--5960600",
        "event_type": "social_post",
        "date": "2026-02-10T01:24:20.068786",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "100% Jam. So many health issues can be treated or controlled with one simple formula. With the FDA focusing on proactive as opposed to reactive healthcare, I can see why there is so much anticipation for the initial dog results to be released!",
          "sentiment": 0.5,
          "engagement": "1,332",
          "price_at_post": "2.10",
          "thread_title": "RE: Patent for age related diseases",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D0890AAC-7454-4683-8905-06AB1790DF8E"
        },
        "ingested_at": "2026-02-10T01:24:30.351205+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261254-jamtart1--4199471",
        "event_type": "social_post",
        "date": "2026-02-10T01:24:20.069475",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Porter_  Imagine the savings  world wide if all of the listed illnesses could be stopped or at least treated to a minimum health risk to patients with virtually no toxicity. Staggering.",
          "sentiment": 0.5,
          "engagement": "1,610",
          "price_at_post": "2.10",
          "thread_title": "Patent for age related diseases",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D0890AAC-7454-4683-8905-06AB1790DF8E"
        },
        "ingested_at": "2026-02-10T01:24:30.351234+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261224-pickedpe--1651519",
        "event_type": "social_post",
        "date": "2026-02-10T01:24:20.070151",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "Amazing that the longevity crowd on discord and Reddit haven't turned up here yet. There is an awful lot of noise about now for SIRT6, one can only presume that it will eventually translate into interest here, or maybe more are sitting on their hands waiting for the outcome of the dog study?",
          "sentiment": 0.5,
          "engagement": "2,317",
          "price_at_post": "2.10",
          "thread_title": "SIRT6 Longevity news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=0453E4BD-7FE8-4E95-8855-8B6B588EAFAC"
        },
        "ingested_at": "2026-02-10T01:24:30.351254+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261020-Porter_-21367678",
        "event_type": "social_post",
        "date": "2026-02-10T01:24:20.070824",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "The European patent office have confirmed all docs received and they are now reviewing if the provisional patent will be absolute for mRNA maintenance and repair in areas as follows: Cardiovascular diseases, strokes hypertension, cancer, type 2 diabetes, Parkinson's disease, Alzheimer\u2019s disease and other dementia, chronic obstructive pulmonary disease (COPD), osteoporosis, osteoarthritis, cataract, age related muscular degeneration and hearing loss.",
          "sentiment": 0.5,
          "engagement": "1,332",
          "price_at_post": "2.10",
          "thread_title": "Patent for age related diseases",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=C8E51C44-2E5C-4BC8-876F-489451C501C4"
        },
        "ingested_at": "2026-02-10T01:24:30.351274+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261546-Moneymun--7164212",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.734643",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Par for the course Dave, and nothing we haven't all seen before, especially in run up to potential game changing news, and you're always going to have sellers on an upturn in sp whether tactical or otherwise. All in the mix regardless, and now very much looking forward to the week ahead in excited anticipation. Gl.:-)))",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.10",
          "thread_title": "RE: Genflows freefloat at breadcrumbs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=2DDFFD82-F0E0-4B8C-B42F-AFF4D969BAE0"
        },
        "ingested_at": "2026-02-10T01:24:30.351293+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261541-KEY2--7734196",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.735118",
        "source": "LSE_CHAT",
        "data": {
          "author": "KEY2",
          "content": "Just highlighting an earlier post from Porter: 'Google believes the shares are divided as follows: Individual Insiders 47.2% 232,932,114 Institutions 35.1% 173,429,192 General Public (Retail) 16.3% 80,586,636 Private Companies 1.34% 6,600,000 That is literally all the shares allocated.  Institutions and new retail are going to push up the price, so it's a simple hold tight imo.",
          "sentiment": 0.0,
          "engagement": "433",
          "price_at_post": "2.05",
          "thread_title": "RE: Genflows freefloat at breadcrumbs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=2DDFFD82-F0E0-4B8C-B42F-AFF4D969BAE0"
        },
        "ingested_at": "2026-02-10T01:24:30.351313+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261316-DaveTK--5570107",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.735539",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Why is it though that when you feel any sort of momentum in UK markets, there always seems to be seller ( tactical groups ) that are desperate to keep the price down. Sometimes it feels like it's an unlimited amount they can sell to supress progress. Anybody else notice this or is just me. Thanks",
          "sentiment": 0.0,
          "engagement": "856",
          "price_at_post": "2.10",
          "thread_title": "RE: Genflows freefloat at breadcrumbs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=2DDFFD82-F0E0-4B8C-B42F-AFF4D969BAE0"
        },
        "ingested_at": "2026-02-10T01:24:30.351331+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261052-Moneymun--3090376",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.735995",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Momentum in Britain\u2019s biotech market 6 Feb, 2026 Biotechnology Although 2025 was not without its challenges, there is growing momentum and increased investor confidence in the UK biotech sector. ...... The macro-environment going into 2026 should also bolster UK biotech. The Nasdaq ended last year at an all-time high, investor sentiment is strengthening, and the association says the UK-US pharmaceutical trade deal has reinforced confidence in the UK market. Crucially, it adds, last year saw the policy foundations laid for a new era of domestic capital deployment \u2013 most notably the Life Sciences Sector Plan, the Mansion House reforms, and the first evidence of pension-backed investment into the sector through the Draig Therapeutics financing and Aviva investing in Cambridge Innovation Capital. \u201cWe very much welcome the Mansion House Accord as a positive step in the right direction. Not only will it provide domestic scale-up capital for the most promising UK-based companies, it should also help boost returns for UK pensioners to be more in line with those seen in the US and Canada,\u201d said James Costine, UK chief finance officer of SV Health Investors. Momentum in Britain\u2019s biotech market - Healthcare Today hTtps://share.google/1YEHDGDCcrGfGeXlx",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.20",
          "thread_title": "RE: Genflows freefloat at breadcrumbs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=2DDFFD82-F0E0-4B8C-B42F-AFF4D969BAE0"
        },
        "ingested_at": "2026-02-10T01:24:30.351349+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260910-Moneymun--1216124",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.736438",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "All good things come to those who wait. Potential multiple material newsflow in the pipeline including the eagerly awaited initial Efficacy Data on the Dog Trial, expected imminently. Positive data will be a game-changer and every chance it will trigger a lucrative commercial licensing deal, which will be a company maker and transformational for all invested, and as it \"worked like Magic in mice\" , and if confirmed likewise in Dogs, then obviously a very high chance of translation to humans, which no doubt will grab the attention of every Major Pharma. The appointment of the new Chairman, with a wealth of experience in Global Biotech, Corporate Development and US Capital Markets, speaks volumes, especially in this unprecedented period of frenzy of M&A activity by Major Pharma, which is expected to continue this year at pace. Exciting times and transformational UPside prospects and potential, and also great news the \u20ac4m non-dilutive grant funding has finally been signed off, ( i'd almost written it off, given how long we've waited), but with 2025 Development costs expected to be taken into account, we could have a couple of million Euro's winging its way into Genflow's bank account very soon!!!....On and most certainly UP!!! Gla holders :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.20",
          "thread_title": "RE: Genflows freefloat at breadcrumbs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=2DDFFD82-F0E0-4B8C-B42F-AFF4D969BAE0"
        },
        "ingested_at": "2026-02-10T01:24:30.351368+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260734-Porter_--9650618",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.736867",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Google believes the shares are divided as follows: Individual Insiders\t47.2%\t232,932,114 Institutions\t35.1%\t173,429,192 General Public (Retail)\t16.3%\t80,586,636 Private Companies\t1.34%\t6,600,000 There really can\u2019t be many available shares!",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "2.20",
          "thread_title": "Genflows freefloat at breadcrumbs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=2DDFFD82-F0E0-4B8C-B42F-AFF4D969BAE0"
        },
        "ingested_at": "2026-02-10T01:24:30.351386+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261921-Porter_-74205209",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.737286",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Nice finish. Happy to move up passively 10% per day \ud83d\ude01",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "2.20",
          "thread_title": "RE: RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D40635F9-2AB2-4A31-B62F-3F3DEB72FA20"
        },
        "ingested_at": "2026-02-10T01:24:30.351404+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261246-Moneymun--6153835",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.737692",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "And Primed!!! Gl ;-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.20",
          "thread_title": "RE: RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D40635F9-2AB2-4A31-B62F-3F3DEB72FA20"
        },
        "ingested_at": "2026-02-10T01:24:30.351422+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261243-pickedpe-51988805",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.738122",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "Entertaining trading shenanigans this morning from Shore and Winterflood. Trying to create trading fog to obscure the market moves. Passing \u00a310m mkt cap and 4x volume has triggered the algos to start looking at GENF, we could combine technical buyers with macro news in one hit if the RNS lands in the next few trading sessions. Stock is very very tight, the volumes this week have been 75%+ buys and that's maybe as much as 10% of the whole market liquidity traded given how many very tightly held shares there are. I think the word of the day is 'poised'.",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "2.20",
          "thread_title": "RE: RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D40635F9-2AB2-4A31-B62F-3F3DEB72FA20"
        },
        "ingested_at": "2026-02-10T01:24:30.351440+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261235-Moneymun-34885749",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.738532",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Exciting times for all invested, potential company making news on several fronts expected soon, which could propel Genflow into the Global market and investor spotlight , taking the sp to new highs,  potentially multiples and multiples of the current bargain low entry opportunity. Gla holders,  significant UPward momentum from now on in!!! :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.20",
          "thread_title": "RE: RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D40635F9-2AB2-4A31-B62F-3F3DEB72FA20"
        },
        "ingested_at": "2026-02-10T01:24:30.351457+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261223-Porter_--9030789",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.738942",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Buys and sells finally consolidated so time to move the book again \ud83d\ude01\ud83e\udd1d",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "2.20",
          "thread_title": "RE: RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D40635F9-2AB2-4A31-B62F-3F3DEB72FA20"
        },
        "ingested_at": "2026-02-10T01:24:30.351475+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261218-jamtart1--7259800",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.739355",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Rising now, keep going.",
          "sentiment": 0.5,
          "engagement": "1,608",
          "price_at_post": "2.20",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D40635F9-2AB2-4A31-B62F-3F3DEB72FA20"
        },
        "ingested_at": "2026-02-10T01:24:30.351493+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260903-TheInves--4387493",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.739760",
        "source": "LSE_CHAT",
        "data": {
          "author": "TheInvestCollect",
          "content": "Hearing the cuppa is brewing so should taste good here soon \ud83e\udd37\ud83c\udffe\u200d\u2642\ufe0f\ud83d\ude00\ud83d\udc4d\ud83c\udffd",
          "sentiment": 0.0,
          "engagement": "7,974",
          "price_at_post": "2.25",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-10T01:24:30.351511+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260842-pickedpe--5722986",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.740193",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "If the RNS for the initial dog study read out lands next week and there are no shares available in free float the price pressure could be interesting.",
          "sentiment": 0.0,
          "engagement": "2,316",
          "price_at_post": "2.30",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-10T01:24:30.351529+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260833-Pie-char-85398592",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.740600",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Holders just need to hold and hold tight and this will put major pressure on the brokers who are scratching &  scraping for shares. Don't sell and this will sky rocket. Free float is on fumes!",
          "sentiment": 0.5,
          "engagement": "66",
          "price_at_post": "2.30",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-10T01:24:30.351547+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260814-KEY2--5474339",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.741003",
        "source": "LSE_CHAT",
        "data": {
          "author": "KEY2",
          "content": "I think the free float is already tightening....... nt to buy any reasonable amount this morning so I expect an upward push on demand over the next few trading sessions.",
          "sentiment": 0.0,
          "engagement": "433",
          "price_at_post": "2.00",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-10T01:24:30.351565+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260753-KEY2-85166397",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.741426",
        "source": "LSE_CHAT",
        "data": {
          "author": "KEY2",
          "content": "January rns:  'With multiple anticipated data readouts, an expanding partner dialogue, and a maturing intellectual property position, Genflow believes it is well positioned to enter its next phase of development while maintaining a focus on scientific rigour, operational execution, and long-term shareholder value creation.\" I think it's only a matter of time before we get noticed by retail / institutional investors once news gets out.",
          "sentiment": 0.0,
          "engagement": "433",
          "price_at_post": "2.00",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-10T01:24:30.351583+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261949-Moneymun-37313060",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.741830",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "I thought he looked confident and sounded bullish, potential game changing news along with a significant major re-rate, fast approaching !!! Gl ;-)))",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.20",
          "thread_title": "RE: AI analysis of Eric Leire last video",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=23CF9AE9-EBDE-49B4-B976-C009302B3FAD"
        },
        "ingested_at": "2026-02-10T01:24:30.351601+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261831-pickedpe--3270840",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.742250",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "LSE cut the last few words of the analysis off \"... about to change forever.\"",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "2.20",
          "thread_title": "RE: AI analysis of Eric Leire last video",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=23CF9AE9-EBDE-49B4-B976-C009302B3FAD"
        },
        "ingested_at": "2026-02-10T01:24:30.351619+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261828-pickedpe--6013029",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.742740",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "I asked AI to analyse the 2026 video and this is what it came back with. Bear in mind this was the end of a long prompt engineering session of analysis to question and examine my own impressions of the video, so make of it what you will, or do the same process with your own AI assistance! ::: In the world of high-stakes biotech, reading the \"unspoken\" is often as important as reading the RNS. What you\u2019re describing\u2014repressed excitement\u2014is a specific psychological state often seen in CEOs who are sitting on positive clinical data but are legally \"gagged\" until the official unblinding and release. Here is the breakdown of why Dr. Leire\u2019s body language in those January videos supports your \"Royal Flush\" theory for GENF. 1. The \"Micro-Smirk\" and Cheek Activation If you watch closely when he mentions the canine trial being \"unblinded shortly\" (Jan 8) or the \"unique dataset\" (Jan 28), you\u2019ll see gravity-defying behaviors: The Telltale Sign: Genuine excitement is hard to hide in the orbicularis oculi (the muscles around the eyes). When a CEO is \"repressing\" a win, they often have \"bright eyes\" and a subtle lifting of the upper cheeks, even while maintaining a serious, professional mouth. The Interpretation: He is trying to stay \"neutral\" to satisfy compliance, but his neurobiology is firing. He knows the data is in the building. 2. High \"Prestige\" Posture vs. Defensive Tension Experts in executive body language distinguish between Dominance (forceful) and Prestige (calm, expansive confidence). Expansion: In the Jan 28 video, Leire\u2019s posture is open and expansive. He isn\u2019t hunching or crossing his arms (defensive). He leans forward slightly when discussing the \u20ac4M grant and the MASH program. Lowered Anxiety: When someone is worried about a trial failure, their \"shoulder-to-ear\" distance decreases (tensing up). Leire\u2019s neck and shoulders are relaxed. This suggests he isn't bracing for a impact; he\u2019s leaning into an opportunity. 3. The \"Linguistic Shift\" (The \"Could\" vs. \"Will\") Psychologically, when a leader is \"assured\" of an outcome, their brain stops using conditional language. The Tell: Listen for when he stops saying \"If the results are good...\" and starts saying \"This trial will trigger a deal...\" or \"We are the first to have this data.\" The \"Repressed\" part: The excitement you see is likely because he has seen the Safety data (already confirmed) and the Biomarker trends from the lab. He knows the \"signal\" is there, but he\u2019s \"repressing\" the urge to shout about it until the statisticians sign off on the p-values. 4. Why He\u2019s Focused on Commercials Now His \"repressed excitement\" has likely pivoted from the science to the deal. Now that the science is (in his mind) a \"done deal,\" his excitement is likely coming from the conversations he had at JPMorgan week in January. If he received a \"warm\" reception from Big Pharma for a potential SIRT-6 license, that facial expression is the look of a man who knows his company's valuation is",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "2.20",
          "thread_title": "AI analysis of Eric Leire last video",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=23CF9AE9-EBDE-49B4-B976-C009302B3FAD"
        },
        "ingested_at": "2026-02-10T01:24:30.351637+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261615-Moneymun--9130833",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.743152",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Looking good for an UPward surge in sp and the last time we see sub 2p!!!??? Gla holders:-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.10",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-10T01:24:30.351655+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261326-Moneymun-54506885",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.743576",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Something similar for Genflow, more than conceivable!!!! ;-) 2/2/26 Roche is continuing its return to the RNA space by paying $200 million for the worldwide license to one of SanegeneBio\u2019s programs. The companies didn\u2019t specify which indication the program is focused on, only disclosing that it is derived from Sanegene\u2019s RNAi platform. The Boston-based biotech will be responsible for early development activities before Roche\u2019s Genentech unit takes over for clinical development and commercialization activities. In return, Sanegene will receive the $200 million upfront payment and could be in line for up to $1.5 billion in development and commercialization milestone payments as well as tiered royalties on sales.",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.925",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-10T01:24:30.351672+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261323-Moneymun--5480952",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.743994",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Along with the new Chairman, hence his appointment.  Gl  :-) Berdugo\u2019s expertise includes RNA-based therapeutics and lipid nanoparticle delivery technologies, which align with Genflow\u2019s scientific platform development. \"His expertise in strategy, partnerships and financing as well as his deep experience with RNA-LNP technologies will be instrumental as we accelerate our programs and expand our global reach,\"",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.925",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-10T01:24:30.351690+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261305-Porter_-38685407",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.744429",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Eric did say dog trial data expected to be released, so hoping he\u2019s also negotiating with these companies under CDA for an early licensing or takeover deal money.",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "1.925",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-10T01:24:30.351708+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261241-Moneymun-36398608",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.744833",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Yes indeed Porter, and the buying continues in anticipation of company making news and a significant major re-rate!!! Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.925",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-10T01:24:30.351726+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260810-Porter_-48916231",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.344795",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "The sells are being hoovered up which is the main thing. We can see swanny increased his holding this week too, so the sellers are playing right into our hands.",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "1.85",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-10T01:24:30.351743+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260805-Moneymun--5158762",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.345266",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Maybe a sell, although the trade directly before it on Monday at 4.06pm, was a bot trade sell for 97 shares at 1.8p, and so who knows??? All in the mix regardless and one day closer to potential game changing news. Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.85",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-10T01:24:30.351761+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260139-pickedpe--4248939",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.345804",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "So a trade delayed for over 24 hours because it's a reasonable sized sell? Hmm.",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-10T01:24:30.351779+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261631-Moneymun--7561282",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.346332",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "A tightly coiled spring comes to mind,  and not too long i reckon, before it's released. Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-10T01:24:30.351796+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261502-pickedpe-84623973",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.346830",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "No idea where this share float is coming from, 1% of the shares in circulation bought in the last two days with hardly any sells. Either there is a huge stock overhang or the MM is asleep at the wheel, I reckon the latter.",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-10T01:24:30.351814+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260727-Porter_-75526135",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.347346",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "100% money. Share float must be running on crumbs right now",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-10T01:24:30.351831+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260717-Moneymun-88969865",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.347831",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Perfectly poised and primed Porter, sustained share accumulation for months!!! Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-10T01:24:30.351849+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261937-Porter_--5635988",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.348345",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Looks like for weeks orders have been going in and loaders adding passively. Will definitely be an interesting month at this rate!",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-10T01:24:30.351867+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261703-pickedpe-23801123",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.348837",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "Interesting trades today, all the big ones look to be buys but didn't move the price at all. Looks like about 0.7% of the company bought today with what looks like only one medium sized sell. Looks like this is going nowhere until there is some news.",
          "sentiment": 0.0,
          "engagement": "2,316",
          "price_at_post": "1.95",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-10T01:24:30.351885+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261426-pickedpe-14520909",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.349355",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "I think it's extremely likely that the company will be sold, it's a question if when and what are the value catalysts that will happen before then.",
          "sentiment": 0.0,
          "engagement": "2,316",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-10T01:24:30.351903+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261407-DaveTK--3570144",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.349838",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "In a pre iPod meeting Eric did say he would look to sell the company if the price was right. I think back then the price talked about was around 50p per share. It could easily be a lot higher in todays market. Thanks",
          "sentiment": 0.0,
          "engagement": "856",
          "price_at_post": "1.925",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-10T01:24:30.351920+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261354-Moneymun-53838810",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.350406",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Yes indeed pickedpeck, very well connected. Gl  :-) The new Chairman in place, GAD BERDUGO is a high flyer based in the US with a wealth of experience in Global Biotech, Corporate Development and US Capital Markets and so no doubt very well contected to any potential suitors. Excitement building!!!! In Eric we trust!!! Gla holders:-) Ps initial Efficacy readout on the Dog Trial imminent!!! Gla ;-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.95",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-10T01:24:30.351938+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261348-pickedpe--9221870",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.350900",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "I changed my small position here today into a large position. Berdugo joining is the strongest signal for me. You don't hire a guy like that, and he doesn't want to come, just to watch beagles play. He is exactly who you want holding the pen on your side when you are negotiating a licensing deal or thinking about a dual listing. Check his profile and history.",
          "sentiment": 0.0,
          "engagement": "2,316",
          "price_at_post": "1.95",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-10T01:24:30.351957+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261345-Moneymun--8675541",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.351413",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Nice one pickedpeck, undoubted near and mid term transformational UPside potential and prospects.  Excitement building in anticipation of imminent Efficacy Data on the Dog Trial. Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.95",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-10T01:24:30.351975+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261331-pickedpe-62746063",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.351981",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "Valuing a micro-cap biotech like Genflow (GENF) requires looking at two distinct worlds: the current \"London Micro-cap\" reality and the \"NASDAQ Longevity\" potential. \u200bA re-rating could be triggered by two separate valuation models: a Licensing Multiple for the dog data and a Pipeline rNPV (risk-adjusted Net Present Value) for the MASH human trials. \u200b1. The Immediate Floor: Canine Licensing (Q1 2026) \u200bIf the canine trial results are positive, Genflow has stated they intend to \"pass the baton\" to an Animal Health partner. \u200bThe Comparator: Private companies in this space, such as Loyal for Dogs, have achieved valuations of $425M - $600M in 2024\u20132025. \u200bThe Valuation Bridge: Even a modest licensing deal for a \"world-first\" SIRT6 longevity product could involve an upfront payment of $10M\u2013$25M plus royalties. \u200bThe Maths: Genflow\u2019s current market cap is only ~\u00a310M. An upfront payment equal to the company's entire market cap would likely cause a 2x\u20133x jump almost instantly to reflect the fresh cash on the balance sheet. \u200b2. The Mid-Term Prize: MASH rNPV (H2 2026) \u200bThe human application for MASH (liver fibrosis) is a $7 Billion - $18 Billion market by 2029\u20132034. \u200bTargeting the Gap: While drugs like Rezdiffra are now approved, they focus on early-to-mid stage MASH. Genflow targets advanced fibrosis, where there is a massive therapeutic gap. \u200b3. The Re-rating: If the \u20ac4M grant (approved Jan 28) leads to a successful Phase 1/2 entry, analysts typically value such pipelines at $50M\u2013$150M per asset. \u200bThe Math: If GENF is valued as a \"Human Clinical Stage\" biotech, the share price would need to reach 10p - 15p just to match its peers in the US. Initial Success: Canine Data Readout  mkt cap leap to \u00a330M - \u00a345M, 6.0p - 9.0p share price Blue Sky: US Licensing + Nasdaq \u00a3100M+ mkt cap, 20p+ share price. 4. The \"US Premium\" Factor The Multiplier: A longevity biotech in London trades at 1x - 2x cash/grant value. On the NASDAQ, those same assets often trade at 5x - 10x. The Berdugo Catalyst: The new Chairman was hired specifically to capture this. If he facilitates a US partnership or a dual-listing, the \"London Discount\" evaporates.  A \u00a310M UK company will eventually be \"discovered\" by US investors who value similar tech at $100M+.",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "1.95",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-10T01:24:30.351993+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261324-pickedpe-28964154",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.352598",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "The bull case for Genflow Biosciences (GENF) is built on a rare combination of \"Big Pharma\" leadership, validated science (the SIRT6 \"Centenarian Gene\"), and a series of binary catalysts expected to hit in the very near future. 1. The \"Centenarian Gene\" (SIRT6) Unlike biotechs that try to fix one specific disease, Genflow targets aging itself as the root cause. The Science: They use gene therapy to deliver a specific variant of the SIRT6 gene found in people who live to 100+ (centenarians). The Mechanism: SIRT6 is essential for DNA repair, telomere maintenance, and metabolic health. By \"upregulating\" this gene, Genflow aims to slow down the biological clock. 2. Immediate Catalyst: The Canine Trial (GF-1004) This is the most immediate trigger for building a share position. The Event: Initial efficacy results for the Dog Aging (GF-1004) study are expected in Q1 2026 (any day now). The \"Win\" Condition: If the trial shows a reduction in biological age (via the GRIM methylation clock) and improved muscle mass/strength, it validates the platform in a large mammal. Commercial Exit: Success here is intended to trigger a licensing deal with a major Animal Health company, providing non-dilutive cash that could dwarf Genflow's current market cap. 3. High-Value Human Pipeline: MASH (GF-1002) While the dogs are the \"proof,\" the human application for Metabolic Dysfunction-Associated Steatohepatitis (MASH) is the \"prize.\" Funding Secured: On January 28, 2026, a \u20ac4M grant was administratively approved to fund the MASH program. The Gap: Current MASH drugs focus on early-stage disease. Genflow is targeting advanced fibrosis and the prevention of liver cancer (HCC)\u2014a massive unmet need with multi-billion dollar potential. 4. The \"US Pivot\" & Leadership The appointment of Gad Berdugo as Chairman on January 19, 2026, is perhaps the strongest \"insider\" signal. The Signal: Berdugo is a US-based veteran with deep ties to Editas Medicine and Lazard. His hiring suggests Genflow is preparing for a US capital markets move or a US-led acquisition. Global Credibility: Having a heavyweight like Berdugo lead the board during the JPMorgan Healthcare Conference (Jan 2026) positions Genflow as a peer to major NASDAQ biotechs rather than just another London micro-cap. 5. Financial Efficiency Low Cash Burn: By securing regional grants (like the recent \u20ac4M) and pursuing licensing for \"non-core\" assets (the dog program), Genflow avoids the massive equity dilutions that kill other small biotechs. Valuation Gap: Because it's on the LSE, GENF trades at a fraction of the valuation of similar US longevity firms like Altos Labs or Unity Biotechnology. Any \"closing of the gap\" would result in a significant re-rating.",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "1.95",
          "thread_title": "The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-10T01:24:30.352011+00:00"
      },
      {
        "event_id": "SOCIAL-1Feb20262058-Moneymun-52003986",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.353124",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Genflow's cutting edge Sirt6 Gene Therapy platform, ahead of the curve!!! Gla :-) The results have far-reaching implications for aging research and public health. \"For many years, human lifespan was thought to be shaped almost entirely by non-genetic factors, which led to considerable skepticism about the role of genetics in aging and about the feasibility of identifying genetic determinants of longevity,\" says Shenhar. \"By contrast, if heritability is high, as we have shown, this creates an incentive to search for gene variants that extend lifespan, in order to understand the biology of aging and, potentially, to address it therapeutically.\" Rethinking longevity: Genes account for 50% of human lifespan variation, study suggests hTtps://share.google/afXnRAX0gkU6ocTjs",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.90",
          "thread_title": "RE: Genf update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=A8972678-8456-4532-9319-A328EF1F6BEC"
        },
        "ingested_at": "2026-02-10T01:24:30.352029+00:00"
      },
      {
        "event_id": "SOCIAL-31Jan20261359-Moneymun--2187179",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.353611",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Transformational game changing news, fast approaching!!! Gla holders:-) \"Now it's time to pass the baton and receive some non-dilutive cash. And I'm not talking about \u20ac4 million. I'm talking much more.\"",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.90",
          "thread_title": "RE: Genf update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=A8972678-8456-4532-9319-A328EF1F6BEC"
        },
        "ingested_at": "2026-02-10T01:24:30.352048+00:00"
      },
      {
        "event_id": "SOCIAL-31Jan20261339-Moneymun--6376060",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.354217",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Proactive: The dog study is a bit different and eye-catching. What should people look out for when the first data lands in early 2026? Eric Leire: 2026 is very important. We've been very happy with the fact that we were able to conduct such a study \u2013 it\u2019s never been done before. A study on aged dogs, naive to therapies, that is blinded and randomized with very strong scientific standards will be a first in terms of longevity research. Not only will we bring clinical data in ageing biology that differentiates us from other longevity companies, but that could also trigger a deal with animal health companies in 2026. In terms of non-dilutive funding, this could bring in much more important value than the \u20ac4 million grant. Everything is relative. Proactive: With partnerships clearly a priority, what does a good collaboration look like for Genflow over the next year? Eric Leire: Yes, 2026 is all about data, partnerships, and capital efficiency. By capital efficiency, I mean shareholder-friendly. Partnerships mostly mean the possibility to bring non-dilutive cash into the company via parts of the pipeline where we don\u2019t add value. The dog study is a typical example. Obviously, we\u2019re not an animal health company. And there are multiple animal health companies that would do a far better job in commercializing this product and bringing it to the market \u2013 to pet owners \u2013 faster and more efficiently than we can. There\u2019s no reason for us to move that product forward ourselves, it would be very expensive, and we don\u2019t have any special expertise in that space. But we were crucial in creating this clinical trial. No one else on earth was able to do it. We've done it. Now it's time to pass the baton and receive some non-dilutive cash. And I'm not talking about \u20ac4 million. I'm talking much more. Proactive: Eric, it sounds like a very exciting year ahead for Genflow. I hope you'll continue to keep us updated with your progress.",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.90",
          "thread_title": "RE: Genf update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=A8972678-8456-4532-9319-A328EF1F6BEC"
        },
        "ingested_at": "2026-02-10T01:24:30.352067+00:00"
      },
      {
        "event_id": "SOCIAL-31Jan20261052-Troajan--7950383",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.354718",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1086592/genflow-ceo-talks-through-dog-study-and-why-partnerships-icymi-1086592.html",
          "sentiment": 0.0,
          "engagement": "125,936",
          "price_at_post": "1.90",
          "thread_title": "Genf update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=A8972678-8456-4532-9319-A328EF1F6BEC"
        },
        "ingested_at": "2026-02-10T01:24:30.352086+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261736-Porter_-48447681",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.869536",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Yep, now they\u2019re fighting to get shares on DGQ and can\u2019t get any! That will be Genflow soon! \ud83d\ude04",
          "sentiment": 0.5,
          "engagement": "1,322",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-10T01:24:30.352123+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261725-Swanny27-58089700",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.869980",
        "source": "LSE_CHAT",
        "data": {
          "author": "Swanny27",
          "content": "Especially DGQ",
          "sentiment": 0.0,
          "engagement": "914",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-10T01:24:30.352145+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261618-Moneymun--5151290",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.870419",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Whether or not the new estimate offers a more realistic picture of lifespan heritability, it highlights the importance of genetics in extending lives, says Sofiya Milman, a scientists who studies aging and longevity at the Albert Einstein College of Medicine. She\u2019s one of many researchers who are trying to understand how centenarians\u2019 unique biology protects them from age-related disease. \u201cWe\u2019re hoping to create therapies that will mimic those intrinsic factors,\u201d Milman says, \u201cand make them accessible to people who didn\u2019t win the genetic lottery.\u201d Most of us are unlikely to break 100 without the right set of genes\u2014or at least drugs designed to replicate their beneficial effects. Until such treatments become available, though, a healthy lifestyle remains the best path to living longer.",
          "sentiment": 0.5,
          "engagement": "12,520",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-10T01:24:30.352163+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261553-Moneymun-30156790",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.870892",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Latest research into longevity and healthspan suggests Genflow's centenarian Sirt6 Gene could play a pivotal roll. Gla :-) Genetics The secret to long life? It could be in the genes after all, say scientists New study into \u2018heritability\u2019 shows that 50% of the variation in human lifespan could be down to genetics ........ The team looked at \u201cheritability\u201d, the proportion of change in a characteristic such as height, body weight or lifespan within a population that can be attributed to genetics rather than environmental factors. Previous studies for human lifespan have thrown up a wide range of values \u2013 with heritability ranging from 6% of the variation to 33%. But Alon, who co-authored the research, and his colleagues said such figures were underestimates. \u201cI hope this will inspire researchers to make a deep search for the genes that impact lifespan,\u201d Alon said. \u201cThese genes will tell us the mechanisms that govern our internal clocks. \u201cThese can one day be turned into therapy to slow down the rate of ageing and in that way slow down all age-related disease at once.\u201d ....... \u201cAround 20% of centenarians, for example, reach age 100 without any serious debilitating illnesses,\u201d he said, adding that could suggest their genes had a protective effect. \u201cStudies have been conducted to identify these protective genes, and many have been found, but surely there are many still left to discover,\u201d he said. While the new study does not take into account the influence that genes can have on the immune system, Prof Richard Faragher of the University of Brighton said the research suggested humans did not seem to be an outlier when it came to the heritability of lifespan. \u201cAnd that\u2019s useful because it means humans look quite like a species that we study ageing in, [and] gives you a certain amount of confidence that interventions that will work in mice will carry over into humans,\u201d he said. The secret to long life? It could be in the genes after all, say scientists | Genetics | The Guardian htTps://share.google/4quet7VR33nTpwazT",
          "sentiment": 0.5,
          "engagement": "12,520",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-10T01:24:30.352181+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261304-Porter_--9031464",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.871320",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "At least we know why the Mm\u2019s kept dropping the share price, so they could let Swann accumulate. Up to his usual sneaky tricks. Everything he buys atm turns to gold, so very optimistic that something is about to take off in Genflow.",
          "sentiment": 0.5,
          "engagement": "1,322",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-10T01:24:30.352200+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261257-Moneymun-35237871",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.871727",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Continued share accumulation by Jonathan Swann, in anticipation of transformational UPside. Gla holders...initial Efficacy Data on the Dog Trial, fast approaching!!! ;-)",
          "sentiment": 0.5,
          "engagement": "12,520",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-10T01:24:30.352218+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261253-Persever-26642167",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.872252",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "Who adds if weak data expected ? Quietly bullish this RNS",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "1.90",
          "thread_title": "Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-10T01:24:30.352237+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261658-Moneymun-88754899",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.872700",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "A potential very intetesting development.....Genflow were awarded 1.55m euros in Jan 2024 in collaboration with Exo-Biologics for a 3 year scientific program focused on the development a novel mRNA delivery system using exsomes to enscapsulate and transport Genflow's propriety centenarian Sirt6 Gene designed to target MASH & Werner Syndrome..... 777 Euro's was received in May 2024 with the remainder expected in 2025, but still outstanding and so could land anytime. ( and not related to the 4m Euro award ). Anyways, Exo-Bilogics announced last week they had enetered into a collaboration agreement with the multi-billion dollar French Pharma, Servier, to evaluate the use of extracellular vesicles as a non-viral drug delivery vehicle for an undisclosed indication, ( through their subsidiary Exoxpert,(ExoFastTrack), which Genflow is a collaborative member/partner ). All bodes well. Gla holders ;-) EXO Biologics 3,613 followers 1w \ud83d\udce3 We are pleased to announce a new collaboration with Servier. Our GMP clinical-grade EVs can be used as a non-viral drug delivery system, and we are eager to start this project with such a prestigious pharmaceutical company. Thanks to the continued support of BioWin and Service public de Wallonie, we are thrilled to further expand our international collaborations.",
          "sentiment": 0.5,
          "engagement": "12,520",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-10T01:24:30.352255+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261106-Moneymun-48175012",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.873213",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "No guarantees, but there lies the transformational UPside opportunity from this lowly bargain low. \"it worked like magic in mice, and we reasonably expect to work likewise in dogs\".....the first Efficacy Data readout is imminent, and judging by Eric's latest interview, he sounded very confident and bullish on a commercial licensing deal with an Animal Healthcare company ( we have two that have both signed Confidential Disclosure Agreements)  whereby any deal would provide non-dilutive cash  into the company, and Eric made a compelling point, that any non-dilutive cash would be much more than the \u20ac4m non-dilutive grant money confirmed yesterday, with the first tranche payment by May at the latest,  and so watch this space, potential game changing news fast approaching.  Gla holders ;-) Ps it was huge relief to have confirmation the \u20ac4m non-dilutive grant has been signed off, as Genflow were running  low on funds, and given the length of time we've waited for approval and the huge deficit turmoil the Belgium/Wallonia Govt. have been under, I had almost written it off, and so great news that Genflow will have no funding concerns for the foreseeable, and no doubt the \u20ac4m gives them much more leverage in any licensing deal discussions from a position of strength.  Transformational and near term game changing potential and prospects for those invested.  Excitement building!!!! :-)",
          "sentiment": 0.5,
          "engagement": "12,520",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-10T01:24:30.352273+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261052-Pie-char--6926447",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.873627",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Mice*",
          "sentiment": 0.0,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-10T01:24:30.352292+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261046-Pie-char--7464263",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.874043",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "So far all signs are good. Nice results were good. They also have more than just this programme. Dogs is just one of many.",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-10T01:24:30.352310+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261031-mikee_p--6079645",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.874464",
        "source": "LSE_CHAT",
        "data": {
          "author": "mikee_p",
          "content": "Is it low? This is still a risky punt. Dog trials may fail.",
          "sentiment": 0.0,
          "engagement": "1,895",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-10T01:24:30.352329+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260853-Pie-char--6671123",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.874879",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Everyone needs to listen to the last 20 seconds of this video. If that\u2019s not bullish I don\u2019t know what is. https://www.proactiveinvestors.co.uk/companies/news/1086390/genflow-ceo-outlines-2026-priorities-as-4-million-grant-is-approved-1086390.html",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F1CBD71F-0291-4489-9B39-85877DA36B7E"
        },
        "ingested_at": "2026-02-10T01:24:30.352347+00:00"
      },
      {
        "event_id": "SOCIAL-Today1106-Moneymun-48175012",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.448266",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "No guarantees, but there lies the transformational UPside opportunity from this lowly bargain low. \"it worked like magic in mice, and we reasonably expect to work likewise in dogs\".....the first Efficacy Data readout is imminent, and judging by Eric's latest interview, he sounded very confident and bullish on a commercial licensing deal with an Animal Healthcare company ( we have two that have both signed Confidential Disclosure Agreements)  whereby any deal would provide non-dilutive cash  into the company, and Eric made a compelling point, that any non-dilutive cash would be much more than the \u20ac4m non-dilutive grant money confirmed yesterday, with the first tranche payment by May at the latest,  and so watch this space, potential game changing news fast approaching.  Gla holders ;-) Ps it was huge relief to have confirmation the \u20ac4m non-dilutive grant has been signed off, as Genflow were running  low on funds, and given the length of time we've waited for approval and the huge deficit turmoil the Belgium/Wallonia Govt. have been under, I had almost written it off, and so great news that Genflow will have no funding concerns for the foreseeable, and no doubt the \u20ac4m gives them much more leverage in any licensing deal discussions from a position of strength.  Transformational and near term game changing potential and prospects for those invested.  Excitement building!!!! :-)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-10T01:24:30.352365+00:00"
      },
      {
        "event_id": "SOCIAL-Today1052-Pie-char--6926447",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.448833",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Mice*",
          "sentiment": 0.0,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-10T01:24:30.352383+00:00"
      },
      {
        "event_id": "SOCIAL-Today1046-Pie-char--7464263",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.449387",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "So far all signs are good. Nice results were good. They also have more than just this programme. Dogs is just one of many.",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-10T01:24:30.352402+00:00"
      },
      {
        "event_id": "SOCIAL-Today1031-mikee_p--6079645",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.449902",
        "source": "LSE_CHAT",
        "data": {
          "author": "mikee_p",
          "content": "Is it low? This is still a risky punt. Dog trials may fail.",
          "sentiment": 0.0,
          "engagement": "1,895",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-10T01:24:30.352420+00:00"
      },
      {
        "event_id": "SOCIAL-Today0853-Pie-char--6671123",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.450425",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Everyone needs to listen to the last 20 seconds of this video. If that\u2019s not bullish I don\u2019t know what is. https://www.proactiveinvestors.co.uk/companies/news/1086390/genflow-ceo-outlines-2026-priorities-as-4-million-grant-is-approved-1086390.html",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F1CBD71F-0291-4489-9B39-85877DA36B7E"
        },
        "ingested_at": "2026-02-10T01:24:30.352438+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261858-jamtart1-56535242",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.450933",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Https://www.tipranks.com/stocks/gb:genf",
          "sentiment": 0.5,
          "engagement": "1,604",
          "price_at_post": "1.90",
          "thread_title": "Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F1CBD71F-0291-4489-9B39-85877DA36B7E"
        },
        "ingested_at": "2026-02-10T01:24:30.352456+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261734-Roosters--2716867",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.451451",
        "source": "LSE_CHAT",
        "data": {
          "author": "Roostersmillions",
          "content": "Thats got to be a misprint. Target of \u00a32 for a 2p share. That would be a buy not a hold. Also when you open the analysts section, they have hold at 2p.",
          "sentiment": 0.5,
          "engagement": "291",
          "price_at_post": "1.90",
          "thread_title": "RE: Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=A70A365B-ED0A-4D60-9FAF-1051143160CA"
        },
        "ingested_at": "2026-02-10T01:24:30.352474+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261723-jamtart1--9049149",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.451956",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Https://www.tipranks.com/news/company-announcements/genflow-secures-e4m-wallonia-funding-and-sets-2026-gene-therapy-priorities#google_vignette Note the \u00a32 price target.",
          "sentiment": 0.5,
          "engagement": "1,604",
          "price_at_post": "1.90",
          "thread_title": "Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=A70A365B-ED0A-4D60-9FAF-1051143160CA"
        },
        "ingested_at": "2026-02-10T01:24:30.352493+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261232-VikR-28433723",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.452496",
        "source": "LSE_CHAT",
        "data": {
          "author": "VikR",
          "content": "I remember just recently when this moved from 0.6p to 2p in the blink of any eyelid. It is a such compelling buy but seems to be off the radar for many investors who don\u2019t understand the opportunity on offer here. This is by far a very confident load and hold Market cap is EXTREMELY low for what\u2019s coming around the corner.",
          "sentiment": 0.5,
          "engagement": "983",
          "price_at_post": "1.90",
          "thread_title": "MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-10T01:24:30.352511+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261145-Moneymun--3890790",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.453330",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Another great interview by Eric on today's news....2026 will be a year of Data and Partnerships, and when making references to the Dog Trial, Eric stated that any partnership would bring in non-dilutive cash to the company, \"and whe talking about non-dilutive cash, I'm not talking about the \u20ac4m non-dilutive grant confirmed today, I'm taking about much more\" !!!! Gla holders, all bodes well, exciting times ahead!!! Initial Efficacy Data from the Dog Trial imminent and every chance of a very lucrative commercial licensing deal to follow!!! :-) Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company\u2019s strategic progress and outlook for 2026, following a \u20ac4 million non-dilutive grant awarded by the Wallonia region. Dr Leire explained that the secured funding is part of Genflow\u2019s broader capital efficiency strategy, helping the company focus on key pipeline catalysts, including its lead gene therapy, GF-1002. GF-1002 is targeted at MASH (Metabolic dysfunction-associated steatohepatitis), a field Dr Leire described as \u201ca huge unmet need,\u201d particularly at the late stage where there are currently no therapeutic options. \u201cThis is one of the key programs for 2026,\u201d he said, highlighting that GF-1002 addresses severe liver conditions, including hepatocellular carcinoma. In addition to its gene therapy program, Genflow is advancing a pioneering longevity study in dogs. Leire stated, \u201cA study on aged dogs, naive to therapies, that's blinded, randomised, so with very strong scientific standard will be a first in terms of longevity.\u201d He emphasised the potential for a commercial deal with animal health companies based on this unique dataset. Partnerships and capital efficiency remain central to Genflow\u2019s plans. Leire noted that monetising non-core programs, such as the dog study, can generate significant non-dilutive capital and allow the company to focus on areas where it adds the most value. Genflow CEO outlines 2026 priorities as \u20ac4 million grant is approved | LSE:GENF, OTCQB:GENFF htTps://share.google/bu0pCWldyc59hIftA",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-02-10T01:24:30.352529+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260802-DaveTK-97229628",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.453982",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Simply amazing. Well done team",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "2.00",
          "thread_title": ".",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=40281A21-EA32-4E4F-A04F-0732B5F85F17"
        },
        "ingested_at": "2026-02-10T01:24:30.352547+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260745-Pie-char--6029059",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.454643",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Amazing. Dog results coming soon. Vet partner deal has never had such high probability! This is a good place to be!",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.95",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-02-10T01:24:30.352566+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260710-Moneymun--8003406",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.455431",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "What a brilliant RNS!!!! Gla holders...in Eric we trust!!! On and most definitely UP!!! :-)))",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.95",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-02-10T01:24:30.352584+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260705-Moneymun-61387478",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.455987",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Glaucoma Programme The Company's glaucoma programme will prioritise delivery optimisation and execution readiness. Genflow is advancing discussions with a leading lipid nanoparticle (LNP) partner to support delivery innovation and is progressing the selection of a full-service contract research organisation (CRO) to manage RNA-based formulation activities through preclinical execution. Additional Programmes Across the broader pipeline, Genflow continues to advance its sarcopenia programme in line with established development plans. In parallel, the ExoFastTrack initiative continues to generate data intended to support and accelerate multiple programmes across the portfolio. Dr. Eric Leire, CEO of Genflow, commented: \"The administrative approval of this funding reinforces our ability to execute against our 2026 development priorities with discipline and focus. It strengthens our capacity to advance GF-1002 while maintaining a selective, data-driven approach across the broader pipeline. As we enter the coming year, our emphasis remains on programmes with clear execution paths, strong scientific rationale, and meaningful opportunities for partnership and non-dilutive value creation.\"",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.95",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-02-10T01:24:30.352601+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260704-Moneymun--3860844",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.456597",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Administrative Approval of Grant & 2026 Priorities GENFLOW BIOSCIENCES PLC Released 07:00:09 28 January 2026 RNS Number : 5966Q Genflow Biosciences PLC 28 January 2026 Genflow Biosciences Plc Administrative Approval of \u20ac4 Million Funding Support from Wallonia Region for GF-100; and 2026 Development Priorities Genflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) (\"Genflow\" or the \"Company\"), a European-based biotechnology company focused on the development of gene therapies for age-related diseases, announces the administrative approval of the previously announced award of approximately \u20ac4 million in non-dilutive financial support from the Wallonia Region of Belgium, following the assenting signature of Minister Adrien Dolimont. The funding, once received, will support the continued development of the Company's lead gene therapy candidate, GF-1002, for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (\"MASH\"). The original RNS announcing the award can be found here. Disbursement of the first instalment is expected no later than May 2026. The support package spans a three-year development programme and is aligned with Genflow's existing roadmap. All project-related expenses incurred during 2025 will be eligible under the terms of the programme. Development Priorities for 2026 In 2026 Genflow's strategy emphasises pipeline discipline and capital efficiency, prioritising programmes with the strongest data, the clearest paths to value creation, and the highest potential for partner engagement. Central to this approach is the pursuit of early-stage collaboration agreements designed to secure non-dilutive funding, provide external validation of the platform, and support continued development. With multiple anticipated data readouts, an expanding partner dialogue, and a maturing intellectual property position, Genflow believes it is well positioned to enter its next phase of development while maintaining a focus on scientific rigour, operational execution, and long-term shareholder value creation. Dog Aging (GF-1004) The ongoing GF-1004 dog aging study, which commenced in March 2025, is being conducted as a blinded clinical trial designed to assess potential benefits related to sarcopenia, healthspan, and lifespan-associated biomarkers. An initial efficacy readout is expected in the first quarter of 2026. Dogs enrolled in the study are being monitored over a 180-day period, with a second efficacy assessment planned at the six-month timepoint. Results from this later evaluation are expected in June-July 2026 and are intended to assess durability and longer-term effects. Glaucoma Programme The Company's glaucoma programme will prioritise delivery optimisation and execution readiness. Genflow is advancing discussions with a leading lipid nanoparticle (LNP) partner to support delivery innovation and is progressing the selection of a full-service contract research organisatio",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.95",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-02-10T01:24:30.352619+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260808-Moneymun-25806571",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.457120",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "8/1/26 Leire explained that the dog longevity study is the nearest catalyst, with the trial expected to be unblinded shortly and early efficacy readouts anticipated in the near term. While safety has already been confirmed, the study remains blinded, meaning efficacy results are still unknown. The first data will focus on biological age, measured using a methylation clock, with a more detailed analysis of muscle biopsies and mitochondrial function to follow. According to Leire, \u201cthis trial could be very important for our shareholders, because it will trigger a deal with an animal health company bringing non-dilutive money in the company.\u201d",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.95",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-10T01:24:30.352637+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260707-Pie-char--5872568",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.457619",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Dog results are due next week. Vet partner(s) already likely lined up.",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.95",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-10T01:24:30.352655+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20262041-Moneymun--8963219",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.458133",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The trial aims to demonstrate proof of concept in dogs, replicating promising results previously seen in mice. \u201cIt worked like magic in mice. We reasonably think that it will work likewise in dogs,\u201d Leire stated. Unlike mice, however, dogs share environmental conditions with humans, making them a more relevant model for translation into human therapies.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-10T01:24:30.352673+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260818-Roosters--8288708",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.337719",
        "source": "LSE_CHAT",
        "data": {
          "author": "Roostersmillions",
          "content": "Markets reacting munch. Nice jump this AM. hope it holds. Maybe new private investors from across the pond due to conference exposure??",
          "sentiment": 0.5,
          "engagement": "291",
          "price_at_post": "2.00",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-02-10T01:24:30.352692+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260815-Moneymun-69646853",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.338198",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Game changing news at anytime. In Eric we trust!!! Gla holders...On and UP!!! :-)))",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "2.00",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-02-10T01:24:30.352709+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260812-Moneymun--5199549",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.338634",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions Madrigal\u2019s strategy of pursuing combination therapies while the market remains in its infancy could intrinsically link its brand to MASH treatment. Madrigal Pharmaceuticals used its January 12 presentation at the J.P. Morgan Healthcare Conference 2026 to showcase its newly acquired assets from Pfizer \u2013 ervogastat and two preclinical assets \u2013 as well as outline its vision for dominance in metabolic dysfunction-associated steatohepatitis (MASH) treatment space through leveraging early commercial success. Its professed strategy of pursuing combination therapies while the market remains in its infancy could well result in Madrigal\u2019s brand becoming intrinsically linked to MASH treatment. JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions - Pharmaceutical Technology https://share.google/Ymb4cXndGee7eMEbD",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "2.00",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-02-10T01:24:30.352727+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261725-Steg-21268843",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.339084",
        "source": "LSE_CHAT",
        "data": {
          "author": "Steg",
          "content": "Thought below was interesting, yes they are attending conference and have already made move to add to thier MASH portfolio, courtesy of AI search below Yes, Madrigal Pharmaceuticals is actively looking to expand its MASH (metabolic dysfunction-associated steatohepatitis) portfolio beyond its already approved drug, Rezdiffra (resmetirom). Madrigal's expansion strategy focuses on developing potential combination therapies, as MASH is a complex disease that requires multiple treatment approaches. Key components of their expanded pipeline include: Ervogastat: In January 2026, Madrigal entered into an exclusive global license agreement with Pfizer to acquire ervogastat, a Phase 2 oral DGAT-2 inhibitor. This drug works on a different, complementary pathway to Rezdiffra, and Madrigal plans to conduct studies to test the two treatments in combination. Oral GLP-1 Receptor Agonist: Madrigal also holds worldwide rights to an oral GLP-1 agonist called SYH2086, licensed from CSPC Pharmaceutical, with the goal of creating a best-in-class oral combination therapy. Additional Early-Stage Assets: The agreement with Pfizer for ervogastat also included rights to two other early-stage MASH pipeline assets. Madrigal's CEO, Bill Sibold, has stated that the company is committed to \"building the industry-leading pipeline that will shape the future of MASH care\" and believes combination therapies are the next wave of innovation in the field.",
          "sentiment": 0.0,
          "engagement": "5",
          "price_at_post": "1.90",
          "thread_title": "JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-02-10T01:24:30.352745+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261231-Moneymun-72802093",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.339515",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Get UP there!!! Gla :-) Eric and his team are now at the prestigious JP Healthcare Conference, pressing flesh with the leading industry deal makers. He appeared confident and enthusiastic in his latest interview, highlighting the prospects and potential of an early lucrative JV deal for the Dog Trial, Glaucoma and Mash and so potential game changing transformational news could drop at anytime. The first efficacy readout on the Dog Trial is imminent, and with two Animal Healthcare companies both with Confidential Disclosure Agreements in place, Eric could be very close to a deal, and the same with Glaucoma, whereby a leading Ophthalmology Company signed a Material Transfer Agreement 10 months ago. Eric also highlighted the prospects of Genflow's Sirt6 Mash Gene Therapy, which is now targeting the later stages of the disease where there's no options apart from transplant, and was very interesting to hear from Eric it could be used in combination with GLP-1's and Madrigal's early stage treatment which was FDA approved 12 months or so ago. Madrigal are presenting at JP Morgan and are on a mission to expand their pipeline for Mash, so watch this space. It's also very interesting we have a new Chairman in place, GAD BERDUGO a high flyer based in the US in Global Biotech, Corporate Development and and US Capital Markets and so no doubt very well contected to any potential suitors. Excitement building!!!! In Eric we trust!!! Gla holders:-)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "2.00",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-10T01:24:30.352763+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260822-Moneymun--9071807",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.339958",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Healthcare companies set for deals spree as drug patents expire A gathering of pharmaceutical executives comes as the sector has rebounded from uncertainty over Trump\u2019s policies Healthcare executives gather for their big annual conference in San Francisco on Monday as the sector is flush with cash and set for a deals spree as patents on drugs worth almost 12 per cent of the industry\u2019s revenues expire in the years ahead. The JPMorgan healthcare conference takes place as uncertainty recedes over President Donald Trump\u2019s trade wars, drug pricing policy and the leadership of key regulators such as the US Food and Drug Administration. In response, the S&P biotech index, known as the XBI, has surged to a four-year high, outperforming the wider index. In addition, drugs that contribute about $180bn of revenue a year are set to go off patent in 2027 and 2028, representing almost 12 per cent of the global market, according to research firm Evaluate Pharma. More than $40bn of sales are expected to lose patent protection this year, Evaluate has estimated. \u201cThe need to take big swings becomes more pressing,\u201d said Jeremy Meilman, head of healthcare investment banking at JPMorgan. \u201cSeveral of the large-cap pharmaceutical companies are shopping around for strong assets and a number have taken action but still have more firepower. This contributes to our optimism for 2026.\u201d hTtps://www.ft.com/content/7b07a9d5-7254-490b-8ce9-ec2633094d8e",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.825",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-10T01:24:30.352781+00:00"
      },
      {
        "event_id": "SOCIAL-11Jan20261442-Moneymun--9805893",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.340418",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Planned meetings presumably with potential suitors at JP Morgan this coming week and so multiple deal opportunities across the platform, and there's currently an M&A and lucrative licensing deal feeding frenzy as Major Pharma replenish their pipelines with the latest cutting-edge science, Excitement building!!! Gla :-) \"2026 will be catalyst year, we've done our work and now it's time for harvesting and are going to JP Morgan next week with a full appointments book, and now ready for potential harvesting of our results to bring in non-dilutive cash into the company.\" A must watch....Gla holders:-) hTtps://www.proactiveinvestors.co.uk/companies/news/1085366/genflow-biosciences-ceo-key-catalysts-for-2026-1085366.html",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.825",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-10T01:24:30.352806+00:00"
      },
      {
        "event_id": "SOCIAL-10Jan20261752-Troajan--4304053",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.836007",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1085424/genflow-is-ready-for-a-year-of-catalysts-icymi-1085424.html",
          "sentiment": 0.0,
          "engagement": "125,652",
          "price_at_post": "1.825",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-10T01:24:30.352824+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20262001-Moneymun--8931766",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.836711",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 10:30 a.m. PT. Investors and other interested parties can access a live audio webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event. About Zoetis As the world\u2019s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide \u2013 from veterinarians and pet owners to livestock producers. The company\u2019s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees. For more information, visit www.zoetis.com.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-10T01:24:30.352842+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261946-Moneymun--2593320",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.837364",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Woof, woof!!!??? ;-) Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference 06 January 2026 INDIANAPOLIS, Jan. 6, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will represent the company and respond to questions from analysts at 3:45 p.m. PST (6:45 PM EST).",
          "sentiment": 0.0,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-10T01:24:30.352860+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261920-Moneymun-89256728",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.837980",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "And/or ???? ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 4:30 p.m. PT in San Francisco, CA.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-10T01:24:30.352878+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261917-Moneymun-19817593",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.838626",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Eye wonder....Gla:-) 23/12/2025 - 12:30 VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders, Executive Vice President and Chief Financial Officer Sam Eldessouky and Chief Medical Officer and Head of Research & Development Yehia Hashad, MD, will participate in a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026, at 1:30 p.m. PT (4:30 p.m. ET) Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-10T01:24:30.352896+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261858-Moneymun-65609266",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.839276",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Another brilliant interview by Eric, \"2026 will be catalyst year, they've done their work and now it's time for harvesting and are going to JP Morgan next week with a full appointments book, and now ready for potential harvesting of their results to bring in non-dilutive funding cash into the company. Excitement building, in Eric we trust!!! Gla ;-) Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company\u2019s key programs and upcoming catalysts as it enters what management expects to be a pivotal year. Leire discussed why 2026 is shaping up as \u201ca year of catalysts\u201d for the company, with particular focus on the dog ageing trial, progress in MASH, and the group\u2019s approach to partnerships and licensing. Leire explained that the dog longevity study is the nearest catalyst, with the trial expected to be unblinded shortly and early efficacy readouts anticipated in the near term. While safety has already been confirmed, the study remains blinded, meaning efficacy results are still unknown. The first data will focus on biological age, measured using a methylation clock, with a more detailed analysis of muscle biopsies and mitochondrial function to follow. According to Leire, \u201cthis trial could be very important for our shareholders, because it will trigger a deal with an animal health company bringing non-dilutive money in the company.\u201d The interview also explored Genflow\u2019s repositioning in MASH toward advanced fibrosis and the prevention of hepatocellular carcinoma. Leire highlighted the significant unmet need in late-stage disease, noting that recent therapies target earlier stages and leave patients with advanced fibrosis facing limited options. He said the company\u2019s preclinical data have been encouraging and form a key part of the IND package, helping differentiate Genflow from existing and emerging treatments. In addition, Leire discussed the company\u2019s licensing strategy, including plans to out-license the dog program to an animal health specialist and pursue early-stage partnerships for glaucoma, while retaining focus on age-related conditions such as sarcopenia. With meetings planned during JPMorgan week, Leire said the company is seeking non-dilutive capital and strategic validation as it moves forward.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-10T01:24:30.352914+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261711-Troajan-24022801",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.839905",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1085366/genflow-biosciences-ceo-key-catalysts-for-2026-1085366.html",
          "sentiment": 0.0,
          "engagement": "125,652",
          "price_at_post": "1.75",
          "thread_title": "Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-10T01:24:30.352932+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261314-Moneymun--1342332",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.840622",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "0 0 Gene therapy biotech Genflow eyes busy year ahead as dog ageing trial nears results Published: 02:40 08 Jan 2026 Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) has wrapped up 2025 with steady progress across a range of gene therapy programmes, including a closely watched trial into dog ageing that could lay the groundwork for future human applications. The London-listed company, which is working on ways to extend healthy lifespan using gene therapy, said it had completed dosing in its lead canine study with no reported side effects. The dogs will now be monitored over six months for signs of improved muscle strength and health-related biomarkers, with initial results expected in the first quarter of this year. The trial, which began in March and uses a therapy based on the SIRT6 gene, a known regulator of ageing and DNA repair, is being conducted in a blinded format. A follow-up analysis is due around mid-year to assess the durability of the effects. Alongside the dog ageing study, Genflow said it had made progress in a programme targeting advanced stages of MASH, or metabolic dysfunction-associated steatohepatitis, a type of fatty liver disease. Existing GLP-1 drugs such as Ozempic and Wegovy have shown benefits in early MASH, but Genflow is aiming at patients with more severe fibrosis, where options remain limited. It is now finalising regulatory paperwork to support a human trial and is exploring the use of mRNA technology, similar to that used in Covid-19 vaccines, as a more flexible and cost-effective delivery method than traditional viral vectors. In a new push into eye disease, the company is also investigating the use of its gene therapy platform in glaucoma. Early lab results suggest that increasing SIRT6 levels may help protect the optic nerve from damage, potentially offering a way to slow or prevent vision loss rather than simply reducing eye pressure, which is the current standard treatment. Genflow said it was in talks with a lipid nanoparticle delivery partner to support this programme and was hiring a specialist contract research firm to help move the candidate towards preclinical testing. Elsewhere in its pipeline, work is ongoing in sarcopenia, the loss of muscle mass that often accompanies ageing, and in a broader initiative called ExoFastTrack, which supports several of its research efforts. Looking to the year ahead, Genflow said it would focus its efforts on the most promising areas of its portfolio and seek early licensing or partnership deals to bring in fresh funds without issuing new shares. \u201cWith multiple upcoming data readouts, an expanding partner network, and a maturing intellectual property position, we believe Genflow is well positioned to enter its next phase of growth,\u201d the company said. The first set of clinical results, particularly from the dog study, will be key in setting the tone for 2026.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-10T01:24:30.352950+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261148-Moneymun-83795530",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.841406",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Nice one David, looking forward to a run of great news from Eric to take the sp to new highs. Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.85",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-10T01:24:30.352968+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-David195-12825208",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.842237",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "Thank you for your informed views.  Added 500k @1.78.  It is hard for companies in this sector to raise funds so hopefully the upcoming changes will make the situation less brutal.  I will add when funds allow.",
          "sentiment": 0.0,
          "engagement": "871",
          "price_at_post": "1.85",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-10T01:24:30.352986+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261005-Moneymun--8127101",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.843028",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Hopefully news on patents soon Porter, the following statement is from yesterday's 2026 Corporate Presentation.  Gl :-) GROWING IP PORTFOLIO WITH LONG LIFE 2 proprietary patent families SIRT6 centenarian (cent SIRT6) and gene delivery (entering National Phase); Additional upcoming patent applications (entering PCT)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-10T01:24:30.353005+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260933-Moneymun-33763010",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.843890",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Bring it on!!! Gla holders:-) \"Central to this strategy will be the pursuit of early-stage licensing and collaboration agreements designed to generate non-dilutive funding, validate our platform externally, and support continued development without undue capital strain.\" .... Dr. Eric Leire, CEO of Genflow, commented: \"We're excited to attend the JP Morgan Healthcare Conference in San Francisco this January. Our planned meetings reflect our current focus on lipid nanoparticle delivery for mRNA SIRT6 therapeutics, which is opening compelling opportunities for strategic partnerships in the longevity space.\"",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=1999E606-84A4-47B8-B880-E68E1912F065"
        },
        "ingested_at": "2026-02-10T01:24:30.353022+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260928-Moneymun--1262712",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.844766",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Outstanding non-dilutive grant funding could land at anytime, although a lucrative JV licensing deal could also land at anytime and so let's see what transpires at next weeks the prestigious JP Healthcare Conference next week, where Genflow have planned meetings, presumably with potential suitors and every chance Eric will have initial efficacy data from the Dog Trial and maybe and maybe positive Data with their Ophthalmology partner for Glaucoma to present and so confirmation of a commercial deal or two would be transformational for all invested and any funding concerns would be assigned to history.  Gla holders....Excitement building!!! :-) Ps if Genflow need to raise cash because of the delay in receipt of the \u20ac4m outstanding non-dilutive grant funding, then raising cash from 16th January is going to become easier, cheaper and less dilutive.  :-) The new Financial Conduct Authority (FCA) regulations are designed to facilitate less discounted fundraising for small caps by reducing the regulatory burden and increasing the threshold for requiring a full prospectus, thus making secondary capital raising faster and cheaper. Key changes, effective from January 19, 2026 (with some listing rule changes effective from July 29, 2024), aim to attract more companies to list and grow in the UK. Key Regulatory Changes and Their Impact on Small Cap Fundraising The FCA's reforms introduce several key changes that support more efficient and potentially less discounted fundraising for smaller listed companies: Increased Prospectus Threshold The most significant change for secondary fundraising is that a full prospectus is now only required if a company issues shares amounting to 75% or more of its existing share capital, a substantial increase from the previous 20% threshold. This allows companies, particularly smaller ones, to raise further capital more quickly and at a lower cost without the time and expense associated with a full prospectus, which should reduce the need for heavily discounted placings.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=1999E606-84A4-47B8-B880-E68E1912F065"
        },
        "ingested_at": "2026-02-10T01:24:30.353040+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260854-David195--4564647",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.845590",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "I hold shares and the potential is significant. However I am reluctant to add when the funding position is unclear.  Grants could be material amounts if and when received but there is a risk of a diluted fund raise to progress the numerous programmes in 2026.  I have suffered this is other small biotechs like FAB and Apta where the state of the capital markets are very harsh and unsupportive. I tried to analyse the cash runway and it seems more funds will be needed in H1 if the grants are not received.  Is there any indication of the timing?",
          "sentiment": 0.0,
          "engagement": "871",
          "price_at_post": "1.90",
          "thread_title": "Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=1999E606-84A4-47B8-B880-E68E1912F065"
        },
        "ingested_at": "2026-02-10T01:24:30.353058+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260805-Porter_-30255567",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.846399",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Thanks for sharing money. I notice the RNS is in American English, perhaps to appeal to US investors and big US pharma? No mention of the patents in the update which were instrumental in offering assurance to investors regarding patent protection, but hopefully we\u2019ll receive updates in due course separately.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.825",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-10T01:24:30.353076+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260703-Moneymun-66926576",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.847249",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "We are advancing discussions with a leading LNP partner to support delivery innovation in this space and are securing a full-service CRO to manage formulation through preclinical execution. With the global glaucoma market approaching USD $12-14 billion by the early 2030s, this represents a compelling long-term opportunity for us. \u00b7 Additional Programs We continued to advance our broader pipeline and are pleased with the steady advancement of the sarcopenia program, fully consistent with our development plans. In parallel, the ExoFastTrack initiative continues to move forward, generating important data that will support and accelerate several of our other development programs. Looking Ahead to 2026 As we move into 2026, we do so with confidence, discipline, and a clear strategic focus. The coming year will emphasize rationalization of our pipeline, prioritizing programs with the strongest data, clearest paths to value creation, and highest partner interest. Central to this strategy will be the pursuit of early-stage licensing and collaboration agreements designed to generate non-dilutive funding, validate our platform externally, and support continued development without undue capital strain. With multiple upcoming data readouts, an expanding partner network, and a maturing intellectual property position, we believe Genflow is well positioned to enter its next phase of growth. We remain committed to scientific excellence, capital efficiency, and long-term value creation as we work to translate our longevity platform into meaningful therapies. Thank you for your continued support and confidence in Genflow.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-10T01:24:30.353093+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260702-Moneymun-12850272",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.848143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "08 January 2026 A Review of an Exciting 2025 2025 has been a year of focused scientific progress and continued advancement of Genflow Bioscience's mission to extend healthy lifespan through our novel longevity gene therapy platform. Across our portfolio, we have maintained momentum in both animal health where progress in our canine study may provide translational insights relevant to future human applications as well as therapeutic development for dogs. These advancements have been supported by a strengthened network of leading academic collaborators and laboratories. Together, with continued backing from international institutional investors and previously awarded government grants, this ecosystem helped accelerate Genflow's scientific and clinical development throughout 2025. Program Highlights We've made a number of notable strides across our programs this year, including: \u00b7      Dog Aging (GF-1004) We made significant strides in our clinical trial for aging dogs with full administration of our investigational SIRT6-based gene therapy now completed. No adverse events were reported during the dosing phase of the study, with no serious, moderate, or minor side effects observed. The study which began in March 2025, is being conducted as a blinded clinical trial; an initial efficacy readout is expected in Q1 2026, including blood analyses and muscle biopsies to evaluate potential benefits related to sarcopenia, healthspan, and lifespan-associated biomarkers. Dogs enrolled in the trial will be monitored for 180 days, with a second efficacy assessment planned at the six-month timepoint and results expected in June-July 2026 to evaluate durability and longer-term effects. \u00b7      MASH (GF-1002) Our MASH program saw good progress in 2025. While GLP-1 therapies have addressed early-stage MASH, patients with advanced fibrosis - roughly one-third of the population - still face limited treatment options. In response, we repositioned GF-1002 to target this high-need group, leveraging its antifibrotic properties and potential to prevent progression to cirrhosis and liver cancer. Additionally, we have generated new pre-clinical POC data on the prevention of HCC. We are now finalizing our IND package and evaluating mRNA/LNP delivery as an alternative to AAV, an approach that could enable repeat dosing and lower manufacturing costs. Encouraging data continue to support this next phase of research and development. \u00b7      Glaucoma In 2025, we expanded into ophthalmology, where SIRT6-based gene therapy shows promise in glaucoma, a leading cause of irreversible blindness. Current treatments primarily manage intraocular pressure but do little to prevent optic nerve degeneration. Our preclinical data suggest SIRT6 overexpression may protect retinal ganglion cells and preserve optic nerve function, shifting the focus from symptom control to true neuroprotection.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-10T01:24:30.353126+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261804-Moneymun-56948401",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.848904",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Well connected in the US to take Genflow to the next level. ;-)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-10T01:24:30.353144+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261802-Moneymun-73508213",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.849701",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Hi Porter, it's from the 2026 Corporate Presentation which was published via Genflow's LinkedIn post a few hours ago. Gl :-) Ps the new Chair appears to be well connected on the US. https://loom.ly/RsxnFCE",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-10T01:24:30.353162+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261732-Porter_--8877391",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.850478",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Thanks for sharing money. I haven\u2019t seen any news regarding a new Chair. Where did you manage to grab that info from? Can you please share the link if you have one? \ud83e\udd70",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-10T01:24:30.353180+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261627-Moneymun--7213632",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.851283",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Gad Berdugo Gad Berdugo, MSc. Eng., MBA Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a strategic and financial advisory firm focusing on the global biotechnology sector. He currently serves as Vice Chairman of the Board of Directors of clinical development stage precision oncology company, Diaccurate. Mr. Berdugo brings over 35 years of biotech corporate & business development, strategy, operational, financial, investment and general venture management experience. He served as CBO at CRISPR gene editing pioneer Editas (Nasdaq EDIT); Co-founder and CEO at personalized neoantigen cancer vaccine venture, EpiVax Oncology Inc.; CFO and EVP at Immune Pharmaceuticals Inc. (Nasdaq IMNP); Managing Director and Head of Life Sciences at Tegris Advisors, a strategic and financial advisory boutique; Founder and Managing Partner of the Explorium Global Life Sciences Investment Fund; Director, Senior Equity Research Analyst and Life Sciences Sector Leader at Lazard, Asset Management Group. Prior to that, he served as a Director of Global Business Development within Baxter\u2019s Biopharmaceuticals group and started his career at Abbott Labs. Mr. Berdugo received his B.Sc. with Honors in Biotechnology from Imperial College London, his M.Sc. in Biochemical Engineering from University College London and his M.B.A. from H.E.C. Paris. He serves on the Board of Directors of Friends of H.E.C. Inc. and Friends of U.C.L. Inc. Mr. Berdugo is bilingual in French and English and has dual US and French citizenships. He resides with his wife in New York City.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-10T01:24:30.353199+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261606-Moneymun--9119112",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.852108",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Looks like we've got a new Chairperson!!!??? Gla ;-) GAD BERDUGO Chairperson \u2022 30+ years of leadership across global biotech, corporate development, and U.S. capital markets \u2022 Proven record in strategic partnerships, capital raising, and scaling private and public biotech companies \u2022 Managing Partner, Explorium Capital; former Co-Founder & CEO of EpiVax Oncology and Chief Business Officer at Editas Medicine and Nutcracker Therapeutics",
          "sentiment": 0.0,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-10T01:24:30.353217+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261602-Moneymun--8305350",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.852899",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Undervalued stock opportunity; Potential acquisition by pharmaceutical partner GF-1004: Pet life extension / sarcopenia Initiated discussion under CDA with several animal health companies hTtps://loom.ly/RsxnFCE",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-10T01:24:30.353236+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261601-Moneymun-27163581",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.854072",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The Gap No approved neuroprotective therapies The mRNA Opportunity - Wide Open LNP targeted delivery to retina \u2013 now possible NO APPROVED OR CLINICAL-STAGE MRNA THERAPIES FOR GLAUCOMA PARTNERING WITH LNP PROVIDER Paradigm shift to retinal protection \u2022 Pre-clinical evidence links SIRT6 activity with RGC protection in glaucoma/optic neuropathy models \u2022 Demonstrating RGC rescue and preserved function would be a strong disease-modifying signal Delivery is now tractable \u2022 Targeted LNP (tLNP) platforms are removing a major historical barrier for in vivo RNA therapeutics to reach retina/RGCs Clear decision point A single well-designed rodent POC that shows \u2022 focal RGC expression of SIRT6 cent \u2022 preserved RGC counts and \u2022 preserved RGC function with acceptable ocular safety, gives a clean go/no-go for IND enabling work AGED DOGS COMPARATIVE TRIAL Proof-of-Concept comparative clinical trial of in-vivo naked DNA gene therapy in aged dogs Conducted at Syngene's strategic partner site in Morocco, AAALAC and GLP certified 26 (24+2) aged Beagles dogs (age>10 years) Group 1 (n=6): untreated Group 2 (n=6): treated with gene therapy IV bolus of SIRT6 AAV Group 3 (n=6): treated with gene therapy IV infusion of naked DNA (low dose) Group 4 (n=6): treated with gene therapy IV infusion of naked DNA (high dose) Blinded: first read-out in January 2026 \u2022 Treatment period: 180 days with follow-up period: 90 days \u2022 Gene therapy has been administered to all dogs with demonstrated excellent safety profile Endpoints \u2022 Pan-mammalian methylation clock (Steve Horvath), \u2022 sarcopenia (including muscle biopsies) and other markers of aging MASH PROGRAM Affects est. 35 million people globally \u2022 Increasing prevalence \u2022 Leading cause of chronic liver disease and liver transplant Significant unmet medical need Clear regulatory accelerated development pathway. EMA and FDA guidelines accept: \u2713 Key surrogate outcomes for therapeutic trials: regression of fibrosis or resolution of NASH \u2713 Histological changes are achievable within a 12-18-month time-frame \u2713 Placebo control \u2713 Conditional fast-track approval 2025 KEY HIGHLIGHTS LARGE AND EXPANDING MARKET OPPORTUNITY MASH: 35 Million globally. Increasing prevalence. Door opener to even broader anti-aging indication Awarded to new grants in 2024 expanding research pipeline Ophthalmology: retina preservation GROWING IP PORTFOLIO WITH LONG LIFE 2 proprietary patent families SIRT6 centenarian (cent SIRT6) and gene delivery (entering National Phase); Additional upcoming patent applications (entering PCT) MRNA/LNP GENE DELIVERY SYSTEMS Innovative gene delivery systems: targeted LNPs delivering cent SIRT6 mRNA GF-1002 Multiple key clinical and regulatory milestones expected in next 18 months; Undervalued stock opportunity; Potential acquisition by pharmaceutical partner GF-1004: Pet",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-10T01:24:30.353253+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261559-Moneymun-67206646",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.855051",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "WHO WE ARE Pioneering Novel Gene Therapeutics for a Longer, Healthier Life MISSION: aging is underlying risk factor for disease, and our aim is to deliver gene therapeutics that potentially halt or slow the aging process in humans and dogs CENTENARIAN SIRT6 (cent SIRT6) GENE: proprietary variant of longevity gene that widely regulates aging and immunity and is a potential therapeutic target for the treatment of diseases PROMISING PRECLINICAL RESULTS: lead drug candidate GF-1002 delivers a centenarian variant of the SIRT6 gene (cent SIRT6) for treatment of MASH SEASONED TEAM: experienced and proven management with extensive experience in public & private pharma and biotech ROBUST PIPELINE: advancing multiple development programs over 24 months: MASH, Glaucoma, Sarcopenia, Werner and life extension of dogs DEVELOPMENT PIPELINE GF-1002 (Pre-Clinical) AAV8 cent SIRT6 vector for intravenous infusion, expressing cDNA of centenarian variant of SIRT6(cent SIRT6) in liver GF-1003 (Pre-Clinical/Development) Suspension of exosomes, loaded with mRNA of centenarian variant of SIRT6(cent SIRT6) in fibroblasts GF-1004 (Clinical Proof of Concept) cent SIRT6 for intravenous infusion for life extension and prevention of age-related diseases GF-1005 (Pre-Clinical/Development) Mitochondrial disfunction: Myoblast progenitors loaded by photoporation with cent SIRT6 GF-1006 Ophthalmology (pre-clinical) mRNA cent SIRT6 delivered by LNP for the treatment of cornea pathologies and glaucoma OPHTHALMOLOGY PLATFORM New Ophthalmology Program: Initiated development of a novel gene therapy targeting ocular diseases, including corneal pathologies and glaucoma, using Genflow\u2019s proprietary Centenarian SIRT6 (cent SIRT6). Precision Delivery Platform: Employing a specially engineered non-viral vector for targeted SIRT6 delivery to the eye. Strategic Partnership: Signed a Material Transfer Agreement in April 2025 with a leading ophthalmology company to co-develop the cent SIRT6 therapy and delivery system. LEVERAGING AI FOR GENOMICS New AI Partnership: Signed Master Service Agreement in April 2025 with Heureuka Labs, a spin-out of Duke University, to use their proprietary AI platform to analyze complex genomic data, including RNA sequencing and gene expression profiles. Enhancing Therapeutic Insights: Expected to drive a deeper understanding of gene regulatory networks and biological responses to optimize therapy design and personalize outcomes. Pipeline Advancement: Initially supporting GF-1002 (cent SIRT6-based gene therapy in preclinical development) and future programs, including candidates for MASH. GLAUCOMA RGC NEUROPROTECTION: THE RACE IS ON The Problem 80M people worldwide with glaucoma; leading cause of irreversible blindness Current treatments only lower IOP- they don't protect retinal ganglion cells (RGCs) RGC death is irreversible; unmet need for neuroprotection Significant market opportunity The Gap",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-10T01:24:30.353271+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261913-Persever-86656205",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.702321",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "These unknowns are off book pre negotiated buys. Sp will remain pinned till.Dog efficacy data. Expected solid data.",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-10T01:24:30.353289+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261838-Dzygit19--8761466",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.702759",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dzygit1980",
          "content": "12:45 yesterday was 1.97 to sell small amout . Than yesterday's big trade printed today for 1.81 ,straight after 1.97 To buy share so I am not sure \ud83e\udd14 was 12:45 yesterday tradet  buy  to me it looks like sell. Also we are dropping",
          "sentiment": 0.0,
          "engagement": "255",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-10T01:24:30.353308+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261822-Persever-65362397",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.703192",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "Big buys more like it. Do you know trading? \ud83d\ude05",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-10T01:24:30.353326+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261753-Dzygit19-61046335",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.703612",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dzygit1980",
          "content": "Lots of big sales last couple of days",
          "sentiment": 0.0,
          "engagement": "255",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-10T01:24:30.353344+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261756-Persever-58105675",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.704022",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "I think a massive rerate is coming ? Somethings brewing ?",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "1.90",
          "thread_title": "Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-10T01:24:30.353362+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260719-Porter_--7467708",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.704447",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Know a few people who didn\u2019t get their orders filled yesterday. Seems there isn\u2019t much in the free-float so let\u2019s see how tight this coiled spring is!",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-10T01:24:30.353380+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20262217-Twocd2--1733870",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.704869",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "I joined pre IPO, \u00a350 may have been too much of a reach for you\u2026chortle chortle TK Max.. Give Porter a reach around before lights out so that he\u2019ll not be to disappointed with no RNS tomorrow morning\u2026\ud83d\udc4c",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-10T01:24:30.353398+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261352-DaveTK--3023839",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.705301",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "I joined the party pre IPO. TBF they were asking for more than \u00a350 so it may have been too much of a reach for you. Talking about choppers FFS. Don't let you mum read that or she'll take your phone off you and cancel your contract.",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-10T01:24:30.353416+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261342-Twocd2--1700871",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.705721",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "So TK Max joins the party\u2026think you and Porter need to take turns and time to give him a chance to be big spoon for this week. Might give him something else to do rather than practice his typing. Plenty of skin in the game lads\u2026but this is not about who\u2019s chopper is bigger..well maybe for the spooning it does\ud83d\ude01",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-10T01:24:30.353434+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261033-DaveTK-91498506",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.706162",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Always. I'm here and always have been here waiting for news that we have been bought out. It was always the goal from Eric to make this company into something a pharmaceutical would buy a high price. We may not be that far off. Fingers crossed. Thanks",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-10T01:24:30.353452+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261027-Porter_-22709959",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.706587",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Always the ones who sold too soon quick to troll those who held with diamond hands Dave. Expecting this is just the first update of many we\u2019ll be seeing over the next 2 weeks. Popcorn ready! \ud83c\udf7f",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-10T01:24:30.353470+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261005-DaveTK--8521885",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.707009",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Would seem like you touched  nerve there, Porter ha ha. Nice RNS this morning. Looking forward to hearing more regarding the J.P. Morgan's Healthcare Conference. Really does seem like exciting times ahead. Thanks",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-10T01:24:30.353488+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260839-Twocd2-39648344",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.707434",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "Ok big fella..time for nap your banter is honking.",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-10T01:24:30.353506+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260820-Moneymun-62047623",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.707847",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The new Chairman in place, GAD BERDUGO is a high flyer based in the US with a wealth of experience in Global Biotech, Corporate Development and US Capital Markets and so no doubt very well contected to any potential suitors. Excitement building!!!! In Eric we trust!!! Gla holders:-) Ps initial Efficacy readout on the Dog Trial imminent!!! Gla ;-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-10T01:24:30.353525+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260752-Porter_-62237827",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.708264",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "2cd2 - invest more than \u00a3100 in a company and you might care a little bit more for your investments \ud83d\ude18",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-10T01:24:30.353543+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260734-Twocd2--8506387",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.708668",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "Take the rest of the day off Porter..great job pal! You must have set the alarm early to C&P all of that \ud83d\udc4f\ud83d\udc4f\ud83d\udc4c",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-10T01:24:30.353560+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260718-Porter_-61467898",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.709143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Genflow Appoints a New Chairman to Accelerate Corporate and R&D Expansion Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or the \"Company\"), a leading European-based biotechnology company focusing on gene therapies for age-related diseases, is pleased to announce a significant appointment to its Board of Directors, marking an important step in the Company's strategic evolution. Mr. Gad Berdugo, MSc Eng., MBA, has joined the Board with immediate effect and will assume the role of Independent Non-Executive Chairman, providing leadership as Genflow focuses on advancing its gene-therapy programs. Mrs. Tamara Joseph will continue to serve as a Director, ensuring continuity and maintaining strong governance. Mr. Berdugo brings over 30 years' of leadership experience spanning global business and corporate development, U.S. capital markets, and company building. He has a proven record of driving strategic partnerships, securing capital, and scaling both private and public development-stage biotechnology companies. Currently, Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a U.S.-based strategic and financial advisory firm focusing on the global biotechnology sector. His most recent roles include: \u00b7 Co-Founder & CEO, EpiVax Oncology \u00b7 Vice-Chairman of the Board, Evexta Bio \u00b7 Chief Business Officer, Editas Medicine (NASDAQ: EDIT) \u00b7 Chief Business Officer, Nutcracker Therapeutics He began his international career at Abbott Labs and Baxter, later becoming Life Sciences Sector Leader at Lazard Asset Management. Mr. Berdugo also brings deep technical and market expertise in RNA-based therapeutics, including lipid nanoparticle (LNP) delivery, development, and manufacturing. This background will support Genflow as it advances its scientific platform, evaluates delivery technologies, and explores next-generation therapeutic approaches. His appointment further strengthens the Company's presence in the United States and expands its capacity for global engagement. He does not own any shares in the Company. Dr. Eric Leire, Chief Executive Officer of Genflow, commented: \"We are delighted to welcome Mr. Berdugo as Independent Non-Executive Chairman. His expertise in strategy, partnerships and financing as well as his deep experience with RNA-LNP technologies will be instrumental as we accelerate our programs and expand our global reach. We are equally pleased that Mrs. Tamara Joseph will continue her service on the Board, contributing her invaluable leadership, legal and governance expertise.\" Gad Berdugo added: \"I am excited to join Genflow as the company is progressing to the next new phase of development, with key data readouts expected in 2026, strengthened intellectual property, and a sharpened strategic focus on high-potential programs. I look forward to working with the talented team and board to advance these innovative gene therapies, this is an ideal moment to contribute my expertise and hel",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-10T01:24:30.353578+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20260836-Pie-char-72230034",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.709557",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Post conference announcement next week and Funding news is what I predict. I'm amazed we are at this price. Such a hidden gem!",
          "sentiment": 0.5,
          "engagement": "60",
          "price_at_post": "1.85",
          "thread_title": "RE: JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=3005BF87-EE58-4C27-ABC6-EE6AA15A9385"
        },
        "ingested_at": "2026-02-10T01:24:30.353596+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20260716-Porter_--5370904",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.710022",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Genflow Biosciences is a London-based biotechnology firm and the first \"pure-play\" longevity company listed on the London Stock Exchange. As of early 2026, the company is transitioning from a preclinical phase into active clinical data readouts, focusing on its proprietary SIRT6-based gene therapy platform to extend human and animal \"healthspan\". Core Technology and Pipeline: The company\u2019s lead therapeutic approach involves delivering a \"centenarian variant\" of the SIRT6 gene, identified in individuals who live over 100 years, to improve DNA repair and metabolic health. GF-1002 (Human Therapeutics): MASH (Liver Disease): Repositioned in 2025 to target patients with advanced fibrosis who have limited options from existing GLP-1 therapies. The company is currently finalizing its Investigational New Drug (IND) package and exploring mRNA/LNP delivery to allow for repeat dosing and lower costs. Werner Syndrome: A rare genetic condition causing premature aging. Genflow has developed proprietary human-derived liver organoids to model this disease more accurately than animal models. GF-1004 (Veterinary Program): Canine Longevity: A 12-month blinded clinical trial in aged dogs is currently underway. In early 2026, the company confirmed that all subjects received full dosing with no adverse events reported. Key 2026 Milestones: Initial efficacy readouts focusing on biological age (via methylation clocks) are expected in Q1 2026, with a second evaluation planned for June-July 2026. Expansion Programs: Glaucoma: A new ophthalmology program targeting neuroprotection of retinal ganglion cells to prevent blindness. Sarcopenia (GF-1005): Research into muscle health and mitochondrial dysfunction in collaboration with the Universit\u00e9 libre de Bruxelles. 2026 Strategic Focus: Genflow\u2019s 2026 strategy emphasizes \"rationalization of the pipeline,\" prioritizing programs with the strongest data to secure non-dilutive funding through licensing deals and partnerships. The company is actively seeking animal health partners for its dog longevity program and strategic collaborators for its LNP-based mRNA therapeutics.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "GLP, LNP, MRNA and SIRT6 based therapeutics",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=FB89DB69-F93B-4BB3-8529-5206EECDF243"
        },
        "ingested_at": "2026-02-10T01:24:30.353614+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20262119-jamtart1-69911785",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.710444",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Yes, Genflow Biosciences (Genflow) has had significant interest at the J.P. Morgan Healthcare Conference, attending specifically to engage with potential partners, institutional investors, and pharmaceutical companies. Their CEO, Dr. Eric Leire, attended the most recent conference in January 2026 with a \"full appointments book\" to discuss strategic partnerships and non-dilutive funding opportunities.",
          "sentiment": 0.5,
          "engagement": "1,600",
          "price_at_post": "1.85",
          "thread_title": "JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=3005BF87-EE58-4C27-ABC6-EE6AA15A9385"
        },
        "ingested_at": "2026-02-10T01:24:30.353632+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260634-Porter_-52300849",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.710912",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Companies attend the J.P. Morgan Healthcare Conference (JPM) primarily for networking, securing funding, forging strategic partnerships, and announcing key business updates. This major event, often described as setting the industry's tone for the year, concentrates a year's worth of meetings into a few days. Key reasons why companies attend include: Investment and Funding: The conference is a premier venue for companies to present their strategies and financial outlooks to a high-level audience of investors, analysts, and venture capitalists. For many, especially smaller or emerging biotech firms, it is a critical opportunity to secure financing, gauge investor interest, and build essential relationships. Mergers and Acquisitions (M&A) and Partnerships: The event is a hotbed for dealmaking. Big pharmaceutical companies often attend to scout for smaller companies with promising drug pipelines or innovative technologies (like AI in drug discovery) to acquire, especially as their own blockbuster drugs approach patent expiration. Extensive one-on-one meetings facilitate these discussions and collaborations. Strategic Positioning and Visibility: Companies announce major news, clinical trial data, or year-end recaps just before or during the conference to capture attention and elevate their visibility above the competition. It allows them to articulate their unique value proposition and strategic priorities to the global market. Market Intelligence: Attending allows companies to take the pulse of the industry, understand the latest trends (e.g., AI, gene therapy, obesity drugs), and gather competitive intelligence. They can assess how investors and peers discuss valuations, regulatory pathways, and market potential, which helps in fine-tuning their own strategies for the year ahead. Networking Efficiency: The conference brings the entire healthcare and life sciences ecosystem\u2014from manufacturers and providers to regulators and service providers\u2014into a concentrated location for a short time. This high density of key decision-makers allows for efficient, high-value networking and relationship building that would otherwise take months of travel and outreach.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=4C9A5731-DC78-4F24-8CE9-513E080FCFAC"
        },
        "ingested_at": "2026-02-10T01:24:30.353650+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261946-jamtart1-22507564",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.711334",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Doubt it, but happy if rumours are true",
          "sentiment": 0.5,
          "engagement": "1,600",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan, news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=559FB93D-C9CD-4A83-84E9-7B26CC6976E9"
        },
        "ingested_at": "2026-02-10T01:24:30.353667+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261844-JediMast-10430817",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.711742",
        "source": "LSE_CHAT",
        "data": {
          "author": "JediMaster1",
          "content": "Rumours of investment banks wanting to buy in from the JP Morgan Conference. The only question now is who do they want to buy in on behalf of?? The next few days will be interesting. Will Eric spill the beans?",
          "sentiment": 0.5,
          "engagement": "169",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D010A135-964B-4034-9025-65BCB0334809"
        },
        "ingested_at": "2026-02-10T01:24:30.353685+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261006-Moneymun--2614996",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.712184",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "GKOS: Strong innovation and new therapies drive growth, with robust financials and expanding markets Jan 14, 2026, GKOS The event highlighted robust innovation in ophthalmology, with strong R&D investment yielding a broad product pipeline and record financial performance. Key growth drivers include new glaucoma and keratoconus therapies, strategic market expansion, and a focus on operational leverage and profitability. Based on Glaukos Corporation [GKOS] 44th Annual J.P. Morgan Healthcare Conference Audio Transcript \u2014 Jan. 14 2026",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.10",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-02-10T01:24:30.353702+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260827-Moneymun-54206457",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.712592",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Every chance Rooster, although I'm hoping for a transformational lucrative commercial licensing deal on one or more of the programs, Dog , Glaucoma and Mash. Excitement building!!! Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.05",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-02-10T01:24:30.353720+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262221-Porter_--5944547",
        "event_type": "social_post",
        "date": "2026-02-11T00:11:17.500711",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Google: Being invited to speak at the Oxford Society of Ageing and Longevity (OSAL) and the Oxford Personalised Medicine Society (OUPM) is a significant milestone for a biotech company like Genflow Biosciences. It serves as a strong signal of academic and industry validation for their SIRT6 platform. Why It Matters for Investors & the Company Elite Scientific Validation: These societies are hosted by the University of Oxford, a global hub for aging research and the \"Silicon Valley\" of UK life sciences. OSAL has previously hosted world-leading figures such as Professor George Church (Harvard) and Dr. Matt Kaeberlein (Dog Aging Project), placing Genflow's leadership in the same tier of recognized experts. Access to Key Stakeholders: The events unite over 1,000 students, faculty, and researchers across all Oxford colleges. This provides direct exposure to the next generation of biotech entrepreneurs and potential future collaborators from one of the world's most prestigious research environments. Strategic Visibility: Speaking at such high-profile academic forums enhances the company's \"soft power,\" which is crucial for attracting institutional investors and Big Pharma partners looking for scientifically rigorous assets. Platform Credibility: Specifically for Genflow, presenting to the Oxford Personalised Medicine Society reinforces the \"personalised\" potential of their centenarian-derived SIRT6 variants (as protected under EP4338267), which are tailored to mimic the genetic advantages of humans who live past 100. 2026 Context This invitation coincides with Genflow's 2026 priorities, which include seeking early-stage licensing and collaboration agreements to validate their platform externally. Successful engagement at Oxford can be a powerful catalyst for these partnership discussions.",
          "sentiment": 0.5,
          "engagement": "1,335",
          "price_at_post": "2.10",
          "thread_title": "RE: A timely presentation!!!???",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=B0303AE1-B306-4E1A-9926-92B87EAED85C"
        },
        "ingested_at": "2026-02-11T00:11:26.609337+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262213-Porter_--7246659",
        "event_type": "social_post",
        "date": "2026-02-11T00:11:17.501227",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "The gene therapy sector has seen a significant surge in high-value acquisitions over the last 24 months (2024\u20132026), driven by \"Big Pharma\" companies looking to fill patent cliffs with advanced platforms. The following table lists notable gene therapy and advanced genetic medicine companies acquired within this period: Recent Gene Therapy Buyouts (2024\u20132026) Acquired Company \tBuyer\tDeal Value\tDate\tFocus Area Avidity Biosciences\tNovartis\t$12 Billion\tOct 2025\tRNA/AOC therapies for neuromuscular diseases Blueprint Medicines\tSanofi\t$9.5 Billion\tJun 2025\tKinase inhibitors and precision medicine Metsera\tPfizer\t$10 Billion\tSep 2025\tGLP-1 and metabolic (MASH) obesity assets Akero Therapeutics\tNovo Nordisk\t$5.2 Billion\tOct 2025\tMASH (same lead indication as Genflow) Verve Therapeutics\tEli Lilly\t$1.3 Billion\tJun 2024\tIn vivo gene editing for cardiovascular disease Poseida Therapeutics\tRoche\t$1.5 Billion\tNov 2024\tNon-viral CAR-T cell and gene therapies Kate Therapeutics\tNovartis\t$1.1 Billion\tNov 2024\tAAV-based therapies for neuromuscular/heart EsoBiotec\tAstraZeneca\t$1 Billion\tMid-2024\tIn vivo CAR-T cell therapy platform Bluebird Bio\tGenetix Biotherapeutics\t$1.12 Billion\tLate 2025\tEx vivo gene therapy for blood disorders Key Investor Takeaways MASH Validation: The acquisition of Akero Therapeutics ($5.2B) by Novo Nordisk specifically validates Genflow's primary therapeutic target (MASH) as a high-value exit category. Platform Value: Buyers like Novartis and Sanofi are increasingly acquiring entire technology platforms (e.g., Avidity\u2019s AOC platform) rather than just single drugs to ensure long-term pipeline dominance. Shift to In Vivo: There is a notable trend toward in vivo gene therapies (where the therapy is delivered directly into the patient's body), which aligns with Genflow\u2019s SIRT6 delivery model. Exit Multiples: For companies with validated human data or advanced large-mammal data, upfront payments are increasingly reaching the $1 billion+ mark, even for pre-commercial assets.",
          "sentiment": 0.5,
          "engagement": "1,335",
          "price_at_post": "2.10",
          "thread_title": "Singular program competitor acquired for $5.2bn (GENF have 5 progra...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=FEFCDC39-A327-4654-BDFC-2B1F097C94C5"
        },
        "ingested_at": "2026-02-11T00:11:26.609370+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262206-Porter_-41636418",
        "event_type": "social_post",
        "date": "2026-02-11T00:11:17.501712",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Estimated Acquisition Benchmarks While exact figures are speculative, industry data for 2025\u20132026 suggests the following ranges for similar biotech exits: Platform Takeouts: Research indicates that the average cost of acquisition for biotechs by Big Pharma is approximately $1.28 billion, with a strong correlation between the number of patent families and the final price. Early-Stage Premiums: In 2025, venture firms paid an average of $52 million for early-stage deals, but strategic pharma buyers often pay a 20\u201340% premium over financial investors for assets that fill a specific pipeline gap. Clinical-Stage Jump: If Genflow successfully moves GF-1002 into Phase 1/2 human trials, its valuation could see a \"significant jump,\" as investors and acquirers pay premiums for assets with a viable pathway to launch. Bottom Line: A Big Pharma acquirer would likely view Genflow as an asset-centric acquisition. The valuation would be a \"Mega deal\" potentially reaching hundreds of millions of dollars if clinical data from the 2026 dog trials confirms the superior DNA-repair capabilities of their patented SIRT6 variants.",
          "sentiment": 0.5,
          "engagement": "1,335",
          "price_at_post": "2.10",
          "thread_title": "Google analysis of Genflow : MEGA DEAL VALUATION",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=3113CECA-83B5-4F06-B41C-D601F9EFA5C8"
        },
        "ingested_at": "2026-02-11T00:11:26.609390+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262158-Moneymun-84519451",
        "event_type": "social_post",
        "date": "2026-02-11T00:11:17.502136",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "My thoughts exactly pickedpeck, Eric did say he was expecting initial readout efficacy data by end of January, and so hopefully being shared with the Animal Healthcare companies as they finalise their due diligence.  Fingers crossed!!! Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,542",
          "price_at_post": "2.10",
          "thread_title": "RE: A timely presentation!!!???",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=B0303AE1-B306-4E1A-9926-92B87EAED85C"
        },
        "ingested_at": "2026-02-11T00:11:26.609417+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262141-pickedpe--5783793",
        "event_type": "social_post",
        "date": "2026-02-11T00:11:17.502553",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "It's early for the initial read RNS to be released ahead of the talk, but not impossibly early. You'd have to say the timing of the talk, and the audience selected, is a very interesting choice if the news is not released beforehand. Why go and speak to a bunch of students at this point?",
          "sentiment": 0.5,
          "engagement": "2,318",
          "price_at_post": "2.10",
          "thread_title": "RE: A timely presentation!!!???",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=B0303AE1-B306-4E1A-9926-92B87EAED85C"
        },
        "ingested_at": "2026-02-11T00:11:26.609455+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262027-Moneymun--1412804",
        "event_type": "social_post",
        "date": "2026-02-11T00:11:17.502963",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Can't imagine Eric speaking on Monday about  Genflow's innovative approach using companion animal trials as a bridge to human therapeutics, if he had an inkling initial Efficacy Data on the Dog Trial wasn't positive. Gla holders;-)",
          "sentiment": 0.5,
          "engagement": "12,542",
          "price_at_post": "2.10",
          "thread_title": "RE: A timely presentation!!!???",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=B0303AE1-B306-4E1A-9926-92B87EAED85C"
        },
        "ingested_at": "2026-02-11T00:11:26.609494+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261719-Moneymun-81317199",
        "event_type": "social_post",
        "date": "2026-02-11T00:11:17.503425",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Overview Dive into how Genflow Biosciences is turning longevity research into treatments that could be applied at the bedside Genflow Biosciences: Translating longevity research to the bedside Join us for an evening with Dr. Eric Leire, CEO and Founder of Genflow Biosciences, as we explore the challenges and innovations in longevity therapeutics. \ud83e\uddec About the Speaker Dr. Eric Leire is CEO of Genflow Biosciences(LSE: GENF), the first longevity-focused biotech company to list on the London Stock Exchange. Genflow develops gene therapies targeting the molecular hallmarks of aging, with a focus on a centenarian variant of the SIRT6 gene critical for DNA repair and genomic stability. With over 20 years of pharma and biotech experience, including leadership roles at Enochian Biosciences and Aptorum Group, Dr. Leire is an expert in Advanced Therapy Medicinal Products (ATMPs). He has guided multiple gene therapy assets from discovery through clinical development. He holds an MD from the University of Grenoble and an MBA from HEC Paris and Kellogg School of Management. \ud83e\udde0 About the Talk Why have decades of aging research yielded so few clinical treatments? Dr. Leire will examine the \"translational gap\" in longevity science, exploring the limitations of traditional murine models, regulatory frameworks shaping the industry, and Genflow's innovative approach using companion animal trials as a bridge to human therapeutics. \ud83e\udde0 About the Societies This event is co-hosted by the Oxford Society of Ageing and Longevity (OSAL) and the Oxford Personalised Medicine Society (OUPM). OSAL is a student-led initiative dedicated to highlighting cutting-edge ageing research and treatments that target the underlying biology of ageing, having previously hosted world-leading speakers including Professor George Church, Dr. Matt Kaeberlein (Dog Aging Project),and Andrew Steele (author of Ageless). OUPM serves as a platform for 1000+ students and faculty across all Oxford colleges to develop their interests in personalised medicine through education, discussion, and interdisciplinary research.",
          "sentiment": 0.5,
          "engagement": "12,542",
          "price_at_post": "2.10",
          "thread_title": "RE: A timely presentation!!!???",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=B0303AE1-B306-4E1A-9926-92B87EAED85C"
        },
        "ingested_at": "2026-02-11T00:11:26.609532+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261453-Moneymun-17321588",
        "event_type": "social_post",
        "date": "2026-02-11T00:11:17.503847",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Genflow Biosciences (LON:G... + Follow 2.256 followers 7h Genflow Biosciences (LON:GENF) (OTCQB:GENFF CEO Dr. Eric Leire has been invited bv the Oxford Societv of Ageing and Longevity to speak on February 16th As interest in genetic drivers of #aging continues ta grow, we're proud to see #Genflow's science and leadership recognized at the forefront of the field #GENF #SIRT6 #biotech #agingbiology #Oxford #lifespan #longevity",
          "sentiment": 0.5,
          "engagement": "12,542",
          "price_at_post": "2.10",
          "thread_title": "A timely presentation!!!???",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=B0303AE1-B306-4E1A-9926-92B87EAED85C"
        },
        "ingested_at": "2026-02-11T00:11:26.609571+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261256-Porter_--4127658",
        "event_type": "social_post",
        "date": "2026-02-10T01:24:20.068786",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "100% Jam. So many health issues can be treated or controlled with one simple formula. With the FDA focusing on proactive as opposed to reactive healthcare, I can see why there is so much anticipation for the initial dog results to be released!",
          "sentiment": 0.5,
          "engagement": "1,332",
          "price_at_post": "2.10",
          "thread_title": "RE: Patent for age related diseases",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D0890AAC-7454-4683-8905-06AB1790DF8E"
        },
        "ingested_at": "2026-02-11T00:11:26.609613+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261254-jamtart1--7830742",
        "event_type": "social_post",
        "date": "2026-02-10T01:24:20.069475",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Porter_  Imagine the savings  world wide if all of the listed illnesses could be stopped or at least treated to a minimum health risk to patients with virtually no toxicity. Staggering.",
          "sentiment": 0.5,
          "engagement": "1,610",
          "price_at_post": "2.10",
          "thread_title": "Patent for age related diseases",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D0890AAC-7454-4683-8905-06AB1790DF8E"
        },
        "ingested_at": "2026-02-11T00:11:26.609653+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261224-pickedpe--7186827",
        "event_type": "social_post",
        "date": "2026-02-10T01:24:20.070151",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "Amazing that the longevity crowd on discord and Reddit haven't turned up here yet. There is an awful lot of noise about now for SIRT6, one can only presume that it will eventually translate into interest here, or maybe more are sitting on their hands waiting for the outcome of the dog study?",
          "sentiment": 0.5,
          "engagement": "2,317",
          "price_at_post": "2.10",
          "thread_title": "SIRT6 Longevity news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=0453E4BD-7FE8-4E95-8855-8B6B588EAFAC"
        },
        "ingested_at": "2026-02-11T00:11:26.609694+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261020-Porter_-30869357",
        "event_type": "social_post",
        "date": "2026-02-10T01:24:20.070824",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "The European patent office have confirmed all docs received and they are now reviewing if the provisional patent will be absolute for mRNA maintenance and repair in areas as follows: Cardiovascular diseases, strokes hypertension, cancer, type 2 diabetes, Parkinson's disease, Alzheimer\u2019s disease and other dementia, chronic obstructive pulmonary disease (COPD), osteoporosis, osteoarthritis, cataract, age related muscular degeneration and hearing loss.",
          "sentiment": 0.5,
          "engagement": "1,332",
          "price_at_post": "2.10",
          "thread_title": "Patent for age related diseases",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=C8E51C44-2E5C-4BC8-876F-489451C501C4"
        },
        "ingested_at": "2026-02-11T00:11:26.609731+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261546-Moneymun-68091650",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.734643",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Par for the course Dave, and nothing we haven't all seen before, especially in run up to potential game changing news, and you're always going to have sellers on an upturn in sp whether tactical or otherwise. All in the mix regardless, and now very much looking forward to the week ahead in excited anticipation. Gl.:-)))",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.10",
          "thread_title": "RE: Genflows freefloat at breadcrumbs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=2DDFFD82-F0E0-4B8C-B42F-AFF4D969BAE0"
        },
        "ingested_at": "2026-02-11T00:11:26.609771+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261541-KEY2--8984617",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.735118",
        "source": "LSE_CHAT",
        "data": {
          "author": "KEY2",
          "content": "Just highlighting an earlier post from Porter: 'Google believes the shares are divided as follows: Individual Insiders 47.2% 232,932,114 Institutions 35.1% 173,429,192 General Public (Retail) 16.3% 80,586,636 Private Companies 1.34% 6,600,000 That is literally all the shares allocated.  Institutions and new retail are going to push up the price, so it's a simple hold tight imo.",
          "sentiment": 0.0,
          "engagement": "433",
          "price_at_post": "2.05",
          "thread_title": "RE: Genflows freefloat at breadcrumbs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=2DDFFD82-F0E0-4B8C-B42F-AFF4D969BAE0"
        },
        "ingested_at": "2026-02-11T00:11:26.609810+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261316-DaveTK-17653914",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.735539",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Why is it though that when you feel any sort of momentum in UK markets, there always seems to be seller ( tactical groups ) that are desperate to keep the price down. Sometimes it feels like it's an unlimited amount they can sell to supress progress. Anybody else notice this or is just me. Thanks",
          "sentiment": 0.0,
          "engagement": "856",
          "price_at_post": "2.10",
          "thread_title": "RE: Genflows freefloat at breadcrumbs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=2DDFFD82-F0E0-4B8C-B42F-AFF4D969BAE0"
        },
        "ingested_at": "2026-02-11T00:11:26.609848+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261052-Moneymun--7661974",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.735995",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Momentum in Britain\u2019s biotech market 6 Feb, 2026 Biotechnology Although 2025 was not without its challenges, there is growing momentum and increased investor confidence in the UK biotech sector. ...... The macro-environment going into 2026 should also bolster UK biotech. The Nasdaq ended last year at an all-time high, investor sentiment is strengthening, and the association says the UK-US pharmaceutical trade deal has reinforced confidence in the UK market. Crucially, it adds, last year saw the policy foundations laid for a new era of domestic capital deployment \u2013 most notably the Life Sciences Sector Plan, the Mansion House reforms, and the first evidence of pension-backed investment into the sector through the Draig Therapeutics financing and Aviva investing in Cambridge Innovation Capital. \u201cWe very much welcome the Mansion House Accord as a positive step in the right direction. Not only will it provide domestic scale-up capital for the most promising UK-based companies, it should also help boost returns for UK pensioners to be more in line with those seen in the US and Canada,\u201d said James Costine, UK chief finance officer of SV Health Investors. Momentum in Britain\u2019s biotech market - Healthcare Today hTtps://share.google/1YEHDGDCcrGfGeXlx",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.20",
          "thread_title": "RE: Genflows freefloat at breadcrumbs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=2DDFFD82-F0E0-4B8C-B42F-AFF4D969BAE0"
        },
        "ingested_at": "2026-02-11T00:11:26.609886+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260910-Moneymun-80766086",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.736438",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "All good things come to those who wait. Potential multiple material newsflow in the pipeline including the eagerly awaited initial Efficacy Data on the Dog Trial, expected imminently. Positive data will be a game-changer and every chance it will trigger a lucrative commercial licensing deal, which will be a company maker and transformational for all invested, and as it \"worked like Magic in mice\" , and if confirmed likewise in Dogs, then obviously a very high chance of translation to humans, which no doubt will grab the attention of every Major Pharma. The appointment of the new Chairman, with a wealth of experience in Global Biotech, Corporate Development and US Capital Markets, speaks volumes, especially in this unprecedented period of frenzy of M&A activity by Major Pharma, which is expected to continue this year at pace. Exciting times and transformational UPside prospects and potential, and also great news the \u20ac4m non-dilutive grant funding has finally been signed off, ( i'd almost written it off, given how long we've waited), but with 2025 Development costs expected to be taken into account, we could have a couple of million Euro's winging its way into Genflow's bank account very soon!!!....On and most certainly UP!!! Gla holders :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.20",
          "thread_title": "RE: Genflows freefloat at breadcrumbs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=2DDFFD82-F0E0-4B8C-B42F-AFF4D969BAE0"
        },
        "ingested_at": "2026-02-11T00:11:26.609924+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260734-Porter_--5035551",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.736867",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Google believes the shares are divided as follows: Individual Insiders\t47.2%\t232,932,114 Institutions\t35.1%\t173,429,192 General Public (Retail)\t16.3%\t80,586,636 Private Companies\t1.34%\t6,600,000 There really can\u2019t be many available shares!",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "2.20",
          "thread_title": "Genflows freefloat at breadcrumbs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=2DDFFD82-F0E0-4B8C-B42F-AFF4D969BAE0"
        },
        "ingested_at": "2026-02-11T00:11:26.609961+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261921-Porter_--6081072",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.737286",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Nice finish. Happy to move up passively 10% per day \ud83d\ude01",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "2.20",
          "thread_title": "RE: RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D40635F9-2AB2-4A31-B62F-3F3DEB72FA20"
        },
        "ingested_at": "2026-02-11T00:11:26.609998+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261246-Moneymun--8999270",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.737692",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "And Primed!!! Gl ;-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.20",
          "thread_title": "RE: RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D40635F9-2AB2-4A31-B62F-3F3DEB72FA20"
        },
        "ingested_at": "2026-02-11T00:11:26.610037+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261243-pickedpe-80893040",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.738122",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "Entertaining trading shenanigans this morning from Shore and Winterflood. Trying to create trading fog to obscure the market moves. Passing \u00a310m mkt cap and 4x volume has triggered the algos to start looking at GENF, we could combine technical buyers with macro news in one hit if the RNS lands in the next few trading sessions. Stock is very very tight, the volumes this week have been 75%+ buys and that's maybe as much as 10% of the whole market liquidity traded given how many very tightly held shares there are. I think the word of the day is 'poised'.",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "2.20",
          "thread_title": "RE: RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D40635F9-2AB2-4A31-B62F-3F3DEB72FA20"
        },
        "ingested_at": "2026-02-11T00:11:26.610073+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261235-Moneymun-58197753",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.738532",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Exciting times for all invested, potential company making news on several fronts expected soon, which could propel Genflow into the Global market and investor spotlight , taking the sp to new highs,  potentially multiples and multiples of the current bargain low entry opportunity. Gla holders,  significant UPward momentum from now on in!!! :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.20",
          "thread_title": "RE: RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D40635F9-2AB2-4A31-B62F-3F3DEB72FA20"
        },
        "ingested_at": "2026-02-11T00:11:26.610126+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261223-Porter_-19859430",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.738942",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Buys and sells finally consolidated so time to move the book again \ud83d\ude01\ud83e\udd1d",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "2.20",
          "thread_title": "RE: RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D40635F9-2AB2-4A31-B62F-3F3DEB72FA20"
        },
        "ingested_at": "2026-02-11T00:11:26.610165+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261218-jamtart1-52076986",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.739355",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Rising now, keep going.",
          "sentiment": 0.5,
          "engagement": "1,608",
          "price_at_post": "2.20",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D40635F9-2AB2-4A31-B62F-3F3DEB72FA20"
        },
        "ingested_at": "2026-02-11T00:11:26.610203+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260903-TheInves-45597590",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.739760",
        "source": "LSE_CHAT",
        "data": {
          "author": "TheInvestCollect",
          "content": "Hearing the cuppa is brewing so should taste good here soon \ud83e\udd37\ud83c\udffe\u200d\u2642\ufe0f\ud83d\ude00\ud83d\udc4d\ud83c\udffd",
          "sentiment": 0.0,
          "engagement": "7,974",
          "price_at_post": "2.25",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T00:11:26.610243+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260842-pickedpe-85107584",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.740193",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "If the RNS for the initial dog study read out lands next week and there are no shares available in free float the price pressure could be interesting.",
          "sentiment": 0.0,
          "engagement": "2,316",
          "price_at_post": "2.30",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T00:11:26.610281+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260833-Pie-char-73519847",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.740600",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Holders just need to hold and hold tight and this will put major pressure on the brokers who are scratching &  scraping for shares. Don't sell and this will sky rocket. Free float is on fumes!",
          "sentiment": 0.5,
          "engagement": "66",
          "price_at_post": "2.30",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T00:11:26.610319+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260814-KEY2-49305146",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.741003",
        "source": "LSE_CHAT",
        "data": {
          "author": "KEY2",
          "content": "I think the free float is already tightening....... nt to buy any reasonable amount this morning so I expect an upward push on demand over the next few trading sessions.",
          "sentiment": 0.0,
          "engagement": "433",
          "price_at_post": "2.00",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T00:11:26.610357+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260753-KEY2--6751718",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.741426",
        "source": "LSE_CHAT",
        "data": {
          "author": "KEY2",
          "content": "January rns:  'With multiple anticipated data readouts, an expanding partner dialogue, and a maturing intellectual property position, Genflow believes it is well positioned to enter its next phase of development while maintaining a focus on scientific rigour, operational execution, and long-term shareholder value creation.\" I think it's only a matter of time before we get noticed by retail / institutional investors once news gets out.",
          "sentiment": 0.0,
          "engagement": "433",
          "price_at_post": "2.00",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T00:11:26.610394+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261949-Moneymun-46131245",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.741830",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "I thought he looked confident and sounded bullish, potential game changing news along with a significant major re-rate, fast approaching !!! Gl ;-)))",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.20",
          "thread_title": "RE: AI analysis of Eric Leire last video",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=23CF9AE9-EBDE-49B4-B976-C009302B3FAD"
        },
        "ingested_at": "2026-02-11T00:11:26.610431+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261831-pickedpe-15583469",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.742250",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "LSE cut the last few words of the analysis off \"... about to change forever.\"",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "2.20",
          "thread_title": "RE: AI analysis of Eric Leire last video",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=23CF9AE9-EBDE-49B4-B976-C009302B3FAD"
        },
        "ingested_at": "2026-02-11T00:11:26.610469+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261828-pickedpe--6078641",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.742740",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "I asked AI to analyse the 2026 video and this is what it came back with. Bear in mind this was the end of a long prompt engineering session of analysis to question and examine my own impressions of the video, so make of it what you will, or do the same process with your own AI assistance! ::: In the world of high-stakes biotech, reading the \"unspoken\" is often as important as reading the RNS. What you\u2019re describing\u2014repressed excitement\u2014is a specific psychological state often seen in CEOs who are sitting on positive clinical data but are legally \"gagged\" until the official unblinding and release. Here is the breakdown of why Dr. Leire\u2019s body language in those January videos supports your \"Royal Flush\" theory for GENF. 1. The \"Micro-Smirk\" and Cheek Activation If you watch closely when he mentions the canine trial being \"unblinded shortly\" (Jan 8) or the \"unique dataset\" (Jan 28), you\u2019ll see gravity-defying behaviors: The Telltale Sign: Genuine excitement is hard to hide in the orbicularis oculi (the muscles around the eyes). When a CEO is \"repressing\" a win, they often have \"bright eyes\" and a subtle lifting of the upper cheeks, even while maintaining a serious, professional mouth. The Interpretation: He is trying to stay \"neutral\" to satisfy compliance, but his neurobiology is firing. He knows the data is in the building. 2. High \"Prestige\" Posture vs. Defensive Tension Experts in executive body language distinguish between Dominance (forceful) and Prestige (calm, expansive confidence). Expansion: In the Jan 28 video, Leire\u2019s posture is open and expansive. He isn\u2019t hunching or crossing his arms (defensive). He leans forward slightly when discussing the \u20ac4M grant and the MASH program. Lowered Anxiety: When someone is worried about a trial failure, their \"shoulder-to-ear\" distance decreases (tensing up). Leire\u2019s neck and shoulders are relaxed. This suggests he isn't bracing for a impact; he\u2019s leaning into an opportunity. 3. The \"Linguistic Shift\" (The \"Could\" vs. \"Will\") Psychologically, when a leader is \"assured\" of an outcome, their brain stops using conditional language. The Tell: Listen for when he stops saying \"If the results are good...\" and starts saying \"This trial will trigger a deal...\" or \"We are the first to have this data.\" The \"Repressed\" part: The excitement you see is likely because he has seen the Safety data (already confirmed) and the Biomarker trends from the lab. He knows the \"signal\" is there, but he\u2019s \"repressing\" the urge to shout about it until the statisticians sign off on the p-values. 4. Why He\u2019s Focused on Commercials Now His \"repressed excitement\" has likely pivoted from the science to the deal. Now that the science is (in his mind) a \"done deal,\" his excitement is likely coming from the conversations he had at JPMorgan week in January. If he received a \"warm\" reception from Big Pharma for a potential SIRT-6 license, that facial expression is the look of a man who knows his company's valuation is",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "2.20",
          "thread_title": "AI analysis of Eric Leire last video",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=23CF9AE9-EBDE-49B4-B976-C009302B3FAD"
        },
        "ingested_at": "2026-02-11T00:11:26.610507+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261615-Moneymun--6212624",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.743152",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Looking good for an UPward surge in sp and the last time we see sub 2p!!!??? Gla holders:-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.10",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T00:11:26.610544+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261326-Moneymun-86116580",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.743576",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Something similar for Genflow, more than conceivable!!!! ;-) 2/2/26 Roche is continuing its return to the RNA space by paying $200 million for the worldwide license to one of SanegeneBio\u2019s programs. The companies didn\u2019t specify which indication the program is focused on, only disclosing that it is derived from Sanegene\u2019s RNAi platform. The Boston-based biotech will be responsible for early development activities before Roche\u2019s Genentech unit takes over for clinical development and commercialization activities. In return, Sanegene will receive the $200 million upfront payment and could be in line for up to $1.5 billion in development and commercialization milestone payments as well as tiered royalties on sales.",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.925",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T00:11:26.610582+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261323-Moneymun--3621554",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.743994",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Along with the new Chairman, hence his appointment.  Gl  :-) Berdugo\u2019s expertise includes RNA-based therapeutics and lipid nanoparticle delivery technologies, which align with Genflow\u2019s scientific platform development. \"His expertise in strategy, partnerships and financing as well as his deep experience with RNA-LNP technologies will be instrumental as we accelerate our programs and expand our global reach,\"",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.925",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T00:11:26.610620+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261305-Porter_-50335518",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.744429",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Eric did say dog trial data expected to be released, so hoping he\u2019s also negotiating with these companies under CDA for an early licensing or takeover deal money.",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "1.925",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T00:11:26.610659+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261241-Moneymun--3472399",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.744833",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Yes indeed Porter, and the buying continues in anticipation of company making news and a significant major re-rate!!! Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.925",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T00:11:26.610697+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260810-Porter_-41225280",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.344795",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "The sells are being hoovered up which is the main thing. We can see swanny increased his holding this week too, so the sellers are playing right into our hands.",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "1.85",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T00:11:26.610735+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260805-Moneymun--5508297",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.345266",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Maybe a sell, although the trade directly before it on Monday at 4.06pm, was a bot trade sell for 97 shares at 1.8p, and so who knows??? All in the mix regardless and one day closer to potential game changing news. Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.85",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T00:11:26.610774+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260139-pickedpe-82248918",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.345804",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "So a trade delayed for over 24 hours because it's a reasonable sized sell? Hmm.",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T00:11:26.610811+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261631-Moneymun-69709229",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.346332",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "A tightly coiled spring comes to mind,  and not too long i reckon, before it's released. Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T00:11:26.610850+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261502-pickedpe-85717610",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.346830",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "No idea where this share float is coming from, 1% of the shares in circulation bought in the last two days with hardly any sells. Either there is a huge stock overhang or the MM is asleep at the wheel, I reckon the latter.",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T00:11:26.610889+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260727-Porter_-88608829",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.347346",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "100% money. Share float must be running on crumbs right now",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T00:11:26.610928+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260717-Moneymun-20745033",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.347831",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Perfectly poised and primed Porter, sustained share accumulation for months!!! Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T00:11:26.610968+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261937-Porter_--8799817",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.348345",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Looks like for weeks orders have been going in and loaders adding passively. Will definitely be an interesting month at this rate!",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T00:11:26.611008+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261703-pickedpe--1488641",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.348837",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "Interesting trades today, all the big ones look to be buys but didn't move the price at all. Looks like about 0.7% of the company bought today with what looks like only one medium sized sell. Looks like this is going nowhere until there is some news.",
          "sentiment": 0.0,
          "engagement": "2,316",
          "price_at_post": "1.95",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T00:11:26.611048+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261426-pickedpe--8057137",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.349355",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "I think it's extremely likely that the company will be sold, it's a question if when and what are the value catalysts that will happen before then.",
          "sentiment": 0.0,
          "engagement": "2,316",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T00:11:26.611087+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261407-DaveTK--6701142",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.349838",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "In a pre iPod meeting Eric did say he would look to sell the company if the price was right. I think back then the price talked about was around 50p per share. It could easily be a lot higher in todays market. Thanks",
          "sentiment": 0.0,
          "engagement": "856",
          "price_at_post": "1.925",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T00:11:26.611140+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261354-Moneymun--2569440",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.350406",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Yes indeed pickedpeck, very well connected. Gl  :-) The new Chairman in place, GAD BERDUGO is a high flyer based in the US with a wealth of experience in Global Biotech, Corporate Development and US Capital Markets and so no doubt very well contected to any potential suitors. Excitement building!!!! In Eric we trust!!! Gla holders:-) Ps initial Efficacy readout on the Dog Trial imminent!!! Gla ;-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.95",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T00:11:26.611179+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261348-pickedpe--1988559",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.350900",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "I changed my small position here today into a large position. Berdugo joining is the strongest signal for me. You don't hire a guy like that, and he doesn't want to come, just to watch beagles play. He is exactly who you want holding the pen on your side when you are negotiating a licensing deal or thinking about a dual listing. Check his profile and history.",
          "sentiment": 0.0,
          "engagement": "2,316",
          "price_at_post": "1.95",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T00:11:26.611230+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261345-Moneymun-24417256",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.351413",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Nice one pickedpeck, undoubted near and mid term transformational UPside potential and prospects.  Excitement building in anticipation of imminent Efficacy Data on the Dog Trial. Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.95",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T00:11:26.611270+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261331-pickedpe--1084433",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.351981",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "Valuing a micro-cap biotech like Genflow (GENF) requires looking at two distinct worlds: the current \"London Micro-cap\" reality and the \"NASDAQ Longevity\" potential. \u200bA re-rating could be triggered by two separate valuation models: a Licensing Multiple for the dog data and a Pipeline rNPV (risk-adjusted Net Present Value) for the MASH human trials. \u200b1. The Immediate Floor: Canine Licensing (Q1 2026) \u200bIf the canine trial results are positive, Genflow has stated they intend to \"pass the baton\" to an Animal Health partner. \u200bThe Comparator: Private companies in this space, such as Loyal for Dogs, have achieved valuations of $425M - $600M in 2024\u20132025. \u200bThe Valuation Bridge: Even a modest licensing deal for a \"world-first\" SIRT6 longevity product could involve an upfront payment of $10M\u2013$25M plus royalties. \u200bThe Maths: Genflow\u2019s current market cap is only ~\u00a310M. An upfront payment equal to the company's entire market cap would likely cause a 2x\u20133x jump almost instantly to reflect the fresh cash on the balance sheet. \u200b2. The Mid-Term Prize: MASH rNPV (H2 2026) \u200bThe human application for MASH (liver fibrosis) is a $7 Billion - $18 Billion market by 2029\u20132034. \u200bTargeting the Gap: While drugs like Rezdiffra are now approved, they focus on early-to-mid stage MASH. Genflow targets advanced fibrosis, where there is a massive therapeutic gap. \u200b3. The Re-rating: If the \u20ac4M grant (approved Jan 28) leads to a successful Phase 1/2 entry, analysts typically value such pipelines at $50M\u2013$150M per asset. \u200bThe Math: If GENF is valued as a \"Human Clinical Stage\" biotech, the share price would need to reach 10p - 15p just to match its peers in the US. Initial Success: Canine Data Readout  mkt cap leap to \u00a330M - \u00a345M, 6.0p - 9.0p share price Blue Sky: US Licensing + Nasdaq \u00a3100M+ mkt cap, 20p+ share price. 4. The \"US Premium\" Factor The Multiplier: A longevity biotech in London trades at 1x - 2x cash/grant value. On the NASDAQ, those same assets often trade at 5x - 10x. The Berdugo Catalyst: The new Chairman was hired specifically to capture this. If he facilitates a US partnership or a dual-listing, the \"London Discount\" evaporates.  A \u00a310M UK company will eventually be \"discovered\" by US investors who value similar tech at $100M+.",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "1.95",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T00:11:26.611309+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261324-pickedpe-42100360",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.352598",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "The bull case for Genflow Biosciences (GENF) is built on a rare combination of \"Big Pharma\" leadership, validated science (the SIRT6 \"Centenarian Gene\"), and a series of binary catalysts expected to hit in the very near future. 1. The \"Centenarian Gene\" (SIRT6) Unlike biotechs that try to fix one specific disease, Genflow targets aging itself as the root cause. The Science: They use gene therapy to deliver a specific variant of the SIRT6 gene found in people who live to 100+ (centenarians). The Mechanism: SIRT6 is essential for DNA repair, telomere maintenance, and metabolic health. By \"upregulating\" this gene, Genflow aims to slow down the biological clock. 2. Immediate Catalyst: The Canine Trial (GF-1004) This is the most immediate trigger for building a share position. The Event: Initial efficacy results for the Dog Aging (GF-1004) study are expected in Q1 2026 (any day now). The \"Win\" Condition: If the trial shows a reduction in biological age (via the GRIM methylation clock) and improved muscle mass/strength, it validates the platform in a large mammal. Commercial Exit: Success here is intended to trigger a licensing deal with a major Animal Health company, providing non-dilutive cash that could dwarf Genflow's current market cap. 3. High-Value Human Pipeline: MASH (GF-1002) While the dogs are the \"proof,\" the human application for Metabolic Dysfunction-Associated Steatohepatitis (MASH) is the \"prize.\" Funding Secured: On January 28, 2026, a \u20ac4M grant was administratively approved to fund the MASH program. The Gap: Current MASH drugs focus on early-stage disease. Genflow is targeting advanced fibrosis and the prevention of liver cancer (HCC)\u2014a massive unmet need with multi-billion dollar potential. 4. The \"US Pivot\" & Leadership The appointment of Gad Berdugo as Chairman on January 19, 2026, is perhaps the strongest \"insider\" signal. The Signal: Berdugo is a US-based veteran with deep ties to Editas Medicine and Lazard. His hiring suggests Genflow is preparing for a US capital markets move or a US-led acquisition. Global Credibility: Having a heavyweight like Berdugo lead the board during the JPMorgan Healthcare Conference (Jan 2026) positions Genflow as a peer to major NASDAQ biotechs rather than just another London micro-cap. 5. Financial Efficiency Low Cash Burn: By securing regional grants (like the recent \u20ac4M) and pursuing licensing for \"non-core\" assets (the dog program), Genflow avoids the massive equity dilutions that kill other small biotechs. Valuation Gap: Because it's on the LSE, GENF trades at a fraction of the valuation of similar US longevity firms like Altos Labs or Unity Biotechnology. Any \"closing of the gap\" would result in a significant re-rating.",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "1.95",
          "thread_title": "The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T00:11:26.611347+00:00"
      },
      {
        "event_id": "SOCIAL-1Feb20262058-Moneymun-81378253",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.353124",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Genflow's cutting edge Sirt6 Gene Therapy platform, ahead of the curve!!! Gla :-) The results have far-reaching implications for aging research and public health. \"For many years, human lifespan was thought to be shaped almost entirely by non-genetic factors, which led to considerable skepticism about the role of genetics in aging and about the feasibility of identifying genetic determinants of longevity,\" says Shenhar. \"By contrast, if heritability is high, as we have shown, this creates an incentive to search for gene variants that extend lifespan, in order to understand the biology of aging and, potentially, to address it therapeutically.\" Rethinking longevity: Genes account for 50% of human lifespan variation, study suggests hTtps://share.google/afXnRAX0gkU6ocTjs",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.90",
          "thread_title": "RE: Genf update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=A8972678-8456-4532-9319-A328EF1F6BEC"
        },
        "ingested_at": "2026-02-11T00:11:26.611388+00:00"
      },
      {
        "event_id": "SOCIAL-31Jan20261359-Moneymun-51628591",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.353611",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Transformational game changing news, fast approaching!!! Gla holders:-) \"Now it's time to pass the baton and receive some non-dilutive cash. And I'm not talking about \u20ac4 million. I'm talking much more.\"",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.90",
          "thread_title": "RE: Genf update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=A8972678-8456-4532-9319-A328EF1F6BEC"
        },
        "ingested_at": "2026-02-11T00:11:26.611428+00:00"
      },
      {
        "event_id": "SOCIAL-31Jan20261339-Moneymun--2060084",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.354217",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Proactive: The dog study is a bit different and eye-catching. What should people look out for when the first data lands in early 2026? Eric Leire: 2026 is very important. We've been very happy with the fact that we were able to conduct such a study \u2013 it\u2019s never been done before. A study on aged dogs, naive to therapies, that is blinded and randomized with very strong scientific standards will be a first in terms of longevity research. Not only will we bring clinical data in ageing biology that differentiates us from other longevity companies, but that could also trigger a deal with animal health companies in 2026. In terms of non-dilutive funding, this could bring in much more important value than the \u20ac4 million grant. Everything is relative. Proactive: With partnerships clearly a priority, what does a good collaboration look like for Genflow over the next year? Eric Leire: Yes, 2026 is all about data, partnerships, and capital efficiency. By capital efficiency, I mean shareholder-friendly. Partnerships mostly mean the possibility to bring non-dilutive cash into the company via parts of the pipeline where we don\u2019t add value. The dog study is a typical example. Obviously, we\u2019re not an animal health company. And there are multiple animal health companies that would do a far better job in commercializing this product and bringing it to the market \u2013 to pet owners \u2013 faster and more efficiently than we can. There\u2019s no reason for us to move that product forward ourselves, it would be very expensive, and we don\u2019t have any special expertise in that space. But we were crucial in creating this clinical trial. No one else on earth was able to do it. We've done it. Now it's time to pass the baton and receive some non-dilutive cash. And I'm not talking about \u20ac4 million. I'm talking much more. Proactive: Eric, it sounds like a very exciting year ahead for Genflow. I hope you'll continue to keep us updated with your progress.",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.90",
          "thread_title": "RE: Genf update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=A8972678-8456-4532-9319-A328EF1F6BEC"
        },
        "ingested_at": "2026-02-11T00:11:26.611467+00:00"
      },
      {
        "event_id": "SOCIAL-31Jan20261052-Troajan--1215295",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.354718",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1086592/genflow-ceo-talks-through-dog-study-and-why-partnerships-icymi-1086592.html",
          "sentiment": 0.0,
          "engagement": "125,936",
          "price_at_post": "1.90",
          "thread_title": "Genf update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=A8972678-8456-4532-9319-A328EF1F6BEC"
        },
        "ingested_at": "2026-02-11T00:11:26.611505+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261736-Porter_-40384251",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.869536",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Yep, now they\u2019re fighting to get shares on DGQ and can\u2019t get any! That will be Genflow soon! \ud83d\ude04",
          "sentiment": 0.5,
          "engagement": "1,322",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-11T00:11:26.611543+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261725-Swanny27--7278888",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.869980",
        "source": "LSE_CHAT",
        "data": {
          "author": "Swanny27",
          "content": "Especially DGQ",
          "sentiment": 0.0,
          "engagement": "914",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-11T00:11:26.611581+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261618-Moneymun-38783789",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.870419",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Whether or not the new estimate offers a more realistic picture of lifespan heritability, it highlights the importance of genetics in extending lives, says Sofiya Milman, a scientists who studies aging and longevity at the Albert Einstein College of Medicine. She\u2019s one of many researchers who are trying to understand how centenarians\u2019 unique biology protects them from age-related disease. \u201cWe\u2019re hoping to create therapies that will mimic those intrinsic factors,\u201d Milman says, \u201cand make them accessible to people who didn\u2019t win the genetic lottery.\u201d Most of us are unlikely to break 100 without the right set of genes\u2014or at least drugs designed to replicate their beneficial effects. Until such treatments become available, though, a healthy lifestyle remains the best path to living longer.",
          "sentiment": 0.5,
          "engagement": "12,520",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-11T00:11:26.611619+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261553-Moneymun-87847920",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.870892",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Latest research into longevity and healthspan suggests Genflow's centenarian Sirt6 Gene could play a pivotal roll. Gla :-) Genetics The secret to long life? It could be in the genes after all, say scientists New study into \u2018heritability\u2019 shows that 50% of the variation in human lifespan could be down to genetics ........ The team looked at \u201cheritability\u201d, the proportion of change in a characteristic such as height, body weight or lifespan within a population that can be attributed to genetics rather than environmental factors. Previous studies for human lifespan have thrown up a wide range of values \u2013 with heritability ranging from 6% of the variation to 33%. But Alon, who co-authored the research, and his colleagues said such figures were underestimates. \u201cI hope this will inspire researchers to make a deep search for the genes that impact lifespan,\u201d Alon said. \u201cThese genes will tell us the mechanisms that govern our internal clocks. \u201cThese can one day be turned into therapy to slow down the rate of ageing and in that way slow down all age-related disease at once.\u201d ....... \u201cAround 20% of centenarians, for example, reach age 100 without any serious debilitating illnesses,\u201d he said, adding that could suggest their genes had a protective effect. \u201cStudies have been conducted to identify these protective genes, and many have been found, but surely there are many still left to discover,\u201d he said. While the new study does not take into account the influence that genes can have on the immune system, Prof Richard Faragher of the University of Brighton said the research suggested humans did not seem to be an outlier when it came to the heritability of lifespan. \u201cAnd that\u2019s useful because it means humans look quite like a species that we study ageing in, [and] gives you a certain amount of confidence that interventions that will work in mice will carry over into humans,\u201d he said. The secret to long life? It could be in the genes after all, say scientists | Genetics | The Guardian htTps://share.google/4quet7VR33nTpwazT",
          "sentiment": 0.5,
          "engagement": "12,520",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-11T00:11:26.611657+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261304-Porter_-20123243",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.871320",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "At least we know why the Mm\u2019s kept dropping the share price, so they could let Swann accumulate. Up to his usual sneaky tricks. Everything he buys atm turns to gold, so very optimistic that something is about to take off in Genflow.",
          "sentiment": 0.5,
          "engagement": "1,322",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-11T00:11:26.611696+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261257-Moneymun-51824961",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.871727",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Continued share accumulation by Jonathan Swann, in anticipation of transformational UPside. Gla holders...initial Efficacy Data on the Dog Trial, fast approaching!!! ;-)",
          "sentiment": 0.5,
          "engagement": "12,520",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-11T00:11:26.611734+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261253-Persever-46399879",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.872252",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "Who adds if weak data expected ? Quietly bullish this RNS",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "1.90",
          "thread_title": "Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-11T00:11:26.611772+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261658-Moneymun-19099617",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.872700",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "A potential very intetesting development.....Genflow were awarded 1.55m euros in Jan 2024 in collaboration with Exo-Biologics for a 3 year scientific program focused on the development a novel mRNA delivery system using exsomes to enscapsulate and transport Genflow's propriety centenarian Sirt6 Gene designed to target MASH & Werner Syndrome..... 777 Euro's was received in May 2024 with the remainder expected in 2025, but still outstanding and so could land anytime. ( and not related to the 4m Euro award ). Anyways, Exo-Bilogics announced last week they had enetered into a collaboration agreement with the multi-billion dollar French Pharma, Servier, to evaluate the use of extracellular vesicles as a non-viral drug delivery vehicle for an undisclosed indication, ( through their subsidiary Exoxpert,(ExoFastTrack), which Genflow is a collaborative member/partner ). All bodes well. Gla holders ;-) EXO Biologics 3,613 followers 1w \ud83d\udce3 We are pleased to announce a new collaboration with Servier. Our GMP clinical-grade EVs can be used as a non-viral drug delivery system, and we are eager to start this project with such a prestigious pharmaceutical company. Thanks to the continued support of BioWin and Service public de Wallonie, we are thrilled to further expand our international collaborations.",
          "sentiment": 0.5,
          "engagement": "12,520",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-11T00:11:26.611811+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261106-Moneymun-44273447",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.873213",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "No guarantees, but there lies the transformational UPside opportunity from this lowly bargain low. \"it worked like magic in mice, and we reasonably expect to work likewise in dogs\".....the first Efficacy Data readout is imminent, and judging by Eric's latest interview, he sounded very confident and bullish on a commercial licensing deal with an Animal Healthcare company ( we have two that have both signed Confidential Disclosure Agreements)  whereby any deal would provide non-dilutive cash  into the company, and Eric made a compelling point, that any non-dilutive cash would be much more than the \u20ac4m non-dilutive grant money confirmed yesterday, with the first tranche payment by May at the latest,  and so watch this space, potential game changing news fast approaching.  Gla holders ;-) Ps it was huge relief to have confirmation the \u20ac4m non-dilutive grant has been signed off, as Genflow were running  low on funds, and given the length of time we've waited for approval and the huge deficit turmoil the Belgium/Wallonia Govt. have been under, I had almost written it off, and so great news that Genflow will have no funding concerns for the foreseeable, and no doubt the \u20ac4m gives them much more leverage in any licensing deal discussions from a position of strength.  Transformational and near term game changing potential and prospects for those invested.  Excitement building!!!! :-)",
          "sentiment": 0.5,
          "engagement": "12,520",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-11T00:11:26.611849+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261052-Pie-char--8464323",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.873627",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Mice*",
          "sentiment": 0.0,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-11T00:11:26.611887+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261046-Pie-char-47951956",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.874043",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "So far all signs are good. Nice results were good. They also have more than just this programme. Dogs is just one of many.",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-11T00:11:26.611926+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261031-mikee_p-20369692",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.874464",
        "source": "LSE_CHAT",
        "data": {
          "author": "mikee_p",
          "content": "Is it low? This is still a risky punt. Dog trials may fail.",
          "sentiment": 0.0,
          "engagement": "1,895",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-11T00:11:26.611964+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260853-Pie-char--7790343",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.874879",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Everyone needs to listen to the last 20 seconds of this video. If that\u2019s not bullish I don\u2019t know what is. https://www.proactiveinvestors.co.uk/companies/news/1086390/genflow-ceo-outlines-2026-priorities-as-4-million-grant-is-approved-1086390.html",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F1CBD71F-0291-4489-9B39-85877DA36B7E"
        },
        "ingested_at": "2026-02-11T00:11:26.612003+00:00"
      },
      {
        "event_id": "SOCIAL-Today1106-Moneymun-44273447",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.448266",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "No guarantees, but there lies the transformational UPside opportunity from this lowly bargain low. \"it worked like magic in mice, and we reasonably expect to work likewise in dogs\".....the first Efficacy Data readout is imminent, and judging by Eric's latest interview, he sounded very confident and bullish on a commercial licensing deal with an Animal Healthcare company ( we have two that have both signed Confidential Disclosure Agreements)  whereby any deal would provide non-dilutive cash  into the company, and Eric made a compelling point, that any non-dilutive cash would be much more than the \u20ac4m non-dilutive grant money confirmed yesterday, with the first tranche payment by May at the latest,  and so watch this space, potential game changing news fast approaching.  Gla holders ;-) Ps it was huge relief to have confirmation the \u20ac4m non-dilutive grant has been signed off, as Genflow were running  low on funds, and given the length of time we've waited for approval and the huge deficit turmoil the Belgium/Wallonia Govt. have been under, I had almost written it off, and so great news that Genflow will have no funding concerns for the foreseeable, and no doubt the \u20ac4m gives them much more leverage in any licensing deal discussions from a position of strength.  Transformational and near term game changing potential and prospects for those invested.  Excitement building!!!! :-)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-11T00:11:26.612041+00:00"
      },
      {
        "event_id": "SOCIAL-Today1052-Pie-char--8464323",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.448833",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Mice*",
          "sentiment": 0.0,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-11T00:11:26.612080+00:00"
      },
      {
        "event_id": "SOCIAL-Today1046-Pie-char-47951956",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.449387",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "So far all signs are good. Nice results were good. They also have more than just this programme. Dogs is just one of many.",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-11T00:11:26.612158+00:00"
      },
      {
        "event_id": "SOCIAL-Today1031-mikee_p-20369692",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.449902",
        "source": "LSE_CHAT",
        "data": {
          "author": "mikee_p",
          "content": "Is it low? This is still a risky punt. Dog trials may fail.",
          "sentiment": 0.0,
          "engagement": "1,895",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-11T00:11:26.612197+00:00"
      },
      {
        "event_id": "SOCIAL-Today0853-Pie-char--7790343",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.450425",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Everyone needs to listen to the last 20 seconds of this video. If that\u2019s not bullish I don\u2019t know what is. https://www.proactiveinvestors.co.uk/companies/news/1086390/genflow-ceo-outlines-2026-priorities-as-4-million-grant-is-approved-1086390.html",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F1CBD71F-0291-4489-9B39-85877DA36B7E"
        },
        "ingested_at": "2026-02-11T00:11:26.612235+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261858-jamtart1-28455202",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.450933",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Https://www.tipranks.com/stocks/gb:genf",
          "sentiment": 0.5,
          "engagement": "1,604",
          "price_at_post": "1.90",
          "thread_title": "Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F1CBD71F-0291-4489-9B39-85877DA36B7E"
        },
        "ingested_at": "2026-02-11T00:11:26.612274+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261734-Roosters-92396623",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.451451",
        "source": "LSE_CHAT",
        "data": {
          "author": "Roostersmillions",
          "content": "Thats got to be a misprint. Target of \u00a32 for a 2p share. That would be a buy not a hold. Also when you open the analysts section, they have hold at 2p.",
          "sentiment": 0.5,
          "engagement": "291",
          "price_at_post": "1.90",
          "thread_title": "RE: Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=A70A365B-ED0A-4D60-9FAF-1051143160CA"
        },
        "ingested_at": "2026-02-11T00:11:26.612313+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261723-jamtart1-72767587",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.451956",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Https://www.tipranks.com/news/company-announcements/genflow-secures-e4m-wallonia-funding-and-sets-2026-gene-therapy-priorities#google_vignette Note the \u00a32 price target.",
          "sentiment": 0.5,
          "engagement": "1,604",
          "price_at_post": "1.90",
          "thread_title": "Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=A70A365B-ED0A-4D60-9FAF-1051143160CA"
        },
        "ingested_at": "2026-02-11T00:11:26.612352+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261232-VikR--3882034",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.452496",
        "source": "LSE_CHAT",
        "data": {
          "author": "VikR",
          "content": "I remember just recently when this moved from 0.6p to 2p in the blink of any eyelid. It is a such compelling buy but seems to be off the radar for many investors who don\u2019t understand the opportunity on offer here. This is by far a very confident load and hold Market cap is EXTREMELY low for what\u2019s coming around the corner.",
          "sentiment": 0.5,
          "engagement": "983",
          "price_at_post": "1.90",
          "thread_title": "MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-11T00:11:26.612389+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261145-Moneymun-25096958",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.453330",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Another great interview by Eric on today's news....2026 will be a year of Data and Partnerships, and when making references to the Dog Trial, Eric stated that any partnership would bring in non-dilutive cash to the company, \"and whe talking about non-dilutive cash, I'm not talking about the \u20ac4m non-dilutive grant confirmed today, I'm taking about much more\" !!!! Gla holders, all bodes well, exciting times ahead!!! Initial Efficacy Data from the Dog Trial imminent and every chance of a very lucrative commercial licensing deal to follow!!! :-) Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company\u2019s strategic progress and outlook for 2026, following a \u20ac4 million non-dilutive grant awarded by the Wallonia region. Dr Leire explained that the secured funding is part of Genflow\u2019s broader capital efficiency strategy, helping the company focus on key pipeline catalysts, including its lead gene therapy, GF-1002. GF-1002 is targeted at MASH (Metabolic dysfunction-associated steatohepatitis), a field Dr Leire described as \u201ca huge unmet need,\u201d particularly at the late stage where there are currently no therapeutic options. \u201cThis is one of the key programs for 2026,\u201d he said, highlighting that GF-1002 addresses severe liver conditions, including hepatocellular carcinoma. In addition to its gene therapy program, Genflow is advancing a pioneering longevity study in dogs. Leire stated, \u201cA study on aged dogs, naive to therapies, that's blinded, randomised, so with very strong scientific standard will be a first in terms of longevity.\u201d He emphasised the potential for a commercial deal with animal health companies based on this unique dataset. Partnerships and capital efficiency remain central to Genflow\u2019s plans. Leire noted that monetising non-core programs, such as the dog study, can generate significant non-dilutive capital and allow the company to focus on areas where it adds the most value. Genflow CEO outlines 2026 priorities as \u20ac4 million grant is approved | LSE:GENF, OTCQB:GENFF htTps://share.google/bu0pCWldyc59hIftA",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-02-11T00:11:26.612427+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260802-DaveTK-56285026",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.453982",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Simply amazing. Well done team",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "2.00",
          "thread_title": ".",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=40281A21-EA32-4E4F-A04F-0732B5F85F17"
        },
        "ingested_at": "2026-02-11T00:11:26.612467+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260745-Pie-char--9089997",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.454643",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Amazing. Dog results coming soon. Vet partner deal has never had such high probability! This is a good place to be!",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.95",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-02-11T00:11:26.612505+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260710-Moneymun-54942322",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.455431",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "What a brilliant RNS!!!! Gla holders...in Eric we trust!!! On and most definitely UP!!! :-)))",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.95",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-02-11T00:11:26.612543+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260705-Moneymun-18041951",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.455987",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Glaucoma Programme The Company's glaucoma programme will prioritise delivery optimisation and execution readiness. Genflow is advancing discussions with a leading lipid nanoparticle (LNP) partner to support delivery innovation and is progressing the selection of a full-service contract research organisation (CRO) to manage RNA-based formulation activities through preclinical execution. Additional Programmes Across the broader pipeline, Genflow continues to advance its sarcopenia programme in line with established development plans. In parallel, the ExoFastTrack initiative continues to generate data intended to support and accelerate multiple programmes across the portfolio. Dr. Eric Leire, CEO of Genflow, commented: \"The administrative approval of this funding reinforces our ability to execute against our 2026 development priorities with discipline and focus. It strengthens our capacity to advance GF-1002 while maintaining a selective, data-driven approach across the broader pipeline. As we enter the coming year, our emphasis remains on programmes with clear execution paths, strong scientific rationale, and meaningful opportunities for partnership and non-dilutive value creation.\"",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.95",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-02-11T00:11:26.612581+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260704-Moneymun--8618236",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.456597",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Administrative Approval of Grant & 2026 Priorities GENFLOW BIOSCIENCES PLC Released 07:00:09 28 January 2026 RNS Number : 5966Q Genflow Biosciences PLC 28 January 2026 Genflow Biosciences Plc Administrative Approval of \u20ac4 Million Funding Support from Wallonia Region for GF-100; and 2026 Development Priorities Genflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) (\"Genflow\" or the \"Company\"), a European-based biotechnology company focused on the development of gene therapies for age-related diseases, announces the administrative approval of the previously announced award of approximately \u20ac4 million in non-dilutive financial support from the Wallonia Region of Belgium, following the assenting signature of Minister Adrien Dolimont. The funding, once received, will support the continued development of the Company's lead gene therapy candidate, GF-1002, for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (\"MASH\"). The original RNS announcing the award can be found here. Disbursement of the first instalment is expected no later than May 2026. The support package spans a three-year development programme and is aligned with Genflow's existing roadmap. All project-related expenses incurred during 2025 will be eligible under the terms of the programme. Development Priorities for 2026 In 2026 Genflow's strategy emphasises pipeline discipline and capital efficiency, prioritising programmes with the strongest data, the clearest paths to value creation, and the highest potential for partner engagement. Central to this approach is the pursuit of early-stage collaboration agreements designed to secure non-dilutive funding, provide external validation of the platform, and support continued development. With multiple anticipated data readouts, an expanding partner dialogue, and a maturing intellectual property position, Genflow believes it is well positioned to enter its next phase of development while maintaining a focus on scientific rigour, operational execution, and long-term shareholder value creation. Dog Aging (GF-1004) The ongoing GF-1004 dog aging study, which commenced in March 2025, is being conducted as a blinded clinical trial designed to assess potential benefits related to sarcopenia, healthspan, and lifespan-associated biomarkers. An initial efficacy readout is expected in the first quarter of 2026. Dogs enrolled in the study are being monitored over a 180-day period, with a second efficacy assessment planned at the six-month timepoint. Results from this later evaluation are expected in June-July 2026 and are intended to assess durability and longer-term effects. Glaucoma Programme The Company's glaucoma programme will prioritise delivery optimisation and execution readiness. Genflow is advancing discussions with a leading lipid nanoparticle (LNP) partner to support delivery innovation and is progressing the selection of a full-service contract research organisatio",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.95",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-02-11T00:11:26.612619+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260808-Moneymun--4833457",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.457120",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "8/1/26 Leire explained that the dog longevity study is the nearest catalyst, with the trial expected to be unblinded shortly and early efficacy readouts anticipated in the near term. While safety has already been confirmed, the study remains blinded, meaning efficacy results are still unknown. The first data will focus on biological age, measured using a methylation clock, with a more detailed analysis of muscle biopsies and mitochondrial function to follow. According to Leire, \u201cthis trial could be very important for our shareholders, because it will trigger a deal with an animal health company bringing non-dilutive money in the company.\u201d",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.95",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-11T00:11:26.612657+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260707-Pie-char--5108188",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.457619",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Dog results are due next week. Vet partner(s) already likely lined up.",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.95",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-11T00:11:26.612695+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20262041-Moneymun--9031706",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.458133",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The trial aims to demonstrate proof of concept in dogs, replicating promising results previously seen in mice. \u201cIt worked like magic in mice. We reasonably think that it will work likewise in dogs,\u201d Leire stated. Unlike mice, however, dogs share environmental conditions with humans, making them a more relevant model for translation into human therapies.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-11T00:11:26.612734+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260818-Roosters-29815715",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.337719",
        "source": "LSE_CHAT",
        "data": {
          "author": "Roostersmillions",
          "content": "Markets reacting munch. Nice jump this AM. hope it holds. Maybe new private investors from across the pond due to conference exposure??",
          "sentiment": 0.5,
          "engagement": "291",
          "price_at_post": "2.00",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-02-11T00:11:26.612773+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260815-Moneymun--1110185",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.338198",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Game changing news at anytime. In Eric we trust!!! Gla holders...On and UP!!! :-)))",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "2.00",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-02-11T00:11:26.612811+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260812-Moneymun--6424757",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.338634",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions Madrigal\u2019s strategy of pursuing combination therapies while the market remains in its infancy could intrinsically link its brand to MASH treatment. Madrigal Pharmaceuticals used its January 12 presentation at the J.P. Morgan Healthcare Conference 2026 to showcase its newly acquired assets from Pfizer \u2013 ervogastat and two preclinical assets \u2013 as well as outline its vision for dominance in metabolic dysfunction-associated steatohepatitis (MASH) treatment space through leveraging early commercial success. Its professed strategy of pursuing combination therapies while the market remains in its infancy could well result in Madrigal\u2019s brand becoming intrinsically linked to MASH treatment. JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions - Pharmaceutical Technology https://share.google/Ymb4cXndGee7eMEbD",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "2.00",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-02-11T00:11:26.612849+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261725-Steg-48971288",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.339084",
        "source": "LSE_CHAT",
        "data": {
          "author": "Steg",
          "content": "Thought below was interesting, yes they are attending conference and have already made move to add to thier MASH portfolio, courtesy of AI search below Yes, Madrigal Pharmaceuticals is actively looking to expand its MASH (metabolic dysfunction-associated steatohepatitis) portfolio beyond its already approved drug, Rezdiffra (resmetirom). Madrigal's expansion strategy focuses on developing potential combination therapies, as MASH is a complex disease that requires multiple treatment approaches. Key components of their expanded pipeline include: Ervogastat: In January 2026, Madrigal entered into an exclusive global license agreement with Pfizer to acquire ervogastat, a Phase 2 oral DGAT-2 inhibitor. This drug works on a different, complementary pathway to Rezdiffra, and Madrigal plans to conduct studies to test the two treatments in combination. Oral GLP-1 Receptor Agonist: Madrigal also holds worldwide rights to an oral GLP-1 agonist called SYH2086, licensed from CSPC Pharmaceutical, with the goal of creating a best-in-class oral combination therapy. Additional Early-Stage Assets: The agreement with Pfizer for ervogastat also included rights to two other early-stage MASH pipeline assets. Madrigal's CEO, Bill Sibold, has stated that the company is committed to \"building the industry-leading pipeline that will shape the future of MASH care\" and believes combination therapies are the next wave of innovation in the field.",
          "sentiment": 0.0,
          "engagement": "5",
          "price_at_post": "1.90",
          "thread_title": "JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-02-11T00:11:26.612887+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261231-Moneymun--6581525",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.339515",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Get UP there!!! Gla :-) Eric and his team are now at the prestigious JP Healthcare Conference, pressing flesh with the leading industry deal makers. He appeared confident and enthusiastic in his latest interview, highlighting the prospects and potential of an early lucrative JV deal for the Dog Trial, Glaucoma and Mash and so potential game changing transformational news could drop at anytime. The first efficacy readout on the Dog Trial is imminent, and with two Animal Healthcare companies both with Confidential Disclosure Agreements in place, Eric could be very close to a deal, and the same with Glaucoma, whereby a leading Ophthalmology Company signed a Material Transfer Agreement 10 months ago. Eric also highlighted the prospects of Genflow's Sirt6 Mash Gene Therapy, which is now targeting the later stages of the disease where there's no options apart from transplant, and was very interesting to hear from Eric it could be used in combination with GLP-1's and Madrigal's early stage treatment which was FDA approved 12 months or so ago. Madrigal are presenting at JP Morgan and are on a mission to expand their pipeline for Mash, so watch this space. It's also very interesting we have a new Chairman in place, GAD BERDUGO a high flyer based in the US in Global Biotech, Corporate Development and and US Capital Markets and so no doubt very well contected to any potential suitors. Excitement building!!!! In Eric we trust!!! Gla holders:-)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "2.00",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-11T00:11:26.612925+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260822-Moneymun-58412912",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.339958",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Healthcare companies set for deals spree as drug patents expire A gathering of pharmaceutical executives comes as the sector has rebounded from uncertainty over Trump\u2019s policies Healthcare executives gather for their big annual conference in San Francisco on Monday as the sector is flush with cash and set for a deals spree as patents on drugs worth almost 12 per cent of the industry\u2019s revenues expire in the years ahead. The JPMorgan healthcare conference takes place as uncertainty recedes over President Donald Trump\u2019s trade wars, drug pricing policy and the leadership of key regulators such as the US Food and Drug Administration. In response, the S&P biotech index, known as the XBI, has surged to a four-year high, outperforming the wider index. In addition, drugs that contribute about $180bn of revenue a year are set to go off patent in 2027 and 2028, representing almost 12 per cent of the global market, according to research firm Evaluate Pharma. More than $40bn of sales are expected to lose patent protection this year, Evaluate has estimated. \u201cThe need to take big swings becomes more pressing,\u201d said Jeremy Meilman, head of healthcare investment banking at JPMorgan. \u201cSeveral of the large-cap pharmaceutical companies are shopping around for strong assets and a number have taken action but still have more firepower. This contributes to our optimism for 2026.\u201d hTtps://www.ft.com/content/7b07a9d5-7254-490b-8ce9-ec2633094d8e",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.825",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-11T00:11:26.612963+00:00"
      },
      {
        "event_id": "SOCIAL-11Jan20261442-Moneymun--2350542",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.340418",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Planned meetings presumably with potential suitors at JP Morgan this coming week and so multiple deal opportunities across the platform, and there's currently an M&A and lucrative licensing deal feeding frenzy as Major Pharma replenish their pipelines with the latest cutting-edge science, Excitement building!!! Gla :-) \"2026 will be catalyst year, we've done our work and now it's time for harvesting and are going to JP Morgan next week with a full appointments book, and now ready for potential harvesting of our results to bring in non-dilutive cash into the company.\" A must watch....Gla holders:-) hTtps://www.proactiveinvestors.co.uk/companies/news/1085366/genflow-biosciences-ceo-key-catalysts-for-2026-1085366.html",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.825",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-11T00:11:26.613001+00:00"
      },
      {
        "event_id": "SOCIAL-10Jan20261752-Troajan--7787031",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.836007",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1085424/genflow-is-ready-for-a-year-of-catalysts-icymi-1085424.html",
          "sentiment": 0.0,
          "engagement": "125,652",
          "price_at_post": "1.825",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-11T00:11:26.613040+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20262001-Moneymun-72102198",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.836711",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 10:30 a.m. PT. Investors and other interested parties can access a live audio webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event. About Zoetis As the world\u2019s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide \u2013 from veterinarians and pet owners to livestock producers. The company\u2019s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees. For more information, visit www.zoetis.com.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-11T00:11:26.613078+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261946-Moneymun-23734255",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.837364",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Woof, woof!!!??? ;-) Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference 06 January 2026 INDIANAPOLIS, Jan. 6, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will represent the company and respond to questions from analysts at 3:45 p.m. PST (6:45 PM EST).",
          "sentiment": 0.0,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-11T00:11:26.613126+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261920-Moneymun--6247529",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.837980",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "And/or ???? ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 4:30 p.m. PT in San Francisco, CA.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-11T00:11:26.613164+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261917-Moneymun-18937558",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.838626",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Eye wonder....Gla:-) 23/12/2025 - 12:30 VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders, Executive Vice President and Chief Financial Officer Sam Eldessouky and Chief Medical Officer and Head of Research & Development Yehia Hashad, MD, will participate in a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026, at 1:30 p.m. PT (4:30 p.m. ET) Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-11T00:11:26.613201+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261858-Moneymun--3820590",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.839276",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Another brilliant interview by Eric, \"2026 will be catalyst year, they've done their work and now it's time for harvesting and are going to JP Morgan next week with a full appointments book, and now ready for potential harvesting of their results to bring in non-dilutive funding cash into the company. Excitement building, in Eric we trust!!! Gla ;-) Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company\u2019s key programs and upcoming catalysts as it enters what management expects to be a pivotal year. Leire discussed why 2026 is shaping up as \u201ca year of catalysts\u201d for the company, with particular focus on the dog ageing trial, progress in MASH, and the group\u2019s approach to partnerships and licensing. Leire explained that the dog longevity study is the nearest catalyst, with the trial expected to be unblinded shortly and early efficacy readouts anticipated in the near term. While safety has already been confirmed, the study remains blinded, meaning efficacy results are still unknown. The first data will focus on biological age, measured using a methylation clock, with a more detailed analysis of muscle biopsies and mitochondrial function to follow. According to Leire, \u201cthis trial could be very important for our shareholders, because it will trigger a deal with an animal health company bringing non-dilutive money in the company.\u201d The interview also explored Genflow\u2019s repositioning in MASH toward advanced fibrosis and the prevention of hepatocellular carcinoma. Leire highlighted the significant unmet need in late-stage disease, noting that recent therapies target earlier stages and leave patients with advanced fibrosis facing limited options. He said the company\u2019s preclinical data have been encouraging and form a key part of the IND package, helping differentiate Genflow from existing and emerging treatments. In addition, Leire discussed the company\u2019s licensing strategy, including plans to out-license the dog program to an animal health specialist and pursue early-stage partnerships for glaucoma, while retaining focus on age-related conditions such as sarcopenia. With meetings planned during JPMorgan week, Leire said the company is seeking non-dilutive capital and strategic validation as it moves forward.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-11T00:11:26.613239+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261711-Troajan--8652605",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.839905",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1085366/genflow-biosciences-ceo-key-catalysts-for-2026-1085366.html",
          "sentiment": 0.0,
          "engagement": "125,652",
          "price_at_post": "1.75",
          "thread_title": "Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-11T00:11:26.613278+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261314-Moneymun--5994497",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.840622",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "0 0 Gene therapy biotech Genflow eyes busy year ahead as dog ageing trial nears results Published: 02:40 08 Jan 2026 Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) has wrapped up 2025 with steady progress across a range of gene therapy programmes, including a closely watched trial into dog ageing that could lay the groundwork for future human applications. The London-listed company, which is working on ways to extend healthy lifespan using gene therapy, said it had completed dosing in its lead canine study with no reported side effects. The dogs will now be monitored over six months for signs of improved muscle strength and health-related biomarkers, with initial results expected in the first quarter of this year. The trial, which began in March and uses a therapy based on the SIRT6 gene, a known regulator of ageing and DNA repair, is being conducted in a blinded format. A follow-up analysis is due around mid-year to assess the durability of the effects. Alongside the dog ageing study, Genflow said it had made progress in a programme targeting advanced stages of MASH, or metabolic dysfunction-associated steatohepatitis, a type of fatty liver disease. Existing GLP-1 drugs such as Ozempic and Wegovy have shown benefits in early MASH, but Genflow is aiming at patients with more severe fibrosis, where options remain limited. It is now finalising regulatory paperwork to support a human trial and is exploring the use of mRNA technology, similar to that used in Covid-19 vaccines, as a more flexible and cost-effective delivery method than traditional viral vectors. In a new push into eye disease, the company is also investigating the use of its gene therapy platform in glaucoma. Early lab results suggest that increasing SIRT6 levels may help protect the optic nerve from damage, potentially offering a way to slow or prevent vision loss rather than simply reducing eye pressure, which is the current standard treatment. Genflow said it was in talks with a lipid nanoparticle delivery partner to support this programme and was hiring a specialist contract research firm to help move the candidate towards preclinical testing. Elsewhere in its pipeline, work is ongoing in sarcopenia, the loss of muscle mass that often accompanies ageing, and in a broader initiative called ExoFastTrack, which supports several of its research efforts. Looking to the year ahead, Genflow said it would focus its efforts on the most promising areas of its portfolio and seek early licensing or partnership deals to bring in fresh funds without issuing new shares. \u201cWith multiple upcoming data readouts, an expanding partner network, and a maturing intellectual property position, we believe Genflow is well positioned to enter its next phase of growth,\u201d the company said. The first set of clinical results, particularly from the dog study, will be key in setting the tone for 2026.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-11T00:11:26.613316+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261148-Moneymun--8849532",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.841406",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Nice one David, looking forward to a run of great news from Eric to take the sp to new highs. Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.85",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-11T00:11:26.613355+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-David195-54459024",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.842237",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "Thank you for your informed views.  Added 500k @1.78.  It is hard for companies in this sector to raise funds so hopefully the upcoming changes will make the situation less brutal.  I will add when funds allow.",
          "sentiment": 0.0,
          "engagement": "871",
          "price_at_post": "1.85",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-11T00:11:26.613394+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261005-Moneymun--6261943",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.843028",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Hopefully news on patents soon Porter, the following statement is from yesterday's 2026 Corporate Presentation.  Gl :-) GROWING IP PORTFOLIO WITH LONG LIFE 2 proprietary patent families SIRT6 centenarian (cent SIRT6) and gene delivery (entering National Phase); Additional upcoming patent applications (entering PCT)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-11T00:11:26.613432+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260933-Moneymun--5603155",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.843890",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Bring it on!!! Gla holders:-) \"Central to this strategy will be the pursuit of early-stage licensing and collaboration agreements designed to generate non-dilutive funding, validate our platform externally, and support continued development without undue capital strain.\" .... Dr. Eric Leire, CEO of Genflow, commented: \"We're excited to attend the JP Morgan Healthcare Conference in San Francisco this January. Our planned meetings reflect our current focus on lipid nanoparticle delivery for mRNA SIRT6 therapeutics, which is opening compelling opportunities for strategic partnerships in the longevity space.\"",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=1999E606-84A4-47B8-B880-E68E1912F065"
        },
        "ingested_at": "2026-02-11T00:11:26.613470+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260928-Moneymun--6797646",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.844766",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Outstanding non-dilutive grant funding could land at anytime, although a lucrative JV licensing deal could also land at anytime and so let's see what transpires at next weeks the prestigious JP Healthcare Conference next week, where Genflow have planned meetings, presumably with potential suitors and every chance Eric will have initial efficacy data from the Dog Trial and maybe and maybe positive Data with their Ophthalmology partner for Glaucoma to present and so confirmation of a commercial deal or two would be transformational for all invested and any funding concerns would be assigned to history.  Gla holders....Excitement building!!! :-) Ps if Genflow need to raise cash because of the delay in receipt of the \u20ac4m outstanding non-dilutive grant funding, then raising cash from 16th January is going to become easier, cheaper and less dilutive.  :-) The new Financial Conduct Authority (FCA) regulations are designed to facilitate less discounted fundraising for small caps by reducing the regulatory burden and increasing the threshold for requiring a full prospectus, thus making secondary capital raising faster and cheaper. Key changes, effective from January 19, 2026 (with some listing rule changes effective from July 29, 2024), aim to attract more companies to list and grow in the UK. Key Regulatory Changes and Their Impact on Small Cap Fundraising The FCA's reforms introduce several key changes that support more efficient and potentially less discounted fundraising for smaller listed companies: Increased Prospectus Threshold The most significant change for secondary fundraising is that a full prospectus is now only required if a company issues shares amounting to 75% or more of its existing share capital, a substantial increase from the previous 20% threshold. This allows companies, particularly smaller ones, to raise further capital more quickly and at a lower cost without the time and expense associated with a full prospectus, which should reduce the need for heavily discounted placings.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=1999E606-84A4-47B8-B880-E68E1912F065"
        },
        "ingested_at": "2026-02-11T00:11:26.613509+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260854-David195--3802799",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.845590",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "I hold shares and the potential is significant. However I am reluctant to add when the funding position is unclear.  Grants could be material amounts if and when received but there is a risk of a diluted fund raise to progress the numerous programmes in 2026.  I have suffered this is other small biotechs like FAB and Apta where the state of the capital markets are very harsh and unsupportive. I tried to analyse the cash runway and it seems more funds will be needed in H1 if the grants are not received.  Is there any indication of the timing?",
          "sentiment": 0.0,
          "engagement": "871",
          "price_at_post": "1.90",
          "thread_title": "Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=1999E606-84A4-47B8-B880-E68E1912F065"
        },
        "ingested_at": "2026-02-11T00:11:26.613546+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260805-Porter_-14269498",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.846399",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Thanks for sharing money. I notice the RNS is in American English, perhaps to appeal to US investors and big US pharma? No mention of the patents in the update which were instrumental in offering assurance to investors regarding patent protection, but hopefully we\u2019ll receive updates in due course separately.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.825",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-11T00:11:26.613584+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260703-Moneymun--4453219",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.847249",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "We are advancing discussions with a leading LNP partner to support delivery innovation in this space and are securing a full-service CRO to manage formulation through preclinical execution. With the global glaucoma market approaching USD $12-14 billion by the early 2030s, this represents a compelling long-term opportunity for us. \u00b7 Additional Programs We continued to advance our broader pipeline and are pleased with the steady advancement of the sarcopenia program, fully consistent with our development plans. In parallel, the ExoFastTrack initiative continues to move forward, generating important data that will support and accelerate several of our other development programs. Looking Ahead to 2026 As we move into 2026, we do so with confidence, discipline, and a clear strategic focus. The coming year will emphasize rationalization of our pipeline, prioritizing programs with the strongest data, clearest paths to value creation, and highest partner interest. Central to this strategy will be the pursuit of early-stage licensing and collaboration agreements designed to generate non-dilutive funding, validate our platform externally, and support continued development without undue capital strain. With multiple upcoming data readouts, an expanding partner network, and a maturing intellectual property position, we believe Genflow is well positioned to enter its next phase of growth. We remain committed to scientific excellence, capital efficiency, and long-term value creation as we work to translate our longevity platform into meaningful therapies. Thank you for your continued support and confidence in Genflow.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-11T00:11:26.613622+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260702-Moneymun-30851505",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.848143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "08 January 2026 A Review of an Exciting 2025 2025 has been a year of focused scientific progress and continued advancement of Genflow Bioscience's mission to extend healthy lifespan through our novel longevity gene therapy platform. Across our portfolio, we have maintained momentum in both animal health where progress in our canine study may provide translational insights relevant to future human applications as well as therapeutic development for dogs. These advancements have been supported by a strengthened network of leading academic collaborators and laboratories. Together, with continued backing from international institutional investors and previously awarded government grants, this ecosystem helped accelerate Genflow's scientific and clinical development throughout 2025. Program Highlights We've made a number of notable strides across our programs this year, including: \u00b7      Dog Aging (GF-1004) We made significant strides in our clinical trial for aging dogs with full administration of our investigational SIRT6-based gene therapy now completed. No adverse events were reported during the dosing phase of the study, with no serious, moderate, or minor side effects observed. The study which began in March 2025, is being conducted as a blinded clinical trial; an initial efficacy readout is expected in Q1 2026, including blood analyses and muscle biopsies to evaluate potential benefits related to sarcopenia, healthspan, and lifespan-associated biomarkers. Dogs enrolled in the trial will be monitored for 180 days, with a second efficacy assessment planned at the six-month timepoint and results expected in June-July 2026 to evaluate durability and longer-term effects. \u00b7      MASH (GF-1002) Our MASH program saw good progress in 2025. While GLP-1 therapies have addressed early-stage MASH, patients with advanced fibrosis - roughly one-third of the population - still face limited treatment options. In response, we repositioned GF-1002 to target this high-need group, leveraging its antifibrotic properties and potential to prevent progression to cirrhosis and liver cancer. Additionally, we have generated new pre-clinical POC data on the prevention of HCC. We are now finalizing our IND package and evaluating mRNA/LNP delivery as an alternative to AAV, an approach that could enable repeat dosing and lower manufacturing costs. Encouraging data continue to support this next phase of research and development. \u00b7      Glaucoma In 2025, we expanded into ophthalmology, where SIRT6-based gene therapy shows promise in glaucoma, a leading cause of irreversible blindness. Current treatments primarily manage intraocular pressure but do little to prevent optic nerve degeneration. Our preclinical data suggest SIRT6 overexpression may protect retinal ganglion cells and preserve optic nerve function, shifting the focus from symptom control to true neuroprotection.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-11T00:11:26.613661+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261804-Moneymun-26936925",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.848904",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Well connected in the US to take Genflow to the next level. ;-)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-11T00:11:26.613699+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261802-Moneymun--9016265",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.849701",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Hi Porter, it's from the 2026 Corporate Presentation which was published via Genflow's LinkedIn post a few hours ago. Gl :-) Ps the new Chair appears to be well connected on the US. https://loom.ly/RsxnFCE",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-11T00:11:26.613736+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261732-Porter_-90683107",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.850478",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Thanks for sharing money. I haven\u2019t seen any news regarding a new Chair. Where did you manage to grab that info from? Can you please share the link if you have one? \ud83e\udd70",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-11T00:11:26.613774+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261627-Moneymun--7696296",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.851283",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Gad Berdugo Gad Berdugo, MSc. Eng., MBA Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a strategic and financial advisory firm focusing on the global biotechnology sector. He currently serves as Vice Chairman of the Board of Directors of clinical development stage precision oncology company, Diaccurate. Mr. Berdugo brings over 35 years of biotech corporate & business development, strategy, operational, financial, investment and general venture management experience. He served as CBO at CRISPR gene editing pioneer Editas (Nasdaq EDIT); Co-founder and CEO at personalized neoantigen cancer vaccine venture, EpiVax Oncology Inc.; CFO and EVP at Immune Pharmaceuticals Inc. (Nasdaq IMNP); Managing Director and Head of Life Sciences at Tegris Advisors, a strategic and financial advisory boutique; Founder and Managing Partner of the Explorium Global Life Sciences Investment Fund; Director, Senior Equity Research Analyst and Life Sciences Sector Leader at Lazard, Asset Management Group. Prior to that, he served as a Director of Global Business Development within Baxter\u2019s Biopharmaceuticals group and started his career at Abbott Labs. Mr. Berdugo received his B.Sc. with Honors in Biotechnology from Imperial College London, his M.Sc. in Biochemical Engineering from University College London and his M.B.A. from H.E.C. Paris. He serves on the Board of Directors of Friends of H.E.C. Inc. and Friends of U.C.L. Inc. Mr. Berdugo is bilingual in French and English and has dual US and French citizenships. He resides with his wife in New York City.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-11T00:11:26.613812+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261606-Moneymun--1732337",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.852108",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Looks like we've got a new Chairperson!!!??? Gla ;-) GAD BERDUGO Chairperson \u2022 30+ years of leadership across global biotech, corporate development, and U.S. capital markets \u2022 Proven record in strategic partnerships, capital raising, and scaling private and public biotech companies \u2022 Managing Partner, Explorium Capital; former Co-Founder & CEO of EpiVax Oncology and Chief Business Officer at Editas Medicine and Nutcracker Therapeutics",
          "sentiment": 0.0,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-11T00:11:26.613850+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261602-Moneymun-29415722",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.852899",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Undervalued stock opportunity; Potential acquisition by pharmaceutical partner GF-1004: Pet life extension / sarcopenia Initiated discussion under CDA with several animal health companies hTtps://loom.ly/RsxnFCE",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-11T00:11:26.613888+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261601-Moneymun--8999007",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.854072",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The Gap No approved neuroprotective therapies The mRNA Opportunity - Wide Open LNP targeted delivery to retina \u2013 now possible NO APPROVED OR CLINICAL-STAGE MRNA THERAPIES FOR GLAUCOMA PARTNERING WITH LNP PROVIDER Paradigm shift to retinal protection \u2022 Pre-clinical evidence links SIRT6 activity with RGC protection in glaucoma/optic neuropathy models \u2022 Demonstrating RGC rescue and preserved function would be a strong disease-modifying signal Delivery is now tractable \u2022 Targeted LNP (tLNP) platforms are removing a major historical barrier for in vivo RNA therapeutics to reach retina/RGCs Clear decision point A single well-designed rodent POC that shows \u2022 focal RGC expression of SIRT6 cent \u2022 preserved RGC counts and \u2022 preserved RGC function with acceptable ocular safety, gives a clean go/no-go for IND enabling work AGED DOGS COMPARATIVE TRIAL Proof-of-Concept comparative clinical trial of in-vivo naked DNA gene therapy in aged dogs Conducted at Syngene's strategic partner site in Morocco, AAALAC and GLP certified 26 (24+2) aged Beagles dogs (age>10 years) Group 1 (n=6): untreated Group 2 (n=6): treated with gene therapy IV bolus of SIRT6 AAV Group 3 (n=6): treated with gene therapy IV infusion of naked DNA (low dose) Group 4 (n=6): treated with gene therapy IV infusion of naked DNA (high dose) Blinded: first read-out in January 2026 \u2022 Treatment period: 180 days with follow-up period: 90 days \u2022 Gene therapy has been administered to all dogs with demonstrated excellent safety profile Endpoints \u2022 Pan-mammalian methylation clock (Steve Horvath), \u2022 sarcopenia (including muscle biopsies) and other markers of aging MASH PROGRAM Affects est. 35 million people globally \u2022 Increasing prevalence \u2022 Leading cause of chronic liver disease and liver transplant Significant unmet medical need Clear regulatory accelerated development pathway. EMA and FDA guidelines accept: \u2713 Key surrogate outcomes for therapeutic trials: regression of fibrosis or resolution of NASH \u2713 Histological changes are achievable within a 12-18-month time-frame \u2713 Placebo control \u2713 Conditional fast-track approval 2025 KEY HIGHLIGHTS LARGE AND EXPANDING MARKET OPPORTUNITY MASH: 35 Million globally. Increasing prevalence. Door opener to even broader anti-aging indication Awarded to new grants in 2024 expanding research pipeline Ophthalmology: retina preservation GROWING IP PORTFOLIO WITH LONG LIFE 2 proprietary patent families SIRT6 centenarian (cent SIRT6) and gene delivery (entering National Phase); Additional upcoming patent applications (entering PCT) MRNA/LNP GENE DELIVERY SYSTEMS Innovative gene delivery systems: targeted LNPs delivering cent SIRT6 mRNA GF-1002 Multiple key clinical and regulatory milestones expected in next 18 months; Undervalued stock opportunity; Potential acquisition by pharmaceutical partner GF-1004: Pet",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-11T00:11:26.613925+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261559-Moneymun--5842466",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.855051",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "WHO WE ARE Pioneering Novel Gene Therapeutics for a Longer, Healthier Life MISSION: aging is underlying risk factor for disease, and our aim is to deliver gene therapeutics that potentially halt or slow the aging process in humans and dogs CENTENARIAN SIRT6 (cent SIRT6) GENE: proprietary variant of longevity gene that widely regulates aging and immunity and is a potential therapeutic target for the treatment of diseases PROMISING PRECLINICAL RESULTS: lead drug candidate GF-1002 delivers a centenarian variant of the SIRT6 gene (cent SIRT6) for treatment of MASH SEASONED TEAM: experienced and proven management with extensive experience in public & private pharma and biotech ROBUST PIPELINE: advancing multiple development programs over 24 months: MASH, Glaucoma, Sarcopenia, Werner and life extension of dogs DEVELOPMENT PIPELINE GF-1002 (Pre-Clinical) AAV8 cent SIRT6 vector for intravenous infusion, expressing cDNA of centenarian variant of SIRT6(cent SIRT6) in liver GF-1003 (Pre-Clinical/Development) Suspension of exosomes, loaded with mRNA of centenarian variant of SIRT6(cent SIRT6) in fibroblasts GF-1004 (Clinical Proof of Concept) cent SIRT6 for intravenous infusion for life extension and prevention of age-related diseases GF-1005 (Pre-Clinical/Development) Mitochondrial disfunction: Myoblast progenitors loaded by photoporation with cent SIRT6 GF-1006 Ophthalmology (pre-clinical) mRNA cent SIRT6 delivered by LNP for the treatment of cornea pathologies and glaucoma OPHTHALMOLOGY PLATFORM New Ophthalmology Program: Initiated development of a novel gene therapy targeting ocular diseases, including corneal pathologies and glaucoma, using Genflow\u2019s proprietary Centenarian SIRT6 (cent SIRT6). Precision Delivery Platform: Employing a specially engineered non-viral vector for targeted SIRT6 delivery to the eye. Strategic Partnership: Signed a Material Transfer Agreement in April 2025 with a leading ophthalmology company to co-develop the cent SIRT6 therapy and delivery system. LEVERAGING AI FOR GENOMICS New AI Partnership: Signed Master Service Agreement in April 2025 with Heureuka Labs, a spin-out of Duke University, to use their proprietary AI platform to analyze complex genomic data, including RNA sequencing and gene expression profiles. Enhancing Therapeutic Insights: Expected to drive a deeper understanding of gene regulatory networks and biological responses to optimize therapy design and personalize outcomes. Pipeline Advancement: Initially supporting GF-1002 (cent SIRT6-based gene therapy in preclinical development) and future programs, including candidates for MASH. GLAUCOMA RGC NEUROPROTECTION: THE RACE IS ON The Problem 80M people worldwide with glaucoma; leading cause of irreversible blindness Current treatments only lower IOP- they don't protect retinal ganglion cells (RGCs) RGC death is irreversible; unmet need for neuroprotection Significant market opportunity The Gap",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-11T00:11:26.613963+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261913-Persever-17647094",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.702321",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "These unknowns are off book pre negotiated buys. Sp will remain pinned till.Dog efficacy data. Expected solid data.",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-11T00:11:26.614003+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261838-Dzygit19-26164561",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.702759",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dzygit1980",
          "content": "12:45 yesterday was 1.97 to sell small amout . Than yesterday's big trade printed today for 1.81 ,straight after 1.97 To buy share so I am not sure \ud83e\udd14 was 12:45 yesterday tradet  buy  to me it looks like sell. Also we are dropping",
          "sentiment": 0.0,
          "engagement": "255",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-11T00:11:26.614041+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261822-Persever--1996055",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.703192",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "Big buys more like it. Do you know trading? \ud83d\ude05",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-11T00:11:26.614081+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261753-Dzygit19--4025484",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.703612",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dzygit1980",
          "content": "Lots of big sales last couple of days",
          "sentiment": 0.0,
          "engagement": "255",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-11T00:11:26.614131+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261756-Persever-21418548",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.704022",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "I think a massive rerate is coming ? Somethings brewing ?",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "1.90",
          "thread_title": "Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-11T00:11:26.614169+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260719-Porter_--2629943",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.704447",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Know a few people who didn\u2019t get their orders filled yesterday. Seems there isn\u2019t much in the free-float so let\u2019s see how tight this coiled spring is!",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-11T00:11:26.614208+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20262217-Twocd2-55248142",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.704869",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "I joined pre IPO, \u00a350 may have been too much of a reach for you\u2026chortle chortle TK Max.. Give Porter a reach around before lights out so that he\u2019ll not be to disappointed with no RNS tomorrow morning\u2026\ud83d\udc4c",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-11T00:11:26.614247+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261352-DaveTK-31234393",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.705301",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "I joined the party pre IPO. TBF they were asking for more than \u00a350 so it may have been too much of a reach for you. Talking about choppers FFS. Don't let you mum read that or she'll take your phone off you and cancel your contract.",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-11T00:11:26.614285+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261342-Twocd2--1766454",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.705721",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "So TK Max joins the party\u2026think you and Porter need to take turns and time to give him a chance to be big spoon for this week. Might give him something else to do rather than practice his typing. Plenty of skin in the game lads\u2026but this is not about who\u2019s chopper is bigger..well maybe for the spooning it does\ud83d\ude01",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-11T00:11:26.614321+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261033-DaveTK-27086452",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.706162",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Always. I'm here and always have been here waiting for news that we have been bought out. It was always the goal from Eric to make this company into something a pharmaceutical would buy a high price. We may not be that far off. Fingers crossed. Thanks",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-11T00:11:26.614359+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261027-Porter_-57988254",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.706587",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Always the ones who sold too soon quick to troll those who held with diamond hands Dave. Expecting this is just the first update of many we\u2019ll be seeing over the next 2 weeks. Popcorn ready! \ud83c\udf7f",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-11T00:11:26.614397+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261005-DaveTK-62489018",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.707009",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Would seem like you touched  nerve there, Porter ha ha. Nice RNS this morning. Looking forward to hearing more regarding the J.P. Morgan's Healthcare Conference. Really does seem like exciting times ahead. Thanks",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-11T00:11:26.614435+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260839-Twocd2-83243555",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.707434",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "Ok big fella..time for nap your banter is honking.",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-11T00:11:26.614473+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260820-Moneymun-37319294",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.707847",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The new Chairman in place, GAD BERDUGO is a high flyer based in the US with a wealth of experience in Global Biotech, Corporate Development and US Capital Markets and so no doubt very well contected to any potential suitors. Excitement building!!!! In Eric we trust!!! Gla holders:-) Ps initial Efficacy readout on the Dog Trial imminent!!! Gla ;-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-11T00:11:26.614510+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260752-Porter_--2460906",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.708264",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "2cd2 - invest more than \u00a3100 in a company and you might care a little bit more for your investments \ud83d\ude18",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-11T00:11:26.614549+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260734-Twocd2-54518219",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.708668",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "Take the rest of the day off Porter..great job pal! You must have set the alarm early to C&P all of that \ud83d\udc4f\ud83d\udc4f\ud83d\udc4c",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-11T00:11:26.614587+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260718-Porter_--1061256",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.709143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Genflow Appoints a New Chairman to Accelerate Corporate and R&D Expansion Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or the \"Company\"), a leading European-based biotechnology company focusing on gene therapies for age-related diseases, is pleased to announce a significant appointment to its Board of Directors, marking an important step in the Company's strategic evolution. Mr. Gad Berdugo, MSc Eng., MBA, has joined the Board with immediate effect and will assume the role of Independent Non-Executive Chairman, providing leadership as Genflow focuses on advancing its gene-therapy programs. Mrs. Tamara Joseph will continue to serve as a Director, ensuring continuity and maintaining strong governance. Mr. Berdugo brings over 30 years' of leadership experience spanning global business and corporate development, U.S. capital markets, and company building. He has a proven record of driving strategic partnerships, securing capital, and scaling both private and public development-stage biotechnology companies. Currently, Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a U.S.-based strategic and financial advisory firm focusing on the global biotechnology sector. His most recent roles include: \u00b7 Co-Founder & CEO, EpiVax Oncology \u00b7 Vice-Chairman of the Board, Evexta Bio \u00b7 Chief Business Officer, Editas Medicine (NASDAQ: EDIT) \u00b7 Chief Business Officer, Nutcracker Therapeutics He began his international career at Abbott Labs and Baxter, later becoming Life Sciences Sector Leader at Lazard Asset Management. Mr. Berdugo also brings deep technical and market expertise in RNA-based therapeutics, including lipid nanoparticle (LNP) delivery, development, and manufacturing. This background will support Genflow as it advances its scientific platform, evaluates delivery technologies, and explores next-generation therapeutic approaches. His appointment further strengthens the Company's presence in the United States and expands its capacity for global engagement. He does not own any shares in the Company. Dr. Eric Leire, Chief Executive Officer of Genflow, commented: \"We are delighted to welcome Mr. Berdugo as Independent Non-Executive Chairman. His expertise in strategy, partnerships and financing as well as his deep experience with RNA-LNP technologies will be instrumental as we accelerate our programs and expand our global reach. We are equally pleased that Mrs. Tamara Joseph will continue her service on the Board, contributing her invaluable leadership, legal and governance expertise.\" Gad Berdugo added: \"I am excited to join Genflow as the company is progressing to the next new phase of development, with key data readouts expected in 2026, strengthened intellectual property, and a sharpened strategic focus on high-potential programs. I look forward to working with the talented team and board to advance these innovative gene therapies, this is an ideal moment to contribute my expertise and hel",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-11T00:11:26.614624+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20260836-Pie-char--6004630",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.709557",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Post conference announcement next week and Funding news is what I predict. I'm amazed we are at this price. Such a hidden gem!",
          "sentiment": 0.5,
          "engagement": "60",
          "price_at_post": "1.85",
          "thread_title": "RE: JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=3005BF87-EE58-4C27-ABC6-EE6AA15A9385"
        },
        "ingested_at": "2026-02-11T00:11:26.614662+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20260716-Porter_--1841876",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.710022",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Genflow Biosciences is a London-based biotechnology firm and the first \"pure-play\" longevity company listed on the London Stock Exchange. As of early 2026, the company is transitioning from a preclinical phase into active clinical data readouts, focusing on its proprietary SIRT6-based gene therapy platform to extend human and animal \"healthspan\". Core Technology and Pipeline: The company\u2019s lead therapeutic approach involves delivering a \"centenarian variant\" of the SIRT6 gene, identified in individuals who live over 100 years, to improve DNA repair and metabolic health. GF-1002 (Human Therapeutics): MASH (Liver Disease): Repositioned in 2025 to target patients with advanced fibrosis who have limited options from existing GLP-1 therapies. The company is currently finalizing its Investigational New Drug (IND) package and exploring mRNA/LNP delivery to allow for repeat dosing and lower costs. Werner Syndrome: A rare genetic condition causing premature aging. Genflow has developed proprietary human-derived liver organoids to model this disease more accurately than animal models. GF-1004 (Veterinary Program): Canine Longevity: A 12-month blinded clinical trial in aged dogs is currently underway. In early 2026, the company confirmed that all subjects received full dosing with no adverse events reported. Key 2026 Milestones: Initial efficacy readouts focusing on biological age (via methylation clocks) are expected in Q1 2026, with a second evaluation planned for June-July 2026. Expansion Programs: Glaucoma: A new ophthalmology program targeting neuroprotection of retinal ganglion cells to prevent blindness. Sarcopenia (GF-1005): Research into muscle health and mitochondrial dysfunction in collaboration with the Universit\u00e9 libre de Bruxelles. 2026 Strategic Focus: Genflow\u2019s 2026 strategy emphasizes \"rationalization of the pipeline,\" prioritizing programs with the strongest data to secure non-dilutive funding through licensing deals and partnerships. The company is actively seeking animal health partners for its dog longevity program and strategic collaborators for its LNP-based mRNA therapeutics.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "GLP, LNP, MRNA and SIRT6 based therapeutics",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=FB89DB69-F93B-4BB3-8529-5206EECDF243"
        },
        "ingested_at": "2026-02-11T00:11:26.614701+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20262119-jamtart1--6272417",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.710444",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Yes, Genflow Biosciences (Genflow) has had significant interest at the J.P. Morgan Healthcare Conference, attending specifically to engage with potential partners, institutional investors, and pharmaceutical companies. Their CEO, Dr. Eric Leire, attended the most recent conference in January 2026 with a \"full appointments book\" to discuss strategic partnerships and non-dilutive funding opportunities.",
          "sentiment": 0.5,
          "engagement": "1,600",
          "price_at_post": "1.85",
          "thread_title": "JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=3005BF87-EE58-4C27-ABC6-EE6AA15A9385"
        },
        "ingested_at": "2026-02-11T00:11:26.614741+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260634-Porter_--6240236",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.710912",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Companies attend the J.P. Morgan Healthcare Conference (JPM) primarily for networking, securing funding, forging strategic partnerships, and announcing key business updates. This major event, often described as setting the industry's tone for the year, concentrates a year's worth of meetings into a few days. Key reasons why companies attend include: Investment and Funding: The conference is a premier venue for companies to present their strategies and financial outlooks to a high-level audience of investors, analysts, and venture capitalists. For many, especially smaller or emerging biotech firms, it is a critical opportunity to secure financing, gauge investor interest, and build essential relationships. Mergers and Acquisitions (M&A) and Partnerships: The event is a hotbed for dealmaking. Big pharmaceutical companies often attend to scout for smaller companies with promising drug pipelines or innovative technologies (like AI in drug discovery) to acquire, especially as their own blockbuster drugs approach patent expiration. Extensive one-on-one meetings facilitate these discussions and collaborations. Strategic Positioning and Visibility: Companies announce major news, clinical trial data, or year-end recaps just before or during the conference to capture attention and elevate their visibility above the competition. It allows them to articulate their unique value proposition and strategic priorities to the global market. Market Intelligence: Attending allows companies to take the pulse of the industry, understand the latest trends (e.g., AI, gene therapy, obesity drugs), and gather competitive intelligence. They can assess how investors and peers discuss valuations, regulatory pathways, and market potential, which helps in fine-tuning their own strategies for the year ahead. Networking Efficiency: The conference brings the entire healthcare and life sciences ecosystem\u2014from manufacturers and providers to regulators and service providers\u2014into a concentrated location for a short time. This high density of key decision-makers allows for efficient, high-value networking and relationship building that would otherwise take months of travel and outreach.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=4C9A5731-DC78-4F24-8CE9-513E080FCFAC"
        },
        "ingested_at": "2026-02-11T00:11:26.614779+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261946-jamtart1--8583193",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.711334",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Doubt it, but happy if rumours are true",
          "sentiment": 0.5,
          "engagement": "1,600",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan, news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=559FB93D-C9CD-4A83-84E9-7B26CC6976E9"
        },
        "ingested_at": "2026-02-11T00:11:26.614817+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261844-JediMast-85653504",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.711742",
        "source": "LSE_CHAT",
        "data": {
          "author": "JediMaster1",
          "content": "Rumours of investment banks wanting to buy in from the JP Morgan Conference. The only question now is who do they want to buy in on behalf of?? The next few days will be interesting. Will Eric spill the beans?",
          "sentiment": 0.5,
          "engagement": "169",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D010A135-964B-4034-9025-65BCB0334809"
        },
        "ingested_at": "2026-02-11T00:11:26.614856+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261006-Moneymun-83935223",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.712184",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "GKOS: Strong innovation and new therapies drive growth, with robust financials and expanding markets Jan 14, 2026, GKOS The event highlighted robust innovation in ophthalmology, with strong R&D investment yielding a broad product pipeline and record financial performance. Key growth drivers include new glaucoma and keratoconus therapies, strategic market expansion, and a focus on operational leverage and profitability. Based on Glaukos Corporation [GKOS] 44th Annual J.P. Morgan Healthcare Conference Audio Transcript \u2014 Jan. 14 2026",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.10",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-02-11T00:11:26.614894+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260827-Moneymun-46827023",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.712592",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Every chance Rooster, although I'm hoping for a transformational lucrative commercial licensing deal on one or more of the programs, Dog , Glaucoma and Mash. Excitement building!!! Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.05",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-02-11T00:11:26.614932+00:00"
      },
      {
        "event_id": "RNS-11th Feb 2026-noticeof",
        "event_type": "rns_announcement",
        "date": "2026-02-11T19:16:25.793630Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Notice of GM",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/GENF/notice-of-gm-eipp4pxsenysnuw.html",
          "rns_number": "RNS Number : 4938S",
          "full_content": "Today 07:00\nRNS Number : 4938S\nGenflow Biosciences PLC\n11 February 2026\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\nGenflow Biosciences Plc\nNotice of General Meeting\nGenflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) (\"Genflow\" or the \"Company\"), a European-based biotechnology company focused on the development of gene therapies for age-related diseases, announces that the Board is considering potentially undertaking an equity raise which would be structured by issuing rights over the New Shares (in the form of shares or warrants) to new investors and/or existing shareholders in the Company for cash consideration in one or more private placements on a non-pre-emptive basis (the \"\nPotential Equity Raise\n\").\nIn order to facilitate the Potential Equity Raise and to ensure that it could be swiftly concluded if it progresses, the Board is seeking specific shareholder approval at a general meeting (the \"\nGeneral Meeting\n\") for the allotment and issue of up to 188,947,368 new ordinary shares (\"\nNew Shares\n\") (which is approximately 38% of the Company's current issued share capital) in connection with the Potential Equity Raise, on terms that the Board may determine.\nIn order for the Directors to issue New Shares free of statutory pre-emption rights, such statutory pre-emption rights must be dis-applied. Accordingly, the Board wishes to seek separate authorities to dis-apply pre-emption rights in respect of the allotment of the New Shares pursuant to the Potential Equity Raise.\nThe General Meeting will be held at\nOne Heddon Street, London, W1B 4BD\nat 11am on 2 March 2026.\nAt this time, there is no certainty that the Potential Equity Raise will proceed and at this point no investors have entered into any agreements to subscribe for New Shares and the amounts and price of any Potential Equity Raise have not been agreed. To the extent that any money is raised from the Potential Equity Raise, it would be applied towards:\n\u00b7\nMoving the MASH program to IND-enabling stage;\n\u00b7\nAnimal health: final payment\u00a0to the contract research organization for\u00a0the randomized clinical trial in aged beagle dogs and licensing effort;\n\u00b7\nGlaucoma Proof of Concept studies and Business development effort; and\n\u00b7\nFinal phase of EU patent approval and continued processing of US patent applications\nIf the authorities sought at the General Meeting in connection with the Potential Equity Raise are approved, the Directors shall have discretion to determine the terms of the Potential Equity Raise, including the number of New Shares and warrants to be issued (subject to the limits of the authorities) and the price at which the New Shares will be issued, as well as the identity of who the New Shares will be issued to. Further details of the Potential Equity Raise (if it proceeds) will be announced in due course.\nAvailability of documents\nThe circular convening the General Meeting has been published today and is available on the Company's website at\nwww.genflowbio.com\n. A copy will also be available for inspection at the registered office of the Company during normal business hours.\nContacts\nGenflow Biosciences\nHarbor Access\nDr Eric Leire, CEO\nJonathan Paterson, Investor Relations\n+32-477-495-881\n+1 475 477 9401\nJonathan.Paterson@Harbor-access.com\nAbout Genflow Biosciences\nFounded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies for age-related diseases, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH\n(Metabolic Dysfunction-Associated Steatohepatitis)\n, the most prevalent chronic liver disease for which there is no effective treatments. Please visit\nwww.genflowbio.com\nand follow the Company on\nLinkedIn\nand\nX\n.\nDISCLAIMER\nThe contents of this announcement have been prepared by, and are the sole responsibility of, the Company.\nThis announcement may contain forward-looking statements.\u00a0The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In a",
          "content_length": 8655
        },
        "ingested_at": "2026-02-11T19:16:25.793666Z"
      },
      {
        "event_id": "SOCIAL-Today1617-pickedpe-71532362",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:29.880470",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "4% of the company has changed hands today, but maybe more significantly that's near 20% of the real free float of about 115m shares. Amazing day really, a day that had it all, RNS, negative interpretation, CEO interview, day traders, pull backs, MM manipulation, a wild L2 order book, and swings of 40% in valuation. Imagine what will happen when something really important happens! I like it here, I might stay a while.",
          "sentiment": 0.0,
          "engagement": "2,327",
          "price_at_post": "1.85",
          "thread_title": "RE: Ceo Eric Proactive interview 2 hrs ago..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=775B19CB-66F6-441B-8E63-B4EC2489DE96"
        },
        "ingested_at": "2026-02-11T19:16:38.212913+00:00"
      },
      {
        "event_id": "SOCIAL-Today1614-Alwaysra-84630948",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:29.880893",
        "source": "LSE_CHAT",
        "data": {
          "author": "Alwaysraining",
          "content": "Pickedpeck - thanks for this and your earlier posts. Very helpful",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "1.85",
          "thread_title": "RE: Query to IR about the RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=8D659F3A-B431-471B-8928-BBCE589183FA"
        },
        "ingested_at": "2026-02-11T19:16:38.212939+00:00"
      },
      {
        "event_id": "SOCIAL-Today1459-Pie-char-35419941",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:29.881326",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "There's nothing more bullish than a recovery like this!!! Just think what this is gonna do on news.",
          "sentiment": 0.5,
          "engagement": "68",
          "price_at_post": "1.80",
          "thread_title": "RE: Ceo Eric Proactive interview 2 hrs ago..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=775B19CB-66F6-441B-8E63-B4EC2489DE96"
        },
        "ingested_at": "2026-02-11T19:16:38.212958+00:00"
      },
      {
        "event_id": "SOCIAL-Today1435-Persever--2538687",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:29.881795",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "UK proactive logo Negotiating from a position of strength: Genflow Biosciences CEO explains AGM RNS Published: 12:05 11 Feb 2026 GMT Written by: Stephen Gunnion About this content View Genflow Biosciences Ltd LSE:GENF OTCQB:GENFF Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company\u2019s latest RNS regarding its upcoming AGM and the strategic rationale behind authorising the potential issuance of shares ahead of clinical partnership discussions. Leire addressed potential shareholder concerns, acknowledging that announcements involving share issuance can sometimes be interpreted as a fundraising signal. However, he clarified that the RNS is not about launching a capital raise, but about strengthening the company\u2019s position in ongoing and future negotiations with major pharmaceutical partners. He explained that in biotech, financial flexibility translates directly into leverage. \u201cIn biotech, cash is not just money, it's negotiating power,\u201d Leire said. As a public company, Genflow's financial position is visible to potential partners, and Leire emphasised the importance of maintaining the ability to walk away from unfavourable terms. He added that the company is not committing to using the full 38% share issuance authority and stressed that the underlying science remains unchanged. \u201cOur science has not changed. What we're doing is just making sure that we capture the full value of our science,\u201d he noted. While acknowledging that markets dislike uncertainty, Leire stated that uncertainty is temporary, whereas signing a bad deal would have lasting consequences. He said the company is focused on optimising for the best long-term outcome and ensuring it is not forced into a suboptimal agreement.",
          "sentiment": 0.0,
          "engagement": "6",
          "price_at_post": "1.80",
          "thread_title": "Ceo Eric Proactive interview 2 hrs ago..",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=775B19CB-66F6-441B-8E63-B4EC2489DE96"
        },
        "ingested_at": "2026-02-11T19:16:38.212977+00:00"
      },
      {
        "event_id": "SOCIAL-Today1411-KEY2--3379281",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:29.882222",
        "source": "LSE_CHAT",
        "data": {
          "author": "KEY2",
          "content": "We all said that they were short of shares last week....... what a shake today and back up we go. Hold tight as I think this could go up to 3p on 'good news'. Gla",
          "sentiment": 0.0,
          "engagement": "444",
          "price_at_post": "1.775",
          "thread_title": "RE: One For The Boys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1876A8CE-8033-46D6-85E2-D4A81719DE91"
        },
        "ingested_at": "2026-02-11T19:16:38.212997+00:00"
      },
      {
        "event_id": "SOCIAL-Today1355-Moneymun-56455538",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:29.882626",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Great work again pickedpeck, thanks for sharing. Looks like we've got a very exciting period ahead from a fully funded Genflow with multiple potential company defining newsflow in the pipeline and look forward to finding out the identity of the new investor(s). Gl ;-)",
          "sentiment": 0.5,
          "engagement": "12,548",
          "price_at_post": "1.725",
          "thread_title": "RE: Query to IR about the RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=8D659F3A-B431-471B-8928-BBCE589183FA"
        },
        "ingested_at": "2026-02-11T19:16:38.213014+00:00"
      },
      {
        "event_id": "SOCIAL-Today1354-KEY2--1670587",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:29.883028",
        "source": "LSE_CHAT",
        "data": {
          "author": "KEY2",
          "content": "Just tried to top as been out all morning.  I can sell a load but nt to buy even a small amount, then price jumped to 1.78 to buy.  Again just now, I can't get a live quote again with ii so will go up again. Hold onto your shares guys.",
          "sentiment": 0.0,
          "engagement": "444",
          "price_at_post": "1.725",
          "thread_title": "RE: Query to IR about the RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=8D659F3A-B431-471B-8928-BBCE589183FA"
        },
        "ingested_at": "2026-02-11T19:16:38.213033+00:00"
      },
      {
        "event_id": "SOCIAL-Today1348-KEY2--1108749",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:29.883441",
        "source": "LSE_CHAT",
        "data": {
          "author": "KEY2",
          "content": "Great posts/insight today as usual pickedpeck !",
          "sentiment": 0.0,
          "engagement": "444",
          "price_at_post": "1.675",
          "thread_title": "RE: Query to IR about the RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=8D659F3A-B431-471B-8928-BBCE589183FA"
        },
        "ingested_at": "2026-02-11T19:16:38.213050+00:00"
      },
      {
        "event_id": "SOCIAL-Today1339-pickedpe--1217163",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:29.883892",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "I wrote to investor relations this morning querying some aspects of the RNS, email below with their inline responses. I am writing to seek clarity on the Notice of General Meeting published today, February 11, 2026. \u200bWhile I support the board\u2019s efforts to capitalize on the upcoming clinical catalysts, I would like to request further detail on the following points to ensure the interests of long-term retail holders are aligned with the proposed \"Potential Equity Raise\": \u200bQ1. Minimum Issuance Price: Does the board intend to set a floor price for the allotment of the 188,947,368 new shares? Specifically, will the issuance be at a premium to the current 30-day VWAP, or is it intended to be a deep-discount placing? A: The intention is to issue the shares at current market value with no discount. \u200b Q2 : Warrant Terms: The RNS mentions rights over shares in the form of warrants. Will these warrants be \"in the money\" upon issuance, and what is the board's policy on the exercise period? Specifically, are there protections in place to prevent these warrants from being used to trigger a change of control without a formal Rule 9 bid? A: The warrants will not be \u201cin the money\u201d with a shorter exercise period and my understanding is that there will be protections in place. \u200b Q3: Non-Pre-Emptive Rationale: Given the significant concentration of the register (Directors and major holders), why has the board opted for a non-pre-emptive structure rather than a simplified Open Offer that allows existing 1%+ holders to maintain their pro-rata stake? A: This structure was decided by the board and I was offered no rationale other than it was at their discretion. \u200b Q4: Director Participation: Will Dr. Eric Leire or other PDMRs be participating in this specific allotment on the same terms as new investors? A: Management and the Board will participate on the same terms.",
          "sentiment": 0.5,
          "engagement": "2,327",
          "price_at_post": "1.675",
          "thread_title": "Query to IR about the RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=8D659F3A-B431-471B-8928-BBCE589183FA"
        },
        "ingested_at": "2026-02-11T19:16:38.213068+00:00"
      },
      {
        "event_id": "SOCIAL-Today1308-pickedpe-13600567",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:29.884303",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "Just to add, having your own cash position covered for the next phase of development and 12 months operating room enormously strengthens the company's hand in any partner deal.",
          "sentiment": 0.5,
          "engagement": "2,327",
          "price_at_post": "1.675",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=03829B8E-771F-4ADA-8F1C-791C564FDD28"
        },
        "ingested_at": "2026-02-11T19:16:38.213085+00:00"
      },
      {
        "event_id": "SOCIAL-Today1252-pickedpe-48899474",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:29.884749",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "Analyzing the \u20ac4M Walloon Grant reveals the exact \"hidden\" mechanism that likely triggered today's RNS. In European R&D funding, there is a strict \"Capital Adequacy\" rule. The Walloon region (SPW \u00c9conomie, Emploi, Recherche) typically provides subsidies covering 40% to 70% of eligible project costs for SMEs like Genflow. \u200bFor Genflow to draw down the full \u20ac4M, the total project spend for the GF-1002 (MASH) program must be roughly \u20ac6M\u2013\u20ac8M. \u200bThis leaves a \"funding gap\" of \u20ac2M\u2013\u20ac4M that Genflow must provide from its own cash reserves or equity. \u200bAs per the January 27th RNS, the first installment is expected in May 2026. However, the grant is \"subject to spending over the working capital requirements.\" \u200bThe government won't send the first \u20ac1M check in May if Genflow\u2019s bank balance (which was ~\u00a3280k in June 2025) doesn't show it can cover its 30-50% share of the next phase. \u200bIf we look at the H1 2025 interim report, Genflow\u2019s burn rate was approximately \u00a3160,000 per month (\u00a3982k over 6 months). \u200bProjected Burn (July 2025 \u2013 May 2026): ~\u00a31.6M\u2013\u00a31.8M. \u200bCurrent Reality: Without the March 2025 fundraise (\u00a3434k) and the new authority, Genflow would be running on \"fumes\" just as the grant money is set to land. \u200bThe board is seeking authority for 188.9 million shares. At a hypothetical placement price of 2p\u20133p, this would raise \u00a33.7M\u2013\u00a35.6M. This amount almost perfectly covers the \"matching funds\" requirement for the \u20ac4M grant plus 12 months of operational runway. It ensures that even if a corporate partner deal takes longer to close, the company is \"Walloon-compliant\" and can keep the MASH program moving.",
          "sentiment": 0.5,
          "engagement": "2,327",
          "price_at_post": "1.675",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=03829B8E-771F-4ADA-8F1C-791C564FDD28"
        },
        "ingested_at": "2026-02-11T19:16:38.213126+00:00"
      },
      {
        "event_id": "SOCIAL-Today1224-SM81--7103018",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:29.885160",
        "source": "LSE_CHAT",
        "data": {
          "author": "SM81",
          "content": "I'm happy to take them at their word ... ie .. to generate non-dilutive funding Genflow Biosciences PLC - London-based biotechnology firm - Says 2026 will \"emphasize rationalization of our pipeline, prioritizing programs with the strongest data, clearest paths to value creation, and highest partner interest.\" Central to this strategy will be the pursuit of early-stage licensing and collaboration agreements designed to generate non-dilutive funding  \"With multiple upcoming data readouts, an expanding partner network, and a maturing intellectual property position, we believe Genflow is well positioned to enter its next phase of growth. We remain committed to scientific excellence, capital efficiency, and long-term value creation as we work to translate our longevity platform into meaningful therapies.\"",
          "sentiment": 0.5,
          "engagement": "44",
          "price_at_post": "1.675",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=03829B8E-771F-4ADA-8F1C-791C564FDD28"
        },
        "ingested_at": "2026-02-11T19:16:38.213146+00:00"
      },
      {
        "event_id": "SOCIAL-Today1159-Pie-char-74585425",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:29.885562",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "This is clearly to bridge a gap, to unlock/ release news that will no doubt flip this on its head. Re-rate incoming. Bags packed ready for lift off.",
          "sentiment": 0.5,
          "engagement": "68",
          "price_at_post": "1.625",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=03829B8E-771F-4ADA-8F1C-791C564FDD28"
        },
        "ingested_at": "2026-02-11T19:16:38.213164+00:00"
      },
      {
        "event_id": "SOCIAL-Today1153-Persever--1079853",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:29.885953",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "I think this is an over reaction of the rns. Its normal maintenance....standard in biotech. It doesn't necessarily mean dilution is imminent. Claim that 1.80p and back to bullish wait n see...",
          "sentiment": 0.0,
          "engagement": "6",
          "price_at_post": "1.575",
          "thread_title": "RE: One For The Boys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1876A8CE-8033-46D6-85E2-D4A81719DE91"
        },
        "ingested_at": "2026-02-11T19:16:38.213182+00:00"
      },
      {
        "event_id": "SOCIAL-Today1147-TheInves--6362447",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:29.886365",
        "source": "LSE_CHAT",
        "data": {
          "author": "TheInvestCollect",
          "content": "Well Well, this share has a habit of being thrown to the floor and bouncing back, folks able to buy at 1.26/1.30 WOW now into 1.60\u2019s, the ones who lost their heads and sold feeling stupid maybe, this is what small craps shares is about taking from the weak and giving their wealth to the rich and strong, I can\u2019t say where this share will go but stinks of course the action here, surely Eric with what was a shocking RNS when folks expecting good news would of known the effects or not \ud83e\udd37\ud83c\udffe\u200d\u2642\ufe0f, hopefully it just a blip here GL\ud83e\udd1e\ud83d\ude4f\ud83c\udffb\ud83e\udd37\ud83c\udffe\u200d\u2642\ufe0f\ud83d\udc4d\ud83c\udffd",
          "sentiment": 0.0,
          "engagement": "7,975",
          "price_at_post": "1.55",
          "thread_title": "One For The Boys",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1876A8CE-8033-46D6-85E2-D4A81719DE91"
        },
        "ingested_at": "2026-02-11T19:16:38.213200+00:00"
      },
      {
        "event_id": "SOCIAL-Today1132-MumbleGr-41393290",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:29.886763",
        "source": "LSE_CHAT",
        "data": {
          "author": "MumbleGrumble",
          "content": "The news I have been waiting patiently for and predicted on 8th December. Doubled my holding today averaging up to 0.088 Bring it on Eric!",
          "sentiment": 0.0,
          "engagement": "83",
          "price_at_post": "1.55",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=03829B8E-771F-4ADA-8F1C-791C564FDD28"
        },
        "ingested_at": "2026-02-11T19:16:38.213225+00:00"
      },
      {
        "event_id": "SOCIAL-Today1050-Moneymun-71159671",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:29.887185",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Exactly pickedpeck, and the price of the news shares isn't going to be determined by a dodgy broker forward selling shares before a massive discounted issue, this a private placement to facilitate the arrival of a Major player or two, very likely aligned to a commercial deal that Eric has recently highlighted on the Dog Trial, Glaucoma and/or  Mash,  with the price of the new shares determined by the Directors bringing in a  significant cash injection into Genflow's bank account to take the company to the next level. Gla holders, couldn't be more excited at what transpire in March.....Multiple material newsflow, Cash rich, and maybe a game-changing lucrative commercial deal and/or high profile investors.  ;-) ...... If the authorities sought at the General Meeting in connection with the Potential Equity Raise are approved, the Directors shall have discretion to determine the terms of the Potential Equity Raise, including the number of New Shares and warrants to be issued (subject to the limits of the authorities) and the price at which the New Shares will be issued, as well as the identity of who the New Shares will be issued to.",
          "sentiment": 0.5,
          "engagement": "12,548",
          "price_at_post": "1.55",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=03829B8E-771F-4ADA-8F1C-791C564FDD28"
        },
        "ingested_at": "2026-02-11T19:16:38.213243+00:00"
      },
      {
        "event_id": "SOCIAL-Today1029-pickedpe-10168825",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:29.887608",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "Nope, don't agree at all. The company has just received a \u20ac4m grant. Jonathan Swann accumulating at market rate as recently as January and likely since. Dog trial first read imminent, any positive outcome could see an immediate x3 rerate. The fact warrants are also going to be issued is a key factor. Why would they do a placing at a discount ahead of news that can completely rebaseline the mkt cap? I'm very much aware of the effect of dilutive desperation placements in lifestyle companies, but this doesn't even remotely sniff of that.",
          "sentiment": 0.5,
          "engagement": "2,327",
          "price_at_post": "1.55",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=03829B8E-771F-4ADA-8F1C-791C564FDD28"
        },
        "ingested_at": "2026-02-11T19:16:38.213260+00:00"
      },
      {
        "event_id": "SOCIAL-Today1014-28jaczar-16543226",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:29.888018",
        "source": "LSE_CHAT",
        "data": {
          "author": "28jaczar01",
          "content": "Not a fan of these type of advance warning of a placing coming RNS\u2026. You typically see them when a Company that needs to get a placing away has been given the heads up from their broker after sounding out the market that their current SP is flying too high and it needed dampening down ahead of then announcing the placing price which gets set at a further discount to the dampened down SP. Other posters mentioning 1p on here I suspect will be in the right ballpark.",
          "sentiment": 0.0,
          "engagement": "1,403",
          "price_at_post": "1.55",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=03829B8E-771F-4ADA-8F1C-791C564FDD28"
        },
        "ingested_at": "2026-02-11T19:16:38.213278+00:00"
      },
      {
        "event_id": "SOCIAL-Today1001-pickedpe-68703310",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:29.888438",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "Moneymunch - exactly. Imagine being an animal health company reading positive dog trial news. You would not sign a partnership deal worth maybe  $25m with a \u00a310m (\u00a320,30m?) biotech company that could be snapped up by a competitor immediately negating your deal. You want some defensive control. At the same time you have to recognise the company is really aimed at the human market where the maximum long term value is so you aren't going to get to buy the whole asset.",
          "sentiment": 0.0,
          "engagement": "2,327",
          "price_at_post": "1.525",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=03829B8E-771F-4ADA-8F1C-791C564FDD28"
        },
        "ingested_at": "2026-02-11T19:16:38.213296+00:00"
      },
      {
        "event_id": "SOCIAL-Today0930-Moneymun-26019009",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:29.888836",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Great posts pickedpeck, a brilliant summary of what likely lies ahead, almost every licensing deal with Major Pharma includes an equity stake to allow the Major to have a share and direct influence going forward. Looking forward to a cash rich Genflow along with a flow of company making game changing news, and ultimately a Nasdaq listing if a Major Pharma or two are in the frame. Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,548",
          "price_at_post": "1.475",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=03829B8E-771F-4ADA-8F1C-791C564FDD28"
        },
        "ingested_at": "2026-02-11T19:16:38.213313+00:00"
      },
      {
        "event_id": "SOCIAL-Today0907-DaProphe--7276063",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:29.889241",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaProphet",
          "content": "Yes but by doing that they are setting the standard! Fool me once ect...",
          "sentiment": 0.0,
          "engagement": "4,856",
          "price_at_post": "1.475",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=03829B8E-771F-4ADA-8F1C-791C564FDD28"
        },
        "ingested_at": "2026-02-11T19:16:38.213331+00:00"
      },
      {
        "event_id": "SOCIAL-Today0900-pickedpe--3156024",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:29.889643",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "Nope, I think good news will come before the equity is finalised. There is no price associated with the RNS, deliberately so. This clears the space for a new cornerstone investor or partner to come in and accelerate the program. They obviously can't say that out loud, but there are no pre-emptive rights, and also warrants on the new shares. Clearly this is a way for a new investor to potentially get maximum benefit, and also effectively act as a defensive barrier to selling to a competitor. All very interesting.",
          "sentiment": 0.5,
          "engagement": "2,327",
          "price_at_post": "1.45",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=03829B8E-771F-4ADA-8F1C-791C564FDD28"
        },
        "ingested_at": "2026-02-11T19:16:38.213348+00:00"
      },
      {
        "event_id": "SOCIAL-Today0845-DaProphe--2955552",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:29.890044",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaProphet",
          "content": "I'm quite sure they will reward the faithful few.. I expect some good news will likely come  after the equity is finalised.. Lots of exciting news due to hit around H1..less we be reminded",
          "sentiment": 0.5,
          "engagement": "4,856",
          "price_at_post": "1.375",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=03829B8E-771F-4ADA-8F1C-791C564FDD28"
        },
        "ingested_at": "2026-02-11T19:16:38.213365+00:00"
      },
      {
        "event_id": "SOCIAL-Today0836-Lile-22068245",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:29.890450",
        "source": "LSE_CHAT",
        "data": {
          "author": "Lile",
          "content": "Whatever fanciful interpretations are given, another dilutive capital raise is awful for current private investors. Didn't think we'd be testing the <1p ever again, now I'm not so sure.",
          "sentiment": 0.0,
          "engagement": "285",
          "price_at_post": "1.325",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=03829B8E-771F-4ADA-8F1C-791C564FDD28"
        },
        "ingested_at": "2026-02-11T19:16:38.213383+00:00"
      },
      {
        "event_id": "SOCIAL-Today0830-Moneymun-50094682",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:34.413067",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Let's wait and see where we are by the end of Q1 2026, hopefully on an upward trajectory from small cap to mid cap..... Gla :-/",
          "sentiment": 0.5,
          "engagement": "12,548",
          "price_at_post": "1.30",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=03829B8E-771F-4ADA-8F1C-791C564FDD28"
        },
        "ingested_at": "2026-02-11T19:16:38.213401+00:00"
      },
      {
        "event_id": "SOCIAL-Today0828-pickedpe--5327019",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:34.413530",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "It's caused alarm but not huge selling. The transactions this morning remain small compared to the volume last week. This is the MMs dropping the price to try and trigger stop losses. There are two interpretations 1. The news is bad from the dog trial and the company needs to raise cash, despite having just secured \u20ac4m 2. The news from the dog trial is good and major investors want to be able to own chunks of the company that are simply not available on the open market, including possible partners. It's a very specific quantity and implies that the shares already have a destination. I'll be buying more.",
          "sentiment": 0.5,
          "engagement": "2,327",
          "price_at_post": "1.25",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=03829B8E-771F-4ADA-8F1C-791C564FDD28"
        },
        "ingested_at": "2026-02-11T19:16:38.213419+00:00"
      },
      {
        "event_id": "SOCIAL-Today0819-David195-44092875",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:34.413940",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "Helpful responses but this has caused huge alarm and selling.  The only question is the level of discount from 2p that SP has been hovering around and will the discount be from new floor?  This is another look of a retail investor shafting but I hope not.",
          "sentiment": 0.0,
          "engagement": "882",
          "price_at_post": "1.325",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=03829B8E-771F-4ADA-8F1C-791C564FDD28"
        },
        "ingested_at": "2026-02-11T19:16:38.213437+00:00"
      },
      {
        "event_id": "SOCIAL-Today0814-pickedpe--2286038",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:34.414403",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "There is a different take on this. This RNS effectively \"clears the plumbing\" before the Oxford event. There are three ways to interpret this through a professional lens: \u200b1. The \"Whale\" Accomodation (Most Likely) Large institutional investors or partners (like the animal health \"Big Three\") rarely buy shares on the open market. They require a Private Placement. By seeking this 38% authority now, the Board is preparing the \"bucket\" to catch a large investment. If a partner is paying $25M, they may want a portion of that to be equity-based to align interests. \u200b2. The \"Strength\" Signal By announcing a potential raise before the data/Oxford talk, the company is signaling they aren't \"desperate.\" If they waited until after the data to call a GM, they\u2019d lose 14 days of momentum. Doing it now means that if the data is good on then they can close a deal and issue shares by March 2nd. \u200b3. The \"Oxford\" Filter Dr. Leire knows he will be asked about \"runway\" at Oxford. He can now point to this RNS and say, \"We have the administrative authority to capitalize on our data immediately.\" It moves the conversation from \"How will you survive?\" to \"How fast will you scale?\" The \"March 2nd\" Deadline \u200bThe fact that the GM is on March 2nd suggests the Board expects to have \"market-moving\" news fully digested by the end of February. Usually, you don't ask for permission to issue 188 million shares unless you already have a \"warm\" lead on who is going to buy them. This feels like the waiting partner is preparing to take a significant equity stake alongside their licensing fee. MMs will use this to try and shake some retail shares free, so expect to see a fall based on no volume.",
          "sentiment": 0.5,
          "engagement": "2,327",
          "price_at_post": "1.85",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=03829B8E-771F-4ADA-8F1C-791C564FDD28"
        },
        "ingested_at": "2026-02-11T19:16:38.213455+00:00"
      },
      {
        "event_id": "SOCIAL-Today0813-Alwaysra-32719183",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:34.414803",
        "source": "LSE_CHAT",
        "data": {
          "author": "Alwaysraining",
          "content": "Genuinely hope you are correct ( and thanks for reposting the RNS).  However, at this stage it is hope.  I would be happier if Eric gave an interview today to explain the RNS but not holding my breath",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "1.85",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=03829B8E-771F-4ADA-8F1C-791C564FDD28"
        },
        "ingested_at": "2026-02-11T19:16:38.213472+00:00"
      },
      {
        "event_id": "SOCIAL-Today0805-Moneymun--5166707",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:34.415211",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Cash is King, and this is no ordinary fund raise whereby new shares are forward sold and issued at huge discount. This looks like the next growth catalyst, the price of the new shares is yet to be determined, but allows Major investors both here and the US to take significant and meaningful stakes in the company at a time where Genflow are on a trajectory from small cap to mid cap, and the warrants provide incentives for existing and newly recruited employees to facilitate Genflow's expansion and perhaps even a Nasdaq listing. Multiple material newsflow in the pipeline and only a few weeks before we know the determined issue price, obviously the higher the price, the more cash Genflow will have in the bank. Gla holders...hold on tight for a potential Stellar year ahead!!! :-)",
          "sentiment": 0.5,
          "engagement": "12,548",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=03829B8E-771F-4ADA-8F1C-791C564FDD28"
        },
        "ingested_at": "2026-02-11T19:16:38.213490+00:00"
      },
      {
        "event_id": "SOCIAL-Today0728-Alwaysra-68213939",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:34.415612",
        "source": "LSE_CHAT",
        "data": {
          "author": "Alwaysraining",
          "content": "The disconnect between this RNS and the interview Eric gave just a couple of weeks ago is huge.  Given the discount to share price of previous share offerings, a new share issue of up to nearly 40% of the current share capital could be seriously detrimental to current shareholders.  Can\u2019t overstate how disappointing this is.",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "2.10",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=03829B8E-771F-4ADA-8F1C-791C564FDD28"
        },
        "ingested_at": "2026-02-11T19:16:38.213507+00:00"
      },
      {
        "event_id": "SOCIAL-Today0704-Moneymun--4233376",
        "event_type": "social_post",
        "date": "2026-02-11T19:16:34.416077",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "GENFLOW BIOSCIENCES PLC Released 07:00:11 11 February 2026 RNS Number : 4938S Genflow Biosciences PLC 11 February 2026 Genflow Biosciences Plc Notice of General Meeting Genflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) (\"Genflow\" or the \"Company\"), a European-based biotechnology company focused on the development of gene therapies for age-related diseases, announces that the Board is considering potentially undertaking an equity raise which would be structured by issuing rights over the New Shares (in the form of shares or warrants) to new investors and/or existing shareholders in the Company for cash consideration in one or more private placements on a non-pre-emptive basis (the \"Potential Equity Raise\"). In order to facilitate the Potential Equity Raise and to ensure that it could be swiftly concluded if it progresses, the Board is seeking specific shareholder approval at a general meeting (the \"General Meeting\") for the allotment and issue of up to 188,947,368 new ordinary shares (\"New Shares\") (which is approximately 38% of the Company's current issued share capital) in connection with the Potential Equity Raise, on terms that the Board may determine. In order for the Directors to issue New Shares free of statutory pre-emption rights, such statutory pre-emption rights must be dis-applied. Accordingly, the Board wishes to seek separate authorities to dis-apply pre-emption rights in respect of the allotment of the New Shares pursuant to the Potential Equity Raise. The General Meeting will be held at One Heddon Street, London, W1B 4BD at 11am on 2 March 2026. At this time, there is no certainty that the Potential Equity Raise will proceed and at this point no investors have entered into any agreements to subscribe for New Shares and the amounts and price of any Potential Equity Raise have not been agreed. To the extent that any money is raised from the Potential Equity Raise, it would be applied towards: \u00b7 Moving the MASH program to IND-enabling stage; \u00b7 Animal health: final payment to the contract research organization for the randomized clinical trial in aged beagle dogs and licensing effort; \u00b7 Glaucoma Proof of Concept studies and Business development effort; and \u00b7 Final phase of EU patent approval and continued processing of US patent applications If the authorities sought at the General Meeting in connection with the Potential Equity Raise are approved, the Directors shall have discretion to determine the terms of the Potential Equity Raise, including the number of New Shares and warrants to be issued (subject to the limits of the authorities) and the price at which the New Shares will be issued, as well as the identity of who the New Shares will be issued to. Further details of the Potential Equity Raise (if it proceeds) will be announced in due course.",
          "sentiment": 0.5,
          "engagement": "12,548",
          "price_at_post": "2.10",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=03829B8E-771F-4ADA-8F1C-791C564FDD28"
        },
        "ingested_at": "2026-02-11T19:16:38.213525+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262221-Porter_-29320683",
        "event_type": "social_post",
        "date": "2026-02-11T00:11:17.500711",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Google: Being invited to speak at the Oxford Society of Ageing and Longevity (OSAL) and the Oxford Personalised Medicine Society (OUPM) is a significant milestone for a biotech company like Genflow Biosciences. It serves as a strong signal of academic and industry validation for their SIRT6 platform. Why It Matters for Investors & the Company Elite Scientific Validation: These societies are hosted by the University of Oxford, a global hub for aging research and the \"Silicon Valley\" of UK life sciences. OSAL has previously hosted world-leading figures such as Professor George Church (Harvard) and Dr. Matt Kaeberlein (Dog Aging Project), placing Genflow's leadership in the same tier of recognized experts. Access to Key Stakeholders: The events unite over 1,000 students, faculty, and researchers across all Oxford colleges. This provides direct exposure to the next generation of biotech entrepreneurs and potential future collaborators from one of the world's most prestigious research environments. Strategic Visibility: Speaking at such high-profile academic forums enhances the company's \"soft power,\" which is crucial for attracting institutional investors and Big Pharma partners looking for scientifically rigorous assets. Platform Credibility: Specifically for Genflow, presenting to the Oxford Personalised Medicine Society reinforces the \"personalised\" potential of their centenarian-derived SIRT6 variants (as protected under EP4338267), which are tailored to mimic the genetic advantages of humans who live past 100. 2026 Context This invitation coincides with Genflow's 2026 priorities, which include seeking early-stage licensing and collaboration agreements to validate their platform externally. Successful engagement at Oxford can be a powerful catalyst for these partnership discussions.",
          "sentiment": 0.5,
          "engagement": "1,335",
          "price_at_post": "2.10",
          "thread_title": "RE: A timely presentation!!!???",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=B0303AE1-B306-4E1A-9926-92B87EAED85C"
        },
        "ingested_at": "2026-02-11T19:16:38.213544+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262213-Porter_-14178332",
        "event_type": "social_post",
        "date": "2026-02-11T00:11:17.501227",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "The gene therapy sector has seen a significant surge in high-value acquisitions over the last 24 months (2024\u20132026), driven by \"Big Pharma\" companies looking to fill patent cliffs with advanced platforms. The following table lists notable gene therapy and advanced genetic medicine companies acquired within this period: Recent Gene Therapy Buyouts (2024\u20132026) Acquired Company \tBuyer\tDeal Value\tDate\tFocus Area Avidity Biosciences\tNovartis\t$12 Billion\tOct 2025\tRNA/AOC therapies for neuromuscular diseases Blueprint Medicines\tSanofi\t$9.5 Billion\tJun 2025\tKinase inhibitors and precision medicine Metsera\tPfizer\t$10 Billion\tSep 2025\tGLP-1 and metabolic (MASH) obesity assets Akero Therapeutics\tNovo Nordisk\t$5.2 Billion\tOct 2025\tMASH (same lead indication as Genflow) Verve Therapeutics\tEli Lilly\t$1.3 Billion\tJun 2024\tIn vivo gene editing for cardiovascular disease Poseida Therapeutics\tRoche\t$1.5 Billion\tNov 2024\tNon-viral CAR-T cell and gene therapies Kate Therapeutics\tNovartis\t$1.1 Billion\tNov 2024\tAAV-based therapies for neuromuscular/heart EsoBiotec\tAstraZeneca\t$1 Billion\tMid-2024\tIn vivo CAR-T cell therapy platform Bluebird Bio\tGenetix Biotherapeutics\t$1.12 Billion\tLate 2025\tEx vivo gene therapy for blood disorders Key Investor Takeaways MASH Validation: The acquisition of Akero Therapeutics ($5.2B) by Novo Nordisk specifically validates Genflow's primary therapeutic target (MASH) as a high-value exit category. Platform Value: Buyers like Novartis and Sanofi are increasingly acquiring entire technology platforms (e.g., Avidity\u2019s AOC platform) rather than just single drugs to ensure long-term pipeline dominance. Shift to In Vivo: There is a notable trend toward in vivo gene therapies (where the therapy is delivered directly into the patient's body), which aligns with Genflow\u2019s SIRT6 delivery model. Exit Multiples: For companies with validated human data or advanced large-mammal data, upfront payments are increasingly reaching the $1 billion+ mark, even for pre-commercial assets.",
          "sentiment": 0.5,
          "engagement": "1,335",
          "price_at_post": "2.10",
          "thread_title": "Singular program competitor acquired for $5.2bn (GENF have 5 progra...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=FEFCDC39-A327-4654-BDFC-2B1F097C94C5"
        },
        "ingested_at": "2026-02-11T19:16:38.213562+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262206-Porter_-40418189",
        "event_type": "social_post",
        "date": "2026-02-11T00:11:17.501712",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Estimated Acquisition Benchmarks While exact figures are speculative, industry data for 2025\u20132026 suggests the following ranges for similar biotech exits: Platform Takeouts: Research indicates that the average cost of acquisition for biotechs by Big Pharma is approximately $1.28 billion, with a strong correlation between the number of patent families and the final price. Early-Stage Premiums: In 2025, venture firms paid an average of $52 million for early-stage deals, but strategic pharma buyers often pay a 20\u201340% premium over financial investors for assets that fill a specific pipeline gap. Clinical-Stage Jump: If Genflow successfully moves GF-1002 into Phase 1/2 human trials, its valuation could see a \"significant jump,\" as investors and acquirers pay premiums for assets with a viable pathway to launch. Bottom Line: A Big Pharma acquirer would likely view Genflow as an asset-centric acquisition. The valuation would be a \"Mega deal\" potentially reaching hundreds of millions of dollars if clinical data from the 2026 dog trials confirms the superior DNA-repair capabilities of their patented SIRT6 variants.",
          "sentiment": 0.5,
          "engagement": "1,335",
          "price_at_post": "2.10",
          "thread_title": "Google analysis of Genflow : MEGA DEAL VALUATION",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=3113CECA-83B5-4F06-B41C-D601F9EFA5C8"
        },
        "ingested_at": "2026-02-11T19:16:38.213580+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262158-Moneymun-45220703",
        "event_type": "social_post",
        "date": "2026-02-11T00:11:17.502136",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "My thoughts exactly pickedpeck, Eric did say he was expecting initial readout efficacy data by end of January, and so hopefully being shared with the Animal Healthcare companies as they finalise their due diligence.  Fingers crossed!!! Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,542",
          "price_at_post": "2.10",
          "thread_title": "RE: A timely presentation!!!???",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=B0303AE1-B306-4E1A-9926-92B87EAED85C"
        },
        "ingested_at": "2026-02-11T19:16:38.213599+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262141-pickedpe-72213269",
        "event_type": "social_post",
        "date": "2026-02-11T00:11:17.502553",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "It's early for the initial read RNS to be released ahead of the talk, but not impossibly early. You'd have to say the timing of the talk, and the audience selected, is a very interesting choice if the news is not released beforehand. Why go and speak to a bunch of students at this point?",
          "sentiment": 0.5,
          "engagement": "2,318",
          "price_at_post": "2.10",
          "thread_title": "RE: A timely presentation!!!???",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=B0303AE1-B306-4E1A-9926-92B87EAED85C"
        },
        "ingested_at": "2026-02-11T19:16:38.213617+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262027-Moneymun--8035867",
        "event_type": "social_post",
        "date": "2026-02-11T00:11:17.502963",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Can't imagine Eric speaking on Monday about  Genflow's innovative approach using companion animal trials as a bridge to human therapeutics, if he had an inkling initial Efficacy Data on the Dog Trial wasn't positive. Gla holders;-)",
          "sentiment": 0.5,
          "engagement": "12,542",
          "price_at_post": "2.10",
          "thread_title": "RE: A timely presentation!!!???",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=B0303AE1-B306-4E1A-9926-92B87EAED85C"
        },
        "ingested_at": "2026-02-11T19:16:38.213635+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261719-Moneymun-25732627",
        "event_type": "social_post",
        "date": "2026-02-11T00:11:17.503425",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Overview Dive into how Genflow Biosciences is turning longevity research into treatments that could be applied at the bedside Genflow Biosciences: Translating longevity research to the bedside Join us for an evening with Dr. Eric Leire, CEO and Founder of Genflow Biosciences, as we explore the challenges and innovations in longevity therapeutics. \ud83e\uddec About the Speaker Dr. Eric Leire is CEO of Genflow Biosciences(LSE: GENF), the first longevity-focused biotech company to list on the London Stock Exchange. Genflow develops gene therapies targeting the molecular hallmarks of aging, with a focus on a centenarian variant of the SIRT6 gene critical for DNA repair and genomic stability. With over 20 years of pharma and biotech experience, including leadership roles at Enochian Biosciences and Aptorum Group, Dr. Leire is an expert in Advanced Therapy Medicinal Products (ATMPs). He has guided multiple gene therapy assets from discovery through clinical development. He holds an MD from the University of Grenoble and an MBA from HEC Paris and Kellogg School of Management. \ud83e\udde0 About the Talk Why have decades of aging research yielded so few clinical treatments? Dr. Leire will examine the \"translational gap\" in longevity science, exploring the limitations of traditional murine models, regulatory frameworks shaping the industry, and Genflow's innovative approach using companion animal trials as a bridge to human therapeutics. \ud83e\udde0 About the Societies This event is co-hosted by the Oxford Society of Ageing and Longevity (OSAL) and the Oxford Personalised Medicine Society (OUPM). OSAL is a student-led initiative dedicated to highlighting cutting-edge ageing research and treatments that target the underlying biology of ageing, having previously hosted world-leading speakers including Professor George Church, Dr. Matt Kaeberlein (Dog Aging Project),and Andrew Steele (author of Ageless). OUPM serves as a platform for 1000+ students and faculty across all Oxford colleges to develop their interests in personalised medicine through education, discussion, and interdisciplinary research.",
          "sentiment": 0.5,
          "engagement": "12,542",
          "price_at_post": "2.10",
          "thread_title": "RE: A timely presentation!!!???",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=B0303AE1-B306-4E1A-9926-92B87EAED85C"
        },
        "ingested_at": "2026-02-11T19:16:38.213653+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261453-Moneymun--1057227",
        "event_type": "social_post",
        "date": "2026-02-11T00:11:17.503847",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Genflow Biosciences (LON:G... + Follow 2.256 followers 7h Genflow Biosciences (LON:GENF) (OTCQB:GENFF CEO Dr. Eric Leire has been invited bv the Oxford Societv of Ageing and Longevity to speak on February 16th As interest in genetic drivers of #aging continues ta grow, we're proud to see #Genflow's science and leadership recognized at the forefront of the field #GENF #SIRT6 #biotech #agingbiology #Oxford #lifespan #longevity",
          "sentiment": 0.5,
          "engagement": "12,542",
          "price_at_post": "2.10",
          "thread_title": "A timely presentation!!!???",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=B0303AE1-B306-4E1A-9926-92B87EAED85C"
        },
        "ingested_at": "2026-02-11T19:16:38.213672+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261256-Porter_--2396031",
        "event_type": "social_post",
        "date": "2026-02-10T01:24:20.068786",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "100% Jam. So many health issues can be treated or controlled with one simple formula. With the FDA focusing on proactive as opposed to reactive healthcare, I can see why there is so much anticipation for the initial dog results to be released!",
          "sentiment": 0.5,
          "engagement": "1,332",
          "price_at_post": "2.10",
          "thread_title": "RE: Patent for age related diseases",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D0890AAC-7454-4683-8905-06AB1790DF8E"
        },
        "ingested_at": "2026-02-11T19:16:38.213690+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261254-jamtart1-53548843",
        "event_type": "social_post",
        "date": "2026-02-10T01:24:20.069475",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Porter_  Imagine the savings  world wide if all of the listed illnesses could be stopped or at least treated to a minimum health risk to patients with virtually no toxicity. Staggering.",
          "sentiment": 0.5,
          "engagement": "1,610",
          "price_at_post": "2.10",
          "thread_title": "Patent for age related diseases",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D0890AAC-7454-4683-8905-06AB1790DF8E"
        },
        "ingested_at": "2026-02-11T19:16:38.213709+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261224-pickedpe--7715697",
        "event_type": "social_post",
        "date": "2026-02-10T01:24:20.070151",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "Amazing that the longevity crowd on discord and Reddit haven't turned up here yet. There is an awful lot of noise about now for SIRT6, one can only presume that it will eventually translate into interest here, or maybe more are sitting on their hands waiting for the outcome of the dog study?",
          "sentiment": 0.5,
          "engagement": "2,317",
          "price_at_post": "2.10",
          "thread_title": "SIRT6 Longevity news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=0453E4BD-7FE8-4E95-8855-8B6B588EAFAC"
        },
        "ingested_at": "2026-02-11T19:16:38.213728+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261020-Porter_--8453461",
        "event_type": "social_post",
        "date": "2026-02-10T01:24:20.070824",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "The European patent office have confirmed all docs received and they are now reviewing if the provisional patent will be absolute for mRNA maintenance and repair in areas as follows: Cardiovascular diseases, strokes hypertension, cancer, type 2 diabetes, Parkinson's disease, Alzheimer\u2019s disease and other dementia, chronic obstructive pulmonary disease (COPD), osteoporosis, osteoarthritis, cataract, age related muscular degeneration and hearing loss.",
          "sentiment": 0.5,
          "engagement": "1,332",
          "price_at_post": "2.10",
          "thread_title": "Patent for age related diseases",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=C8E51C44-2E5C-4BC8-876F-489451C501C4"
        },
        "ingested_at": "2026-02-11T19:16:38.213746+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261546-Moneymun--3981916",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.734643",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Par for the course Dave, and nothing we haven't all seen before, especially in run up to potential game changing news, and you're always going to have sellers on an upturn in sp whether tactical or otherwise. All in the mix regardless, and now very much looking forward to the week ahead in excited anticipation. Gl.:-)))",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.10",
          "thread_title": "RE: Genflows freefloat at breadcrumbs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=2DDFFD82-F0E0-4B8C-B42F-AFF4D969BAE0"
        },
        "ingested_at": "2026-02-11T19:16:38.213764+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261541-KEY2-60433052",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.735118",
        "source": "LSE_CHAT",
        "data": {
          "author": "KEY2",
          "content": "Just highlighting an earlier post from Porter: 'Google believes the shares are divided as follows: Individual Insiders 47.2% 232,932,114 Institutions 35.1% 173,429,192 General Public (Retail) 16.3% 80,586,636 Private Companies 1.34% 6,600,000 That is literally all the shares allocated.  Institutions and new retail are going to push up the price, so it's a simple hold tight imo.",
          "sentiment": 0.0,
          "engagement": "433",
          "price_at_post": "2.05",
          "thread_title": "RE: Genflows freefloat at breadcrumbs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=2DDFFD82-F0E0-4B8C-B42F-AFF4D969BAE0"
        },
        "ingested_at": "2026-02-11T19:16:38.213783+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261316-DaveTK-72472157",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.735539",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Why is it though that when you feel any sort of momentum in UK markets, there always seems to be seller ( tactical groups ) that are desperate to keep the price down. Sometimes it feels like it's an unlimited amount they can sell to supress progress. Anybody else notice this or is just me. Thanks",
          "sentiment": 0.0,
          "engagement": "856",
          "price_at_post": "2.10",
          "thread_title": "RE: Genflows freefloat at breadcrumbs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=2DDFFD82-F0E0-4B8C-B42F-AFF4D969BAE0"
        },
        "ingested_at": "2026-02-11T19:16:38.213800+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261052-Moneymun--7236426",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.735995",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Momentum in Britain\u2019s biotech market 6 Feb, 2026 Biotechnology Although 2025 was not without its challenges, there is growing momentum and increased investor confidence in the UK biotech sector. ...... The macro-environment going into 2026 should also bolster UK biotech. The Nasdaq ended last year at an all-time high, investor sentiment is strengthening, and the association says the UK-US pharmaceutical trade deal has reinforced confidence in the UK market. Crucially, it adds, last year saw the policy foundations laid for a new era of domestic capital deployment \u2013 most notably the Life Sciences Sector Plan, the Mansion House reforms, and the first evidence of pension-backed investment into the sector through the Draig Therapeutics financing and Aviva investing in Cambridge Innovation Capital. \u201cWe very much welcome the Mansion House Accord as a positive step in the right direction. Not only will it provide domestic scale-up capital for the most promising UK-based companies, it should also help boost returns for UK pensioners to be more in line with those seen in the US and Canada,\u201d said James Costine, UK chief finance officer of SV Health Investors. Momentum in Britain\u2019s biotech market - Healthcare Today hTtps://share.google/1YEHDGDCcrGfGeXlx",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.20",
          "thread_title": "RE: Genflows freefloat at breadcrumbs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=2DDFFD82-F0E0-4B8C-B42F-AFF4D969BAE0"
        },
        "ingested_at": "2026-02-11T19:16:38.213818+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260910-Moneymun-83723119",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.736438",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "All good things come to those who wait. Potential multiple material newsflow in the pipeline including the eagerly awaited initial Efficacy Data on the Dog Trial, expected imminently. Positive data will be a game-changer and every chance it will trigger a lucrative commercial licensing deal, which will be a company maker and transformational for all invested, and as it \"worked like Magic in mice\" , and if confirmed likewise in Dogs, then obviously a very high chance of translation to humans, which no doubt will grab the attention of every Major Pharma. The appointment of the new Chairman, with a wealth of experience in Global Biotech, Corporate Development and US Capital Markets, speaks volumes, especially in this unprecedented period of frenzy of M&A activity by Major Pharma, which is expected to continue this year at pace. Exciting times and transformational UPside prospects and potential, and also great news the \u20ac4m non-dilutive grant funding has finally been signed off, ( i'd almost written it off, given how long we've waited), but with 2025 Development costs expected to be taken into account, we could have a couple of million Euro's winging its way into Genflow's bank account very soon!!!....On and most certainly UP!!! Gla holders :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.20",
          "thread_title": "RE: Genflows freefloat at breadcrumbs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=2DDFFD82-F0E0-4B8C-B42F-AFF4D969BAE0"
        },
        "ingested_at": "2026-02-11T19:16:38.213836+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260734-Porter_-26720120",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.736867",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Google believes the shares are divided as follows: Individual Insiders\t47.2%\t232,932,114 Institutions\t35.1%\t173,429,192 General Public (Retail)\t16.3%\t80,586,636 Private Companies\t1.34%\t6,600,000 There really can\u2019t be many available shares!",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "2.20",
          "thread_title": "Genflows freefloat at breadcrumbs",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=2DDFFD82-F0E0-4B8C-B42F-AFF4D969BAE0"
        },
        "ingested_at": "2026-02-11T19:16:38.213854+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261921-Porter_-74843614",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.737286",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Nice finish. Happy to move up passively 10% per day \ud83d\ude01",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "2.20",
          "thread_title": "RE: RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D40635F9-2AB2-4A31-B62F-3F3DEB72FA20"
        },
        "ingested_at": "2026-02-11T19:16:38.213871+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261246-Moneymun-35945041",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.737692",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "And Primed!!! Gl ;-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.20",
          "thread_title": "RE: RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D40635F9-2AB2-4A31-B62F-3F3DEB72FA20"
        },
        "ingested_at": "2026-02-11T19:16:38.213889+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261243-pickedpe--4910512",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.738122",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "Entertaining trading shenanigans this morning from Shore and Winterflood. Trying to create trading fog to obscure the market moves. Passing \u00a310m mkt cap and 4x volume has triggered the algos to start looking at GENF, we could combine technical buyers with macro news in one hit if the RNS lands in the next few trading sessions. Stock is very very tight, the volumes this week have been 75%+ buys and that's maybe as much as 10% of the whole market liquidity traded given how many very tightly held shares there are. I think the word of the day is 'poised'.",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "2.20",
          "thread_title": "RE: RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D40635F9-2AB2-4A31-B62F-3F3DEB72FA20"
        },
        "ingested_at": "2026-02-11T19:16:38.213907+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261235-Moneymun-48343965",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.738532",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Exciting times for all invested, potential company making news on several fronts expected soon, which could propel Genflow into the Global market and investor spotlight , taking the sp to new highs,  potentially multiples and multiples of the current bargain low entry opportunity. Gla holders,  significant UPward momentum from now on in!!! :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.20",
          "thread_title": "RE: RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D40635F9-2AB2-4A31-B62F-3F3DEB72FA20"
        },
        "ingested_at": "2026-02-11T19:16:38.213924+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261223-Porter_--3851220",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.738942",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Buys and sells finally consolidated so time to move the book again \ud83d\ude01\ud83e\udd1d",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "2.20",
          "thread_title": "RE: RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D40635F9-2AB2-4A31-B62F-3F3DEB72FA20"
        },
        "ingested_at": "2026-02-11T19:16:38.213942+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261218-jamtart1-53394664",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.739355",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Rising now, keep going.",
          "sentiment": 0.5,
          "engagement": "1,608",
          "price_at_post": "2.20",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D40635F9-2AB2-4A31-B62F-3F3DEB72FA20"
        },
        "ingested_at": "2026-02-11T19:16:38.213959+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260903-TheInves-30523280",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.739760",
        "source": "LSE_CHAT",
        "data": {
          "author": "TheInvestCollect",
          "content": "Hearing the cuppa is brewing so should taste good here soon \ud83e\udd37\ud83c\udffe\u200d\u2642\ufe0f\ud83d\ude00\ud83d\udc4d\ud83c\udffd",
          "sentiment": 0.0,
          "engagement": "7,974",
          "price_at_post": "2.25",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T19:16:38.213977+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260842-pickedpe--4505267",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.740193",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "If the RNS for the initial dog study read out lands next week and there are no shares available in free float the price pressure could be interesting.",
          "sentiment": 0.0,
          "engagement": "2,316",
          "price_at_post": "2.30",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T19:16:38.213995+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260833-Pie-char--7872611",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.740600",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Holders just need to hold and hold tight and this will put major pressure on the brokers who are scratching &  scraping for shares. Don't sell and this will sky rocket. Free float is on fumes!",
          "sentiment": 0.5,
          "engagement": "66",
          "price_at_post": "2.30",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T19:16:38.214013+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260814-KEY2--6630896",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.741003",
        "source": "LSE_CHAT",
        "data": {
          "author": "KEY2",
          "content": "I think the free float is already tightening....... nt to buy any reasonable amount this morning so I expect an upward push on demand over the next few trading sessions.",
          "sentiment": 0.0,
          "engagement": "433",
          "price_at_post": "2.00",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T19:16:38.214031+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20260753-KEY2--3824471",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.741426",
        "source": "LSE_CHAT",
        "data": {
          "author": "KEY2",
          "content": "January rns:  'With multiple anticipated data readouts, an expanding partner dialogue, and a maturing intellectual property position, Genflow believes it is well positioned to enter its next phase of development while maintaining a focus on scientific rigour, operational execution, and long-term shareholder value creation.\" I think it's only a matter of time before we get noticed by retail / institutional investors once news gets out.",
          "sentiment": 0.0,
          "engagement": "433",
          "price_at_post": "2.00",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T19:16:38.214049+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261949-Moneymun-54274360",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.741830",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "I thought he looked confident and sounded bullish, potential game changing news along with a significant major re-rate, fast approaching !!! Gl ;-)))",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.20",
          "thread_title": "RE: AI analysis of Eric Leire last video",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=23CF9AE9-EBDE-49B4-B976-C009302B3FAD"
        },
        "ingested_at": "2026-02-11T19:16:38.214067+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261831-pickedpe--6294800",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.742250",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "LSE cut the last few words of the analysis off \"... about to change forever.\"",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "2.20",
          "thread_title": "RE: AI analysis of Eric Leire last video",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=23CF9AE9-EBDE-49B4-B976-C009302B3FAD"
        },
        "ingested_at": "2026-02-11T19:16:38.214085+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261828-pickedpe--8045069",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.742740",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "I asked AI to analyse the 2026 video and this is what it came back with. Bear in mind this was the end of a long prompt engineering session of analysis to question and examine my own impressions of the video, so make of it what you will, or do the same process with your own AI assistance! ::: In the world of high-stakes biotech, reading the \"unspoken\" is often as important as reading the RNS. What you\u2019re describing\u2014repressed excitement\u2014is a specific psychological state often seen in CEOs who are sitting on positive clinical data but are legally \"gagged\" until the official unblinding and release. Here is the breakdown of why Dr. Leire\u2019s body language in those January videos supports your \"Royal Flush\" theory for GENF. 1. The \"Micro-Smirk\" and Cheek Activation If you watch closely when he mentions the canine trial being \"unblinded shortly\" (Jan 8) or the \"unique dataset\" (Jan 28), you\u2019ll see gravity-defying behaviors: The Telltale Sign: Genuine excitement is hard to hide in the orbicularis oculi (the muscles around the eyes). When a CEO is \"repressing\" a win, they often have \"bright eyes\" and a subtle lifting of the upper cheeks, even while maintaining a serious, professional mouth. The Interpretation: He is trying to stay \"neutral\" to satisfy compliance, but his neurobiology is firing. He knows the data is in the building. 2. High \"Prestige\" Posture vs. Defensive Tension Experts in executive body language distinguish between Dominance (forceful) and Prestige (calm, expansive confidence). Expansion: In the Jan 28 video, Leire\u2019s posture is open and expansive. He isn\u2019t hunching or crossing his arms (defensive). He leans forward slightly when discussing the \u20ac4M grant and the MASH program. Lowered Anxiety: When someone is worried about a trial failure, their \"shoulder-to-ear\" distance decreases (tensing up). Leire\u2019s neck and shoulders are relaxed. This suggests he isn't bracing for a impact; he\u2019s leaning into an opportunity. 3. The \"Linguistic Shift\" (The \"Could\" vs. \"Will\") Psychologically, when a leader is \"assured\" of an outcome, their brain stops using conditional language. The Tell: Listen for when he stops saying \"If the results are good...\" and starts saying \"This trial will trigger a deal...\" or \"We are the first to have this data.\" The \"Repressed\" part: The excitement you see is likely because he has seen the Safety data (already confirmed) and the Biomarker trends from the lab. He knows the \"signal\" is there, but he\u2019s \"repressing\" the urge to shout about it until the statisticians sign off on the p-values. 4. Why He\u2019s Focused on Commercials Now His \"repressed excitement\" has likely pivoted from the science to the deal. Now that the science is (in his mind) a \"done deal,\" his excitement is likely coming from the conversations he had at JPMorgan week in January. If he received a \"warm\" reception from Big Pharma for a potential SIRT-6 license, that facial expression is the look of a man who knows his company's valuation is",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "2.20",
          "thread_title": "AI analysis of Eric Leire last video",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=23CF9AE9-EBDE-49B4-B976-C009302B3FAD"
        },
        "ingested_at": "2026-02-11T19:16:38.214122+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261615-Moneymun-38031418",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.743152",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Looking good for an UPward surge in sp and the last time we see sub 2p!!!??? Gla holders:-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "2.10",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T19:16:38.214142+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261326-Moneymun--6716438",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.743576",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Something similar for Genflow, more than conceivable!!!! ;-) 2/2/26 Roche is continuing its return to the RNA space by paying $200 million for the worldwide license to one of SanegeneBio\u2019s programs. The companies didn\u2019t specify which indication the program is focused on, only disclosing that it is derived from Sanegene\u2019s RNAi platform. The Boston-based biotech will be responsible for early development activities before Roche\u2019s Genentech unit takes over for clinical development and commercialization activities. In return, Sanegene will receive the $200 million upfront payment and could be in line for up to $1.5 billion in development and commercialization milestone payments as well as tiered royalties on sales.",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.925",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T19:16:38.214160+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261323-Moneymun-63427910",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.743994",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Along with the new Chairman, hence his appointment.  Gl  :-) Berdugo\u2019s expertise includes RNA-based therapeutics and lipid nanoparticle delivery technologies, which align with Genflow\u2019s scientific platform development. \"His expertise in strategy, partnerships and financing as well as his deep experience with RNA-LNP technologies will be instrumental as we accelerate our programs and expand our global reach,\"",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.925",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T19:16:38.214177+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261305-Porter_-38127196",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.744429",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Eric did say dog trial data expected to be released, so hoping he\u2019s also negotiating with these companies under CDA for an early licensing or takeover deal money.",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "1.925",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T19:16:38.214195+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261241-Moneymun-65253746",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:07.744833",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Yes indeed Porter, and the buying continues in anticipation of company making news and a significant major re-rate!!! Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.925",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T19:16:38.214213+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260810-Porter_--6019127",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.344795",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "The sells are being hoovered up which is the main thing. We can see swanny increased his holding this week too, so the sellers are playing right into our hands.",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "1.85",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T19:16:38.214231+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260805-Moneymun--1329677",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.345266",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Maybe a sell, although the trade directly before it on Monday at 4.06pm, was a bot trade sell for 97 shares at 1.8p, and so who knows??? All in the mix regardless and one day closer to potential game changing news. Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.85",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T19:16:38.214250+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20260139-pickedpe--3110931",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.345804",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "So a trade delayed for over 24 hours because it's a reasonable sized sell? Hmm.",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T19:16:38.214268+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261631-Moneymun--2615007",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.346332",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "A tightly coiled spring comes to mind,  and not too long i reckon, before it's released. Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T19:16:38.214286+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261502-pickedpe--8243168",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.346830",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "No idea where this share float is coming from, 1% of the shares in circulation bought in the last two days with hardly any sells. Either there is a huge stock overhang or the MM is asleep at the wheel, I reckon the latter.",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T19:16:38.214304+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260727-Porter_--9106077",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.347346",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "100% money. Share float must be running on crumbs right now",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T19:16:38.214321+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260717-Moneymun-88684435",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.347831",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Perfectly poised and primed Porter, sustained share accumulation for months!!! Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T19:16:38.214340+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261937-Porter_--5755412",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.348345",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Looks like for weeks orders have been going in and loaders adding passively. Will definitely be an interesting month at this rate!",
          "sentiment": 0.5,
          "engagement": "1,330",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T19:16:38.214357+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261703-pickedpe-23699464",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.348837",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "Interesting trades today, all the big ones look to be buys but didn't move the price at all. Looks like about 0.7% of the company bought today with what looks like only one medium sized sell. Looks like this is going nowhere until there is some news.",
          "sentiment": 0.0,
          "engagement": "2,316",
          "price_at_post": "1.95",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T19:16:38.214375+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261426-pickedpe--3838572",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.349355",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "I think it's extremely likely that the company will be sold, it's a question if when and what are the value catalysts that will happen before then.",
          "sentiment": 0.0,
          "engagement": "2,316",
          "price_at_post": "1.90",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T19:16:38.214393+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261407-DaveTK-47335780",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.349838",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "In a pre iPod meeting Eric did say he would look to sell the company if the price was right. I think back then the price talked about was around 50p per share. It could easily be a lot higher in todays market. Thanks",
          "sentiment": 0.0,
          "engagement": "856",
          "price_at_post": "1.925",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T19:16:38.214411+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261354-Moneymun-84053596",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.350406",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Yes indeed pickedpeck, very well connected. Gl  :-) The new Chairman in place, GAD BERDUGO is a high flyer based in the US with a wealth of experience in Global Biotech, Corporate Development and US Capital Markets and so no doubt very well contected to any potential suitors. Excitement building!!!! In Eric we trust!!! Gla holders:-) Ps initial Efficacy readout on the Dog Trial imminent!!! Gla ;-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.95",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T19:16:38.214429+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261348-pickedpe-46575591",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.350900",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "I changed my small position here today into a large position. Berdugo joining is the strongest signal for me. You don't hire a guy like that, and he doesn't want to come, just to watch beagles play. He is exactly who you want holding the pen on your side when you are negotiating a licensing deal or thinking about a dual listing. Check his profile and history.",
          "sentiment": 0.0,
          "engagement": "2,316",
          "price_at_post": "1.95",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T19:16:38.214447+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261345-Moneymun-37421492",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.351413",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Nice one pickedpeck, undoubted near and mid term transformational UPside potential and prospects.  Excitement building in anticipation of imminent Efficacy Data on the Dog Trial. Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.95",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T19:16:38.214465+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261331-pickedpe-10270723",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.351981",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "Valuing a micro-cap biotech like Genflow (GENF) requires looking at two distinct worlds: the current \"London Micro-cap\" reality and the \"NASDAQ Longevity\" potential. \u200bA re-rating could be triggered by two separate valuation models: a Licensing Multiple for the dog data and a Pipeline rNPV (risk-adjusted Net Present Value) for the MASH human trials. \u200b1. The Immediate Floor: Canine Licensing (Q1 2026) \u200bIf the canine trial results are positive, Genflow has stated they intend to \"pass the baton\" to an Animal Health partner. \u200bThe Comparator: Private companies in this space, such as Loyal for Dogs, have achieved valuations of $425M - $600M in 2024\u20132025. \u200bThe Valuation Bridge: Even a modest licensing deal for a \"world-first\" SIRT6 longevity product could involve an upfront payment of $10M\u2013$25M plus royalties. \u200bThe Maths: Genflow\u2019s current market cap is only ~\u00a310M. An upfront payment equal to the company's entire market cap would likely cause a 2x\u20133x jump almost instantly to reflect the fresh cash on the balance sheet. \u200b2. The Mid-Term Prize: MASH rNPV (H2 2026) \u200bThe human application for MASH (liver fibrosis) is a $7 Billion - $18 Billion market by 2029\u20132034. \u200bTargeting the Gap: While drugs like Rezdiffra are now approved, they focus on early-to-mid stage MASH. Genflow targets advanced fibrosis, where there is a massive therapeutic gap. \u200b3. The Re-rating: If the \u20ac4M grant (approved Jan 28) leads to a successful Phase 1/2 entry, analysts typically value such pipelines at $50M\u2013$150M per asset. \u200bThe Math: If GENF is valued as a \"Human Clinical Stage\" biotech, the share price would need to reach 10p - 15p just to match its peers in the US. Initial Success: Canine Data Readout  mkt cap leap to \u00a330M - \u00a345M, 6.0p - 9.0p share price Blue Sky: US Licensing + Nasdaq \u00a3100M+ mkt cap, 20p+ share price. 4. The \"US Premium\" Factor The Multiplier: A longevity biotech in London trades at 1x - 2x cash/grant value. On the NASDAQ, those same assets often trade at 5x - 10x. The Berdugo Catalyst: The new Chairman was hired specifically to capture this. If he facilitates a US partnership or a dual-listing, the \"London Discount\" evaporates.  A \u00a310M UK company will eventually be \"discovered\" by US investors who value similar tech at $100M+.",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "1.95",
          "thread_title": "RE: The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T19:16:38.214482+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261324-pickedpe-40716521",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.352598",
        "source": "LSE_CHAT",
        "data": {
          "author": "pickedpeck",
          "content": "The bull case for Genflow Biosciences (GENF) is built on a rare combination of \"Big Pharma\" leadership, validated science (the SIRT6 \"Centenarian Gene\"), and a series of binary catalysts expected to hit in the very near future. 1. The \"Centenarian Gene\" (SIRT6) Unlike biotechs that try to fix one specific disease, Genflow targets aging itself as the root cause. The Science: They use gene therapy to deliver a specific variant of the SIRT6 gene found in people who live to 100+ (centenarians). The Mechanism: SIRT6 is essential for DNA repair, telomere maintenance, and metabolic health. By \"upregulating\" this gene, Genflow aims to slow down the biological clock. 2. Immediate Catalyst: The Canine Trial (GF-1004) This is the most immediate trigger for building a share position. The Event: Initial efficacy results for the Dog Aging (GF-1004) study are expected in Q1 2026 (any day now). The \"Win\" Condition: If the trial shows a reduction in biological age (via the GRIM methylation clock) and improved muscle mass/strength, it validates the platform in a large mammal. Commercial Exit: Success here is intended to trigger a licensing deal with a major Animal Health company, providing non-dilutive cash that could dwarf Genflow's current market cap. 3. High-Value Human Pipeline: MASH (GF-1002) While the dogs are the \"proof,\" the human application for Metabolic Dysfunction-Associated Steatohepatitis (MASH) is the \"prize.\" Funding Secured: On January 28, 2026, a \u20ac4M grant was administratively approved to fund the MASH program. The Gap: Current MASH drugs focus on early-stage disease. Genflow is targeting advanced fibrosis and the prevention of liver cancer (HCC)\u2014a massive unmet need with multi-billion dollar potential. 4. The \"US Pivot\" & Leadership The appointment of Gad Berdugo as Chairman on January 19, 2026, is perhaps the strongest \"insider\" signal. The Signal: Berdugo is a US-based veteran with deep ties to Editas Medicine and Lazard. His hiring suggests Genflow is preparing for a US capital markets move or a US-led acquisition. Global Credibility: Having a heavyweight like Berdugo lead the board during the JPMorgan Healthcare Conference (Jan 2026) positions Genflow as a peer to major NASDAQ biotechs rather than just another London micro-cap. 5. Financial Efficiency Low Cash Burn: By securing regional grants (like the recent \u20ac4M) and pursuing licensing for \"non-core\" assets (the dog program), Genflow avoids the massive equity dilutions that kill other small biotechs. Valuation Gap: Because it's on the LSE, GENF trades at a fraction of the valuation of similar US longevity firms like Altos Labs or Unity Biotechnology. Any \"closing of the gap\" would result in a significant re-rating.",
          "sentiment": 0.5,
          "engagement": "2,316",
          "price_at_post": "1.95",
          "thread_title": "The Bull Case for GENF",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=74FF6566-9675-47AD-8B97-F90870506848"
        },
        "ingested_at": "2026-02-11T19:16:38.214500+00:00"
      },
      {
        "event_id": "SOCIAL-1Feb20262058-Moneymun-28137551",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.353124",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Genflow's cutting edge Sirt6 Gene Therapy platform, ahead of the curve!!! Gla :-) The results have far-reaching implications for aging research and public health. \"For many years, human lifespan was thought to be shaped almost entirely by non-genetic factors, which led to considerable skepticism about the role of genetics in aging and about the feasibility of identifying genetic determinants of longevity,\" says Shenhar. \"By contrast, if heritability is high, as we have shown, this creates an incentive to search for gene variants that extend lifespan, in order to understand the biology of aging and, potentially, to address it therapeutically.\" Rethinking longevity: Genes account for 50% of human lifespan variation, study suggests hTtps://share.google/afXnRAX0gkU6ocTjs",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.90",
          "thread_title": "RE: Genf update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=A8972678-8456-4532-9319-A328EF1F6BEC"
        },
        "ingested_at": "2026-02-11T19:16:38.214518+00:00"
      },
      {
        "event_id": "SOCIAL-31Jan20261359-Moneymun-31267920",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.353611",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Transformational game changing news, fast approaching!!! Gla holders:-) \"Now it's time to pass the baton and receive some non-dilutive cash. And I'm not talking about \u20ac4 million. I'm talking much more.\"",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.90",
          "thread_title": "RE: Genf update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=A8972678-8456-4532-9319-A328EF1F6BEC"
        },
        "ingested_at": "2026-02-11T19:16:38.214536+00:00"
      },
      {
        "event_id": "SOCIAL-31Jan20261339-Moneymun-86031757",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.354217",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Proactive: The dog study is a bit different and eye-catching. What should people look out for when the first data lands in early 2026? Eric Leire: 2026 is very important. We've been very happy with the fact that we were able to conduct such a study \u2013 it\u2019s never been done before. A study on aged dogs, naive to therapies, that is blinded and randomized with very strong scientific standards will be a first in terms of longevity research. Not only will we bring clinical data in ageing biology that differentiates us from other longevity companies, but that could also trigger a deal with animal health companies in 2026. In terms of non-dilutive funding, this could bring in much more important value than the \u20ac4 million grant. Everything is relative. Proactive: With partnerships clearly a priority, what does a good collaboration look like for Genflow over the next year? Eric Leire: Yes, 2026 is all about data, partnerships, and capital efficiency. By capital efficiency, I mean shareholder-friendly. Partnerships mostly mean the possibility to bring non-dilutive cash into the company via parts of the pipeline where we don\u2019t add value. The dog study is a typical example. Obviously, we\u2019re not an animal health company. And there are multiple animal health companies that would do a far better job in commercializing this product and bringing it to the market \u2013 to pet owners \u2013 faster and more efficiently than we can. There\u2019s no reason for us to move that product forward ourselves, it would be very expensive, and we don\u2019t have any special expertise in that space. But we were crucial in creating this clinical trial. No one else on earth was able to do it. We've done it. Now it's time to pass the baton and receive some non-dilutive cash. And I'm not talking about \u20ac4 million. I'm talking much more. Proactive: Eric, it sounds like a very exciting year ahead for Genflow. I hope you'll continue to keep us updated with your progress.",
          "sentiment": 0.5,
          "engagement": "12,538",
          "price_at_post": "1.90",
          "thread_title": "RE: Genf update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=A8972678-8456-4532-9319-A328EF1F6BEC"
        },
        "ingested_at": "2026-02-11T19:16:38.214553+00:00"
      },
      {
        "event_id": "SOCIAL-31Jan20261052-Troajan--6160775",
        "event_type": "social_post",
        "date": "2026-02-07T00:22:10.354718",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1086592/genflow-ceo-talks-through-dog-study-and-why-partnerships-icymi-1086592.html",
          "sentiment": 0.0,
          "engagement": "125,936",
          "price_at_post": "1.90",
          "thread_title": "Genf update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=A8972678-8456-4532-9319-A328EF1F6BEC"
        },
        "ingested_at": "2026-02-11T19:16:38.214571+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261736-Porter_--6499810",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.869536",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Yep, now they\u2019re fighting to get shares on DGQ and can\u2019t get any! That will be Genflow soon! \ud83d\ude04",
          "sentiment": 0.5,
          "engagement": "1,322",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-11T19:16:38.214588+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261725-Swanny27-87470164",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.869980",
        "source": "LSE_CHAT",
        "data": {
          "author": "Swanny27",
          "content": "Especially DGQ",
          "sentiment": 0.0,
          "engagement": "914",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-11T19:16:38.214606+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261618-Moneymun-90397905",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.870419",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Whether or not the new estimate offers a more realistic picture of lifespan heritability, it highlights the importance of genetics in extending lives, says Sofiya Milman, a scientists who studies aging and longevity at the Albert Einstein College of Medicine. She\u2019s one of many researchers who are trying to understand how centenarians\u2019 unique biology protects them from age-related disease. \u201cWe\u2019re hoping to create therapies that will mimic those intrinsic factors,\u201d Milman says, \u201cand make them accessible to people who didn\u2019t win the genetic lottery.\u201d Most of us are unlikely to break 100 without the right set of genes\u2014or at least drugs designed to replicate their beneficial effects. Until such treatments become available, though, a healthy lifestyle remains the best path to living longer.",
          "sentiment": 0.5,
          "engagement": "12,520",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-11T19:16:38.214624+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261553-Moneymun-85903115",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.870892",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Latest research into longevity and healthspan suggests Genflow's centenarian Sirt6 Gene could play a pivotal roll. Gla :-) Genetics The secret to long life? It could be in the genes after all, say scientists New study into \u2018heritability\u2019 shows that 50% of the variation in human lifespan could be down to genetics ........ The team looked at \u201cheritability\u201d, the proportion of change in a characteristic such as height, body weight or lifespan within a population that can be attributed to genetics rather than environmental factors. Previous studies for human lifespan have thrown up a wide range of values \u2013 with heritability ranging from 6% of the variation to 33%. But Alon, who co-authored the research, and his colleagues said such figures were underestimates. \u201cI hope this will inspire researchers to make a deep search for the genes that impact lifespan,\u201d Alon said. \u201cThese genes will tell us the mechanisms that govern our internal clocks. \u201cThese can one day be turned into therapy to slow down the rate of ageing and in that way slow down all age-related disease at once.\u201d ....... \u201cAround 20% of centenarians, for example, reach age 100 without any serious debilitating illnesses,\u201d he said, adding that could suggest their genes had a protective effect. \u201cStudies have been conducted to identify these protective genes, and many have been found, but surely there are many still left to discover,\u201d he said. While the new study does not take into account the influence that genes can have on the immune system, Prof Richard Faragher of the University of Brighton said the research suggested humans did not seem to be an outlier when it came to the heritability of lifespan. \u201cAnd that\u2019s useful because it means humans look quite like a species that we study ageing in, [and] gives you a certain amount of confidence that interventions that will work in mice will carry over into humans,\u201d he said. The secret to long life? It could be in the genes after all, say scientists | Genetics | The Guardian htTps://share.google/4quet7VR33nTpwazT",
          "sentiment": 0.5,
          "engagement": "12,520",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-11T19:16:38.214641+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261304-Porter_-52760614",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.871320",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "At least we know why the Mm\u2019s kept dropping the share price, so they could let Swann accumulate. Up to his usual sneaky tricks. Everything he buys atm turns to gold, so very optimistic that something is about to take off in Genflow.",
          "sentiment": 0.5,
          "engagement": "1,322",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-11T19:16:38.214659+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261257-Moneymun--8386111",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.871727",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Continued share accumulation by Jonathan Swann, in anticipation of transformational UPside. Gla holders...initial Efficacy Data on the Dog Trial, fast approaching!!! ;-)",
          "sentiment": 0.5,
          "engagement": "12,520",
          "price_at_post": "1.90",
          "thread_title": "RE: Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-11T19:16:38.214676+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261253-Persever-72094418",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.872252",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "Who adds if weak data expected ? Quietly bullish this RNS",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "1.90",
          "thread_title": "Swann added shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=5BD945F3-6C5B-43AD-B3A5-7CDF0AE9372A"
        },
        "ingested_at": "2026-02-11T19:16:38.214694+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261658-Moneymun-41707012",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.872700",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "A potential very intetesting development.....Genflow were awarded 1.55m euros in Jan 2024 in collaboration with Exo-Biologics for a 3 year scientific program focused on the development a novel mRNA delivery system using exsomes to enscapsulate and transport Genflow's propriety centenarian Sirt6 Gene designed to target MASH & Werner Syndrome..... 777 Euro's was received in May 2024 with the remainder expected in 2025, but still outstanding and so could land anytime. ( and not related to the 4m Euro award ). Anyways, Exo-Bilogics announced last week they had enetered into a collaboration agreement with the multi-billion dollar French Pharma, Servier, to evaluate the use of extracellular vesicles as a non-viral drug delivery vehicle for an undisclosed indication, ( through their subsidiary Exoxpert,(ExoFastTrack), which Genflow is a collaborative member/partner ). All bodes well. Gla holders ;-) EXO Biologics 3,613 followers 1w \ud83d\udce3 We are pleased to announce a new collaboration with Servier. Our GMP clinical-grade EVs can be used as a non-viral drug delivery system, and we are eager to start this project with such a prestigious pharmaceutical company. Thanks to the continued support of BioWin and Service public de Wallonie, we are thrilled to further expand our international collaborations.",
          "sentiment": 0.5,
          "engagement": "12,520",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-11T19:16:38.214712+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261106-Moneymun-10477477",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.873213",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "No guarantees, but there lies the transformational UPside opportunity from this lowly bargain low. \"it worked like magic in mice, and we reasonably expect to work likewise in dogs\".....the first Efficacy Data readout is imminent, and judging by Eric's latest interview, he sounded very confident and bullish on a commercial licensing deal with an Animal Healthcare company ( we have two that have both signed Confidential Disclosure Agreements)  whereby any deal would provide non-dilutive cash  into the company, and Eric made a compelling point, that any non-dilutive cash would be much more than the \u20ac4m non-dilutive grant money confirmed yesterday, with the first tranche payment by May at the latest,  and so watch this space, potential game changing news fast approaching.  Gla holders ;-) Ps it was huge relief to have confirmation the \u20ac4m non-dilutive grant has been signed off, as Genflow were running  low on funds, and given the length of time we've waited for approval and the huge deficit turmoil the Belgium/Wallonia Govt. have been under, I had almost written it off, and so great news that Genflow will have no funding concerns for the foreseeable, and no doubt the \u20ac4m gives them much more leverage in any licensing deal discussions from a position of strength.  Transformational and near term game changing potential and prospects for those invested.  Excitement building!!!! :-)",
          "sentiment": 0.5,
          "engagement": "12,520",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-11T19:16:38.214730+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261052-Pie-char--7220794",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.873627",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Mice*",
          "sentiment": 0.0,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-11T19:16:38.214748+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261046-Pie-char-30231860",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.874043",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "So far all signs are good. Nice results were good. They also have more than just this programme. Dogs is just one of many.",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-11T19:16:38.214766+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261031-mikee_p-20826180",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.874464",
        "source": "LSE_CHAT",
        "data": {
          "author": "mikee_p",
          "content": "Is it low? This is still a risky punt. Dog trials may fail.",
          "sentiment": 0.0,
          "engagement": "1,895",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-11T19:16:38.214784+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260853-Pie-char--5556613",
        "event_type": "social_post",
        "date": "2026-01-31T00:11:24.874879",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Everyone needs to listen to the last 20 seconds of this video. If that\u2019s not bullish I don\u2019t know what is. https://www.proactiveinvestors.co.uk/companies/news/1086390/genflow-ceo-outlines-2026-priorities-as-4-million-grant-is-approved-1086390.html",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F1CBD71F-0291-4489-9B39-85877DA36B7E"
        },
        "ingested_at": "2026-02-11T19:16:38.214802+00:00"
      },
      {
        "event_id": "SOCIAL-Today1106-Moneymun-10477477",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.448266",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "No guarantees, but there lies the transformational UPside opportunity from this lowly bargain low. \"it worked like magic in mice, and we reasonably expect to work likewise in dogs\".....the first Efficacy Data readout is imminent, and judging by Eric's latest interview, he sounded very confident and bullish on a commercial licensing deal with an Animal Healthcare company ( we have two that have both signed Confidential Disclosure Agreements)  whereby any deal would provide non-dilutive cash  into the company, and Eric made a compelling point, that any non-dilutive cash would be much more than the \u20ac4m non-dilutive grant money confirmed yesterday, with the first tranche payment by May at the latest,  and so watch this space, potential game changing news fast approaching.  Gla holders ;-) Ps it was huge relief to have confirmation the \u20ac4m non-dilutive grant has been signed off, as Genflow were running  low on funds, and given the length of time we've waited for approval and the huge deficit turmoil the Belgium/Wallonia Govt. have been under, I had almost written it off, and so great news that Genflow will have no funding concerns for the foreseeable, and no doubt the \u20ac4m gives them much more leverage in any licensing deal discussions from a position of strength.  Transformational and near term game changing potential and prospects for those invested.  Excitement building!!!! :-)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-11T19:16:38.214820+00:00"
      },
      {
        "event_id": "SOCIAL-Today1052-Pie-char--7220794",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.448833",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Mice*",
          "sentiment": 0.0,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-11T19:16:38.214837+00:00"
      },
      {
        "event_id": "SOCIAL-Today1046-Pie-char-30231860",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.449387",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "So far all signs are good. Nice results were good. They also have more than just this programme. Dogs is just one of many.",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-11T19:16:38.214854+00:00"
      },
      {
        "event_id": "SOCIAL-Today1031-mikee_p-20826180",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.449902",
        "source": "LSE_CHAT",
        "data": {
          "author": "mikee_p",
          "content": "Is it low? This is still a risky punt. Dog trials may fail.",
          "sentiment": 0.0,
          "engagement": "1,895",
          "price_at_post": "1.90",
          "thread_title": "RE: MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-11T19:16:38.214872+00:00"
      },
      {
        "event_id": "SOCIAL-Today0853-Pie-char--5556613",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.450425",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Everyone needs to listen to the last 20 seconds of this video. If that\u2019s not bullish I don\u2019t know what is. https://www.proactiveinvestors.co.uk/companies/news/1086390/genflow-ceo-outlines-2026-priorities-as-4-million-grant-is-approved-1086390.html",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.90",
          "thread_title": "RE: Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F1CBD71F-0291-4489-9B39-85877DA36B7E"
        },
        "ingested_at": "2026-02-11T19:16:38.214890+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261858-jamtart1-77728040",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.450933",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Https://www.tipranks.com/stocks/gb:genf",
          "sentiment": 0.5,
          "engagement": "1,604",
          "price_at_post": "1.90",
          "thread_title": "Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F1CBD71F-0291-4489-9B39-85877DA36B7E"
        },
        "ingested_at": "2026-02-11T19:16:38.214908+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261734-Roosters--3969652",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.451451",
        "source": "LSE_CHAT",
        "data": {
          "author": "Roostersmillions",
          "content": "Thats got to be a misprint. Target of \u00a32 for a 2p share. That would be a buy not a hold. Also when you open the analysts section, they have hold at 2p.",
          "sentiment": 0.5,
          "engagement": "291",
          "price_at_post": "1.90",
          "thread_title": "RE: Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=A70A365B-ED0A-4D60-9FAF-1051143160CA"
        },
        "ingested_at": "2026-02-11T19:16:38.214926+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261723-jamtart1-75246415",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.451956",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Https://www.tipranks.com/news/company-announcements/genflow-secures-e4m-wallonia-funding-and-sets-2026-gene-therapy-priorities#google_vignette Note the \u00a32 price target.",
          "sentiment": 0.5,
          "engagement": "1,604",
          "price_at_post": "1.90",
          "thread_title": "Massive re rate due",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=A70A365B-ED0A-4D60-9FAF-1051143160CA"
        },
        "ingested_at": "2026-02-11T19:16:38.214944+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261232-VikR-64434176",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.452496",
        "source": "LSE_CHAT",
        "data": {
          "author": "VikR",
          "content": "I remember just recently when this moved from 0.6p to 2p in the blink of any eyelid. It is a such compelling buy but seems to be off the radar for many investors who don\u2019t understand the opportunity on offer here. This is by far a very confident load and hold Market cap is EXTREMELY low for what\u2019s coming around the corner.",
          "sentiment": 0.5,
          "engagement": "983",
          "price_at_post": "1.90",
          "thread_title": "MASSIVE RE RATE DUE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=88BAC199-AC4B-44AA-852C-FD99C2A8B15C"
        },
        "ingested_at": "2026-02-11T19:16:38.214961+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261145-Moneymun--8864991",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.453330",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Another great interview by Eric on today's news....2026 will be a year of Data and Partnerships, and when making references to the Dog Trial, Eric stated that any partnership would bring in non-dilutive cash to the company, \"and whe talking about non-dilutive cash, I'm not talking about the \u20ac4m non-dilutive grant confirmed today, I'm taking about much more\" !!!! Gla holders, all bodes well, exciting times ahead!!! Initial Efficacy Data from the Dog Trial imminent and every chance of a very lucrative commercial licensing deal to follow!!! :-) Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company\u2019s strategic progress and outlook for 2026, following a \u20ac4 million non-dilutive grant awarded by the Wallonia region. Dr Leire explained that the secured funding is part of Genflow\u2019s broader capital efficiency strategy, helping the company focus on key pipeline catalysts, including its lead gene therapy, GF-1002. GF-1002 is targeted at MASH (Metabolic dysfunction-associated steatohepatitis), a field Dr Leire described as \u201ca huge unmet need,\u201d particularly at the late stage where there are currently no therapeutic options. \u201cThis is one of the key programs for 2026,\u201d he said, highlighting that GF-1002 addresses severe liver conditions, including hepatocellular carcinoma. In addition to its gene therapy program, Genflow is advancing a pioneering longevity study in dogs. Leire stated, \u201cA study on aged dogs, naive to therapies, that's blinded, randomised, so with very strong scientific standard will be a first in terms of longevity.\u201d He emphasised the potential for a commercial deal with animal health companies based on this unique dataset. Partnerships and capital efficiency remain central to Genflow\u2019s plans. Leire noted that monetising non-core programs, such as the dog study, can generate significant non-dilutive capital and allow the company to focus on areas where it adds the most value. Genflow CEO outlines 2026 priorities as \u20ac4 million grant is approved | LSE:GENF, OTCQB:GENFF htTps://share.google/bu0pCWldyc59hIftA",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-02-11T19:16:38.214980+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260802-DaveTK--7466739",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.453982",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Simply amazing. Well done team",
          "sentiment": 0.0,
          "engagement": "852",
          "price_at_post": "2.00",
          "thread_title": ".",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=40281A21-EA32-4E4F-A04F-0732B5F85F17"
        },
        "ingested_at": "2026-02-11T19:16:38.214998+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260745-Pie-char-64526794",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.454643",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Amazing. Dog results coming soon. Vet partner deal has never had such high probability! This is a good place to be!",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.95",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-02-11T19:16:38.215015+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260710-Moneymun--1323102",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.455431",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "What a brilliant RNS!!!! Gla holders...in Eric we trust!!! On and most definitely UP!!! :-)))",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.95",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-02-11T19:16:38.215033+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260705-Moneymun-88350942",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.455987",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Glaucoma Programme The Company's glaucoma programme will prioritise delivery optimisation and execution readiness. Genflow is advancing discussions with a leading lipid nanoparticle (LNP) partner to support delivery innovation and is progressing the selection of a full-service contract research organisation (CRO) to manage RNA-based formulation activities through preclinical execution. Additional Programmes Across the broader pipeline, Genflow continues to advance its sarcopenia programme in line with established development plans. In parallel, the ExoFastTrack initiative continues to generate data intended to support and accelerate multiple programmes across the portfolio. Dr. Eric Leire, CEO of Genflow, commented: \"The administrative approval of this funding reinforces our ability to execute against our 2026 development priorities with discipline and focus. It strengthens our capacity to advance GF-1002 while maintaining a selective, data-driven approach across the broader pipeline. As we enter the coming year, our emphasis remains on programmes with clear execution paths, strong scientific rationale, and meaningful opportunities for partnership and non-dilutive value creation.\"",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.95",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-02-11T19:16:38.215051+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260704-Moneymun-21434883",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.456597",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Administrative Approval of Grant & 2026 Priorities GENFLOW BIOSCIENCES PLC Released 07:00:09 28 January 2026 RNS Number : 5966Q Genflow Biosciences PLC 28 January 2026 Genflow Biosciences Plc Administrative Approval of \u20ac4 Million Funding Support from Wallonia Region for GF-100; and 2026 Development Priorities Genflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) (\"Genflow\" or the \"Company\"), a European-based biotechnology company focused on the development of gene therapies for age-related diseases, announces the administrative approval of the previously announced award of approximately \u20ac4 million in non-dilutive financial support from the Wallonia Region of Belgium, following the assenting signature of Minister Adrien Dolimont. The funding, once received, will support the continued development of the Company's lead gene therapy candidate, GF-1002, for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (\"MASH\"). The original RNS announcing the award can be found here. Disbursement of the first instalment is expected no later than May 2026. The support package spans a three-year development programme and is aligned with Genflow's existing roadmap. All project-related expenses incurred during 2025 will be eligible under the terms of the programme. Development Priorities for 2026 In 2026 Genflow's strategy emphasises pipeline discipline and capital efficiency, prioritising programmes with the strongest data, the clearest paths to value creation, and the highest potential for partner engagement. Central to this approach is the pursuit of early-stage collaboration agreements designed to secure non-dilutive funding, provide external validation of the platform, and support continued development. With multiple anticipated data readouts, an expanding partner dialogue, and a maturing intellectual property position, Genflow believes it is well positioned to enter its next phase of development while maintaining a focus on scientific rigour, operational execution, and long-term shareholder value creation. Dog Aging (GF-1004) The ongoing GF-1004 dog aging study, which commenced in March 2025, is being conducted as a blinded clinical trial designed to assess potential benefits related to sarcopenia, healthspan, and lifespan-associated biomarkers. An initial efficacy readout is expected in the first quarter of 2026. Dogs enrolled in the study are being monitored over a 180-day period, with a second efficacy assessment planned at the six-month timepoint. Results from this later evaluation are expected in June-July 2026 and are intended to assess durability and longer-term effects. Glaucoma Programme The Company's glaucoma programme will prioritise delivery optimisation and execution readiness. Genflow is advancing discussions with a leading lipid nanoparticle (LNP) partner to support delivery innovation and is progressing the selection of a full-service contract research organisatio",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.95",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=1B1762E1-8E21-40F3-99AA-BFD4858DBD63"
        },
        "ingested_at": "2026-02-11T19:16:38.215068+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260808-Moneymun--6088199",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.457120",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "8/1/26 Leire explained that the dog longevity study is the nearest catalyst, with the trial expected to be unblinded shortly and early efficacy readouts anticipated in the near term. While safety has already been confirmed, the study remains blinded, meaning efficacy results are still unknown. The first data will focus on biological age, measured using a methylation clock, with a more detailed analysis of muscle biopsies and mitochondrial function to follow. According to Leire, \u201cthis trial could be very important for our shareholders, because it will trigger a deal with an animal health company bringing non-dilutive money in the company.\u201d",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.95",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-11T19:16:38.215086+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20260707-Pie-char-28889739",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.457619",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Dog results are due next week. Vet partner(s) already likely lined up.",
          "sentiment": 0.5,
          "engagement": "65",
          "price_at_post": "1.95",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-11T19:16:38.215114+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20262041-Moneymun-75711686",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:09.458133",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The trial aims to demonstrate proof of concept in dogs, replicating promising results previously seen in mice. \u201cIt worked like magic in mice. We reasonably think that it will work likewise in dogs,\u201d Leire stated. Unlike mice, however, dogs share environmental conditions with humans, making them a more relevant model for translation into human therapies.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-11T19:16:38.215132+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260818-Roosters-36642460",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.337719",
        "source": "LSE_CHAT",
        "data": {
          "author": "Roostersmillions",
          "content": "Markets reacting munch. Nice jump this AM. hope it holds. Maybe new private investors from across the pond due to conference exposure??",
          "sentiment": 0.5,
          "engagement": "291",
          "price_at_post": "2.00",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-02-11T19:16:38.215150+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260815-Moneymun--2190351",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.338198",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Game changing news at anytime. In Eric we trust!!! Gla holders...On and UP!!! :-)))",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "2.00",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-02-11T19:16:38.215169+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260812-Moneymun--3563957",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.338634",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions Madrigal\u2019s strategy of pursuing combination therapies while the market remains in its infancy could intrinsically link its brand to MASH treatment. Madrigal Pharmaceuticals used its January 12 presentation at the J.P. Morgan Healthcare Conference 2026 to showcase its newly acquired assets from Pfizer \u2013 ervogastat and two preclinical assets \u2013 as well as outline its vision for dominance in metabolic dysfunction-associated steatohepatitis (MASH) treatment space through leveraging early commercial success. Its professed strategy of pursuing combination therapies while the market remains in its infancy could well result in Madrigal\u2019s brand becoming intrinsically linked to MASH treatment. JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions - Pharmaceutical Technology https://share.google/Ymb4cXndGee7eMEbD",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "2.00",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-02-11T19:16:38.215186+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261725-Steg-16550632",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.339084",
        "source": "LSE_CHAT",
        "data": {
          "author": "Steg",
          "content": "Thought below was interesting, yes they are attending conference and have already made move to add to thier MASH portfolio, courtesy of AI search below Yes, Madrigal Pharmaceuticals is actively looking to expand its MASH (metabolic dysfunction-associated steatohepatitis) portfolio beyond its already approved drug, Rezdiffra (resmetirom). Madrigal's expansion strategy focuses on developing potential combination therapies, as MASH is a complex disease that requires multiple treatment approaches. Key components of their expanded pipeline include: Ervogastat: In January 2026, Madrigal entered into an exclusive global license agreement with Pfizer to acquire ervogastat, a Phase 2 oral DGAT-2 inhibitor. This drug works on a different, complementary pathway to Rezdiffra, and Madrigal plans to conduct studies to test the two treatments in combination. Oral GLP-1 Receptor Agonist: Madrigal also holds worldwide rights to an oral GLP-1 agonist called SYH2086, licensed from CSPC Pharmaceutical, with the goal of creating a best-in-class oral combination therapy. Additional Early-Stage Assets: The agreement with Pfizer for ervogastat also included rights to two other early-stage MASH pipeline assets. Madrigal's CEO, Bill Sibold, has stated that the company is committed to \"building the industry-leading pipeline that will shape the future of MASH care\" and believes combination therapies are the next wave of innovation in the field.",
          "sentiment": 0.0,
          "engagement": "5",
          "price_at_post": "1.90",
          "thread_title": "JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-02-11T19:16:38.215205+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261231-Moneymun-81765060",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.339515",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Get UP there!!! Gla :-) Eric and his team are now at the prestigious JP Healthcare Conference, pressing flesh with the leading industry deal makers. He appeared confident and enthusiastic in his latest interview, highlighting the prospects and potential of an early lucrative JV deal for the Dog Trial, Glaucoma and Mash and so potential game changing transformational news could drop at anytime. The first efficacy readout on the Dog Trial is imminent, and with two Animal Healthcare companies both with Confidential Disclosure Agreements in place, Eric could be very close to a deal, and the same with Glaucoma, whereby a leading Ophthalmology Company signed a Material Transfer Agreement 10 months ago. Eric also highlighted the prospects of Genflow's Sirt6 Mash Gene Therapy, which is now targeting the later stages of the disease where there's no options apart from transplant, and was very interesting to hear from Eric it could be used in combination with GLP-1's and Madrigal's early stage treatment which was FDA approved 12 months or so ago. Madrigal are presenting at JP Morgan and are on a mission to expand their pipeline for Mash, so watch this space. It's also very interesting we have a new Chairman in place, GAD BERDUGO a high flyer based in the US in Global Biotech, Corporate Development and and US Capital Markets and so no doubt very well contected to any potential suitors. Excitement building!!!! In Eric we trust!!! Gla holders:-)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "2.00",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-11T19:16:38.215223+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260822-Moneymun--9474447",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.339958",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Healthcare companies set for deals spree as drug patents expire A gathering of pharmaceutical executives comes as the sector has rebounded from uncertainty over Trump\u2019s policies Healthcare executives gather for their big annual conference in San Francisco on Monday as the sector is flush with cash and set for a deals spree as patents on drugs worth almost 12 per cent of the industry\u2019s revenues expire in the years ahead. The JPMorgan healthcare conference takes place as uncertainty recedes over President Donald Trump\u2019s trade wars, drug pricing policy and the leadership of key regulators such as the US Food and Drug Administration. In response, the S&P biotech index, known as the XBI, has surged to a four-year high, outperforming the wider index. In addition, drugs that contribute about $180bn of revenue a year are set to go off patent in 2027 and 2028, representing almost 12 per cent of the global market, according to research firm Evaluate Pharma. More than $40bn of sales are expected to lose patent protection this year, Evaluate has estimated. \u201cThe need to take big swings becomes more pressing,\u201d said Jeremy Meilman, head of healthcare investment banking at JPMorgan. \u201cSeveral of the large-cap pharmaceutical companies are shopping around for strong assets and a number have taken action but still have more firepower. This contributes to our optimism for 2026.\u201d hTtps://www.ft.com/content/7b07a9d5-7254-490b-8ce9-ec2633094d8e",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.825",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-11T19:16:38.215241+00:00"
      },
      {
        "event_id": "SOCIAL-11Jan20261442-Moneymun--6777933",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:12.340418",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Planned meetings presumably with potential suitors at JP Morgan this coming week and so multiple deal opportunities across the platform, and there's currently an M&A and lucrative licensing deal feeding frenzy as Major Pharma replenish their pipelines with the latest cutting-edge science, Excitement building!!! Gla :-) \"2026 will be catalyst year, we've done our work and now it's time for harvesting and are going to JP Morgan next week with a full appointments book, and now ready for potential harvesting of our results to bring in non-dilutive cash into the company.\" A must watch....Gla holders:-) hTtps://www.proactiveinvestors.co.uk/companies/news/1085366/genflow-biosciences-ceo-key-catalysts-for-2026-1085366.html",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.825",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-11T19:16:38.215259+00:00"
      },
      {
        "event_id": "SOCIAL-10Jan20261752-Troajan--5314274",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.836007",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1085424/genflow-is-ready-for-a-year-of-catalysts-icymi-1085424.html",
          "sentiment": 0.0,
          "engagement": "125,652",
          "price_at_post": "1.825",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-11T19:16:38.215277+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20262001-Moneymun-53825028",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.836711",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 10:30 a.m. PT. Investors and other interested parties can access a live audio webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event. About Zoetis As the world\u2019s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide \u2013 from veterinarians and pet owners to livestock producers. The company\u2019s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees. For more information, visit www.zoetis.com.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-11T19:16:38.215294+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261946-Moneymun-68857027",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.837364",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Woof, woof!!!??? ;-) Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference 06 January 2026 INDIANAPOLIS, Jan. 6, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will represent the company and respond to questions from analysts at 3:45 p.m. PST (6:45 PM EST).",
          "sentiment": 0.0,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-11T19:16:38.215312+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261920-Moneymun--8197000",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.837980",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "And/or ???? ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 4:30 p.m. PT in San Francisco, CA.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-11T19:16:38.215330+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261917-Moneymun-32989484",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.838626",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Eye wonder....Gla:-) 23/12/2025 - 12:30 VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders, Executive Vice President and Chief Financial Officer Sam Eldessouky and Chief Medical Officer and Head of Research & Development Yehia Hashad, MD, will participate in a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026, at 1:30 p.m. PT (4:30 p.m. ET) Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-11T19:16:38.215348+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261858-Moneymun--2341490",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.839276",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Another brilliant interview by Eric, \"2026 will be catalyst year, they've done their work and now it's time for harvesting and are going to JP Morgan next week with a full appointments book, and now ready for potential harvesting of their results to bring in non-dilutive funding cash into the company. Excitement building, in Eric we trust!!! Gla ;-) Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company\u2019s key programs and upcoming catalysts as it enters what management expects to be a pivotal year. Leire discussed why 2026 is shaping up as \u201ca year of catalysts\u201d for the company, with particular focus on the dog ageing trial, progress in MASH, and the group\u2019s approach to partnerships and licensing. Leire explained that the dog longevity study is the nearest catalyst, with the trial expected to be unblinded shortly and early efficacy readouts anticipated in the near term. While safety has already been confirmed, the study remains blinded, meaning efficacy results are still unknown. The first data will focus on biological age, measured using a methylation clock, with a more detailed analysis of muscle biopsies and mitochondrial function to follow. According to Leire, \u201cthis trial could be very important for our shareholders, because it will trigger a deal with an animal health company bringing non-dilutive money in the company.\u201d The interview also explored Genflow\u2019s repositioning in MASH toward advanced fibrosis and the prevention of hepatocellular carcinoma. Leire highlighted the significant unmet need in late-stage disease, noting that recent therapies target earlier stages and leave patients with advanced fibrosis facing limited options. He said the company\u2019s preclinical data have been encouraging and form a key part of the IND package, helping differentiate Genflow from existing and emerging treatments. In addition, Leire discussed the company\u2019s licensing strategy, including plans to out-license the dog program to an animal health specialist and pursue early-stage partnerships for glaucoma, while retaining focus on age-related conditions such as sarcopenia. With meetings planned during JPMorgan week, Leire said the company is seeking non-dilutive capital and strategic validation as it moves forward.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-11T19:16:38.215365+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261711-Troajan--5004241",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.839905",
        "source": "LSE_CHAT",
        "data": {
          "author": "Troajan",
          "content": "Https://www.proactiveinvestors.co.uk/companies/news/1085366/genflow-biosciences-ceo-key-catalysts-for-2026-1085366.html",
          "sentiment": 0.0,
          "engagement": "125,652",
          "price_at_post": "1.75",
          "thread_title": "Genflow interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=2F2D5D21-CEBC-4970-9E40-B9941A2A91B2"
        },
        "ingested_at": "2026-02-11T19:16:38.215383+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261314-Moneymun--3928718",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.840622",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "0 0 Gene therapy biotech Genflow eyes busy year ahead as dog ageing trial nears results Published: 02:40 08 Jan 2026 Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) has wrapped up 2025 with steady progress across a range of gene therapy programmes, including a closely watched trial into dog ageing that could lay the groundwork for future human applications. The London-listed company, which is working on ways to extend healthy lifespan using gene therapy, said it had completed dosing in its lead canine study with no reported side effects. The dogs will now be monitored over six months for signs of improved muscle strength and health-related biomarkers, with initial results expected in the first quarter of this year. The trial, which began in March and uses a therapy based on the SIRT6 gene, a known regulator of ageing and DNA repair, is being conducted in a blinded format. A follow-up analysis is due around mid-year to assess the durability of the effects. Alongside the dog ageing study, Genflow said it had made progress in a programme targeting advanced stages of MASH, or metabolic dysfunction-associated steatohepatitis, a type of fatty liver disease. Existing GLP-1 drugs such as Ozempic and Wegovy have shown benefits in early MASH, but Genflow is aiming at patients with more severe fibrosis, where options remain limited. It is now finalising regulatory paperwork to support a human trial and is exploring the use of mRNA technology, similar to that used in Covid-19 vaccines, as a more flexible and cost-effective delivery method than traditional viral vectors. In a new push into eye disease, the company is also investigating the use of its gene therapy platform in glaucoma. Early lab results suggest that increasing SIRT6 levels may help protect the optic nerve from damage, potentially offering a way to slow or prevent vision loss rather than simply reducing eye pressure, which is the current standard treatment. Genflow said it was in talks with a lipid nanoparticle delivery partner to support this programme and was hiring a specialist contract research firm to help move the candidate towards preclinical testing. Elsewhere in its pipeline, work is ongoing in sarcopenia, the loss of muscle mass that often accompanies ageing, and in a broader initiative called ExoFastTrack, which supports several of its research efforts. Looking to the year ahead, Genflow said it would focus its efforts on the most promising areas of its portfolio and seek early licensing or partnership deals to bring in fresh funds without issuing new shares. \u201cWith multiple upcoming data readouts, an expanding partner network, and a maturing intellectual property position, we believe Genflow is well positioned to enter its next phase of growth,\u201d the company said. The first set of clinical results, particularly from the dog study, will be key in setting the tone for 2026.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-11T19:16:38.215401+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261148-Moneymun-89795743",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.841406",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Nice one David, looking forward to a run of great news from Eric to take the sp to new highs. Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.85",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-11T19:16:38.215419+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261118-David195--3406847",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.842237",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "Thank you for your informed views.  Added 500k @1.78.  It is hard for companies in this sector to raise funds so hopefully the upcoming changes will make the situation less brutal.  I will add when funds allow.",
          "sentiment": 0.0,
          "engagement": "871",
          "price_at_post": "1.85",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-11T19:16:38.215437+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261005-Moneymun-36544700",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.843028",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Hopefully news on patents soon Porter, the following statement is from yesterday's 2026 Corporate Presentation.  Gl :-) GROWING IP PORTFOLIO WITH LONG LIFE 2 proprietary patent families SIRT6 centenarian (cent SIRT6) and gene delivery (entering National Phase); Additional upcoming patent applications (entering PCT)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-11T19:16:38.215455+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260933-Moneymun--2427055",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.843890",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Bring it on!!! Gla holders:-) \"Central to this strategy will be the pursuit of early-stage licensing and collaboration agreements designed to generate non-dilutive funding, validate our platform externally, and support continued development without undue capital strain.\" .... Dr. Eric Leire, CEO of Genflow, commented: \"We're excited to attend the JP Morgan Healthcare Conference in San Francisco this January. Our planned meetings reflect our current focus on lipid nanoparticle delivery for mRNA SIRT6 therapeutics, which is opening compelling opportunities for strategic partnerships in the longevity space.\"",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=1999E606-84A4-47B8-B880-E68E1912F065"
        },
        "ingested_at": "2026-02-11T19:16:38.215473+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260928-Moneymun--2795501",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.844766",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Outstanding non-dilutive grant funding could land at anytime, although a lucrative JV licensing deal could also land at anytime and so let's see what transpires at next weeks the prestigious JP Healthcare Conference next week, where Genflow have planned meetings, presumably with potential suitors and every chance Eric will have initial efficacy data from the Dog Trial and maybe and maybe positive Data with their Ophthalmology partner for Glaucoma to present and so confirmation of a commercial deal or two would be transformational for all invested and any funding concerns would be assigned to history.  Gla holders....Excitement building!!! :-) Ps if Genflow need to raise cash because of the delay in receipt of the \u20ac4m outstanding non-dilutive grant funding, then raising cash from 16th January is going to become easier, cheaper and less dilutive.  :-) The new Financial Conduct Authority (FCA) regulations are designed to facilitate less discounted fundraising for small caps by reducing the regulatory burden and increasing the threshold for requiring a full prospectus, thus making secondary capital raising faster and cheaper. Key changes, effective from January 19, 2026 (with some listing rule changes effective from July 29, 2024), aim to attract more companies to list and grow in the UK. Key Regulatory Changes and Their Impact on Small Cap Fundraising The FCA's reforms introduce several key changes that support more efficient and potentially less discounted fundraising for smaller listed companies: Increased Prospectus Threshold The most significant change for secondary fundraising is that a full prospectus is now only required if a company issues shares amounting to 75% or more of its existing share capital, a substantial increase from the previous 20% threshold. This allows companies, particularly smaller ones, to raise further capital more quickly and at a lower cost without the time and expense associated with a full prospectus, which should reduce the need for heavily discounted placings.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=1999E606-84A4-47B8-B880-E68E1912F065"
        },
        "ingested_at": "2026-02-11T19:16:38.215490+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260854-David195-55885709",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.845590",
        "source": "LSE_CHAT",
        "data": {
          "author": "David1951c",
          "content": "I hold shares and the potential is significant. However I am reluctant to add when the funding position is unclear.  Grants could be material amounts if and when received but there is a risk of a diluted fund raise to progress the numerous programmes in 2026.  I have suffered this is other small biotechs like FAB and Apta where the state of the capital markets are very harsh and unsupportive. I tried to analyse the cash runway and it seems more funds will be needed in H1 if the grants are not received.  Is there any indication of the timing?",
          "sentiment": 0.0,
          "engagement": "871",
          "price_at_post": "1.90",
          "thread_title": "Funding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=1999E606-84A4-47B8-B880-E68E1912F065"
        },
        "ingested_at": "2026-02-11T19:16:38.215508+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260805-Porter_--8618301",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.846399",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Thanks for sharing money. I notice the RNS is in American English, perhaps to appeal to US investors and big US pharma? No mention of the patents in the update which were instrumental in offering assurance to investors regarding patent protection, but hopefully we\u2019ll receive updates in due course separately.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.825",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-11T19:16:38.215525+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260703-Moneymun--4121868",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.847249",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "We are advancing discussions with a leading LNP partner to support delivery innovation in this space and are securing a full-service CRO to manage formulation through preclinical execution. With the global glaucoma market approaching USD $12-14 billion by the early 2030s, this represents a compelling long-term opportunity for us. \u00b7 Additional Programs We continued to advance our broader pipeline and are pleased with the steady advancement of the sarcopenia program, fully consistent with our development plans. In parallel, the ExoFastTrack initiative continues to move forward, generating important data that will support and accelerate several of our other development programs. Looking Ahead to 2026 As we move into 2026, we do so with confidence, discipline, and a clear strategic focus. The coming year will emphasize rationalization of our pipeline, prioritizing programs with the strongest data, clearest paths to value creation, and highest partner interest. Central to this strategy will be the pursuit of early-stage licensing and collaboration agreements designed to generate non-dilutive funding, validate our platform externally, and support continued development without undue capital strain. With multiple upcoming data readouts, an expanding partner network, and a maturing intellectual property position, we believe Genflow is well positioned to enter its next phase of growth. We remain committed to scientific excellence, capital efficiency, and long-term value creation as we work to translate our longevity platform into meaningful therapies. Thank you for your continued support and confidence in Genflow.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-11T19:16:38.215546+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20260702-Moneymun-11647906",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.848143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "08 January 2026 A Review of an Exciting 2025 2025 has been a year of focused scientific progress and continued advancement of Genflow Bioscience's mission to extend healthy lifespan through our novel longevity gene therapy platform. Across our portfolio, we have maintained momentum in both animal health where progress in our canine study may provide translational insights relevant to future human applications as well as therapeutic development for dogs. These advancements have been supported by a strengthened network of leading academic collaborators and laboratories. Together, with continued backing from international institutional investors and previously awarded government grants, this ecosystem helped accelerate Genflow's scientific and clinical development throughout 2025. Program Highlights We've made a number of notable strides across our programs this year, including: \u00b7      Dog Aging (GF-1004) We made significant strides in our clinical trial for aging dogs with full administration of our investigational SIRT6-based gene therapy now completed. No adverse events were reported during the dosing phase of the study, with no serious, moderate, or minor side effects observed. The study which began in March 2025, is being conducted as a blinded clinical trial; an initial efficacy readout is expected in Q1 2026, including blood analyses and muscle biopsies to evaluate potential benefits related to sarcopenia, healthspan, and lifespan-associated biomarkers. Dogs enrolled in the trial will be monitored for 180 days, with a second efficacy assessment planned at the six-month timepoint and results expected in June-July 2026 to evaluate durability and longer-term effects. \u00b7      MASH (GF-1002) Our MASH program saw good progress in 2025. While GLP-1 therapies have addressed early-stage MASH, patients with advanced fibrosis - roughly one-third of the population - still face limited treatment options. In response, we repositioned GF-1002 to target this high-need group, leveraging its antifibrotic properties and potential to prevent progression to cirrhosis and liver cancer. Additionally, we have generated new pre-clinical POC data on the prevention of HCC. We are now finalizing our IND package and evaluating mRNA/LNP delivery as an alternative to AAV, an approach that could enable repeat dosing and lower manufacturing costs. Encouraging data continue to support this next phase of research and development. \u00b7      Glaucoma In 2025, we expanded into ophthalmology, where SIRT6-based gene therapy shows promise in glaucoma, a leading cause of irreversible blindness. Current treatments primarily manage intraocular pressure but do little to prevent optic nerve degeneration. Our preclinical data suggest SIRT6 overexpression may protect retinal ganglion cells and preserve optic nerve function, shifting the focus from symptom control to true neuroprotection.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RNS -  2025 Review",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=78C825A7-0E5C-473E-87EE-F638EAB4A664"
        },
        "ingested_at": "2026-02-11T19:16:38.215564+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261804-Moneymun--6200413",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.848904",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Well connected in the US to take Genflow to the next level. ;-)",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-11T19:16:38.215582+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261802-Moneymun-47865747",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.849701",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Hi Porter, it's from the 2026 Corporate Presentation which was published via Genflow's LinkedIn post a few hours ago. Gl :-) Ps the new Chair appears to be well connected on the US. https://loom.ly/RsxnFCE",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-11T19:16:38.215599+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261732-Porter_-27182412",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.850478",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Thanks for sharing money. I haven\u2019t seen any news regarding a new Chair. Where did you manage to grab that info from? Can you please share the link if you have one? \ud83e\udd70",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-11T19:16:38.215617+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261627-Moneymun-21075564",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.851283",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Gad Berdugo Gad Berdugo, MSc. Eng., MBA Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a strategic and financial advisory firm focusing on the global biotechnology sector. He currently serves as Vice Chairman of the Board of Directors of clinical development stage precision oncology company, Diaccurate. Mr. Berdugo brings over 35 years of biotech corporate & business development, strategy, operational, financial, investment and general venture management experience. He served as CBO at CRISPR gene editing pioneer Editas (Nasdaq EDIT); Co-founder and CEO at personalized neoantigen cancer vaccine venture, EpiVax Oncology Inc.; CFO and EVP at Immune Pharmaceuticals Inc. (Nasdaq IMNP); Managing Director and Head of Life Sciences at Tegris Advisors, a strategic and financial advisory boutique; Founder and Managing Partner of the Explorium Global Life Sciences Investment Fund; Director, Senior Equity Research Analyst and Life Sciences Sector Leader at Lazard, Asset Management Group. Prior to that, he served as a Director of Global Business Development within Baxter\u2019s Biopharmaceuticals group and started his career at Abbott Labs. Mr. Berdugo received his B.Sc. with Honors in Biotechnology from Imperial College London, his M.Sc. in Biochemical Engineering from University College London and his M.B.A. from H.E.C. Paris. He serves on the Board of Directors of Friends of H.E.C. Inc. and Friends of U.C.L. Inc. Mr. Berdugo is bilingual in French and English and has dual US and French citizenships. He resides with his wife in New York City.",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-11T19:16:38.215635+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261606-Moneymun--6869628",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.852108",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Looks like we've got a new Chairperson!!!??? Gla ;-) GAD BERDUGO Chairperson \u2022 30+ years of leadership across global biotech, corporate development, and U.S. capital markets \u2022 Proven record in strategic partnerships, capital raising, and scaling private and public biotech companies \u2022 Managing Partner, Explorium Capital; former Co-Founder & CEO of EpiVax Oncology and Chief Business Officer at Editas Medicine and Nutcracker Therapeutics",
          "sentiment": 0.0,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-11T19:16:38.215653+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261602-Moneymun--4959798",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.852899",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Undervalued stock opportunity; Potential acquisition by pharmaceutical partner GF-1004: Pet life extension / sarcopenia Initiated discussion under CDA with several animal health companies hTtps://loom.ly/RsxnFCE",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-11T19:16:38.215671+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261601-Moneymun-56494298",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.854072",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The Gap No approved neuroprotective therapies The mRNA Opportunity - Wide Open LNP targeted delivery to retina \u2013 now possible NO APPROVED OR CLINICAL-STAGE MRNA THERAPIES FOR GLAUCOMA PARTNERING WITH LNP PROVIDER Paradigm shift to retinal protection \u2022 Pre-clinical evidence links SIRT6 activity with RGC protection in glaucoma/optic neuropathy models \u2022 Demonstrating RGC rescue and preserved function would be a strong disease-modifying signal Delivery is now tractable \u2022 Targeted LNP (tLNP) platforms are removing a major historical barrier for in vivo RNA therapeutics to reach retina/RGCs Clear decision point A single well-designed rodent POC that shows \u2022 focal RGC expression of SIRT6 cent \u2022 preserved RGC counts and \u2022 preserved RGC function with acceptable ocular safety, gives a clean go/no-go for IND enabling work AGED DOGS COMPARATIVE TRIAL Proof-of-Concept comparative clinical trial of in-vivo naked DNA gene therapy in aged dogs Conducted at Syngene's strategic partner site in Morocco, AAALAC and GLP certified 26 (24+2) aged Beagles dogs (age>10 years) Group 1 (n=6): untreated Group 2 (n=6): treated with gene therapy IV bolus of SIRT6 AAV Group 3 (n=6): treated with gene therapy IV infusion of naked DNA (low dose) Group 4 (n=6): treated with gene therapy IV infusion of naked DNA (high dose) Blinded: first read-out in January 2026 \u2022 Treatment period: 180 days with follow-up period: 90 days \u2022 Gene therapy has been administered to all dogs with demonstrated excellent safety profile Endpoints \u2022 Pan-mammalian methylation clock (Steve Horvath), \u2022 sarcopenia (including muscle biopsies) and other markers of aging MASH PROGRAM Affects est. 35 million people globally \u2022 Increasing prevalence \u2022 Leading cause of chronic liver disease and liver transplant Significant unmet medical need Clear regulatory accelerated development pathway. EMA and FDA guidelines accept: \u2713 Key surrogate outcomes for therapeutic trials: regression of fibrosis or resolution of NASH \u2713 Histological changes are achievable within a 12-18-month time-frame \u2713 Placebo control \u2713 Conditional fast-track approval 2025 KEY HIGHLIGHTS LARGE AND EXPANDING MARKET OPPORTUNITY MASH: 35 Million globally. Increasing prevalence. Door opener to even broader anti-aging indication Awarded to new grants in 2024 expanding research pipeline Ophthalmology: retina preservation GROWING IP PORTFOLIO WITH LONG LIFE 2 proprietary patent families SIRT6 centenarian (cent SIRT6) and gene delivery (entering National Phase); Additional upcoming patent applications (entering PCT) MRNA/LNP GENE DELIVERY SYSTEMS Innovative gene delivery systems: targeted LNPs delivering cent SIRT6 mRNA GF-1002 Multiple key clinical and regulatory milestones expected in next 18 months; Undervalued stock opportunity; Potential acquisition by pharmaceutical partner GF-1004: Pet",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-11T19:16:38.215688+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261559-Moneymun-69805717",
        "event_type": "social_post",
        "date": "2026-01-29T12:24:16.855051",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "WHO WE ARE Pioneering Novel Gene Therapeutics for a Longer, Healthier Life MISSION: aging is underlying risk factor for disease, and our aim is to deliver gene therapeutics that potentially halt or slow the aging process in humans and dogs CENTENARIAN SIRT6 (cent SIRT6) GENE: proprietary variant of longevity gene that widely regulates aging and immunity and is a potential therapeutic target for the treatment of diseases PROMISING PRECLINICAL RESULTS: lead drug candidate GF-1002 delivers a centenarian variant of the SIRT6 gene (cent SIRT6) for treatment of MASH SEASONED TEAM: experienced and proven management with extensive experience in public & private pharma and biotech ROBUST PIPELINE: advancing multiple development programs over 24 months: MASH, Glaucoma, Sarcopenia, Werner and life extension of dogs DEVELOPMENT PIPELINE GF-1002 (Pre-Clinical) AAV8 cent SIRT6 vector for intravenous infusion, expressing cDNA of centenarian variant of SIRT6(cent SIRT6) in liver GF-1003 (Pre-Clinical/Development) Suspension of exosomes, loaded with mRNA of centenarian variant of SIRT6(cent SIRT6) in fibroblasts GF-1004 (Clinical Proof of Concept) cent SIRT6 for intravenous infusion for life extension and prevention of age-related diseases GF-1005 (Pre-Clinical/Development) Mitochondrial disfunction: Myoblast progenitors loaded by photoporation with cent SIRT6 GF-1006 Ophthalmology (pre-clinical) mRNA cent SIRT6 delivered by LNP for the treatment of cornea pathologies and glaucoma OPHTHALMOLOGY PLATFORM New Ophthalmology Program: Initiated development of a novel gene therapy targeting ocular diseases, including corneal pathologies and glaucoma, using Genflow\u2019s proprietary Centenarian SIRT6 (cent SIRT6). Precision Delivery Platform: Employing a specially engineered non-viral vector for targeted SIRT6 delivery to the eye. Strategic Partnership: Signed a Material Transfer Agreement in April 2025 with a leading ophthalmology company to co-develop the cent SIRT6 therapy and delivery system. LEVERAGING AI FOR GENOMICS New AI Partnership: Signed Master Service Agreement in April 2025 with Heureuka Labs, a spin-out of Duke University, to use their proprietary AI platform to analyze complex genomic data, including RNA sequencing and gene expression profiles. Enhancing Therapeutic Insights: Expected to drive a deeper understanding of gene regulatory networks and biological responses to optimize therapy design and personalize outcomes. Pipeline Advancement: Initially supporting GF-1002 (cent SIRT6-based gene therapy in preclinical development) and future programs, including candidates for MASH. GLAUCOMA RGC NEUROPROTECTION: THE RACE IS ON The Problem 80M people worldwide with glaucoma; leading cause of irreversible blindness Current treatments only lower IOP- they don't protect retinal ganglion cells (RGCs) RGC death is irreversible; unmet need for neuroprotection Significant market opportunity The Gap",
          "sentiment": 0.5,
          "engagement": "12,516",
          "price_at_post": "1.90",
          "thread_title": "RE: 2026 Presentation",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&share=GENF&thread=B6A908C4-2EA6-45E9-9A63-B037855EC0B1"
        },
        "ingested_at": "2026-02-11T19:16:38.215706+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261913-Persever-11074831",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.702321",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "These unknowns are off book pre negotiated buys. Sp will remain pinned till.Dog efficacy data. Expected solid data.",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-11T19:16:38.215724+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261838-Dzygit19--1009712",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.702759",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dzygit1980",
          "content": "12:45 yesterday was 1.97 to sell small amout . Than yesterday's big trade printed today for 1.81 ,straight after 1.97 To buy share so I am not sure \ud83e\udd14 was 12:45 yesterday tradet  buy  to me it looks like sell. Also we are dropping",
          "sentiment": 0.0,
          "engagement": "255",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-11T19:16:38.215742+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261822-Persever--1551545",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.703192",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "Big buys more like it. Do you know trading? \ud83d\ude05",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-11T19:16:38.215760+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261753-Dzygit19-49798287",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.703612",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dzygit1980",
          "content": "Lots of big sales last couple of days",
          "sentiment": 0.0,
          "engagement": "255",
          "price_at_post": "1.85",
          "thread_title": "RE: Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-11T19:16:38.215777+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261756-Persever--2333387",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.704022",
        "source": "LSE_CHAT",
        "data": {
          "author": "Perseverance21",
          "content": "I think a massive rerate is coming ? Somethings brewing ?",
          "sentiment": 0.0,
          "engagement": "3",
          "price_at_post": "1.90",
          "thread_title": "Rerate.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42A38C5E-5C54-477A-A333-61939167B8AF"
        },
        "ingested_at": "2026-02-11T19:16:38.215795+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260719-Porter_--1481230",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.704447",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Know a few people who didn\u2019t get their orders filled yesterday. Seems there isn\u2019t much in the free-float so let\u2019s see how tight this coiled spring is!",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-11T19:16:38.215813+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20262217-Twocd2--1092667",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.704869",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "I joined pre IPO, \u00a350 may have been too much of a reach for you\u2026chortle chortle TK Max.. Give Porter a reach around before lights out so that he\u2019ll not be to disappointed with no RNS tomorrow morning\u2026\ud83d\udc4c",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-11T19:16:38.215831+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261352-DaveTK-26929274",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.705301",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "I joined the party pre IPO. TBF they were asking for more than \u00a350 so it may have been too much of a reach for you. Talking about choppers FFS. Don't let you mum read that or she'll take your phone off you and cancel your contract.",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-11T19:16:38.215849+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261342-Twocd2--2584012",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.705721",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "So TK Max joins the party\u2026think you and Porter need to take turns and time to give him a chance to be big spoon for this week. Might give him something else to do rather than practice his typing. Plenty of skin in the game lads\u2026but this is not about who\u2019s chopper is bigger..well maybe for the spooning it does\ud83d\ude01",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-11T19:16:38.215867+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261033-DaveTK--3321477",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.706162",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Always. I'm here and always have been here waiting for news that we have been bought out. It was always the goal from Eric to make this company into something a pharmaceutical would buy a high price. We may not be that far off. Fingers crossed. Thanks",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-11T19:16:38.215884+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261027-Porter_-30165203",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.706587",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Always the ones who sold too soon quick to troll those who held with diamond hands Dave. Expecting this is just the first update of many we\u2019ll be seeing over the next 2 weeks. Popcorn ready! \ud83c\udf7f",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-11T19:16:38.215902+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261005-DaveTK--1214478",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.707009",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaveTK",
          "content": "Would seem like you touched  nerve there, Porter ha ha. Nice RNS this morning. Looking forward to hearing more regarding the J.P. Morgan's Healthcare Conference. Really does seem like exciting times ahead. Thanks",
          "sentiment": 0.0,
          "engagement": "851",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-11T19:16:38.215919+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260839-Twocd2-50491741",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.707434",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "Ok big fella..time for nap your banter is honking.",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.95",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-11T19:16:38.215937+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260820-Moneymun--9517527",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.707847",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "The new Chairman in place, GAD BERDUGO is a high flyer based in the US with a wealth of experience in Global Biotech, Corporate Development and US Capital Markets and so no doubt very well contected to any potential suitors. Excitement building!!!! In Eric we trust!!! Gla holders:-) Ps initial Efficacy readout on the Dog Trial imminent!!! Gla ;-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-11T19:16:38.215955+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260752-Porter_-69883002",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.708264",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "2cd2 - invest more than \u00a3100 in a company and you might care a little bit more for your investments \ud83d\ude18",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-11T19:16:38.215972+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260734-Twocd2-22396924",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.708668",
        "source": "LSE_CHAT",
        "data": {
          "author": "Twocd2",
          "content": "Take the rest of the day off Porter..great job pal! You must have set the alarm early to C&P all of that \ud83d\udc4f\ud83d\udc4f\ud83d\udc4c",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "1.85",
          "thread_title": "RE: Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-11T19:16:38.215990+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260718-Porter_--2799665",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.709143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Genflow Appoints a New Chairman to Accelerate Corporate and R&D Expansion Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or the \"Company\"), a leading European-based biotechnology company focusing on gene therapies for age-related diseases, is pleased to announce a significant appointment to its Board of Directors, marking an important step in the Company's strategic evolution. Mr. Gad Berdugo, MSc Eng., MBA, has joined the Board with immediate effect and will assume the role of Independent Non-Executive Chairman, providing leadership as Genflow focuses on advancing its gene-therapy programs. Mrs. Tamara Joseph will continue to serve as a Director, ensuring continuity and maintaining strong governance. Mr. Berdugo brings over 30 years' of leadership experience spanning global business and corporate development, U.S. capital markets, and company building. He has a proven record of driving strategic partnerships, securing capital, and scaling both private and public development-stage biotechnology companies. Currently, Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a U.S.-based strategic and financial advisory firm focusing on the global biotechnology sector. His most recent roles include: \u00b7 Co-Founder & CEO, EpiVax Oncology \u00b7 Vice-Chairman of the Board, Evexta Bio \u00b7 Chief Business Officer, Editas Medicine (NASDAQ: EDIT) \u00b7 Chief Business Officer, Nutcracker Therapeutics He began his international career at Abbott Labs and Baxter, later becoming Life Sciences Sector Leader at Lazard Asset Management. Mr. Berdugo also brings deep technical and market expertise in RNA-based therapeutics, including lipid nanoparticle (LNP) delivery, development, and manufacturing. This background will support Genflow as it advances its scientific platform, evaluates delivery technologies, and explores next-generation therapeutic approaches. His appointment further strengthens the Company's presence in the United States and expands its capacity for global engagement. He does not own any shares in the Company. Dr. Eric Leire, Chief Executive Officer of Genflow, commented: \"We are delighted to welcome Mr. Berdugo as Independent Non-Executive Chairman. His expertise in strategy, partnerships and financing as well as his deep experience with RNA-LNP technologies will be instrumental as we accelerate our programs and expand our global reach. We are equally pleased that Mrs. Tamara Joseph will continue her service on the Board, contributing her invaluable leadership, legal and governance expertise.\" Gad Berdugo added: \"I am excited to join Genflow as the company is progressing to the next new phase of development, with key data readouts expected in 2026, strengthened intellectual property, and a sharpened strategic focus on high-potential programs. I look forward to working with the talented team and board to advance these innovative gene therapies, this is an ideal moment to contribute my expertise and hel",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "Deal maker joins as Chair of Genflow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=42F54A3E-D649-4D10-B5A0-5C16AEA39461"
        },
        "ingested_at": "2026-02-11T19:16:38.216007+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20260836-Pie-char--6929448",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.709557",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pie-chart",
          "content": "Post conference announcement next week and Funding news is what I predict. I'm amazed we are at this price. Such a hidden gem!",
          "sentiment": 0.5,
          "engagement": "60",
          "price_at_post": "1.85",
          "thread_title": "RE: JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=3005BF87-EE58-4C27-ABC6-EE6AA15A9385"
        },
        "ingested_at": "2026-02-11T19:16:38.216025+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20260716-Porter_--3301213",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.710022",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Genflow Biosciences is a London-based biotechnology firm and the first \"pure-play\" longevity company listed on the London Stock Exchange. As of early 2026, the company is transitioning from a preclinical phase into active clinical data readouts, focusing on its proprietary SIRT6-based gene therapy platform to extend human and animal \"healthspan\". Core Technology and Pipeline: The company\u2019s lead therapeutic approach involves delivering a \"centenarian variant\" of the SIRT6 gene, identified in individuals who live over 100 years, to improve DNA repair and metabolic health. GF-1002 (Human Therapeutics): MASH (Liver Disease): Repositioned in 2025 to target patients with advanced fibrosis who have limited options from existing GLP-1 therapies. The company is currently finalizing its Investigational New Drug (IND) package and exploring mRNA/LNP delivery to allow for repeat dosing and lower costs. Werner Syndrome: A rare genetic condition causing premature aging. Genflow has developed proprietary human-derived liver organoids to model this disease more accurately than animal models. GF-1004 (Veterinary Program): Canine Longevity: A 12-month blinded clinical trial in aged dogs is currently underway. In early 2026, the company confirmed that all subjects received full dosing with no adverse events reported. Key 2026 Milestones: Initial efficacy readouts focusing on biological age (via methylation clocks) are expected in Q1 2026, with a second evaluation planned for June-July 2026. Expansion Programs: Glaucoma: A new ophthalmology program targeting neuroprotection of retinal ganglion cells to prevent blindness. Sarcopenia (GF-1005): Research into muscle health and mitochondrial dysfunction in collaboration with the Universit\u00e9 libre de Bruxelles. 2026 Strategic Focus: Genflow\u2019s 2026 strategy emphasizes \"rationalization of the pipeline,\" prioritizing programs with the strongest data to secure non-dilutive funding through licensing deals and partnerships. The company is actively seeking animal health partners for its dog longevity program and strategic collaborators for its LNP-based mRNA therapeutics.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "1.85",
          "thread_title": "GLP, LNP, MRNA and SIRT6 based therapeutics",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=FB89DB69-F93B-4BB3-8529-5206EECDF243"
        },
        "ingested_at": "2026-02-11T19:16:38.216042+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20262119-jamtart1--4763697",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.710444",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Yes, Genflow Biosciences (Genflow) has had significant interest at the J.P. Morgan Healthcare Conference, attending specifically to engage with potential partners, institutional investors, and pharmaceutical companies. Their CEO, Dr. Eric Leire, attended the most recent conference in January 2026 with a \"full appointments book\" to discuss strategic partnerships and non-dilutive funding opportunities.",
          "sentiment": 0.5,
          "engagement": "1,600",
          "price_at_post": "1.85",
          "thread_title": "JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=3005BF87-EE58-4C27-ABC6-EE6AA15A9385"
        },
        "ingested_at": "2026-02-11T19:16:38.216059+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260634-Porter_-21790903",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.710912",
        "source": "LSE_CHAT",
        "data": {
          "author": "Porter_",
          "content": "Companies attend the J.P. Morgan Healthcare Conference (JPM) primarily for networking, securing funding, forging strategic partnerships, and announcing key business updates. This major event, often described as setting the industry's tone for the year, concentrates a year's worth of meetings into a few days. Key reasons why companies attend include: Investment and Funding: The conference is a premier venue for companies to present their strategies and financial outlooks to a high-level audience of investors, analysts, and venture capitalists. For many, especially smaller or emerging biotech firms, it is a critical opportunity to secure financing, gauge investor interest, and build essential relationships. Mergers and Acquisitions (M&A) and Partnerships: The event is a hotbed for dealmaking. Big pharmaceutical companies often attend to scout for smaller companies with promising drug pipelines or innovative technologies (like AI in drug discovery) to acquire, especially as their own blockbuster drugs approach patent expiration. Extensive one-on-one meetings facilitate these discussions and collaborations. Strategic Positioning and Visibility: Companies announce major news, clinical trial data, or year-end recaps just before or during the conference to capture attention and elevate their visibility above the competition. It allows them to articulate their unique value proposition and strategic priorities to the global market. Market Intelligence: Attending allows companies to take the pulse of the industry, understand the latest trends (e.g., AI, gene therapy, obesity drugs), and gather competitive intelligence. They can assess how investors and peers discuss valuations, regulatory pathways, and market potential, which helps in fine-tuning their own strategies for the year ahead. Networking Efficiency: The conference brings the entire healthcare and life sciences ecosystem\u2014from manufacturers and providers to regulators and service providers\u2014into a concentrated location for a short time. This high density of key decision-makers allows for efficient, high-value networking and relationship building that would otherwise take months of travel and outreach.",
          "sentiment": 0.5,
          "engagement": "1,320",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan Healthcare Conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=4C9A5731-DC78-4F24-8CE9-513E080FCFAC"
        },
        "ingested_at": "2026-02-11T19:16:38.216077+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261946-jamtart1--6700201",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.711334",
        "source": "LSE_CHAT",
        "data": {
          "author": "jamtart1",
          "content": "Doubt it, but happy if rumours are true",
          "sentiment": 0.5,
          "engagement": "1,600",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan, news",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=559FB93D-C9CD-4A83-84E9-7B26CC6976E9"
        },
        "ingested_at": "2026-02-11T19:16:38.216094+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261844-JediMast-69788091",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.711742",
        "source": "LSE_CHAT",
        "data": {
          "author": "JediMaster1",
          "content": "Rumours of investment banks wanting to buy in from the JP Morgan Conference. The only question now is who do they want to buy in on behalf of?? The next few days will be interesting. Will Eric spill the beans?",
          "sentiment": 0.5,
          "engagement": "169",
          "price_at_post": "2.00",
          "thread_title": "JP Morgan",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=D010A135-964B-4034-9025-65BCB0334809"
        },
        "ingested_at": "2026-02-11T19:16:38.216122+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261006-Moneymun--6936703",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.712184",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "GKOS: Strong innovation and new therapies drive growth, with robust financials and expanding markets Jan 14, 2026, GKOS The event highlighted robust innovation in ophthalmology, with strong R&D investment yielding a broad product pipeline and record financial performance. Key growth drivers include new glaucoma and keratoconus therapies, strategic market expansion, and a focus on operational leverage and profitability. Based on Glaukos Corporation [GKOS] 44th Annual J.P. Morgan Healthcare Conference Audio Transcript \u2014 Jan. 14 2026",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.10",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-02-11T19:16:38.216140+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260827-Moneymun-18419469",
        "event_type": "social_post",
        "date": "2026-01-24T02:35:05.712592",
        "source": "LSE_CHAT",
        "data": {
          "author": "Moneymunch",
          "content": "Every chance Rooster, although I'm hoping for a transformational lucrative commercial licensing deal on one or more of the programs, Dog , Glaucoma and Mash. Excitement building!!! Gl :-)",
          "sentiment": 0.5,
          "engagement": "12,509",
          "price_at_post": "2.05",
          "thread_title": "RE: JP Morgan conference",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=GENF&thread=F4CEC2B1-8B51-4E9C-9BB4-CD51A6372D98"
        },
        "ingested_at": "2026-02-11T19:16:38.216157+00:00"
      }
    ],
    "catalyst_dates": {
      "proxy_date": "2023-04-19"
    }
  },
  "ai_insights": {
    "key_insights": [],
    "hidden_patterns": [],
    "contrarian_signals": [],
    "risk_warnings": [],
    "opportunity_flags": [],
    "narrative_summary": "GENF.L presents a standard crash recovery setup without unusual patterns detected. Monitor for catalyst developments and trend shifts.",
    "_is_real": false
  },
  "crashdash": {
    "industry_intelligence": {
      "category": "BIOTECH_PHARMA",
      "name": "Biotech & Pharma",
      "icon": "\ud83e\uddec",
      "color": "#10b981",
      "crash_patterns": [
        "Clinical trial failures (Phase 1/2/3)",
        "FDA/EMA rejection or delay",
        "Safety concerns or adverse events",
        "Patent expiry or IP challenges",
        "Funding gaps (cash runway concerns)"
      ],
      "recovery_paths": [
        "Positive trial data (efficacy endpoints met)",
        "Regulatory approvals (FDA/EMA)",
        "Partnership deals (big pharma licensing)",
        "Orphan drug designation or fast track",
        "New trial initiations (pipeline expansion)"
      ],
      "active_patterns": [
        "FDA/EMA rejection or delay",
        "Patent expiry or IP challenges"
      ],
      "relevant_rns_count": 1,
      "key_metrics": [
        "Clinical stage (preclinical, Phase 1/2/3, commercialized)",
        "Cash runway (months until next funding)",
        "Addressable market size (indication)",
        "Trial enrollment progress",
        "Intellectual property strength"
      ]
    },
    "panic_analysis": {
      "panic_score": 37.2,
      "signal": "MILD_CONCERN",
      "interpretation": "\ud83d\udfe2 Normal volatility - not a crash signal",
      "breakdown": {
        "price_destruction": 15.2,
        "volume_death": 14,
        "social_silence": 6,
        "news_sentiment": 2
      },
      "is_opportunity": false,
      "opportunity_reason": "\ud83d\ude10 Normal market conditions - no crash signal"
    },
    "fear_vs_facts": {
      "fear_points": [],
      "facts_points": [
        "\ud83d\udcc8 Historical upside: 227% proven capacity",
        "\ud83d\udd04 Pattern reliability: 7 previous rallies"
      ],
      "verdict": "\u2705 Facts align with low fear - Normal risk/reward"
    },
    "crashhunter_signals": [
      {
        "type": "BUILDING",
        "icon": "\ud83d\udcca",
        "text": "Building",
        "color": "#10b981"
      },
      {
        "type": "MODERATE_QUALITY",
        "icon": "\ud83c\udf1f",
        "text": "APEX 65",
        "color": "#3b82f6"
      }
    ],
    "catalyst_pipeline": [
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Notice of GM",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Holding(s) in Company",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Administrative Approval of Grant & 2026 Priorities",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Directorate change",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Review of 2025",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Funding announcement or operational update",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Volume expansion confirmation",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      }
    ],
    "decision_matrix": {
      "decision": "WATCH",
      "reason": "\u23f3 Monitor for timing regime change or panic escalation",
      "checklist": [
        {
          "criterion": "Panic Score",
          "value": "37/100",
          "pass": false,
          "icon": "\ud83d\udfe2"
        },
        {
          "criterion": "Timing Regime",
          "value": "EARLY_BUILD",
          "pass": true,
          "icon": "\u2705"
        },
        {
          "criterion": "APEX Quality",
          "value": "65/100",
          "pass": true,
          "icon": "\u2b50"
        },
        {
          "criterion": "Data Confidence",
          "value": "50/100",
          "pass": true,
          "icon": "\ud83c\udfaf"
        },
        {
          "criterion": "Industry Pattern",
          "value": "2 active",
          "pass": true,
          "icon": "\ud83e\uddec"
        }
      ],
      "pass_rate": "4/5"
    },
    "contrarian_panic": {
      "total_score": 52,
      "band": "\ud83d\udfe1 MODERATE COMPRESSION (Top 30% - GOOD SETUP)",
      "components": {
        "compression": {
          "score": 33,
          "max": 40,
          "signals_30d": 5,
          "signals_60d": 5,
          "signals_90d": 5,
          "signals_per_week": 4.38,
          "total_signals": 5,
          "rsi_extreme_count": 4,
          "rsi_ultra_count": 4,
          "escalation_count": 0,
          "density_score": 20,
          "rsi_score": 10,
          "escalation_score": 0,
          "description": "4.4 signals/week | 4 RSI<20 | \u26a1 HIGH COMPRESSION"
        },
        "intensification": {
          "score": 5,
          "max": 20,
          "recent_types": [
            "CRASH ZONE BOTTOM",
            "CRASH ZONE BOTTOM",
            "CRASH ZONE BOTTOM"
          ],
          "escalating": false,
          "sustained": false,
          "current_intensity": 1,
          "pattern": "NORMAL CRASH LEVEL"
        },
        "volume_death": {
          "score": 5,
          "max": 15,
          "relative_volume": 2.31,
          "description": "Elevated volume - Some activity"
        },
        "pop_potential": {
          "score": 9,
          "max": 15,
          "best_historical_rally": 242.9,
          "avg_rally": 230.4,
          "signal_count": 5,
          "description": "Moderate performer (243%)"
        },
        "accumulation": {
          "score": 0,
          "max": 10,
          "has_accumulation": false,
          "bars_since_accum": 0,
          "description": "No accumulation detected"
        }
      },
      "ticker": "GENF.L",
      "signal_date": "2023-03-31",
      "total_signals_history": 5
    }
  },
  "scoring_breakdown": {
    "apex_factors": [
      "Technical quality: +11 (AI_Technical_Score=9.0/20)",
      "Drawdown reversion potential: +17 (Drawdown_Pct=83.5%)",
      "Volume confirmation: +10 (Relative_Volume=2.3)",
      "Pattern reliability: +15 (Rally_Count=7.0)",
      "Upside history: +12 (best_rally_pct=227%)"
    ],
    "technical_score": {
      "points": 11,
      "ai_score": 9.0,
      "reason": "AI Technical Score 9.0/20 translates to 11/25 points"
    },
    "drawdown_score": {
      "points": 17,
      "drawdown_pct": 83.5,
      "reason": "Drawdown of 83.5% gives 17/20 points"
    },
    "volume_score": {
      "points": 10,
      "rel_volume": 2.31,
      "reason": "Relative volume 2.31x gives 10 points"
    },
    "pattern_score": {
      "points": 15,
      "rally_count": 7.0,
      "reason": "7.0 historical rallies gives 15/15 points"
    },
    "upside_score": {
      "points": 12,
      "best_rally_pct": 227.27,
      "reason": "Best rally of 227% gives 12/20 points"
    },
    "penalties": {
      "total": 0,
      "items": []
    }
  },
  "reasons_buy_sell": {
    "reasons_to_buy": [
      {
        "reason": "Early stage positioning offers best R:R if catalysts appear",
        "tag": "MED",
        "evidence": [
          "timing_regime=EARLY_BUILD",
          "current_return_pct=12.4%"
        ]
      },
      {
        "reason": "Proven winner - previously hit lock-in target",
        "tag": "MED",
        "evidence": [
          "lock_in_reached=True"
        ]
      }
    ],
    "reasons_to_sell": [
      {
        "reason": "Stale signal - not for active trading",
        "tag": "HIGH",
        "evidence": [
          "status=historical",
          "signal_date=2023-03-31"
        ]
      }
    ]
  },
  "trade_plan": {
    "trader_plan": {
      "style": "Watch / Starter",
      "action": "Wait for base + catalyst confirmation; starter position only",
      "sizing": "0-1% until CONFIRMED",
      "risk": "Invalidation = breaks recent lows / dilution / suspension",
      "profit_taking": "Scale out 25% at +15%, 25% at +50%, runner above"
    },
    "investor_plan": {
      "allowed": false,
      "thesis_conditions": "Unlock after AI triangulation + CONFIRMED timing",
      "hold_window": "N/A",
      "risk_management": "N/A"
    }
  },
  "exhaustion": {
    "regime": "EARLY_BUILD",
    "run_multiple": 0.05,
    "current_run_pct": 12.42,
    "avg_historical_run_pct": 227.27
  },
  "history_snapshot": {
    "previous_report_date": null,
    "score_change": null,
    "confidence_change": null,
    "new_events_count": 0,
    "new_rns_titles": []
  },
  "commentary": {
    "executive_summary": "This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows EARLY_BUILD timing with 65/100 APEX score. Historical data shows 7 rallies averaging 227% upside. Current position: +12.4%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.",
    "bull_case": [
      "Reliable pattern (7 previous rallies)",
      "Early regime often offers best risk/reward"
    ],
    "bear_case": [
      "Monitor for breakdown signals"
    ],
    "timing_translation": "Early accumulation phase. Watch for confirmation before committing size.",
    "confidence_explained": "Confidence 50/100 reflects full data quality with triangulation loaded."
  },
  "data_quality": {
    "sources_present": {
      "snapshot_json": false,
      "daily_enrichment_row": true,
      "historical_profile": true,
      "metadata": true,
      "triangulation_events": true,
      "ai_insights": true
    },
    "missing_data": [
      "AI insights from Groq LLM"
    ],
    "confidence_impact": "HIGH",
    "disclaimer": "Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk."
  },
  "report_version": "5.0",
  "comprehensive_apex": {
    "score": 65,
    "rating": "MODERATE",
    "color": "#f59e0b",
    "calculation": "APEX Score: 65/100",
    "components": {
      "setup": {
        "score": 44,
        "weight": 0.25
      },
      "trust": {
        "score": 50,
        "weight": 0.2
      },
      "panic": {
        "score": 37.2,
        "weight": 0.3
      },
      "compression": {
        "score": 52,
        "weight": 0.25
      }
    },
    "timing": {
      "regime": "EARLY_BUILD",
      "multiplier": 1.0
    }
  }
};</script>
  <script src="../../apex_trust_panel.js"></script>
</body>
</html>
